

PA (RIBO-) RIBOZYME PHARM INC.
 XX Beigelman I, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 DR WPI; 1996-300653/30.
 XX
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 XX Claim 10; Page 204; 307pp; English.
 XX
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 57.1%; Pred. No. 5.4e+02;
 Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1678 CCTGGTGTCTCTC 1691
 ||||| : |||||
 Db 2 CCUGGUCUACCCUC 15

RESULT 898
 AAX24191
 ID AAX24191 standard; DNA; 15 BP.
 AC AAX24191;
 XX
 XX 01-JUL-1999 (first entry)
 DE
 DE Phosphonomonoester oligonucleotide analogue 8.
 XX
 KW Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
 KW ribozyme; diagnostic agent; detection; treatment; disease; virus;
 KW integrin; cell-cell adhesion receptor; TNF-alpha; ss.
 XX
 OS Synthetic.
 XX
 PN DE19508923-A1.
 XX
 PD 19-SEP-1996.
 XX
 PF 13-MAR-1995; 95DE-01008923.
 XX
 PR 13-MAR-1995; 95DE-01008923.
 XX
 PA (FARH) HOECHST AG.
 XX
 PI Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;
 XX
 DR WPI; 1996-425893/43.

XX New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for
 PT therapeutic inhibition of gene expression, e.g. in cancer or viral
 PT infection, with good specificity and in vivo stability.
 XX
 PS Disclosure; Page 22; 36pp; German.
 XX
 CC This invention describes novel phosphonomonoester oligonucleotide
 CC analogues which act as inhibitors of gene expression (as sense/antisense,
 CC ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.
 CC probes for detecting nucleic acid) or for treatment of diseases caused by
 CC viruses, influenced by integrins or cell-cell adhesion receptors, induced
 CC by factors such as TNF-alpha, or cancer or restenosis. The products of
 CC the invention satisfy the requirements of good in-vivo stability; ability
 CC to cross cellular and nuclear membranes, and specific binding to target
 CC nucleic acid better than known oligonucleotides
 XX
 SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1668 CAGCTGGAACCCCTG 1691
 ||||| |||||
 Db 1 CAGCTGCAACCCAG 14
 RESULT 899
 AAT50231/c
 ID AAT50231 standard; RNA; 15 BP.
 XX
 AC AAT50231;
 XX
 XX 07-MAR-1997 (first entry)
 DT
 XX Rabbit CTPP HH ribozyme target sequence #513.
 DE
 XX Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
 KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
 KW reverse cholesterol transport; high density lipoprotein; therapy; CERP;
 KW familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
 KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
 KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
 KW LDL; ss.
 XX
 OS Oryctolagus cuniculus.
 XX
 PN WO9620279-A1.
 XX
 XX 04-JUL-1996.
 PD
 XX 11-DEC-1995; 95WO-US016000.
 PF
 XX 23-DEC-1994; 94US-00363240.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (WARN) WARNER LAMBERT CO.
 PA
 XX Couture L, Stinchcomb D, Mcswiggen J, Bisgaier C, Page M;
 PI WPI; 1996-321852/32.
 XX
 XX New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
 PT useful for preventing or treating initial development, progression or
 PT regression of vascular diseases, esp. familial hypercholesterolaemia.
 XX
 PS Claim 4; Page 41; 72pp; English.
 XX
 CC AAT50138-T50359 represent target sequences for the rabbit cholesterol
 CC ester transfer protein (CTPP) hammerhead (HH) ribozymes (see AAT50360-
 CC T50546). CERP is a 74 kD glycoprotein that facilitates neutral lipid
 CC transfer between plasma lipoproteins. The numbering of the targets refers

CC to the position of the cleavage site in full length CETP. The ribozyme
CC then binds to 5 nucleotides either side of this site. The ribozymes are
CC able to cleave mRNA from the gene encoding CETP, thereby blocking
CC synthesis and/or expression of the mRNA. By inhibiting CETP, the reverse
CC cholesterol transport (RCT) pathway can be inhibited (or eliminated)
CC thereby preventing the reduction in size density of the high density
CC lipoproteins (HDL), prolonging HDL half life, and therefore increasing
CC HDL levels. The ribozymes can be used to treat conditions associated with
CC abnormal levels of CETP, specifically atherosclerosis, familial
CC hypercholesterolaemia, peripheral vascular disease, dyslipidaemia,
CC hyperbetalipoproteinaemia, hypopalipoproteinaemia, vascular
CC complications of diabetes, transplant, atherectomy and angioplasty
CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
CC decrease in LDL levels, and a corresponding increase in HDL levels). The
CC HH ribozymes can also be used diagnostically to study genetic drift and
CC mutations in diseased cells, and to detect CETP mRNA. As the HH ribozymes
CC target specific regions of the CETP gene, they have low non-specific
CC activity
XX
SQ Sequence 15 BP; 4 A; 6 C; 0 G; 0 T; 5 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
DB 14 GGAGATGAAGTTG 1

RESULT 900
AAT50229/c
ID AAT50229 standard; RNA; 15 BP.

XX AAT50229;
DT 07-MAR-1997 (first entry)
DE Rabbit CETP HH ribozyme target sequence #512.
XX Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW familial hypercholesterolaemia; dyslipidaemia; hypopalipoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplasty restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.
XX Oryctolagus cuniculus.
XX WO9620279-A1.
XX 04-JUL-1996.
XX 11-DEC-1995; 95WO-US016000.
XX 23-DEC-1994; 94US-00363240.
XX (RIBO-) RIBOZYME PHARM INC.
XX (WARN) WARNER LAMBERT CO.
XX Couture L, Stinchcomb D, Mcswiggen J, Bisgaier C, Page M;
XX WPI; 1996-321852/32.
XX New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
XX useful for preventing or treating initial development, progression or
XX regression of vascular diseases, esp. familial hypercholesterolaemia.
XX Claim 4; Page 41; 72pp; English.
XX AAT50138-T50359 represent target sequences for the rabbit cholesterol
CC

CC ester transfer protein (CETP) hammerhead (HH) ribozymes (see AAT50360-
CC T50546). CETP is a 74 kD glycoprotein that facilitates neutral lipid
CC transfer between plasma glycoproteins. The numbering of the targets refers
CC to the position of the cleavage site in full length CETP. The ribozyme
CC then binds to 5 nucleotides either side of this site. The ribozymes are
CC able to cleave mRNA from the gene encoding CETP, thereby blocking
CC synthesis and/or expression of the mRNA. By inhibiting CETP, the reverse
CC cholesterol transport (RCT) pathway can be inhibited (or eliminated)
CC thereby preventing the reduction in size density of the high density
CC lipoproteins (HDL), prolonging HDL half life, and therefore increasing
CC HDL levels. The ribozymes can be used to treat conditions associated with
CC abnormal levels of CETP, specifically atherosclerosis, familial
CC hypercholesterolaemia, peripheral vascular disease, dyslipidaemia,
CC hyperbetalipoproteinaemia, hypopalipoproteinaemia, vascular
CC complications of diabetes, transplant, atherectomy and angioplasty
CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
CC decrease in LDL levels, and a corresponding increase in HDL levels). The
CC HH ribozymes can also be used diagnostically to study genetic drift and
CC mutations in diseased cells, and to detect CETP mRNA. As the HH ribozymes
CC target specific regions of the CETP gene, they have low non-specific
CC activity
XX

SQ Sequence 15 BP; 5 A; 6 C; 0 G; 0 T; 4 U; 0 Other;
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
DB 15 GGAGATGAAGTTG 2

RESULT 901
AAV48892/c
ID AAV48892 standard; DNA; 15 BP.

XX AAV48892;
DT 15-OCT-1998 (first entry)
DE c-fos gene antisense oligonucleotide c-fos-6.
XX c-fos; antisense oligonucleotide; modulate; gene expression; ss.
XX Synthetic.
XX Homo sapiens.
XX EP856579-A1.
XX 05-AUG-1998.
XX 31-JAN-1997; 97EP-00101531.
XX 31-JAN-1997; 97EP-00101531.
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX Schlingensiepen K, Brysch W;
XX WPI; 1998-400910/35.
XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
XX consecutive guanosine or inosine - and have specific ratio of residues
XX able to form two or three hydrogen bonds, have greater activity and
XX reduced toxicity, used therapeutically or to modulate growth of cells in
XX culture.
XX Claim 10; Fig 7; 286pp; English.
XX AAV48897-929 represent antisense oligonucleotides directed against the c-
XX fos gene. Of these, only oligonucleotides AAV48887-917 resulted in
CC

CC significant reduction in c-fos protein expression, while oligonucleotides
 CC AAV4918-29 had little effect. The oligonucleotides exemplify the
 CC invention. The specification describes oligonucleotides that contain 8-30
 CC nucleotides, which contain at most 8 nucleotides that can each form three
 CC hydrogen bonds to cytosine; do not contain four consecutive nucleotides
 CC able to form three H-bonds each to four consecutive cytosines; do not
 CC contain two sequences of three consecutive nucleotides each able to form
 CC three H-bonds to three consecutive cytosines, and the ratio between
 CC residues able to form two H-bonds each (2R) or three such bonds (3R) is
 CC given by $2R/3R = 0.33-0.72$. The oligonucleotides are used to modulate
 CC expression of genes, particularly the genes for p53, Erb-2, JunB, JunD,
 CC TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
 CC (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
 CC and/or keratinocytes). The oligonucleotides can also be used to analyse
 CC function of proteins (by altering their expression or activity) and
 CC therapeutically, e.g. in cases of cancer or (targeting TGF) for
 CC stimulating the immune system
 CC
 XX
 SQ Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1686 CTCCTCCACGCTGG 1699
 Db 14 CTCCTCCACGCTGG 1
 RESULT 902
 AAZ10279
 ID AAZ10279 standard; DNA; 15 BP.
 AC AAZ10279;
 XX
 DT 09-NOV-1999 (first entry)
 XX
 DE Primer ZC4048 used to amplify human prostatic transglutaminase cDNA.
 XX
 KW Human placental transglutaminase; calcium ion-dependent crosslinking;
 KW basement membrane structure; wound repair; adhesive; wound healing;
 KW ulcer; skin graft; food preparation; cheese; prostatic transglutaminase;
 KW enzymatic labeling; cell apoptosis; Alzheimer's disease; dried fish;
 KW Parkinson's disease; chemotherapy; blood cell count;
 KW hyperproliferative disease; fat deposition; obesity; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5952011-A.
 XX
 PD 14-SEP-1999.
 XX
 XX 30-MAY-1995; 95US-00452800.
 XX
 PR 31-DEC-1991; 91US-00816284.
 PR 30-DEC-1992; 92US-00998973.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Sheppard PO, Grant FU, O'hara PJ;
 DR WPI; 1999-539175/45.
 XX
 PT New human placental transglutaminase useful for promoting healing of
 PT wounds.
 XX
 PS Example 1; Col 33; 19pp; English.
 XX
 CC PCR primers AAZ10279-80 were used to amplify a 468 bp fragment of Human
 CC placental transglutaminase cDNA for use as a probe to isolate the full
 CC length sequence. The specification also describes Human placental
 CC transglutaminase, which catalyses calcium ion-dependent crosslinking of

CC protein-bound glutamine and lysine residues, i.e. stabilizes basement
 CC membrane structures. Compositions comprising Human placental
 CC transglutaminase can be used to facilitate wound repair in a patient. The
 CC protein can also be used in adhesives to promote wound healing, e.g.
 CC ulcers or skin grafts, in preparation of foods e.g. cheese or pastes, to
 CC prevent deterioration of dried fish caused by protozoans, for enzymatic
 CC labeling of proteins or cell membranes, to introduce cleavable
 CC crosslinks, and in solid-phase reversible removal of specific proteins
 CC from biological systems. Expression of Human placental transglutaminase
 CC is also a marker for identification of antagonists and agonists of cell
 CC apoptosis which are potentially useful for treating Alzheimer's or
 CC Parkinson's diseases, to inhibit apoptosis in patients undergoing
 CC chemotherapy and to increase their blood cell counts or for control of
 CC hyperproliferative disease or as a marker to identify agents that control
 CC fat deposition in some forms of obesity
 XX
 SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1663 GCTCACAGCTGGAA 1676
 Db 1 GCGCTCAGCTGGAA 14
 RESULT 903
 AAF60907
 ID AAF60907 standard; DNA; 15 BP.
 XX
 AC AAF60907;
 XX
 DT 15-MAY-2001 (first entry)
 XX
 DE Anti-c-Ha-ras oligonucleotide SEQ ID 16.
 XX
 KW Transport; membrane; cytostatic; virucide; vasotropic; dermatological;
 KW antipsoriatic; antiasthmatic; gene therapy; tumor cell; antisense;
 KW tumor therapy; drug; ss.
 XX
 OS Unidentified.
 XX
 PN DE19935302-A1.
 XX
 PD 08-FEB-2001.
 XX
 PF 28-JUL-1999; 99DE-01035302.
 XX
 PR 28-JUL-1999; 99DE-01035302.
 XX
 PA (AVET) AVENTIS PHARMA DEUT GMBH.
 XX
 PI Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
 DR WPI; 2001-203679/21.
 XX
 PT New substituted aryl conjugates of parent molecules, especially
 PT oligonucleotides, having improved transmembrane and intracellular
 PT transport properties, useful as medicaments or diagnostic agents.
 XX
 PS Disclosure; Page 6; 28pp; German.
 XX
 CC This invention describes a novel conjugate (I) which consists of (A) a
 CC molecule to be transported and (B) at least one aryl residue of formula -
 CC Ar-(X-C(Y)-R₁)-n (ii). Ar = group containing at least one aromatic ring;
 CC X = O or N (sic); Y = O, S or NH-R₂ (sic); R₁ = optionally substituted
 CC 1-23C alkyl (optionally containing double and/or triple bonds); R₂ =
 CC optionally substituted 1-18C alkyl (optionally containing double and/or
 CC triple bonds); n = integer of 1 or more. (A) is bonded to (B) directly or
 CC via a chemical group, provided that the chemical group is other than CH₂
 CC -S if the bond is via a phosphodiester linkage of (A). The invention also
 CC describes (i) the preparation of a conjugate (I') of (A') a molecule to

CC be transported and (B') at least one aryl residue (not restricted to
 CC (II)), by preparing (A') containing a reactive function at the position
 CC at which (B') is to be bonded, preparing (B') and reacting (A') and (B');
 CC and (ii) the use of aryl groups (II) (optionally bonded via a chemical
 CC group) for transporting (A) across biological membranes. The products of
 CC the invention have cytostatic, virucide, vasotropic, dermatological,
 CC antiproliferative and antitumor activity and can be used for gene
 CC therapy. Conjugation of (A) with (B) is useful for transporting (A)
 CC across biological membranes or into eukaryotic or prokaryotic cells
 CC (specifically tumor cells). Medicaments, diagnostic agents and test kits
 CC containing (I) are also claimed. Typically (I) are antisense
 CC oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
 CC treating viral infections or diseases associated with integrins or cell-
 CC cell interactions (e.g. restenosis, vitiligo, psoriasis or asthma); or
 CC labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
 CC hybridization. Conjugation with (B) markedly improves the cellular uptake
 CC of (A), e.g. in tumor cells. (B) include fluorescein derivative residues,
 CC in which case the conjugates (I) are fluorescently labeled, allowing
 CC microscopic monitoring of cellular uptake etc. The cellular uptake of (I)
 CC is superior to that obtained using other conjugated groups related to
 CC (II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
 CC the scope of (B)) have superior uptake to corresponding fluorescein
 CC conjugates
 XX
 SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1668 CAGCTGGAACCTG 1681
 DB 1 CAGCTGCACCCAG 14
 RESULT 904
 AAS04348/c
 ID AAS04348 standard; DNA; 15 BP.
 XX
 AC AAS04348;
 DT 07-SEP-2001 (first entry)
 XX Human DAXX DNA allele-specific oligonucleotide primer #11.
 DE Death-associated protein 6; DAXX; polymorphism; haplotype pair; human;
 XX immune disorder; autoimmune disease; population diversity; ss;
 KW paternity testing; anthropological lineage; forensic application;
 KW oligonucleotide primer.
 XX Homo sapiens.
 OS WO200125245-A2.
 XX 12-APR-2001.
 PD 05-OCT-2000; 2000WO-US027487.
 XX 06-OCT-1999; 99US-0157909P.
 PR (GENA-) GENAISSANCE PHARM INC.
 XX Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;
 PI WPI; 2001-308220/32.
 XX New human death-associated protein 6 (DAXX) gene variants comprising 19
 DR polymorphic sites useful in studying the effect of variation on the
 PT biological activity of DAXX and in developing drugs targeting the
 PT protein.
 XX Claim 15; Page 19; 97pp; English.
 PS

XX Sequences AAS04338-AAS04413 represent oligonucleotide primers specific
 CC for a DNA encoding human death-associated protein 6 (DAXX). This DNA may
 CC comprise one or more polymorphisms at specific nucleotide positions to
 CC form one of nineteen possible polymorphic variants. Associations between
 CC a trait and a genotype or a haplotype of the DAXX gene can be identified
 CC by comparing the frequency of the genotype or haplotype in a population
 CC exhibiting the trait with that of a reference population. A higher
 CC frequency in the trait population indicates an association. Methods
 CC involving genotyping or haplotyping of the DAXX gene of an individual can
 CC lead to prediction of haplotype pairs for the DAXX gene of related
 CC individuals, and may be useful in studying the expression and biological
 CC function of DAXX, as well as in developing drugs targeting this protein.
 CC Polymorphic variants of DAXX are useful in studying the effect of the
 CC variation on the biological activity of DAXX as well as on the binding
 CC affinity of candidate drugs targeting DAXX for the treatment of
 CC autoimmune diseases and other immune disorders. Polymorphism is also
 CC useful for studying population diversity, anthropological lineage,
 CC paternity testing, forensic applications, and for identifying
 CC associations between the DAXX genetic variation and a trait such as level
 CC of drug response or susceptibility to disease. DAXX proteins may be used
 CC to measure binding affinities of one or more candidate drugs targeting
 CC the DAXX protein
 XX
 SQ Sequence 15 BP; 4 A; 9 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1632 GATGGGGCTGTGAG 1645
 DB 15 GTTGGGGCTGTGAG 2
 RESULT 905
 AAS04346/c
 ID AAS04346 standard; DNA; 15 BP.
 XX
 AC AAS04346;
 DT 07-SEP-2001 (first entry)
 XX Human DAXX DNA allele-specific oligonucleotide primer #9.
 DE Death-associated protein 6; DAXX; polymorphism; haplotype pair; human;
 XX immune disorder; autoimmune disease; population diversity; ss;
 KW paternity testing; anthropological lineage; forensic application;
 KW oligonucleotide primer
 XX Homo sapiens.
 OS WO200125245-A2.
 XX 12-APR-2001.
 PD 05-OCT-2000; 2000WO-US027487.
 XX 06-OCT-1999; 99US-0157909P.
 PR (GENA-) GENAISSANCE PHARM INC.
 XX Chew A, Choi JY, Denton RR, Nandabalan K, Stephens JC;
 PI WPI; 2001-308220/32.
 XX New human death-associated protein 6 (DAXX) gene variants comprising 19
 DR polymorphic sites useful in studying the effect of variation on the
 PT biological activity of DAXX and in developing drugs targeting the
 PT protein.
 XX Claim 15; Page 19; 97pp; English.
 PS

Sequences AAS04338-AAS04413 represent oligonucleotide primers specific for a DNA encoding human death-associated protein 6 (DAXX). This DNA may comprise one or more polymorphisms at specific nucleotide positions to form one of nineteen possible polymorphic variants. Associations between a trait and a genotype or a haplotype of the DAXX gene can be identified by comparing the frequency of the genotype or haplotype in a population exhibiting the trait with that of a reference population. A higher frequency in the trait population indicates an association. Methods involving genotyping or haplotyping of the DAXX gene of an individual can lead to prediction of haplotype pairs for the DAXX gene of an individual can individuals, and may be useful in studying the expression and biological function of DAXX, as well as in developing drugs targeting this protein. Polymorphic variants of DAXX are useful in studying the effect of the variation on the biological activity of DAXX as well as on the binding affinity of candidate drugs targeting DAXX for the treatment of autoimmune diseases and other immune disorders. Polymorphism is also useful for studying population diversity, anthropological lineage, paternity testing, forensic applications, and for identifying associations between the DAXX genetic variation and a trait such as level of drug response or susceptibility to disease. DAXX proteins may be used to measure binding affinities of one or more candidate drugs targeting the DAXX protein

Sequence 15 BP; 3 A; 10 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1632 GATGGGCTGTAG 1645
 Db 15 GGTGGGCTGGAG 2
 |||||

RESULT 906
 AAF51267/C
 ID AAF51267 standard; DNA; 15 BP.
 XX
 AC AAF51267;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #2227.

Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

Homo sapiens.
 WO200078341-A1.
 28-DEC-2000.
 21-JUN-2000; 2000WO-AU000693.
 21-JUN-1999; 99US-0140345P.
 (MURD-) MURDOCH CHILDRENS RES INST.

Wright CJ, Werther GA, Edmondson SR;
 WPI; 2001-041421/05.
 Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

Example 8; Page 86; 201pp; English.
 The present invention relates to a method for ameliorating the effects of

XX Example 8; Page 75; 201pp; English.
 PS

The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

Sequence 15 BP; 3 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1719 ACGGAGTGGAGAT 1732
 Db 14 ACGAAGATGGAGTT 1
 |||||

RESULT 907
 AAF52888
 ID AAF52888 standard; DNA; 15 BP.
 XX
 AC AAF52888;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #3848.

Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

Homo sapiens.
 WO200078341-A1.
 28-DEC-2000.
 21-JUN-2000; 2000WO-AU000693.
 21-JUN-1999; 99US-0140345P.
 (MURD-) MURDOCH CHILDRENS RES INST.

Wright CJ, Werther GA, Edmondson SR;
 WPI; 2001-041421/05.
 Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

Example 8; Page 86; 201pp; English.
 The present invention relates to a method for ameliorating the effects of

CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1721 GGAGATGGAGATTG 1734
 DB 2 GGAGATGGAGCTG 15
 RESULT 908
 AAF45991/c
 ID AAF45991 standard; DNA; 15 BP.
 XX AAF45991;
 XX 30-MAR-2001 (first entry)
 XX IGFBP2 oligonucleotide #830.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU0000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 6; Page 39; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 3 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1726 TGGAGATGGCTCC 1739
 DB 15 TGGAGATCCGCTCC 2
 RESULT 909
 AAF52892
 ID AAF52892 standard; DNA; 15 BP.
 XX AAF52892;
 XX 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #3852.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU0000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 8; Page 86; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC F45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1724 GATGGAGATTGGCT 1737
 Db 1 GATGGAGCTGGCT 14

RESULT 910
 AAF51599/c
 ID AAF51599 standard; DNA; 15 BP.

XX AC AAF51599;

XX DT 30-MAR-2001 (first entry)

XX DE IGF-I oligonucleotide #2559.

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU000693.

XX PR 21-JUN-1999; 99US-0140345P.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wright CJ, Werther GA, Edmondson SR;

XX PT WPI; 2001-041421/05.

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX PS Example 8; Page 77; 201pp; English.

XX CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic

CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1732 TTGGTCTCCCACTC 1745
 Db 14 TTGGTCTCCAGGTC 1

RESULT 911
 AAF47177/c
 ID AAF47177 standard; DNA; 15 BP.

XX AC AAF47177;

XX DT 30-MAR-2001 (first entry)

XX DE IGFBP3 oligonucleotide #597.

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU000693.

XX PR 21-JUN-1999; 99US-0140345P.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wright CJ, Werther GA, Edmondson SR;

XX PT WPI; 2001-041421/05.

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX PS Example 7; Page 48; 201pp; English.

XX CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX SQ Sequence 15 BP; 3 A; 9 C; 1 G; 2 T; 0 U; 0 Other;

1719 ACGGAGTGGAGAT 1732
||| |||||
15 ACGAGATGGAGTT 2

Db

RESULT 913
AAF47173/C
ID AAF47173 standard; DNA; 15 BP.
XX AC AC
XX AAF47173;
XX AC AC
DT 30-MAR-2001 (first entry)
XX AC AC
XX IGFBP3 oligonucleotide #593.
DE XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX AC AC
XX Homo sapiens.
OS XX
XX WO200078341-A1.
PN XX
XX 28-DEC-2000.
PD XX
XX 21-JUN-2000; 2000WO-AU000693.
PF XX
XX 21-JUN-1999; 99US-0140345P.
PR XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI WPI; 2001-041421/05.
DR XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX XX
XX Example 7; Page 48; 201pp; English.
PS XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX XX
XX Sequence 15 BP; 4 A; 6 C; 2 G; 3 T; 0 U; 0 Other;
SQ

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	1699	GTGGAACTTGGGAT	1712
DB	15	GTGGAACTTGGGAT	2

```
RESULT 914
AAF51501
ID AAF51501 standard; DNA; 15 BP.
AC AAF51501;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #2461.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 77; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC R45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1652 GCAAGCACCAGGCT 1665
Db 2 GCAACCCAGGCT 15
RESULT 915
AAF45992/c
ID AAF45992 standard; DNA; 15 BP.
XX
XX AAF45992;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #831.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
PN
XX 28-DEC-2000.
PD
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 6; Page 39; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC R45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1726 TGGAGATTCGCTCC 1739
Db 14 TGGAGATTCGCTCC 1
RESULT 916
AAF51598/c
ID AAF51598 standard; DNA; 15 BP.
XX
XX AAF51598;
XX
XX AAF51598;
XX
```

KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.
XX	Homio sapiens.
OS	WO200078341-A1.
XX	28-DEC-2000.
PD	21-JUN-2000; 2000WO-AU000693.
XX	21-JUN-1999; 99US-014345P.
PF	(MURD-) MURDOCH CHILDRENS RES INST.
XX	Wright CJ, Werther GA, Edmondson SR;
PI	WPI; 2001-041421/05.
XX	Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.
PT	Example 8; Page 75; 201pp; English.
XX	The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-145161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia
CC	Sequence 15 BP; 2 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
XX	Query Match 7.6%; Score 10.8; DB 1; Length 15;
CC	Best Local Similarity 85.7%; Pred. No. 5.4e+02;
XX	Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0
QY	1717 GTACGGAGATGGAG 1730
DB	15 GCACGAAGATGGAG 2
XX	RESULT 918
AA	AAF51502
ID	AAF51502 standard; DNA; 15 BP.
XX	AAF51502;
AC	30-MAR-2001 (first entry)
XX	IGF-I oligonucleotide #2462.
DT	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX	

DT	30-MAR-2001	(first entry)	
XX			
XX	IGF-I oligonucleotide #2558.		
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;		
KW	cytostatic; dermatological; cardiact; virucide; ophthalmological; keloid;		
KW	skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;		
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;		
KW	growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;		
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;		
KW	hyperneovascular condition; hyperplasia; kidney disease;		
XX	neovascular condition of the retina; ss.		
OS	Homo sapiens.		
XX	WO200078341-A1.		
XX	28-DEC-2000.		
XX	21-JUN-2000; 2000MO-AU000693.		
XX	21-JUN-1999; 99US-0140345P.		
XX	(MURD-) MURDOCH CHILDRENS RES INST.		
XX	Wright CJ, Werther GA, Edmondson SR;		
XX	WPT; 2001-041421/05.		
XX	Ameliorating the effects of a disorder, e.g. psoriasis, by administering		
PT	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that		
PT	inhibits or reduces growth factor mediated cell proliferation and/or		
PT	inflammation.		
XX	Example 8; Page 77; 201pp; English.		
PS	The present invention relates to a method for ameliorating the effects of		
CC	skin disorders. The method comprises contacting the skin with an		
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1		
CC	receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of		
CC	inhibiting or reducing growth factor mediated cell proliferation,		
CC	inflammation and/or other disorders. The present sequence is an		
CC	oligonucleotide which can be used to design the antisense		
CC	oligonucleotides of the present invention (see AAF45151 and AAF45153-		
CC	F45161). The method is useful for ameliorating the effects of psoriasis,		
CC	ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,		
CC	neoplasias, scleroderma, warts, benign growths, cancers of the skin, a		
CC	neovascular condition such as a neovascular condition of the retina,		
CC	brain or skin, growth factor-mediated malignancies, other sclerotic		
CC	disease, kidney disease, hyperproliferation of the inside of blood		
CC	vessels or any other hyperplasia		
XX	Sequence 15 BP; 4 A; 4 C; 5 G; 2 T; 0 U; 0 Other;		
XX	Query Match 7.8%; Score 10.8; DB 1; Length 15;		
XX	Best Local Similarity 85.7%; Pred. No. 5.4e+02;		
XX	Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	1732 TTGGCTCCCACTC 1745		
Db	15 TTGGCTCCCACTC 2		
XX	RESULT 917		
XX	AAF51268/c		
ID	AAF51268 standard; DNA; 15 BP.		
XX	AAF51268;		
XX	AAF51268;		
XX	30-MAR-2001 (first entry)		
XX	IGF-I oligonucleotide #2228.		

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 OS Homo sapiens.
 PN WO200078341-A1.
 XX 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 8; Page 77; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 4 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.46+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1652 GCAAGCACCAGGCT 1665
 Db 1 GCAACCCAGGCT 14
 RESULT 919
 AAF51269/C
 ID AAF51269 standard; DNA; 15 BP.
 XX AAF51269;
 XX 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #2229.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.
 XX WO200078341-A1.
 XX 28-DEC-2000.
 XX 21-JUN-2000; 2000WO-AU000693.
 XX 21-JUN-1999; 99US-0140345P.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 8; Page 75; 201pp; English.
 XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 1 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred. No. 5.46+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1717 GTACGGAGATGGAG 1730
 Db 14 GCACGAGATGGAG 1
 RESULT 920
 AAF69956
 ID AAF69956 standard; DNA; 15 BP.
 XX AAF69956;
 XX 18-APR-2001 (first entry)
 XX Human TNFRSF11B gene ASO probe, SEQ ID NO: 12.
 XX Human; TNFRSF11B; osteoclastogenesis inhibitory factor;
 KW single nucleotide polymorphism; SNP; osteoclast recruitment;
 KW osteoclast function; osteoporosis; metastatic bone disease;
 KW Pager's disease; rheumatoid arthritis; periodontal bone disease;
 KW allele-specific oligonucleotide; probe; ss.
 XX Homo sapiens.
 XX WO200104137-A1.
 XX 18-JAN-2001.

Mon Aug 30 09:26:45 2004

receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference sequence). Polynucleotides comprising polymorphic gene variants are useful for therapeutic purposes. For example, where a patient may benefit from expression of a particular IL4Ralpha protein isoform, an expression vector encoding the isoform may be administered to the patient. It may be desirable to decrease or block expression of a particular IL4Ralpha isoform, which may be done by turning off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA for the isogene. Specific therapeutics identified by these methods may be useful for allergic diseases. The present sequence is a probe for human IL4R-alpha

Sequence 15 BP; 3 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1728 GAGATTGGCTCCCA 1741
Db 15 GAGCTTGGCTCCCA 2
|||||
|||||

RESULT 922
AAH49214
ID AAH49214 standard; DNA; 15 BP.

XX AC AAH49214;
XX DT 26-NOV-2001 (first entry)
XX DE Anti-c-Ha-ras oligonucleotide VIII.
XX KW Polyamide-oligonucleotide derivative; anticancer; antiproliferative;
KW antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;
KW integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;
KW peptide nucleic acid; ss.
XX OS Synthetic.
XX PN EP1113021-A2.
XX PD 04-JUL-2001.
XX PF 08-MAR-1995; 2001EP-00104012.
XX PR 14-MAR-1994; 94DE-04408528.
XX PR 08-MAR-1995; 95EP-00103332.
XX PA (AVET) AVENTIS PHARMA DEUT GMBH.
XX PI Uhlmann E, Breipohl G.
XX DR WPI; 2001-591267/67.
XX PT New DNA-peptide nucleic acid chimeras, useful e.g. as antisense agents
XX for treating e.g. cancer, also as diagnostic probes and primers.
XX PS Disclosure; Page 22; 54pp; German.
XX CC This invention describes novel polyamide-oligonucleotide derivatives (I)
CC and their physiologically acceptable salts of formula F(DNA-Li).q(PNA-
CC Li) r(DNA-Li) s(PNA) t) xP' where q, r, s, t = 0 or 1, with the sum of
CC two or more adjacent "l" letters at least 2; x = 1-20; DNA = nucleic acid
CC (such as DNA or RNA or their known derivatives); Li = covalent linkage
CC between DNA and PNA, i.e. a bond or a residue containing at least one
CC atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure
CC containing at least one nucleobase different from thymine; and F, P' =
CC end groups and/or are connected through a covalent bond. The products of
CC the invention have anticancer, antiproliferative, antiviral, hepatotropic
CC and vasotropic activity and can be used for the inhibition of gene
CC expression by antisense, ribozyme, sense, or triple-helix methods, or by
CC binding to proteins (aptamers). (I) are used for treating diseases caused

receptor-alpha gene (IL4R-alpha; see AAF57718 for the reference sequence). Polynucleotides comprising polymorphic gene variants are useful for therapeutic purposes. For example, where a patient may benefit from expression of a particular IL4Ralpha protein isoform, an expression vector encoding the isoform may be administered to the patient. It may be desirable to decrease or block expression of a particular IL4Ralpha isoform, which may be done by turning off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA for the isogene. Specific therapeutics identified by these methods may be useful for allergic diseases. The present sequence is a probe for human IL4R-alpha

Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCTGGTGTCTCCT 1690
Db 2 CCTGGTGTCTCCT 15
|||||
|||||

RESULT 921
AAF69487/c
ID AAF69487 standard; DNA; 15 BP.
XX AC AAF69487;
XX DT 18-APR-2001 (first entry)
XX DE Human IL4Ralpha gene probe #127.
XX KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
KW allergic disease; probe; ss.
XX OS Homo sapiens.
XX PN WO200104270-A1.
XX PD 18-JAN-2001.
XX PF 13-JUL-2000; 2000WO-US019094.
XX PR 13-JUL-1999; 99US-0143435P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI Windemuth AK;
XX WPI; 2001-103078/11.
XX CC New isolated polynucleotide useful for the identification of therapeutics
XX in allergic diseases is new.
XX PS Claim 15; Page 44; 168pp; English.
XX CC The present invention relates to polymorphisms of the human interleukin 4

Human Osteoclastogenesis Inhibitory Factor nucleotides, comprising single nucleotide polymorphisms, useful for studying e.g. osteoporosis, Paget's disease and rheumatoid arthritis.

Claim 15; Page 21; 114pp; English.

The present sequence is a probe used to detect polymorphisms in the human osteoclastogenesis inhibitory factor (TNFRSF11B). Polynucleotides comprising one or more of twenty four novel single nucleotide polymorphisms in the TNFRSF11B gene have been identified. TNFRSF11B regulate osteoclast recruitment and function. An understanding of variations in the gene should thus be useful in developing new therapies for metabolic disorders caused by abnormal osteoclast recruitment and function such as osteoporosis, metastatic bone disease, Paget's disease, rheumatoid arthritis and periodontal bone disease

Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCTGGTGTCTCCT 1690
Db 2 CCTGGTGTCTCCT 15
|||||
|||||

RESULT 921
AAF69487/c
ID AAF69487 standard; DNA; 15 BP.
XX AC AAF69487;
XX DT 18-APR-2001 (first entry)
XX DE Human IL4Ralpha gene probe #127.
XX KW Polymorphism; human; interleukin 4 receptor-alpha; IL4R-alpha;
KW allergic disease; probe; ss.
XX OS Homo sapiens.
XX PN WO200104270-A1.
XX PD 18-JAN-2001.
XX PF 13-JUL-2000; 2000WO-US019094.
XX PR 13-JUL-1999; 99US-0143435P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI Windemuth AK;
XX WPI; 2001-103078/11.
XX CC New isolated polynucleotide useful for the identification of therapeutics
XX in allergic diseases is new.
XX PS Claim 15; Page 44; 168pp; English.
XX CC The present invention relates to polymorphisms of the human interleukin 4

CC by viruses (human immune deficiency, herpes simplex, influenza, vesicular
 CC stomatitis, hepatitis B or papilloma), or mediated by integrins or cell-
 CC cell adhesion reactions, for treating cancer, or for inhibiting
 CC restenosis, particularly as antisense reagents. They are also useful in
 CC heterogeneous or homogeneous assays, as primers or probes, particularly
 CC where the target is amplified before being detected by hybridization, for
 CC diagnosis of genetic, malignant or pathogen-related diseases. (I) retain
 CC the increased affinity for complementary strands and better stability in
 CC serum, associated with conventional peptide nucleic acids (PNA), but lack
 CC the disadvantages, i.e. have improved cellular uptake, do not aggregate
 CC in aqueous solution, and have reduced affinity for purification
 CC materials, reduced cytotoxicity, better sequence specificity. They are
 CC more active than either DNA or PNA oligomers. When used as probes, (I)
 CC show different responses to base-pair mismatches in the DNA and PNA
 CC segments, allowing better discrimination between pathogenic and non-
 CC pathogenic conditions such as the transition from proto-oncogene to
 CC oncogene, also, when used as primers, with the PNA segment at the 5'-end,
 CC they produce amplicons resistant to 5'-exonuclease, allowing this enzyme
 CC to be used to eliminate RNA or DNA primers. The DNA component allows
 CC additional reactions not possible with PNA alone, e.g. 3'-tailing and (I)
 CC may be incorporated into a gene. AAH49208-AAH49264 represent
 CC oligonucleotides used to illustrate the method of the invention
 XX
 SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAAACCTG 1681
 ||||| |||||
 Db 1 CAGCTGCAACCCAG 14

RESULT 923

ABL01599
 ID ABL01599 standard; DNA; 15 BP.
 XX
 AC ABL01599;
 XX
 DT 15-MAR-2002 (first entry)
 XX
 DE c-Ha-ras targeted antisense peptide nucleic acid SEQ ID NO: 5.
 XX
 KW Peptide nucleic acid; PNA; cytosstatic; virucide; dermatological;
 KW antiasthmatic; overexpression; viral infection; vitiligo; antisense;
 KW pigmentation disorder; asthma; polyamide backbone; ss.
 XX
 OS Unidentified.

Key Location/Qualifiers
 modified_base 1..15
 FT /*tag= a
 FT /note= "This sequence is a peptide nucleic acid, i.e. it
 FT contains a polyamide backbone instead of a deoxyribose
 FT backbone"
 FT modified_base 1
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "linked to one of the peptides shown in ABR04517
 FT and ABR04518 to form a PNA-peptide conjugate"
 XX

W0200179216-A2.

25-OCT-2001.

07-APR-2001; 2001WO-EP004030.

18-APR-2000; 2000DE-01019135.

(AVET) AVENTIS PHARMA DEUT GMBH.

Uhlmann E, Breipohl G, Will DW;

XX WPI; 2002-075055/10.
 DR

XX New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
 PT diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
 PT improved solubility.

XX Disclosure; Page 19; 93pp; German.

XX The present invention relates to peptide nucleic acid (PNA) derivatives
 CC having at the C-, and optionally N-, terminus one or more phosphoryl
 CC groups, at least one of which contains one or more deprotonisable groups,
 CC preferably hydroxy or mercapto. These PNAs are useful in the treatment of
 CC tumours or any disease associated with (over)expression of particular
 CC genes, including viral infections, vitiligo or other pigmentation
 CC disorders, and asthma. The present sequence is a peptide nucleic acid
 CC described in the exemplification of the invention

SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
 Best Local Similarity 85.7%; Pred No. 5.4e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAAACCTG 1681
 ||||| |||||
 Db 1 CAGCTGCAACCCAG 14

RESULT 924

ABA97499
 ID ABA97499 standard; DNA; 15 BP.

XX ABA97499;

DT 16-APR-2002 (first entry)

DE c-Ha-ras targeted antisense peptide nucleic acid SEQ ID NO: 45.

XX Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
 KW cytosstatic; virucide; dermatological; antiasthmatic; cancer; antisense;
 KW viral infection; vitiligo; pigmentation disorder; asthma; ss.

OS Unidentified.

OS Synthetic.

PN W0200179249-A2.

PD 25-OCT-2001.

07-APR-2001; 2001WO-EP004027.

18-APR-2000; 2000DE-01019136.

(AVET) AVENTIS PHARMA DEUT GMBH.

Uhlmann E, Breipohl G, Will DW;

WPI; 2002-089643/12.

XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.

XX Disclosure; Page 90; 96pp; German.

XX The present invention relates to peptide nucleic acid (PNA) derivatives.
 CC These can be used in the treatment of cancer, viral infections, vitiligo
 CC or other pigmentation disorders, and asthma. The present sequence is an
 CC oligonucleotide fragment of a PNA described in the exemplification of the
 CC invention

XX Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Mon Aug 30 09:26:45 2004

```

CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC The polymorphisms in the human genes cited in the invention are useful as
CC genetic linkage markers for locating and characterizing the genes that
CC are responsible for specific traits within the genome and eventually
CC identifying the genes responsible for a variety of disorder-related
CC traits as a result of their e.g., overexpression, constitutive
CC expression, mutation or underexpression. The nucleic acid molecules comprising the
CC and/or treating the disorders. The nucleic acid molecules comprising the
CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,
CC ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC used to screen for altered cardiovascular function, in COX2 for altered central
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC nervous system function, in FLAP and HNNMT for altered pulmonary,
CC immunological or haematological function, in KUK2 for altered serine
CC protease activity in the prostate, in LTF for altered immunological or
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC peripheral nervous system function. The present sequence represents a PCR
CC primer used to amplify the sequences of the invention
XX
SQ Sequence 15 BP; 3 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1724 GATGGAGATGGCT 1737
Db 1 GAGGGAGATGGCT 14

RESULT 926
AAL46735
ID AAL46735 standard; DNA; 15 BP.
XX
AC AAL46735;
XX
XX 08-AUG-2002 (first entry)
DT
DE c-Ha-ras antisense oligonucleotide #1.
XX
XX Modified antisense oligonucleotide; antisense; cancer; infection;
XX cytostatic; virucide; anti-HIV; hepatotropic; antiinflammatory; c-Ha-ras;
XX phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers
XX modified_base 1..7
XX /*tag= a
XX /mod_base= OTHER
XX /note= "optionally phosphorothioate backbone"
XX modified_base 10..14
XX /*tag= b
XX /mod_base= OTHER
XX /note= "optionally phosphorothioate backbone"
XX
XX EPI182206-A2.
XX
XX 27-FEB-2002.
XX
XX 07-NOV-1994; 2001EP-00124078.
XX
XX 12-NOV-1993; 93DE-04338704.
XX 07-NOV-1994; 94EP-00117513.
XX (FARH ) HOECHST AG.
XX
XX
XX

```

```

CC CC
CC Query Match 7.8%; Score 10.8; DB 1; Length 15;
CC Best Local Similarity 85.7%; Pred. No. 5.4e+02;
CC Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1668 CAGCTGGACCCCTG 1681
Db 1 CAGCTGCAACCCG 14

RESULT 925
ABS97484
ID ABS97484 standard; DNA; 15 BP.
XX
AC ABS97484;
XX
XX 23-DEC-2002 (first entry)
DT
DE Human epoxide hydroxylase 2 PCR primer #11.
XX
XX Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
XX cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
XX adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NRI12;
XX aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
XX cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
XX NNMT; Kallikrein 2; KUK2; nicotinamide-N-methyl transferase; NNMT;
XX NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
XX UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
XX UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
XX multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
XX multidrug resistance associated protein 3; cancer; prostate;
XX acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
XX altered drug metabolism; cardiovascular function; colorectal tumour;
XX central nervous system; pulmonary; immunological.
XX
XX Homo sapiens.
XX
XX WO200257410-A2.
XX
XX 25-JUL-2002.
XX
XX 28-NOV-2001; 2001WO-US044838.
XX
XX 28-NOV-2000; 2000US-00724389.
XX
XX (DNAS-) DNA SCI LAB INC.
XX
XX Guida M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX
XX Example 10; Page 116; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
XX cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (NNMT), (kallikrein 2) KUK2, nicotinamide -N-methyl
XX sulfotransferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
XX sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
XX

```

PI Peymann A, Uhlmann E, Mag M, Kretschmar G, Helsberg M, Winkler I;
XX WPI; 2002-353922/39.
XX
PT New nuclease-resistant oligonucleotides having modified non-terminal
PT Pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
PT diseases or as diagnostic reagents.
XX
PS Disclosure; Page 9; 19pp; German.
XX
XX The present invention relates to oligonucleotides having at least one non
CC -terminal pyrimidine nucleoside modified and additionally having the 5'-
CC and/or 3'-terminal modified. These can be used in the treatment of viral
CC infections, such as HIV, HSV-1, HSV-2, influenza virus, VSV, hepatitis B
CC and papilloma viruses, cancer and diseases involving integrins and cell-
CC cell adhesion receptors. The present sequence is an antisense
CC oligonucleotide of the invention
XX
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1668 CAGCTGGACCCCTG 1681
Db 1 CAGCTGGACCCAG 14
RESULT 927
ACD82348/c
ID ACD82348 standard; DNA; 15 BP.
XX AC
AC ACD82348;
XX
DT 19-SEP-2003 (first entry)
XX
DE Nucleic acid cloning associated adaptor molecule #49.
XX
KW Adaptor molecule; nucleic acid cloning; nucleic acid ligation;
KW internal deletion mutagenesis analysis; cloning vehicle; ss.
OS Synthetic.
XX
XX US2003044791-A1.
FN
PD 06-MAR-2003.
XX
PF 13-JUN-2001; 2001US-00880313.
XX
PR 13-JUN-2001; 2001US-00880313.
XX
XX (FLEM/) FLEMINGTON E K.
PA
PI Flemington EK;
XX
XX WPI; 2003-521745/49.
DR
XX
PT New adaptor molecules, useful for cloning nucleic acid molecules that
PT does not require the design and synthesis of oligonucleotides or PCR
PT primers.
XX
PS Claim 12; Fig 1; 100pp; English.
XX
XX The invention describes adaptor molecules, where each end of the adaptor
CC is compatible with a nucleic acid digested with a restriction enzyme or a
CC nucleic acid comprising an end that is compatible with a nucleic acid
CC digested with a restriction enzyme. The adaptor molecules, compositions,
CC kits and arrays are useful for cloning nucleic acid molecules that does
CC not require the design and synthesis of oligonucleotides or PCR primers.
CC The adaptors, kits and arrays are also useful for ligating two ends of a
CC single nucleic acid molecule, or ligating two or more nucleic acid
CC molecules. The kits can also be used for performing internal deletion

CC mutagenesis analysis. The adaptor molecules are ligated to a cloning
CC vehicle, making the cloning procedure more rapid and efficient, and less
CC error-prone. This sequence represents a nucleic acid cloning associated
CC adaptor molecule
XX
SQ Sequence 15 BP; 2 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1644 AGCAGAGGCAAGC 1657
Db 15 AGCTGAGGCAAGC 2
RESULT 928
ADC84126/c
ID ADC84126 standard; DNA; 15 BP.
XX AC
AC ADC84126;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human papillomavirus type 61 (HPV 61) detection oligonucleotide #1.
XX
KW probe; human papilloma virus; HPV; detection; identification; ss.
XX
OS Human papillomavirus type 61.
XX
FN EP1302550-A1.
XX
PD 16-APR-2003.
XX
PF 10-OCT-2001; 2001EP-00123379.
XX
PR 10-OCT-2001; 2001EP-00123379.
XX
XX (KING-) KING CAR FOOD IND CO LTD.
XX
XX Lin C, Lin R, You C, Huang H, Lee B, Lee H, Lin Y, Fan C;
PI Hsu H, Shih C, Yeh C, Kao Y, Pan C, Chan P;
XX
XX WPI; 2003-432398/41.
DR
XX
XX Detector for identifying human papilloma virus subtypes, comprises
PT carrier having two parts carrying first and second oligonucleotides that
PT respectively hybridize with DNA contained in first and second subtypes of
PT the virus.
XX
PS Claim 4; SEQ ID NO 356; 221pp; English.
XX
XX The invention comprises oligonucleotides for detecting and identifying
CC subtypes of human papilloma virus (HPV) contained in a sample. The
CC oligonucleotides of the invention are useful for simultaneously detecting
CC and identifying subtypes of HPVs. The present DNA sequence represents an
CC HPV detection oligonucleotide of the invention.
XX
SQ Sequence 15 BP; 2 A; 9 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 5.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1635 GGGGCTGTAGCAG 1648
Db 14 GGGGATGTAGCAG 1
RESULT 929
AAQ29796/c
ID AAQ29796 standard; DNA; 16 BP.
XX

XX 07-MAY-1991; 91US-00636793.
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX Saiki RK, Nasarabadi SL;
XX WPI; 1992-374679/46.
XX
XX Determn. of an individuals genotype at the gamma-globin locus - using
XX sequence-specific oligo-nucleotide probes corresp. to 3 alleles.
XX
XX Disclosure; Page 14; 29pp; English.
XX
XX The sequences given in AAQ29787-816 are probes which were used within the
XX method of the invention for detecting the presence of a variant sequence
XX in the G-gamma globulin (GGG) locus. The A, B and C alleles can be
XX distinguished from one another by the polymorphic sequence corresponding
XX to the HindIII site of the A allele. The sequences of the three alleles
XX are given in AAQ29842-44. The methods for determining an individuals
XX genotype at the GGG locus with respect to a set of alleles improves the
XX discriminatory power of GGG typing methodology compared to previous
XX methods using two alleles. (Updated on 25-MAR-2003 to correct FN field.)
XX
XX Sequence 16 BP; 4 A; 9 C; 1 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.8%; Score 10.8; DB 1; Length 16;
XX Best Local Similarity 85.7%; Pred. No. 5.8e+02;
XX Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1698 GGTGGAAAGTTGGG 1711
XX |||||
XX 15 GTTGGAAAGTTGGT 2
XX
XX RESULT 931
XX AAQ29787/c
XX ID AAQ29787 standard; DNA; 16 BP.
XX AC AAQ29787;
XX XX
XX 25-MAR-2003 (revised)
XX 19-MAR-1993 (first entry)
XX XX
XX A allele probe SN27.
XX G-gamma globulin; GGG; polymorphism; HindIII; A allele; B; C; genotype;
XX paternity; forensic; ss.
XX OS Synthetic.
XX PN EP512342-A2.
XX PD 11-NOV-1992.
XX XX
XX 25-APR-1992; 92EP-00107084.
XX XX
XX 07-MAY-1991; 91US-00396793.
XX XX
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX XX
XX Saiki RK, Nasarabadi SL;
XX WPI; 1992-374679/46.
XX
XX Determn. of an individuals genotype at the gamma-globin locus - using
XX sequence-specific oligo-nucleotide probes corresp. to 3 alleles.
XX
XX Disclosure; Page 13; 29pp; English.
XX
XX The sequences given in AAQ29787-816 are probes which were used within the
XX method of the invention for detecting the presence of a variant sequence
XX in the G-gamma globulin (GGG) locus. The A, B and C alleles can be

CC distinguished from one another by the polymorphic sequence corresponding
 CC to the HindIII site of the A allele. The sequences of the three alleles
 CC are given in AAQ29842-44. The methods for determining an individual's
 CC genotype at the GGG locus with respect to a set of alleles improves the
 CC discriminatory power of GGG typing methodology compared to previous
 CC methods using two alleles. (Updated on 25-MAR-2003 to correct PN field.)
 SQ Sequence 16 BP; 5 A; 8 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
 Best Local Similarity 85.7%; Pred. No. 5.8e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGT 1685
 Db 15 TGGAACTTGGTGT 2

RESULT 932
 AAQ29809/c
 ID AAQ29809 standard; DNA; 16 BP.

AC AAQ29809;

DT 25-MAR-2003 (revised)

DT 19-MAR-1993 (first entry)

DE C allele probe RS339.

DE C allele probe RS339.

KW G-gamma globulin; GGG, polymorphism; HindIII; A allele; B; C; genotype;
 KW paternity; forensic; ss.

OS Synthetic.

OS EP512342-A2.

PN 11-NOV-1992.

PN 25-APR-1992; 92EP-00107084.

PN 07-MAY-1991; 91US-00696793.

PN (HOFF) HOFFMANN LA ROCHE & CO AG F.

PI Saiki RK, Nasarabadi SL;

PI WPI; 1992-374679/46.

PT Determn. of an individuals genotype at the gamma-globin locus - using

PT sequence-specific oligo-nucleotide probes corres. to 3 alleles.

PT Disclosure; Page 18; 29pp; English.

PS The sequences given in AAQ29787-816 are probes which were used within the
 PS method of the invention for detecting the presence of a variant sequence
 PS in the G-gamma globulin (GGG) locus. The A, B and C alleles can be
 PS distinguished from one another by the polymorphic sequence corresponding
 PS to the HindIII site of the A allele. The sequences of the three alleles
 PS are given in AAQ29842-44. The methods for determining an individual's
 PS genotype at the GGG locus with respect to a set of alleles improves the
 PS discriminatory power of GGG typing methodology compared to previous
 PS methods using two alleles. (Updated on 25-MAR-2003 to correct PN field.)
 SQ Sequence 16 BP; 6 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
 Best Local Similarity 85.7%; Pred. No. 5.8e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGT 1685
 Db 15 TGGAACTTGGTGT 2

RESULT 933
 AAT53422

ID AAT53422 standard; RNA; 16 BP.

AC AAT53422;

AC AAT53422;

DT 25-MAR-2003 (revised)

DT 25-MAR-1997 (first entry)

DE Rat-ICAM hairpin ribozyme target sequence (nt. position 1858).

DE Rat-ICAM hairpin ribozyme target sequence (nt. position 1858).

KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.

OS Rattus rattus.

OS WO9523225-A2.

PN 31-AUG-1995.

PN 23-FEB-1995; 95WO-IB000156.

PN 23-FEB-1994; 94US-00201109.

PN 29-MAR-1994; 94US-00218934.

PN 04-APR-1994; 94US-00222795.

PN 07-APR-1994; 94US-00224483.

PN 15-APR-1994; 94US-00227958.

PN 15-APR-1994; 94US-00228041.

PN 18-MAY-1994; 94US-00245736.

PN 06-JUL-1994; 94US-00271280.

PN 15-AUG-1994; 94US-00291932.

PN 16-AUG-1994; 94US-00291433.

PN 17-AUG-1994; 94US-00292620.

PN 19-AUG-1994; 94US-00293520.

PN 02-SEP-1994; 94US-00300000.

PN 08-SEP-1994; 94US-00303039.

PN 23-SEP-1994; 94US-00311486.

PN 28-SEP-1994; 94US-00311749.

PN 03-OCT-1994; 94US-00316771.

PN 07-OCT-1994; 94US-00319492.

PN 11-OCT-1994; 94US-00321993.

PN 04-NOV-1994; 94US-00334847.

PN 10-NOV-1994; 94US-00337608.

PN 28-NOV-1994; 94US-00345516.

PN 16-DEC-1994; 94US-00357577.

PN 23-DEC-1994; 94US-00363233.

PN 30-JAN-1995; 95US-00380734.

PN (RIBO-) RIBOZYME PHARM INC.

PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LM;

PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;

PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;

PI Tracz D, Usman N, Wincott FE, Woolf T;

PI WPI; 1995-351090/45.

PI Ribozymes having modified bases and methods for producing them - for use

PI in inhibiting disease related genes.

PS Claim 2; Page 200; 407pp; English.

CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX

SQ Sequence 16 BP; 2 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 5.8e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1689 CTCACGCGTGGTGG 1702
|: ||||| :||:|
Db 1 CUACAGCCUGGUGG 14

RESULT 934
AAT70568/c
ID AAT70568 standard; DNA; 16 BP.

XX AAT70568;
AC
DT 04-NOV-1997 (first entry)

XX Haemoglobin G gamma-globin allele A-specific probe.

XX Glycophorin A: sialoglycoprotein; human; erythrocyte; membrane;
KW M blood group antigen; N blood group antigen; allele A; B; A'; A''; B';
KW polymorphism; detection; sequence-specific oligonucleotide probe;
KW genotype; forensic; primer; PCR; polymerase chain reaction; amplify; ss.
XX Synthetic.

XX US5643724-A.

XX 01-JUL-1997.

XX 06-JUN-1994; 94US-00255264.

XX 06-JUN-1994; 94US-00255264.

XX (HOFF) ROCHE MOLECULAR SYSTEMS INC.

XX Fildes NJ, Reynolds RL;

XX WPI; 1997-350231/32.

XX Detection of glycophorin A allele(s) - by hybridisation assay using
PT sequence-specific oligo:nucleotide probes.

XX Example 3; Col 15-16; 16pp; English.

XX Glycophorin A is a major sialoglycoprotein of the human erythrocyte
CC membrane. Glycophorin A carries the M or N blood group antigen, which is
CC determined by the amino acid at residues 1 and 5. Allele A encodes the
CC protein carrying the M blood group antigen and allele B encodes the
CC protein carrying the N blood group antigen. Three additional alleles have
CC been discovered, designated A', A'', and B'. Detecting an A', A'' or B'
CC allele of the Glycophorin A locus in a human nucleic acid sample
CC comprises mixing the sample under stringent hybridisation conditions with
CC a sequence-specific oligonucleotide probe that distinguishes the A', A''
CC or B' allele from A and B alleles, and detecting any hybridisation. The
CC method and probes are used for determining an individual's Glycophorin A
CC genotype, especially useful for determining individual identity for
CC forensic purposes. AAT70558-67 (and also AAT70582-83) are primers from

CC the AmpliType (R) PM kit used in a Glycophorin A typing system developed
CC by Hoffmann-La Roche. The primers direct the simultaneous amplification
CC of specific regions of the following six genetic loci: Glycophorin A, HLA
CC DQA1, Low density lipoprotein receptor, Haemoglobin G gamma-globin, D7S8
CC and group specific component. Probe strips are also provided in the kit
CC (AAT70568-81)
XX

SQ Sequence 16 BP; 5 A; 8 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCCCTGGTGT 1685
||||| |
Db 15 TGGAAAGCTTGGTGT 2

RESULT 935
AAT85750
ID AAT85750 standard; DNA; 16 BP.

XX AAT85750;

XX 15-JAN-1998 (first entry)

XX FMR2 gene exon 11-intron 11 junction.

XX FMR2 gene; FRAXE; rate folate-sensitive fragile site;
KW X-linked mental retardation; diagnosis; therapy; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

FT exon 1..10
FT /tag= a
FT /note= "exon 11 (1011 bp) 5' region"
FT intron 11..116
FT /tag= b
FT /note= "intron 11 5' region"

XX WO9723610-A1.

XX 03-JUL-1997.

XX 20-DEC-1996; 96WO-AU000825.

XX 22-DEC-1995; 95AU-00007366.

XX (WOMEN-) WOMEN'S & CHILDREN'S HOSPITAL.

XX Mulley JC, Gecz J;

XX WPI; 1997-351051/32.

XX DNA containing gene associated with FRAXE mental retardation - useful for
PT diagnosis and therapy of FRAXE mental retardation.

XX Disclosure; Page 8; 39pp; English.

XX This nucleotide sequence comprises the junction region between exon 11
CC and intron 11 of the human FMR2 gene (see also AAT85728). Splice sites
CC were determined for exons 1-19 of the FMR2 gene (see AAT85729-64). The
CC FMR2 gene is associated with FRAXE (a rare folate-sensitive fragile site)
CC mental retardation. This can be caused either by CCG expansion within the
CC 5' untranslated region of the FMR2 gene or by deletion of coding
CC sequences. Isolation of the FMR2 gene permits an improvement in
CC diagnostic techniques, as well as the possibility for genetic
CC manipulation to overcome FRAXE-associated mental retardation

SQ Sequence 16 BP; 7 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;


```
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 AGCAGAGGCGACG 1657
DB 3 AGCACAAGGTAAAGC 16

RESULT 936
AAZ09804
ID AAZ09804 standard; DNA; 16 BP.
XX
XX
AC AAZ09804;
XX
XX 26-NOV-1999 (first entry)
XX
XX p53 exon 7 PCR primer 2.
XX
XX Primer extension; primer; preamplification; 3'-5' exonuclease activity;
KW PEP-PCR; mutation analysis; microsatellite analysis; DNA polymerase; p53;
XX ss.
XX Synthetic.
XX DE19813317-A1.
XX
XX 30-SEP-1999.
XX
XX 26-MAR-1998; 98DE-01013317.
XX
XX 26-MAR-1998; 98DE-01013317.
XX
XX (HOFF ) ROCHE DIAGNOSTICS GMBH.
XX
XX Rueschoff J, Dietmaier W;
XX
XX WPI; 1999-541759/46.
XX
XX Nucleic acid amplification involving primer extension preamplification,
PT especially for whole genome amplification.
XX
XX Example 6; Page 7; 24pp; German.
XX
XX This invention describes a novel method for the amplification of nucleic
CC acid fragments from a sample in two or three thermal cycling reactions
CC using random primers in the first reaction and specific primers in the
CC second reaction is new and comprises using a mixture of at least two DNA
CC polymerases, at least one of which has 3'-5' exonuclease activity. The
CC process is useful for whole genome amplification by primer extension
CC preamplification polymerase chain reaction (PEP-PCR). DNA amplified by
CC the process can be used for mutation analysis, as a template for
CC sequencing reactions, or for microsatellite analysis. The use of a
CC mixture of DNA polymerases, including at least one with proofreading
CC ability, results in increased sensitivity, such that cell-specific
CC amplification products can be generated with a probability of more than
CC 90% from samples containing no more than 100 cells, preferably no more
CC than 5-10 cells. AAZ09799-Z09815 represent PCR primers used in the method
CC of the invention
XX
XX Sequence 16 BP; 6 A; 1 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1713 AGCAGTACGAGAT 1726
DB 2 AGCAGTAAGGAGAT 15

RESULT 937
AAZ97659
ID AAZ97659 standard; DNA; 16 BP.

Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
DB 3 GGAGTTGGAGTTG 16

RESULT 938
AAS06834/c
ID AAS06834 standard; DNA; 16 BP.
XX
XX AAS06834;
AC
XX
XX 12-SEP-2001 (first entry)
XX
XX SNP containing protein kinase DNA sequence #3.
XX
XX Human; protein kinase; PTK; STK; cancer; cardiovascular disease; SNP;
```

```
XX AAZ97659;
AC
XX
XX 15-SEP-2003 (revised)
DT
XX 26-APR-2000 (first entry)
DT
XX
DE HIV-1 protease gene probe SEQ ID NO:149.
DE
XX Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.
XX
XX Human immunodeficiency virus 1.
OS
XX
XX WO9967428-A2.
PN
XX
XX 29-DEC-1999.
PD
XX
XX 22-JUN-1999; 99WO-EP004317.
PF
XX
XX 24-JUN-1998; 98EP-00870143.
PR
XX (INNO-) INNOGENETICS NV.
PA
XX Stuyver L;
PI
XX
XX WPI; 2000-147219/13.
DR
XX
XX Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.
PT
XX
XX Claim 3; Page 35; 76pp; English.
PS
XX
XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC drug resistance. The method may also be used for HIV protease genotyping
CC assays. The probes are able to discriminate between wild type and mutated
CC protease sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)
XX
XX Sequence 16 BP; 2 A; 0 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
DB 3 GGAGTTGGAGTTG 16

RESULT 938
AAS06834/c
ID AAS06834 standard; DNA; 16 BP.
XX
XX AAS06834;
AC
XX
XX 12-SEP-2001 (first entry)
XX
XX SNP containing protein kinase DNA sequence #3.
XX
XX Human; protein kinase; PTK; STK; cancer; cardiovascular disease; SNP;
```

KW metabolic disorder; immune related disease; neurological disorder;
 KW neurodegenerative disorder; inflammatory disorder; infectious disease;
 KW reproductive disorder; gene therapy; single nucleotide polymorphism; ds.
 XX
 OS Homo sapiens.
 XX WO200138503-A2.
 XX 31-MAY-2001.
 XX 22-NOV-2000; 2000WO-US032085.
 XX 24-NOV-1999; 99US-0167482P.
 XX (SUCG-) SUGEN INC.
 XX Plowman GD, Whyte D, Manning G, Sudarsanam S, Martinez R;
 XX Flanagan P, Clary D;
 XX WPI; 2001-343950/36.
 XX Nucleic acids encoding human kinase polypeptides, useful for preventing
 XX diagnosing and/or treating e.g. cancer, immune, cardiovascular and
 XX neuronal-associated diseases, and microbial infections.
 XX
 XX Example 8B; Page 329; 433pp; English.
 XX
 XX AAS06832-AAS06897 represent part of a polynucleotide sequence encoding
 XX for novel human protein kinases where a single nucleotide polymorphism
 XX (SNP) has been identified. The SNP occurs at the last position of the
 XX present sequence. The sequences are described relating to the invention
 XX of novel human protein kinases #1-57 (AAU03501-AAU03557). The novel
 XX protein kinases have been identified as members of the tyrosine or
 XX serine/threonine kinase (PTK and STK) families. The polynucleotides
 XX encoding protein kinases and the polypeptides may be used in the
 XX prevention, diagnosis and treatment of diseases associated with
 XX inappropriate kinase expression. For example, they may be used to treat
 XX cancers (especially cancers of haematopoietic origin), cardiovascular
 XX disease (e.g. atherosclerosis), metabolic disorders (e.g. diabetes),
 XX immune related diseases (e.g. rheumatoid arthritis), neurological
 XX disorders (e.g. schizophrenia), neurodegenerative disorders (e.g.
 XX Parkinson's disease), inflammatory disorders (e.g. asthma), infectious
 XX disease (e.g. HIV) and reproductive disorders (e.g. infertility).
 XX Additionally, polynucleotides encoding protein kinases may be used for
 XX gene therapy and as DNA probes in diagnostic assays. The protein kinase
 XX polypeptides may be used as antigens in the production of antibodies
 XX against the protein kinases and in assays to identify modulators of
 XX protein kinase expression and activity
 XX
 XX Sequence 16 BP; 5 A; 4 C; 5 G; 1 T; 0 U; 1 Other;

XX Homo sapiens.
 OS Synthetic.
 XX WO200198537-A2.
 XX 27-DEC-2001.
 XX 15-JUN-2001; 2001WO-US019401.
 XX 17-JUN-2000; 2000US-0212308P.
 XX 15-JUN-2001; 2001US-00212308.
 XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX Lyamichiev V, Allawi H, Dong F, Neri BP, Vener IT;
 XX WPI; 2002-049698/06.
 XX Identifying oligonucleotides hybridizing to nucleic acids containing
 XX secondary structure, useful in clinical diagnosis, comprises identifying
 XX primers that interact with the target to form an extension product under
 XX amplification conditions.
 XX Claim 48; Fig 78; 409pp; English.
 XX
 XX The present invention describes a method for identifying oligonucleotides
 XX with desired hybridisation properties to nucleic acid targets containing
 XX secondary structure. The method comprises amplifying a target nucleic
 XX acid having at least one accessible and one inaccessible site. Primers
 XX that form an extension product are identified as the oligonucleotides
 XX which can interact with the folded target nucleic acid. Oligonucleotides
 XX from the present invention can be used in novel detection methods for
 XX clinical diagnostic purposes, including the detection and identification
 XX of pathogenic organisms (e.g. HIV). The method allows the ability to
 XX rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
 XX sequences used in the exemplification of the present invention
 XX
 XX Sequence 16 BP; 6 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 7.8%; Score 10.8; DB 1; Length 16;
 XX Best Local Similarity 85.7%; Pred. No. 5.8e+02;
 XX Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1685 TCTCTCCACGCGTG 1698
 Db 16 TCTCTCCATCATG 3
 RESULT 940
 AAD37972/C
 ID AAD37972 standard; RNA; 16 BP.
 XX AAD37972;
 XX 10-SEP-2002 (first entry)
 XX RNA binding peptide RNA binding domain #5 specific RNA tag #1.
 XX RNA binding protein; mRNA quantification; gene expression; RNA tag; ss.
 XX Unidentified.
 XX WO200227031-A2.
 XX 04-APR-2002.
 XX 28-SEP-2001; 2001WO-US030438.
 XX 28-SEP-2000; 2000US-0236407P.
 XX (CELL-) CELLOMICS INC.
 XX

KW metabolic disorder; immune related disease; neurological disorder;
 KW neurodegenerative disorder; inflammatory disorder; infectious disease;
 KW reproductive disorder; gene therapy; single nucleotide polymorphism; ds.
 XX
 OS Homo sapiens.
 XX WO200138503-A2.
 XX 31-MAY-2001.
 XX 22-NOV-2000; 2000WO-US032085.
 XX 24-NOV-1999; 99US-0167482P.
 XX (SUCG-) SUGEN INC.
 XX Plowman GD, Whyte D, Manning G, Sudarsanam S, Martinez R;
 XX Flanagan P, Clary D;
 XX WPI; 2001-343950/36.
 XX Nucleic acids encoding human kinase polypeptides, useful for preventing
 XX diagnosing and/or treating e.g. cancer, immune, cardiovascular and
 XX neuronal-associated diseases, and microbial infections.
 XX
 XX Example 8B; Page 329; 433pp; English.
 XX
 XX AAS06832-AAS06897 represent part of a polynucleotide sequence encoding
 XX for novel human protein kinases where a single nucleotide polymorphism
 XX (SNP) has been identified. The SNP occurs at the last position of the
 XX present sequence. The sequences are described relating to the invention
 XX of novel human protein kinases #1-57 (AAU03501-AAU03557). The novel
 XX protein kinases have been identified as members of the tyrosine or
 XX serine/threonine kinase (PTK and STK) families. The polynucleotides
 XX encoding protein kinases and the polypeptides may be used in the
 XX prevention, diagnosis and treatment of diseases associated with
 XX inappropriate kinase expression. For example, they may be used to treat
 XX cancers (especially cancers of haematopoietic origin), cardiovascular
 XX disease (e.g. atherosclerosis), metabolic disorders (e.g. diabetes),
 XX immune related diseases (e.g. rheumatoid arthritis), neurological
 XX disorders (e.g. schizophrenia), neurodegenerative disorders (e.g.
 XX Parkinson's disease), inflammatory disorders (e.g. asthma), infectious
 XX disease (e.g. HIV) and reproductive disorders (e.g. infertility).
 XX Additionally, polynucleotides encoding protein kinases may be used for
 XX gene therapy and as DNA probes in diagnostic assays. The protein kinase
 XX polypeptides may be used as antigens in the production of antibodies
 XX against the protein kinases and in assays to identify modulators of
 XX protein kinase expression and activity
 XX
 XX Sequence 16 BP; 5 A; 4 C; 5 G; 1 T; 0 U; 1 Other;
 XX
 XX Query Match 7.8%; Score 10.8; DB 1; Length 16;
 XX Best Local Similarity 75.0%; Pred. No. 5.8e+02;
 XX Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
 QY 1680 TGGTGCTCTCTCCAGC 1695
 Db 16 YGTGCTCTCTCCAGC 1
 RESULT 939
 ABL46301/C
 ID ABL46301 standard; DNA; 16 BP.
 XX ABL46301;
 XX 26-APR-2002 (first entry)
 XX Human ribosomal protein L5 oligonucleotide SEQ ID NO:268.
 XX Nucleic acid accessible hybridisation site; detection; hybridisation;
 XX characterisation; identification; nucleic acid structure; diagnosis;
 XX PCR primer; probe; ss.
 XX

PI Busa WB;
XX
DR WPI; 2002-454466/48.
XX
XX
PT Quantifying target gene expression in living cells that possess a target
PT gene of interest tagged with the binding site for an RNA binding protein
PT and fluorescently labeled RNA binding polypeptide including an RNA
PT binding domain.
PS
XX Claim 27; Page 40; 51pp; English.
XX
XX The present invention relates to a method of quantifying the expression
CC of target genes in living cells. The method involves providing cells that
CC possess a target gene of interest which has been tagged with the binding
CC site for an RNA binding protein and a fluorescently labelled RNA binding
CC polypeptide that includes an RNA binding domain and calculating the
CC quantity of target gene expression in the cells using fluorescence
CC signalling techniques. The method is useful for quantifying expression of
CC one or more target genes in living cells which comprise two or more
CC distinct populations of cells. It is used to quantitate the expression of
CC any target gene, including expression of protein-encoding messenger RNA
CC genes, ribosomal RNA encoding genes and transfer RNA encoding genes so
CC long as the RNA expression product from the target gene possesses a
CC sequence or structure (the RNA tag) that is bound specifically by the RNA
CC binding polypeptide being used. The present sequence is RNA binding
XX peptide RNA binding domain #3 specific RNA tag
XX
SQ Sequence 16 BP; 3 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCAGCTGG 1674
DB 16 AGGCTCAGCTGG 3

RESULT 941
AAA92609/C
ID AAA92609 standard; DNA; 18 BP.
XX
AC AAA92609;
XX
DT 04-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide ISIS# 30428.
XX
KW Human; SRA; steroid receptor RNA activator; cytostatic; antiinflammatory;
KW SRA inhibitor; cancer; infection; antisense oligonucleotide; ss.
XX
OS Synthetic.
XX
XX US6107092-A.
PN
XX 22-AUG-2000.
PD
XX
XX 29-MAR-1999; 99US-00280409.
PF
XX 29-MAR-1999; 99US-00280409.
PR
XX (ISIS-) ISIS PHARM INC.
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
XX Cowseert LM, Bennett CF, O'malley BW;
PI WPI; 2000-586211/55.
DR
XX Antisense compounds targeted to steroid receptor RNA activator useful for
PT diagnosis, prophylaxis and treatment of diseases associated with the
PT steroid activator, such as infection, inflammation or tumor formation.
XX
PS Claim 3; Col 42; 47pp; English.

XX The present sequence is one of a large number of antisense
CC oligonucleotides which is directed against one of four human steroid
CC receptor RNA activator (SRA) nucleic acid sequences. Two series of
CC antisense oligonucleotides were synthesised. The first series comprised 8
CC -30 oligodeoxynucleotides with a phosphorothioate backbone. The second
CC series comprised chimeric oligonucleotides composed of a central gap
CC region, consisting of ten 2'-deoxynucleotides, which was flanked on both
CC sides by four-nucleotide wings. The wings were composed of 2'-
CC methoxyethyl (2'-MOE) nucleotides. Both series contained the same
CC nucleotide sequences. The antisense compounds are useful for research,
CC diagnosis, treatment and prophylaxis to prevent or delay infection,
CC inflammation or tumour formation. Therapeutically the oligonucleotides
CC are highly safe and are effectively administered to humans
XX
SQ Sequence 18 BP; 3 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 7.8%; Score 10.8; DB 1; Length 18;
Best Local Similarity 85.7%; Pred. No. 6.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1658 ACCAGGCTTCAGC 1671
DB 15 ACCAGGCTTCAGC 2

RESULT 942
ABN81420/C
ID ABN81420 standard; DNA; 15 BP.
XX
AC ABN81420;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human HTATIP allele specific probe SEQ ID NO 21.
XX
KW Human; HIV-1 Tat interactive protein; HTATIP; haplotyping; genotyping;
KW transgenic; probe; ss.
XX
OS Homo sapiens.
XX
XX WO200229089-A2.
PN
XX 11-APR-2002.
PD
XX
XX 05-OCT-2001; 2001WO-US031593.
PF
XX 06-OCT-2000; 2000US-0238655P.
PR
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Armstrong B, Bentivegna SC, Choi JY, Gilson CR, Parks KE;
PI Sausker EA;
PI WPI; 2002-330173/36.
DR
XX New HIV-1 tat interactive protein, 60 kDa (HTATIP) gene polymorphic
PT variants, for studying the expression and function of HTATIP and
PT screening candidate drugs for treating familial glucocorticoid deficiency
PT and cancer.
XX
PS Claim 14; Page 13; 89pp; English.
XX
XX The invention relates to novel genetic variants of the HIV-1 Tat
CC interactive protein, 60 kDa (HTATIP) gene. The polymorphic variants are
CC useful in studying the expression and function of HTATIP, in expressing
CC HTATIP protein for use in screening for candidate drugs to treat diseases
CC related to HTATIP activity, in studying the effect of the variation on
CC the biological activity of HTATIP and the binding affinity of candidate
CC drugs targeting HTATIP for the treatment of disorders. Haplotyping
CC methods are useful in validating HTATIP as a candidate target for
CC treating a specific condition or disease predicted to be associated with
CC HTATIP activity or in the design of clinical trials of candidate drugs

CC for treating a specific condition or disease associated with HTATIP
 CC activity. Transgenic animals are useful for studying expression of the
 CC HTATIP isogenes in vivo, for in vivo screening and testing of drugs
 CC targeted against HTATIP protein and for testing the efficacy of
 CC therapeutic agents and compounds for disorders. The present sequence is
 CC that of a HTATIP allele specific oligonucleotide probe of the invention
 XX
 SQ Sequence 15 BP; 1 A; 4 C; 5 G; 4 T; 0 U; 1 Other;

Query Match 7.6%; Score 10.6; DB 1; Length 15;
 Best Local Similarity 90.9%; Pred. No. 5.9e+02;
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCT 1665
 Db 11 AGCCAGGCT 1

RESULT 943
 ABN80551/C
 ID ABN80551 standard; DNA; 15 BP.
 XX
 AC ABN80551;
 XX
 DT 19-JUL-2002 (first entry)
 XX
 DE Human P450(cytochrome) oxidoreductase allele specific probe #17.
 XX
 KW Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;
 KW single nucleotide polymorphism; flavoprotein; enzyme; probe; ss.
 XX
 OS Homo sapiens.
 XX
 EN WO200226768-A2.
 XX
 PD 04-APR-2002.
 XX
 PF 01-OCT-2001; 2001WO-US030877.
 XX
 PR 29-SEP-2000; 2000US-0236449P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Kazemi A, Kliem SE, Lanz EM, Messer C, Tanguay DA;
 XX
 WPI; 2002-394236/42.
 XX
 DR New genetic variants comprising haplotypes of the P450 (cytochrome)
 XX oxidoreductase (POR) isogene, useful in improving the efficiency of drug
 XX screening protocols for compounds targeting POR.
 XX
 PS Claim 14; Page 14; 141pp; English.
 XX
 CC The present invention provides the protein, gene and cDNA sequences of
 CC human P450(cytochrome) oxidoreductase, POR, and single nucleotide
 CC polymorphisms (SNPs) identified therein. The sequences can be used to
 CC haplotype the POR gene of an individual, and to establish whether POR is
 CC a suitable target for drugs to treat cancer and disorders associated with
 CC impaired protein synthesis in cells. The present sequence is an allele
 CC specific probe for the coding sequences of the invention
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 5 G; 1 T; 0 U; 1 Other;

Query Match 7.6%; Score 10.6; DB 1; Length 15;
 Best Local Similarity 90.9%; Pred. No. 5.9e+02;
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1688 CCTCCAGGTG 1698
 Db 15 CCTCCAGGTG 5

ACD55655
 ID ACD55655 standard; RNA; 17 BP.
 XX
 AC ACD55655;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE HBV amberzyme substrate sequence #165.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis B virus.
 XX
 EN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0295876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Example 1; Page 206; 3&7pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
 CC disclosed in the present invention
 XX
 SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;

Query Match 7.6%; Score 10.6; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 6, 8e+02;
Matches 10; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

1694 GCGTGGTGGAGTGGG 1710
| | | | | | | | | | | | | | | | | | | | | |
1 GAGUGGGAGGAGUUGG 17

LSULT 945
V91247/c
ABV91247 standard; DNA; 17 BP.
ABV91247;
23-DEC-2002 (first entry)
Human POSHL1 scanning oligonucleotide SEQ ID NO 1960.
Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
Rho GTPase; signal transduction; gene expression; cancer; vaccine;
gene therapy; transgenic; ss.
Homo sapiens.
EP1239051-A2.
11-SEP-2002.
28-JAN-2002; 2002EP-00001165.
30-JAN-2001; 2001WO-US0000663.
30-JAN-2001; 2001WO-US0000664.
30-JAN-2001; 2001WO-US0000665.
30-JAN-2001; 2001WO-US0000666.
30-JAN-2001; 2001WO-US0000667.
30-JAN-2001; 2001WO-US0000668.
30-JAN-2001; 2001WO-US0000669.
30-JAN-2001; 2001WO-US0000670.
23-MAY-2001; 2001US-00864761.
10-OCT-2001; 2001US-0328205P.
(AEOM-) AEOMICA INC.
Shannon M;
WPI; 2002-684061/74.
Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
-1, useful for treating disorders associated with decreased expression or
activity of human POSHL1.
Example 2; SEQ ID NO 1960; 60pp + Sequence Listing; English.
The invention relates to an isolated SH3 domain (POSH)-like signalling
protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
acids (S1, ABB81999), a sequence having 65% sequence identity to (S1),
(S1) having 95% deviations, especially conservative substitutions or a
fragment of the sequences comprising at least 8 contiguous amino acids.
Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
adaptor protein that interacts with Rho family small GTPases as well as
downstream components of the signal transduction pathway. (I) is useful
for identifying a specific binding partner. (I) and nucleic acids (II)
encoding (I) are useful for diagnosing, monitoring disease and treating
caused by altered expression of human POSHL1 including diagnosing and
treating cancer, they useful in the development of vaccines and (II) is
useful in gene therapy. (II) is useful for constructing microarrays which
are useful for measuring and for surveying gene expression and creating
transgenic non-human animals capable of producing the proteins. The
present sequence is that of a scanning oligonucleotide useful in examples
of the invention. Note: The present sequence did not form part of the

CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office

XX SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 7.6%; Score 10.6; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 6.8e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1732 TTGGTCCCACTCTC 1748

DB 17 TTGGACCCCATCTCCAC 1

RESULT 947

AAV28522

ID AAV28522 standard; DNA; 12 BP.

XX AC AAV28522;

XX DT 28-AUG-1998 (first entry)

XX DE Blackcurrant reversion virus RNA2 3' proximal fragment primer 2.

XX KW Blackcurrant reversion disease; BRV; RNA2; diagnosis; Ribes; PCR; primer;

XX KW ss.

XX OS Synthetic.

XX OS Blackcurrant reversion virus.

XX PN WO9810100-A1.

XX PD 12-MAR-1998.

XX PF 01-SEP-1997; 97WO-FI000507.

XX PR 05-SEP-1996; 96FI-00003474.

XX PA (ABCA-) ABOATECH OY AB.

XX PI Lehto K, Lemmetty A, Latvala S, Susi P;

XX DR WPI; 1998-193642/17.

XX PT Diagnosing blackcurrant reversion disease in plants e.g. blackcurrant -

XX PT using reverse transcriptase-PCR with primers amplifying cDNA fragment

XX PT complementary to fragment of new blackcurrant reversion virus.

XX PS Claim 13; Page 29; 38pp; English.

XX CC Primer 2 corresponds to nucleotides 199-210 upstream of the poly-A tail

XX CC of a 230 bp fraction (see AAV28520) of a blackcurrant reversion virus

XX CC (BRV) nucleotide sequence, as converted to DNA. It is used with primer 1

XX CC (see AAV28521) to amplify a cDNA fragment complementary to a 3' proximal

XX CC 210 bp fragment of BRV RNA. A claimed method for diagnosing blackcurrant

XX CC reversion disease in a plant by detecting BRV involves: providing a

XX CC sample from the plant to be tested; performing a reverse transcription

XX CC reaction to prepare single stranded cDNA from viral RNA in the sample;

XX CC amplifying the cDNA by PCR; and detecting the amplified product. A

XX CC claimed diagnostic test kit includes a primer pair designed to amplify a

XX CC cDNA fragment complementary to the 3' proximal 210 bp fragment of viral

XX CC RNA. The method allows rapid, reliable diagnosis of blackcurrant

XX CC reversion disease in plants, especially blackcurrant. The viral sequence

XX CC detected by primer pair 1.2 is conserved in isolates from widely

XX CC different geographic locations

XX SQ Sequence 12 BP; 0 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1677 CCTGTGTCTC 1688

DB 1 CGCTGTGTCTC 12

RESULT 948

ABH71060

ID ABH71060 standard; DNA; 12 BP.

XX AC ABH71060;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide prime: SEQ ID NO 271037 for detecting SNP TSC0002376.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 271037; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073

XX CC represent the oligomers described in the invention. NOTE: the sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1706 TTGGTTAGGAG 1717

DB 1 TTGGTTAGGAG 12

RESULT 949

ABH84710

ID ABH84710 standard; DNA; 12 BP.

XX AC ABH84710;

XX DT 22-FEB-2002 (first entry)

XX Oligonucleotide primer SEQ ID NO 284703 for detecting SNP TSC0011953.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 284703; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
SQ
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
SQ
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1631 GGATGGGGCTTG 1642
DB 1 GGATGGGGCTTG 12
XX
XX RESULT 950
XX ABI13903
XX ID ABI13903 standard; DNA; 12 BP.
XX AC
XX ABI13903;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 313876 for detecting SNP TSC0026006.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 313876; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 5 G; 3 T; 0 U; 0 Other;
SQ
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1702 GAAGTTGGGTTA 1713
DB 1 GAAGTTGGGATA 12
XX
XX RESULT 951
XX ABH71789/c
XX ID ABH71789 standard; DNA; 12 BP.
XX AC
XX ABH71789;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 271766 for detecting SNP TSC0002608.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

XX PS Claim 1; SEQ ID NO 271766; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC CC range of diseases including immune system, gastrointestinal, respiratory, CC CC central nervous system, cardiovascular and metabolic disorders. The CC CC oligomers are also used for detecting cell type differentiation. ABC00010 CC CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC CC represent the oligomers described in the invention. NOTE: The sequence CC CC data for this patent did not form part of the printed specification, but CC CC was obtained in electronic format from WIPO at CC CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGGTT 1712
DB 12 GCGAGTTGGGTT 1

RESULT 952

ABI22425

ID ABI22425 standard; DNA; 12 BP.

AC ABI22425;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 322398 for detecting SNP TSC0030840.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

XX PS Claim 1; SEQ ID NO 322398; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC CC range of diseases including immune system, gastrointestinal, respiratory, CC CC central nervous system, cardiovascular and metabolic disorders. The CC CC oligomers are also used for detecting cell type differentiation. ABC00010 CC CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC CC represent the oligomers described in the invention. NOTE: The sequence CC CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGG 1709
DB 1 GTTGAAGTTGG 12

RESULT 953

ABI24271/C

ID ABI24271 standard; DNA; 12 BP.

XX AC ABI24271;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 324244 for detecting SNP TSC0031898.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

XX PS Claim 1; SEQ ID NO 324244; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC CC range of diseases including immune system, gastrointestinal, respiratory, CC CC central nervous system, cardiovascular and metabolic disorders. The CC CC oligomers are also used for detecting cell type differentiation. ABC00010 CC CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC CC represent the oligomers described in the invention. NOTE: The sequence CC CC data for this patent did not form part of the printed specification, but CC CC was obtained in electronic format from WIPO at CC CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 5 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1714 GAGTACGGAGA 1725
DB 12 CGATTACGGAGA 1


```
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 315999; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1701 GGAAGTGGGTT 1712
XX DB 12 GGAAGTTAGGTT 1
XX
XX RESULT 957
XX ABI17584/c
XX ID ABI17584 standard; DNA; 12 BP.
XX AC ABI17584;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 371557 for detecting SNP TSC0059858.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB0000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 371557; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1741 AACCTCTCCCTA 1752
XX DB 12 AACCTCTCCCTA 1
XX
XX RESULT 958
XX ABI73215
XX ID ABI73215 standard; DNA; 12 BP.
XX AC ABI73215;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 373188 for detecting SNP TSC0059897.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB0000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 373188; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
```

```
Query Match          7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1696 GTGGTGAAGTT 1707
Db 1 GAGGTGGAAGTT 12

RESULT 959
AB118149
ID AB118149 standard; DNA; 12 BP.
AC AB118149;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318122 for detecting SNP TSC0028456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
EN
XX 18-OCT-2001.
PD
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 318122 for detecting SNP TSC0028456.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
EN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 318122; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 1 C; 5 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match          7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1709 GGTAGGAGTAC 1720
Db 1 GGTAGGAGTTC 12

RESULT 960
ABH72659/c
ID ABH72659 standard; DNA; 12 BP.
XX
```

```
AC ABH72659;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 272644 for detecting SNP TSC0002888.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
EN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 272644; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match          7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1706 TTGGTTAGGAG 1717
Db 12 TTGGTTAGGAG 1

RESULT 961
ABI02394
ID ABI02394 standard; DNA; 12 BP.
XX
XX ABI02394;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 302367 for detecting SNP TSC0019966.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
EN
```

```
XX 18-OCT-2001.
PD
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 302367; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1740 CAACTCCTCCCT 1751
Db 1 CAAATCCTCCCT 12
XX
RESULT 962
ABI07435/c
ID ABI07435 standard; DNA; 12 BP.
XX
XX ABI07435;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 307408 for detecting SNP TSC0022484.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
```

```
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 307408; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1747 TCCCTATCCTAA 1758
Db 12 TCCCTTTCCTAA 1
XX
RESULT 963
ABI13369
ID ABI13369 standard; DNA; 12 BP.
XX
XX ABI13369;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 313342 for detecting SNP TSC0025688.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 313342; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
XX
```

CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1704 AGTGGGTTAGG 1715
| ||||| |||||
Db 1 ATTTGGGTTAGG 12

RESULT 964
ABI16174
ID ABI16174 standard; DNA; 12 BP.
XX AC
XX ABI16174;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 316147 for detecting SNP TSC0027307.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 316147; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1703 AAGTTGGTTAG 1714

Db 1 AAGTTAGTTAG 12
| ||||| |||||

RESULT 965
ABI1618
ID ABI1618 standard; DNA; 12 BP.
XX AC
XX ABI1618;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 341591 for detecting SNP TSC0042119.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 341591; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1706 TTGGGTTAGGAG 1717
| ||||| |||||
Db 1 TTGGTTTAGGAG 12

RESULT 966
ABI46964/C
ID ABI46964 standard; DNA; 12 BP.
XX AC
XX ABI46964;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 345937 for detecting SNP TSC0044839.

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 346937; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1698 GGTGAGGTTGG 1709
Db |||||
12 GGTGAGGTTGG 1
RESULT 967
ABI18906/c
ID ABI18906 standard; DNA; 12 BP.
XX
XX AC ABI18906;
XX
XX AC ABI18906;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 318879 for detecting SNP TSC0028931.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 346937; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1698 GGTGAGGTTGG 1709
Db |||||
12 GGTGAGGTTGG 1
RESULT 968
ABI08058/c
ID ABI08058 standard; DNA; 12 BP.
XX
XX AC ABI08058;
XX
XX AC ABI08058;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 308031 for detecting SNP TSC0022848.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 308031; 29pp + Sequence Listing; German.
```

```
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 318879; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1704 AGTGGGTTAGG 1715
Db |||||
12 AGTGGGTTAGG 1
RESULT 968
ABI08058/c
ID ABI08058 standard; DNA; 12 BP.
XX
XX AC ABI08058;
XX
XX AC ABI08058;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 308031 for detecting SNP TSC0022848.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 308031; 29pp + Sequence Listing; German.
```



```

ABIS5710
ID  ABI55710 standard; DNA; 12 BP.
XX
AC  ABI55710;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 355683 for detecting SNP TSC0004944.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 355683 for detecting SNP TSC0004944.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 355683; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1723 AGATGAGATTG 1734
Db 1 AGATGAGATTG 12
|||||
RESULT 972
ABI66750/c
ID  ABI66750 standard; DNA; 12 BP.
XX
AC  ABI66750;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 366723 for detecting SNP TSC0055937.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 366723 for detecting SNP TSC0055937.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 366723; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TGGGTTAGGAGT 1718
Db 12 TGGGTTAGGCGT 1
|||||
RESULT 973
ABI30472
ID  ABI30472 standard; DNA; 12 BP.
XX
AC  ABI30472;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 330445 for detecting SNP TSC0035529.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 366723; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TGGGTTAGGAGT 1718
Db 12 TGGGTTAGGCGT 1
|||||

```

```

OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 366723; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TGGGTTAGGAGT 1718
Db 12 TGGGTTAGGCGT 1
|||||
RESULT 973
ABI30472
ID  ABI30472 standard; DNA; 12 BP.
XX
AC  ABI30472;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 330445 for detecting SNP TSC0035529.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 366723; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TGGGTTAGGAGT 1718
Db 12 TGGGTTAGGCGT 1
|||||
RESULT 973
ABI30472
ID  ABI30472 standard; DNA; 12 BP.
XX
AC  ABI30472;
XX
DT  22-FEB-2002 (first entry)
XX
DE  Oligonucleotide primer SEQ ID NO 330445 for detecting SNP TSC0035529.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
DT  06-APR-2001; 2001WO-IB000713.
XX
DE  (EPIG-) EPIGENOMICS AG.
XX
KW  Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 366723; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 12 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TGGGTTAGGAGT 1718
Db 12 TGGGTTAGGCGT 1
|||||

```


XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 330445; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGAT 1732
DB 1 GGAGATGGAGT 12
RESULT 974
ABI07173
ID ABI07173 standard; DNA; 12 BP.
XX AC ABI07173;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 307146 for detecting SNP TSC0022360.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 307146; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1739 CCAACTCTCTCC 1750
DB 1 CCAACCTCTCC 12
RESULT 975
ABI13408/c
ID ABI13408 standard; DNA; 12 BP.
XX AC ABI13408;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 313381 for detecting SNP TSC0025710.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 313381; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;

```

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCGAACCTCCTC 1748
Db 12 TTCCAACCTCCTC 1
RESULT 976
ABH92015/c
ID ABH92015 standard; DNA; 12 BP.
XX AC ABH92015;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 292008 for detecting SNP TSC0015047.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI WIPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 292008; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC Sequence 12 BP; 3 A; 0 C; 8 G; 1 T; 0 U; 0 Other;
XX CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX CC Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754
Db 12 CCCCTCCCTATC 1
RESULT 977
AB118788/c
ID AB118788 standard; DNA; 12 BP.
XX AC AB118788;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 294238 for detecting SNP TSC0016014.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI WIPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 318761; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX CC Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1697 TGGTGGAGGTTG 1708
Db 12 TGGTGGAGGTTG 1
RESULT 978
ABH94245
ID ABH94245 standard; DNA; 12 BP.
XX AC ABH94245;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 294238 for detecting SNP TSC0016014.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WI WIPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 318761; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX CC Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX CC Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 294238; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1723 AGATGGAGATTG 1734
Db 1 AGTGGAGATTG 12
RESULT 979
ABH73848
ID ABH73848 standard; DNA; 12 BP.
XX
XX ABH73848;
AC
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 273833 for detecting SNP TSC0003326.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PT methylation status.
XX Claim 1; SEQ ID NO 273833; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1711 TTAGGAGTACGG 1722
Db 1 TTAGGATACGG 12
RESULT 980
ABI03256
ID ABI03256 standard; DNA; 12 BP.
XX
XX ABI03256;
AC
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 303229 for detecting SNP TSC0020398.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 303229; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 6 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754

Db 1 CTCCTCCCTATC 12

RESULT 981
ABI11679/c
ID ABI11679 standard; DNA; 12 BP.

XX AC ABI11679;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 311652 for detecting SNP TSC0024599.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX PS Claim 1; SEQ ID NO 311652; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1632 GATGGGCTTGT 1643

Db 12 GATGGGCTTGT 1

RESULT 982

ABI66422/c
ID ABI66422 standard; DNA; 12 BP.

XX AC ABI66422;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 366395 for detecting SNP TSC0055720.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX PS Claim 1; SEQ ID NO 366395; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCAACTCCTC 1748

Db 12 TCCCAACTACTC 1

RESULT 983

ABI18936
ID ABI18936 standard; DNA; 12 BP.

XX AC ABI18936;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 318909 for detecting SNP TSC0028948.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 318909; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 3 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1741 AACTCCTCCCTA 1752
 Db 1 AACTCCTCCCTA 12
 RESULT 984
 ABI25117/C
 ID ABI25117 standard; DNA; 12 BP.
 XX AC ABI25117;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 325090 for detecting SNP TSC0032385.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 325090; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 2 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1734 GCCTCCCACTC 1745
 Db 12 GCCTCCCACTC 1
 RESULT 985
 ABI00532/C
 ID ABI00532 standard; DNA; 12 BP.
 XX AC ABI00532;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 300505 for detecting SNP TSC0019067.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 DT 18-OCT-2001.
 XX
 DE 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 300505; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1747 TCCTATCCTAA 1758
Db 12 TCCTATCCTAA 1

RESULT 986
ABI03600/c
ID ABI03600 standard; DNA; 12 BP.
XX
AC ABI03600;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 303573 for detecting SNP TSC0020536.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 303573; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTAA 1759
Db 12 CCTATCCTAA 1

RESULT 987
ABI06503
ID ABI06503 standard; DNA; 12 BP.
XX
AC ABI06503;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306476 for detecting SNP TSC0022038.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 306476; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCAACTCTC 1748
Db 1 TCCCAACTCTC 12

RESULT 988
ABH85010
ID ABH85010 standard; DNA; 12 BP.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 351439; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1707 TCGGTTAGGAGT 1718
Db 12 TCGGTTAGGGGT 1
RESULT 991
ABI68217
ID ABI68217 standard; DNA; 12 BP.
XX
XX AC ABI68217;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 368190 for detecting SNP TSC0056843.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX Oligonucleotide primer SEQ ID NO 368190 for detecting SNP TSC0056843.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 368190; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1723 AGATGGAGATTG 1734
Db 1 AGATGGAGTTG 12
RESULT 992
ABI69091
ID ABI69091 standard; DNA; 12 BP.
XX
XX AC ABI69091;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 369064 for detecting SNP TSC0057436.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 369064; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 316457; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1756 TAAAGGCCCACT 1767
Db 1 TAAAGGCCCACT 12
RESULT 996
ABH91477
ID ABH91477 standard; DNA; 12 BP.
XX
AC ABH91477;
XX
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 291470 for detecting SNP TSC0014803.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 291470; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1716 AGTAGGGAGATG 1727
Db 1 AGTAGGGAGATG 12
RESULT 997
ABI42917/c
ID ABI42917 standard; DNA; 12 BP.
XX
AC ABI42917;
XX
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 342890 for detecting SNP TSC0042764.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 342890; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1746 CTCCTCTACCTTA 1752
Db 12 CTCCTCTACCTTA 1

RESULT 998
ABI43245
ID ABI43245 standard; DNA; 12 BP.
XX
AC ABI43245;
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 343218 for detecting SNP TSC0042953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 343218; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABH99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GGAAGTTGGGTT 1712
Db 1 GGAAGTTGGGTT 12

RESULT 999
ABI68275
ID ABI68275 standard; DNA; 12 BP.
XX
XX ABI68275;
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 368248 for detecting SNP TSC0056884.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 368248; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABH99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1741 AACTCCTACCTTA 1752
Db 1 AACTCCTACCTTA 12

RESULT 1000
ABI80271
ID ABI80271 standard; DNA; 12 BP.
XX
XX ABI80271;
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 380244 for detecting SNP TSC0001268.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```

XX OS Homo sapiens.
XX EN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 366722; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
    Query Match 7.5%; Score 10.4; DB 1; Length 12;
    Best Local Similarity 91.7%; Pred. No. 4.9e+02;
    Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    QY 1737 TCCCACTCTC 1748
    Db 1 TCCCACTACTC 12
RESULT 1001
ABI66749/c
ID ABI66749 standard; DNA; 12 BP.
XX AC ABI66749;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 366722 for detecting SNP TSC0055937.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 366722; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
    Query Match 7.5%; Score 10.4; DB 1; Length 12;
    Best Local Similarity 91.7%; Pred. No. 4.9e+02;
    Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    QY 1737 TCCCACTCTC 1748
    Db 1 TCCCACTACTC 12
RESULT 1002
ABH98561
ID ABH98561 standard; DNA; 12 BP.
XX AC ABH98561;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 298554 for detecting SNP TSC0018170.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 298554; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 GTGGAAGTTGGG 1710
DB 1 GAGGAAGTTGGG 12

RESULT 1003
ABH98748/c
ID ABH98748 standard; DNA; 12 BP.
XX
AC ABH98748;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 298741 for detecting SNP TSC0018259.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
DN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 298741; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCGCAACTCCT 1747
DB 12 CTCGCAACTACT 1

RESULT 1004
ABH76068
ID ABH76068 standard; DNA; 12 BP.
XX
AC ABH76068;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 276061 for detecting SNP TSC0004079.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
DN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 276061; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 12 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
DB 1 GAGATGGAGTTT 12

RESULT 1005
ABI06534
ID ABI06534 standard; DNA; 12 BP.
XX
AC ABI06534;

```

XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 306507 for detecting SNP TSC0022057.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.
XX PS Claim 1; SEQ ID NO 306507; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 1698 GGTGGAAGTTGG 1709
XX DB 1 GGTGGAATTGG 12
XX RESULT 1006
XX ABH91224/c
XX ID ABH91224 standard; DNA; 12 BP.
XX AC ABH91224;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 291217 for detecting SNP TSC0014696.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.
XX PS Claim 1; SEQ ID NO 306507; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 1698 GGTGGAAGTTGG 1709
XX DB 1 GGTGGAATTGG 12
XX RESULT 1006
XX ABH91224/c
XX ID ABH91224 standard; DNA; 12 BP.
XX AC ABH91224;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 291217 for detecting SNP TSC0014696.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.
XX PS Claim 1; SEQ ID NO 291217; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 1633 ATGGGGCTTGTA 1644
XX DB 12 ATGGGGCTTGTA 1
XX RESULT 1007
XX ABI81369/c
XX ID ABI81369 standard; DNA; 12 BP.
XX AC ABI81369;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 381342 for detecting SNP TSC0064297.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
XX CC designed to detect single-nucleotide polymorphisms and cytosine
XX CC methylation status.

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 381342; 29pp + Sequence Listing; German.

XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTTAAA 1759

Db 12 CTCTATCCTTAAA 1

RESULT 1008

ABH78792/C

ID ABH78792 standard; DNA; 12 BP.

XX AC ABH78792;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 278785 for detecting SNP TSC0006380.

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 278785; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTTAAA 1759

Db 12 CCCAATCCTTAAA 1

RESULT 1009

ABI69250/C

ID ABI69250 standard; DNA; 12 BP.

XX AC ABI69250;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 369223 for detecting SNP TSC0057525.

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 369223; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1738 CCCAATCCTTCC 1749

Db 12 CCCAACTCTAC 1

RESULT 1010
ABI70995
ID ABI70995 standard; DNA; 12 BP.
XX
AC ABI70995;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370968 for detecting SNP TSC0058497.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 370968 for detecting SNP TSC0058497.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 370968; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1706 TTGGGTTAGGAG 1717
Db 1 TTGGGTTAGGAG 12
RESULT 1011
ABI79597/c
ID ABI79597 standard; DNA; 12 BP.
XX
AC ABI79597;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 379570 for detecting SNP TSC0063355.
XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 379570; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 AAGTTGGATTAG 1714
Db 12 AAGTTGGATTAG 1
RESULT 1012
ABH74230/c
ID ABH74230 standard; DNA; 12 BP.
XX
AC ABH74230;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 274215 for detecting SNP TSC0003480.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
DE 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 274215; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1697 TGGTGGAGCTG 1708
 DB 12 TGGTGGAGCTG 1
 RESULT 1013
 ABH74324
 ID ABH74324 standard; DNA; 12 BP.
 AC ABH74324;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 274309 for detecting SNP TSC0003509.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 274309; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 12 BP; 1 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1694 GCGTGGTGGAG 1705
 DB 1 GCGTGGTGGTAG 12
 RESULT 1014
 ABI25200
 ID ABI25200 standard; DNA; 12 BP.
 AC ABI25200;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide primer SEQ ID NO 325173 for detecting SNP TSC0032434.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 325173; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

```
SQ Sequence 12 BP; 5 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGTGGAGAT 1732
Db 1 GAAGATGGAGAT 12

RESULT 1015
ABI27537
ID ABI27537 standard; DNA; 12 BP.
XX
AC ABI27537;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 327510 for detecting SNP TSC0033693.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 327510; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1739 CCAACTCTCTCC 1750
Db 1 CAAACTCTCTCC 12

RESULT 1016
ABI05067
ID ABI05067 standard; DNA; 12 BP.
XX
AC ABI05067;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 313652 for detecting SNP TSC0025892.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
```

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 313652; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTACG 12
RESULT 1018
ABI74121/c
ID ABI74121 standard; DNA; 12 BP.
XX ABI74121;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 374094 for detecting SNP TSC0060488.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 313652; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTACG 12
RESULT 1019
ABI76760/c
ID ABI76760 standard; DNA; 12 BP.
XX ABI76760;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 376733 for detecting SNP TSC0061961.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 376733; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTACG 12
RESULT 1019
ABI76760/c
ID ABI76760 standard; DNA; 12 BP.
XX ABI76760;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 376733 for detecting SNP TSC0061961.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 376733; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 374094; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTACG 12
RESULT 1019
ABI76760/c
ID ABI76760 standard; DNA; 12 BP.
XX ABI76760;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide primer SEQ ID NO 376733 for detecting SNP TSC0061961.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 376733; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1745 CTCCTCCTATCCT 1756
Db 12 CTCCTCCTATCCT 1

RESULT 1020
ABH93219/C
ID ABH93219 standard; DNA; 12 BP.
XX
AC ABH93219;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 293212 for detecting SNP TSC0015547.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 293212; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCTATC 1754
Db 12 CTCCTCCTATC 1

RESULT 1021
ABI45848/C
ID ABI45848 standard; DNA; 12 BP.
XX
AC ABI45848;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 345821 for detecting SNP TSC0044228.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 345821; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTT 1707
Db 12 GTGGTGAAGTT 1

RESULT 1022
ABI48545
ID ABI48545 standard; DNA; 12 BP.
XX
AC ABI48545;
XX
DT 22-FEB-2002 (first entry)

```

XX DE Oligonucleotide primer SEQ ID NO 348518 for detecting SNP TSC0045630.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 348518; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 1 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTTTCG 12

RESULT 1023
ABI67505/c
ID ABI67505 standard; DNA; 12 BP.
XX AC ABI67505;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 367478 for detecting SNP TSC0056370.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 348518; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 2 A; 1 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTTTCG 12

RESULT 1023
ABI67505/c
ID ABI67505 standard; DNA; 12 BP.
XX AC ABI67505;
XX AC
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 367478 for detecting SNP TSC0056370.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 367478; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1696 GTGCTGGGAAGTT 1707
Db 12 GTTGTGGGAAGTT 1

RESULT 1024
ABI54852
ID ABI54852 standard; DNA; 12 BP.
XX
AC ABI54852;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 354825 for detecting SNP TSC0049316.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

XX PS Claim 1; SEQ ID NO 354825; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
Db 1 GAGATGGAGATT 12
|||||

RESULT 1025
ABI55339
ID ABI55339 standard; DNA; 12 BP.

XX AC ABI55339;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 355312 for detecting SNP TSC0007163.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 355312; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1640 TTGTAGTAGAAG 1551
Db 1 TTGTAGTAGAAG 12
|||||

RESULT 1026
ABI63114
ID ABI63114 standard; DNA; 12 BP.

XX AC ABI63114;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 363087 for detecting SNP TSC0053645.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01C19173.

XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

XX Claim 1; SEQ ID NO 363087; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 1 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1720 CGGATATGGAGA 1731
Db 1 CGGATATGGAGA 12
|||||

```

RESULT 1027
ABI28532/c
ID ABI28532 standard; DNA; 12 BP.
XX
XX
AC ABI28532;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 328505 for detecting SNP TSC0034359.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
EN
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 328505; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1726 TGGAGATTGGCT 1737
XX 12 TGGAGATTGGTT 1
XX
XX RESULT 1028
ABI50660/c
ID ABI50660 standard; DNA; 12 BP.
XX
XX ABI50660;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 350633 for detecting SNP TSC0046789.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 350633; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1596 GTGGTGGAGTT 1707
XX 12 GTGGTGGATGTT 1
XX
XX RESULT 1029
ABI71189/c
ID ABI71189 standard; DNA; 12 BP.
XX
XX ABI71189;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 371162 for detecting SNP TSC0058621.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.

```

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
PI CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
DR CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
PT CC represent the oligomers described in the invention. NOTE: The sequence
PT CC data for this patent did not form part of the printed specification, but
PT CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX PS Claim 1; SEQ ID NO 371162; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX PS Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX CC Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 1702 GAAGTTGGGTTA 1713
XX DB 12 GATGTTGGGTTA 1
XX RESULT 1030
XX ABI81529
XX ID ABI81529 standard; DNA; 12 BP.
XX AC ABI81529;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 391502 for detecting SNP TSC0064394.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 381502; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX PS Sequence 12 BP; 2 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX CC Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY 1738 CCCAACTCCTCC 1749
XX DB 1 CCCAACTCCTCC 12
XX RESULT 1031
XX ABH92917/c
XX ID ABH92917 standard; DNA; 12 BP.
XX XX
XX AC ABH92917;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 292910 for detecting SNP TSC0015404.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX CC Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX PS Claim 1; SEQ ID NO 292910; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX PS Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;


```
Query Match          7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1703 AAGTTGGGTTAG 1714
DB 12 AAGTTGGGTTG 1

RESULT 1032
ABH96992/c
ID ABH96992 standard; DNA; 12 BP.
AC ABH96992;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 296985 for detecting SNP TSC0017381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 296985; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match          7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 GTGGAGTTGGG 1710
DB 12 GTGGAGTTGGG 1

RESULT 1033
ABH77660/c
ID ABH77660 standard; DNA; 12 BP.
XX
XX
XX
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 328269 for detecting SNP TSC0034208.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
```


CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GGAAAGTTGGTT 1712
 Db 12 GGTAGTTGGTT 1

RESULT 1037
 ABI58975/c

ID ABI58975 standard; DNA; 12 BP.

XX AC ABI58975;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 358948 for detecting SNP TSC0051393.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 358948; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1703 AAGTTGGTTAG 1714

Db 12 AGTTGGTTAG 1

RESULT 1038

ABI61446/c
 ID ABI61446 standard; DNA; 12 BP.

XX AC ABI61446;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 361419 for detecting SNP TSC0052628.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX PS Claim 1; SEQ ID NO 361419; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 AGTTGGTTAGG 1715
 Db 12 AGTTGGTTAG 1

RESULT 1039

ABH67931
 ID ABH67931 standard; DNA; 12 BP.

XX AC ABH67931;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 267908 for detecting SNP TSC0000674.

```
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 267908; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
PS Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
PS Sequence 12 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1701 GGAAGTTGGTT 1712
DB 1 GGAAGTTGGTT 12
XX
RESULT 1040
ABH69474/c
ID ABH69474 standard; DNA; 12 BP.
XX
XX ABH69474;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 269451 for detecting SNP TSC0001769.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX Claim 1; SEQ ID NO 296173; 29pp + Sequence Listing; German.
```

```
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 269451; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1707 TCGGTTAGGAGT 1718
DB 12 TCGGTTGGGAGT 1
XX
RESULT 1041
ABH96180/c
ID ABH96180 standard; DNA; 12 BP.
XX
XX ABH96180;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 296173 for detecting SNP TSC0016943.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 296173; 29pp + Sequence Listing; German.
```


ABH90089/c
ID ABH90089 standard; DNA; 12 BP.
XX AC
XX ABH90089;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 290082 for detecting SNP TSC0014210.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 290082; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1709 GGTAGGAGTAC 1720
Db 12 GGTAGGAGTTC 1
RESULT 1045
ABH93470/c
ID ABH93470 standard; DNA; 12 BP.
XX AC
XX ABH93470;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 293463 for detecting SNP TSC0015629.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 293463; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
CC Query Match 7.5%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 4.9e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1711 TTAGGAGTACGG 1722
Db 12 TTAGGAGTATGG 1
RESULT 1046
ABH78187/c
ID ABH78187 standard; DNA; 12 BP.
XX AC
XX ABH78187;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 278180 for detecting SNP TSC0005767.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 278180; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

XX

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;

XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;

XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX

XX QY 1634 TGGGGCTGTAG 1645

XX 12 TGGGGCTGTAG 1

XX

XX RESULT 1047

XX ABI28998

XX ID ABI28998 standard; DNA; 12 BP.

XX AC

XX ABI28998;

XX

XX 22-FEB-2002 (first entry)

XX

XX Oligonucleotide primer SEQ ID NO 328971 for detecting SNP TSC0034676.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX OS

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIG-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K;

XX

XX WPI; 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 328971; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

XX

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;

XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;

XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX

XX QY 1634 TGGGGCTGTAG 1645

XX 12 TGGGGCTGTAG 1

XX

XX RESULT 1047

XX ABI28998

XX ID ABI28998 standard; DNA; 12 BP.

XX AC

XX ABI28998;

XX

XX 22-FEB-2002 (first entry)

XX

XX Oligonucleotide primer SEQ ID NO 328971 for detecting SNP TSC0034676.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX OS

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIG-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K;

XX

XX WPI; 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 328971; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

XX

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;

XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;

XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX

XX QY 1634 TGGGGCTGTAG 1645

XX 12 TGGGGCTGTAG 1

XX

XX RESULT 1047

XX ABI28998

XX ID ABI28998 standard; DNA; 12 BP.

XX AC

XX ABI28998;

XX

XX 22-FEB-2002 (first entry)

XX

XX Oligonucleotide primer SEQ ID NO 328971 for detecting SNP TSC0034676.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX OS

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIG-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K;

XX

XX WPI; 2001-657177/75.

XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 328971; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

XX

XX Query Match 7.5%; Score 10.4; DB 1; Length 12;

XX Best Local Similarity 91.7%; Pred. No. 4.9e+02;

XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX

XX QY 1634 TGGGGCTGTAG 1645

XX 12 TGGGGCTGTAG 1

XX

XX RESULT 1047

XX ABI28998

XX ID ABI28998 standard; DNA; 12 BP.

XX AC

XX ABI28998;

XX

XX 22-FEB-2002 (first entry)

XX

XX Oligonucleotide primer SEQ ID NO 328971 for detecting SNP TSC0034676.

XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

XX Homo sapiens.

XX OS

XX WO200177384-A2.

XX

XX 18-OCT-2001.

XX

XX 06-APR-2001; 2001WO-IB000713.

XX

XX 07-APR-2000; 2000DE-01019173.

XX

XX (EPIG-) EPIGENOMICS AG.

XX

XX Olek A, Piepenbrock C, Berlin K;

XX

XX WPI; 2001-

DT	22-FEB-2002 (first entry)	Matches	11; Conservative	0; Mismatches	1; Indels	0; Gaps	0;
XX	Oligonucleotide primer SEQ ID NO 345371 for detecting SNP TSC0044001.	Qy	1706 TTGGGTTAGGAG	1717			
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	Db	12 TTGGGTTAGGAG	1			
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;						
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.						
OS	Homo sapiens.	RESULT 1049					
XX	WO200177384-A2.	ABH90546					
XX	18-OCT-2001.	ID	ABH90546	standard; DNA; 12 BP.			
XX	06-APR-2001; 2001WO-IB000713.	AC	ABH90546;				
XX	07-APR-2000; 2000DE-01019173.	DT	22-FEB-2002 (first entry)				
XX	(EPIG-) EPIGENOMICS AG.	DE	Oligonucleotide primer SEQ ID NO 290539 for detecting SNP TSC0014397.				
XX	Olek A, Piepenbrock C, Berlin K;	XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;				
XX	WPI; 2001-657177/75.	XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;				
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is	XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.				
XX	designed to detect single-nucleotide polymorphisms and cytosine	OS	Homo sapiens.				
XX	methylation status.	XX	WO200177384-A2.				
XX	Claim 1; SEQ ID NO 345371; 29pp + Sequence Listing; German.	XX	18-OCT-2001.				
XX	This invention describes novel oligonucleotide primers or peptide nucleic	XX	06-APR-2001; 2001WO-IB000713.				
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	XX	07-APR-2000; 2000DE-01019173.				
XX	and cytosine methylation status in chemically pretreated genomic DNA. The	XX	(EPIG-) EPIGENOMICS AG.				
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	XX	Olek A, Piepenbrock C, Berlin K;				
XX	range of diseases including immune system, gastrointestinal, respiratory,	XX	WPI; 2001-657177/75.				
XX	central nervous system, cardiovascular and metabolic disorders. The	XX	Set of oligonucleotides, useful for diagnosis and cell typing, is				
XX	oligomers are also used for detecting cell type differentiation. ABC00010	XX	designed to detect single-nucleotide polymorphisms and cytosine				
XX	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073	XX	methylation status.				
XX	represent the oligomers described in the invention. NOTE: The sequence	XX	Claim 1; SEQ ID NO 290539; 29pp + Sequence Listing; German.				
XX	data for this patent did not form part of the printed specification, but	XX	This invention describes novel oligonucleotide primers or peptide nucleic				
XX	was obtained in electronic format from WIPO at	XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)				
XX	ftp.wipo.int/pub/published_pct_sequences	XX	and cytosine methylation status in chemically pretreated genomic DNA. The				
SQ	Sequence 12 BP; 4 A; 0 C; 7 G; 1 T; 0 U; 0 Other;	XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a				
		XX	range of diseases including immune system, gastrointestinal, respiratory,				
		XX	central nervous system, cardiovascular and metabolic disorders. The				
		XX	oligomers are also used for detecting cell type differentiation. ABC00010				
		XX	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073				
		XX	represent the oligomers described in the invention. NOTE: The sequence				
		XX	data for this patent did not form part of the printed specification, but				
		XX	was obtained in electronic format from WIPO at				
		XX	ftp.wipo.int/pub/published_pct_sequences				
		XX	Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;				
		Query Match	7.5%;	Score	10.4;	DB	1;
		Best Local Similarity	91.7%;	Pred.	No. 4.9e+02;	Length	12;
		Matches	11; Conservative	0; Mismatches	1; Indels	0; Gaps	0;
Qy	1738 CCCAACTCTCTCC	1749					
Db	1 CCCAACTCTCTCC	12					

XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 363191; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC000010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1747 TCCCTATCCTAA 1758
 DB 12 TCCCTATCCTCA 1
 |||||
 RESULT 1052
 AAZ93102
 ID AAZ93102 standard; DNA; 13 BP.
 AC AAZ93102;
 XX 16-AUG-2000 (first entry)
 DT 5'UTR sequence used in cold shock expression construct.
 DE Expression construct; cold shock; inducible gene; gene expression;
 KW downstream box; bacteria; antibiotic; ss.
 KW Escherichia coli.
 OS WO200011148-A2.
 PN 02-MAR-2000.
 PD 20-AUG-1999; 99WO-US019030.
 XX 20-AUG-1998; 98US-0096938P.
 PR 16-APR-1999; 99US-00293427.
 PR 12-JUL-1999; 99US-0143380P.
 XX (UYNE-) UNIV NEW JERSEY.
 PA Fang L, Jiang W, Mitta M, Inouye M, Etchegaray J;
 XX WPI; 2000-246559/21.
 XX New nucleic acid useful for regulating bacterial gene expression under

PT conditions of physiological stress that induce the cold shock response of
 PT a bacterium.
 XX Claim 15; Page 55; 100pp; English.
 XX New expression constructs are described which prolong the expression of
 CC cold shock inducible genes under conditions that elicit the response in
 CC bacteria. The constructs comprise either a downstream box, a nucleic acid
 CC that enhances the translation of cold shock inducible genes under
 CC conditions that elicit the cold shock response; or a cold box and at
 CC least a portion of the 5'UTR of a cold shock inducible gene that
 CC represses the expression or enhances the translation of the cold shock
 CC inducible gene and a downstream box sequence. The overexpression of the
 CC cold shock inducible gene causes a reduction in the expression of at
 CC least one endogenous protein. The constructs are useful as an antibiotic
 CC to kill or to stop the growth of bacteria in plants and animals
 XX
 SQ Sequence 13 BP; 4 A; 5 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1754 CCTAAGGCCCA 1765
 DB 2 CCGAAGGCCCA 13
 |||||
 RESULT 1053
 ABC69426
 ID ABC69426 standard; DNA; 13 BP.
 XX AC ABC69426;
 XX 21-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 69443 for detecting SNP TSC0019070.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 KW Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 PR (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 69443; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC000010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
Db 1 GAAGATGGAGAT 12
|||||
|

RESULT 1054
ABF18044
ID ABF18044 standard; DNA; 13 BP.
XX
AC ABF18044;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 118041 for detecting SNP TSC0029517.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 118041; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1711 TTAGGAGTACGG 1722
Db 2 TTAGGAGTACGG 13
|||||
|

RESULT 1056
ABF46002
ID ABF46002 standard; DNA; 13 BP.
XX
AC ABF46002;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 145999 for detecting SNP TSC0036789.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

RESULT 1055
ABF25942
ID ABF25942 standard; DNA; 13 BP.
XX
AC ABF25942;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 125939 for detecting SNP TSC0031508.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 125939; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 5 G; 4 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTACG 12
|||||
|

RESULT 1056
ABF46002
ID ABF46002 standard; DNA; 13 BP.
XX
AC ABF46002;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 145999 for detecting SNP TSC0036789.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 145999; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1707 TGGGTTAGGAGCT 1718
 Db 1 TGGGTTAGGAGCT 12
 RESULT 1057
 ABF55622
 ID ABF55622 standard; DNA; 13 BP.
 XX AC ABF55622;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 155619 for detecting SNP TSC0001748.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 247600; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 155619; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1726 TGGAGATTGGCT 1737
 Db 1 TGGAGATTGGCT 12
 RESULT 1058
 ABH47623/c
 ID ABH47623 standard; DNA; 13 BP.
 XX AC ABH47623;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 247600 for detecting SNP TSC0060506.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 247600; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

```
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;

Query Match          7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGTTRAGGA 1716
Db      ||||| |||||
12 GTTGGATTAGGA 1

RESULT 1059
ABC69427/c
ID ABC69427 standard; DNA; 13 BP.
XX
AC ABC69427;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 69444 for detecting SNP TSC0018070.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 69444; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match          7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGTTRAGGA 1716
Db      ||||| |||||
12 GTTGGATTAGGA 1

RESULT 1059
ABC69427/c
ID ABC69427 standard; DNA; 13 BP.
XX
AC ABC69427;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 69444 for detecting SNP TSC0018070.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 69444; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match          7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGGTT 1712
Db      ||||| |||||
13 GGAAGTTGGGAT 2

RESULT 1061
ABC31788
ID ABC31788 standard; DNA; 13 BP.
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match          7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGGTT 1712
Db      ||||| |||||
13 GGAAGTTGGGAT 2

RESULT 1061
ABC31788
ID ABC31788 standard; DNA; 13 BP.
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
```

XX ABC31786;
 XX AC
 XX DT
 XX DT 20-FEB-2002 (first entry)
 XX DE
 XX DE Oligonucleotide SEQ ID NO 31805 for detecting SNP TSC0009913.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 31805; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1705 GTTGGGTAGCA 1716
 |||||
 Db 2 GTTGGGTAGCA 13
 RESULT 1062
 ABC31801/c
 ID ABC31801 standard; DNA; 13 BP.
 XX AC ABC31801;
 XX DT 20-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 31818 for detecting SNP TSC0009913.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

PN WO200177384-A2.
 XX 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 31818; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1705 GTTGGGTAGCA 1716
 |||||
 Db 12 GTTGGGTAGCA 1
 RESULT 1063
 ABC31809/c
 ID ABC31809 standard; DNA; 13 BP.
 XX AC ABC31809;
 XX DT 20-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 31826 for detecting SNP TSC0009913.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 31826; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 2 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1705 GTTGGGTTAGGA 1716
Db 12 GTTGGGTTCCGA 1
RESULT 1064
ABC11715/c
ID ABC11715 standard; DNA; 13 BP.
XX
AC ABC11715;
XX
XX 20-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 11722 for detecting SNP TSC0002832.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11722; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 2 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1705 GTTGGGTTAGGA 1716
Db 12 GTTGGGTTCCGA 1

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1704 AGTTGGGTTAGG 1715
Db 13 AGTTGGGTTGG 2
RESULT 1065
ABF20795/c
ID ABF20795 standard; DNA; 13 BP.
XX
AC ABF20795;
XX
XX 21-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 120792 for detecting SNP TSC0030144.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 120792; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GAAGTTGGGTTA 1713

Db 1 GTAGTTGGGTTA 12

RESULT 1071

ID ABH37503 standard; DNA; 13 BP.

XX AC ABH37503;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 237480 for detecting SNP TSC0057920.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 237480; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 4 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGG 1761

Db 2 CTATCCTAAACG 13

RESULT 1072

ABC47423
ID ABC47423 standard; DNA; 13 BP.

XX AC ABC47423;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 47440 for detecting SNP TSC0013623.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

PN WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.

PS Claim 1; SEQ ID NO 47440; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1742 ACTCTCCCTAT 1753

Db 2 ACTCTCTCTAT 13

RESULT 1073

ABC49575
ID ABC49575 standard; DNA; 13 BP.

XX AC ABC49575;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 49592 for detecting SNP TSC0014010.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 49592; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1744 TCCTCCCTATCC 1755
XX Db 1 TCCTCCCTATCC 12
XX
XX RESULT 1074
XX ABC00211/c
XX ID ABC00211 standard; DNA; 13 BP.
XX AC ABC00211;
XX XX
XX XX 20-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 202 for detecting SNP TSC0000040.
XX SN
XX SN SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX XX 18-OCT-2001.
XX PD
XX XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX XX 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 49592; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1744 TCCTCCCTATCC 1755
XX Db 1 TCCTCCCTATCC 12
XX
XX RESULT 1075
XX ABC31792
XX ID ABC31792 standard; DNA; 13 BP.
XX AC ABC31792;
XX XX
XX XX 20-FEB-2002 (first entry)
XX DT
XX DE Oligonucleotide SEQ ID NO 31809 for detecting SNP TSC0000913.
XX SN
XX SN SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX XX 18-OCT-2001.
XX PD
XX XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX XX 07-APR-2000; 2000DE-01019173.
XX PR
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 31809; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGTTAGGA 1716
 DB 2 GTTGGTTTGA 13

RESULT 1076

ABF11506
 ID ABF11506 standard; DNA; 13 BP.

XX AC ABF11506;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 111503 for detecting SNP TSC0027852.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PR WIPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX PS Claim 1; SEQ ID NO 111503; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GAAGTTGGTTA 1713
 DB 1 GGAGTTGGTTA 12

RESULT 1077

ABF25379

ID ABF25379 standard; DNA; 13 BP.

XX AC ABF25379;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 125376 for detecting SNP TSC0031340.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PR WIPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX PS Claim 1; SEQ ID NO 125376; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754
 DB 1 CTCACCCCTATC 12

RESULT 1078

ABF25943/C

ID ABF25943 standard; DNA; 13 BP.

XX AC ABF25943;

```
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 125940 for detecting SNP TSC0031508.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 125940; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 1 Other;
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
DB 13 GTTAGGAGTTCG 2
RESULT 1079
ABF39732
ID ABF39732 standard; DNA; 13 BP.
AC ABF39732;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 139729 for detecting SNP TSC0034974.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 139729; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTACG 1721
DB 13 GTTAGGAGTTCG 2
RESULT 1079
ABF39732
ID ABF39732 standard; DNA; 13 BP.
AC ABF39732;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 139729 for detecting SNP TSC0034974.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 139729; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATCGAGATT 1733
DB 1 GATATGGAGATT 12
RESULT 1080
ABH00390
ID ABH00390 standard; DNA; 13 BP.
AC ABH00390;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 200367 for detecting SNP TSC0049306.
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 200367; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 1 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732

Db 1 GGAGCGGAGAT 12
||||| |||||

RESULT 1081

ABF53254

ID ABF53254 standard; DNA; 13 BP.

XX AC ABF53254;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 153251 for detecting SNP TSC0038744.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 153251; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 2 C; 5 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1710 GTTAGGACTAGC 1721

Db 1 GTTAGGCGTAGC 12
||||| |||||

RESULT 1082

ABF79386/c

ID ABF79386 standard; DNA; 13 BP.

XX AC ABF79386;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 179383 for detecting SNP TSC0044413.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 179383; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCCACTCCT 1747

||||| |||||

[illegible]

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 263180; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1721 GGAGATGGAGAT 1732
 Db 13 GTAGATGGAGAT 2
 XX
 RESULT 1086
 ID ABC44244 standard; DNA; 13 BP.
 XX ABC44244;
 AC ABC44244;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 44261 for detecting SNP TSC0013010.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 44261; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1699 GTGGAAGTTGGG 1710
 Db 1 GAGGAAGTTGGG 12
 XX
 RESULT 1087
 ID ABC19753 standard; DNA; 13 BP.
 XX ABC19753;
 AC ABC19753;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 19770 for detecting SNP TSC0004089.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 19770; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ	Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;	
XX	Query Match	7.5%; Score 10.4; DB 1; Length 13;
XX	Best Local Similarity	91.7%; Pred. No. 5.4e+02;
XX	Matches 11; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	1754 CCTAAAGGCCCA 1765	
DB		
DB	1 CCTAAAGGCCCA 12	
RESULT 1088		
ABC24273		
ID	ABC24273 standard; DNA; 13 BP.	
XX	AC ABC24273;	
XX	AC ABC24273;	
DT	20-FEB-2002 (first entry)	
XX	XX	
DE	Oligonucleotide SEQ ID NO 24290 for detecting SNP TSC0005767.	
XX	XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX	XX	
OS	Homo sapiens.	
XX	XX	
PN	WO200177384-A2.	
PD	18-OCT-2001.	
XX	XX	
PF	06-APR-2001; 2001WO-IB000713.	
XX	XX	
PR	07-APR-2000; 2000DE-01019173.	
XX	XX	
PA	(EPIG-) EPIGENOMICS AG.	
XX	XX	
PI	Olek A, Piepenbrock C, Berlin K;	
XX	XX	
DR	WPI; 2001-657177/75.	
XX	XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX	XX	
PS	Claim 1; SEQ ID NO 24290; 29pp + Sequence Listing; German.	
XX	XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX	XX	
SQ	Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;	
XX	Query Match	7.5%; Score 10.4; DB 1; Length 13;
XX	Best Local Similarity	91.7%; Pred. No. 5.4e+02;
XX	Matches 11; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	1748 CCCTATCCTAAA 1759	
DB		
DB	2 CCCATCCTAAA 13	
RESULT 1089		
ABC00210		
ID	ABC00210 standard; DNA; 13 BP.	
XX	AC ABC00210;	
XX	AC ABC00210;	
DT	20-FEB-2002 (first entry)	
XX	XX	
DE	Oligonucleotide SEQ ID NO 201 for detecting SNP TSC0000040.	
XX	XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX	XX	
OS	Homo sapiens.	
XX	XX	
PN	WO200177384-A2.	
PD	18-OCT-2001.	
XX	XX	
PF	06-APR-2001; 2001WO-IB000713.	
XX	XX	
PR	07-APR-2000; 2000DE-01019173.	
XX	XX	
PA	(EPIG-) EPIGENOMICS AG.	
XX	XX	
PI	Olek A, Piepenbrock C, Berlin K;	
XX	XX	
DR	WPI; 2001-657177/75.	
XX	XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX	XX	
PS	Claim 1; SEQ ID NO 201; 29pp + Sequence Listing; German.	
XX	XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX	XX	
SQ	Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;	
XX	Query Match	7.5%; Score 10.4; DB 1; Length 13;
XX	Best Local Similarity	91.7%; Pred. No. 5.4e+02;
XX	Matches 11; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	1722 GAGATCGAGATT 1733	
DB		
DB	1 GAGATCGAGTTT 12	
RESULT 1090		
ABC8050		
ID	ABC8050 standard; DNA; 13 BP.	
XX	AC ABC8050;	
XX	AC ABC8050;	
DT	21-FEB-2002 (first entry)	
XX	XX	
DE	Oligonucleotide SEQ ID NO 88067 for detecting SNP TSC0022140.	
XX	XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX	XX	
OS	Homo sapiens.	

XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 89067; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, cardiovascular and metabolic disorders.
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABH99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX QY 1722 GAGATGGAGATT 1733
 XX Db |||||
 XX 2 GAGATGGAGTTT 13
 RESULT 1091
 ABC40889/C
 ID ABC40889 standard; DNA; 13 BP.
 XX AC ABC40889;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 40906 for detecting SNP TSC0012352.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 40906; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, cardiovascular and metabolic disorders.
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABH99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX QY 1722 GAGATGGAGATT 1733
 XX Db |||||
 XX 13 GAGATGGAGATT 2
 RESULT 1092
 ABF25378/C
 ID ABF25378 standard; DNA; 13 BP.
 XX AC ABF25378;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 125375 for detecting SNP TSC0031340.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 125375; 29pp + Sequence Listing; German.
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754
Db 13 CTCACCCCTATC 2

RESULT 1093
ABF25382/c
ID ABF25382 standard; DNA; 13 BP.
XX
AC ABF25382;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 125379 for detecting SNP TSC0031340.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 125379; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754
Db 13 CTCACCCCTATC 2

RESULT 1093
ABF25382/c
ID ABF25382 standard; DNA; 13 BP.
XX
AC ABF25382;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 125379 for detecting SNP TSC0031340.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 125379; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATC 1754
Db 13 CTCACCCCTATC 2

RESULT 1094
ABF28968
ID ABF28968 standard; DNA; 13 BP.
XX
AC ABF28968;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 128965 for detecting SNP TSC0032287.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 128965; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1707 TGGGTAGGAGT 1718
Db 1 TGAGTTAGGAGT 12

RESULT 1095
ABF28969/c
ID ABF28969 standard; DNA; 13 BP.
XX
AC ABF28969;
XX
DT 21-FEB-2002 (first entry)

RESULT 1100
ABH00760
ID ABH00760 standard; DNA; 13 BP.
XX
AC ABH00760;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200737 for detecting SNP TSC0049389.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 200737; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1705 GTTGGGTTAGGA 1716
DB 1 GTTGAGTTAGGA 12
XX
RESULT 1101
ABH00761/c
ID ABH00761 standard; DNA; 13 BP.
XX
AC ABH00761;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200738 for detecting SNP TSC0049389.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 200738; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1705 GTTGGGTTAGGA 1716
DB 13 GTTGAGTTAGGA 2
XX
RESULT 1102
ABF55723/c
ID ABF55723 standard; DNA; 13 BP.
XX
AC ABF55723;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 155720 for detecting SNP TSC0039321.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 155720; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 6 C; 1 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 AAGTTGGTTAG 1714
DB 12 AAGTTGGTTAG 1
RESULT 1103
ABF66103/C
ID ABF66103 standard; DNA; 13 BP.
XX
AC ABF66103;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166100 for detecting SNP TSC0007702.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 166100; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 AAGTTGGTTAG 1714
DB 12 AAGTTGGTTAG 1
RESULT 1104
ABC46628/C
ID ABC46628 standard; DNA; 13 BP.
XX
AC ABC46628;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 46645 for detecting SNP TSC0013460.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 46645; 29pp + Sequence Listing; German.
PS
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1740 CAACTCTCCCT 1751
 DB 13 CAACTCGCCCT 2

RESULT 1105
 ABC52598/c
 ID ABC52598 standard; DNA; 13 BP.
 XX
 AC ABC52598;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 52615 for detecting SNP TSC0014589.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX
 PF 06-APR-2001; 2001WO-IB000713.

XX
 PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 52615; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCACTCTC 1748
 DB 13 TCCCACTACTC 2

RESULT 1106
 ABC57208
 ID ABC57208 standard; DNA; 13 BP.
 XX

AC ABC57208;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 57225 for detecting SNP TSC0015477.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 57225; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGAGATT 1733

DB 1 GAGATGAGATT 12

RESULT 1107

ABC57209/c

ID ABC57209 standard; DNA; 13 BP.

XX ABC57209;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 57226 for detecting SNP TSC0015477.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.


```
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1736 CTCCTCAACTCCT 1747
DB 12 CTCCTCAACTCCT 1
RESULT 1110
ABF18155/c
ID ABF18155 standard; DNA; 13 BP.
AC ABF18155;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 118152 for detecting SNP TSC0029550.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS Claim 1; SEQ ID NO 118152; 29pp + Sequence Listing; German.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 118152; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 8 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1714 GGAGTAGCGAGA 1725
```

```
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 9 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1736 CTCCTCAACTCCT 1747
DB 12 CTCCTCAACTCCT 1
RESULT 1111
ABF20794
ID ABF20794 standard; DNA; 13 BP.
XX
AC ABF20794;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 120791 for detecting SNP TSC0030144.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 120791; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1707 TGGGTTAGAGT 1718
DB 1 TGGGTTAGAGT 12
RESULT 1112
ABF33959
ID ABF33959 standard; DNA; 13 BP.
XX
AC ABF33959;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 133956 for detecting SNP TSC0033403.
```

Mon Aug 30 09:26:45 2004

```

XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 133956; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1748 CCTATCCTCTAA 1759
DB 2 CCTATCCTCTAA 13
XX
RESULT 1113
ABH61554/C
ID ABH61554 standard; DNA; 13 BP.
XX
XX ABH61554;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 261531 for detecting SNP TSC0063469.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 133956; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1748 CCTATCCTCTAA 1759
DB 2 CCTATCCTCTAA 13
XX
RESULT 1113
ABH61554/C
ID ABH61554 standard; DNA; 13 BP.
XX
XX ABH61554;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 261531 for detecting SNP TSC0063469.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 46642; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1747 TCCTATCCTCTAA 1758
DB 13 TCCTATCCTCTAA 2
XX
RESULT 1114
ABC46625
ID ABC46625 standard; DNA; 13 BP.
XX
XX ABC46625;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 46642 for detecting SNP TSC0013460.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 46642; 29pp + Sequence Listing; German.

```

```

XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1740 CAACTCCTCCCT 1751
Db 1 CAACTCCACCT 12

RESULT 1115
ABC77643/c
ID ABC77643 standard; DNA; 13 BP.
XX AC ABC77643;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 77660 for detecting SNP TSC0019778.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 77660; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
Db 12 GAGATGGGATT 1

RESULT 1116
ABC31789/c
ID ABC31789 standard; DNA; 13 BP.
XX AC ABC31789;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 31806 for detecting SNP TSC0009913.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WIPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 31806; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGGTTAGGA 1716
Db 12 GTTGGGTTTGA 1

RESULT 1117

```

RESULT 1117

Mon Aug 30 09:26:45 2004

```

ABC31793/c
ID ABC31793 standard; DNA; 13 BP.
XX
AC ABC31793;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31810 for detecting SNP TSC0009913.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 32510; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1705 GTTCGGTTAGGA 1716
Db 12 GTTCGGTTAGGA 1
XX
RESULT 1118
ABC32493/c
ID ABC32493 standard; DNA; 13 BP.
XX
AC ABC32493;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 32510 for detecting SNP TSC0010144.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 31810; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1705 GTTCGGTTAGGA 1716
Db 12 GTTCGGTTAGGA 1
XX
RESULT 1119
ABC84790/c
ID ABC84790 standard; DNA; 13 BP.
XX
AC ABC84790;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 84807 for detecting SNP TSC0021343.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;

```

XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 84807; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1746 CTCCTATCCTAA 1757
DB 12 CTCCTATCCTAA 1
RESULT 1120
ABC66988/c
ID ABC66988 standard; DNA; 13 BP.
XX AC ABC66988;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 67005 for detecting SNP TSC0017552.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 67005; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1747 TCCCTATCCTAA 1758
DB 13 TCCATATCCTAA 2
RESULT 1121
ABF53255/c
ID ABF53255 standard; DNA; 13 BP.
XX AC ABF53255;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 153252 for detecting SNP TSC0038744.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 153252; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 5 C; 2 G; 2 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;

Matches	11; Conservative	0; Mismatches	1; Indels	0; Gaps	0;
QY	1710 GTTAGGAGTACG 1721				
DB	13 GTTAGGCGTACG 2				
RESULT 1122					
ABH15230/c					
ID	ABH15230 standard; DNA; 13 BP.				
XX	AC ABH15230;				
XX	22-FEB-2002 (first entry)				
DT	Oligonucleotide SEQ ID NO 215207 for detecting SNP TSC0052373.				
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;				
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;				
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.				
XX	Homo sapiens.				
XX	WO200177384-A2.				
XX	18-OCT-2001.				
XX	06-APR-2001; 2001WO-IB000713.				
XX	07-APR-2000; 2000DE-01019173.				
XX	(EPIG-) EPIGENOMICS AG.				
XX	Olek A, Piepenbrock C, Berlin K;				
XX	WPI; 2001-657177/75.				
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is				
XX	designed to detect single-nucleotide polymorphisms and cytosine				
XX	methylation status.				
XX	Claim 1; SEQ ID NO 215207; 29pp + Sequence Listing; German.				
XX	This invention describes novel oligonucleotide primers or peptide nucleic				
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)				
XX	and cytosine methylation status in chemically pretreated genomic DNA. The				
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a				
XX	range of diseases including immune system, gastrointestinal, respiratory,				
XX	central nervous system, cardiovascular and metabolic disorders. The				
XX	oligonucleotides are also used for detecting cell type differentiation. ABC00010				
XX	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073				
XX	represent the oligomers described in the invention. NOTE: The sequence				
XX	data for this patent did not form part of the printed specification, but				
XX	was obtained in electronic format from WIPO at				
XX	ftp.wipo.int/pub/published_pct_sequences				
XX	Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;				
XX	This invention describes novel oligonucleotide primers or peptide nucleic				
XX	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)				
XX	and cytosine methylation status in chemically pretreated genomic DNA. The				
XX	oligonucleotides are used for diagnosis and/or prognosis of cancer and a				
XX	range of diseases including immune system, gastrointestinal, respiratory,				
XX	central nervous system, cardiovascular and metabolic disorders. The				
XX	oligonucleotides are also used for detecting cell type differentiation. ABC00010				
XX	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073				
XX	represent the oligomers described in the invention. NOTE: The sequence				
XX	data for this patent did not form part of the printed specification, but				
XX	was obtained in electronic format from WIPO at				
XX	ftp.wipo.int/pub/published_pct_sequences				
XX	Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;				
XX	Query Match 7.5%; Score 10.4; DB 1; Length 13;				
XX	Best Local Similarity 91.7%; Pred. No. 5.4e+02;				
XX	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
QY	1748 CCTATCCTTAA 1759				
DB	12 CCTATCCTTAA 1				
RESULT 1123					
ABF90783/c					
ID	ABF90783 standard; DNA; 13 BP.				
XX	AC ABF90783;				

XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 46646; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1740 CAACTCTCCCT 1751
Db 1 CAACTCGCCT 12
RESULT 1125
ABC49574/c
ID ABC49574 standard; DNA; 13 BP.
XX AC ABC49574;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 49591 for detecting SNP TSC0014010.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
XX Claim 1; SEQ ID NO 49591; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1744 TCCCTCCCTATCC 1755
Db 13 TCCCTCCCTTCC 2
RESULT 1126
ABC02829
ID ABC02829 standard; DNA; 13 BP.
XX AC ABC02829;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 2820 for detecting SNP TSC00011100.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 2820; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTAA 1759

DB 1 CCTATCCTAA 12

RESULT 1127
ABC53246/C
ID ABC53246 standard; DNA; 13 BP.

XX AC ABC53246;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 53263 for detecting SNP TSC0014711.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 53263; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTAA 1759

DB 12 CCTATCCTAA 1

RESULT 1128

ABC53247

ID ABC53247 standard; DNA; 13 BP.

XX AC ABC53247;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 53264 for detecting SNP TSC0014711.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 53264; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTAA 1759

DB 2 CCTATCCTAA 13

RESULT 1129

ABC04730/C

ID ABC04730 standard; DNA; 13 BP.

XX AC ABC04730;

XX DT 20-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 4721 for detecting SNP TSC0001698.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 4721; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 CC
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1741 AACTCTCTCCCTA 1752
 DB 12 AACTCTCTCCCAA 1
 RESULT 1130
 ABC80341
 ID ABC80341 standard; DNA; 13 BP.
 XX
 XX ABC80341;
 AC
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 80358 for detecting SNP TSC0020399.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 80358; 29pp + Sequence Listing; German.
 PS
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;
 CC
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1742 ACTCTCTCCCTAT 1753
 DB 2 ACTCTCTCCCTAT 13
 RESULT 1131
 ABC31002
 ID ABC31002 standard; DNA; 13 BP.
 XX
 XX ABC31002;
 AC
 XX
 XX 20-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 31019 for detecting SNP TSC0009554.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 31019; 29pp + Sequence Listing; German.
 PS
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

Mon Aug 30 09:26:45 2004

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
 Db 2 GGAGAAGGAGAT 13

RESULT 1132
 ABF24348
 ID ABF24348 standard; DNA; 13 BP.
 XX
 AC ABF24348;
 XX
 XX 21-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 124345 for detecting SNP TSC0031088.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 124345; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1723 AGATGGAGATTG 1734
 Db 1 AGATGGAGATCG 13

RESULT 1133
 ABF32774
 ID ABF32774 standard; DNA; 13 BP.
 XX
 AC ABF32774;
 XX
 XX 21-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 132771 for detecting SNP TSC0033108.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 132771; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTGGGTT 1712
 Db 1 GGAAGTGGGTT 12

RESULT 1134
 ABF32776
 ID ABF32776 standard; DNA; 13 BP.

```

XX AC ABF32776;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 132773 for detecting SNP TSC0033108.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 132773; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 1 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1701 GGAAGTTGGGTT 1712
Db 1 GGAAGTAGGGTT 12
XX
RESULT 1135
ID ABF39733/c
XX AC ABF39733 standard; DNA; 13 BP.
XX AC ABF39733;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 139730 for detecting SNP TSC0034974.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

```

```

PN WO200177384-A2.
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 139730; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 1 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATGGAGATT 1733
Db 13 GATATGGAGATT 2
XX
RESULT 1136
ID ABF51621
XX AC ABF51621 standard; DNA; 13 BP.
XX AC ABF51621;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 151618 for detecting SNP TSC0038312.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.

```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 151618; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1741 AACTCCTCCCTA 1752
XX |||||
XX 1 AAATCCTCCCTA 12
XX
XX RESULT 1137
XX ABC44245/c
XX ID ABC44245 standard; DNA; 13 BP.
XX
XX AC ABC44245;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 44262 for detecting SNP TSC0013010.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WC200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 44262; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX

CC	oligonucleotides are also used for detecting cell type differentiation. ABC000010					
CC	-ABF9989,	ABF0010-ABF9989,	ABH0010-ABH9989	and	ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence					
CC	data for this patent did not form part of the printed specification, but					
CC	was obtained in electronic format from WIPO at					
CC	ftp.wipo.int/pub/published_pct_sequences					
XX						
SQ	Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;					
<hr/>						
	Query Match	7.5%;	Score 10.4;	DB 1;	Length 13;	
	Best Local Similarity	91.7%;	Pred. No. 5.4e+02;			
	Matches 11;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;	
QY	1699 GTGGAAGTTGGG	1710				
Dd						
	13 GAGGAAGTTGGG	2				
<hr/>						
RESULT 1138						
ID	ABC46624/c					
XX	ABC46624 standard; DNA; 13 BP.					
AC	ABC46624;					
XX						
DT	21-FEB-2002 (first entry)					
DE	Oligonucleotide SEQ ID NO 46641 for detecting SNP TSC0013460.					
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;					
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;					
XW	central nervous system; gastrointestinal; respiratory; immune; metabolic.					
XX	Homo sapiens.					
OS						
XX	WO200177384-A2.					
PN						
XX	18-OCT-2001.					
PD						
XX	06-APR-2001; 2001WO-IB000713.					
PF						
XX	07-APR-2000; 2000DE-01019173.					
PR	(BPIG-) EPIGENOMICS AG.					
XX	Olek A, Piepenbrock C, Berlin K;					
XX	WPI; 2001-657177/75.					
DR						
XX	Set of oligonucleotides, useful for diagnosis and cell typing, is					
PT	designed to detect single-nucleotide polymorphisms and cytosine					
PT	methylation status.					
XX	Claim 1; SEQ ID NO 46641; 29pp + Sequence Listing; German.					
PS						
XX	This invention describes novel oligonucleotide primers or peptide nucleic					
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)					
CC	and cytosine methylation status in chemically pretreated genomic DNA. The					
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a					
CC	range of diseases including immune system, gastrointestinal, respiratory,					
CC	metabolic disorders. The					
CC	central nervous system, cardiovascular and metastatic disorders. The					
CC	oligomers are also used for detecting cell type differentiation. ABC000010					
CC	-ABF9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073					
CC	represent the oligomers described in the invention. NOTE: The sequence					
CC	data for this patent did not form part of the printed specification, but					
CC	was obtained in electronic format from WIPO at					
CC	ftp.wipo.int/pub/published_pct_sequences					
XX						
SQ	Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;					
<hr/>						
	Query Match	7.5%;	Score 10.4;	DB 1;	Length 13;	
	Best Local Similarity	91.7%;	Pred. No. 5.4e+02;			
	Matches 11;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;	

QY 1740 CCACTCCTCCT 1751
 DB 13 CCACTCCTCCT 2

RESULT 1139
 ABF38485
 ID ABF38485 standard; DNA; 13 BP.
 AC ABF38485;
 DT 21-FEB-2002 (first entry)
 XX

Oligonucleotide SEQ ID NO 138482 for detecting SNP TSC0034676.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 Claim 1; SEQ ID NO 138482; 29pp + Sequence Listing; German.
 This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTAA 1759
 DB 2 CACTATCCTAA 13

RESULT 1140
 ABF41114
 ID ABF41114 standard; DNA; 13 BP.
 AC ABF41114;
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 141111 for detecting SNP TSC0035363.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
 Claim 1; SEQ ID NO 141111; 29pp + Sequence Listing; German.
 This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1694 GCGTGGTGGTAG 1705
 DB 2 GCGTGGTGGTAG 13

RESULT 1141
 ABF95707/C
 ID ABF95707 standard; DNA; 13 BP.
 AC ABF95707;
 DT 22-FEB-2002 (first entry)
 XX

Oligonucleotide SEQ ID NO 195704 for detecting SNP TSC0009428.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 195704; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1702 GAAGTTGGGTTA 1713
XX Db 13 GAAGTTAGGTTA 2
XX
XX RESULT 1142
XX ABF95709/c
XX ID ABF95709 standard; DNA; 13 BP.
XX AC ABF95709;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 195706 for detecting SNP TSC0009428.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 173138; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1702 GAAGTTGGGTTA 1713
XX Db 13 GAAGTTAGGTTA 2
XX
XX RESULT 1143
XX ABF73141
XX ID ABF73141 standard; DNA; 13 BP.
XX AC ABF73141;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 173138 for detecting SNP TSC0043123.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 173138; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX

```

```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;
  Query Match 7.5%; Score 10.4; DB 1; Length 13;
  Best Local Similarity 91.7%; Pred. No. 5.4e+02;
  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1744 TCCTCCCTATCC 1755
  |||||
  2 TCCTCCCATCC 13
Db
RESULT 1144
ABH00391/c
ID ABH00391 standard; DNA; 13 BP.
XX
AC ABH00391;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200368 for detecting SNP TSC0049306.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PWPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 200368; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 7 C; 1 G; 4 T; 0 U; 0 Other;
  Query Match 7.5%; Score 10.4; DB 1; Length 13;
  Best Local Similarity 91.7%; Pred. No. 5.4e+02;
  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGAT 1732
  |||||
  13 GGAGACGGAGAT 2
Db
RESULT 1146
ABF82123
ID ABF82123 standard; DNA; 13 BP.
XX
AC ABF82123;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 182120 for detecting SNP TSC0045020.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
  Query Match 7.5%; Score 10.4; DB 1; Length 13;
  Best Local Similarity 91.7%; Pred. No. 5.4e+02;
  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 AAGTTGGTTAG 1714
  |||||
  2 AAGTTGGTTAG 13
Db
RESULT 1145
ABF55722
ID ABF55722 standard; DNA; 13 BP.
XX
AC ABF55722;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 155719 for detecting SNP TSC0039321.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PWPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 155719; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
  Query Match 7.5%; Score 10.4; DB 1; Length 13;
  Best Local Similarity 91.7%; Pred. No. 5.4e+02;
  Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 AAGTTGGTTAG 1714
  |||||
  2 AAGTTGGTTAG 13
Db
```


oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match
Best Local Similarity 91.7%; Pred. No. 5.4e+02; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1703 AAGTTGGGTTAG 1714
Db 1 ATGTTGGGTTAG 12

RESULT 1149
ABF66102
ID ABF66102 standard; DNA; 13 BP.
XX AC
XX ABF66102;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166099 for detecting SNP TSC0007702.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 166099; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 4 A; 1 C; 6 G; 2 T; 0 U; 0 Other;

Query Match
7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02; Mismatches 1; Indels 0; Gaps 0;

QY 1693 AGCGTGGTGAA 1704
Db 2 AGCGTGGTGAA 13

RESULT 1150
ABC05021/c
ID ABC05021 standard; DNA; 13 BP.
XX AC
XX ABC05021;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5012 for detecting SNP TSC0001740.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.
XX
XX Claim 1; SEQ ID NO 5012; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 1 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match
7.5%; Score 10.4; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
Db 12 GGAGATGGAGAT 1

RESULT 1151
ABC31005/c
ID ABC31005 standard; DNA; 13 BP.
XX AC
XX ABC31005;

XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 31022 for detecting SNP TSC0009554.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 31022; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 8 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGAT 1732
Db 12 GGAGAGGGAGAT 1
RESULT 1152
ABC32492
ID ABC32492 standard; DNA; 13 BP.
XX AC ABC32492;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 32509 for detecting SNP TSC0010144.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PD 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 32509; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1706 TTGGGTTAGGAG 1717
Db 2 TTAGGTTAGGAG 13
RESULT 1153
ABC84322
ID ABC84322 standard; DNA; 13 BP.
XX AC ABC84322;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 84339 for detecting SNP TSC0021205.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 84339; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733

Db 1 GAGATGAAGATT 12

RESULT 1154

ABC87616
ID ABC87616 standard; DNA; 13 BP.

AC ABC87616;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 87633 for detecting SNP TSC0022046.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 87633; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733

Db 2 GAGATGGAGATT 13

RESULT 1155

ABC63274
ID ABC63274 standard; DNA; 13 BP.

AC ABC63274;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 63291 for detecting SNP TSC0016721.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 63291; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTG 1708

Db 1 TGGTGGGAGTTG 12

RESULT 1156
 ABC16398
 ID ABC16398 standard; DNA; 13 BP.
 XX
 AC ABC16398;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 16405 for detecting SNP TSC0003579.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 16405; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
 XX
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1721 GGAGATGGAGAT 1732
 DB 2 GGAGGTGGAGAT 13
 XX
 RESULT 1157
 ABC66449/c
 ID ABC66449 standard; DNA; 13 BP.
 XX
 AC ABC66449;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 66466 for detecting SNP TSC0017469.
 XX

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX Claim 1; SEQ ID NO 66466; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
 XX
 CC Query Match 7.5%; Score 10.4; DB 1; Length 13;
 CC Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 CC Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1708 GGCTTAGGAGTA 1719
 DB 13 GGATTAGGAGTA 2
 XX
 RESULT 1158
 ABF20156/c
 ID ABF20156 standard; DNA; 13 BP.
 XX
 AC ABF20156;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 120153 for detecting SNP TSC0029992.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 120153; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 5 A; 0 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1746 CTCCTATCCTA 1757
 Db 13 CTACCTATCCTA 2

RESULT 1159
 ABF20157
 ID ABF20157 standard; DNA; 13 BP.
 AC ABF20157;
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 120154 for detecting SNP TSC0029992.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 120154; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 3 A; 5 C; 0 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1746 CTCCTATCCTA 1757
 Db 1 CTACCTATCCTA 12

RESULT 1160
 ABF30620
 ID ABF30620 standard; DNA; 13 BP.
 AC ABF30620;
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 130617 for detecting SNP TSC0033620.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 130617; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

```
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 3 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGAGTAAG 1721
|||||
Db 1 GTTAGGAGTAAG 12

RESULT 1161
ABF32047/C
ID ABF32047 standard; DNA; 13 BP.
AC ABF32047;
XX
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132044 for detecting SNP TSC0032957.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 132044; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1704 AGTTGGGTAGG 1715
|||||
Db 12 AGTTGGGTGGG 1

RESULT 1162
ABF32777/C
ID ABF32777 standard; DNA; 13 BP.
AC ABF32777;
XX
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132774 for detecting SNP TSC0043388.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 132774; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1701 GGAAGTGGGTT 1712
|||||
Db 13 GGAAGTGGGTT 2

RESULT 1163
ABF74437/C
ID ABF74437 standard; DNA; 13 BP.
AC ABF74437;
XX
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 174434 for detecting SNP TSC0043388.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
```

XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 174434; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1702 GAGTTCGGTTA 1713
XX DB 13 GTAGTTCGGTTA 2
XX
XX RESULT 1164
XX ABH00387/C
XX ID ABH00387 standard; DNA; 13 BP.
XX AC ABH00387;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 200364 for detecting SNP TSC0049306.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PF Claim 1; SEQ ID NO 200364; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1721 GGAGATGGAGAT 1732
XX DB 13 GGAGATAGAGAT 2
XX
XX RESULT 1165
XX ABF79387
XX ID ABF79387 standard; DNA; 13 BP.
XX AC ABF79387;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 179384 for detecting SNP TSC0044413.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 179384; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCCACTCTC 1747
DB 2 CTCCCACTACT 13

RESULT 1166
ABF58666/C
ID ABF58666 standard; DNA; 13 BP.
XX
AC ABF58666;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 158663 for detecting SNP TSC0039936.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 158663; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCCACTCTC 1747
DB 2 CTCCCACTACT 13

RESULT 1166
ABF58666/C
ID ABF58666 standard; DNA; 13 BP.
XX
AC ABF58666;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 158663 for detecting SNP TSC0039936.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 158663; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

QY 1737 TCCCACTCTCTC 1748
DB 12 TCCCAACACCTC 1

RESULT 1167
ABH35975
ID ABH35975 standard; DNA; 13 BP.
XX
AC ABH35975;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 235952 for detecting SNP TSC0005348.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 235952; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCTCTAAA 1759
DB 2 CCTATCTCTAAA 13

RESULT 1168
ABF87483
ID ABF87483 standard; DNA; 13 BP.
XX
AC ABF87483;
XX
DT 22-FEB-2002 (first entry)


```

XX DE Oligonucleotide SEQ ID NO 187480 for detecting SNP TSC0046214.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 187480; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1748 CCTATCCTAAA 1759
XX Db ||||| |||||
XX 2 CCTTTCTCTAAA 13
XX
XX RESULT 1169
XX ABH13554/c
XX ID ABH13554 standard; DNA; 13 BP.
XX AC ABH13554;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 213531 for detecting SNP TSC0051991.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 187480; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1748 CCTATCCTAAA 1759
XX Db ||||| |||||
XX 2 CCTTTCTCTAAA 13
XX
XX RESULT 1169
XX ABH13554/c
XX ID ABH13554 standard; DNA; 13 BP.
XX AC ABH13554;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 213531 for detecting SNP TSC0051991.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 213531; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1737 TCCCAACTCCTC 1748
XX Db ||||| |||||
XX 13 TCCCAACTCCAC 2
XX
XX RESULT 1170
XX ABH50618/c
XX ID ABH50618 standard; DNA; 13 BP.
XX AC ABH50618;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 250595 for detecting SNP TSC0061192.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1747 TCCCTATCCTAA 1758
Db 1 TCTCTATCCTAA 12
RESULT 1172
ABH63202
ID ABH63202 standard; DNA; 13 BP.
XX
AC ABH63202;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 263179 for detecting SNP TSC0063836.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01C19173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PP WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 263179; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1746 CTCCTATCCTA 1757
Db 13 CTCCTATCCTA 2
RESULT 1171
ABH61555
ID ABH61555 standard; DNA; 13 BP.
XX
AC ABH61555;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 261532 for detecting SNP TSC0063469.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PP WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 261532; 29pp + Sequence Listing; German.
XX
SQ This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

RESULT 1173
 ABC00338
 ID ABC00338 standard; DNA; 13 BP.
 XX
 AC ABC00338;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 329 for detecting SNP TSC0000062.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DE Oligonucleotide SEQ ID NO 329 for detecting SNP TSC0000062.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 329; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1701 GGAAGTTGGGTT 1712
 DB 1 GGAAGTTGGGAT 12
 RESULT 1174
 ABC77733/c
 ID ABC77733 standard; DNA; 13 BP.
 XX
 AC ABC77733;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 77750 for detecting SNP TSC0019796.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 77750; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1708 GGGTTAGGAGTA 1719
 DB 13 GGGTTGGAGTA 2
 RESULT 1175
 ABC04731
 ID ABC04731 standard; DNA; 13 BP.
 XX
 AC ABC04731;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 4722 for detecting SNP TSC0001698.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

Mon Aug 30 09:26:45 2004

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 1 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1705 GTTGGGTTAGGA 1716
 Db 2 GTTGGGTTCCGA 13
 RESULT 1177
 ABC57210
 ID ABC57210 standard; DNA; 13 BP.
 XX
 XX AC ABC57210;
 XX 21-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 57227 for detecting SNP TSC0015477.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 57227; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 4 A; 1 C; 4 G; 3 T; 0 U; 1 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1741 AACTCTCTCCCTA 1752
 Db 2 AACTCTCTCCAA 13
 RESULT 1176
 ABC31808
 ID ABC31808 standard; DNA; 13 BP.
 XX
 XX AC ABC31808;
 XX 20-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 31825 for detecting SNP TSC0009913.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 31825; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 4722; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1741 AACTCTCTCCCTA 1752
 Db 2 AACTCTCTCCAA 13
 RESULT 1176
 ABC31808
 ID ABC31808 standard; DNA; 13 BP.
 XX
 XX AC ABC31808;
 XX 20-FEB-2002 (first entry)
 DT
 XX Oligonucleotide SEQ ID NO 31825 for detecting SNP TSC0009913.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 31825; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATCGAGATT 1733
DB 1 GAGATCGAGATT 12

RESULT 1178

ABC40890
ID ABC40890 standard; DNA; 13 BP.

AC ABC40890;
DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 40907 for detecting SNP TSC0012352.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX WO200177384-A2.

PN 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine

methylation status.

PS Claim 1; SEQ ID NO 40907; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a

range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The

oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but

was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 5 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATCGAGATT 1733
DB 1 GAGATCGAGATT 12

RESULT 1179

ABC40891/c

ID ABC40891 standard; DNA; 13 BP.

XX

AC ABC40891;
XX 21-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 40908 for detecting SNP TSC0012352.

DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX WO200177384-A2.

PN 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine

methylation status.

PS Claim 1; SEQ ID NO 40908; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a

range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The

oligonucleotides are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but

was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 4 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATCGAGATT 1733

DB 13 GAGATCGAGATT 2

RESULT 1180

ABF18045/c

ID ABF18045 standard; DNA; 13 BP.

AC ABF18045;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 118042 for detecting SNP TSC0029517.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX WO200177384-A2.

PN 18-OCT-2001.

```
XX PD 18-OCT-2001.
XX PF
XX PP
XX PS
XX PR
XX PR 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX PR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 118042; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1711 TTAGGAGTACGG 1722
XX Db 12 TTAGGAGTAGGG 1
XX
XX RESULT 1181
XX ABF24346
XX ID ABF24346 standard; DNA; 13 BP.
XX AC ABF24346;
XX XX
XX XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 124343 for detecting SNP TSC0031088.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX XX 18-OCT-2001.
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX XX designed to detect single-nucleotide polymorphisms and cytosine
XX XX methylation status.
XX XX Claim 1; SEQ ID NO 118042; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1711 TTAGGAGTACGG 1722
XX Db 12 TTAGGAGTAGGG 1
XX
XX RESULT 1181
XX ABF24346
XX ID ABF24346 standard; DNA; 13 BP.
XX AC ABF24346;
XX XX
XX XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 124343 for detecting SNP TSC0031088.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX XX 18-OCT-2001.
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX XX designed to detect single-nucleotide polymorphisms and cytosine
XX XX methylation status.
XX XX Claim 1; SEQ ID NO 124343; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1723 AGATGGAGATTG 1734
XX Db 1 AGATGGGGATTG 12
XX
XX RESULT 1182
XX ABF24347/c
XX ID ABF24347 standard; DNA; 13 BP.
XX AC ABF24347;
XX XX
XX XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 124344 for detecting SNP TSC0031088.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX XX
XX XX 18-OCT-2001.
XX XX 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX XX (EPIG-) EPIGENOMICS AG.
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX XX designed to detect single-nucleotide polymorphisms and cytosine
XX XX methylation status.
XX XX Claim 1; SEQ ID NO 124344; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1723 AGATGGGATTG 1734
 DB 13 AGATGGGATTG 2
 RESULT 1183
 ABF30621/c
 ID ABF30621 standard; DNA; 13 BP.
 XX
 XX AC ABF30621;
 XX
 XX DT 21-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 130618 for detecting SNP TSC0032620.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 130618; 29pp + Sequence Listing; German.
 XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 3 A; 5 C; 0 G; 4 T; 0 U; 1 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1710 GTTAGGATTACG 1721

DB 13 GTTAGGATTACG 2
 RESULT 1184
 ABF34098
 ID ABF34098 standard; DNA; 13 BP.
 XX
 XX AC ABF34098;
 XX
 XX DT 21-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 134095 for detecting SNP TSC0033433.
 XX
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200177384-A2.
 XX
 XX PD 18-OCT-2001.
 XX
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX PR 07-APR-2000; 2000DE-01019173.
 XX
 XX PA (EPIG-) EPIGENOMICS AG.
 XX
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX DR WPI; 2001-657177/75.
 XX
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX
 XX PS Claim 1; SEQ ID NO 134095; 29pp + Sequence Listing; German.
 XX
 XX CC This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences
 XX
 XX SQ Sequence 13 BP; 5 A; 1 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1714 GGAGTACGAGA 1725
 DB 1 GGAGTACGAGA 12
 RESULT 1185
 ABF95706
 ID ABF95706 standard; DNA; 13 BP.
 XX
 XX AC ABF95706;
 XX
 XX DT 22-FEB-2002 (first entry)
 XX
 XX DE Oligonucleotide SEQ ID NO 195703 for detecting SNP TSC0009428.

```

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 195703; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GAAGTTGGGTTA 1713
DB 1 GAAGTTAGGTTA 12

RESULT 1186
ABH26445
ID ABH26445 standard; DNA; 13 BP.
XX AC ABH26445;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 226422 for detecting SNP TSC0055194.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 158664; 29pp + Sequence Listing; German.

```

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 226422; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCAACTCTCTC 1748
DB 2 TCCCAACTCTCTC 13

RESULT 1187
ABF58667
ID ABF58667 standard; DNA; 13 BP.
XX AC ABF58667;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 158664 for detecting SNP TSC0039936.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB0000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX PS Claim 1; SEQ ID NO 158664; 29pp + Sequence Listing; German.

```


XX CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) CC and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC was obtained in electronic format from WIPO at CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1737 TCCCAACTCCTC 1748
Db 2 TCCCAACACCTC 13
||||| |||||

RESULT 1188
ABH37502/c
ID ABH37502 standard; DNA; 13 BP.
XX AC ABH37502;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 237479 for detecting SNP TSC0057920.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 237479; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1750 CTATCCTAAAGG 1761
Db 12 CTATCCTAAAGG 1
||||| |||||

RESULT 1189
ABF87482/c
ID ABF87482 standard; DNA; 13 BP.
XX AC ABF87482;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 187479 for detecting SNP TSC0046214.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 187479; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1748 CCTATCCTAA 1759
Db 12 CCTTCTCTAA 1
||||| |||||

RESULT 1190

```
ABH12821/c
ID ABH12821 standard; DNA; 13 BP.
XX
AC ABH12821;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 212798 for detecting SNP TSC0051845.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 212798; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GAAGTTGGGTTA 1713
Db 13 GAAGTTGAGTTA 2
|||||
RESULT 1191
ABF66672
ID ABF66672 standard; DNA; 13 BP.
XX
AC ABF66672;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166669 for detecting SNP TSC0041743.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 166669; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1710 GTTAGGAGTACG 1721
Db 1 GTTAGGAGTTCG 12
|||||
RESULT 1192
ABF66673/c
ID ABF66673 standard; DNA; 13 BP.
XX
AC ABF66673;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166670 for detecting SNP TSC0041743.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
```

```
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 166670; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 5 C; 1 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1710 GTTAGGAGTACG 1721.
XX | | | | | | | |
XX 13 GTTAGGAGTTCG 2
XX
XX RESULT 1193
XX ABH42002/c
XX ID ABH42002 standard; DNA; 13 BP.
XX AC ABH42002;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 241979 for detecting SNP TSC0059020.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 241979; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1748 CCTATCCTCTAAA 1759
XX | | | | | | | |
XX 13 CACTATCCTCTAAA 2
XX
XX Db
XX
XX RESULT 1194
XX ABC77642
XX ID ABC77642 standard; DNA; 13 BP.
XX AC ABC77642;
XX XX
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 77659 for detecting SNP TSC0019778.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 77659; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
```

```

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATGGAGATT 1733
    ||||| |||
Db 2 GAGATGGGATT 13

RESULT 1195
ABC09988/c
ID ABC09988 standard; DNA; 13 BP.
XX AC ABC09988;
XX DT
XX DT 20-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 9979 for detecting SNP TSC0002575.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT Claim 1; SEQ ID NO 9979; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1741 AACTCTCCCTA 1752
    ||||| |||
Db 13 ACCTCTCCCTA 2

RESULT 1196
ABC88051/c
ID ABC88051 standard; DNA; 13 BP.
XX AC ABC88051;
XX AC

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATGGAGATT 1733
    ||||| |||
Db 2 GAGATGGGATT 13

RESULT 1197
ABC40067/c
ID ABC40067 standard; DNA; 13 BP.
XX AC ABC40067;
XX DT
XX DT 21-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 40084 for detecting SNP TSC0012198.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT Claim 1; SEQ ID NO 88068; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
    ||||| |||
Db 12 GAGATGGGATT 1

RESULT 1197
ABC40067/c
ID ABC40067 standard; DNA; 13 BP.
XX AC ABC40067;
XX DT
XX DT 21-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 40084 for detecting SNP TSC0012198.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT Claim 1; SEQ ID NO 88068; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

XX PF 06-APR-2001; 2001WO-IB000713.
XX XX 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 40084; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX QY 1705 GTTGGGTTAGGA 1716
XX Db 13 GTGGGGTTAGGA 2

XX RESULT 1198
XX ABC16399/c
XX ID ABC16399 standard; DNA; 13 BP.
XX AC ABC16399;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 16406 for detecting SNP TSC0003579.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 16406; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;

PT methylation status.
XX Claim 1; SEQ ID NO 16406; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX QY 1721 GGAGTGGAGAT 1732
XX Db 12 GGAGTGGAGAT 1

XX RESULT 1199
XX ABF43821/c
XX ID ABF43821 standard; DNA; 13 BP.
XX AC ABF43821;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 143818 for detecting SNP TSC0036107.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 143818; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1713 AGGAGTACGAG 1724
|||||
DB 12 AGGAGTAAGGAG 1
RESULT 1200
ABF95708
ID ABF95708 standard; DNA; 13 BP.
XX
AC ABF95708;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 195705 for detecting SNP TSC0009428.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 195705; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1702 GAAGTGGGTTA 1713
|||||
DB 1 GAAGTCGGGTTA 12
RESULT 1201
ABF73140/c
ID ABF73140 standard; DNA; 13 BP.
XX
AC ABF73140;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173137 for detecting SNP TSC0043123.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173137; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF0010-ABF99989, ABH0010-ABH99989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1744 TCCTCCCATATCC 1755
|||||
DB 12 TCCTCCCAATCC 1
RESULT 1202
ABF54762
ID ABF54762 standard; DNA; 13 BP.
XX
AC ABF54762;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 154759 for detecting SNP TSC0039120.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 154759; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1703 AAGTTGGGTTAG 1714
 Db 1 AGGTTGGGTTAG 12
 RESULT 1203
 ABF61036
 ID ABF61036 standard; DNA; 13 BP.
 XX AC ABF61036;
 XX DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 161033 for detecting SNP TSC0040546.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 161033; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1723 AGATGGAGTTG 1734
 Db 1 AGATGGAGTTG 12
 RESULT 1204
 ABH36660/C
 ID ABH36660 standard; DNA; 13 BP.
 XX AC ABH36660;
 XX DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 236637 for detecting SNP TSC0057760.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 236637; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic

XX AC ABH50619;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 250596 for detecting SNP TSC0061192.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX DR WPI; 2001-657177/75.
XX XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
XX Claim 1; SEQ ID NO 250596; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05796, ABF05796, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX XX
SQ Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;
XX XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
QY 1746 CTCCTATCCTA 1757
| | | | | | | | | |
DB 1 CTCCTATCCTA 12
XX XX
RESULT 1208
ABF05796/c
ID ABF05796 standard; DNA; 13 BP.
XX XX
AC ABF05796;
XX XX
XX 21-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 105793 for detecting SNP TSC0026522.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX XX

PN WO200177384-A2.
XX XX
PD 18-OCT-2001.
XX XX
PF 06-APR-2001; 2001WO-IB000713.
XX XX
PR 07-APR-2000; 2000DE-01019173.
XX XX
PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX WPI; 2001-657177/75.
XX XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX XX
XX Claim 1; SEQ ID NO 105793; 29pp + Sequence Listing; German.
XX XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF05796, ABF05796, ABH00010-ABH99989 and ABH00010-ABH82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX XX
SQ Sequence 13 BP; 1 A; 1 C; 8 G; 3 T; 0 U; 0 Other;
XX XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
QY 1735 GCTCCCAACTCC 1746
| | | | | | | | | |
DB 12 GCTCCCAACTCC 1
XX XX
RESULT 1209
ABC33106/c
ID ABC33106 standard; DNA; 13 BP.
XX XX
AC ABC33106;
XX XX
XX 20-FEB-2002 (first entry)
XX XX
DE Oligonucleotide SEQ ID NO 33123 for detecting SNP TSC0010560.
XX XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX KW
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX XX
XX 18-OCT-2001.
XX XX
XX 06-APR-2001; 2001WO-IB000713.
XX XX
XX 07-APR-2000; 2000DE-01019173.
XX XX
XX (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX XX
XX WPI; 2001-657177/75.
XX XX

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 33123; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTCTAAA 1759
Db 12 CCTATCCTCTAAA 1

RESULT 1210
ABC33107
ID ABC33107 standard; DNA; 13 BP.
XX
XX AC ABC33107;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 33124 for detecting SNP TSC0010560.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 33124; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTCTAAA 1759
Db 2 CCTATCCTCTAAA 13

RESULT 1211
ABC40066
ID ABC40066 standard; DNA; 13 BP.
XX
XX AC ABC40066;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 40083 for detecting SNP TSC0012198.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 40083; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGGTAGGA 1716
 Db 1 GTGGGGTTAGGA 12
 RESULT 1212
 ABC66989
 ID ABC66989 standard; DNA; 13 BP.
 XX AC ABC66989;
 XX DT 21-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 67006 for detecting SNP TSC0017552.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 67006; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
 XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1747 TCCCTATCCTAA 1758
 Db 1 TCCATACTCTAA 12
 RESULT 1213
 ABH26444/C
 ID ABH26444 standard; DNA; 13 BP.
 XX AC ABH26444;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 235951 for detecting SNP TSC0005348.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.

DE Oligonucleotide SEQ ID NO 226421 for detecting SNP TSC0055194.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 226421; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
 XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1737 TCCCAACTCCTC 1748
 Db 12 TCCCAACTACTC 1
 RESULT 1214
 ABH35974/C
 ID ABH35974 standard; DNA; 13 BP.
 XX AC ABH35974;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 235951 for detecting SNP TSC0005348.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 235951; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1748 CCTATCCTCTAA 1759
Db 12 CCTATCCTCTAA 1
RESULT 1215
ABC24272/c
ID ABC24272 standard; DNA; 13 BP.
AC ABC24272;
XX 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 24289 for detecting SNP TSC0005767.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 235951; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1748 CCTATCCTCTAA 1759
Db 12 CCTATCCTCTAA 1
RESULT 1215
ABC24272/c
ID ABC24272 standard; DNA; 13 BP.
AC ABC24272;
XX 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 24289 for detecting SNP TSC0005767.
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 24289; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1748 CCTATCCTCTAA 1759
Db 12 CCTATCCTCTAA 1
RESULT 1216
ABC52599
ID ABC52599 standard; DNA; 13 BP.
XX
AC ABC52599;
XX 21-FEB-2002 (first entry)
DT
DE Oligonucleotide SEQ ID NO 52616 for detecting SNP TSC0014588.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 52616; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

```

CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1737 TCCCACTCCTC 1748

Db 1 TCCCACTACTC 12

RESULT 1217

ABC05020
ID ABC05020 standard; DNA; 13 BP.

XX AC ABC05020;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 5011 for detecting SNP TSC0001740.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 5011; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1721 GGAGATCGAGAT 1732

Db 2 GGACGGAGAT 13

RESULT 1218

ABC0340/c
ID ABC0340 standard; DNA; 13 BP.

XX AC ABC0340;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 80357 for detecting SNP TSC0020399.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 80357; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1742 ACTCTCCCTAT 1753

Db 12 ACTCTCCCTAT 1

RESULT 1219

ABC31800
ID ABC31800 standard; DNA; 13 BP.

XX AC ABC31800;

XX 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 31817 for detecting SNP TSC0009913.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 82544; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1705 GTTGGGTTAGGA 1716
Db 2 GTTGGGTTCCGA 13
|||||
RESULT 1220
ABC82527
ID ABC82527 standard; DNA; 13 BP.
XX AC ABC82527;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 82544 for detecting SNP TSC0020825.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 11721; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1741 AACTCTCTCCCTA 1752
Db 2 AACTCTCTACCTA 13
|||||
RESULT 1221
ABC11714
ID ABC11714 standard; DNA; 13 BP.
XX AC ABC11714;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 11721 for detecting SNP TSC0002832.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 11721; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 AGTTGGGTAGG 1715
 Db 1 AGTTGGGTGG 12
 |||||

RESULT 1222

ABC63275/c

ID ABC63275 standard; DNA; 13 BP.

XX ABC63275;

XX DT

21-FEB-2002 (first entry)

XX DE

Oligonucleotide SEQ ID NO 63292 for detecting SNP TSC0016721.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX DT

18-OCT-2001.

XX PF

06-APR-2001; 2001WO-IB000713.

XX PR

07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX PF

WPI; 2001-657177/75.

XX PT

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

XX PS

Claim 1; SEQ ID NO 63292; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1697 TGGTGAAGTTG 1708
 |||||

Db 13 TGGTGGGAGTTG 2
 |||||

RESULT 1223

ABC14559

ID ABC14559 standard; DNA; 13 BP.

XX AC ABC14559;

XX DT

20-FEB-2002 (first entry)

XX DE

Oligonucleotide SEQ ID NO 14566 for detecting SNP TSC0003286.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX DT

18-OCT-2001.

XX PF

06-APR-2001; 2001WO-IB000713.

XX PR

07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR

WPI; 2001-657177/75.

XX PT

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

XX PS

Claim 1; SEQ ID NO 14566; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 9 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1736 CTCGCCACTCCT 1747
 |||||

Db 2 CTCGCCACTCCT 13
 |||||

RESULT 1224

ABC40888

ID ABC40888 standard; DNA; 13 BP.

XX AC ABC40888;

```

XX 21-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 40905 for detecting SNP TSC0012352.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 40905; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATGGAGATT 1733
DB 1 GAGATTGAGATT 12
RESULT 1225
ABF32046
ID ABF32046 standard; DNA; 13 BP.
XX
XX ABF32046;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 132043 for detecting SNP TSC0032957.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 40905; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1722 GAGATGGAGATT 1733
DB 1 GAGATTGAGATT 12
RESULT 1225
ABF32046
ID ABF32046 standard; DNA; 13 BP.
XX
XX ABF32046;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 132043 for detecting SNP TSC0032957.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 132043; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1704 AGTTGGGTAGG 1715
DB 2 AGTTGGGTGGG 13
RESULT 1226
ABF32775/c
ID ABF32775 standard; DNA; 13 BP.
XX
XX ABF32775;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 132772 for detecting SNP TSC0033108.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB0000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 132043; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
SQ

```


PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 132772; 29pp + Sequence Listing; German.

XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGGTT 1712

Db 13 GGAAGTTGGGTT 2

RESULT 1227

ABF92685/c

ID ABF92685 standard; DNA; 13 BP.

XX AC ABF92685;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 192682 for detecting SNP TSC0047412.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 192682; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTG 1708

Db 12 TGGTGAAGTTG 1

RESULT 1228

ABF54763/c

ID ABF54763 standard; DNA; 13 BP.

XX AC ABF54763;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 154760 for detecting SNP TSC0039120.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 154760; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1703 AAGTTGGGTTAG 1714

|||||

```

Db      13 AGTTGGGTTAG 2
RESULT 1229
ABF55623/c
ID      ABF55623 standard; DNA; 13 BP.
XX
AC      ABF55623;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 155620 for detecting SNP TSC0001748.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 155620; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABH0010-ABH82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match      7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1726 TGGAGATTGGCT 1737
DB      13 TGGAGATTGGGT 2
|||||||
RESULT 1230
ABF82122/c
ID      ABF82122 standard; DNA; 13 BP.
XX
AC      ABF82122;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 182119 for detecting SNP TSC0045020.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPiG-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 155620; 29pp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABH0010-ABH82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
XX
Query Match      7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1747 TCCCTATCCTAA 1758
DB      13 TCCCTATCCTTA 2
|||||||
RESULT 1231
ABH36975/c
ID      ABH36975 standard; DNA; 13 BP.
XX
AC      ABH36975;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 236952 for detecting SNP TSC0057811.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX

```

XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 236952; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1726 TGGAGATTGGCT 1737
 Db |||||
 12 TGGAGATTGGTT 1
 RESULT 1232
 ABH13559
 ID ABH13559 standard; DNA; 13 BP.
 XX AC ABH13559;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 213536 for detecting SNP TSC0051991.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 213536; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1737 TCCCACTCCGTC 1748
 Db |||||
 1 TCCCACTCCGC 12
 RESULT 1233
 ABF63800/C
 ID ABF63800 standard; DNA; 13 BP.
 XX AC ABF63800;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 163797 for detecting SNP TSC0010383.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 163797; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX Sequence 13 BP; 2 A; 7 C; 1 G; 3 T; 0 U; 0 Other;
 SQ

```
SQ Sequence 13 BP; 5 A; 0 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1745 CCTCCCTATCCT 1756
DB 12 CCTCCCTTCCT 1

RESULT 1234
ABC47685/c
ID ABC47685 standard; DNA; 13 BP.
XX
AC ABC47685;
XX
AC ABC47685;
XX
21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 47702 for detecting SNP TSC0013677.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPTG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 47702; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1704 AGTTGGGTTAGG 1715
DB 12 ATTGGGTTAGG 1

RESULT 1235
ABC31004
ID ABC31004 standard; DNA; 13 BP.
XX
AC ABC31004;
XX
20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31021 for detecting SNP TSC0009554.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPTG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 31021; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
DB 2 GGAGAGGGAGAT 13

RESULT 1236
ABC57211/c
ID ABC57211 standard; DNA; 13 BP.
XX
AC ABC57211;
XX
21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 57228 for detecting SNP TSC0015477.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
```

XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 57228; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 4 C; 1 G; 4 T; 0 U; 1 Other;
 XX
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1722 GAGATGAGATT 1733
 DB 13 GAGATCGAGATT 2
 XX
 RESULT 1237
 ABC82526/c
 ID ABC82526 standard; DNA; 13 BP.
 XX
 AC ABC82526;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 82543 for detecting SNP TSC0020825.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 82543; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1741 AACTCTCCCTTA 1752
 DB 12 AACTCTTACCTA 1
 XX
 RESULT 1238
 ABC84323/c
 ID ABC84323 standard; DNA; 13 BP.
 XX
 AC ABC84323;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 84340 for detecting SNP TSC0021205.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 84340; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
Db 13 GAGATGAGATT 2

RESULT 1239
ABF16774
ID ABF16774 standard; DNA; 13 BP.
XX
AC ABF16774;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116771 for detecting SNP TSC0029218.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 116771; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1714 GGAGTAGGGAGA 1725
Db 2 GGAGTAGGGAGA 13

RESULT 1241
ABF38484/C
ID ABF38484 standard; DNA; 13 BP.
XX
AC ABF38484;
XX
DT 21-FEB-2002 (first entry)

QY 1711 TTAGGAGTACGG 1722
Db 1 TTAGAAGTACGG 12

RESULT 1240
ABF18154
ID ABF18154 standard; DNA; 13 BP.
XX
AC ABF18154;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 118151 for detecting SNP TSC0029550.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 118151; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1714 GGAGTAGGGAGA 1725
Db 2 GGAGTAGGGAGA 13

RESULT 1241
ABF38484/C
ID ABF38484 standard; DNA; 13 BP.
XX
AC ABF38484;
XX
DT 21-FEB-2002 (first entry)

```

XX DE Oligonucleotide SEQ ID NO 138481 for detecting SNP TSC0034676.
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 138481; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX Qy 1748 CCTATCTCTAAA 1759
XX Db 12 CACTATCTCTAAA 1
XX RESULT 1242
XX ABF43731
XX ID ABF43731 standard; DNA; 13 BP.
XX AC ABF43731;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 143728 for detecting SNP TSC0036088.
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 143728; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX Qy 1748 CCTATCTCTAAA 1759
XX Db 12 CACTATCTCTAAA 1
XX RESULT 1242
XX ABF43731
XX ID ABF43731 standard; DNA; 13 BP.
XX AC ABF43731;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 151617 for detecting SNP TSC0038312.
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 143728; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 7 C; 0 G; 4 T; 0 U; 0 Other;
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX Qy 1738 CCCAACTCTCTCC 1749
XX Db 1 CCCAACTCTCTCC 12
XX RESULT 1243
XX ABF51620/C
XX ID ABF51620 standard; DNA; 13 BP.
XX AC ABF51620;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 151617 for detecting SNP TSC0038312.
XX KW SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

```

XX PS Claim 1; SEQ ID NO 151617; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1741 AACTCTCTCCCTA 1752

Db 13 AAATCTCTCCCTA 2

RESULT 1244

ABF53251/C

ID ABF53251 standard; DNA; 13 BP.

XX AC ABF53251;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 153248 for detecting SNP TSC0038744.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 153248; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 5 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1710 GTTAGGAGTACG 1721

Db 13 GTTAGGAGTACG 2

RESULT 1245

ABF61037/C

ID ABF61037 standard; DNA; 13 BP.

XX AC ABF61037;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 161034 for detecting SNP TSC0040546.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 161034; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 5.4e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1723 AGATGGAGATTG 1734

Db 13 AGATGGAGATTG 2

RESULT 1246
ABH36974
ID ABH36974 standard; DNA; 13 BP.
XX
XX AC ABH36974;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 236951 for detecting SNP TSC0057811.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 236951; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1726 TGGAGATTGGCT 1737
XX
XX DB 2 TGGAGATTGGTT 13
XX
XX RESULT 1247
XX ABH13555
XX ID ABH13555 standard; DNA; 13 BP.
XX
XX XX AC ABH13555;
XX
XX XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 213532 for detecting SNP TSC0051991.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 213532; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1737 TCCCAACTCCTC 1748
XX
XX DB 1 TCCCAACTCCAC 12
XX
XX RESULT 1248
XX ABC47422/c
XX ID ABC47422 standard; DNA; 13 BP.
XX
XX XX AC ABC47422;
XX
XX XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 47439 for detecting SNP TSC0013623.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIG-) EPIGENOMICS AG.

```
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 47439; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1742 ACTCTCTCTAT 1753
XX DB 12 ACTCTCTCTAT 1
XX
XX RESULT 1249
XX ABC47684
XX ID ABC47684 standard; DNA; 13 BP.
XX AC ABC47684;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 47701 for detecting SNP TSC0013677.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX DR designed to detect single-nucleotide polymorphisms and cytosine
XX DR methylation status.
XX PS Claim 1; SEQ ID NO 47701; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 7.5%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 5.4e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1704 AGTTGGGTAGG 1715
XX DB 2 ATTTGGGTAGG 13
XX
XX RESULT 1250
XX ABC75934/C
XX ID ABC75934 standard; DNA; 13 BP.
XX AC ABC75934;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 75951 for detecting SNP TSC0019457.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX DR designed to detect single-nucleotide polymorphisms and cytosine
XX DR methylation status.
XX PS Claim 1; SEQ ID NO 75951; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
```

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCTCTAAA 1759
 DB 13 CCTTAACCTAAA 2

RESULT 1251
 ABC77732
 ID ABC77732 standard; DNA; 13 BP.
 AC ABC77732;
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 77749 for detecting SNP TSC0019796.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
 PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

Claim 1; SEQ ID NO 77749; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 range of diseases including immune system, gastrointestinal, respiratory,
 central nervous system, cardiovascular and metabolic disorders. The
 oligomers are also used for detecting cell type differentiation. ABC00010
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 represent the oligomers described in the invention. NOTE: The sequence
 data for this patent did not form part of the printed specification, but
 was obtained in electronic format from WIPO at
 ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1708 GGGTTAGGAGTA 1719
 DB 1 GGGTTTGGAGTA 12

RESULT 1252

ABF05797

ID ABF05797 standard; DNA; 13 BP.

XX

AC ABF05797;
 XX 21-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 105794 for detecting SNP TSC0026522.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

Claim 1; SEQ ID NO 105794; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 range of diseases including immune system, gastrointestinal, respiratory,
 central nervous system, cardiovascular and metabolic disorders. The
 oligomers are also used for detecting cell type differentiation. ABC00010
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 represent the oligomers described in the invention. NOTE: The sequence
 data for this patent did not form part of the printed specification, but
 was obtained in electronic format from WIPO at
 ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 8 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1735 GCTCCCACTCC 1746

DB 2 GCTCCCACTCC 13

RESULT 1253

ABC31003/c

ID ABC31003 standard; DNA; 13 BP.

AC ABC31003;

DT 20-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 31020 for detecting SNP TSC0009554.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 9980; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1741 AACCTCCTCCCTA 1752
Db 1 ACCCTCCTCCCTA 12

RESULT 1255
ABF16775/C
ID ABF16775 standard; DNA; 13 BP.
XX
XX AC ABF16775;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 116772 for detecting SNP TSC0029218.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 116772; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC

[illegible]

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 5 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1711 TTAGGAGTACGG 1722
 ||||| |||||

DB 13 TTAGAAGTACGG 2

RESULT 1256

ABF34099/c
 ID ABF34099 standard; DNA; 13 BP.

XX AC ABF34099;

XX DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 134096 for detecting SNP TSC0033433.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 134096; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1714 GGAGTACGGAGA 1725

DB 13 GGATACGGAGA 2
 ||||| |||||

RESULT 1257

ABF41115/c
 ID ABF41115 standard; DNA; 13 BP.

XX AC ABF41115;

XX DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 141112 for detecting SNP TSC0035363.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 141112; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 8 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1694 GCGTGGTGGAG 1705
 ||||| |||||

DB 12 GCGTGGTGGTAG 1

RESULT 1258

ABH00386
 ID ABH00386 standard; DNA; 13 BP.

XX AC ABH00386;

XX DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 200363 for detecting SNP TSC0049306.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 200363; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGAT 1732
DB 1 GGAGATAGAGAT 12
RESULT 1259
ABF53250
ID ABF53250 standard; DNA; 13 BP.
XX AC ABF53250;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 153247 for detecting SNP TSC0038744.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX Claim 1; SEQ ID NO 215208; 29pp + Sequence Listing; German.

PR 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 153247; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX Sequence 13 BP; 2 A; 1 C; 5 G; 4 T; 0 U; 1 Other;
SQ Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1710 GTTAGGATGACG 1721
DB 1 GTTAGGATGACG 12
RESULT 1260
ABH15231
ID ABH15231 standard; DNA; 13 BP.
XX AC ABH15231;
XX 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 215208 for detecting SNP TSC0052373.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 215208; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCTATCCTCTAA 1759
DB 2 CCTATCCTCTAA 13

RESULT 1261
ABF65199/c
ID ABF65199 standard; DNA; 13 BP.
XX
AC ABF65199;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 165196 for detecting SNP TSC0041433.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 165196; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGTT 1712
DB 12 GGAAGTTGGTT 1

RESULT 1262
ABH47622
ID ABH47622 standard; DNA; 13 BP.
XX
AC ABH47622;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 247599 for detecting SNP TSC0060506.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 247599; 29pp + Sequence Listing; German.
XX

This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
SQ

Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGATTAGA 1716
DB 2 GTTGGATTAGA 13

RESULT 1263

```

ABC19752/c
ID  ABC19752 standard; DNA; 13 BP.
XX
AC  ABC19752;
XX
DT  20-FEB-2002 (first entry)
XX
DE  Oligonucleotide SEQ ID NO 19769 for detecting SNP TSC0004089.
XX
KW  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
PN  WO200177384-A2.
XX
PD  18-OCT-2001.
XX
PF  06-APR-2001; 2001WO-IB000713.
XX
PR  07-APR-2000; 2000DE-01019173.
XX
PA  (EPIG-) EPIGENOMICS AG.
XX
PI  Olek A, Piepenbrock C, Berlin K;
XX
PW  WPI; 2001-657177/75.
XX
PT  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 75952; 29pp + Sequence Listing; German.
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
XX
CC  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1754 CCTAAGGCCCA 1765
Db 13 CCTAAGGCCCA 2
XX
RESULT 1264
ABC75935
ID ABC75935 standard; DNA; 13 BP.
XX
AC ABC75935;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 75952 for detecting SNP TSC0019457.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PW WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 19769; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1754 CCTAAGGCCCA 1765
Db 13 CCTAAGGCCCA 2
XX
RESULT 1265
ABC02828/c
ID ABC02828 standard; DNA; 13 BP.
XX
AC ABC02828;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 2819 for detecting SNP TSC0001100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PW WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 75952; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 5.4e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1748 CCTATCCTCTAAA 1759
Db 1 CCTATCCTCTAAA 12
XX
RESULT 1265
ABC02828/c
ID ABC02828 standard; DNA; 13 BP.
XX
AC ABC02828;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 2819 for detecting SNP TSC0001100.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
```


XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 2819; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1748 CCCTATCCTATAA 1759
 Db 13 CTCATCCTATAA 2
 RESULT 1266
 ABF11507/c
 ID ABF11507 standard; DNA; 13 BP.
 XX AC ABF11507;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 111504 for detecting SNP TSC0027852.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 111504; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1702 GAAGTTGGCTTA 1713
 Db 13 GGAGTTGGCTTA 2
 RESULT 1267
 ABC87617/c
 ID ABC87617 standard; DNA; 13 BP.
 XX AC ABC87617;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 87634 for detecting SNP TSC0022046.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 87634; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;

XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 163798; 29pp + Sequence Listing; German.
 PS
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 8 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1745 CCTCCCTATCCT 1756
 Db 2 CCTCCCTTCT 13
 RESULT 1271
 ID AAL56800
 AC AAL56800; DNA; 13 BP.
 XX
 XX
 DT 06-NOV-2003 (first entry)
 XX
 DE Oligodeoxynucleotide B used to study INA/DNA and INA/RNA duplexes.
 XX
 DE Intercalator pseudonucleotide; gene transcription; DNA binding protein;
 KW INA; oligonucleotide analogue; oligodeoxynucleotide; ODN; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_binding 1..6
 FT /*tag= a
 FT /bound moiety= "Target DNA oligo 2 (12-mer) and target
 FT RNA oligo 2 (12-mer)"
 FT /note= "Forms double stranded region with nucleotides 12-
 FT 7 of sequences in AAL56725 and AAL56732"
 FT 8..13
 FT misc_binding
 FT /*tag= a
 FT /bound moiety= "Target DNA oligo 2 (12-mer) and target
 FT RNA oligo 2 (12-mer)"
 FT /note= "Forms double stranded region with nucleotides 1-6
 FT of sequences in AAL56725 and AAL56732"
 FT
 XX WC2003052133-A2.
 PN
 XX 26-JUN-2003.
 PD

XX 18-DEC-2002; 2002WO-DK000875.
 XX 18-DEC-2001; 2001DK-00001897.
 PR 18-DEC-2001; 2001DK-00001898.
 PR 18-DEC-2001; 2001DK-00001899.
 PR 18-DEC-2001; 2001DK-00001900.
 PR 20-MAR-2002; 2002US-0365545P.
 PR 14-OCT-2002; 2002DK-00001575.
 PR 14-OCT-2002; 2002DK-00001576.
 PR 14-OCT-2002; 2002DK-00001577.
 PR 14-OCT-2002; 2002DK-00001578.
 XX (UNES-) UNEST AS.
 XX Christensen UB, Pedersen EB;
 XX WPI; 2003-618026/58.
 DR
 XX Novel oligonucleotide analog, has one intercalator pseudonucleotide that
 PT comprise backbone unit that incorporates into nucleic acid backbone and
 PT intercalator capable of co-stacking with nucleobases of nucleic acid.
 XX Example 26; Page; 274pp; English.
 XX This invention relates to novel oligonucleotide analogues containing at
 CC least one intercalator pseudonucleotide (INA). Wherein the INA comprises
 CC a backbone monomer unit capable of being incorporated into the DNA
 CC backbone and that is linked to an intercalator, which is capable of co-
 CC stacking with a DNA nucleobase. Specifically, the present invention
 CC describes single stranded oligo analogues, as well as pairs of
 CC homogeneously complementary oligos containing INAs that can be used for
 CC PCR, RT-PCR and differentiating between target and point mutated DNA
 CC sequences. Furthermore, these analogues can be used to specifically
 CC modulate gene transcription and/ or translation by modulating the
 CC biological activity of DNA (and RNA) binding proteins i.e. by targeting
 CC and inhibiting specific transcription factors. A final object of the
 CC invention provides improved methods to deliver oligonucleotide analogues
 CC to living cells by passive cellular uptake. This invention describes the
 CC investigations carried out to explore the hybridisation and detection
 CC properties of these analogues, both in DNA, RNA and DNA/RNA hybrid
 CC duplexes, as well as their improved resistance to endogenous nuclease.
 CC This oligonucleotide sequence is the oligodeoxynucleotide B, used as part
 CC of the investigation into INA/DNA and INA/RNA duplexes, a method of the
 CC invention. NOTE: This sequence is not given in the specification, but is
 CC derived from sequence information provided in figure 38
 XX
 SQ Sequence 13 BP; 5 A; 4 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 5.4e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1646 CAGAAGGCAGC 1657
 Db 1 CACAAGGCAGC 12
 RESULT 1272
 ID AAQ78441/c
 XX AAQ78441 standard; DNA; 14 BP.
 AC AAQ78441;
 XX
 XX 25-MAR-2003 (revised)
 DT 27-JUN-1995 (first entry)
 XX
 DE TGF-beta gene phosphorothioate antisense oligonucleotide.
 XX Transforming growth factor beta; TGF-beta; antisense; treatment; tumour;
 KW angiogenesis; breast tumour; neurofibroma; glioma; glioblastoma;
 KW carcinogenesis; carcinoma; oesophagus; oesophageal; gastric; gut;
 KW immunosuppression; oligonucleotide; ss.

```

XX OS Synthetic.
XX PN WO9425588-A2.
XX XX 10-NOV-1994.
XX PD 29-APR-1994; 94WO-EP001362.
XX PF 30-APR-1993; 93EP-00107089.
XX XX 13-MAY-1993; 93EP-00107849.
XX PR
XX XX (BIOG) BIOGOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX PA Schlingensiepen G, Brysch W, Schlingensiepen K, Schlingensiepen R;
XX PI Bogdahn U;
XX XX WPI; 1994-358266/44.
XX DR New transforming growth factor beta antisense oligo:nucleotide(s) - for
XX PT treating immunosuppression, tumours, etc.
XX PT
XX PS Claim 6; Page 50; 74pp; English.
XX XX The antisense oligonucleotides are useful in the treatment of tumours in
XX CC which expression of TGF-beta is of relevance for pathogenicity and/or
XX CC inhibition of pathological angiogenesis. They are used especially for the
XX CC treatment of the immunosuppressive effect of TGF-beta, augmentation of
XX CC the proliferation of cytotoxic lymphocytes, treatment of endogenous
XX CC hyperexpression of TGF-beta, treatment of breast tumours, neurofibromas
XX CC and malignant gliomas, including glioblastomas, treatment and prophylaxis
XX CC of skin carcinogenesis, and treatment of oesophageal and gastric
XX CC carcinomas. See AAQ78352-Q78488. The sequences given in GENESEQ files
XX CC AAQ78352-Q78407 and AAQ78488 are antisense oligodeoxynucleotides of TGF-
XX CC beta 1. The sequences given in GENESEQ files AAQ78408-78487 are antisense
XX CC oligodeoxynucleotides of TGF-beta 2 in the form of phosphorothioate
XX CC analogues. (Updated on 25-MAR-2003 to correct PN field.)
XX XX
XX SQ Sequence 14 BP; 1 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 AGCAGAAGCGCA 1655
Db 14 AGCAGAAGCGCA 3

RESULT 1273
AAV99069/C
ID AAV99069 standard; RNA; 14 BP.
XX AC AAV99069;
XX XX 17-MAR-1999 (first entry)
XX DE Human EGF-R target sequence nucleotide position 4310.
XX DE
XX DE Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
XX KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
XX KW cancer; genetic drift; detection; mutation; ss.
XX XX
XX OS Homo sapiens.
XX XX WO9833893-A2.
XX PN 06-AUG-1998.
XX XX 14-JAN-1998; 98WO-US000730.
XX PF 31-JAN-1997; 97US-0036476P.
XX PR 04-DEC-1997; 97US-00985162.
XX XX

XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI (UYAS-) UNIV ASTON.
XX XX Akhtar S, Fell P, Mcswiggen JA;
XX XX WPI; 1998-437449/37.
XX DR Enzymatic nucleic acids - which cleave RNA derived from an epidermal
XX PT growth factor receptor, useful for inhibiting cell proliferation and for
XX PT treating cancers.
XX XX
XX PS Claim 6; Page 89; 109pp; English.
XX XX The present invention describes enzymatic nucleic acid molecules (NAMS)
XX CC which specifically cleave RNA derived from an epidermal growth factor
XX CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
XX CC represent specifically claimed target sequence from human EGF-R. AAV98044
XX CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
XX CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
XX CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
XX CC expression levels e.g. to inhibit cell proliferation in the prevention or
XX CC treatment of cancers. The NAMS can also be used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of EGF-R RNA in a cell
XX XX
XX SQ Sequence 14 BP; 2 A; 3 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1639 CTTGTAGCAGAA 1650
Db 13 CTTGAAGCAGAA 2

RESULT 1274
AAAI7659
ID AAAI7659 standard; RNA; 14 BP.
XX AC AAAI7659;
XX XX 19-JUN-2000 (first entry)
XX DE Aryl hydrocarbon nuclear transport target site SEQ ID NO:885.
XX DE
XX KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
XX KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX KW hammerhead ribozyme; arginogenic factor; cytostatic; antidiabetic;
XX KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX KW age related macular degeneration; inflammation; neovascular glaucoma;
XX KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
XX KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX XX
XX OS Homo sapiens.
XX XX WO9950403-A2.
XX PN 07-OCT-1999.
XX PD 24-MAR-1999; 99WO-US006507.
XX XX 27-MAR-1998; 98US-0079678P.
XX PR (RIBO-) RIBOZYME PHARM INC.
XX PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX XX WPI; 1999-591315/50.
XX XX

```

PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.

PS Claim 53; Page 90; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC AAA17168 and AAA17560 to AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA22476 to AAA22477 represent ribozyme sequences
 CC for integrin subunit beta 3, and AAA22476 to AAA22477 to AAA22478 to
 CC AAA22479 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3

SQ Sequence 14 BP; 3 A; 5 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;
 Best Local Similarity 83.3%; Pred. No. 6e+02;

Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1667 ACAGCTGGAC 1678

DB 3 ACAGCUGGAC 14

RESULT 1275

AAA26158

ID AAA26158 standard; DNA; 14 BP.

AC AAA26158;

XX 19-JUL-2000 (first entry)

XX Oestrogen receptor hairpin ribozyme target sequence SEQ ID NO:2656.

XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.

OS Homo sapiens.

XX WO9954459-A2.

XX 28-OCT-1999.

XX 19-APR-1999; 99WO-US008547.

XX 20-APR-1998; 98US-0082404P.

XX 23-JUN-1998; 98US-00103636.

XX (RIBO-) RIBOZYME PHARM INC.

XX

PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;

PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;

PI Matulic-Adamic J;

XX WPI; 2000-013248/01.

XX New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.

PS Claim 79; Page 100; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphorodithioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AAA24748 to AAA25992 represent their corresponding target sequences.
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention

SQ Sequence 14 BP; 1 A; 8 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 14;

Best Local Similarity 91.7%; Pred. No. 6e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1738 CCCAAGCTCTCC 1749

DB 2 CCCAGCTCTCC 13

RESULT 1276

ABZ26045/C

ID ABZ26045 standard; DNA; 15 BP.

AC ABZ26045;

XX 21-MAR-2003 (first entry)

XX HMG1 related oligonucleotide SEQ ID NO 14.

XX Yeast; HMG-CoA reductase; squalene; zymosterol; cholesta-7,24-dienol;
 KW cholesta-5, 7, 24-trienol; zymosterol-24-methyl transferase;
 KW ergosta-5, 7, 24 (28)-trienol-22-dehydrogenase; ergosta; dienol;
 KW episterol-5-dehydrogenase; linker region; catalytic domain;
 KW membrane binding region; HMG1; ss.

OS Synthetic.

XX US5460949-A.

XX 24-OCT-1995.

XX 28-OCT-1991; 91US-00783861.

XX 15-NOV-1990; 90US-00613380.

XX (STAD) AMOCO CORP.

XX Mukharji I, Saunders CA, Wolf FR;

XX WPI; 1992-168867/21.

XX Increasing squalene and specific sterol accumulation in yeasts - by

PT transforming mutant yeasts to increase 3-hydroxy-3-methyl:glutaryl COA
 PT reductase activity in the yeasts.
 XX
 XX
 PS Example 5; Col 21; 60pp; English.
 XX
 XX The invention relates to: (A) a method of increasing squalene,
 CC zymosterol, cholesta-7,24-dienol and ergosta-5, 7, 24-trienol
 CC accumulation in yeast comprising increasing the expression level of a
 CC structural gene encoding a polypeptide having HMG-CoA reductase activity
 CC in a mutant yeast having defects in the expression of zymosterol-24-
 CC methyl transferase and ergosta-5, 7, 24 (28) -trienol-22-dehydrogenase;
 CC (B) a method of increasing squalene, ergosta-8, 22-dienol, ergosta-7, 22-
 CC dieneol, ergosta-8-enol and ergosta-7-enol accumulation in *S. cerevisiae*
 CC comprising transforming a mutant *S. cerevisiae* having a defect in the
 CC expression of episterol-5-dehydrogenase with a recombinant DNA molecule
 CC comprising a vector operatively linked to an exogenous DNA segment that
 CC encodes the catalytic region and at least a portion of the linker region
 CC but is free from the membrane binding region of an HMG-CoA reductase
 CC enzyme and a promoter suitable for driving the expression of the
 CC reductase in the yeast; (C) a method of increasing squalene, zymosterol
 CC and cholesta-7, 24-dienol accumulation in *S. cerevisiae* comprising
 CC transforming a mutant *S. cerevisiae* having a defect in the expression of
 CC zymosterol-24-methyl transferase and episterol-5-dehydrogenase with a
 CC recombinant DNA molecule as in (E); (D) a method of increasing squalene,
 CC zymosterol, ergosta-5, 7, 24(28)-trienol and ergosta-5, 7-dienol
 CC accumulation in *S. cerevisiae* comprising transforming a mutant *S.*
 CC *cerevisiae* having a defect in the expression of ergosta-5, 7, 24(28)-
 CC trieneol-22-dehydrogenase with a recombinant DNA molecule as in (B); (E) a
 CC mutant *S. cerevisiae* having defects in the expression of zymosterol-24-
 CC methyl transferase and ergosta-5, 7, 24(28)-trienol-22-dehydrogenase
 CC enzymes, which mutant is designated ANCO402nm; (F) a mutant of *S.*
 CC *cerevisiae* having single or double defects in the expression of enzymes
 CC that catalyse the conversion of squalene to ergosterol, transformed with
 CC a recombinant DNA molecule as in (B). The present sequence is that of a
 CC synthetic oligonucleotide used in the generation of integrating plasmids
 CC expressing a truncated form of the *S. cerevisiae* HMG-CoA reductase 1
 CC (HGM1) protein under the control of the PGK promoter
 XX
 XX Sequence 15 BP; 3 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1666 CACAGCTGGAAC 1677
 DB 12 CACAGCTGGATC 1
 RESULT 1277
 ID AAQ43232 standard; DNA; 15 BP.
 XX
 XX AAQ43232;
 XX
 XX 25-MAR-2003 (revised)
 DT 13-OCT-1993 (first entry)
 XX
 XX B-B10 V region primer Vkrfor.
 DE
 XX Complementarity-determining region; CDR; humanised; antibody; hIL2R;
 KW human; interleukin; IL-2; receptor; murine; anti-human; Ab; T-cell;
 KW monoclonal antibody; B-B10; mixed lymphocyte reaction; variable; V;
 KW region; PCR; framework; plasmid; heavy; H; light; L; amplify; primer;
 KW polymerase chain reaction; ss.
 XX
 XX Synthetic.
 OS
 XX WO9311238-A1.
 PN
 XX 10-JUN-1993.
 PD
 XX 03-DEC-1992; 92WO-JP001583.
 PF

XX
 PR 06-DEC-1991; 91JP-00323319.
 XX
 PA (SUMU) SUMITOMO PHARM CO LTD.
 PA (BIOT) BIOTEST PHARMA GMBH.
 PA (INNO-) INNOTHERAPIE LAB.
 XX
 XX Nakatani T, Gomi H, Wijdenes J, Noguchi H;
 PI WPI; 1993-197057/24.
 XX
 DR Humanised antibody comprising - CDR region of mouse MAB B-B10 specific
 XX for IL-2 receptor useful for treating carcinoma expressing IL-2 receptor.
 PT
 XX Disclosure; Page 45; 62pp; English.
 PS
 XX The sequences given in AAQ43226-32 are primers which were used in the
 CC cloning of DNA encoding the variable (V) regions of the murine anti-
 CC human IL-2 receptor monoclonal Ab (MAB) B-B10. This MAB was used in the
 CC construction of a humanised antibody (Ab) which binds specifically to
 CC human interleukin (IL)-2 receptor (hIL2R). The complementarity-
 CC determining regions (CDRs) for the hIL2R MAB were derived from B-B10 (see
 CC also AAR37599-04). The hIL2R MAB is antagonistic to the binding of IL-2
 CC to the IL-2 receptor on human T-cells. It also inhibits the human mixed
 CC lymphocyte reaction. The cDNA encoding the variable (V) region of the B-
 CC B10 Ab was cloned by PCR and sequenced (see also AAQ43233-36) A human Ab
 CC with high levels of amino acid sequence homology to the murine sequence
 CC was selected and the framework of this Ab was bound with the B-B10 V
 CC region CDR and a part of the framework to design several kinds of the
 CC humanised B-B10 V region. The DNA sequence coding this humanised B-B10
 CC was synthesised and a plasmid expressing humanised B-B10 was constructed.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 15 BP; 1 A; 7 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1689 CTCACGCTGGGT 1700
 DB 1 CTCACGCTGGGT 12
 RESULT 1278
 AAT55017/c
 ID AAT55017 standard; RNA; 15 BP.
 XX
 XX AAT55017;
 XX
 XX 25-MAR-2003 (revised)
 DT 18-APR-1997 (first entry)
 XX
 XX Human relA hammerhead ribozyme target sequence (nt. position 186).
 DE
 XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO9523225-A2.
 PN
 XX 31-AUG-1995.
 PD
 XX

PF 23-FEB-1995; 95WO-IB000156.
 XX 23-FEB-1994; 94US-00201109.
 PR 29-MAR-1994; 94US-00218934.
 PR 04-APR-1994; 94US-00222795.
 PR 07-APR-1994; 94US-00224483.
 PR 15-APR-1994; 94US-00227958.
 PR 15-APR-1994; 94US-00228041.
 PR 18-MAY-1994; 94US-00245736.
 PR 06-JUL-1994; 94US-00271280.
 PR 15-AUG-1994; 94US-00291932.
 PR 16-AUG-1994; 94US-00291433.
 PR 17-AUG-1994; 94US-00292620.
 PR 19-AUG-1994; 94US-00293520.
 PR 02-SEP-1994; 94US-00300000.
 PR 08-SEP-1994; 94US-00303039.
 PR 23-SEP-1994; 94US-00311486.
 PR 23-SEP-1994; 94US-00311749.
 PR 28-SEP-1994; 94US-00314397.
 PR 03-OCT-1994; 94US-00316771.
 PR 07-OCT-1994; 94US-00319492.
 PR 11-OCT-1994; 94US-00321993.
 PR 04-NOV-1994; 94US-00334847.
 PR 10-NOV-1994; 94US-00337608.
 PR 28-NOV-1994; 94US-00345516.
 PR 16-DEC-1994; 94US-00357577.
 PR 23-DEC-1994; 94US-00363233.
 PR 30-JAN-1995; 95US-00390734.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Stinchcomb DT, Chowrika B, Dorenzo A, Draper KG, Dudycz LW;
 PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
 PI Modak A, Pavco P, Beigelman L, Sullivan SM, Sweedler D, Thompson JD;
 PI Tracz D, Usman N, Wincott F, Woolf T;
 XX WPI; 1995-351090/45.
 DR Ribozyms having modified bases and methods for producing them - for use
 XX in inhibiting disease related genes.
 PT Claim 2; Page 228; 407pp; English.
 XX The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves relA mRNA at the
 CC nucleotide base position indicated in the DE line. The relA gene product
 CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
 CC specifically in the induction of inflammatory responses. Regions of the
 CC mRNA that do not form secondary folding structures and that contain
 CC potential hammerhead and hairpin ribozyme cleavage sites were identified
 CC by computer analysis. Ribozymes directed against these mRNA sequences
 CC were designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the target
 CC sequences and thereby inhibit relA expression, making them potentially
 CC useful for treating rheumatoid arthritis, restenosis and asthma as well
 CC as for increasing tolerance to transplanted tissues. The potential
 CC immunosuppressive properties of a ribozyme that cleaves relA mRNA means
 CC that uses are limited to local delivery, acute indications or ex vivo
 CC treatment. (Updated on 25-MAR-2003 to correct PI field.)
 XX Sequence 15 BP; 3 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1639 CTTGTAGCGAA 1650
 Db |||||
 12 CTTGTAGCGAA 1

ID AAX65776 standard; RNA; 15 BP.
 XX AAX65776;
 AC 20-JUL-1999 (first entry)
 DT Human B7-2 hammerhead ribozyme target SEQ ID NO:2408.
 DE Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX Homo sapiens.
 OS WO9618736-A2.
 PN 20-JUN-1996.
 PD 22-NOV-1995; 95WO-US015516.
 PF 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX WPI; 1996-300653/30.
 DR Enzymatic nucleic acid molecules having a hammer-head motif - used for
 XX the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 PT Claim 10; Page 188; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX Sequence 15 BP; 5 A; 2 C; 4 G; 0 T; 4 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 66.7%; Pred. No. 6.5e+02;
 Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY	1636	GGGCTTGAGCA 1647	Best Local Similarity 75.0%; Pred. No. 6.5e+02;			
		: :	Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;			
Db	3	GGGCTUGUAUCA 14				
RESULT 1280						
AAT50326						
ID	AAT50326	standard; RNA; 15 BP.				
XX						
AC	AAT50326;					
XX						
DT	11-MAR-1997	(first entry)				
XX						
DE	Rabbit CETP HH ribozyme target sequence #1587.					
XX						
KW	Hammerhead ribozyme; cholesterol ester transfer protein; mRNA cleavage;					
KW	neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;					
KW	reverse cholesterol transport; high density lipoprotein; therapy; CETP;					
KW	familial hypercholesterolaemia; dyslipidaemia; hypopalipoproteinaemia;					
KW	peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;					
KW	angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;					
KW	LDL; ss.					
OS	Oryctolagus cuniculus.					
XX						
PN	WO9620279-A1.					
XX						
PD	04-JUL-1996.					
XX						
PF	11-DEC-1995; 95WO-US016000.					
XX						
PR	23-DEC-1994; 94US-00363240.					
XX						
PA	(RIBO-) RIBOZYME PHARM INC.					
PA	(WARN) WARNER LAMBERT CO.					
XX						
PI	Couture L, Stinchcomb D, Mcswiggen J, Bisgaier C, Pape M;					
XX						
DR	WPI; 1996-321852/32.					
XX						
PT	New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -					
PT	useful for preventing or treating initial development, progression or					
PT	regression of vascular diseases, esp. familial hypercholesterolaemia.					
XX						
PS	Claim 4; Page 43; 72pp; English.					
XX						
CC	AAT50138-T50359 represent target sequences for the rabbit cholesterol					
CC	ester transfer protein (CETP) hammerhead (HH) ribozymes (see AAT50360-					
CC	T50546). CETP is a 74 kD glycoprotein that facilitates neutral lipid					
CC	transfer between plasma lipoproteins. The numbering of the targets refers					
CC	to the position of the cleavage site in full length CETP. The ribozyme					
CC	then binds to 5 nucleotides either side of this site. The ribozymes are					
CC	able to cleave mRNA from the gene encoding CETP, thereby blocking					
CC	synthesis and/or expression of the mRNA. By inhibiting CETP, the reverse					
CC	cholesterol transport (RCT) pathway can be inhibited (or eliminated)					
CC	thereby preventing the reduction in size density of the high density					
CC	lipoproteins (HDL), prolonging HDL half life, and therefore increasing					
CC	HDL levels. The ribozymes can be used to treat conditions associated with					
CC	abnormal levels of CETP, specifically atherosclerosis, familial					
CC	hypercholesterolaemia, peripheral vascular disease, dyslipidaemia,					
CC	hyperbetalipoproteinaemia, hypopalipoproteinaemia, vascular					
CC	complications of diabetes, transplant, atherectomy and angioplastic					
CC	restenosis. By inhibiting CETP, the levels of HDL and low density					
CC	lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a					
CC	decrease in LDL levels, and a corresponding increase in HDL levels). The					
CC	HH ribozymes can also be used diagnostically to study genetic drift and					
CC	mutations in diseased cells, and to detect CETP mRNA. As the HH ribozymes					
CC	target specific regions of the CETP gene, they have low non-specific					
CC	activity					
XX						
SQ	Sequence 15 BP; 2 A; 7 C; 1 G; 0 T; 5 U; 0 Other;					
	Query Match	7.5%; Score 10.4; DB 1; Length 15;				
	Best Local Similarity	91.7%; Pred. No. 6.5e+02;				
	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;					
QY	1733	TGGTCCCAACT 1744				
	: :					
Db	3	TGGATCCCAACT 14				
RESULT 1282						
AAV93861/C						
ID	AAV93861	standard; RNA; 15 BP.				
XX						
AC	AAV93861;					

XX DT 18-FEB-1999 (first entry)

XX DE Target sequence with sequence homology to c-raf and B-raf position 1662.

XX ID Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;

XX AC target; substrate; catalyst; modulation; expression; Raf gene; delivery;

XX KW screening; identification; synthesis; deprotection; purification; cancer;

XX KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;

XX KW restenosis; rheumatoid arthritis; ss.

XX OS Homo sapiens.

XX PN WO9850530-A2.

XX PD 12-NOV-1998.

XX PF 05-MAY-1998; 98WO-US009249.

XX PR 09-MAY-1997; 97US-0046059P.

XX PR 09-JUN-1997; 97US-0049002P.

XX PR 03-JUL-1997; 97US-0051718P.

XX PR 22-AUG-1997; 97US-0058808P.

XX PR 02-OCT-1997; 97US-0061321P.

XX PR 02-OCT-1997; 97US-0061324P.

XX PR 05-NOV-1997; 97US-0064866P.

XX PR 19-DEC-1997; 97US-0068212P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;

XX PI Parry T, Beigelman L, Mcswigen JA, Karpeisky A, Burgin A;

XX PI Thompson J, Workman CT, Beaudry A, Sweedler D;

XX DR WPI; 1999-009494/01.

XX PT Identifying new catalytic nucleic acid that modulates selected processes

XX PT - especially ribozymes that cleave Raf RNA for treating cancer,

XX PT restenosis, and also new ribozymes and modified nucleoside triphosphates

XX PT used as antiviral agents and synthons.

XX PS Claim 180; Page 177; 259pp; English.

XX CC A method has been developed for the identification of a nucleic acid

XX CC capable of modulating a process in a biological system. The method

XX CC comprises: (a) introducing into the system a random library of nucleic

XX CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising

XX CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC

XX CC in systems where modulation has occurred and/or determining the sequence

XX CC of at least part of the SBDs in such systems. Nucleic acid molecules with

XX CC endonuclease activity and catalytic activity, from the present invention,

XX CC are used to modulate gene expression in plant and mammalian cells and to

XX CC cleave target nucleic acid, particularly for treating systemic diseases

XX CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic

XX CC ascites and infection. They may also be used to detect genetic drift and

XX CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs

XX CC with RNA-cleaving activity that modulate expression of the Raf gene, are

XX CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or

XX CC generally any condition associated with the level of c-raf. Introduction

XX CC of sugar/phosphate modifications increases stability against nuclease and

XX CC activity. AAV9922 to AAV93877 represent NACs that can be used in the

XX CC method, specifically for modulating the expression of a Raf gene

XX CC

XX SQ Sequence 15 BP; 2 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;

Best Local Similarity 91.7%; Pred. No. 6.5e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1669 AGCTGGNACCCCT 1680

DB |||||

13 AGCTGGNACCCCT 2

RESULT 1283

AAV81796/c

ID AAV81796 standard; DNA; 15 BP.

XX AC AAV81796;

XX DT 04-MAR-1999 (first entry)

XX DE Granulocytic Ehrlichia protein PCR forward primer S22.

XX KW Granulocytic ehrlichiosis; Ehrlichia sp; GE protein; infection; tick;

XX KW diagnosis; vaccine; antigenic protein; antibody; immune response;

XX KW PCR primer; ss.

XX OS Synthetic.

XX OS Ehrlichia sp.

XX PN WO9849313-A2.

XX PD 05-NOV-1998.

XX PF 24-APR-1998; 98WO-US008265.

XX PR 25-APR-1997; 97US-0044933P.

XX PA (AQUI-) AQUILA BIOPHARMACEUTICALS INC.

XX PI Murphy CA, Storey J, Beltz GA, Coughlin RT;

XX DR WPI; 1999-009432/01.

XX PT New nucleic acid from the human granulocytic ehrlichiosis agent - and

XX PT related antigenic proteins, vectors, transformed cells and antibodies,

XX PT useful for diagnosis and in protective vaccines.

XX PS Example 4; Page 59; 154pp; English.

XX CC The present sequence represents a PCR primer for granulocytic ehrlichia

XX CC (GE) proteins used in an example from the present invention. GE nucleic

XX CC acids, vectors and host cells are used for the recombinant production of

XX CC GE proteins, and also in research to further characterise the proteins.

XX CC GE protein-encoding nucleic acid molecules are detected by hybridisation

XX CC to GE nucleic acid fragments or by using the fragments as primers for

XX CC polymerase chain reaction (PCR) amplification. GE proteins, their

XX CC immunogenic fragments, and GE nucleic acid molecules encoding them are

XX CC used to generate an immune response against GE, specifically as (genetic)

XX CC vaccines, especially to control ehrlichiosis in humans and dogs, but also

XX CC to raise Ab and to study DNA-protein interactions. Ab are used to detect

XX CC GE proteins by forming an immune complex in standard assays, and

XX CC correspondingly GE proteins can detect specific antibodies, especially

XX CC for diagnosis, assessment and prognosis of GE infection, or of

XX CC contamination of biological samples with GE

XX SQ Sequence 15 BP; 2 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;

Best Local Similarity 91.7%; Pred. No. 6.5e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1642 GTAGCGAAGGC 1653

DB |||||

15 GTAGAAGAGGC 4

RESULT 1284

AAZ62728/c

ID AAZ62728 standard; RNA; 15 BP.

XX AC AAZ62728;

XX DT 28-MAR-2000 (first entry)

XX

DE Substrate for HH ribozyme HCV-6638 which cleaves HCV RNA at nt. 6638.
 XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
 KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
 KW autoimmune disease; ss.
 XX Hepatitis C virus.
 OS WO9955847-A2.
 PN 04-NOV-1999.
 PD 26-APR-1999; 99WO-US009027.
 XX 27-APR-1998; 98US-0083217P.
 XX 18-SEP-1998; 98US-0100842P.
 PR 25-FEB-1999; 99US-00257608.
 PR 23-MAR-1999; 99US-00274553.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;
 PI WPI; 2000-062023/05.
 XX Novel ribozymes for the treatment of diseases and conditions related to
 DR hepatitis C infection.
 PT Claim 1; Page 61; 123pp; English.
 PS The present sequence represents the preferred target sequence of an
 XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
 CC the descriptor line. The HCV sequence was screened for optimal ribozyme
 CC target sites using a computer folding algorithm and regions of the mRNA
 CC which did not form secondary folding structures and contained potential
 CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
 CC target these sites and their activities optimised by either varying the
 CC length of the binding arms or by modification to prevent degradation by
 CC nucleases. The ribozymes of the invention inhibit gene expression and/or
 CC viral replication, and are used to treat diseases associated with
 CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
 CC hepatocellular carcinoma. The ribozymes may be used in combination with
 CC interferon to treat HCV infection, other infectious diseases, autoimmune
 CC diseases, and cancer
 XX Sequence 15 BP; 3 A; 5 C; 4 G; 0 T; 3 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1695 CGTGGTGGAGT 1706
 DB 15 CGTAGTGGAGT 4
 RESULT 1285
 AAZ64116
 ID AAZ64116 standard; RNA; 15 BP.
 XX AAZ64116;
 AC 28-MAR-2000 (first entry)
 XX Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 5149.
 DE Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
 KW cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
 KW autoimmune disease; ss.
 XX Hepatitis C virus.
 OS

PN WO9955847-A2.
 XX 04-NOV-1999.
 PD 26-APR-1999; 99WO-US009027.
 XX 27-APR-1998; 98US-0083217P.
 PR 18-SEP-1998; 98US-0100842P.
 PR 25-FEB-1999; 99US-00257608.
 PR 23-MAR-1999; 99US-00274553.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;
 PI WPI; 2000-062023/05.
 XX Novel ribozymes for the treatment of diseases and conditions related to
 DR hepatitis C infection.
 PT Claim 1; Page 81; 123pp; English.
 PS The present sequence represents the preferred target sequence of an
 XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
 CC the descriptor line. The HCV sequence was screened for optimal ribozyme
 CC target sites using a computer folding algorithm and regions of the mRNA
 CC which did not form secondary folding structures and contained potential
 CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
 CC target these sites and their activities optimised by either varying the
 CC length of the binding arms or by modification to prevent degradation by
 CC nucleases. The ribozymes of the invention inhibit gene expression and/or
 CC viral replication, and are used to treat diseases associated with
 CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
 CC hepatocellular carcinoma. The ribozymes may be used in combination with
 CC interferon to treat HCV infection, other infectious diseases, autoimmune
 CC diseases, and cancer
 XX Sequence 15 BP; 2 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 75.0%; Pred. No. 6.5e+02;
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1688 CCTCCAGCGTGG 1699
 DB 1 CCUCCAUUGUGG 12
 RESULT 1286
 AAAG7020/C
 ID AAA67020 standard; DNA; 15 BP.
 XX AAA67020;
 AC 19-OCT-2000 (first entry)
 XX Human leukocyte antigen C allele DNA probe C-3 SEQ ID NO:78.
 DE Human leukocyte antigen; HLA; class I allele type; probe; PCR primer;
 XX amplification; hybridisation; organ transplant; gene typing; diagnosis;
 KW ss.
 KW Homo sapiens.
 OS WO200031295-A1.
 XX 02-JUN-2000.
 PD 07-OCT-1999; 99WO-JP005527.
 XX 26-NOV-1998; 98JP-00335151.
 PR XX

PA (SHIO) SHIONOGI & CO LTD.
 XX Moribe T, Kaneshige T;
 PI WPI; 2000-40097/34.
 XX Simple, rapid and accurate method for distinguishing HLA class I allele
 PT type with possibility of mechanization and automation, applicable in
 PT judging donor-recipient compatibility during organ transplant and disease
 PT diagnosis.
 XX Claim 8; Page 67; 83pp; Japanese.
 XX The present invention describes a method for distinguishing a human
 CC leukocyte antigen (HLA) class I antigen or allele by a combination of
 CC polymerase chain reaction (PCR) using a primer pair whereby all HLA-A, -B
 CC or -C alleles can be amplified or using reverse hybridisation analysis
 CC comprising a DNA probe covalently bonded to microtitre plate wells which
 CC are hybridisable specifically with the base sequence of at least one
 CC specific HLA-A, -B or -C allele. The method is applicable in gene typing,
 CC judging donor-recipient compatibility during organ transplant and
 CC correlation analysis for diagnosis of various diseases. The method is
 CC simple, rapid and accurate, with possibility of mechanisation and
 CC automation, without the problems encountered by using the prior-art
 CC techniques. AAA66943 to AAA67072 represent oligonucleotide probes and PCR
 CC primers for use in the method of the present invention
 XX Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1662 GGCTCACAGCTG 1673
 DB ||||| |||||
 15 GGCTCTCAGCTG 4
 RESULT 1287
 ID AAC68385/C
 XX AAC68385 standard; DNA; 15 BP.
 XX AAC68385;
 AC
 XX 20-FEB-2001 (first entry)
 DE Human IRRR oligonucleotide #41.
 XX Insulin receptor-related receptor; IRRR; chromosome 1q21-q24; obesity;
 KW dyslipidemia; diabetes; ss.
 KW Homo sapiens.
 OS
 XX WO200065090-A2.
 XX 02-NOV-2000.
 XX 19-APR-2000; 2000WO-US010644.
 XX 22-APR-1999; 99US-00296906.
 PR 22-JUN-1999; 99US-00337976.
 XX (ZYMO) ZYMOGENETICS INC.
 PA Lok S, Whitmore TE;
 PI WPI; 2000-687365/67.
 XX Detecting a chromosome 1q21-q24 abnormality for diagnosing metabolic
 PT disease, such as human obesity and diabetic disorders, comprises
 PT examining insulin receptor-related receptor gene and its gene products.
 XX Claim 10; Page 43; 111pp; English.

XX The present invention relates to insulin receptor-related receptor
 CC (IRRR). Mutations in this gene indicate a chromosome 1q21-q24
 CC abnormality. IRRR polypeptides and DNA may be useful in the diagnosis of
 CC of disorders associated with abnormal expression of the IRRR protein, for
 CC example obesity, dyslipidemia and diabetes
 XX Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1662 GGCTCACAGCTG 1673
 DB ||||| |||||
 12 GACTCACAGCTG 1
 RESULT 1288
 ID AAH18851/C
 XX AAH18851 standard; DNA; 15 BP.
 XX AAH18851;
 AC
 XX 21-JUN-2001 (first entry)
 DE UCP3 polymorphism detection allele specific probe #2.
 XX UCP3; uncoupling protein 3; polymorphism; obesity; diabetes mellitus; ss.
 KW Homo sapiens.
 OS
 XX WO200118232-A2.
 XX 15-MAR-2001.
 XX 08-SEP-2000; 2000WO-US024784.
 XX 08-SEP-1999; 99US-0152789P.
 XX (GENA-) GENAISSANCE PHARM INC.
 PA (STEP-) STEPHENS J C.
 XX Chew A, Choi JY, Denton RR, Nandabalan K;
 PI WPI; 2001-218562/22.
 XX Nucleic acids encoding uncoupling protein 3 (mitochondrial, proton
 PT carrier) (UCP3) proteins comprising single nucleotide polymorphisms,
 PT useful for the design of drugs for treating obesity.
 XX Claim 15; Page 21; 94pp; English.
 XX The present invention relates to the human uncoupling protein 3
 CC (mitochondrial, proton carrier) (UCP3) gene and polymorphisms. The
 CC polymorphisms are associated with obesity, especially diabetes mellitus
 CC associated obesity. They polymorphisms may be identified and analysed to
 CC determine whether an individual is susceptible to obesity and may be used
 CC as the basis for targeted design of drugs to treat obesity. The present
 CC sequence was used in the identification and amplification of UCP3
 CC polymorphisms
 XX Sequence 15 BP; 1 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1659 CCAGGCTCACAG 1670
 DB ||||| |||||
 12 CCAGGGTCACAG 1

RESULT 1289
AAD05853/c
ID AAD05853 standard; DNA; 15 BP.
XX
XX AAD05853;
AC
XX
XX
31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO probe #5.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping;
KW chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
OS
XX WO200129176-A2.
XX
XX 26-APR-2001.
PD
XX 12-OCT-2000; 2000WO-US028247.
PF
XX 15-OCT-1999; 99US-0159860P.
XX
XX (GENA-) GENAISANCE PHARM INC.
PA
XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX MPI; 2001-300326/31.
XX
XX Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX
XX Claim 15; Page 19; 54pp; English.
XX
XX The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) probe used for detecting human
CC CHRM3 gene polymorphism
XX
SQ Sequence 15 BP; 3 A; 1 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1738 CCCAAGCTCTCC 1749
||| |||||
Db 12 CCCAGCTCTCC 1

RESULT 1290
AAD05854
ID AAD05854 standard; DNA; 15 BP.
XX

DE Human cholinergic receptor, muscarinic 3 gene ASO probe #6.
 XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 KW single nucleotide polymorphism; forensic application; gene therapy;
 KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 KW sudden infant death syndrome; genotyping; haplotyping;
 KW chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200129176-A2.
 PN
 XX 26-APR-2001.
 PD
 XX 12-OCT-2000; 2000WO-US028247.
 XX
 XX 15-OCT-1999; 99US-0159860P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
 PI
 XX WPI; 2001-300326/31.
 DR
 XX Novel polymorphic variant of reference sequence for human cholinergic
 PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 PT purposes.
 PT
 XX Claim 15; Page 19; 54pp; English.
 PS
 XX The patent relates to polymorphic variants of human cholinergic receptor,
 CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
 CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
 CC for genotyping and haplotyping the CHRM3 gene for identification of
 CC variants. The polymorphic variant is useful for therapeutic purposes, for
 CC studying the expression and biological function of CHRM3, as well as for
 CC developing drugs targeting the CHRM3 protein. The variant is also useful
 CC in diagnostics and forensic applications. The recombinant nonhuman
 CC organism transfected with the polymorphic variant is useful for studying
 CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
 CC therapeutic agents and compounds for Alzheimer's disease. Sjogren's
 CC syndrome, disorders associated with smooth muscle contractility and
 CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 CC screening assays and its antibodies are useful in immunoassays to detect
 CC CHRM3 protein variants in biological samples. The present sequence is an
 CC allele-specific oligonucleotide (ASO) probe used for detecting human
 CC CHRM3 gene polymorphism
 XX
 SQ Sequence 15 BP; 4 A; 0 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1738 CCCAATCTCTCTCC 1749
 Db 12 CCCATCTCTCTCC 1
 RESULT 1292
 AAS57269/c
 ID AAS57269 standard; DNA; 15 BP.
 XX
 XX AAS57269;
 AC
 XX 16-JAN-2002 (first entry)
 DT
 XX Human CHRN2 allele specific oligonucleotide (ASO) PCR primer #42.
 DE
 XX Human; cholinergic receptor, nicotinic, beta polypeptide 2; neuronal;
 KW CHRN2; memory disorder; Alzheimer's disease; epilepsy; learning;

KW chromosome 1q21; schizophrenia; attention deficit/hyperactivity disorder;
 KW ADHD; autosomal dominant nocturnal frontal lobe epilepsy; ADNFLE; ss;
 XX allele specific oligonucleotide; ASO; PCR primer.
 OS Homo sapiens.
 XX
 XX WO200174833-A2.
 PN
 XX 11-OCT-2001.
 PD
 XX 03-APR-2001; 2001WO-US010666.
 XX
 XX 03-APR-2000; 2000US-0194155P.
 PR
 XX 13-JUL-2000; 2000US-0217952P.
 XX
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Choi JY, Kliem SE, Koshy B, Lee HH, Sanchis A;
 PI
 XX WPI; 2001-626374/72.
 DR
 XX Genotyping cholinergic receptor, nicotinic, beta-polypeptide 2 gene of an
 PT individual involves determining for two copies of the gene, the identity
 PT of nucleotide pair at polymorphic sites selected from PS1-24.
 PT
 XX Claim 15; Page 15; 82pp; English.
 PS
 XX The invention relates to genotyping/haplotyping the cholinergic receptor,
 CC nicotinic, beta-polypeptide 2 (neuronal) (CHRN2) gene of an individual,
 CC comprising determining for the two copies of the CHRN2 gene present in
 CC the individual, the identity of the nucleotide pair at one or more
 CC polymorphic sites selected from PS1-24. Also include are oligonucleotides
 CC for performing the method and the nucleotide sequence of the polymorphic
 CC variants of CHRN2. The method is useful for detecting novel CHRN2
 CC polymorphisms and for determining if an individual has a haplotype or
 CC haplotype pairs defined in the specification and to validate CHRN2 as a
 CC candidate agent for treating a specific condition or disease predicted to
 CC be associated with CHRN2 activity (e.g. a memory disorder, Alzheimer's
 CC disease, epilepsy, a learning disorder, schizophrenia, attention
 CC deficit/hyperactivity disorder, (ADHD) and autosomal dominant nocturnal
 CC frontal lobe epilepsy (ADNFLE)), and in the design of clinical trials of
 CC candidate drugs for treating a specific condition or disease predicted to
 CC be associated with CHRN2 activity. The method is useful to screen for
 CC compounds targeting CHRN2 to treat a specific conditions or disease
 CC associated with CHRN2 activity. The polymorphic nucleic acids are useful
 CC in studying the expression and function of CHRN2, and in expressing
 CC CHRN2 protein for use in screening for candidate drugs to treat diseases
 CC related to CHRN2 activity and are useful for therapeutic purposes. The
 CC CHRN2 gene is located on chromosome 1q21. The present sequence is an
 CC allele specific oligonucleotide (ASO) PCR primer for performing the
 CC method of the invention
 XX
 SQ Sequence 15 BP; 4 A; 2 C; 8 G; 0 T; 0 U; 1 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 78.6%; Pred. No. 6.5e+02;
 Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1742 ACTCTCCCTATCC 1755
 Db 14 MCTCTCCGCTCC 1
 RESULT 1293
 AAF52917/c
 ID AAF52917 standard; DNA; 15 BP.
 XX
 XX AAF52917;
 AC
 XX 30-MAR-2001 (first entry)
 DT
 XX IGF-I oligonucleotide #3877.
 DE
 XX

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.
 XX WO200078341-A1.
 XX PD 28-DEC-2000.
 XX PF 21-JUN-2000; 2000WO-AU000693.
 XX PR 21-JUN-1999; 99US-0140345P.
 XX PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX PI Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

PS Example 8; Page 86; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC 45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1641 TGTAGCAGAGG 1652
 DB 13 TGTAGTAGAGG 2

RESULT 1294
 AAF51492
 ID AAF51492 standard; DNA; 15 BP.
 XX AC AAF51492;
 XX 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #2452.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.
 XX WO200078341-A1.
 XX PD 28-DEC-2000.
 XX PF 21-JUN-2000; 2000WO-AU000693.
 XX PR 21-JUN-1999; 99US-0140345P.
 XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wright CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

PS Example 8; Page 76; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC 45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 5 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAAC 1677
 DB 4 CACAGCTGGAAC 15

RESULT 1295
 AAF53418/c
 ID AAF53418 standard; DNA; 15 BP.
 XX AC AAF53418;
 XX 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #4378.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

```

XX OS Homo sapiens.
XX PN WO200078341-A1.
XX XX
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 89; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for insulin-like Growth factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 4 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
      Query Match          7.5%; Score 10.4; DB 1; Length 15;
      Best Local Similarity 91.7%; Pred. No. 6.5e+02;
      Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1754 CCTAAGGCCCA 1765
Db 15 CTTAAGGCCCA 4
      |||||
RESULT 1296
AAF51496
ID AAF51496 standard; DNA; 15 BP.
XX AC
XX AC AAF51496;
XX DT 30-MAR-2001 (first entry)
XX DE
XX DE IGF-I oligonucleotide #2456.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; insulin-like Growth factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX XX

```

```

XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 76; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for insulin-like Growth factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 5 A; 6 C; 3 G; 1 T; 0 U; 0 Other;
      Query Match          7.5%; Score 10.4; DB 1; Length 15;
      Best Local Similarity 91.7%; Pred. No. 6.5e+02;
      Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1667 ACAGCTGCAC 1678
Db 1 ACAGCTGCAC 12
      |||||
RESULT 1297
AAF52916/C
ID AAF52916 standard; DNA; 15 BP.
XX AC
XX AC AAF52916;
XX DT 30-MAR-2001 (first entry)
XX DE
XX DE IGF-I oligonucleotide #3876.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; insulin-like Growth factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX XX
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.

```

```

XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenese nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 86; 20lpp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 6 C; 1 G; 5 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1641 TGTAGCAGGAGG 1652
Db ||||| |||||
14 TGTAGTAGAGG 3

RESULT 1298
AAF52918/C
ID AAF52918 standard; DNA; 15 BP.
XX
XX AAF52918;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #3878.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.

```

```

XX PI Wraight CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisenese nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 8; Page 86; 20lpp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1641 TGTAGCAGGAGG 1652
Db ||||| |||||
12 TGTAGTAGAGG 1

RESULT 1299
AAF52915/C
ID AAF52915 standard; DNA; 15 BP.
XX
XX AAF52915;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #3875.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX XX WPI; 2001-041421/05.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.

```


XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 86; 201pp; English.
PS
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 6 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1641 TGTCAGCAGG 1652
Db 15 TGTCAGCAGG 4

RESULT 1300
AAF53422/c
ID AAF53422 standard; DNA; 15 BP.
XX
XX AAF53422;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #4382.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or

PT inflammation.
XX
PS Example 8; Page 89; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 4 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1753 TCCTAAAGGCC 1764
Db 12 TCCTAAAGGCC 1

RESULT 1301
AAF53672
ID AAF53672 standard; DNA; 15 BP.
XX
XX AAF53672;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #4632.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytosatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 91; 201pp; English.
XX

CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 5 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Mismatches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATT 1733
 |||||
 DB 1 GAGATGGAAATT 12

RESULT 1302
 AAF53668
 ID AAF53668 standard; DNA; 15 BP.
 XX AAF53668;
 AC AAF53668;
 XX 30-MAR-2001 (first entry)
 DT IGF-I oligonucleotide #4628.
 DE Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.
 OS WO200078341-A1.
 PN 28-DEC-2000.
 PD 21-JUN-2000; 2000WO-AU000693.
 PF 21-JUN-1999; 99US-0140345P.
 PR (MURD-) MURDOCH CHILDRENS RES INST.
 PA Wright CJ, Werther GA, Edmondson SR;
 PI WPI; 2001-041421/05.
 DR Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX Example 8; Page 91; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 5 A; 1 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Mismatches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
 |||||
 DB 4 GGAGATGGAAAT 15

RESULT 1303
 AAF70093
 ID AAF70093 standard; DNA; 15 BP.
 XX AAF70093;
 AC AAF70093;
 XX 18-APR-2001 (first entry)
 DT Human TNFRSF11B gene ASO probe, SEQ ID NO: 149.
 DE Human; TNFRSF11B; osteoclastogenesis inhibitory factor;
 KW single nucleotide polymorphism; SNP; osteoclast recruitment;
 KW osteoclast function; osteoporosis; metastatic bone disease;
 KW Paget's disease; rheumatoid arthritis; periodontal bone disease; ASO;
 KW allele-specific oligonucleotide; probe; ss.

XX Homo sapiens.
 OS WO200104137-A1.
 PN 18-JAN-2001.
 PD 10-JUL-2000; 2000WO-US018803.
 PF 09-JUL-1999; 99US-0143020P.
 PR (GENA-) GENAISANCE PHARM INC.
 PA Chew A, Denton RR, Duda A, Mandabalan K, Stephens JC;
 PI WPI; 2001-147175/15.
 DR Human Osteoclastogenesis Inhibitory Factor nucleotides, comprising single
 XX nucleotide polymorphisms, useful for studying e.g. osteoporosis, Paget's
 PT disease and rheumatoid arthritis.
 XX Claim 15; Page 24; 114pp; English.

XX The present sequence is a probe used to detect polymorphisms in the human
 CC osteoclastogenesis inhibitory factor (TNFRSF11B). Polynucleotides
 CC comprising one or more of twenty four novel single nucleotide
 CC polymorphisms in the TNFRSF11B gene have been identified. TNFRSF11B
 CC regulate osteoclast recruitment and function. An understanding of
 CC variations in the gene should thus be useful in developing new therapies
 CC for metabolic disorders caused by abnormal osteoclast recruitment and
 CC function such as osteoporosis, metastatic bone disease, Paget's disease,
 CC rheumatoid arthritis and periodontal bone disease
 XX Sequence 15 BP; 5 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1640 TTGTAGCAGAAG 1651
 DB 2 TTGTATCAGAAG 13
 ||||| |||||

RESULT 1304
 AAF70091
 ID AAF70091 standard; DNA; 15 BP.
 AC AAF70091;
 XX
 DT 18-APR-2001 (first entry)
 XX

DE Human TNFRSF11B gene ASO probe, SEQ ID NO: 147.
 XX
 KW Human; TNFRSF11B; osteoclastogenesis inhibitory factor;
 KW single nucleotide polymorphism; SNP; osteoclast recruitment;
 KW osteoclast function; osteoporosis; metastatic bone disease;
 KW Paget's disease; rheumatoid arthritis; periodontal bone disease; ASO;
 KW allele-specific oligonucleotide; probe; ss.
 XX
 OS Homo sapiens.
 XX

PN WO200104137-A1.
 XX
 XX 18-JAN-2001.
 PD
 XX
 PF 10-JUL-2000; 2000WO-US018803.
 PR 09-JUL-1999; 93US-0143020P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX

PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
 XX WPI; 2001-147175/15.
 XX
 DR Human Osteoclastogenesis Inhibitory Factor nucleotides, comprising single
 PT nucleotide polymorphisms, useful for studying e.g. osteoporosis, Paget's
 PT disease and rheumatoid arthritis.
 XX
 PS Claim 15; Page 24; 114pp; English.
 XX

CC The present sequence is a probe used to detect polymorphisms in the human
 CC osteoclastogenesis inhibitory factor (TNFRSF11B). Polynucleotides
 CC comprising one or more of twenty four novel single nucleotide
 CC polymorphisms in the TNFRSF11B gene have been identified. TNFRSF11B
 CC regulate osteoclast recruitment and function. An understanding of
 CC variations in the gene should thus be useful in developing new therapies
 CC for metabolic disorders caused by abnormal osteoclast recruitment and
 CC function such as osteoporosis, metastatic bone disease, Paget's disease,
 CC rheumatoid arthritis and periodontal bone disease
 XX
 SQ Sequence 15 BP; 5 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1640 TTGTAGCAGAAG 1651
 DB 2 TTGTATCAGAAG 13
 ||||| |||||

RESULT 1305
 ABX03889/c
 ID ABX03889 standard; DNA; 15 BP.
 XX
 AC ABX03889;

XX 06-AUG-2003 (revised)
 DT 09-JAN-2003 (first entry)
 XX
 DE T. vincentii16S rRNA fragment.
 XX
 KW Detection; probe; diagnosis; oral disease; paradontitis; caries; therapy;
 KW polymorphism; virulence factor; antibiotic resistance gene; prognosis;
 KW oral infection; detection; pathogen; coronary heart disease;
 KW diabetic symptom; ss.
 XX
 OS Treponema vincentii.
 XX
 PN DE20110013-U1.
 XX
 PD 18-OCT-2001.
 XX
 PF 13-MAR-2001; 2001DE-02010013.
 XX
 PR 13-MAR-2001; 2001DE-01012348.
 PR 13-MAR-2001; 2001DE-02010013.
 XX
 PA (ROET/) ROETGER A.
 XX
 XX WPI; 2001-657777/76.
 DR
 XX
 XX Oligonucleotide array, useful for diagnosing oral diseases, particularly
 PT paradontitis, carries human or microbial reference sequences.
 PT
 XX
 PS Claim 8; Page 17; 58pp; German.
 XX
 CC This invention describes a novel nucleotide carrier with probes used for
 CC diagnosis of oral diseases, particularly paradontitis, but also caries,
 CC especially to identify genetic predisposition (as indicated by
 CC polymorphisms) to disease and to identify causative microorganisms or
 CC their associated virulence factors and antibiotic resistance genes, e.g.
 CC for selection of therapy and for prognosis. They are also useful for
 CC research into oral infections. The carriers allow simultaneous detection
 CC of both host and pathogen parameters, providing quickly and simply an
 CC individual's paradontitis profile, including detection of pathogens that
 CC are associated with increased risk of coronary heart diseases and/or
 CC aggravation of diabetic symptoms, and of opportunistic pathogens.
 CC ABX03870-ABX04044 represent DNA fragments used to illustrate the method
 CC of the invention. (Updated on 06-AUG-2003 to correct OS field.)
 XX
 SQ Sequence 15 BP; 3 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1658 ACCAGGCTCACA 1669
 DB 15 ACCAGGCTTACA 4
 ||||| |||||

RESULT 1306
 AAD25233
 ID AAD25233 standard; DNA; 15 BP.
 XX
 AC AAD25233;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CCR3 gene polymorphism detecting ASO primer #7.
 XX
 KW Human; chemokine (C-C motif) receptor 3; CCR3 gene; haplotyping;
 KW genotyping; type IV hypersensitivity reaction; HIV-1; gene therapy;
 KW human immunodeficiency virus 1; allele specific oligonucleotide; ASO;
 KW polymorphism; primer; ss.
 XX
 OS Homo sapiens.
 XX

PN W0200187908-A2.
XX
XX
PD 22-NOV-2001.
XX
XX
PF 18-MAY-2001; 2001WO-US016278.
XX
XX
PR 19-MAY-2000; 2000US-0205191P.
XX
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
XX
PI Choi JY, Kazemi A, Koshy B;
XX
XX
DR WPI; 2002-055681/07.
XX
XX
XX Isolated polymorphic variants of chemokine (C-C motif) receptor 3 (CCR3)
PT gene useful for studying function of CCR3, expressing the CCR3 protein
PT and to screen drugs to treat CCR3 activity-related diseases.
XX
XX
PS Claim 16; Page 13; 53pp; English.
XX
XX The invention relates to genetic variants of human chemokine (C-C motif)
CC receptor 3 (CCR3) gene. The invention also relates to compositions and
CC methods for haplotyping and/or genotyping the CCR3 gene in an individual.
CC Polynucleotides of the invention are useful for studying the expression
CC and function of CCR3 and in expressing CCR3 proteins for use in screening
CC candidate drugs to treat diseases related to CCR3 activity. They are also
CC used in gene therapy. The polymorphism and haplotype data is useful for
CC validating whether CCR3 is a suitable target for drugs to treat type IV
CC hypersensitivity reactions and human immunodeficiency virus (HIV)-1,
CC screening for such drugs and reducing bias cells in clinical trials of
CC such drugs. The genotyping method is useful for determining whether an
CC individual has one haplotype or haplotype pairs. The haplotyping method
CC is useful for improving the efficiency and outcome of several steps in
CC the discovery and development of drugs for treating diseases associated
CC with CCR3 activity such as type IV hypersensitivity reactions and HIV-1.
CC The present sequence is an allele specific oligonucleotide (ASO) primer
CC used for detecting human CCR3 gene polymorphisms
XX
XX
SQ Sequence 15 BP; 4 A; 5 C; 5 G; 0 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1666 CACAGCTGGAACCC 1679
Db 2 CAGAGCGGGAACYC 15
RESULT 1307
ABK85670
ID ABK85670 standard; DNA; 15 BP.
XX
XX
AC ABK85670;
XX
XX 15-AUG-2002 (first entry)
XX
XX Human SCYB6 gene polymorphism detection ASO primer #9.
XX
XX Human; small inducible cytokine subfamily B (Cys-X-Cys);
XX Member 6 (granulocyte chemotactic protein 2); SCYB6; primer; ss;
XX inflammatory disorder; cancer; antiinflammatory; cytostatic;
XX gene therapy; SCYB6 isogene expression modulator; ASO; SNP;
XX allele-specific oligonucleotide; single nucleotide polymorphism.
XX
XX Homo sapiens.
XX
XX W0200227030-A1.
XX
XX 04-APR-2002.
XX
XX 27-SEP-2001; 2001WO-US030413.
XX
XX
PR 27-SEP-2000; 2000US-0235809P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Anastasio AE, Bentivegna SC, Choi JY, Monroe G, Russo DP;
XX
XX WPI; 2002-405057/43.
XX
XX New isolated polymorphic variant of small inducible cytokine subfamily B
PT (Cys-X-Cys), Member 6 (granulocyte chemotactic protein 2) gene, useful
PT for expressing protein isoform used in drug screening techniques.
XX
XX
PS Claim 14; Page 12; 71pp; English.
XX
XX The present invention relates to a new polynucleotide having small
CC inducible cytokine subfamily B (Cys-X-Cys), Member 6 (granulocyte
CC chemotactic protein 2) (SCYB6) isogene. The invention is useful for
CC studying expression and function of SCYB6 and expressing SCYB6 protein
CC for use in screening for candidate drugs to treat diseases related to
CC SCYB6 activity. The polymorphism and haplotype data is useful for
CC validating whether SCYB6 is a suitable target for drugs to inflammatory
CC disorders and cancer, screening for such drugs and reducing bias in
CC clinical trials of such drugs. The invention is also useful for
CC identifying an association between susceptibility to a disease, staging
CC of a disease, or response to a drug. The present nucleic acid sequence
CC represents one of a collection of allele-specific oligonucleotide (ASO)
CC primers (ABK85662-ABK85679) that were used in the invention to detect
CC polymorphisms in the human SCYB6 gene
XX
XX
SQ Sequence 15 BP; 2 A; 4 C; 2 G; 6 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1683 TGTCTCTCTCCAG 1694
Db 1 TGTATCTCTCCAG 12
RESULT 1308
AAS98731
ID AAS98731 standard; DNA; 15 BP.
XX
XX
AC AAS98731;
XX
XX 26-MAR-2002 (first entry)
XX
XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #97.
XX
XX Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
XX cytostatic; gene therapy; malignant histiocytosis; isogene;
XX myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
XX genotype; human; allele specific oligonucleotide; ASO; primer; ss.
XX
XX Homo sapiens.
XX
XX W0200179225-A2.
XX
XX 25-OCT-2001.
XX
XX 12-APR-2001; 2001WO-US012044.
XX
XX 12-APR-2000; 2000US-0196411P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Choi JY, Koshy B;
XX
XX WPI; 2002-075058/10.
XX
XX Novel polymorphic variants of colony stimulating factor 1 receptor useful

PT in studying expression and function of the protein, useful for screening
 PT candidate drugs to treat diseases e.g. inflammatory disorders.

XX Claim 15; Page 16; 164pp; English.

XX The invention describes a novel isolated polynucleotide (I) comprising a
 CC sequence which is a polymorphic variant (PV) of a reference sequence for
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the
 CC polypeptide are useful for improving the discovery and development of
 CC drugs for treating diseases associated with CSF1R activity, e.g.,
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
 CC and the haplotypes can be used to validate CSF1R as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
 CC be used in developing diagnostic tests and therapeutic treatments. (I) is
 CC useful in studying the expression and function of CSF1R, and in
 CC expressing CSF1R protein for use in screening for candidate drugs to
 CC treat diseases related to CSF1R activity and in studying the effect of
 CC the variation on the biological activity of CSF1R as well as on the
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
 CC useful in a variety of diagnostic and prognostic formats and therapeutic
 CC methods. A transgenic animal is useful in studying expression of the
 CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
 CC targeted against CSF1R protein, and for testing the efficacy of
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
 CC are useful as probes and primers, and for assaying a polymorphism in the
 CC target region. Without requiring any a priori knowledge of the phenotypic
 CC effect of any particular CSF1R or haplotype the invention provides a
 CC method for identifying lead compounds that are more likely to show
 CC efficacy in clinical trials. This sequence is an allele specific
 CC oligonucleotide primer used for detecting CSF1R gene polymorphisms,
 CC described in the method of the invention

XX Sequence 15 BP; 0 A; 7 C; 4 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 78.6%; Pred. No. 6.5e+02;
 Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1681 GGTCCTCTCCAG 1694
 ||| ||||| |||
 Db 2 GGTCCTCTCCCG 15

RESULT 1309

AAS96178/c
 ID AAS96178 standard; DNA; 15 BP.

XX AAS96178;

XX 26-FEB-2002 (first entry)

DE Human Acetylcholinesterase gene allele specific primer #25.

XX Human; ss; PCR primer; allele specific oligonucleotide; ASO; AChE;
 KW acetylcholinesterase; polymorphic variant; haplotyping; genotyping;
 KW neurological disease; Parkinson's disease; Alzheimer's disease; cancer;
 KW leukaemia; tumour; chromosome 7q22.

OS Homo sapiens.

XX WO200179219-A2.

XX 25-OCT-2001.

PF 11-APR-2001; 2001WO-US011853.

XX 14-APR-2000; 2000US-0197173P.

XX (GENA-) GENAISSANCE PHARM INC.

PA (KAZE/) KAZEMI A.

XX Bentivegna SC, Chew A, Choi JY, Koshy B;

XX

DR MPI; 2002-055248/07.

XX New polymorphic variants comprising acetylcholinesterase (ACHE) isogene,
 PT useful in expressing AChE protein for use in screening for candidate
 PT drugs to treat diseases related to AChE activity, e.g. neurological
 PT diseases or cancer.

PS Claim 16; Page 13; 79pp; English.

XX The invention relates to a polynucleotide comprising a polymorphic
 CC variant of an acetylcholinesterase (ACHE) gene or fragment, protein or
 CC complement, the variant comprising an AChE isogene defined by a haplotype
 CC selected from haplotypes 1-20 listed in the specification. Also included
 CC are methods for haplotyping and genotyping the AChE gene of an
 CC individual, a method for predicting a haplotype pair for the AChE gene of
 CC an individual, a method for identifying an association between a trait
 CC and at least one haplotype or haplotype pair of AChE gene, recombinant
 CC nonhuman organisms transformed or transfected with the polynucleotide
 CC where the organism expresses AChE protein encoded by the first nucleotide
 CC sequence or encoded by the polymorphic variant sequence, an isolated
 CC antibody specific for and immunoreactive with AChE, a method of screening
 CC for drugs targeting the polypeptide contacting AChE, a polymorphic variant
 CC with a candidate agent and assaying for binding activity, a computer
 CC system for storing and analysing polymorphism data for AChE gene and a
 CC genome anthology for AChE gene which comprises AChE isogenes defined by
 CC haplotypes 1-20 given in the specification. The polymorphisms are useful
 CC for studying the biological function of AChE as well as in identifying
 CC drugs targeting this protein for the treatment of disorder related to its
 CC abnormal expression or function. The polymorphic variants may also be
 CC used in screening for compounds targeting AChE to treat a specific
 CC condition or disease predicted to be associated with AChE activity e.g.
 CC neurological diseases (e.g. Parkinson's disease and Alzheimer's disease),
 CC cancer, leukaemia, and tumours. The AChE gene maps to human chromosome
 CC 7q22. The present sequence is an allele specific oligonucleotide (ASO)
 CC PCR primer used to detect the polymorphic AChE variants of the invention

XX Sequence 15 BP; 2 A; 2 C; 7 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 78.6%; Pred. No. 6.5e+02;
 Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1653 CAGCACCAGCTC 1666
 ||| ||||| |||
 Db 15 CRAGCCCGAGCTC 2

RESULT 1310

ABK16934

ID ABK16934 standard; DNA; 15 BP.

XX ABK16934;

XX 26-MAR-2002 (first entry)

DE Pyridoxal (Pyridoxine, vitamin B6) Kinase (PDXK) probe #14.

KW Pyridoxal kinase; pyridoxine; vitamin B6;

KW PDXK autoimmune polyglandular disease type 1; transgenic animal;
 KW gene therapy; allele specific oligonucleotide; ASO; probe; ss.

OS Homo sapiens.

XX WO200190125-A2.

XX 29-NOV-2001.

XX 24-MAY-2001; 2001WO-US016909.

XX 24-MAY-2000; 2000US-0206664P.

XX (GENA-) GENAISSANCE PHARM INC.

```
XX PI Chew A, Duda A, Koshy B;
XX DR WPI; 2002-106169/14.
XX PT Isolated human pyridoxal (pyridoxine, vitamin B6) kinase polyNTs, useful
XX PT for therapeutic purposes, for studying the expression and function of the
XX PT polyNT, and for expressing pyridoxal protein.
XX PS Claim 17; Page 13; 135pp; English.
XX CC The invention describes an isolated human pyridoxal (pyridoxine, vitamin
XX CC B6) kinase, (PDXK) polynucleotide. The polynucleotide is useful in
XX CC studying the expression and function of PDXK, and in expressing PDXK
XX CC protein for use in screening for candidate drugs to treat PDXK related
XX CC diseases and for therapeutic purposes. A transgenic animal is useful for
XX CC studying expression of the PDXK isogenes in vivo, for in vivo screening
XX CC and testing of drugs targeted against PDXK protein, and for testing the
XX CC efficacy of therapeutic agents and compounds for autoimmune polyglanular
XX CC disease type 1. The polypeptide is useful for studying the effect of the
XX CC variation on the biological activity of PDXK and the binding affinity of
XX CC candidate drugs targeting PDXK for the treatment of autoimmune
XX CC polyglanular disease type 1. Genotyping and haplotyping is useful for
XX CC improving the efficacy and reliability of several steps in the discovery
XX CC and development of drugs for treating diseases associated with PDXK
XX CC activity, e.g., autoimmune polyglanular disease type 1, to validate PDXK
XX CC as a candidate agent for treating a specific condition or disease
XX CC predicted to be associated with PDXK activity, and in the design of
XX CC clinical trials of candidate drugs. This sequence is one of 20 (see
XX CC AK16921-ASK16940) allele specific oligonucleotide (ASO) probe used for
XX CC detecting PDXK gene polymorphisms, described in the method of the
XX CC invention
XX SQ Sequence 15 BP; 4 A; 5 C; 4 G; 1 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1655 AGCACCAGGCTCAC 1668
Db 2 AGCACCAGGATGAC 15
RESULT 1311
ABL52230/C
ID ABL52230 standard; DNA; 15 BP.
XX AC ABL52230;
XX DT 15-JUL-2002 (first entry)
XX DE Human PHKG2 allele specific oligonucleotide primer SEQ ID NO:17.
XX KW Human; phosphorylase kinase gamma 2 (testis); PHKG2; enzyme; SNP;
XX KW phosphorylase kinase gamma 2; single nucleotide polymorphism;
XX KW polymorphic; hepatotropic; gene therapy; glycogen storage disease;
XX KW liver cirrhosis; allele specific oligonucleotide; ASO; primer; ss.
XX OS Homo sapiens.
XX PH Key Location/Qualifiers
XX FT misc_feature 14
XX FT /tag= a
XX FT /note= "polymorphic site indicated by an ambiguity base"
XX PN WO200194365-A2.
XX PD 13-DEC-2001.
XX PF 11-JUN-2001; 2001WO-US018814.
XX PX 09-JUN-2000; 2000US-0210568P.
XX PI
```

```
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Choi JY, Koshy B, Sanchis A, Sausker EA;
XX DR WPI; 2002-404359/43.
XX PT New variants of phosphorylase kinase gamma 2 isogenes, useful for
XX PT improving efficiency and reliability in the development of drugs for
XX PT treating diseases e.g. liver cirrhosis.
XX PS Claim 16; Page 13; 76pp; English.
XX CC The present invention describes an isolated polynucleotide (I) comprising
XX CC a nucleotide sequence which is a polymorphic variant of a reference
XX CC sequence for human phosphorylase kinase gamma2 (testis) (PHKG2) gene or
XX CC its fragment, or a polymorphic variant of a reference sequence for a
XX CC PHKG2 cDNA or its fragment. Also described is an isolated polypeptide
XX CC (II) comprising an amino acid sequence which is a polymorphic variant of
XX CC a reference sequence for PHKG2 protein or its fragment, where the
XX CC reference sequence comprises a sequence (see ABB09290) of 406 amino
XX CC acids, and the polymorphic variant comprises one or more variant amino
XX CC acids selected from glutamic acid at a position corresponding to amino
XX CC acid position 153 and tryptophan at position corresponding to amino acid
XX CC position 329. (I) has hepatotropic activity and can be used in gene
XX CC therapy. (II) is useful in screening for drugs targeting (II), by
XX CC contacting a PHKG2 polymorphic variant with a candidate agent and
XX CC assaying for binding activity. The identified candidate agents targeting
XX CC PHKG2, are useful for treating liver cirrhosis and glycogen storage
XX CC diseases. The present sequence represents an allele specific
XX CC oligonucleotide (ASO) primer for the PHKG2 gene, which is used in the
XX CC exemplification of the present invention
XX SQ Sequence 15 BP; 3 A; 1 C; 9 G; 1 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1736 CTCCCACTCCCTCC 1749
Db 15 CYCCCACTCCCTGC 2
RESULT 1312
ABT05335/C
ID ABT05335 standard; DNA; 15 BP.
XX AC ABT05335;
XX DT 24-OCT-2002 (first entry)
XX DE Human N-acetylgalactosaminidase (NAGA) alpha gene ASO primer 27.
XX KW Human; PCR; primer; ss; gene therapy; N-acetylgalactosaminidase alpha;
XX KW chromosome 22q13.2-q13.31; lysosomal glycohydrolase; screening; SNP;
XX KW NAGA-related disease; single nucleotide polymorphism; haplotyping; NAGA;
XX KW genotyping.
XX OS Homo sapiens.
XX PN WO200194637-A1.
XX PD 13-DEC-2001.
XX PF 07-JUN-2001; 2001WO-US018456.
XX PX 07-JUN-2000; 2000US-02-0110P.
XX PI (GENA-) GENAISSANCE PHARM INC.
XX PI Duda A, Kazemi A, Koshy B, Parks KE;
```

DR WPI; 2002-566449/60.

PT New genetic variants of isolated N-acetylgalactosaminidase (NAGA), Alpha

PT gene, useful for therapeutic purposes, for studying the expression and

PT function of the polynucleotide, and for expressing NAGA protein.

XX Claim 16; Page 13; 91pp; English.

XX The invention comprises the amino acid and coding sequence of the human N

CC -acetylgalactosaminidase (NAGA) alpha protein. The invention specifically

CC comprises novel polymorphic sites identified within the NAGA gene. The

CC NAGA gene is located on chromosome 22q13.2-q13.31, and encodes a

CC lysosomal glycosylase that cleaves alpha-N-acetylgalactosaminyl

CC moieties in glycoconjugates. The NAGA DNA and protein sequences of the

CC invention are useful for studying the expression and function of NAGA and

CC for screening candidate drugs to treat diseases related to NAGA activity.

CC The NAGA gene polymorphisms identified in the present invention are

CC useful for haplotyping and genotyping the NAGA gene of an individual. The

CC present DNA sequence represents an N-acetylgalactosaminidase gene allele-

CC specific oligonucleotide primer

XX Sequence 15 BP; 3 A; 2 C; 7 G; 2 T; 0 U; 1 Other;

SQ

Query Match 7.5%; Score 10.4; DB 1; Length 15;

Best Local Similarity 91.7%; Pred. No. 6.5e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCAACTCCTC 1748

Db | | | | | | | | | |

12 TCCCAAGTCTCTC 1

RESULT 1313

ABA96065/C

ID ABA96065 standard; DNA; 15 BP.

XX ABA96065;

XX

DT 08-APR-2002 (first entry)

XX

DE CYP8B1 allele-specific oligonucleotide primer #8.

XX

XX Primer; CYP8B1; allele-specific oligonucleotide; ASO; cytochrome P450;

KW VIIIB; cardiant; gene therapy; cardiovascular disorder; human; ss.

KW

XX Homo sapiens.

OS

XX WO200179224-A2.

PN

XX 25-OCT-2001.

PD

XX 12-APR-2001; 2001WO-US011946.

XX

PF 12-APR-2000; 2000US-0196408P.

XX

PR (GENA-) GENAISSANCE PHARM INC.

XX

PA Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;

XX

PI WPI; 2002-075057/10.

XX

DR Novel polymorphic variants of cytochrome P450 subfamily VIIIB gene useful

PT in studying expression and function of the protein, for screening

PT candidate drugs to treat diseases e.g. cardiovascular disorders.

XX Claim 15; Page 13; 63pp; English.

XX

XX The sequence represents an allele-specific oligonucleotide (ASO) primer,

CC used in the invention to detect polymorphisms in the CYP8B1 gene. The

CC invention relates to a novel isolated polynucleotide which is a

CC polymorphic variant of a reference sequence for cytochrome P450 subfamily

CC VIIIB (CYP8B1) gene or their fragment. The polynucleotides of the

CC invention have cardiant activity, and may have a use in gene therapy. A

CC polymorphic variant of the CYP8B1 protein is useful for screening drugs

CC targeting CYP8B1. A haplotype or haplotype pair is useful for improving

CC the efficiency and reliability of several steps in the discovery and

CC development of drugs for treating diseases associated with CYP8B1

CC activity e.g., cardiovascular disorders. The invention includes a method

CC for haplotyping CYP8B1 gene in an individual, which can also be used to

CC validate CYP8B1 as a candidate target for, and in design of clinical

CC trials of candidate drugs for, treating a specific condition drugs or

CC disease predicted to be associated with CYP8B1 activity. A method is also

CC included for genotyping CYP8B1 gene of an individual which can also be

CC used in developing diagnostic tests and therapeutic treatments. The

CC advantage to this is that without requiring any a prior knowledge of the

CC phenotypic effect of any particular CYP8B1 haplotype or haplotype pair,

CC the invention provides a method to identify lead compounds that are more

CC likely to show efficacy in clinical trials

XX

SQ Sequence 15 BP; 2 A; 2 C; 6 G; 4 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;

Best Local Similarity 78.6%; Pred. No. 6.5e+02;

Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1748 CCTATCTCTAAAGG 1761

Db | | | | | | | | | |

15 CYCCATCTCTAAGG 2

RESULT 1314

ABQ72276

ID ABQ72276 standard; DNA; 15 BP.

XX

XX ABQ72276;

AC

XX

DT 02-SEP-2002 (first entry)

XX

DE Human CYP2D6 allele-specific oligonucleotide (ASO) primer, SEQ ID NO:63.

XX

KW Human; cytochrome P450; subfamily IID polypeptide 6; CYP2D6; enzyme;

KW chromosome 22q13.1; drug metabolism; detoxification; mono-oxygenase;

KW antiarrhythmic; arrhythmia; adrenoceptor antagonist; hypertension;

KW tricyclic antidepressant; procainamide; drug induced lupus syndrome;

KW environmentally linked disease; Parkinson's disease; haptocyping;

KW genotyping; haplotype; genetic variant; single nucleotide polymorphism;

KW SNP; drug screening; drug discovery; allele-specific oligonucleotide;

KW ASO; primer; ss.

XX

XX Homo sapiens.

OS

XX WO200238589-A2.

PN

XX 16-MAY-2002.

PD

XX 09-NOV-2001; 2001WO-US047396.

XX

PF 09-NOV-2000; 2000US-0247943P.

XX

PR (GENA-) GENAISSANCE PHARM INC.

XX

PA Anastasio AE, Chew A, Choi JY, Denton RR, Nandabalan K;

XX

PI Petersen N, Rounds E;

XX

XX WPI; 2002-519292/55.

DR

XX Novel genetic variants of Cytochrome P450, Subfamily IID, Polypeptide 6

PT isoenzymes, useful for improving efficiency and reliability in drug

PT development for treating hypertension, arrhythmias and Parkinson's

PT disease.

XX Claim 15; Page 18; 158pp; English.

PS

XX The invention relates to a method for haplotyping the cytochrome P450,

CC subfamily IID, polypeptide 6 (CYP2D6) gene (ABQ72215, ABQ72364) of an

CC individual, and also describes 29 novel polymorphic sites within the

CC human CYP2D6 gene. The CYP2D6 gene is located on chromosome 22q13.1 and
CC contains 9 exons which encode a 497 amino acid protein (AB095633). CYP2D6
CC is a mono-oxygenase involved in the detoxification of many drugs and
CC environmental chemicals. It plays a role in the metabolism of drugs such
CC as antiarrhythmics, adrenoceptor antagonists and tricyclic
CC antidepressants, and is also involved in the formation of a metabolite
CC linked to the drug-induced lupus syndrome observed with procainamide.
CC Variations in CYP2D6 activity or expression may also influence an
CC individual's susceptibility to environmentally-linked diseases, and it
CC has been demonstrated that CYP2D6 activity may be involved in the
CC pathogenesis of Parkinson's disease, with individuals with a less active
CC form of the enzyme tending to have an earlier onset of this condition.
CC CYP2D6 nucleic acid sequences are useful in studying the expression and
CC function of CYP2D6, and in expressing CYP2D6 protein for use in screening
CC drugs for the treatment of CYP2D6-associated diseases (e.g.,
CC hypertension, atrial and ventricular arrhythmias, Parkinson's disease,
CC and drug-induced lupus syndrome) or which are metabolised by CYP2D6.
CC CYP2D6 nucleic acids and proteins are also useful in studying the effect
CC of polymorphisms on the biological activity of CYP2D6. Polymorphisms in
CC the target region may be determined by the use of allele-specific
CC oligonucleotides (ASOs; ABQ7217-ABQ72303) as probes and primers, and by
CC primer extension using oligonucleotide primers comprising sequences
CC ABQ72304-ABQ72361. The method of the invention is useful for haplotyping
CC the CYP2D6 gene in populations and in individuals, enabling decisions to
CC be made as to whether CYP2D6 is a likely therapeutic target for a disease
CC of interest, and to control for genetically-based bias in the design of
CC drugs that target or are metabolised by CYP2D6. In addition, transgenic
CC animals comprising a human CYP2D6 gene are useful for studying the
CC expression of CYP2D6 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted to or metabolised by CYP2D6, and for testing the
CC efficacy of therapeutic agents and compounds for treating CYP2D6-
CC associated conditions in a biological system. Sequences ABQ72246-
CC ABQ72303 represent specifically claimed allele-specific oligonucleotide
CC (ASO) primers used for detecting polymorphisms in the CYP2D6 gene
XX
SQ Sequence 15 BP; 4 A; 3 C; 7 G; 0 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1650 AGGCAGCACCAGG 1663
DB 1 AGGCAGCAGCGGK 14

RESULT 1315
ABL91070/c
ID ABL91070 standard; DNA; 15 BP.
XX
AC ABL91070;
XX
XX 27-MAY-2002 (first entry)
DT
XX
DE Hominiidae LDL receptor related DNA sequence #123.
XX
XX Hominiidae; low density lipoprotein receptor; LDL receptor; LDL-R;
XX detection; lipid metabolic error; hyperlipaemia; mutation;
XX arteriosclerosis; ischaemic heart disease; ischaemia; ds.
XX
XX Hominiidae.
OS Synthetic.
OS
XX WO200206467-A1.
XX
XX 24-JAN-2002.
XX
XX 17-JUL-2001; 2001WO-JP006153.
PF
XX 18-JUL-2000; 2000JP-00218039.
XX
XX (BMLB-) BML INC.
PA
PS

PI Hattori H, Tsuji M, Okada T, Nagano M, Egashira T, Ishihara M;
PI Iwasaki T;
XX
DR WPI; 2002-179794/23.
XX
PT Set of specific low density lipoprotein receptor gene mutations for
PT diagnosis of familial lipid metabolism errors including hyperlipemia.
XX
PS Example; Fig 45; 123pp; Japanese.
XX
CC The present invention describes a method for detecting lipid metabolism
CC errors in patients using as indicators a set of 65 specific low density
CC lipoprotein (LDL) receptor gene mutations. The method can be used in the
CC diagnosis of an inherited predisposition to the development of diseases
CC associated with hyperlipaemia, such as arteriosclerosis and ischaemic
CC heart disease. ABL91141 encodes the LDL receptor given in AB908325.
CC ABL91142 to ABL91183 represent PCR primers used in the amplification of
CC the receptor gene. ABL90990 to ABL91140 and AB90445 to AB90524
CC represents sequences used in the exemplification of the present invention
XX
SQ Sequence 15 BP; 3 A; 9 C; 1 G; 1 T; 0 U; 1 Other;
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1631 GGATGGGCTTGT 1643
DB 13 GGATGGGCTGCT 1
RESULT 1316
ABL51958/c
ID ABL51958 standard; DNA; 15 BP.
XX
AC ABL51958;
XX
DT 11-JUL-2002 (first entry)
XX
DE Human SLC18A2 allele specific oligonucleotide probe SEQ ID NO:6.
XX
XX Human; solute carrier family 18 member 2; SLC18A2; vesicular monoamine;
XX vesicular monoamine transporter; VMAT2; polymorphic site; SNP;
XX single nucleotide polymorphism; antiinflammatory; neuroleptic;
XX haplotyping; genotyping; respiratory inflammatory disease;
XX neuropsychiatric disorder; monoaminergic brain system; probe; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_feature 8
FT /*tag= a
FT /note= "polymorphic site indicated by an ambiguity base"
XX
XX WO200222652-A2.
PN
XX 21-MAR-2002.
PD
XX 17-SEP-2001; 2001WO-US042217.
PF
XX 15-SEP-2000; 2000US-0232895P.
PR
XX (GENA-) GENAISANCE PHARM INC.
PA
XX Anastasio AE, Han J, Kliem SE, Sausker EA;
PI
XX WPI; 2002-393942/42.
DR
XX Novel genetic variants of soluble carrier family 18 (vesicular
XX monoamine), member 2 gene useful for screening drugs to treat diseases
XX e.g. neuropsychiatric disorders involving monoaminergic brain systems.
XX
XX Claim 17; Page 14; 183pp; English.

XX The present invention describes an isolated polynucleotide (I) having a
 CC sequence (S1) comprising soluble carrier family 18 (vesicular monoamine),
 CC member 2 (SLC18A2) isogene selected from 49 isoforms with regions of a
 CC sequence (S2) of 40023 bp (see ABU51954), and defined by a corresponding
 CC set of polymorphisms whose locations and identities are given in the
 CC specification; or a sequence (S2) complementary to (S1). (I) has
 CC antiinflammatory and neuroleptic activities, and can be used in gene
 CC therapy. Methods from the present invention can be used for haplotyping
 CC and genotyping the SLC18A2 gene in an individual. SLC18A2 is also known
 CC as the vesicular monoamine transporter (VMAT2). (I) is useful in studying
 CC the expression and function of SLC18A2, and in expressing the SLC18A2
 CC protein for use in screening for candidate drugs to treat diseases
 CC related to SLC18A2 activity and in studying the effect of the variation
 CC on the biological activity of SLC18A2 as well as on the binding affinity
 CC of candidate drugs targeting SLC18A2 for the treatment of respiratory
 CC inflammatory diseases such as neuropsychiatric disorders involving
 CC monoaminergic brain systems. The present sequence represents an allele
 CC specific oligonucleotide (ASO) probe for human SLC18A2, which is given in
 CC the present invention
 XX
 SQ Sequence 15 BP; 4 A; 3 C; 4 G; 3 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 78.6%; Pred. No. 6.5e+02;
 Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1662 GGCTCAGCTGGA 1675
 DB 14 GGCTCAYACCTGTA 1

RESULT 1317
 ABK15156
 ID ABK15156 standard; DNA; 15 BP.
 AC ABK15156;
 XX
 XX 23-APR-2002 (first entry)
 XX Human HNF3A allele-specific oligonucleotide primer #9.
 DE
 XX Hepatocyte nuclear factor 3 alpha; HNF3A; human; genotype; primer;
 KW allele specific oligonucleotide; polymorphism; chromosome 14q12-q13;
 KW glucose homeostasis; hypoglycaemia; diabetes; haplotype; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200200675-A2.
 XX
 XX 03-JAN-2002.
 XX
 XX 25-JUN-2001; 2001WO-US020213.
 XX
 XX 23-JUN-2000; 2000US-0213635P.
 XX
 XX (GENA-) GENAISSANCE PHARM INC.
 PA (LANZ/) LANZ E. M.
 PA (PARK/) PARKS K. E.
 PA (SANC/) SANCHIS A.
 XX
 PI Lanz EM, Parks KE, Sanchis A;
 XX
 XX WPI; 2002-130872/17.
 XX
 XX Isolated polynucleotide comprising a polymorphic variant of the
 PT Hepatocyte Nuclear Factor 3, Alpha (HNF3A) gene useful for providing
 PT haplotype information and in therapy for treating related disorders.
 XX
 XX Claim 16; Page 13; 67pp; English.
 XX
 XX This invention relates to novel polymorphic genetic variants of the human
 CC hepatocyte nuclear Factor 3, Alpha (HNF3A) gene, the HNF3A gene is

CC located on human chromosome 14q12-q13. HNF3A is required in mice for the
 CC full activation of glucagon in the pancreas and as such this gene may be
 CC important for the treatment of glucose homeostasis disorders such as
 CC hypoglycaemia and diabetes. The invention also comprises the nucleotide
 CC probes and primer sequences that can be used in a method of the invention
 CC to genotype individuals and detect polymorphic sites. The HNF3A isoforms
 CC and polymorphic variants of the invention are useful for providing
 CC haplotype and genotype information about an individual. Furthermore, this
 CC sequence is useful for the treatment of diseases or disorders related to
 CC its abnormal expression or function. The present sequence represents the
 CC HNF3A allele specific oligonucleotide (ASO) primer #9 used in conjunction
 CC with an ASO probe in the method of the invention to detect and
 CC discriminate between different alleles of the HNF3A polymorphic variants
 XX
 SQ Sequence 15 BP; 1 A; 6 C; 5 G; 2 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 78.6%; Pred. No. 6.5e+02;
 Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1688 COTCCAGCTGGTG 1701
 DB 2 COTCCATCGGGYG 15

RESULT 1318
 ABL91860/c
 ID ABL91860 standard; DNA; 15 BP.
 XX
 AC ABL91860;
 XX

XX 11-JUL-2002 (first entry)

XX Human LIPG gene allele specific oligonucleotide primer 39.

XX Human; ss; allele specific oligonucleotide; primer;
 KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
 KW drug screening; atherosclerosis; cardiovascular disorder;
 KW LIPG haplotyping; LIPG genotyping.
 XX

OS Homo sapiens.

XX WO200216397-A2.

XX 28-FEB-2002.

XX 17-AUG-2001; 2001WO-US026639.

XX 25-AUG-2000; 2000US-0227825P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Duda A, Kazemi A, Kliehm SE, Messer C;
 XX

XX WPI; 2002-292055/33.

XX Novel genetic variants of Lipase, Endothelial isogenes, useful for
 PT improving efficiency and reliability in drug development for treating
 PT diseases associated with LIPG activity, e.g. atherosclerosis.
 XX
 XX Claim 16; Page 14; 134pp; English.

XX The invention comprises the DNA and amino acid sequence of the human
 CC lipase, endothelial (LIPG) isogene. Specifically, the invention relates
 CC to the discovery of 20 novel polymorphic sites within the LIPG gene. The
 CC LIPG coding sequence and protein are useful for screening drugs that can
 CC be used to treat atherosclerosis and other cardiovascular disorders. The
 CC LIPG coding sequence can also be used to haplotype and genotype the LIPG
 CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
 CC LIPG gene allele specific oligonucleotide primers
 XX

SQ Sequence 15 BP; 1 A; 4 C; 7 G; 2 T; 0 U; 1 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps
0;

QY 1660 CAGGCTCACAGTGTG 1673
DB |:-|||-||-|||||
 15 CRGGCACCACAGTG 2

RESULT 1319

ABK96133
ID ABK96133 standard; DNA; 15 BP.
XX AC
XX AKB96133;
XX AC
XX DT
XX DT
DE 24-SEP-2002 (first entry)
DE Human CYP1A2 allele specific PCR primer #32.
XX DE
XX Human; ss; PCR; Cytochrome P450 subfamily 1 polypeptide 2; primer:
KW CYP1A2; cancer; tardive dyskinesia; TD; porphyria cutanea tarda; PCT;
KW chromosome 15q22-qter; haplotype; genotype; cytostatic; muscular-gen;
KW hepatotrophic.
XX KW
XX Homo sapiens.
OS XX
PN WO200236608-A2.
PN XX
PD 10-MAY-2002.
PP XX
PF 11-OCT-2001; 2001WO-USO42637.
PX XX
PR 11-OCT-2000; 2000US-023974OP.
RX XX
PA (GENA-) GENAISSANCE PHARM INC.
XX PA
XX Bentivegna SC, Kazemi A, Koshy B, Parks KE, Rounds E, Sausker EA;
PI WPI; 2002-519230/55.
DR XX
DX Novel genetic variants of Cytochrome P450, Subfamily I (Aromatic Compound
PT -Inducible) isoenzymes, useful for improving efficiency and reliability in
PT drug development for treating cancers.

Claim 14; Page 15; 93pp; English.

The invention relates to an isolated polynucleotide comprising a first nucleotide sequence which comprises cytochrome P450, subfamily I (aromatic compound-inducible) (CYP1A2), selected from isoforms 1-8 and 10 given in the specification, where the isoforms comprise the regions of a CYP1A2 gene sequence (ABK87391) or the cDNA (ABK87392). Also included are haplotyping or genotyping CYP1A2 gene of an individual, predicting a haplotype pair for CYP1A2 gene of an individual, identifying an association between a trait and at least one haplotype or haplotype pair of CYP1A2 gene, primers and probes for performing the genotyping/haplotyping, a recombinant non-human organism transformed or transfected with the CYP1A2 polynucleotide, where the organism expresses a CYP1A2 protein or variant, a fragment of a CYP1A2 isogene comprising at least 10 nucleotides and a polymorphism selected from the 18 identified polymorphisms, polymorphic variants of the CYP1A2 polypeptide, an anti-CYP1A2 monoclonal antibody, a computer system for storing and analyzing polymorphism data for the CYP1A2 gene, and a genome anthology for CYP1A2 gene. The polymorphic variants, haplotyping/genotyping methods and antibodies are useful in diagnostic, prognostic and therapeutic methods CC and in screening for drugs that are useful for treating cancers, tardive CC dyskinesia (TD) and porphyria cutanea tarda (PCT). The gene for CYP1A2 is located on chromosome 15q22-qter. The present sequence is an allele CC specific PCR primer used to detect the polymorphisms CC Sequence 15 BP; 1 A; 3 C; 3 G; 7 T; 0 U; 1 Other; SQ Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 6.5e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps
0;

KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic;
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KW substrate; hammerhead ribozyme; HH ribozyme; ss.

OS Hepatitis C virus.

PN US2002082225-A1.

PD 27-JUN-2002.

PF 23-MAR-1999; 99US-00274553.

PR 23-MAR-1999; 99US-00274553.

XX (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PA (ROBE/) ROBERTS B.

PA (PAVC/) PAVCO P A.

PA (MACE/) MACEJACK D.

PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;

DR WPI; 2002-617759/66.

XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis, liver failure or hepatocellular carcinoma.

PS Claim 1; Page 48; 80pp; English.

CC The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of
 CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdbEntry.html

XX Sequence 15 BP; 2 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 75.0%; Pred. No. 6.5e+02;
 Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1688 CCTCCAGCGTGG 1699

Db 1 CCUCCAUUGUGG 12

RESULT 1322

ABX00579/c

ID ABX00579 standard; RNA; 15 BP.

XX AC ABX00579;

XX 23-DEC-2002 (first entry)

XX Hepatitis C virus substrate #361 for HCV hammerhead ribozyme #361.

DE Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
 KW type I interferon; interferon alpha; interferon beta; cytostatic;

KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
 KW substrate; hammerhead ribozyme; HH ribozyme; ss.

OS Hepatitis C virus.

PN US2002082225-A1.

PD 27-JUN-2002.

PF 23-MAR-1999; 99US-00274553.

PR 23-MAR-1999; 99US-00274553.

XX (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

PA (ROBE/) ROBERTS B.

PA (PAVC/) PAVCO P A.

PA (MACE/) MACEJACK D.

PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;

DR WPI; 2002-617759/66.

XX New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
 PT replication and are useful to treat hepatitis C virus infections and
 PT cirrhosis, liver failure or hepatocellular carcinoma.

PS Claim 1; Page 31; 80pp; English.

CC The present invention relates to enzymatic nucleic acids which
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
 CC (HP) motif where the binding arms comprise sequences complementary to one
 CC of the substrate sequences defined in the specification. The HCV
 CC ribozymes are useful for modulating the expression and/or replication of
 CC HCV. They can be used to treat cirrhosis, liver failure and/or
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
 CC a condition associated with HCV infection in conjunction with one or more
 CC other drug therapies, particularly type I interferon, especially
 CC interferon alpha, beta or gamma or consensus interferon. The present
 CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdbEntry.html

XX Sequence 15 BP; 3 A; 5 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 15;
 Best Local Similarity 91.7%; Pred. No. 6.5e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1695 CGTGGTGGAGCT 1706

Db 15 CGTAGTGGAGCT 4

RESULT 1323

AAS99325/c

ID AAS99325 standard; DNA; 15 BP.

XX AC AAS99325;

XX 12-MAR-2002 (first entry)

XX Aldehyde dehydrogenase 5 family, member A1, oligonucleotide #18.

KW Aldehyde dehydrogenase 5 family member A1; ALDH5A1;
 KW succinate-semialdehyde dehydrogenase; gene therapy; probe;
 KW antisense technology; allele specific oligonucleotide; ASO;
 KW 4-hydroxybutyric aciduria; metabolic disease; transgenic animal; ss.
 XX Synthetic.


```

PD 17-OCT-2002.
XX
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PVC/) PAVCO P.
PA (LEPP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 212; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinczymes, amberyzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC enzymatic nucleic acid sequences disclosed in the present invention
XX
XX Sequence 15 BP; 0 A; 4 C; 3 G; 0 T; 8 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 6.5e+02;
Matches 6; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 1680 TGGTGTCCTCC 1691
Db :|:|:|:|:|
2 UUGUGUCCUC 13
RESULT 1326
AAQ68223/c
ID AAQ68223 standard; DNA; 16 BP.
XX
XX AAQ68223;
XX
XX 25-MAR-2003 (revised)
DT 02-MAR-1995 (first entry)
XX
XX Sequence of 5'-hexylamine modified antisense oligo (ODN1).
XX
XX Antisense oligonucleotide; ODN; modified oligo;
KW Hepatitis B surface antigen; Hep3B cells, ss.
XX

```

```

XX Synthetic.
XX
XX Key Location/Qualifiers
FT misc_feature 1
FT /tag= a
FT /label= H2N-(CH2)6-O-PO2-
FT /note= "modified site"
XX
XX WO9413325-A2.
XX
XX 23-JUN-1994.
XX
XX 15-DEC-1993; 93WO-US012246.
XX
XX 15-DEC-1992; 92US-00991199.
XX
XX (MICR-) MICROPROBE CORP.
XX
XX Meyer RB, Gall AA, Reed MW;
PI WPI; 1994-217541/26.
XX
XX New covalently linked conjugates of oligo:nucleotide, peptide and carrier
PT -utilising surfactant, poly:amine or targeting ligand as lyso
PT somotropic drug carrier.
XX
XX Disclosure; Page 19; 77pp; English.
XX
XX The inventors claim an oligo-peptide-carrier conjugate in which the three
CC moieties are covalently linked to one another. The peptide provides a
CC cleavable linker which is cleaved by enzymes which do not degrade
CC antisense oligos (ODNs). The ODN-targeting ligand linkage must be stable
CC to serum proteases, yet cleaved by the lysosomal enzymes in the target
CC cell. The method involves conjugation of an ODN bearing an electrophilic
CC crosslinking gp. to a peptide which bears two nucleophilic gps of
CC differing reactivity. The resulting ODN-peptide conjugate is prepd. to
CC that a nucleophilic handle remains on the peptide. This gp. is used to
CC further attach the lysosomotropic carrier to the peptide portion of the
CC ODN-peptide conjugate. The peptide is therefore also used as a
CC heterobifunctional linker. Two different model ODNs were used - ODN1 and
CC ODN2. ODN1 is complementary to the initiation codon region of the mRNA
CC transcript for the Hepatitis B surface antigen in Hep3B cells. (Updated
CC on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 16 BP; 3 A; 7 C; 1 G; 5 T; 0 U; 0 Other;
SQ
Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1719 ACGGAGATGGAG 1730
Db |||||
12 ACGAAGATGGAG 1
RESULT 1327
AAS15518
ID AAS15518 standard; DNA; 16 BP.
XX
XX AAS15518;
XX
XX 16-JAN-2002 (first entry)
DT
XX
XX N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #15.
XX
XX N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
KW single nucleotide polymorphism; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT variation replace(8,G)

```

```

FT      /*tag= a
FT      /standard_name= "Single nucleotide polymorphism"
FT      replace(8,G)
FT      /*tag= b
FT      /standard_name= "Single nucleotide polymorphism"
XX      WO200166804-A2.
PN      13-SEP-2001.
XX      09-MAR-2001; 2001WO-US007775.
XX      09-MAR-2000; 2000US-00521983.
PR      10-JUL-2000; 2000US-00613517.
XX      (PROT-) PROTOGENE LAB INC.
PA      Cronin MT, Frueh F, Brennan TM;
PI      WPI; 2001-616243/71.
XX      Determining sequence variation in, or monitoring expression of genes in
XX      target nucleic acid for high-throughput genotyping of (un)known
XX      polymorphisms/mutations, comprises hybridization pattern differences
XX      between target and probe sequences.
XX      Example 5; Page 35; 60pp; English.
XX      The invention relates to a method of simultaneously determining the
XX      presence of 2 or more sequence variations in target nucleic acids, or
XX      simultaneously monitoring expression of 2 or more genes. The method
XX      comprises determining differences in hybridisation between the target
XX      nucleic acid and immobilised probes, where differences in hybridisation
XX      between indicates sequence variations or transcription levels. The method
XX      is used for simultaneously determining the presence or absence of two or
XX      more sequence variations in target nucleic acids or simultaneously
XX      monitoring expression of two or more genes in target nucleic acids. The
XX      methods are applicable to high-throughput genotyping of known and unknown
XX      polymorphisms and mutations. The method maximises the information yield
XX      of hybridisation-based array applications by increasing the number of
XX      informative array-immobilised polynucleotide probes. The present sequence
XX      represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
XX      polymorphism (SNP) hybridisation probe #15
XX      Sequence 16 BP; 1 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1676 ACCCTGGTGTCT 1687
DB      ||||| |||
         4 ACCCTGGTTTCT 15

RESULT 1328
AAS15509
ID      AAS15509 standard; DNA; 16 BP.
XX      AAS15509;
XX      16-JAN-2002 (first entry)
XX      N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #6.
XX      N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
XX      single nucleotide polymorphism; ss.
XX      Synthetic.
XX      Key      Location/Qualifiers
XX      Key      replace(7,C)
XX      variation /*tag= a
FT      /standard_name= "Single nucleotide polymorphism"
FT      FT

```

```

FT      /*tag= a
FT      /standard_name= "Single nucleotide polymorphism"
FT      replace(9,G)
FT      /*tag= b
FT      /standard_name= "Single nucleotide polymorphism"
XX      WO200166804-A2.
PN      13-SEP-2001.
XX      09-MAR-2001; 2001WO-US007775.
XX      09-MAR-2000; 2000US-00521983.
PR      10-JUL-2000; 2000US-00613517.
XX      (PROT-) PROTOGENE LAB INC.
PA      Cronin MT, Frueh F, Brennan TM;
PI      WPI; 2001-616243/71.
XX      Determining sequence variation in, or monitoring expression of genes in
XX      target nucleic acid for high-throughput genotyping of (un)known
XX      polymorphisms/mutations, comprises hybridization pattern differences
XX      between target and probe sequences.
XX      Example 5; Page 35; 60pp; English.
XX      The invention relates to a method of simultaneously determining the
XX      presence of 2 or more sequence variations in target nucleic acids, or
XX      simultaneously monitoring expression of 2 or more genes. The method
XX      comprises determining differences in hybridisation between the target
XX      nucleic acid and immobilised probes, where differences in hybridisation
XX      between indicates sequence variations or transcription levels. The method
XX      is used for simultaneously determining the presence or absence of two or
XX      more sequence variations in target nucleic acids or simultaneously
XX      monitoring expression of two or more genes in target nucleic acids. The
XX      methods are applicable to high-throughput genotyping of known and unknown
XX      polymorphisms and mutations. The method maximises the information yield
XX      of hybridisation-based array applications by increasing the number of
XX      informative array-immobilised polynucleotide probes. The present sequence
XX      represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
XX      polymorphism (SNP) hybridisation probe #16
XX      Sequence 16 BP; 1 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1676 ACCCTGGTGTCT 1687
DB      ||||| |||
         4 ACCCTGGTTTCT 15

RESULT 1328
AAS15507
ID      AAS15507 standard; DNA; 16 BP.
XX      AAS15507;
XX      16-JAN-2002 (first entry)
XX      N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #4.
XX      N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
XX      single nucleotide polymorphism; ss.
XX      Synthetic.
XX      Key      Location/Qualifiers
XX      Key      replace(8,G)
XX      variation /*tag= a
FT      /standard_name= "Single nucleotide polymorphism"
FT      FT

```

XX PN WO200166804-A2.
 XX PD 13-SEP-2001.
 XX PA 09-MAR-2001; 2001WO-US007775.
 XX PF 09-MAR-2000; 2000US-00521983.
 XX PR 10-JUL-2000; 2000US-00613517.
 XX XX (PROT-) PROTOGENE LAB INC.
 XX PA Cronin MT, Frueh F, Brenman TM;
 XX PI WPI; 2001-616243/71.
 XX DR
 XX PT Determining sequence variation in, or monitoring expression of genes in
 PT target nucleic acid for high-throughput genotyping of (un)known
 PT polymorphisms/mutations, comprises hybridization pattern differences
 PT between target and probe sequences.
 XX XX
 XX PS Example 5; Page 35; 60pp; English.
 XX CC The invention relates to a method of simultaneously determining the
 CC presence of 2 or more sequence variations in target nucleic acids, or
 CC simultaneously monitoring expression of 2 or more genes. The method
 CC comprises determining differences in hybridisation between the target
 CC nucleic acid and immobilised probes, where differences in hybridisation
 CC between indicates sequence variations or transcription levels. The method
 CC is used for simultaneously determining the presence or absence of two or
 CC more sequence variations in target nucleic acids or simultaneously
 CC monitoring expression of two or more genes in target nucleic acids. The
 CC methods are applicable to high-throughput genotyping of known and unknown
 CC polymorphisms and mutations. The method maximises the information yield
 CC of hybridisation-based array applications by increasing the number of
 CC informative array-immobilised polynucleotide probes. The present sequence
 CC represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
 CC polymorphism (SNP) hybridisation probe #4
 XX SQ Sequence 16 BP; 1 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 16;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1676 ACCCTGGTGTCT 1687
 |||||
 4 ACCCTGGTGTCT 15
 Db
 RESULT 1330
 ABL57869/C
 ID ABL57869 standard; DNA; 16 BP.
 XX AC ABL57869;
 XX AC
 XX DT 05-AUG-2002 (first entry)
 XX DE Human ABCA7 gene PCR primer ABCA7_AO.
 XX KW Human; ABCA7; promoter; immunomodulatory; antiinflammatory; metabolic;
 KW ATP-Binding Cassette; lipid metabolism disorder; immune response;
 KW inflammation; gene therapy; PCR; primer; ss.
 XX OS Homo sapiens.
 XX XX
 XX PN WO200234903-A2.
 XX XX
 XX PD 02-MAY-2002.
 XX PF 17-OCT-2001; 2001WO-FR003219.
 XX PR 24-OCT-2000; 2000FR-00013649.

PR XX 28-NOV-2000; 2000US-0253141P.
 XX PA (AVET) AVENTIS PHARMA SA.
 XX PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 XX PI Deneffe P, Rosier M, Prades C, Arnould-Reguigne I;
 PI Osorio Y Forteau, Duverger N, Chimini G;
 XX DR WPI; 2002-362799/39.
 XX PT
 XX PT New promoter of the ABCA7 gene, useful for identifying modulators of
 PT transcription and in gene therapy of e.g. disorders of lipid metabolism.
 XX XX
 XX PS Example 3; Page 98; 126pp; French.
 XX CC The present invention relates to ABCA7 gene promoter sequences (ABC
 CC stands for ATP-Binding Cassette), which are used to identify agents (A)
 CC that modulate transcription of nucleic acids placed under control of the
 CC promoter. (A) is potentially useful for treating or preventing defects in
 CC lipid metabolism and defects in mechanisms involved in the immune
 CC response and inflammation. The promoters can also be used in gene therapy
 CC to control expression of therapeutic genes. Analysis of the promoter
 CC sequences can be used diagnostically, particularly to identify subjects
 CC at risk of lipid metabolism disorders. The present sequence is a PCR
 CC primer for human ABCA7, used to illustrate the invention
 XX SQ Sequence 16 BP; 5 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 7.5%; Score 10.4; DB 1; Length 16;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1678 CCTGGTGTCTCC 1689
 |||||
 14 CCTGGTGTCTCC 3
 Db
 RESULT 1331
 ACC43260
 ID ACC43260 standard; DNA; 16 BP.
 XX AC ACC43260;
 XX AC
 XX DT 11-AUG-2003 (first entry)
 XX DE Nucleotide sequence of a fragment from an actin binding protein exon.
 XX KW Sequence tag; trapped gene; gene-trap vector; actin binding protein; ss.
 XX OS Mus musculus.
 XX XX
 XX PN WO2003018765-A2.
 XX XX
 XX PD 06-MAR-2003.
 XX XX
 XX PF 26-AUG-2002; 2002WO-US027102.
 XX PR 24-AUG-2001; 2001US-0314991P.
 XX PA (HEAL-) HEALTH RES INC.
 XX PI Pruitt SC, Mielnicki LM;
 XX DR WPI; 2003-300726/29.
 XX PT Identifying Sequence Tags from trapped genes, useful for diagnostic
 PT applications, comprises using a gene-trap vector having a splice donor, a
 PT type IIS restriction endonuclease cleavage site and a splice donor or
 PT polyadenylation site.
 XX PS Example 3; Page 25; 51pp; English.
 XX CC The specification describes a method of identifying sequence tags from

CC trapped genes. The method comprises using a gene-trap vector that has a
 CC splice donor, a type IIS restriction endonuclease cleavage site and a
 CC splice donor or a polyadenylation site. mRNA is prepared from cells
 CC stably transfected with the gene-trap vector; first and second cDNA
 CC strands are synthesised from the mRNA; the cDNA strands are digested with
 CC restriction endonucleases including the type IIS restriction
 CC endonucleases to produce assay tags, where each assay tag comprises a
 CC sequence tag and a portion of the gene-trap vector; the assay tags are
 CC concatenated; and the concatamers are amplified and sequenced to identify
 CC the sequence of the assay tags and the sequence tags. The method is
 CC useful for high throughput sequence tag identification based on
 CC modifications of the serial analysis of gene expression technology, which
 CC may be used in diagnosing or in finding cures for various pathological
 CC conditions. The present sequence represents a sequence tag, identified
 CC using the method of the invention
 XX
 SQ Sequence 16 BP; 3 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 16;
 Best Local Similarity 91.7%; Pred. No. 7e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1740 CAACTCCTCCTCCT 1751
 |||||
 Db 5 CATCTCTCCTCCT 16

RESULT 1332

ADE14013/c
 ID ADE14013 standard; DNA; 16 BP.

XX
 AC ADE14013;

XX 29-JAN-2004 (first entry)

XX Optineurin promoter motif, repeat element or regulatory region #122.

XX Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
 KW SNP; glaucoma; progressive ocular hypertensive disorder;
 KW glaucoma related disorder; motif; repeat element; regulatory region.

XX Homo sapiens.

XX US2003190617-A1.

XX 09-OCT-2003.

XX 06-MAR-2002; 2002US-00091281.

XX 06-MAR-2002; 2002US-00091281.

XX (SIEE/) SI E.

XX (RAYM/) RAYMOND V.

XX (MORI/) MORISSETTE J.

XX Raymond V, Morissette J, Si E;

XX WPI; 2003-864168/80.

XX New nucleic acid sequences of the optineurin gene are useful to detect
 XX polymorphisms particularly single nucleotide polymorphisms in the
 PT optineurin promoter to diagnose, prognosis and treat glaucoma and related
 PT disorders.

XX Claim 11; SEQ ID NO 124; 159pp; English.

XX The invention relates to an isolated nucleic acid (N1) comprising at
 CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
 CC promoter appearing as ADE13890. Also included are the optineurin promoter
 CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
 CC detecting a single nucleotide polymorphism (SNP) in the optineurin
 CC promoter, a host cell comprising the promoter operably linked to a
 CC heterologous sequence, diagnosing or prognosing glaucoma in a sample

CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
 CC in a promoter region of the optineurin gene, associated with a glaucoma
 CC phenotype), detecting a SNP sequence variation in a sample containing
 CC DNA, detecting the presence of an optineurin promoter sequence variation
 CC in a sample containing DNA, determining the presence or increased
 CC susceptibility to glaucoma or to a progressive ocular hypertensive
 CC disorder resulting in loss of visual field in a patient (or the severity
 CC or progression of glaucoma in a patient, comprising providing
 CC amplification reaction primers that direct amplification of a selected
 CC nucleic acid region containing the DNA) and detecting a polymorphism (comprising
 CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
 CC obtaining a sample containing human genomic DNA, providing a nucleic acid
 CC capable of detecting a SNP located within an optineurin promoter, and
 CC detecting the polymorphism). The invention is used to diagnose and
 CC prognose glaucoma and also to treat glaucoma related disorders. The
 CC present sequence is an optineurin promoter motif, repeat element or
 CC putative regulatory region.

XX
 SQ Sequence 16 BP; 1 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 7.5%; Score 10.4; DB 1; Length 16;

Best Local Similarity 91.7%; Pred. No. 7e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1650 AGGCACGACCA 1661
 |||||
 Db 16 AGGCACGACCA 5

Search completed: August 30, 2004, 09:20:35
 Job time : 6 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 30, 2004, 09:22:41 ; Search time 0.001 Seconds
(without alignments)
2393.302 Million cell updates/sec

Title: US-09-925-139-3
Perfect score: 139
Sequence: 1 ggatggggctgttagcagaa.....ctatcctaaggccactgg 139

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 546 seqs, 8609 residues

Total number of hits satisfying chosen parameters: 1092

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 581 summaries

Database : rni3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	12.9	18	1	US-08-363-240A-1125
2	16.4	11.8	20	1	Sequence 1125, Ap
3	16.2	11.7	22	1	Sequence 19, Appl
4	15.2	10.9	23	1	Sequence 102, Ap
5	15	10.8	15	1	Sequence 19, Appl
6	15	10.8	15	1	Sequence 240, Ap
7	15	10.8	15	1	Sequence 241, Ap
8	15	10.8	15	1	Sequence 242, Ap
9	15	10.8	15	1	Sequence 243, Ap
10	15	10.8	15	1	Sequence 244, Ap
11	15	10.8	15	1	Sequence 245, Ap
12	15	10.8	15	1	Sequence 246, Ap
13	15	10.8	15	1	Sequence 247, Ap
14	15	10.8	15	1	Sequence 248, Ap
15	15	10.8	15	1	Sequence 249, Ap
16	15	10.8	15	1	Sequence 250, Ap
17	15	10.8	15	1	Sequence 251, Ap
18	15	10.8	15	1	Sequence 252, Ap
19	15	10.8	15	1	Sequence 253, Ap
20	15	10.8	15	1	Sequence 254, Ap
21	15	10.8	15	1	Sequence 255, Ap
22	14.6	10.5	21	1	Sequence 256, Ap
23	14.2	10.2	20	1	Sequence 231, Ap
24	14.2	10.2	20	1	Sequence 2, Appl
25	14.2	10.2	20	1	Sequence 4, Appl
26	14.2	10.2	20	1	Sequence 1, Appl
27	14.2	10.2	20	1	Sequence 5, Appl
28	14.2	10.2	20	1	Sequence 123, Ap
29	14.2	10.2	20	1	Sequence 16, Appl
30	14.2	10.2	20	1	Sequence 109, Ap
31	13.8	9.9	20	1	PCT-US94-06284-2
32	13.8	9.9	20	1	Sequence 74, Appl
33	13.6	9.8	20	1	Sequence 4, Appl
					Sequence 434, Ap

34	13.6	9.8	20	1	US-08-718-596-2	Sequence 2, Appl
35	13.6	9.8	20	1	US-08-881-037-95	Sequence 95, Appl
36	13.6	9.8	20	1	US-08-881-037-103	Sequence 103, Appl
37	13.6	9.8	20	1	US-09-021-701-587	Sequence 587, Appl
38	13.6	9.8	20	1	US-09-467-642-88	Sequence 88, Appl
39	13.6	9.8	20	1	US-09-422-978-10402	Sequence 10402, A
40	13.6	9.8	20	1	US-09-198-452A-6657	Sequence 6657, Ap
41	13.6	9.8	20	1	US-09-198-452A-6714	Sequence 6714, Ap
42	13.6	9.8	20	1	US-09-428-583-84	Sequence 84, Appl
43	13.4	9.6	20	1	US-09-360-416-9	Sequence 9, Appl
44	13.2	9.5	18	1	US-08-802-547-12	Sequence 12, Appl
45	13.2	9.5	18	1	US-08-712-357-12	Sequence 12, Appl
46	13.2	9.5	18	1	US-09-255-912-28	Sequence 28, Appl
47	13.2	9.5	18	1	US-09-280-409-75	Sequence 75, Appl
48	13.2	9.5	18	1	US-09-723-534-10	Sequence 10, Appl
49	13.2	9.5	18	1	US-09-721-822A-116	Sequence 116, Appl
50	13.2	9.5	18	1	US-09-077-619-15	Sequence 15, Appl
51	13.2	9.5	19	1	US-08-486-962-16	Sequence 16, Appl
52	13.2	9.5	19	1	US-09-972-115A-27	Sequence 27, Appl
53	13.2	9.5	19	1	PCT-US94-06284-16	Sequence 16, Appl
54	13.2	9.5	20	1	US-07-696-793A-17	Sequence 17, Appl
55	13.2	9.5	20	1	US-07-977-694-17	Sequence 17, Appl
56	13.2	9.5	20	1	US-09-357-070-43	Sequence 43, Appl
57	13.2	9.5	20	1	US-09-593-711A-114	Sequence 114, Appl
58	13.2	9.5	20	1	US-09-742-703-19	Sequence 19, Appl
59	13.2	9.5	20	1	US-09-198-452A-6149	Sequence 6149, Ap
60	13.2	9.5	20	1	US-09-823-549-1	Sequence 1, Appl
61	13	9.4	15	1	US-08-363-240A-758	Sequence 758, Appl
62	13	9.4	15	1	US-08-363-240A-759	Sequence 759, Appl
63	12.8	9.2	17	1	US-08-486-962-12	Sequence 12, Appl
64	12.8	9.2	17	1	US-08-584-040-7909	Sequence 7909, Ap
65	12.8	9.2	17	1	US-09-371-772B-3692	Sequence 3692, Ap
66	12.8	9.2	17	1	PCT-US94-06284-12	Sequence 12, Appl
67	12.8	9.2	18	1	US-08-486-962-15	Sequence 15, Appl
68	12.8	9.2	18	1	US-08-671-975A-7	Sequence 7, Appl
69	12.8	9.2	18	1	US-08-280-409-109	Sequence 109, Appl
70	12.8	9.2	18	1	US-09-280-409-142	Sequence 142, Appl
71	12.8	9.2	18	1	PCT-US94-06284-15	Sequence 15, Appl
72	12.8	9.2	19	1	US-08-785-247-12	Sequence 12, Appl
73	12.6	9.1	19	1	US-08-267-803B-68	Sequence 68, Appl
74	12.6	9.1	19	1	US-09-422-978-8278	Sequence 8278, Ap
75	12.4	8.9	15	1	US-07-912-900-11	Sequence 11, Appl
76	12.4	8.9	15	1	US-08-285-309-11	Sequence 11, Appl
77	12.4	8.9	15	1	US-08-502-046-11	Sequence 11, Appl
78	12.4	8.9	16	1	US-07-696-793A-22	Sequence 22, Appl
79	12.4	8.9	16	1	US-07-977-694-22	Sequence 22, Appl
80	12.4	8.9	16	1	US-08-255-264-24	Sequence 24, Appl
81	12.4	8.9	16	1	US-08-161-674B-20	Sequence 20, Appl
82	12.4	8.9	16	1	US-09-371-772B-5908	Sequence 5908, Ap
83	12.4	8.9	17	1	US-07-696-793A-20	Sequence 20, Appl
84	12.4	8.9	17	1	US-07-977-694-20	Sequence 20, Appl
85	12.4	8.9	17	1	US-09-371-772B-4993	Sequence 4993, Ap
86	12.4	8.9	18	1	US-07-696-793A-12	Sequence 12, Appl
87	12.4	8.9	18	1	US-07-977-694-12	Sequence 12, Appl
88	12.4	8.9	18	1	US-08-802-547-8	Sequence 8, Appl
89	12.4	8.9	18	1	US-08-802-547-10	Sequence 10, Appl
90	12.4	8.9	18	1	US-08-802-547-11	Sequence 11, Appl
91	12.4	8.9	18	1	US-08-712-357-8	Sequence 8, Appl
92	12.4	8.9	18	1	US-08-712-357-10	Sequence 10, Appl
93	12.4	8.9	18	1	US-08-712-357-11	Sequence 11, Appl
94	12.4	8.9	18	1	US-08-584-040-3040	Sequence 3040, Ap
95	12.4	8.9	18	1	US-09-422-978-11223	Sequence 11223, A
96	12.4	8.9	18	1	US-09-371-772B-1468	Sequence 1468, Ap
97	12.4	8.9	18	1	5179198-15	Patent No. 5179198
98	12.4	8.9	18	1	5521296-11	Patent No. 5521296
99	12.4	8.9	19	1	US-08-070-517-1	Sequence 1, Appl
100	12.4	8.9	19	1	US-08-118-441-1	Sequence 1, Appl
101	12.4	8.9	19	1	US-08-422-699A-13	Sequence 13, Appl
102	12.4	8.9	19	1	US-08-422-706B-13	Sequence 13, Appl
103	12.4	8.9	19	1	US-08-338-579A-1	Sequence 1, Appl
104	12.4	8.9	19	1	US-09-078-294-1	Sequence 1, Appl
105	12.4	8.9	19	1	US-09-422-978-10908	Sequence 10908, A
106	12.4	8.9	19	1	PCT-US94-09851-1	Sequence 1, Appl

107	12.2	8.8	17	1	US-08-373-124A-1709	Sequence 1709, Ap	180	11.4	8.2	13	1	US-09-922-445-27	Sequence 27, Appl
108	12.2	8.8	17	1	US-08-435-628-1709	Sequence 1709, Ap	181	11.4	8.2	14	1	US-08-913-833-9	Sequence 9, Appl
109	12.2	8.8	17	1	US-08-292-492D-6	Sequence 6, Appl	182	11.4	8.2	14	1	US-08-580-794C-9	Sequence 9, Appl
110	12.2	8.8	17	1	US-09-633-994-6	Sequence 6, Appl	183	11.4	8.2	15	1	US-08-111-076-17	Sequence 17, Appl
111	12.2	8.8	17	1	US-09-866-108A-527	Sequence 527, App	184	11.4	8.2	15	1	US-08-398-305-17	Sequence 17, Appl
112	12.2	8.8	17	1	US-09-866-108A-528	Sequence 528, App	185	11.4	8.2	15	1	US-08-182-968A-452	Sequence 452, App
113	12.2	8.8	17	1	US-09-866-108A-1264	Sequence 1264, Ap	186	11.4	8.2	15	1	US-08-705-225-17	Sequence 17, Appl
114	12.2	8.8	17	1	US-09-866-108A-7831	Sequence 7831, Ap	187	11.4	8.2	15	1	US-08-513-841-16	Sequence 16, Appl
115	12.2	8.8	17	1	US-09-866-108A-9658	Sequence 9658, Ap	188	11.4	8.2	15	1	US-08-696-834-17	Sequence 17, Appl
116	12.2	8.8	17	1	US-09-280-403-142	Sequence 142, App	189	11.4	8.2	15	1	US-08-942-673-16	Sequence 16, Appl
117	12.2	8.8	18	1	US-08-127-954-45	Sequence 45, Appl	190	11.4	8.2	15	1	US-08-774-306A-452	Sequence 452, App
118	12.2	8.8	18	1	US-07-923-260A-13	Sequence 13, Appl	191	11.4	8.2	15	1	US-09-064-156A-452	Sequence 452, App
119	12.2	8.8	18	1	US-08-890-980-46	Sequence 46, Appl	192	11.4	8.2	15	1	US-09-118-317-16	Sequence 16, Appl
120	12.2	8.8	18	1	US-08-890-979-46	Sequence 46, Appl	193	11.4	8.2	16	1	US-07-696-793A-18	Sequence 18, Appl
121	12.2	8.8	18	1	US-09-032-894-46	Sequence 46, Appl	194	11.4	8.2	16	1	US-07-977-694-18	Sequence 18, Appl
122	12.2	8.8	18	1	US-08-894-736-10	Sequence 10, Appl	195	11.4	8.2	16	1	US-08-303-004-32	Sequence 32, Appl
123	12.2	8.8	18	1	US-08-894-736-21	Sequence 21, Appl	196	11.4	8.2	16	1	US-08-491-978-5	Sequence 5, Appl
124	12.2	8.8	18	1	US-09-050-159-111	Sequence 11, App	197	11.4	8.2	17	1	US-08-985-162-299	Sequence 299, App
125	12.2	8.8	18	1	US-09-031-626-46	Sequence 46, Appl	198	11.4	8.2	17	1	US-09-187-946-16	Sequence 16, Appl
126	12.2	8.8	18	1	US-09-632-580A-49	Sequence 49, Appl	199	11.4	8.2	17	1	US-09-564-805-88	Sequence 88, Appl
127	12.2	8.8	18	1	US-09-640-198D-20	Sequence 20, Appl	200	11.4	8.2	17	1	US-08-584-040-2852	Sequence 2852, Ap
128	12.2	8.8	18	1	US-09-639-667-16	Sequence 16, Appl	201	11.4	8.2	17	1	US-08-584-040-2853	Sequence 2853, Ap
129	12	8.6	16	1	US-09-586-376-5	Sequence 5, Appl	202	11.4	8.2	17	1	US-08-679-648-53	Sequence 53, Appl
130	12	8.6	18	1	US-08-937-580-9	Sequence 9, Appl	203	11.4	8.2	17	1	US-09-474-432B-460	Sequence 460, App
131	12	8.6	18	1	US-09-336-039-9	Sequence 9, Appl	204	11.4	8.2	17	1	US-09-371-772B-1376	Sequence 1376, App
132	11.8	8.5	15	1	US-08-310-501-4	Sequence 4, Appl	205	11.4	8.2	17	1	US-09-371-772B-1377	Sequence 1377, Ap
133	11.8	8.5	15	1	US-08-469-177-4	Sequence 4, Appl	206	11.4	8.2	17	1	US-09-371-772B-4992	Sequence 4992, Ap
134	11.8	8.5	15	1	US-08-484-551-1	Sequence 1, Appl	207	11.4	8.2	17	1	US-09-476-387-459	Sequence 459, App
135	11.8	8.5	15	1	US-08-484-551-5	Sequence 5, Appl	208	11.4	8.2	17	1	US-09-401-063-2399	Sequence 2399, App
136	11.8	8.5	15	1	US-08-486-963-18	Sequence 18, Appl	209	11.4	8.2	17	1	US-09-866-108A-7827	Sequence 7827, Ap
137	11.8	8.5	15	1	US-08-913-833-5	Sequence 5, Appl	210	11.4	8.2	17	1	US-08-866-108A-7828	Sequence 7828, Ap
138	11.8	8.5	15	1	US-09-580-794C-5	Sequence 5, Appl	211	11.4	8.2	16	1	US-07-696-793A-7	Sequence 7, Appl
139	11.8	8.5	15	1	US-09-813-781-48	Sequence 48, Appl	212	11.2	8.1	16	1	US-07-696-793A-9	Sequence 9, Appl
140	11.8	8.5	16	1	US-08-486-962-14	Sequence 14, Appl	213	11.2	8.1	16	1	US-07-977-694-7	Sequence 7, Appl
141	11.8	8.5	16	1	US-08-975-522A-6	Sequence 6, Appl	214	11.2	8.1	16	1	US-07-977-694-9	Sequence 9, Appl
142	11.8	8.5	17	1	US-08-432-871C-4	Sequence 4, Appl	215	11.2	8.1	16	1	US-08-872-917-11	Sequence 11, Appl
143	11.8	8.5	17	1	US-08-985-162-338	Sequence 338, App	216	11.2	8.1	16	1	US-09-371-772B-5657	Sequence 5657, Ap
144	11.8	8.5	17	1	US-08-584-040-1876	Sequence 1876, Ap	217	11.2	8.1	16	1	US-09-371-772B-5658	Sequence 5658, Ap
145	11.8	8.5	17	1	US-08-584-040-1877	Sequence 1877, Ap	218	11.2	8.1	16	1	Sequence 5954, Ap	
146	11.8	8.5	17	1	US-09-270-956-4	Sequence 4, Appl	219	11.2	8.1	16	1	Sequence 154, App	
147	11.8	8.5	17	1	US-09-474-432B-404	Sequence 404, App	220	11.2	8.1	16	1	Sequence 2, Appl	
148	11.8	8.5	17	1	US-09-474-432B-504	Sequence 504, App	221	11.2	8.1	17	1	Sequence 3, Appl	
149	11.8	8.5	17	1	US-09-474-432B-505	Sequence 505, App	222	11.2	8.1	17	1	Sequence 24, Appl	
150	11.8	8.5	17	1	US-09-474-432B-513	Sequence 513, App	223	11.2	8.1	17	1	Sequence 25, Appl	
151	11.8	8.5	17	1	US-09-474-432B-549	Sequence 549, App	224	11.2	8.1	17	1	Sequence 26, Appl	
152	11.8	8.5	17	1	US-09-371-772B-421	Sequence 421, App	225	11.2	8.1	17	1	Sequence 28, Appl	
153	11.8	8.5	17	1	US-09-371-772B-422	Sequence 422, App	226	11.2	8.1	17	1	Sequence 29, Appl	
154	11.8	8.5	17	1	US-09-476-387-403	Sequence 403, App	227	11.2	8.1	17	1	Sequence 2, Appl	
155	11.8	8.5	17	1	US-09-476-387-503	Sequence 503, App	228	11.2	8.1	17	1	Sequence 3, Appl	
156	11.8	8.5	17	1	US-09-476-387-504	Sequence 504, App	229	11.2	8.1	17	1	Sequence 24, Appl	
157	11.8	8.5	17	1	US-09-476-387-512	Sequence 512, App	230	11.2	8.1	17	1	Sequence 25, Appl	
158	11.8	8.5	17	1	US-09-476-387-548	Sequence 548, App	231	11.2	8.1	17	1	Sequence 26, Appl	
159	11.8	8.5	17	1	US-09-401-063-338	Sequence 338, App	232	11.2	8.1	17	1	Sequence 28, Appl	
160	11.8	8.5	17	1	US-09-866-108A-525	Sequence 525, App	233	11.2	8.1	17	1	Sequence 29, Appl	
161	11.8	8.5	17	1	US-09-866-108A-526	Sequence 526, App	234	11.2	8.1	17	1	Sequence 1363, Ap	
162	11.8	8.5	17	1	US-09-866-108A-2351	Sequence 2351, Ap	235	11.2	8.1	17	1	Sequence 16, Appl	
163	11.8	8.5	17	1	US-09-866-108A-2352	Sequence 2352, Ap	236	11.2	8.1	17	1	Sequence 16, Appl	
164	11.8	8.5	17	1	US-09-866-108A-2353	Sequence 2353, Ap	237	11.2	8.1	17	1	Sequence 1363, Ap	
165	11.8	8.5	17	1	US-09-866-108A-7829	Sequence 7829, Ap	238	11.2	8.1	17	1	Sequence 1670, Ap	
166	11.8	8.5	17	1	US-09-866-108A-7830	Sequence 7830, Ap	239	11.2	8.1	17	1	Sequence 1974, Ap	
167	11.8	8.5	18	1	US-08-204-697-1	Sequence 1, Appl	240	11.2	8.1	17	1	Sequence 300, App	
168	11.8	8.5	18	1	US-08-744-332-1	Sequence 66, Appl	241	11.2	8.1	17	1	Sequence 371, App	
169	11.8	8.5	18	1	US-09-161-244-66	Sequence 3, Appl	242	11.2	8.1	17	1	Sequence 28, Appl	
170	11.8	8.5	18	1	US-09-025-701-3	Sequence 3, Appl	243	11.2	8.1	17	1	Sequence 12, Appl	
171	11.8	8.5	18	1	US-09-045-301-3	Sequence 4, Appl	244	11.2	8.1	17	1	Sequence 1670, Ap	
172	11.8	8.5	18	1	US-09-045-301-4	Sequence 10, Appl	245	11.2	8.1	17	1	Sequence 1974, Ap	
173	11.8	8.5	18	1	US-09-205-995-10	Sequence 10, Appl	246	11.2	8.1	17	1	Sequence 371, App	
174	11.8	8.5	18	1	US-09-422-978-6052	Sequence 6052, Ap	247	11.2	8.1	17	1	Sequence 28, Appl	
175	11.8	8.5	18	1	US-09-747-391-20	Sequence 20, Appl	248	11.2	8.1	17	1	Sequence 1670, Ap	
176	11.8	8.5	18	1	US-09-548-797B-106	Sequence 106, App	249	11.2	8.1	17	1	Sequence 28, Appl	
177	11.4	8.2	13	1	US-08-544-381B-27	Sequence 27, Appl	250	11.2	8.1	17	1	Sequence 10, Appl	
178	11.4	8.2	13	1	US-08-778-794A-85	Sequence 85, Appl	251	11.2	8.1	17	1	Sequence 1477, Ap	
179	11.4	8.2	13	1	US-09-922-445-17	Sequence 17, Appl	252	11.2	8.1	17	1	Sequence 2237, Ap	

C 253 11.2 8.1 17 1 US-08-584-040-5698 Sequence 5698, Ap 326
C 254 11.2 8.1 17 1 US-08-584-040-6055 Sequence 6055, Ap 327
C 255 11.2 8.1 17 1 US-08-584-040-6056 Sequence 6056, Ap C 328
C 256 11.2 8.1 17 1 US-08-584-040-6074 Sequence 6074, Ap C 329
C 257 11.2 8.1 17 1 US-08-679-645-687 Sequence 687, App C 330
C 258 11.2 8.1 17 1 US-09-025-343-3 Sequence 3, Appli C 331
C 259 11.2 8.1 17 1 US-09-474-432B-580 Sequence 580, App C 332
C 260 11.2 8.1 17 1 US-09-371-772B-222 Sequence 22, Appli C 333
C 261 11.2 8.1 17 1 US-09-371-772B-782 Sequence 782, App C 334
C 262 11.2 8.1 17 1 US-09-371-772B-2582 Sequence 2582, Ap C 335
C 263 11.2 8.1 17 1 US-09-371-772B-2892 Sequence 2892, Ap C 336
C 264 11.2 8.1 17 1 US-09-371-772B-2893 Sequence 2893, Ap C 337
C 265 11.2 8.1 17 1 US-09-371-772B-2911 Sequence 2911, Ap C 338
C 266 11.2 8.1 17 1 US-09-371-772B-4204 Sequence 4204, Ap C 339
C 267 11.2 8.1 17 1 US-09-371-772B-4205 Sequence 4205, Ap C 340
C 268 11.2 8.1 17 1 US-09-371-772B-5053 Sequence 5053, Ap C 341
C 269 11.2 8.1 17 1 US-09-371-772B-5054 Sequence 5054, Ap C 342
C 270 11.2 8.1 17 1 US-09-371-772B-5167 Sequence 5167, Ap C 343
C 271 11.2 8.1 17 1 US-09-476-387-579 Sequence 579, App C 344
C 272 11.2 8.1 17 1 US-09-401-063-300 Sequence 300, App C 345
C 273 11.2 8.1 17 1 US-09-401-063-371 Sequence 371, App C 346
C 274 11.2 8.1 17 1 US-09-554-726A-24 Sequence 24, Appli C 347
C 275 11.2 8.1 17 1 US-09-805-127-4 Sequence 4, Appli C 348
C 276 11.2 8.1 17 1 US-09-805-127-5 Sequence 5, Appli C 349
C 277 11.2 8.1 17 1 US-09-529-812A-4 Sequence 4, Appli C 350
C 278 11.2 8.1 17 1 US-09-866-108A-529 Sequence 529, App C 351
C 279 11.2 8.1 17 1 US-09-866-108A-1263 Sequence 1263, Ap C 352
C 280 11.2 8.1 17 1 US-09-866-108A-1265 Sequence 1265, Ap C 353
C 281 11.2 8.1 17 1 US-09-866-108A-1285 Sequence 1285, Ap C 354
C 282 11.2 8.1 17 1 US-09-866-108A-1286 Sequence 1286, Ap C 355
C 283 11.2 8.1 17 1 US-09-866-108A-7832 Sequence 7832, Ap C 356
C 284 11.2 8.1 17 1 US-09-866-108A-7984 Sequence 7984, Ap C 357
C 285 11.2 8.1 17 1 US-09-866-108A-7985 Sequence 7985, Ap C 358
C 286 11.2 8.1 17 1 US-09-866-108A-9657 Sequence 9657, Ap C 359
C 287 11.2 8.1 17 1 US-09-866-108A-9659 Sequence 9659, Ap C 360
C 288 11.2 8.1 17 1 US-09-866-108A-10208 Sequence 10208, A C 361
C 289 11.2 8.1 17 1 US-09-866-108A-10209 Sequence 10209, A C 362
C 290 11.2 8.1 17 1 PCT-US95-16806A-16 Sequence 16, Appli C 363
C 291 11.2 8.1 18 1 US-09-280-409-75 Sequence 75, Appli C 364
C 292 11.2 8.1 20 1 US-09-624-945-19 Sequence 19, Appli C 365
C 293 11 7.9 15 1 US-09-081-646-218 Sequence 218, App C 366
C 294 11 7.9 15 1 US-09-081-646-855 Sequence 855, App C 367
C 295 11 7.9 16 1 US-08-135-511-2 US-08-135-511-2 Sequence 2, Appli C 368
C 296 11 7.9 16 1 US-08-187-453-2 US-08-187-453-2 Sequence 2, Appli C 369
C 297 11 7.9 16 1 US-08-379-482A-6 US-08-379-482A-6 Sequence 6, Appli C 370
C 298 11 7.9 16 1 US-08-464-582-16 US-08-464-582-16 Sequence 16, Appli C 371
C 299 11 7.9 16 1 US-08-462-513-16 US-08-462-513-16 Sequence 16, Appli C 372
C 300 11 7.9 16 1 US-08-031-801-17 US-08-031-801-17 Sequence 17, Appli C 373
C 301 11 7.9 16 1 US-08-031-801-29 US-08-031-801-29 Sequence 29, Appli C 374
C 302 10.8 7.8 14 1 US-08-173-489C-179 US-08-173-489C-179 Sequence 179, App C 375
C 303 10.8 7.8 14 1 US-09-913-833-4 US-09-913-833-4 Sequence 4, Appli C 376
C 304 10.8 7.8 14 1 US-09-580-794C-4 US-09-580-794C-4 Sequence 4, Appli C 377
C 305 10.8 7.8 15 1 US-07-998-973A-18 US-07-998-973A-18 Sequence 18, Appli C 378
C 306 10.8 7.8 15 1 US-08-479-248-1 US-08-479-248-1 Sequence 1, Appli C 379
C 307 10.8 7.8 15 1 US-08-479-248-2 US-08-479-248-2 Sequence 2, Appli C 380
C 308 10.8 7.8 15 1 US-08-462-305-8 US-08-462-305-8 Sequence 8, Appli C 381
C 309 10.8 7.8 15 1 US-08-363-240A-602 US-08-363-240A-602 Sequence 602, App C 382
C 310 10.8 7.8 15 1 US-08-363-240A-603 US-08-363-240A-603 Sequence 603, App C 383
C 311 10.8 7.8 15 1 US-08-311-486C-598 US-08-311-486C-598 Sequence 598, App C 384
C 312 10.8 7.8 15 1 US-08-311-486C-599 US-08-311-486C-599 Sequence 599, App C 385
C 313 10.8 7.8 15 1 US-08-613-417A-8 US-08-613-417A-8 Sequence 8, Appli C 386
C 314 10.8 7.8 15 1 US-08-585-684B-2047 US-08-585-684B-2047 Sequence 2047, Ap C 387
C 315 10.8 7.8 15 1 US-08-432-600-18 US-08-432-600-18 Sequence 18, Appli C 388
C 316 10.8 7.8 15 1 US-08-594-452-8 US-08-594-452-8 Sequence 8, Appli C 389
C 317 10.8 7.8 15 1 US-08-578-686C-7 US-08-578-686C-7 Sequence 7, Appli C 390
C 318 10.8 7.8 15 1 US-09-094-405-8 US-09-094-405-8 Sequence 8, Appli C 391
C 319 10.8 7.8 15 1 US-09-258-408-8 US-09-258-408-8 Sequence 8, Appli C 392
C 320 10.8 7.8 15 1 US-09-136-132-8 US-09-136-132-8 Sequence 8, Appli C 393
C 321 10.8 7.8 15 1 US-09-144-112-7 US-09-144-112-7 Sequence 7, Appli C 394
C 322 10.8 7.8 15 1 US-09-038-073-2047 US-09-038-073-2047 Sequence 2047, Ap C 395
C 323 10.8 7.8 15 1 US-08-410-390-3 US-08-410-390-3 Sequence 3, Appli C 396
C 324 10.8 7.8 15 1 US-08-895-981-8 US-08-895-981-8 Sequence 8, Appli C 397
C 325 10.8 7.8 15 1 US-08-337-120A-8 US-08-337-120A-8 Sequence 8, Appli C 398

15 7.8 10.8 326
15 7.8 10.8 327
16 7.8 10.8 C 328
16 7.8 10.8 C 329
16 7.8 10.8 C 330
16 7.8 10.8 C 331
16 7.8 10.8 C 332
16 7.8 10.8 C 333
16 7.8 10.8 C 334
16 7.8 10.8 C 335
16 7.8 10.8 C 336
16 7.8 10.8 C 337
16 7.8 10.8 C 338
16 7.8 10.8 C 339
16 7.8 10.8 C 340
16 7.8 10.8 C 341
16 7.8 10.8 C 342
16 7.8 10.8 C 343
18 7.8 10.8 C 344
13 7.5 10.4 C 345
14 7.5 10.4 C 346
14 7.5 10.4 C 347
14 7.5 10.4 C 348
15 7.5 10.4 C 349
15 7.5 10.4 C 350
15 7.5 10.4 C 351
15 7.5 10.4 C 352
15 7.5 10.4 C 353
16 7.5 10.4 C 354
15 7.5 10.4 C 355
15 7.5 10.4 C 356
15 7.5 10.4 C 357
15 7.5 10.4 C 358
16 7.5 10.4 C 359
16 7.5 10.4 C 360
16 7.5 10.4 C 361
16 7.5 10.4 C 362
15 7.3 10.2 C 363
15 7.3 10.2 C 364
15 7.3 10.2 C 365
15 7.3 10.2 C 366
15 7.3 10.2 C 367
15 7.3 10.2 C 368
15 7.3 10.2 C 369
15 7.3 10.2 C 370
15 7.3 10.2 C 371
15 7.3 10.2 C 372
15 7.3 10.2 C 373
15 7.3 10.2 C 374
15 7.3 10.2 C 375
15 7.3 10.2 C 376
15 7.3 10.2 C 377
15 7.3 10.2 C 378
15 7.3 10.2 C 379
15 7.3 10.2 C 380
15 7.3 10.2 C 381
15 7.3 10.2 C 382
15 7.3 10.2 C 383
15 7.3 10.2 C 384
15 7.3 10.2 C 385
15 7.3 10.2 C 386
15 7.3 10.2 C 387
15 7.3 10.2 C 388
15 7.3 10.2 C 389
15 7.3 10.2 C 390
20 7.3 10.2 C 391
20 7.3 10.2 C 392
10 7.2 10.2 C 393
10 7.2 10.2 C 394
10 7.2 10.2 C 395
10 7.2 10.2 C 396
10 7.2 10.2 C 397
10 7.2 10.2 C 398

US-09-643-233-7 Sequence 7, Appli
PCT-US92-11353-18 Sequence 18, Appli
US-07-696-793A-1 Sequence 1, Appli
US-07-696-793A-5 Sequence 5, Appli
US-07-696-793A-10 Sequence 10, Appli
US-07-696-793A-23 Sequence 23, Appli
US-07-977-694-1 Sequence 1, Appli
US-07-977-694-5 Sequence 5, Appli
US-07-977-694-10 Sequence 10, Appli
US-08-255-694-23 Sequence 23, Appli
US-08-255-694-23 Sequence 23, Appli
US-08-292-620A-1628 Sequence 1628, Ap
US-09-071-845-1628 Sequence 1628, Ap
US-09-071-845-1628 Sequence 6, Appli
US-09-371-772B-5803 Sequence 5803, Ap
US-09-371-772B-5880 Sequence 5880, Ap
US-09-371-772B-5912 Sequence 5912, Ap
US-09-516-667-56 Sequence 109, App
US-08-985-162-1849 Sequence 1628, Ap
US-08-535-249-90 Sequence 1849, Ap
US-09-401-063-1849 Sequence 1849, Ap
US-07-783-861C-14 Sequence 14, Appli
US-08-182-968A-339 Sequence 339, App
US-08-291-932A-211 Sequence 211, App
US-08-363-240A-760 Sequence 760, App
US-08-774-306A-339 Sequence 339, App
US-08-585-684B-1270 Sequence 1270, Ap
US-08-232-081B-16 Sequence 16, Appli
US-08-064-156A-339 Sequence 339, App
US-09-038-073-1270 Sequence 1270, Ap
US-09-066-046-42 Sequence 42, Appli
US-09-081-646-436 Sequence 436, App
US-07-991-199D-8 Sequence 8, Appli
US-09-371-772B-5910 Sequence 5910, Ap
US-09-371-772B-7125 Sequence 7125, Ap
PCT-US93-12246-8 Sequence 8, Appli
US-08-363-240A-242 Sequence 242, App
US-08-136-118-12 Sequence 12, Appli
US-08-319-492B-378 Sequence 378, App
US-08-291-932A-340 Sequence 340, App
US-08-363-240A-227 Sequence 227, App
US-08-363-240A-228 Sequence 228, App
US-08-311-486C-82 Sequence 82, Appli
US-08-311-486C-151 Sequence 151, App
US-08-311-486C-747 Sequence 747, App
US-08-292-620A-352 Sequence 352, App
US-08-232-620A-424 Sequence 424, App
US-08-292-620A-529 Sequence 529, App
US-08-531-743-4 Sequence 4, Appli
US-08-585-684B-263 Sequence 263, App
US-08-585-684B-1201 Sequence 1201, Ap
US-08-757-024-579 Sequence 579, App
US-08-913-833-61 Sequence 61, Appli
US-08-873-437-24 Sequence 24, Appli
US-09-071-845-352 Sequence 352, App
US-09-071-845-424 Sequence 424, App
US-09-071-845-529 Sequence 529, App
US-09-038-073-262 Sequence 263, App
US-09-038-073-1201 Sequence 1201, Ap
US-09-580-794C-61 Sequence 61, Appli
US-09-081-646-467 Sequence 342, App
US-09-081-646-467 Sequence 467, App
US-09-011-336-18 Sequence 18, Appli
US-09-593-312-24 Sequence 24, Appli
US-07-696-793A-17 Sequence 17, Appli
US-07-977-694-17 Sequence 17, Appli
US-08-171-718-43 Sequence 43, Appli
US-08-388-353-425 Sequence 425, App
US-08-388-353-501 Sequence 501, App
US-08-388-353-502 Sequence 502, App
US-08-488-551B-425 Sequence 425, App
US-08-488-551B-501 Sequence 501, App

C 399	10	7.2	10	1	US-08-488-551B-502	Sequence 502, App	C 472	9.8	7.1	15	1	US-08-182-067-11	Sequence 11, Appl
C 400	10	7.2	10	1	US-08-488-551B-519	Sequence 818, App	C 473	9.8	7.1	15	1	US-08-465-313-11	Sequence 11, Appl
C 401	10	7.2	10	1	US-08-488-551B-820	Sequence 820, App	C 474	9.8	7.1	15	1	US-08-486-343A-6	Sequence 6, Appl
C 402	10	7.2	10	1	US-08-478-087-43	Sequence 43, Appl	C 475	9.8	7.1	15	1	US-08-913-833-2	Sequence 2, Appl
C 403	10	7.2	12	1	US-08-173-489C-255	Sequence 255, App	C 476	9.8	7.1	15	1	US-08-963-472-6	Sequence 6, Appl
C 404	10	7.2	12	1	US-08-889-502-3	Sequence 3, Appl	C 477	9.8	7.1	15	1	US-08-963-472-10	Sequence 10, Appl
C 405	10	7.2	12	1	US-08-889-502-16	Sequence 16, Appl	C 478	9.8	7.1	15	1	US-09-064-156A-29	Sequence 29, Appl
C 406	10	7.2	12	1	US-08-192-943-11	Sequence 11, Appl	C 479	9.8	7.1	15	1	US-09-064-156A-483	Sequence 483, App
C 407	10	7.2	14	1	US-08-434-503-10	Sequence 10, Appl	C 480	9.8	7.1	15	1	US-09-064-156A-494	Sequence 494, App
C 408	10	7.2	15	1	US-08-440-787A-128	Sequence 128, App	C 481	9.8	7.1	15	1	US-09-071-845-500	Sequence 500, App
C 409	10	7.2	15	1	US-08-292-620A-105	Sequence 105, App	C 482	9.8	7.1	15	1	US-09-038-073-186	Sequence 186, App
C 410	10	7.2	15	1	US-08-292-620A-106	Sequence 106, App	C 483	9.8	7.1	15	1	US-09-038-073-1364	Sequence 1364, App
C 411	10	7.2	15	1	US-09-071-845-105	Sequence 105, App	C 484	9.8	7.1	15	1	US-09-038-073-2048	Sequence 2048, App
C 412	10	7.2	15	1	US-09-071-845-106	Sequence 106, App	C 485	9.8	7.1	15	1	US-09-580-794C-2	Sequence 2, Appl
C 413	10	7.2	15	1	US-09-377-310-26	Sequence 26, Appl	C 486	9.8	7.1	15	1	US-09-081-646-50	Sequence 50, Appl
C 414	10	7.2	20	1	US-08-227-370-2	Sequence 2, Appl	C 487	9.8	7.1	15	1	US-09-081-646-294	Sequence 294, App
C 415	10	7.2	20	1	US-08-486-962-4	Sequence 4, Appl	C 488	9.8	7.1	15	1	US-09-081-646-621	Sequence 621, App
C 416	10	7.2	20	1	US-08-458-347-1	Sequence 1, Appl	C 489	9.8	7.1	15	1	US-09-081-646-639	Sequence 639, App
C 417	10	7.2	20	1	US-08-975-522A-5	Sequence 5, Appl	C 490	9.8	7.1	15	1	US-08-584-040-8497	Sequence 8497, App
C 418	10	7.2	20	1	PCT-US94-06284-2	Sequence 2, Appl	C 491	9.8	7.1	15	1	US-09-479-770A-13	Sequence 13, Appl
C 419	10	7.2	20	1	US-09-198-452A-6714	Sequence 6714, App	C 492	9.8	7.1	15	1	US-09-456-773-5	Sequence 5, Appl
C 420	9.8	7.1	13	1	US-08-544-381B-19	Sequence 19, Appl	C 493	9.8	7.1	15	1	US-09-371-772B-4151	Sequence 4151, App
C 421	9.8	7.1	13	1	US-08-544-381B-23	Sequence 23, Appl	C 494	9.8	7.1	15	1	US-10-112-547-21	Sequence 21, Appl
C 422	9.8	7.1	13	1	US-08-544-381B-24	Sequence 24, Appl	C 495	9.8	7.1	15	1	US-10-112-241-21	Sequence 21, Appl
C 423	9.8	7.1	13	1	US-08-544-381B-26	Sequence 26, Appl	C 496	9.8	7.1	15	1	US-10-104-611-21	Sequence 21, Appl
C 424	9.8	7.1	13	1	US-08-544-381B-28	Sequence 28, Appl	C 497	9.8	7.1	15	1	PCT-US95-07349-6	Sequence 6, Appl
C 425	9.8	7.1	13	1	US-08-544-381B-29	Sequence 29, Appl	C 498	9.8	7.1	18	1	US-09-050-159-111	Sequence 111, App
C 426	9.8	7.1	13	1	US-08-778-794A-77	Sequence 77, Appl	C 499	9.8	7.1	18	1	US-09-548-797B-106	Sequence 106, App
C 427	9.8	7.1	13	1	US-08-778-794A-81	Sequence 81, Appl	C 500	9.6	6.9	13	1	US-08-544-381B-13	Sequence 13, Appl
C 428	9.8	7.1	13	1	US-08-778-794A-84	Sequence 84, Appl	C 501	9.6	6.9	13	1	US-08-778-794A-71	Sequence 71, Appl
C 429	9.8	7.1	13	1	US-08-778-794A-86	Sequence 86, Appl	C 502	9.6	6.9	13	1	US-08-778-794A-95	Sequence 95, Appl
C 430	9.8	7.1	13	1	US-08-778-794A-87	Sequence 87, Appl	C 503	9.6	6.9	16	1	US-07-696-793A-9	Sequence 9, Appl
C 431	9.8	7.1	13	1	US-09-922-445-16	Sequence 16, Appl	C 504	9.6	6.9	16	1	US-07-977-694-9	Sequence 9, Appl
C 432	9.8	7.1	13	1	US-09-922-445-26	Sequence 26, Appl	C 505	9.6	6.9	16	1	US-09-371-772B-5954	Sequence 5954, App
C 433	9.8	7.1	14	1	US-08-913-833-8	Sequence 8, Appl	C 506	9.6	6.9	17	1	US-09-187-946-16	Sequence 16, Appl
C 434	9.8	7.1	14	1	US-09-328-174A-40	Sequence 40, Appl	C 507	9.6	6.9	17	1	US-08-584-040-2237	Sequence 2237, App
C 435	9.8	7.1	14	1	US-09-230-652-23	Sequence 23, Appl	C 508	9.6	6.9	17	1	US-09-371-772B-782	Sequence 782, App
C 436	9.8	7.1	14	1	US-08-050-073-153	Sequence 153, App	C 509	9.6	6.9	17	1	US-09-371-772B-5167	Sequence 5167, App
C 437	9.8	7.1	15	1	US-08-182-968A-29	Sequence 29, Appl	C 510	9.6	6.9	20	1	US-08-754-477A-109	Sequence 109, App
C 438	9.8	7.1	15	1	US-08-182-968A-43	Sequence 43, App	C 511	9.4	6.8	11	1	US-08-757-024-530	Sequence 12, Appl
C 439	9.8	7.1	15	1	US-08-182-968A-483	Sequence 483, App	C 512	9.4	6.8	11	1	US-09-617-548-12	Sequence 43, Appl
C 440	9.8	7.1	15	1	US-08-182-968A-494	Sequence 494, App	C 513	9.4	6.8	11	1	US-09-249-155A-181	Sequence 181, App
C 441	9.8	7.1	15	1	US-08-291-932A-8	Sequence 8, Appl	C 514	9.4	6.8	11	1	PCT-US94-08023-37	Sequence 37, Appl
C 442	9.8	7.1	15	1	US-08-291-932A-54	Sequence 54, Appl	C 515	9.4	6.8	11	1	US-08-192-300-5	Sequence 5, Appl
C 443	9.8	7.1	15	1	US-08-291-932A-159	Sequence 159, App	C 516	9.4	6.8	12	1	US-08-221-815B-27	Sequence 27, Appl
C 444	9.8	7.1	15	1	US-08-291-932A-161	Sequence 161, App	C 517	9.4	6.8	12	1	US-08-441-887A-338	Sequence 338, App
C 445	9.8	7.1	15	1	US-08-291-932A-189	Sequence 189, App	C 518	9.4	6.8	12	1	US-08-441-887A-339	Sequence 339, App
C 446	9.8	7.1	15	1	US-08-291-932A-339	Sequence 339, App	C 519	9.4	6.8	12	1	US-08-757-024-501	Sequence 501, App
C 447	9.8	7.1	15	1	US-08-291-932A-348	Sequence 348, App	C 520	9.4	6.8	12	1	US-08-757-024-529	Sequence 529, App
C 448	9.8	7.1	15	1	US-08-393-219-8	Sequence 8, Appl	C 521	9.4	6.8	12	1	US-07-794-396-6	Sequence 6, Appl
C 449	9.8	7.1	15	1	US-08-334-847-309	Sequence 309, App	C 522	9.4	6.8	12	1	US-08-959-853-8	Sequence 8, Appl
C 450	9.8	7.1	15	1	US-08-305-699-1	Sequence 1, Appl	C 523	9.4	6.8	12	1	US-08-713-742-8	Sequence 8, Appl
C 451	9.8	7.1	15	1	US-08-363-240A-626	Sequence 626, App	C 524	9.4	6.8	12	1	US-08-211-882-5	Sequence 5, Appl
C 452	9.8	7.1	15	1	US-08-363-240A-684	Sequence 684, App	C 525	9.4	6.8	12	1	US-08-211-882-9	Sequence 9, Appl
C 453	9.8	7.1	15	1	US-08-221-816B-21	Sequence 21, Appl	C 526	9.4	6.8	12	1	US-09-372-856-8	Sequence 8, Appl
C 454	9.8	7.1	15	1	US-08-311-486C-77	Sequence 77, Appl	C 527	9.4	6.8	12	1	US-09-281-418-20	Sequence 20, Appl
C 455	9.8	7.1	15	1	US-08-311-486C-78	Sequence 78, Appl	C 528	9.4	6.8	12	1	US-09-281-418-74	Sequence 74, Appl
C 456	9.8	7.1	15	1	US-08-311-486C-600	Sequence 600, App	C 529	9.4	6.8	12	1	US-09-688-394-8	Sequence 8, Appl
C 457	9.8	7.1	15	1	US-08-311-486C-621	Sequence 621, App	C 530	9.4	6.8	12	1	US-09-633-659-5	Sequence 5, Appl
C 458	9.8	7.1	15	1	US-08-311-486C-622	Sequence 622, App	C 531	9.4	6.8	12	1	US-09-633-659-9	Sequence 9, Appl
C 459	9.8	7.1	15	1	US-08-292-620A-500	Sequence 500, App	C 532	9.4	6.8	12	1	US-10-112-547-27	Sequence 27, Appl
C 460	9.8	7.1	15	1	US-08-173-489C-277	Sequence 277, App	C 533	9.4	6.8	12	1	US-09-574-117A-26	Sequence 26, Appl
C 461	9.8	7.1	15	1	US-08-173-489C-283	Sequence 283, App	C 534	9.4	6.8	12	1	US-10-112-241-27	Sequence 27, Appl
C 462	9.8	7.1	15	1	US-08-173-489C-327	Sequence 327, App	C 535	9.4	6.8	12	1	US-10-104-611-27	Sequence 27, Appl
C 463	9.8	7.1	15	1	US-08-173-489C-337	Sequence 337, App	C 536	9.4	6.8	12	1	5240847-3	Patent No. 5240847
C 464	9.8	7.1	15	1	US-08-173-489C-343	Sequence 343, App	C 537	9.4	6.8	12	1	5427911-12	Patent No. 5427911
C 465	9.8	7.1	15	1	US-08-173-489C-347	Sequence 347, App	C 538	9.4	6.8	12	1	5427911-14	Patent No. 5427911
C 466	9.8	7.1	15	1	US-08-774-306A-29	Sequence 29, Appl	C 539	9.4	6.8	12	1	US-08-123-449A-17	Sequence 17, Appl
C 467	9.8	7.1	15	1	US-08-774-306A-483	Sequence 483, App	C 540	9.4	6.8	13	1	US-08-458-050-17	Sequence 17, Appl
C 468	9.8	7.1	15	1	US-08-774-306A-494	Sequence 494, App	C 541	9.4	6.8	13	1	US-08-667-023-3	Sequence 3, Appl
C 469	9.8	7.1	15	1	US-08-585-684B-186	Sequence 186, App	C 542	9.4	6.8	13	1	US-08-671-975A-17	Sequence 17, Appl
C 470	9.8	7.1	15	1	US-08-585-684B-1364	Sequence 1364, App	C 543	9.4	6.8	13	1	US-08-757-024-471	Sequence 471, App
C 471	9.8	7.1	15	1	US-08-585-684B-2048	Sequence 2048, App	C 544	9.4	6.8	13	1		

Sequence 500, App
Sequence 528, App
Sequence 17, Appl
Sequence 120, App
Sequence 18, Appl
Sequence 120, App
Sequence 1, Appl
Sequence 1, Appl
Sequence 7, Appl
Sequence 28, Appl
Sequence 5, Appl
Sequence 1, Appl
Sequence 440, App
Sequence 470, App
Sequence 499, App
Sequence 527, App
Sequence 1845, App
Sequence 1, Appl
Sequence 21, Appl
Sequence 36, Appl
Sequence 34, Appl
Sequence 1845, App
Sequence 5, Appl
Sequence 120, App
Patent No. 5171843
Sequence 8497, App
Sequence 4151, App
Sequence 16, Appl
Sequence 622, App
Sequence 7909, App
Sequence 3692, App
Sequence 4, Appl
Sequence 1, Appl
Sequence 43, Appl
Sequence 181, App

104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281

104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281

ALIGNMENTS

RESULT 1
US-08-363-240A-1125
; Sequence 1125, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Page, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994

Query Match 11.8%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 16;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1658 ACCAGGCTCAGCTGGA 1675
Db 1 ACCAGGCTGACAGCTGGA 18

RESULT 3
US-08-927-219-102
; Sequence 102, Application US/08927219
; Patent No. 6187533
; GENERAL INFORMATION:
; APPLICANT: Bell, Graeme I.
; APPLICANT: Yamagata, Kazuya
; APPLICANT: Oda, Naohisa
; APPLICANT: Kaisaki, Pamela J.
; APPLICANT: Furuta, Hiroto
; APPLICANT: Horikawa, Yukio
; APPLICANT: Menzel, Stephen
; TITLE OF INVENTION: MUTATIONS IN THE DIABETES SUSCEPTIBILITY

PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1125:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-1125

Query Match 12.9%; Score 18; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 5.5;
Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1663 GCTCAGCTGGAACCT 1680
Db 1 GCUCACGUGGAACCCU 18

RESULT 2
US-09-624-945-19
; Sequence 19, Application US/09624945
; Patent No. 6607915
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Wanciewicz, Edward
; TITLE OF INVENTION: Antisense Modulation of E2A-Pbx1 Expression
; FILE REFERENCE: ISPH-0477
; CURRENT APPLICATION NUMBER: US/09/624,945
; CURRENT FILING DATE: 2000-07-25
; PRIOR APPLICATION NUMBER: 60/156,836
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-624-945-19

;; TITLE OF INVENTION: GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA, HNF-1BETA

;; TITLE OF INVENTION: AND HNF-4ALPHA

;; NUMBER OF SEQUENCES: 147

;; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: Arnold, White & Durkee

;; STREET: P.O. Box 4433

;; CITY: Houston

;; STATE: Texas

;; COUNTRY: USA

;; ZIP: 77210

;; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk

;; COMPUTER: IBM PC compatible

;; OPERATING SYSTEM: PC-DOS/MS-DOS

;; SOFTWARE: PatentIn Release #1.0, Version #1.30

;; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/08/927,219

;; FILING DATE: Concurrently Herewith

;; CLASSIFICATION: 435

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 60/029,679

;; FILING DATE: 30-OCT-1996

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 60/028,056

;; FILING DATE: 02-OCT-1996

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 60/025,719

;; FILING DATE: 10-SEP-1996

;; ATTORNEY/AGENT INFORMATION:

;; NAME: Wilson, Mark B.

;; REGISTRATION NUMBER: 37,259

;; REFERENCE/DOCKET NUMBER: ARCD:272

;; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: 512/418-3000

;; TELEFAX: 512/474-7577

;; INFORMATION FOR SEQ ID NO: 102:

;; SEQUENCE CHARACTERISTICS:

;; LENGTH: 22 base pairs

;; TYPE: nucleic acid

;; STRANDEDNESS: single

;; TOPOLOGY: linear

;; US-08-927-219-102

Best Local Similarity 85.0%; Pred. No. 42;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1713 AGGAGTACGGAGATGACAT 1732

Db 4 AGGAGGAGGAGATGACAT 23

RESULT 5

US-08-363-240A-240

; Sequence 240, Application US/08363240A

; Patent No. 5705388

; GENERAL INFORMATION:

; APPLICANT: Couture, Larry

; APPLICANT: McSwiggen, James

; APPLICANT: Bisgaier, Charles

; APPLICANT: Pape, Michael

; TITLE OF INVENTION: METHOD AND REAGENT FOR

; TITLE OF INVENTION: PREVENTION, INHIBITION OF

; TITLE OF INVENTION: PROGRESSION AND REGRESSION

; TITLE OF INVENTION: OF VASCULAR DISEASES

; NUMBER OF SEQUENCES: 1243

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IEM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/363,240A

; FILING DATE: December 23, 1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 210/096

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 240:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-363-240A-240

Query Match 10.8%; Score 15; DB 1; Length 15;

Best Local Similarity 73.3%; Pred. No. 20;

Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1634 TGGGGCTTGTAGCAG 1648

Db 1 UGGGGCUUAGCAG 15

RESULT 6

US-08-363-240A-241

; Sequence 241, Application US/08363240A

; Patent No. 5705388

; GENERAL INFORMATION:

; APPLICANT: Couture, Larry

APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 241:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-241
Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 20;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 1637 GGCTTGAGCAGAAG 1651
Db 1 GGCUGUAGCAGAAG 15
|||:|:|||||
RESULT 7
US-08-363-240A-242
Sequence 242, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 242:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-242
Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 20;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1659 CCAGGCTCACAGCTG 1673
Db 1 CCAGGCUCACAGCUG 15
|||:|:|||||
RESULT 8
US-08-363-240A-243
Sequence 243, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

US-08-363-240A-244

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 243:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-243

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 20;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1679 CTGCTGTCTCCTCCA 1693
|:|:|:|:|:|:|
Db 1 CUGGUGUCCUCCCA 15

RESULT 9
US-08-363-240A-244
Sequence 244, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
TITLE OF INVENTION: METHOD AND REAGENT FOR PREVENTION, INHIBITION OF PROGRESSION AND REGRESSION OF VASCULAR DISEASES
TITLE OF INVENTION: PREVENTION, INHIBITION OF PROGRESSION AND REGRESSION OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 244:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-363-240A-246

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 20;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1681 GGTGTCTCTCCAGT 1695
|:|:|:|:|:|:|
Db 1 GGUGUCCUCCAGT 15

RESULT 10
US-08-363-240A-245
Sequence 245, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
TITLE OF INVENTION: METHOD AND REAGENT FOR PREVENTION, INHIBITION OF PROGRESSION AND REGRESSION OF VASCULAR DISEASES
TITLE OF INVENTION: PREVENTION, INHIBITION OF PROGRESSION AND REGRESSION OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 245:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-245

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 20;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1684 GTCTCTCCACGGTG 1698
|:|:|:|:|:|:|
Db 1 GUCUCCUCCACGGTG 15

RESULT 11
US-08-363-240A-246
Sequence 246, Application US/08363240A


```
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-246

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred.No. 20;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1700 TCGAAGTTGGTTAG 1714
|:|||||:|
Db 1 UGGAAGUUGGUAG 15

RESULT 12
US-08-363-240A-247
; Sequence 247, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-246

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred.No. 20;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1700 TCGAAGTTGGTTAG 1714
|:|||||:|
Db 1 UGGAAGUUGGUAG 15

RESULT 13
US-08-363-240A-248
; Sequence 248, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 247:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-247

Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 66.7%; Pred.No. 20;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1705 GTTGGTTAGGAGTA 1719
|:|||||:|
Db 1 GUUGGUUAGGAGUA 15
```

```

;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 248:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-248
;
; Query Match 10.8%; Score 15; DB 1; Length 15;
; Best Local Similarity 66.7%; Pred. No. 20;
; Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
;
QY 1706 TTGGGTAGGATAC 1720
Db :||||:||||:|
1 UUGGGUAGGAGUAC 15

RESULT 14
US-08-363-240A-249
; Sequence 249, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 249:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-250
;
; Query Match 10.8%; Score 15; DB 1; Length 15;
; Best Local Similarity 73.3%; Pred. No. 20;
; Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
;
QY 1726 TGGAGATTGGCTCC 1740
Db :||||:||||:|
1 UGGAGAUUGGCCUCC 15

RESULT 15
US-08-363-240A-250
; Sequence 250, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 250:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-250
;
; Query Match 10.8%; Score 15; DB 1; Length 15;
; Best Local Similarity 73.3%; Pred. No. 20;
; Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
;
QY 1726 TGGAGATTGGCTCC 1740
Db :||||:||||:|
1 UGGAGAUUGGCCUCC 15

```

RESULT 16

```
US-08-363-240A-251
; Sequence 251, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 251:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-251
```

```
Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 20;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1731 ATTGGCTCCCAATC 1745
Db 1 AUGGGCUCCCAAC 15
```

RESULT 17

```
US-08-363-240A-252
; Sequence 252, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 252:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-252
```

```
Query Match 10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 20;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1738 CCCAACTCCTCCCTA 1752
Db 1 CCCAACTCCTCCCTA 15
```

RESULT 18

```
US-08-363-240A-253
; Sequence 253, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
```

```
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
```

Qy
1747 TCCCTATCCTAAAGG 1761

```
Db      1  UCCCUAUCUAAAGG 15

RESULT 21
US-08-363-240A-256
; Sequence 256, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwigen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 210/096
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 256:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-256

Query Match      10.8%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 20;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1750  CTATCTTAAGGCC 1764
Db      1  CUAUCCUAAAGGCC 15

RESULT 22
US-09-382-552-231/c
; Sequence 231, Application US/09382552
; Patent No. 6673909
; GENERAL INFORMATION:
; APPLICANT: Brown, Jr., Robert H.
; APPLICANT: Liu, Jing
; APPLICANT: Aoki, Masashi
; APPLICANT: Ho, Meng
; APPLICANT: Matsuda-Asada, Chie
; TITLE OF INVENTION: DYSFERLIN, A GENE MUTATED IN DISTAL MYOPATHY AND LIMB

; TITLE OF INVENTION: GIRDLE MUSCULAR DYSTROPHY
; FILE REFERENCE: 00786/399002
; CURRENT APPLICATION NUMBER: US/09/382,552
; CURRENT FILING DATE: 1999-08-25
; EARLIER APPLICATION NUMBER: US 60/097,927
; EARLIER FILING DATE: 1998-08-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 231
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-382-552-231

Query Match      10.5%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 48;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1677  CCTGTGTCTCTCCAGCGT 1697
Db      21  CCGTGGGGTCCCTCCAGCAT 1

RESULT 23
US-08-227-370-2/c
; Sequence 2, Application US/08227370
; Patent No. 5559207
; GENERAL INFORMATION:
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Smith, Daniel A.
; APPLICANT: Miller, Richard
; APPLICANT: Ross, Kevin
; APPLICANT: Wright, Meredith
; APPLICANT: Hemmi, Gregory W.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir
; APPLICANT: Iverson, Brent
; APPLICANT: Magda, Darren
; TITLE OF INVENTION: Tetraphyrin Metal Complex Mediated Ester
; TITLE OF INVENTION: Hydrolysis
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/227,370
; FILING DATE: 14-APR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UT58:562
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/320-7200
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-227-370-2
```

Query Match	Score	DB	Length	Indels	Mismatches	Gaps
Best Local Similarity	10.2%;	DB 1;	Length 20;			
Matches	16;	Conservative	0;	Indels 3;	Mismatches 0;	Gaps 0;
Db	1655 AGCACCAGGCTCACAGCTG 1673					
	19 AACACCCGGCTCACAGATG 1					
RESULT 24						
US-08-486-962-4/c						
Sequence 4, Application US/08486962						
Patent No. 5763172						
GENERAL INFORMATION:						
APPLICANT: Magda, Darren						
APPLICANT: Sessler, Jonathan L.						
APPLICANT: Wright, Meredith						
APPLICANT: Ross, Kevin L.						
APPLICANT: Miller, Richard A.						
APPLICANT: Dow, William C.						
APPLICANT: Kral, Vladimir A.						
APPLICANT: Smith, Daniel A.						
TITLE OF INVENTION: METHOD OF PHOSPHATE ESTER HYDROLYSIS						
NUMBER OF SEQUENCES: 18						
CORRESPONDENCE ADDRESSES:						
ADDRESS: Pharmacyclics, Inc.						
STREET: 995 E. Arques Avenue						
CITY: Sunnyvale						
STATE: California						
COUNTRY: USA						
ZIP: 94086-4521						
COMPUTER READABLE FORM:						
MEDIUM TYPE: Floppy disk						
COMPUTER: IBM PC compatible						
OPERATING SYSTEM: PC-DOS/MS-DOS						
SOFTWARE: Patent In Release #1.0, Version #1.30						
CURRENT APPLICATION DATA:						
APPLICATION NUMBER: US/08/486,962						
FILING DATE: 07-JUN-1995						
CLASSIFICATION: 530						
ATTORNEY/AGENT INFORMATION:						
NAME: Larson, Jacqueline S.						
REGISTRATION NUMBER: 30,279						
REFERENCE/DOCKET NUMBER: PHAY:053						
TELECOMMUNICATION INFORMATION:						
TELEPHONE: (408) 774-0340						
TELEFAX: (408) 774-0340						
INFORMATION FOR SEQ ID NO: 4:						
SEQUENCE CHARACTERISTICS:						
LENGTH: 20 base pairs						
TYPE: nucleic acid						
TOPOLOGY: linear						
MOLECULE TYPE: other nucleic acid						
DESCRIPTION: /desc = "DNA"						
US-08-486-962-4						
Query Match	10.2%;	Score 14.2;	DB 1;	Length 20;		
Best Local Similarity	84.2%;	Pred. No. 54;				
Matches	16;	Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;
Db	1655 AGCACCAGGCTCACAGCTG 1673					
	19 AACACCCGGCTCACAGATG 1					
RESULT 25						
US-08-458-347-1/c						
Sequence 1, Application US/08458347						
Patent No. 5798491						
GENERAL INFORMATION:						
APPLICANT: Magda, Darren						

```
/ CLASSIFICATION: 536
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (512) 499-6200
/ TELEFAX: (512) 499-6290
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-975-522A-5

Query Match          10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1655 AGCACAGGCTCACAGTG 1673
Db 19 AACACCGGCTCACAGTG 1

RESULT 27
US-09-103-875-123/c
; Sequence 123, Application US/09103875A
; Patent No. 6221849
; GENERAL INFORMATION:
; APPLICANT: Szyf, Moshe
; APPLICANT: Bigey, Pascal
; APPLICANT: Ramchandani, Shyam
; TITLE OF INVENTION: DNA METHYLTRANSFERASE GENOMIC SEQUENCES AND ANTISENSE
; FILE REFERENCE: 106101.194
; CURRENT APPLICATION NUMBER: US/09/103,875A
; CURRENT FILING DATE: 1998-06-24
; EARLIER APPLICATION NUMBER: 60/069,865
; EARLIER FILING DATE: 1997-12-17
; EARLIER APPLICATION NUMBER: 08/866,340
; EARLIER FILING DATE: 1997-05-30
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-09-103-875-123

Query Match          10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1681 GGTGTCCTCCAGCGTGG 1699
Db 20 GGGGTCTGCTCCTCGGTGG 2

RESULT 28
US-09-798-096-16/c
; Sequence 16, Application US/09798096
; Patent No. 6393378
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF RECQL2 EXPRESSION
; FILE REFERENCE: RTS-0207
; CURRENT APPLICATION NUMBER: US/09/798,096
; CURRENT FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
```

```
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-09-798-096-16

Query Match          10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCACAGCTGGAACCT 1680
Db 20 GGCTCACAGCTGTAATCCT 2

RESULT 29
US-08-754-477A-109
; Sequence 109, Application US/08754477A
; Patent No. 6518411
; GENERAL INFORMATION:
; APPLICANT: Murray, Jeffrey
; APPLICANT: Semina, Elena
; TITLE OF INVENTION: RIB COMPOSITIONS AND THERAPEUTIC
; TITLE OF INVENTION: AND DIAGNOSTIC USES THEREFOR
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477A
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-754-477A-109

Query Match          10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1733 TGGTCCCAACTCTCCCT 1751
Db 2 TGTCTCCCAATCTCTACT 20

RESULT 30
PCT-US94-06284-2/c
; Sequence 2, Application PC/TUS9406284
; GENERAL INFORMATION:
; APPLICANT:
; APPLICANT: NAME: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
; APPLICANT: SYSTEM
; APPLICANT: STREET: 201 West 7th Street
; APPLICANT: CITY: Austin
```

schul tz139-3.rni

```

; CURRENT FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-844-525A-74

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1662 GGCTCACAGCTGAACC 1678
      ||||| ||||| |||||
DB 17 GGCTCACACCTGGATCC 1

RESULT 32
US-08-921-497-4
; Sequence 4, Application US/08921497
; Patent No. 6521225
; GENERAL INFORMATION:
; APPLICANT: Srivastava, Arun
; APPLICANT: Ponnazhagan, Selvarangan
; APPLICANT: Chloemer, Robert H.
; APPLICANT: Wang, Xu-Shan
; APPLICANT: Yoder, Mervin C.
; APPLICANT: Zhou, Shang-Zhen
; APPLICANT: Escobedo, Jaime
; APPLICANT: Varivani, Dwaraki
; TITLE OF INVENTION: An AAV Vector Having Two Modified D-Sequences (As Amended)
; FILE REFERENCE: 1242.003
; CURRENT APPLICATION NUMBER: US/08/921,497
; CURRENT FILING DATE: 1997-09-02
; PRIOR APPLICATION NUMBER: US 60/025,616
; PRIOR FILING DATE: 1996-09-06
; PRIOR APPLICATION NUMBER: US 60/025,649
; PRIOR FILING DATE: 1996-09-11
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapiens
; NAME/KEY: misc-feature
; OTHER INFORMATION: primer for human gamma-globin
US-08-921-497-4

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1681 GGTGTCTCTCTCAGCGT 1697
      ||| ||||| ||||| ||
DB 2 GGTTCCTCTCCAGCAT 18

RESULT 33
US-08-222-177A-434
; Sequence 434, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dC-da)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Demitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison

```



```
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 434:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-222-177A-434

Query Match          9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1713 AGGAGTACGGAGATGGAGAT 1732
Db      1 AGGAGTTAGGAGCTGGAGGT 20

RESULT 34
US-08-718-596-2
; Sequence 2, Application US/08718596
; Patent No. 5827661
; GENERAL INFORMATION:
; APPLICANT: Blais, Burton W.
; TITLE OF INVENTION: Method for Enhancing Detection Ability of Nucleic
; TITLE OF INVENTION: Acid Assays Employing Polymerase Chain Reaction
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, Ltd.
; STREET: 10 S. Wacker Drive
; CITY: Chicago
; STATE: IL
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/718,596
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/366,619
; FILING DATE: 30-12-1994
; APPLICATION NUMBER: No. 5827661 Assigned
; FILING DATE: 23-12-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: McDonnell, John J

; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 434:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-222-177A-434

Query Match          9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1684 GTCTCTCCAGCGTGGTGA 1703
Db      1 GTATCTCCAGAGTGATCGA 20

RESULT 35
US-08-881-037-95
; Sequence 95, Application US/08881037
; Patent No. 6080588
; GENERAL INFORMATION:
; APPLICANT: Glick, Gary D.
; APPLICANT: Swanson, Patrick C.
; TITLE OF INVENTION: DNA BINDING ANTIBODIES
; NUMBER OF SEQUENCES: 113
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/881,037
; FILING DATE: 23-JUN-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/443,540
; FILING DATE: 18-MAY-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Kanski, Antoinette F.
; REGISTRATION NUMBER: 34,202
; REFERENCE/DOCKET NUMBER: 203442110710
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 813-5600
; TELEFAX: (650) 494-0792
; TELEX:
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 8..20
```

US-09-021-701-587/c
; Sequence 587, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Woller, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; TITLE OF INVENTION: probe sequences
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 587:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-09-021-701-587
Query Match 5.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1701 GGAAGTTGGTTAGGAGTAC 1720
Db 20 GGAAGTTCATTAGGATAC 1
RESULT 38
US-09-467-642-88
; Sequence 88, Application US/09467642
; Patent No. 6300132
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2 EXPRES
; FILE REFERENCE: RTS-0106
; CURRENT APPLICATION NUMBER: US/09/467,642
; CURRENT FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

OTHER INFORMATION: /note= "Portion of the germline
OTHER INFORMATION: gene incorporated into the CDR3 construct"
US-08-881-037-95
Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1692 CAGCGTGGTGGAGTTGGT 1711
Db 1 CACTGTGGTGGACGTTGGT 20
RESULT 36
US-08-881-037-103
; Sequence 103, Application US/08881037
; Patent No. 6080588
; GENERAL INFORMATION:
; APPLICANT: Glick, Gary D.
; APPLICANT: Swanson, Patrick C.
; TITLE OF INVENTION: DNA BINDING ANTIBODIES
; NUMBER OF SEQUENCES: 113
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/881,037
; FILING DATE: 23-JUN-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/443,540
; FILING DATE: 18-MAY-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Kanski, Antoinette F.
; REGISTRATION NUMBER: 34,202
; REFERENCE/DOCKET NUMBER: 203442110710
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 813-5600
; TELEFAX: (650) 494-0792
; TELEX:
; INFORMATION FOR SEQ ID NO: 103:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 8..20
; OTHER INFORMATION: /note= "Portion of the germline
OTHER INFORMATION: gene incorporated into the CDR3 construct"
US-08-881-037-103
Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1692 CAGCGTGGTGGAGTTGGT 1711
Db 1 CACTGTGGTGGACGTTGGT 20
RESULT 37

US-09-467-642-88

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1640 TTGTAGCAGAAGGCAAGCAC 1659
||| ||||| ||||| |||||
Db 1 TTGCATCAGAAGGCCAGAAC 20

RESULT 39
US-09-422-978-10402/c
; Sequence 10402, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10402
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-11658 for SEQ 2537, in complement
US-09-422-978-10402

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1746 CTCCTATCTCTAAAGGCCCA 1765
||| ||||| ||||| |||||
Db 20 CTCCTATCTCTACTCCCA 1

RESULT 40
US-09-198-452A-6657/c
; Sequence 6657, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6657
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6657

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1633 ATGGGGCTTGTAGCAGAAG 1652

Db 20 ATGGTGCTAGTATCAGCAGG 1

RESULT 41
US-09-198-452A-6714/c
; Sequence 6714, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6714
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6714

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1720 CGGAGATCGAGATTGGCTCC 1739
||| ||||| ||||| |||||
Db 20 CGGATAGGAGACTGGCTGC 1

RESULT 42
US-09-428-583-84
; Sequence 84, Application US/09428583
; Patent No. 6271029
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOCHESIN-2 EXPRESSION
; FILE REFERENCE: RTS-0096
; CURRENT APPLICATION NUMBER: US/09/428,583
; CURRENT FILING DATE: 1999-10-27
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-428-583-84

Query Match 9.6%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 82;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1685 TCTCCTCCAGCGTGG 1699
||| ||||| ||||| |||||
Db 5 TCTCCTCCTCGGTGG 19

RESULT 43
US-09-360-416-9/c
; Sequence 9, Application US/09360416
; Patent No. 6458536
; GENERAL INFORMATION:
; APPLICANT: Richard A. Gatti
; TITLE OF INVENTION: METHODS FOR DETECTION OF ATAXIA
; TITLE OF INVENTION: TELANGIECTASIA MUTATIONS
; FILE REFERENCE: 510015-222
; CURRENT APPLICATION NUMBER: US/09/360,416
; CURRENT FILING DATE: 1999-07-23
; NUMBER OF SEQ ID NOS: 143

```

; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human
US-09-360-416-9

Query Match          9.6%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 82;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1742 ACTCTCTCCCTATCCT 1756
Db 15 ACTCTCTCCCTATCCT 1

RESULT 44
US-08-802-547-12/C
; Sequence 12, Application US/08802547
; Patent No. 5780611
; GENERAL INFORMATION:
; APPLICANT: Guntaka, Ramareddy V.
; APPLICANT: Weber, Karl T.
; APPLICANT: Kovacs, Attila
; APPLICANT: Kandala, Jagannadhachari
; TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT EXPRESSION OF
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hovey, Williams, Timmons & Collins
; STREET: 2405 Grand Boulevard, Suite 400
; CITY: Kansas City
; STATE: MO
; COUNTRY: USA
; ZIP: 64108
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/802,547
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Collins, John M.
; REGISTRATION NUMBER: 26,262
; REFERENCE/DOCKET NUMBER: 24129-B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 816-474-9050
; TELEFAX: 816-474-9057
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; POSITION IN GENOME:
; UNITS: bp
US-08-802-547-12

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1736 CTCCCAACTCTCCCTAT 1753
Db 18 CTCCCTCCCTCTCCCTTT 1

RESULT 46
US-09-255-912-28
; Sequence 28, Application US/09255912
; Patent No. 6037142
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD2 EXPRESSION
; FILE REFERENCE: RTS-0044
; CURRENT APPLICATION NUMBER: US/09/255,912
; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-255-912-28

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1699 GTGGAAGTTGGTTAGGA 1716
Db 1 CGGGAAGTTCTGTAGGA 18

RESULT 47
US-09-280-409-75
; Sequence 75, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: C. Frank Bennett
; APPLICANT: Bert W. O'Malley
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
; FILE REFERENCE: RTS-0048
; CURRENT APPLICATION NUMBER: US/09/280,409
; CURRENT FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 75
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-75

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCTGTGT 1685
Db 1 CTGCTGGAGCTGTAT 18

RESULT 48
US-09-534-10/c
; Sequence 10, Application US/09723534
; Patent No. 6294382
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRC-1 EXPRESSION
; FILE REFERENCE: RTS-0225
; CURRENT APPLICATION NUMBER: US/09/723,534
; CURRENT FILING DATE: 2000-11-27
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-723-534-10

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCTGGTGGAGTTG 1708
Db 18 CCAGTGGTGGATTTCG 1

RESULT 49
US-09-721-822A-116/c
; Sequence 116, Application US/09721822A
; Patent No. 6306606
; GENERAL INFORMATION:
; APPLICANT: Michael J. Weber
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF MP-1 EXPRESSION
; FILE REFERENCE: RTS-0142
; CURRENT APPLICATION NUMBER: US/09/721,822A
; CURRENT FILING DATE: 2000-11-22
; NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 116
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-721-822A-116

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAACCTG 1681
Db 18 CTCAGTGGCAACCTG 1

RESULT 50
US-09-077-619-15/c
; Sequence 15, Application US/09077619
; Patent No. 6500614
; GENERAL INFORMATION:
; APPLICANT: ARGUELLO, Rafael
; APPLICANT: AVAKIAN, Hovanes
; APPLICANT: MADRIGAL, Alejandro
; TITLE OF INVENTION: METHOD FOR IDENTIFYING AN UNKNOWN ALLELE
; FILE REFERENCE: 028979/0104
; CURRENT APPLICATION NUMBER: US/09/077,619
; CURRENT FILING DATE: 2000-03-31
; PRIOR FILING DATE: 1996-11-29
; PRIOR APPLICATION NUMBER: PCT/GB96/02959
; PRIOR FILING DATE: 1995-11-29
; PRIOR APPLICATION NUMBER: GB 9524381.2
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-077-619-15

Query Match          9.5%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1732 TTGGTCCCAACTCTCC 1749
Db 18 TAGGCTCTCAACTGCTCC 1

RESULT 51
US-08-486-962-16/c
; Sequence 16, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Wright, Meredith
; APPLICANT: Ross, Kevin L.
; APPLICANT: Miller, Richard A.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir A.
```

Query Match 9.5%; Score 13.2; DB 1; Length 19;

Query Match	9.5%	Score 13.2;	DB 1;	Length 19;
Best Local Similarity	83.3%	Pred. No. 82;		

```
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1655 AGCACCAGGCTCACAGCT 1672
DB 18 AACACCGGCTCACAGAT 1

RESULT 54
US-07-696-793A-17/c
; Sequence 17, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; CORRESPONDENCE ADDRESS: 58
; NUMBER OF SEQUENCES: 58
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-07-696-793A-17

Query Match 9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGACCGCTGTGTCT 1687
DB 19 GGTGAAGCGCTGTGTGT 2

RESULT 55
US-07-694-17/c
; Sequence 17, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.

Query Match 9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGACCGCTGTGTCT 1687
DB 19 GGTGAAGCGCTGTGTGT 2

RESULT 56
US-09-357-070-43/c
; Sequence 43, Application US/09357070
; Patent No. 6046049
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF P13 KINASE P110 DELTA EXPRESSION
; FILE REFERENCE: RTS-0076
; CURRENT APPLICATION NUMBER: US/09/357,070
; CURRENT FILING DATE: 1999-07-19
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-357-070-43

Query Match 9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1656 GCACCGGCTCACAGCTG 1673
DB 18 GCACCTGGCTCTCGGCTG 1

RESULT 57
US-09-593-711A-114
```

```

; Sequence 114, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-114

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 TCGGGCTCTAGCAGAG 1651
Db 2 TCGGGCTCTAGTAGAAG 19

RESULT 58
US-09-742-703-19/c
; Sequence 19, Application US/09742703
; Patent No. 6423543
; GENERAL INFORMATION:
; APPLICANT: Patrick Allen Marcotte
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HEPsin EXPRESSION
; FILE REFERENCE: RTS-0090
; CURRENT APPLICATION NUMBER: US/09/742,703
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-742-703-19

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGACCCCTG 1681
Db 19 CTCACCTGGGGGACCCCTG 2

RESULT 59
US-09-198-452A-6149
; Sequence 6149, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6149
; LENGTH: 20
; TYPE: DNA

```

```

; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6149

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1744 TCCTCCCTATCCTAAAGG 1761
Db 3 TCCTCTCTACCTAAAGG 20

RESULT 60
US-09-823-549-1/c
; Sequence 1, Application US/09823549
; Patent No. 6664442
; GENERAL INFORMATION:
; APPLICANT: McConlogue, Lisa C
; APPLICANT: Games, Kate L.
; APPLICANT: Yednock, Theodore A.
; APPLICANT: Hua, Tan
; APPLICANT: Messersmith, Elizabeth
; APPLICANT: Bard, Frederique
; TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS
; FILE REFERENCE: 015270-009110US
; CURRENT APPLICATION NUMBER: US/09/823,549
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: US 60/193,847
; PRIOR FILING DATE: 2000-03-30
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MoGapdh251F forward primer
US-09-823-549-1

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1723 AGATGGAGATTGGCTCCC 1740
Db 19 AGATGGTGGGCTTCC 2

RESULT 61
US-08-363-240A-758
; Sequence 758, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR PREVENTION, INHIBITION OF PROGRESSION AND REGRESSION OF VASCULAR DISEASES
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage

```


schultz139-3.rni

Mon Aug 30 09:26:46 2004

```

;
;
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 759:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-363-240A-759
;
; Query Match 9.4%; Score 13; DB 1; Length 15;
; Best Local Similarity 76.9%; Pred. No. 58;
; Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1733 TGGCTCCCACTC 1745
; :|||:|||||:|
; Db 3 UGGCUCCCAACUC 15
;
; RESULT 63
; US-08-486-962-12/c
; Sequence 12, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Wright, Meredith
; APPLICANT: Ross, Kevin L.
; APPLICANT: Miller, Richard A.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir A.
; APPLICANT: Smith, Daniel A.
; TITLE OF INVENTION: METHOD OF PHOSPHATE ESTER HYDROLYSIS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmacyclics, Inc.
; STREET: 995 E. Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: USA
; ZIP: 94086-4521
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,962
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PHAY:053
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 774-0330
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
;
; US-08-486-962-12
;
; Query Match 9.2%; Score 12.8; DB 1; Length 17;
; Best Local Similarity 87.5%; Pred. No. 82;
; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; QY 1655 AGCACCAGGCTCACAG 1670
;

```

Db 16 AACACCGGCTCACAG 1

RESULT 64

US-08-584-040-7909/c
Sequence 7909, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:

ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 218/064

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 7909:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-584-040-7909

Query Match

Best Local Similarity 9.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1646 CAGAAGCGCACCA 1661

Db 17 CAGAAGCGCACCA 2

RESULT 65

US-09-371-772B-3692/c

Sequence 3692, Application US/09371772B

Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MEH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patent in version 3.0

SEQ ID NO 3692

LENGTH: 17

TYPE: RNA

ORGANISM: Mus sp.

US-09-371-772B-3692

Query Match

Best Local Similarity 9.2%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1646 CAGAAGCGCACCA 1661

Db 17 CAGAAGCGCACCA 2

RESULT 66

PCT-US94-06284-12/c

Sequence 12, Application PC/TUS9406284

GENERAL INFORMATION:

APPLICANT:

APPLICANT: NAME: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS

APPLICANT: SYSTEM

APPLICANT: STREET: 201 West 7th Street

APPLICANT: CITY: Austin

APPLICANT: STATE: Texas

APPLICANT: COUNTRY: United States of America

APPLICANT: POSTAL CODE: 78701

APPLICANT: TELEPHONE NO: (512)499-4462

APPLICANT: TELEFAX: (512)499-4523

APPLICANT: STREET: 995 East Arques Ave.

APPLICANT: CITY: Sunnyvale

APPLICANT: STATE: California

APPLICANT: COUNTRY: United States of America

APPLICANT: POSTAL CODE: 94086-4593

APPLICANT: TELEPHONE NO: (408)774-0330

APPLICANT: TELEFAX: (408)774-0340

TITLE OF INVENTION: TEXAPHYRIN METAL COMPLEX

NUMBER OF SEQUENCES: 16

CORRESPONDENCE ADDRESS:

ADDRESSEE: Arnold, White & Durkee

STREET: P.O. Box 4433

CITY: Houston

STATE: Texas

COUNTRY: USA

ZIP: 77210

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/06284

FILING DATE: CONCURRENTLY HERewith

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: USSN 08/075,123

FILING DATE: 09 JUNE 1993 (09.06.93)

CLASSIFICATION:

APPLICATION NUMBER: USSN 08/227,370

FILING DATE: 14 APRIL 1994 (14.04.94)

```

;
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTFB570P--
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/320-7200
; TELEFAX: 713/789-2679
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; PCT-US94-06284-12

Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 82;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCACAG 1670
Db 16 AACACCCGGCTCACAG 1

RESULT 67
US-08-486-962-15/c
; Sequence 15, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Wright, Meredith
; APPLICANT: Ross, Kevin L.
; APPLICANT: Miller, Richard A.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir A.
; APPLICANT: Smith, Daniel A.
; TITLE OF INVENTION: METHOD OF PHOSPHATE ESTER HYDROLYSIS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmacystics, Inc.
; STREET: 995 E. Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: USA
; ZIP: 94086-4521
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,962
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PHAY:053
; TELEPHONE: (408) 774-0330
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"

US-08-486-962-15
Query Match          9.2%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCACAG 1670
Db 17 AACACCCGGCTCACAG 2

RESULT 68
US-08-671-975A-7
; Sequence 7, Application US/08671975A
; Patent No. 5830656
; GENERAL INFORMATION:
; APPLICANT: Milo, George
; TITLE OF INVENTION: CATR GENE
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CALFEE, HALTER & GRISWOLD
; STREET: 800 SUPERIOR AVENUE, SUITE 1400
; CITY: CLEVELAND
; STATE: OHIO
; COUNTRY: USA
; ZIP: 44114
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/671,975A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: GOLRICK, MARY E
; REGISTRATION NUMBER: 34,829
; REFERENCE/DOCKET NUMBER: 22727/00134
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (216) 622-8200
; TELEFAX: (216) 241-0816
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-671-975A-7

Query Match          9.2%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1691 CCAGCTGGTGGAAAGT 1706
Db 2 CCAGCTGGTGGAAATT 17

RESULT 69
US-09-280-409-109
; Sequence 109, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: C. Frank Bennett
; APPLICANT: Bert W. O'Malley
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
; FILE REFERENCE: RTS-0048
; CURRENT APPLICATION NUMBER: US/09/280,409
```

```
; CURRENT FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 109
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-109

Query Match          9.2%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGT 1685
Db 2 GCTGGAAGCCTGGTAT 17

RESULT 70
US-09-280-409-142
; Sequence 142, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: C. Frank Bennett
; APPLICANT: Bert W. O'Malley
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
; FILE REFERENCE: RTS-0048
; CURRENT APPLICATION NUMBER: US/09/280,409
; CURRENT FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 142
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-142

Query Match          9.2%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCTGGT 1683
Db 2 CTGCTGGAAGCCTGGT 17

RESULT 71
PCT-US94-06284-15/c
; Sequence 15, Application PC/TUS9406284
; GENERAL INFORMATION:
; APPLICANT: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
; APPLICANT: NAME:
; APPLICANT: SYSTEM
; APPLICANT: STREET: 201 West 7th Street
; APPLICANT: CITY: Austin
; APPLICANT: STATE: Texas
; APPLICANT: COUNTRY: United States of America
; APPLICANT: POSTAL CODE: 78701
; APPLICANT: TELEPHONE NO: (512)499-4462
; APPLICANT: TELEFAX: (512)499-4523
; APPLICANT: STREET: 995 East Arques Ave.
; APPLICANT: CITY: Sunnyvale
; APPLICANT: STATE: California
; APPLICANT: COUNTRY: United States of America
; APPLICANT: POSTAL CODE: 94086-4593
; APPLICANT: TELEPHONE NO: (408)774-0330
; APPLICANT: TELEFAX: (408)774-0340
; TITLE OF INVENTION: TEXAPHYRIN METAL COMPLEX
; TITLE OF INVENTION: MEDIATED ESTER HYDROLYSIS
; NUMBER OF SEQUENCES: 16
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/06284
; FILING DATE: CONCURRENTLY HERewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 08/075,123
; FILING DATE: 09 JUNE 1993 (09.06.93)
; CLASSIFICATION:
; APPLICATION NUMBER: USSN 08/227,370
; FILING DATE: 14 APRIL 1994 (14.04.94)
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: PARKER, DAVID L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTB570P--
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/320-7200
; TELEFAX: 713/789-2679
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-06284-15

Query Match          9.2%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 92;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1655 AGCACCAGGCTCACAG 1670
Db 17 AACACCCGCTCACAG 2

RESULT 72
US-08-785-247-12
; Sequence 12, Application US/08785247
; Patent No. 6040149
; GENERAL INFORMATION:
; APPLICANT: Kolesnick, Richard N.
; APPLICANT: Liu, Jun
; APPLICANT: Zhang, Yuhua
; TITLE OF INVENTION: ASSAY FOR IDENTIFYING AGENTS WHICH ACT ON THE
; TITLE OF INVENTION: CERAMIDE-ACTIVATED PROTEIN KINASE, KINASE
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
```

; APPLICATION NUMBER: US/08/785,247
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 48582-A/JPW/CCA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-278-0400
; TELEFAX: 212-381-0526
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-785-247-12

Query Match 9.2%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1648 GAAGGCAAGCTCAGG 1663
Db 1 GAAGGCAAGCTCAGG 16

RESULT 73
US-08-267-803B-68
; Sequence 68, Application US/08267803B
; Patent No. 5834183
; GENERAL INFORMATION:
; APPLICANT: Orr, Harry T.
; APPLICANT: Ranum, Laura P.W.
; APPLICANT: Chung, Ming-Yi
; APPLICANT: Zoghbi, Huda Y.
; TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
; Patent No. 5834183
; TITLE OF INVENTION: Type 1 and Method for Diagnosis
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Muehling, Raasch, Gebhardt & Schwappach, P.A.
; STREET: P.O. Box 581415
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55458-1415
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/267,803B
; FILING DATE: 28-JUN-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McCormack, Myra H.
; REGISTRATION NUMBER: 36,602
; REFERENCE/DOCKET NUMBER: 110.00030120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1217
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-267-803B-68

Query Match 9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1657 CACCAGGCTCACAGTGA 1675
Db 1 CACCAAGCTCCCTGATGA 19

RESULT 74
US-09-422-978-8278/c
; Sequence 8278, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8278
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: downstream amplification primer 99-14699 for SEQ 413, in complemer
US-09-422-978-8278

Query Match 9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1694 GCCTGTGGAGTGGGTT 1712
Db 19 GAGTTGGATGTTGGGGT 1

RESULT 75
US-07-912-900-11
; Sequence 11, Application US/07912900
; Patent No. 5349125
; GENERAL INFORMATION:
; APPLICANT: Holton, Timothy A.
; APPLICANT: Cornish, Edwina C.
; APPLICANT: Kovacic, Filippa
; APPLICANT: Tanaka, Yoshikazu
; APPLICANT: Lester, Diane R.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID
; TITLE OF INVENTION: PATHWAY ENZYMES AND USES THEREFOR
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/912,900-11
; FILING DATE: 07-11-2000
; CLASSIFICATION: C12N 1/00
; ATTORNEY/AGENT INFORMATION:
; NAME: McCormack, Myra H.
; REGISTRATION NUMBER: 36,602
; REFERENCE/DOCKET NUMBER: 110.00030120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 612-305-1217
; TELEFAX: 612-305-1228
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-07-912-900-11

```
; APPLICATION NUMBER: US/07/912,900
; FILING DATE: 19920713
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8633
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-912-900-11

Query Match      8.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1683 TGTCTCTCCAGCG 1696
Db      2 TGTCTCTCCAGTG 15

RESULT 76
US-08-285-309-11
; Sequence 11, Application US/08285309
; Patent No. 5569832
; GENERAL INFORMATION:
; APPLICANT: Holton, Timothy A.
; APPLICANT: Cornish, Edwina C.
; APPLICANT: Kovacic, Filipa
; APPLICANT: Tanaka, Yoshikazu
; APPLICANT: Lester, Diane R.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING A 3,5'-
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/285,309
; FILING DATE: 03-AUG-1994
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/285,309
; FILING DATE: 03-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8633Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-285-309-11

Query Match      8.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1683 TGTCTCTCCAGCG 1696
Db      2 TGTCTCTCCAGTG 15

RESULT 77
US-08-502-046-11
; Sequence 11, Application US/08502046
; Patent No. 5861487
; GENERAL INFORMATION:
; APPLICANT: Holton, Timothy A.
; APPLICANT: Cornish, Edwina C.
; APPLICANT: Kovacic, Filipa
; APPLICANT: Tanaka, Yoshikazu
; APPLICANT: Lester, Diane R.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING A 3,5'-
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/502,046
; FILING DATE: 14-JUL-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/285,309
; FILING DATE: 03-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8633Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-502-046-11

Query Match      8.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1683 TGTCTCTCCAGCG 1696
Db      2 TGTCTCTCCAGTG 15

RESULT 78
US-07-696-793A-22/c
; Sequence 22, Application US/07696793A
; Patent No. 5220004
```

```
US-08-285-309-11

Query Match      8.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1683 TGTCTCTCCAGCG 1696
Db      2 TGTCTCTCCAGTG 15

RESULT 77
US-08-502-046-11
; Sequence 11, Application US/08502046
; Patent No. 5861487
; GENERAL INFORMATION:
; APPLICANT: Holton, Timothy A.
; APPLICANT: Cornish, Edwina C.
; APPLICANT: Kovacic, Filipa
; APPLICANT: Tanaka, Yoshikazu
; APPLICANT: Lester, Diane R.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING A 3,5'-
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/502,046
; FILING DATE: 14-JUL-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/285,309
; FILING DATE: 03-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 8633Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-502-046-11

Query Match      8.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 80;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1683 TGTCTCTCCAGCG 1696
Db      2 TGTCTCTCCAGTG 15

RESULT 78
US-07-696-793A-22/c
; Sequence 22, Application US/07696793A
; Patent No. 5220004
```

GENERAL INFORMATION:
APPLICANT: Saiki, Randall K.
APPLICANT: Nasarabadi, Shanavaz L.
TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cetus Corporation
STREET: 1400 Fifty-Third Street
CITY: Emeryville
STATE: California
COUNTRY: U.S.A.
ZIP: 94608
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/696,793A
FILING DATE: 19910507
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kevin R. Kaster
REGISTRATION NUMBER: 32704
REFERENCE/DOCKET NUMBER: 2598
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 420-3444
TELEFAX: (415) 658-5239
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-696-793A-22

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 90;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGGT 1711
|||||
Db 16 GGTGGAAGCTGGGT 3

RESULT 79
US-07-977-694-22/c
Sequence 22, Application US/07977694
Patent No. 5273883
GENERAL INFORMATION:
APPLICANT: Saiki, Randall K.
APPLICANT: Nasarabadi, Shanavaz L.
TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/977,694
FILING DATE: 19921117
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Stacey R. Sias, Ph.D.
REGISTRATION NUMBER: 32,630
REFERENCE/DOCKET NUMBER: 8733
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2863
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-977-694-22

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 90;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGGT 1711
|||||
Db 16 GGTGGAAGCTGGGT 3

RESULT 80
US-08-255-264-24/c
Sequence 24, Application US/08255264
Patent No. 5643724
GENERAL INFORMATION:
APPLICANT: Fildes, Nicola J.
APPLICANT: Reynolds, Rebecca L.
TITLE OF INVENTION: Methods and Reagents for Glycophorin A
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/255,264
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry Ph.D., Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8865
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-255-264-24

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 90;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGAAGTGGGT 1711
|||||
DB 16 GGTGGAAGCTGGGT 3

RESULT 81
US-08-161-674B-20/c
; Sequence 20, Application US/08161674B
; Patent No. 6180766
; GENERAL INFORMATION:
; APPLICANT: Schinazi, Raymond F.
; APPLICANT: Fulcrand-El Kattan, Geraldine
; APPLICANT: Lesnikowski, Zibigniew J.
; TITLE OF INVENTION: Nucleosides and Oligonucleotides Containing Boron
; TITLE OF INVENTION: Clusters
; FILE REFERENCE: 18085.105068
; CURRENT APPLICATION NUMBER: US/08/161,674B
; CURRENT FILING DATE: 1993-12-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus type 1
US-08-161-674B-20

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 90;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1677 CCTGTGTCTCT 1690
|||||
DB 16 CCTGTGTCTCAT 3

RESULT 82
US-09-371-772B-5908/c
; Sequence 5908, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5908
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5908

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 90;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCAGCTGGAA 1676
|||||
DB 16 GCCCAGCTGGAA 3

RESULT 83
US-07-696-793A-20/c
; Sequence 20, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-20

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGAAGTGGGT 1711
|||||
DB 17 GGTGGAAGCTGGGT 4

RESULT 84
US-07-977-694-20/c
; Sequence 20, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199


```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-07-977-694-20
Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGGT 1711
Db 17 GGTGGAAGTTGGGT 4

RESULT 85
US-09-371-772B-4993/c
; Sequence 4993, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MRH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4993
Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1663 GCTCACAGCTGAA 1676
Db 15 GCCACAGCTGAA 2

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-07-977-694-20
Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGGT 1711
Db 17 GGTGGAAGTTGGGT 4

RESULT 86
US-07-696-793A-12/c
; Sequence 12, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-07-696-793A-12
Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGTTGGGT 1711
Db 17 GGTGGAAGTTGGGT 4

RESULT 87
US-07-977-694-12/c
; Sequence 12, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
```

COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,694
FILING DATE: 19921117
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Stacey R. Sias, Ph.D.
REGISTRATION NUMBER: 32,630
REFERENCE/DOCKET NUMBER: 8733
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2863
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-977-694-12

Query Match 8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGT 1711
|||||
DB 17 GGTGGAAGTTGGT 4

RESULT 88

US-08-802-547-8/c
Sequence 8, Application US/08802547
Patent No. 5780611
GENERAL INFORMATION:
APPLICANT: Guntaka, Ramareddy V.
APPLICANT: Weber, Karl T.
APPLICANT: Kovacs, Attila
APPLICANT: Kandala, Jagannadhachari
TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT EXPRESSION OF
TITLE OF INVENTION: COLLAGEN GENES
NUMBER OF SEQUENCES: 14

CORRESPONDENCE ADDRESS:
ADDRESSEE: Hovey, Williams, Timmons & Collins
STREET: 2405 Grand Boulevard, Suite 400
CITY: Kansas City
STATE: MO
COUNTRY: USA
ZIP: 64108

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/802,547
FILING DATE:

CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Collins, John M.
REGISTRATION NUMBER: 26,262
REFERENCE/DOCKET NUMBER: 24129-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 816-474-9050
TELEFAX: 816-474-9057
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
POSITION IN GENOME:
UNITS: bp
US-08-802-547-8

Query Match 8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCT 1756
|||||
DB 17 CTCCTCCCTATCCT 4

RESULT 89

US-08-802-547-10/c
Sequence 10, Application US/08802547
Patent No. 5780611
GENERAL INFORMATION:
APPLICANT: Guntaka, Ramareddy V.
APPLICANT: Weber, Karl T.
APPLICANT: Kovacs, Attila
APPLICANT: Kandala, Jagannadhachari
TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT EXPRESSION OF
TITLE OF INVENTION: COLLAGEN GENES
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hovey, Williams, Timmons & Collins
STREET: 2405 Grand Boulevard, Suite 400
CITY: Kansas City
STATE: MO
COUNTRY: USA
ZIP: 64108

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/802,547
FILING DATE:

CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Collins, John M.
REGISTRATION NUMBER: 26,262
REFERENCE/DOCKET NUMBER: 24129-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 816-474-9050
TELEFAX: 816-474-9057
INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: YES
POSITION IN GENOME:
UNITS: bp
US-08-802-547-10

Query Match 8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCT 1756
|||||

```

Db      17 CTCCTCCCTTTCCT 4

RESULT 90
US-08-802-547-11/c
; Sequence 11, Application US/0802547
; Patent No. 5780611
; GENERAL INFORMATION:
; APPLICANT: Guntaka, Ramareddy V.
; APPLICANT: Weber, Karl T.
; APPLICANT: Kovacs, Attila
; APPLICANT: Kandala, Jagannadhachari
; TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT EXPRESSION OF
; TITLE OF INVENTION: COLLAGEN GENES
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hovey, Williams, Timmons & Collins
; STREET: 2405 Grand Boulevard, Suite 400
; CITY: Kansas City
; STATE: MO
; COUNTRY: USA
; ZIP: 64108
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/802,547
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Collins, John M.
; REGISTRATION NUMBER: 26,262
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 816-474-9050
; TELEFAX: 816-474-9057
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; POSITION IN GENOME:
; UNITS: bp
; US-08-802-547-11

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1743 CTCCTCCCTATCCT 1756
        |||||
Db      17 CTCCTCCCTTTCCT 4

RESULT 91
US-08-712-357-8/c
; Sequence 8, Application US/08712357
; Patent No. 5808037
; GENERAL INFORMATION:
; APPLICANT: Guntaka, Ramareddy V.
; APPLICANT: Weber, Karl T.
; APPLICANT: Kovacs, Attila
; APPLICANT: Kandala, Jagannadhachari
; TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT
; TITLE OF INVENTION: EXPRESSION OF COLLAGEN GENES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hovey, Williams, Timmons & Collins
; STREET: 2405 Grand Boulevard, Suite 400
; CITY: Kansas City
; STATE: Missouri
; COUNTRY: U.S.A.
; ZIP: 64108
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/712,357
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Collins, John M.

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1743 CTCCTCCCTATCCT 1756
        |||||
Db      17 CTCCTCCCTTTCCT 4

RESULT 92
US-08-712-357-10/c
; Sequence 10, Application US/08712357
; Patent No. 5808037
; GENERAL INFORMATION:
; APPLICANT: Guntaka, Ramareddy V.
; APPLICANT: Weber, Karl T.
; APPLICANT: Kovacs, Attila
; APPLICANT: Kandala, Jagannadhachari
; TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT
; TITLE OF INVENTION: EXPRESSION OF COLLAGEN GENES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hovey, Williams, Timmons & Collins
; STREET: 2405 Grand Boulevard, Suite 400
; CITY: Kansas City
; STATE: Missouri
; COUNTRY: U.S.A.
; ZIP: 64108
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/712,357
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Collins, John M.

```

```

; REGISTRATION NUMBER: 26262
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (816) 474-9050
; TELEFAX: (816) 474-9057
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; POSITION IN GENOME:
; UNITS: bp
US-08-712-357-10

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTTCTCT 1756
Db 17 CTCCTCCCTTCTCT 4

RESULT 93
US-08-712-357-11/c
; Sequence 11, Application US/08712357
; Patent No. 5808037
; GENERAL INFORMATION:
; APPLICANT: Guntaka, Ramareddy V.
; APPLICANT: Weber, Karl T.
; APPLICANT: Kovacs, Attila
; APPLICANT: Kandala, Jagannadhachari
; TITLE OF INVENTION: OLIGOMERS WHICH INHIBIT
; TITLE OF INVENTION: EXPRESSION OF COLLAGEN GENES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hovey, Williams, Timmons & Collins
; STREET: 2405 Grand Boulevard, Suite 400
; CITY: Kansas City
; STATE: Missouri
; COUNTRY: U.S.A.
; ZIP: 64108
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/712,357
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Collins, John M.
; REGISTRATION NUMBER: 26262
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (816) 474-9050
; TELEFAX: (816) 474-9057
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; POSITION IN GENOME:
; UNITS: bp
US-08-712-357-11

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTTCTCT 1756
Db 17 CTCCTCCCTTCTCT 4

RESULT 94
US-08-584-040-3040/c
; Sequence 3040, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3040:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3040

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAA 1676
Db 16 GCCCACAGCTGGAA 3

RESULT 95
US-09-422-978-11223
; Sequence 11223, Application US/09422978
```

```
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11223
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-3479 for SEQ 3358, in compleme
US-09-422-978-11223

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATTGG 1735
Db      |||||
5 GAGATGGAGATAGG 18

RESULT 96
; Sequence 1468, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1468
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1468

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1663 GCTCAGCTGGAA 1676
Db      |||||
16 GCCACAGCTGGAA 3

RESULT 97
5179198-15
```

```
; Patent No. 5179198
; APPLICANT: OKADA, HIDECHIKA;OKADA, NORIKO;NAGAMI, YOICHI;
; TAKASHI, KAZUHIRO;TAKIZAWA, HISAO;KONDO, JUN
; TITLE OF INVENTION: GLYCOPROTEIN AND GENE CODING THEREFOR
; NUMBER OF SEQUENCES: 17
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/376,828
; FILING DATE: 07-JUL-1989
; SEQ ID NO:15
; LENGTH: 18
5179198-15

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1702 GAAGTTGGGTTAGG 1715
Db      |||||
5 GCAGTTGGGTTAGG 18

RESULT 98
5521296-11
; Patent No. 5521296
; APPLICANT: OKADA, HIDECHIKA;OKADA, NORIKO;NAGAMI, YOICHI;
; TAKAHASHI, KAZUHIRO;TAKIZAWA, HISAO;KONDO, JUN
; TITLE OF INVENTION: GLYCOPROTEIN AND GENE CODING THEREFOR
; NUMBER OF SEQUENCES: 12
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/739,211
; FILING DATE: 01-AUG-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 376,828
; FILING DATE: 07-JUL-1989
; SEQ ID NO:11
; LENGTH: 18
5521296-11

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1702 GAAGTTGGGTTAGG 1715
Db      |||||
5 GCAGTTGGGTTAGG 18

RESULT 99
US-08-070-517-1/c
; Sequence 1, Application US/08070517
; Patent No. 5538869
; GENERAL INFORMATION:
; APPLICANT: Michael J. Siciliano
; APPLICANT: Pu Liu
; TITLE OF INVENTION: In-Situ Hybridization Probes for
; TITLE OF INVENTION: Identification and Banding of
; TITLE OF INVENTION: Specific Human Chromosomes and
; TITLE OF INVENTION: Regions
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/070,517
```

1 FILING DATE: 19930601
1 CLASSIFICATION: 435
1 ATTORNEY/AGENT INFORMATION:
1 NAME: Barbara S. Kitchell
1 REGISTRATION NUMBER: 33,928
1 REFERENCE/DOCKET NUMBER: UTSC:290/KIT
1 TELECOMMUNICATION INFORMATION:
1 TELEPHONE: (512) 320-7200
1 TELEFAX: (512) 474-7577
1 INFORMATION FOR SEQ ID NO: 1:
1 SEQUENCE CHARACTERISTICS:
1 LENGTH: 19 base pairs
1 TYPE: nucleic acid
1 STRANDEDNESS: single
1 TOPOLOGY: linear
1 US-08-070-517-1

Query Match 8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 GGCTCACAGCTGGAACCC 1679
Db 18 GGCTCAIRCCTGTATCC 1

1 RESULT 100
1 US-08-118-441-1/c
1 Sequence 1, Application US/08118441
1 Patent No. 5578493
1 GENERAL INFORMATION:
1 APPLICANT: Gilliam, T. Conrad
1 APPLICANT: Tanzi, Rudolph E.
1 TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S DISEASE
1 TITLE OF INVENTION: GENE
1 NUMBER OF SEQUENCES: 29
1 CORRESPONDENCE ADDRESS:
1 ADDRESSEE: Cooper & Dunham
1 STREET: 30 Rockefeller Plaza
1 CITY: New York
1 STATE: New York
1 COUNTRY: United States of America
1 ZIP: 10112
1 COMPUTER READABLE FORM:
1 MEDIUM TYPE: Floppy disk
1 COMPUTER: IBM PC compatible
1 OPERATING SYSTEM: PC-DOS/MS-DOS
1 SOFTWARE: PatentIn Release #1.0, Version #1.25
1 CURRENT APPLICATION DATA:
1 APPLICATION NUMBER: US/08/118,441
1 FILING DATE:
1 CLASSIFICATION: 435
1 ATTORNEY/AGENT INFORMATION:
1 NAME: White, John P.
1 REGISTRATION NUMBER: 28,678
1 REFERENCE/DOCKET NUMBER: 0575/44011
1 TELECOMMUNICATION INFORMATION:
1 TELEPHONE: (212) 977-9550
1 TELEFAX: (212) 664-0525
1 TELEX: 422523 COOP UI
1 INFORMATION FOR SEQ ID NO: 1:
1 SEQUENCE CHARACTERISTICS:
1 LENGTH: 19 base pairs
1 TYPE: nucleic acid
1 STRANDEDNESS: single
1 TOPOLOGY: linear
1 MOLECULE TYPE: DNA (genomic)
1 HYPOTHETICAL: NO
1 US-08-118-441-1

Query Match 8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 GGCTCACAGCTGGAACCC 1679
Db 18 GGCTCAIRCCTGTATCC 1

1 RESULT 101
1 US-08-422-699A-13/c
1 Sequence 13, Application US/08422699A
1 Patent No. 5955265
1 GENERAL INFORMATION:
1 APPLICANT: Brook, J. David
1 APPLICANT: Housman, David E.
1 APPLICANT: Shaw, Duncan J.
1 APPLICANT: Harley, Helen G.
1 APPLICANT: Johnson, Keith J.
1 TITLE OF INVENTION: DNA SEQUENCE ENCODING THE MYOTONIC
1 TITLE OF INVENTION: DYSTROPHY GENE AND USES THEREOF
1 NUMBER OF SEQUENCES: 14
1 CORRESPONDENCE ADDRESS:
1 ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
1 STREET: Two Militia Drive
1 CITY: Lexington
1 STATE: Massachusetts
1 COUNTRY: US
1 ZIP: 02713
1 COMPUTER READABLE FORM:
1 MEDIUM TYPE: Floppy disk
1 COMPUTER: IBM PC compatible
1 OPERATING SYSTEM: PC-DOS/MS-DOS
1 SOFTWARE: PatentIn Release #1.0, Version #1.30
1 CURRENT APPLICATION DATA:
1 APPLICATION NUMBER: US/08/422,699A
1 FILING DATE:
1 CLASSIFICATION:
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: 08/422,706
1 FILING DATE:
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: US 08/023,612
1 FILING DATE: 26-FEB-1993
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: US 07/839,255
1 FILING DATE: 20-FEB-1992
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: PCT/US93/01545
1 FILING DATE: 19-FEB-1993
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: PCT/GB93/00253
1 FILING DATE: 05-FEB-1993
1 PRIOR APPLICATION DATA:
1 APPLICATION NUMBER: GB9202485.0
1 FILING DATE: 06-FEB-1992
1 ATTORNEY/AGENT INFORMATION:
1 NAME: Granahan, Patricia
1 REGISTRATION NUMBER: 32,227
1 REFERENCE/DOCKET NUMBER: MIT-5830A2
1 TELECOMMUNICATION INFORMATION:
1 TELEPHONE: 617-861-6240
1 TELEFAX: 617-861-9540
1 INFORMATION FOR SEQ ID NO: 13:
1 SEQUENCE CHARACTERISTICS:
1 LENGTH: 19 base pairs
1 TYPE: nucleic acid
1 STRANDEDNESS: single
1 TOPOLOGY: linear
1 MOLECULE TYPE: DNA (genomic)
1 US-08-422-699A-13

Query Match 8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCACAGCTGGAACCC 1679
Db 18 GGCTCAVRCCTGTATCC 1

RESULT 102
US-08-422-706B-13/c
; Sequence 13, Application US/08422706B
; Patent No. 5977333
; GENERAL INFORMATION:
; APPLICANT: Brook, J. David
; APPLICANT: Housman, David E.
; APPLICANT: Shaw, Duncan J.
; APPLICANT: Harley, Helen G.
; APPLICANT: Johnson, Keith J.
; TITLE OF INVENTION: DNA SEQUENCE ENCODING THE MYOTONIC
; TITLE OF INVENTION: DYSTROPHY GENE AND USES THEREOF
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: US
; ZIP: 02713
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,706B
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/284,543
; FILING DATE: 08-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/023,612
; FILING DATE: 26-FEB-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/839,255
; FILING DATE: 20-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/01545
; FILING DATE: 19-FEB-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB93/00253
; FILING DATE: 05-FEB-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB9202485.0
; FILING DATE: 06-FEB-1992
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: MIT-5830A2
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-422-706B-13

Query Match 8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
QY 1662 GGCTCACAGCTGGAACCC 1679

Db 18 GGCTCAVRCCTGTATCC 1

RESULT 103
US-08-338-579A-1/c
; Sequence 1, Application US/08338579A
; Patent No. 6068975
; GENERAL INFORMATION:
; APPLICANT: Gilliam, T. Conrad
; APPLICANT: Tanzi, Rudolph E.
; TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S
; TITLE OF INVENTION: DISEASE GENE
; NUMBER OF SEQUENCES: 107
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/338,579A
; FILING DATE: June 17, 1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 0575/44011-A-PCT-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400
; TELEFAX: (212) 391-0525
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; US-08-338-579A-1

Query Match 8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
QY 1662 GGCTCACAGCTGGAACCC 1679
Db 18 GGCTCAVRCCTGTATCC 1

RESULT 104
US-09-078-294-1/c
; Sequence 1, Application US/09078294
; Patent No. 6265211
; GENERAL INFORMATION:
; APPLICANT: Choo, Kong-Hong Andy
; APPLICANT: Du Sart, Desiree
; APPLICANT: Cancilla, Michael R.
; TITLE OF INVENTION: A NOVEL NUCLEIC ACID MOLECULE
; FILE REFERENCE: Davies Col
; CURRENT APPLICATION NUMBER: US/09/078,294
; CURRENT FILING DATE: 1998-05-13
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 19

```
; TYPE: DNA
; ORGANISM: DNA primer
US-09-078-294-1

Query Match      8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 GGCTCAGCTGGACCC 1679
Db 18 GGCTCAIRCCCTGTATCC 1

RESULT 105
US-09-422-978-10908/c
; Sequence 10908, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/422,978
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10908
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: downstream amplification primer 99-21827 for SEQ 3043, in complete
US-09-422-978-10908

Query Match      8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 GGATGGGCTTGTGA 1644
Db 19 GGTGGGGCTTGTGA 6

RESULT 106
PCT-US94-09851-1/c
; Sequence 1, Application PC/TUS9409851
; GENERAL INFORMATION:
; APPLICANT: Gilliam, T. Conrad
; APPLICANT: Tanzi, Rudolph E.
; TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S
; TITLE OF INVENTION: DISEASE GENE
; NUMBER OF SEQUENCES: 92
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10112
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
```

```
; APPLICATION NUMBER: PCT/US94/09851
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 0575/44011-PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 977-9550
; TELEFAX: (212) 664-0525
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
PCT-US94-09851-1

Query Match      8.9%; Score 12.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 GGCTCAGCTGGACCC 1679
Db 18 GGCTCAIRCCCTGTATCC 1

RESULT 107
US-08-373-124A-1709
; Sequence 1709, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2527
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
```



```
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1709:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1709

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAACCTG 1681
Db 1 UCUCAGCUGAACUCUG 17

RESULT 108
US-08-435-628-1709
; Sequence 1709, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1709:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-492D-6

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAACCTG 1681
Db 1 UCUCAGCUGAACUCUG 17

RESULT 109
US-08-292-492D-6
; Sequence 6, Application US/08292492D
; Patent No. 6328971
; GENERAL INFORMATION:
; APPLICANT: van der Bruggen, Pierre; Szikora, Jean-
; Pierre; Coullie, Pierre; Wildman, Claude; Bol,
; Pascale;
; Boon-Ralleur, Thierry
; TITLE OF INVENTION: METHOD FOR IDENTIFYING
; INDIVIDUALS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski LLP
; STREET: 666 Fifth Avenue
; CITY: New York City
; STATE: New York
; COUNTRY: USA
; ZIP: 10103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,492D
; FILING DATE: 18-Aug-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/195,186
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: 08/008,446
; FILING DATE: 22-JANUARY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Hanson, No. 6328971man D.
; REGISTRATION NUMBER: 30,946
; REFERENCE/DOCKET NUMBER: LUD 5361.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 318-3100
; TELEFAX: (212) 318-3400
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
; US-08-292-492D-6

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1653 CAAGCACCAGGCTCACA 1669
Db 1 CAAGCCGCGGACAGAGA 17
```

RESULT 110

US-09-633-994-6

; Sequence 6, Application US/09633994

; Patent No. 6680056

; GENERAL INFORMATION:

; APPLICANT: van der Bruggen, Pierre; Szikora, Jean-Pierre; Coulie, Pierre; Wildman, Claude; Bol, Pascale;

; Boon-Fallieur, Thierry

; TITLE OF INVENTION: METHOD FOR IDENTIFYING

; INDIVIDUALS

; SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE

; ABNORMAL CELLS PRESENT COMPLEXES OF HLA-

; NUMBER OF SEQUENCES: 17

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fulbright & Jaworski LLP

; STREET: 666 Fifth Avenue

; CITY: New York City

; STATE: New York

; COUNTRY: USA

; ZIP: 10103

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage

; COMPUTER: IBM PS/2

; OPERATING SYSTEM: PC-DOS

; SOFTWARE: Wordperfect

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/633,994

; FILING DATE: 08-Aug-2000

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/292,492

; FILING DATE: 18-Aug-1994

; APPLICATION NUMBER: 08/195,186

; FILING DATE: 14-FEB-1994

; APPLICATION NUMBER: 08/008,446

; FILING DATE: 22-JANUARY-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Hanson, No. 6680056man D.

; REGISTRATION NUMBER: 30,946

; REFERENCE/DOCKET NUMBER: LUD 5361.1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 318-3100

; TELEFAX: (212) 318-3400

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 6:

US-09-633-994-6

Query Match

Best Local Similarity 8.8%; Score 12.2; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1653

CAAGCACCAGGCTCACA 1669

||||| ||||| |||||

1 CAAGGCCAGGCACAGA 17

RESULT 111

US-09-866-108A-527

; Sequence 527, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-03-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006685
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006688
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006683
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 527
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-527

Query Match

Best Local Similarity 8.8%; Score 12.2; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644

AGCAGAGGCAAGCACC 1660

||||| ||||| |||||

1 AGCAGATGACAGCATC 17

RESULT 112

US-09-866-108A-528

; Sequence 528, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AECOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-03-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-03-27

; PRIOR APPLICATION NUMBER: PCT/US01/006666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/006667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/006664

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 528
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-528

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1645 GCAGAGGCAAGCACCA 1661
|||||
Db 1 GCAGATGACAAGCATCA 17

RESULT 113
US-09-866-108A-1264/c
; Sequence 1264, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1264
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1264

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1729 AGATTGGCTCCCAACTC 1745
|||||
Db 17 AGATCGTCCCCCAACTC 1

RESULT 114
US-09-866-108A-7831
; Sequence 7831, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7831
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7831

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1661 AGGCTCACAGCTGAAC 1677
|||||
Db 1 AGGCTCACAGCTGAAGC 17

RESULT 115
US-09-866-108A-9658/c
; Sequence 9658, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AECOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecmica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9658
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9658

Query Match 8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1672 TGGACCCCTGGTGCTC 1688
Db 17 TGGACCCCTGGCCCTC 1

RESULT 116
US-09-280-409-142/c
Sequence 142, Application US/09280409
Patent No. 6107092
GENERAL INFORMATION:
APPLICANT: Lex M. Cowseert
APPLICANT: C. Frank Bennett
APPLICANT: Bert W. O'Malley
TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
FILE REFERENCE: RTS-0048
CURRENT APPLICATION NUMBER: US/09/280,409
CURRENT FILING DATE: 1999-03-29
NUMBER OF SEQ ID NOS: 142
SEQ ID NO 142
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-142

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1658 ACCAGGCTCACAGCTGG 1674

Db 17 ACCAGGCTTCCAGCAGG 1
RESULT 117
US-08-127-954-45/c
Sequence 45, Application US/08127954
Patent No. 5451512
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
TITLE OF INVENTION: Methods and Reagents for HLA Class I A
TITLE OF INVENTION: Locus DNA Typing
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION NUMBER: US/08/127,954
FILING DATE:
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8873
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-127-954-45

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1732 TTGGCTCCCAACTCTC 1748
Db 17 TAGGCTCTCAACTGTC 1

RESULT 118
US-07-923-260A-13
Sequence 13, Application US/07923260A
Patent No. 5719021
GENERAL INFORMATION:
APPLICANT: Inouye, Masayori
TITLE OF INVENTION: PROTEIN ACTIVATION
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Gerard J. Weiser
STREET: 230 South Fifteenth Street, Suite 500
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19102
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

```
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/923,260A
/ FILING DATE: 31-JUL-1992
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Weiser, Gerard J.
/ REGISTRATION NUMBER: 19,763
/ REFERENCE/DOCKET NUMBER: 377,5638P
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-875-8383
/ TELEFAX: 215-875-8394
/ INFORMATION FOR SEQ ID NO: 13:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-07-923-260A-13
Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1636 GGGCTTGTAGCAGAAG 1652
Db 2 GGGTTTGTTCAGAAG 18

RESULT 119
US-08-890-980-46/c
; Sequence 46, Application US/08890980
; Patent No. 5998141
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; TITLE OF INVENTION: SR-BI NUCLEIC ACIDS AND USES THEREFOR
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,980
; FILING DATE: 10-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: MIA-005.02
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
/
US-08-890-980-46
Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCTCCAGGTG 1698
Db 17 GTCTCTCTCCGCGCTG 1

RESULT 120
US-08-890-979-46/c
; Sequence 46, Application US/08890979
; Patent No. 6030778
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; APPLICANT: Ordovas, Jose M.
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS
; TITLE OF INVENTION: DISORDERS
; NUMBER OF SEQUENCES: 75
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,979
; FILING DATE: 10-JUL-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: MIA-005.02
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
/
US-08-890-979-46
Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCTCCAGGTG 1698
Db 17 GTCTCTCTCCGCGCTG 1

RESULT 121
US-09-032-894-46/c
; Sequence 46, Application US/09032894
; Patent No. 6130041
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; TITLE OF INVENTION: SR-BI NUCLEIC ACIDS AND USES THEREFOR
; FILE OF INVENTION: MIA-005.03
; CURRENT APPLICATION NUMBER: US/09/032,894
; CURRENT FILING DATE: 1998-02-27
; EARLIER APPLICATION NUMBER: 08/890,980
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
;
US-09-032-894-46/c
Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-032-894-46

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCTCCAGCGTG 1698
DB 17 GTCTCTCTCCGCGCTG 1

RESULT 122
US-08-894-736-10/c
; Sequence 10, Application US/08894736A
; Patent No. 6140492
; GENERAL INFORMATION:
; APPLICANT: MORELLI, Susanna
; APPLICANT: NICOLIN, Angelo
; APPLICANT: QUATTRONE, Alessandro
; TITLE OF INVENTION: ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND
; TITLE OF INVENTION: SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE
; TITLE OF INVENTION: ACTIVITY THEREOF
; FILE REFERENCE: 10309-0002-0PCT
; CURRENT APPLICATION NUMBER: US/08/894,736A
; CURRENT FILING DATE: 1998-04-06
; EARLIER APPLICATION NUMBER: PCT/EP96/00853
; EARLIER FILING DATE: 1996-03-01
; EARLIER APPLICATION NUMBER: IT M195A000419
; EARLIER FILING DATE: 1997-03-03
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-894-736-10

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644 AGCAGAGGCGAGCACC 1660
DB 17 AGCAGAGCGCCGCATC 1

RESULT 123
US-08-894-736-21
; Sequence 21, Application US/08894736A
; Patent No. 6140492
; GENERAL INFORMATION:
; APPLICANT: MORELLI, Susanna
; APPLICANT: NICOLIN, Angelo
; APPLICANT: QUATTRONE, Alessandro
; TITLE OF INVENTION: ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND
; TITLE OF INVENTION: SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE
; TITLE OF INVENTION: ACTIVITY THEREOF
; FILE REFERENCE: 10309-0002-0PCT
; CURRENT APPLICATION NUMBER: US/08/894,736A
; CURRENT FILING DATE: 1998-04-06
; EARLIER APPLICATION NUMBER: PCT/EP96/00853
; EARLIER FILING DATE: 1996-03-01
; EARLIER APPLICATION NUMBER: IT M195A000419
; EARLIER FILING DATE: 1997-03-03
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18

; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-894-736-21

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCCCTATC 1754
DB 2 CCAACTCTCCCTATC 18

RESULT 125
US-09-031-626-46/c
; Sequence 46, Application US/09031626
; Patent No. 6228581
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; APPLICANT: Ordovas, Jose M.
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS AND
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS
; FILE REFERENCE: MIA-005.04
; CURRENT APPLICATION NUMBER: US/09/031,626
; CURRENT FILING DATE: 1998-02-27
; EARLIER APPLICATION NUMBER: 08/890,979
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-031-626-46

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-894-736-21

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1682 GTGTCCTCCAGCGTG 1698
Db 17 GTCTCTCTCCCGCGTG 1

RESULT 126
US-09-632-580A-49/c
; Sequence 49, Application US/09632580A
; Patent No. 6255111
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF HER-4 EXPRESSION
; FILE REFERENCE: RTS-0054
; CURRENT APPLICATION NUMBER: US/09/632.580A
; CURRENT FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 93
; SEQ ID NO 49
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-632-580A-49

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1723 AGATGGAGATTGGCTCC 1739
Db 18 AGTTGAGATGGCTCC 2

RESULT 127
US-09-640-198D-20/c
; Sequence 20, Application US/09640198D
; Patent No. 6586411
; GENERAL INFORMATION:
; APPLICANT: Russell, Stephen
; APPLICANT: Kay Whye, Peng
; TITLE OF INVENTION: System for Monitoring the Location of
; FILE REFERENCE: Transgenes
; CURRENT APPLICATION NUMBER: US/09/640.198D
; CURRENT FILING DATE: 2000-08-16
; PRIOR FILING DATE: 1999-08-17
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-640-198D-20

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGAGATT 1733
Db 17 GTAGGCAGATGAAGATT 1

RESULT 128
US-09-639-667-16/c
; Sequence 16, Application US/09639667
; Patent No. 6632800
; GENERAL INFORMATION:
; APPLICANT: Russell, Stephen James
; APPLICANT: Peng, Kah Whye
; TITLE OF INVENTION: SYSTEM FOR MONITORING THE EXPRESSION OF
```

```
; TITLE OF INVENTION: TRANSGENES
; FILE REFERENCE: 07039-292001
; CURRENT APPLICATION NUMBER: US/09/639.667
; CURRENT FILING DATE: 2001-06-04
; PRIOR FILING DATE: 1999-08-17
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: cleavage signal
US-09-639-667-16

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGAGATT 1733
Db 17 GTAGGCAGATGAAGATT 1

RESULT 129
US-09-586-376-5
; Sequence 5, Application US/09586376
; Patent No. 6492115
; GENERAL INFORMATION:
; APPLICANT: Guida, Marco
; APPLICANT: Hall, Jeff
; TITLE OF INVENTION: GENETIC TYPING OF THE HUMAN CYTOCHROME P450 2A6 GENE
; FILE REFERENCE: 4389-20
; CURRENT APPLICATION NUMBER: US/09/586.376
; CURRENT FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-586-376-5-5

Query Match 8.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1634 TGGGGCTTGTAG 1645
Db 1 TGGGGCTTGTAG 12

RESULT 130
US-08-937-580-9
; Sequence 9, Application US/08937580
; Patent No. 6013510
; GENERAL INFORMATION:
; APPLICANT: Harris, James M.
; APPLICANT: You, Qimin
; TITLE OF INVENTION: Identification of a DNA Region
; TITLE OF INVENTION: Potentially Useful for the Detection of Mycobacterium
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Becton Dickinson and Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07417-6800
; COMPUTER READABLE FORM:
```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/937,580
; FILING DATE: 25-SEP-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3690/5510-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-847-7166
; TELEFAX: 201-848-9228
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
US-08-937-580-9

Query Match      8.6%  Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
Db 4 GGAGATGGAGAT 15

RESULT 131
US-09-336-039-9
; Sequence 9, Application US/09336039
; Patent No. 6291176
; GENERAL INFORMATION:
; APPLICANT: Harris, James M.
; You, Qimin
; TITLE OF INVENTION: Identification of a DNA Region
; Potentially Useful for the Detection of Mycobacterium
; kanasii
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Becton Dickinson and Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07417-6800
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/336,039
; FILING DATE: 18-Jun-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/937,580
; FILING DATE: 25-SEP-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3690/5510-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-847-7166
; TELEFAX: 201-848-9228
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-336-039-9

Query Match      8.6%  Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
Db 4 GGAGATGGAGAT 15

RESULT 132
US-08-310-501-4/c
; Sequence 4, Application US/08310501
; Patent No. 5567687
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Iverson, Brent
; APPLICANT: Jansen, Petra I.
; APPLICANT: Wright, Meredith
; APPLICANT: Mody, Tarak D.
; APPLICANT: Hemmi, Gregory W.
; TITLE OF INVENTION: Texaphyrins and Uses Thereof
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: US
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/310,501
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/112,872
; FILING DATE: 25-AUG-1993
; APPLICATION NUMBER: PCT/US94/06284
; FILING DATE: 09-JUN-1994
; APPLICATION NUMBER: US 07/822,964
; FILING DATE: 21-JAN-1992
; APPLICATION NUMBER: US 08/227,370
; FILING DATE: 14-APR-1994
; APPLICATION NUMBER: US 08/075,123
; FILING DATE: 09-JUN-1993
; APPLICATION NUMBER: US 07/822,964
; FILING DATE: 21-JAN-1992
; APPLICATION NUMBER: US 07/771,393
; FILING DATE: 30-SEP-1991
; APPLICATION NUMBER: US 07/539,975
; FILING DATE: 18-JUN-1990
; APPLICATION NUMBER: PCT/US90/01208
; FILING DATE: 06-MAR-1990
; APPLICATION NUMBER: US 07/320,293
; FILING DATE: 06-MAR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: PHAY:034/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577

```



```
;
; TELEX: n/a
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
US-08-310-501-4
Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1659 CCAGGCTCACAGCTG 1673
Db      15 CCGGCTCACAGATG 1

RESULT 133
US-08-469-177-4/c
; Sequence 4, Application US/08469177
; Patent No. 5607924
; GENERAL INFORMATION:
; APPLICANT: MAGDA, Darren
; APPLICANT: SESSLER, Jonathan L.
; APPLICANT: IVERSON, Brent L.
; APPLICANT: SANSOM, Petra I.
; APPLICANT: WRIGHT, Meredith
; TITLE OF INVENTION: DNA PHOTOCLEAVAGE USING TEXAPHYRINS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmacyclics, Inc.
; STREET: 995 East Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: United States of America
; ZIP: 94086
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,177
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PHAY:057
; TELEPHONE: (408) 774-3363
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "RNA"
US-08-469-177-4
Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1659 CCAGGCTCACAGCTG 1673
Db      15 CCGGCTCACAGATG 1

RESULT 134
US-08-484-551-1/c
; Sequence 1, Application US/08484551
; Patent No. 5714328
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; TITLE OF INVENTION: RNA PHOTOCLEAVAGE USING TEXAPHYRINS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,551
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: PHAY:047/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 747-7577
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-484-551-1
Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1659 CCAGGCTCACAGCTG 1673
Db      15 CCGGCTCACAGATG 1

RESULT 135
US-08-484-551-5/c
; Sequence 5, Application US/08484551
; Patent No. 5714328
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; TITLE OF INVENTION: RNA PHOTOCLEAVAGE USING TEXAPHYRINS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: United States of America
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,551
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: PRAY:047/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 747-7577
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "RNA"
US-08-484-551-5

Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACAGCTG 1673
DB 15 CCGGCTCACAGATG 1

RESULT 137
US-08-913-833-5
; Sequence 5, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 154
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,833
; FILING DATE: 15 Sep 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/00211
; FILING DATE: 17 Jan 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-913-833-5

Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 GTACCGAGATGAGA 1731
DB 1 GTACAGAGATGAAA 15

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,551
; FILING DATE: Concurrently herewith
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: PRAY:047/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000
; TELEFAX: (512) 747-7577
; TELEX: 79-0924
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "RNA"
US-08-484-551-5

Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACAGCTG 1673
DB 15 CCGGCTCACAGATG 1

RESULT 136
US-08-486-962-18/c
; Sequence 18, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Wright, Meredith
; APPLICANT: Ross, Kevin L.
; APPLICANT: Miller, Richard A.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir A.
; APPLICANT: Smith, Daniel A.
; TITLE OF INVENTION: METHOD OF PHOSPHATE ESTER HYDROLYSIS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmacyclics, Inc.
; STREET: 995 E. Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: USA
; ZIP: 94086-4521
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,962
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PRAY:053
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 774-0330
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
```

RESULT 138
US-09-580-794C-5
; Sequence 5, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; APPLICANT: Louwagie, Joost
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
; FILE REFERENCE: INNS008-2
; CURRENT APPLICATION NUMBER: US/09/580,794C
; CURRENT FILING DATE: 2000-05-30
; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
; PRIOR FILING DATE: 1997-09-15
; PRIOR APPLICATION NUMBER: PCT/EP 97/00211
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: EP 96870005.4
; PRIOR FILING DATE: 1996-01-26
; PRIOR APPLICATION NUMBER: EP 96870081.5
; PRIOR FILING DATE: 1996-06-25
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-580-794C-5

Query Match 8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1717 GTACGGAGATGGAGA 1731
Db 1 GTACAGAGATGGAAA 15

RESULT 139
US-09-813-781-48/c
; Sequence 48, Application US/09813781
; Patent No. 6405989
; GENERAL INFORMATION:
; APPLICANT: WEIDANZ, JON A.
; APPLICANT: CARD, KIMBERLYN F.
; APPLICANT: WONG, HING C.
; TITLE OF INVENTION: FUSION PROTEINS COMPRISING BACTERIOPHAGE COAT PROTEIN
; FILE REFERENCE: AND A SINGLE-CHAIN T-CELL RECEPTOR
; FILE REFERENCE: 46745(1758)
; CURRENT APPLICATION NUMBER: US/09/813,781
; CURRENT FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: oligonucleotide
US-09-813-781-48

Query Match 8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1656 GCACCGAGCTCACAG 1670
Db 15 GAACAGACTCACAG 1

RESULT 140
US-08-486-962-14/c
; Sequence 14, Application US/08486962
; Patent No. 5763172
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Sessler, Jonathan L.
; APPLICANT: Wright, Meredith
; APPLICANT: Ross, Kevin L.
; APPLICANT: Miller, Richard A.
; APPLICANT: Dow, William C.
; APPLICANT: Kral, Vladimir A.
; APPLICANT: Smith, Daniel A.
; TITLE OF INVENTION: METHOD OF PHOSPHATE ESTER HYDROLYSIS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmaclytics, Inc.
; STREET: 995 E. Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: USA
; ZIP: 94086-4521
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,962
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PHAY:053
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 774-0330
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-08-486-962-14

Query Match 8.5%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1655 AGCACCAGGCTCACA 1669
Db 15 AACACCGGCTCACA 1

RESULT 141
US-08-975-522A-6/c
; Sequence 6, Application US/08975522A
; Patent No. 6022959
; GENERAL INFORMATION:
; APPLICANT: Magda, Darren
; APPLICANT: Crofts, Shaun P.
; APPLICANT: Wright, Meredith
; TITLE OF INVENTION: NUCLEIC ACIDS INTERNALLY-
; TITLE OF INVENTION: DERIVATIZED WITH A TEXAPHYRIN
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmaclytics, Inc.
; STREET: 995 E. Arques Avenue

CITY: Sunnyvale
STATE: California
COUNTRY: USA
ZIP: 94085
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/975.522A
FILING DATE: No. 6022959 September 20, 1997
CLASSIFICATION: 536
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 499-6200
TELEFAX: (512) 499-6290
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-975-522A-6

Query Match 8.5%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1655 AGCACCAGGCTCAC 1669
DB 15 AACACCGGCTCAC 1

RESULT 142
US-08-432-871C-4
Sequence 4, Application US/08432871C
Patent No. 5877010
GENERAL INFORMATION:
APPLICANT: Loeb, Lawrence A.
APPLICANT: Black, Margaret E.
TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/432.871C
FILING DATE: 02-MAY-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.409C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-432-871C-4

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGGT 1700
DB 1 CCCCTCCAGCGCGGT 15

RESULT 143
US-08-985-162-338
Sequence 338, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1377
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985.162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 50/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-3440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-338

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGG 1699
DB 3 UCUCUCCAUCCUGG 17

RESULT 144
US-08-584-040-1876
Sequence 1876, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1876:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1876

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1745 CCTCCCTATCCTAA 1759
||:|:|:|:|:|:|
Db 3 CCUCUUUCCGAAA 17

RESULT 145
US-08-584-040-1877
; Sequence 1877, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1877:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1877

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1745 CCTCCCTATCCTAA 1759
||:|:|:|:|:|:|
Db 2 CCUCUUUCCGAAA 16

RESULT 146
US-09-270-956-4
; Sequence 4, Application US/09270956
; Patent No. 6451571
; GENERAL INFORMATION:
; APPLICANT: Loeb, Lawrence A.
; APPLICANT: Black, Margaret E.
; TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/270,956
; FILING DATE: 17-MAR-1999
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963

; REFERENCE/DOCKET NUMBER: 240052.409C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; TELEX: 3723836
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-270-956-4

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGGT 1700
| | | | | | | | | |
Db 1 CCCCTCCAGCGCGT 15

RESULT 147
US-09-474-432B-404/c
; Sequence 404, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-404

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCAGCTGG 1674
| | | | | | | | | |
Db 15 CGGGCGCACAGCTGG 1

RESULT 148
US-09-474-432B-504/c
; Sequence 504, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1525
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 504
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-504

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCAGCTGG 1674
| | | | | | | | | |
Db 17 CAGTCACACAGCTGG 3

RESULT 149
US-09-474-432B-505/c
; Sequence 505, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1525
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-505

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCAGCTGG 1674
| | | | | | | | | |
Db 15 CAGTCACACAGCTGG 1

```
RESULT 150
US-09-474-432B-513/c
; Sequence 513, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 513
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-513

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1660 CAGGCTCACAGCTGG 1674
Db      17  CGGGCGCACAGCTGG 3

RESULT 151
US-09-474-432B-549
; Sequence 549, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 549
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-549

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1660 CAGGCTCACAGCTGG 1674
Db      17  CGGGCGCACAGCTGG 3
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-549

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.4e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      1677 CCTCGGTGTCCTCTC 1691
Db      2  CCCUGAUGUGUCCUC 16

RESULT 152
US-09-371-772B-421
; Sequence 421, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-421

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1745 CTCCTCTATCCTAAA 1759
Db      3  CCUCUUUCCGAAA 17

RESULT 153
US-09-371-772B-422
; Sequence 422, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-422
```

```
; ORGANISM: Homo sapiens
US-09-371-772B-422

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1745 CCTCCCTATCTATAA 1759
Db 2 CCUCCUAUCCGAAA 16

RESULT 154
US-09-476-387-403/c
; Sequence 403, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-403

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCACAGCTGG 1674
Db 15 CGGGCCACAGCTGG 1

RESULT 155
US-09-476-387-503/c
; Sequence 503, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-403

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCACAGCTGG 1674
Db 15 CGGGCCACAGCTGG 1

RESULT 156
US-09-476-387-504/c
; Sequence 504, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 504
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-504

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCACAGCTGG 1674
Db 15 CAGTCACACAGCTGG 1

RESULT 157
US-09-476-387-512/c
; Sequence 512, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
```

```
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 503
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-503
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1660 CAGGCTCACAGCTGG 1674
Db 17 CAGTCACACAGCTGG 3
```

RESULT 156

```
US-09-476-387-504/c
; Sequence 504, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 504
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-504
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1660 CAGGCTCACAGCTGG 1674
Db 15 CAGTCACACAGCTGG 1
```

RESULT 157

```
US-09-476-387-512/c
; Sequence 512, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
```



```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-525

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 AGCAGAAGCAAGCA 1658
      ||||| |||||
Db 3 AGCAGATGACAAGCA 17

RESULT 161
US-09-866-108A-526
; Sequence 526, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-525
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-526

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 AGCAGAAGCAAGCA 1658
      ||||| |||||
Db 2 AGCAGATGACAAGCA 16

RESULT 162
US-09-866-108A-2351/c
; Sequence 2351, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
```

```
; SEQ ID NO 2351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2351

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1632 GATGGGCGCTGTAGC 1646
    |||| ||| |||||
Db 17 GATGCGGCGCTGTAGC 3

RESULT 163
US-09-866-108A-2352/c
; Sequence 2352, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2352

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1632 GATGGGCGCTGTAGC 1646
    |||| ||| |||||
Db 16 GATGCGGCGCTGTAGC 2

RESULT 164
US-09-866-108A-2353/c
; Sequence 2353, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2353

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1632 GATGGGCGCTGTAGC 1646
    |||| ||| |||||
Db 15 GATGCGGCGCTGTAGC 1

RESULT 165
US-09-866-108A-7829
; Sequence 7829, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2353

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1632 GATGGGCGCTGTAGC 1646
    |||| ||| |||||
Db 15 GATGCGGCGCTGTAGC 1
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7829
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7829

```

Query Match	8.5%	Score 11.8;	DB 1;	Length 17;
Best Local Similarity	86.7%	Pred. No. 1.4e+02;		
Matches 13; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
Db 3 AGCCTCACAGCTGAA 17

RESULT 166
US-09-866-108A-7830
; Sequence 7830, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188
 ; SEQ ID NO 7830
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo s
 US-09-866-108A-7830

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
Db 2 AGCCTCACAGCTGAA 16

RESULT 167
US-08-204-697-1
Sequence 1, Application US/08204697
Patent No. 5648482
GENERAL INFORMATION:
APPLICANT: Meyer, Urs A
TITLE OF INVENTION: DETECTION OF POOR METABOLIZERS OF DRUGS
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/204,697
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/716,500
FILING DATE: 17-JUN-1991
APPLICATION NUMBER: EP 90810467.2
FILING DATE: 22-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 91108867.2
FILING DATE: 29-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Schlager, John J.
REGISTRATION NUMBER: 20942
REFERENCE/DOCKET NUMBER: RAN 4095/3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-235-2363
TELEFAX: 201-235-3503
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-204-697-1

Query Match	8.5%;	Score 11.8;	DB 1;	Length 18;
Best Local Similarity	86.7%;	Pred. No. 1.5e+02;		
Matches 13: Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 1665 TCACAGCTGGAACCC 1679
Db 4 TCCCAGCTGGAATCC 18

RESULT 168
US-08-744-332-1
; Sequence 1, Application US/08744332
; Patent No. 5844108
; GENERAL INFORMATION:
; APPLICANT: Meyer, Urs A
; TITLE OF INVENTION: DETECTION OF POOR METABOLIZERS OF DRUGS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/744,332
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/716,500
; FILING DATE: 17-JUN-1991
; APPLICATION NUMBER: EP 90810467.2
; FILING DATE: 22-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 91108867.2
; FILING DATE: 29-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Schlager, John J.
; REGISTRATION NUMBER: 20942
; REFERENCE/DOCKET NUMBER: RAN 4095/3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-235-2863
; TELEFAX: 201-235-3500
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-744-332-1
Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1665 TCACAGCTGGAACCC 1679
Db 4 TCCAGCTGGAATCC 18
RESULT 169
US-09-161-244-66
; Sequence 66, Application US/09161244
; Patent No. 6004814
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cossett, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD71 EXPRESSION
; FILE REFERENCE: RTS-0007
; CURRENT APPLICATION NUMBER: US/09/161,244
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 91

; SEQ ID NO 66
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-244-66
Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1676 ACCTGGTGTCTCT 1690
Db 3 AACCTGGTATCTCT 17
RESULT 170
US-09-025-701-3/c
; Sequence 3, Application US/09025701
; Patent No. 6262337
; GENERAL INFORMATION:
; APPLICANT: VON EULER, Gabriel
; APPLICANT: AASE, Karin
; APPLICANT: BETHSHOLTZ, Christer
; APPLICANT: ERIKSSON, Ulf
; APPLICANT: PERNY, Milos
; APPLICANT: GEBRE-MEDHIN, Samuel
; APPLICANT: LI, Xuri
; TITLE OF INVENTION: TRANSGENIC ANIMAL WITH RECOMBINANT
; TITLE OF INVENTION: VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) DNA AND USES
; TITLE OF INVENTION: THEREOF
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Evenson, McKeown, Edwards & Lenahan, P.L.L.C.
; STREET: 1200 G Street, N.W., Suite 700
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,701
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/038,202
; FILING DATE: 18-FEB-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: EVANS, Joseph D
; REGISTRATION NUMBER: 26,269
; REFERENCE/DOCKET NUMBER: 1064/43342
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 628-8800
; TELEFAX: (202) 628-8844
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-025-701-3
Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1660 CAGGTCACAGCTGG 1674

Db 17 CAGTCACACAGCTGG 3
|||||

RESULT 171
US-09-045-301-3
; Sequence 3, Application US/09045301A
; Patent No. 6265388
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-045-301-3

Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATTGGC 1736
|||||

Db 4 GAGATGGTGGATGGC 18
|||||

RESULT 172
US-09-045-301-4/c
; Sequence 4, Application US/09045301A
; Patent No. 6265388
; GENERAL INFORMATION:
; APPLICANT: Olson, Karen W.
; APPLICANT: Feltt, James W.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/045,301A
; CURRENT FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-045-301-4

Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATTGGC 1736
|||||

Db 15 GAGATGGTGGATGGC 1
|||||

RESULT 173
US-09-205-995-10
; Sequence 10, Application US/09205995

; Patent No. 6368855
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/09/205,995
; CURRENT FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide corresponding to a specific region
; OTHER INFORMATION: of the mouse II gene.
US-09-205-995-10

Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1656 GCACCAGGCTCACAG 1670
|||||

Db 3 GCATCTGGCTCACAG 17
|||||

RESULT 174

US-09-422-978-6052/c
; Sequence 6052, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6052
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8626 for SEQ 2118,
US-09-422-978-6052

Query Match 8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTGG 1735
|||||

Db 18 GAAGTTGGAGATTGG 4
|||||

RESULT 175

Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Length	Mismatches	Indels	Gaps
US-09-747-391-20	Sequence 20, Application US/09747391	8.5%;	Score 11.8;	DB 1;	Length 18;		0;		0;
Patent No. 6670124	Sequence 106, Application US/09548797B	86.7%;	Pred. No. 1.5e+02;				0;		0;
GENERAL INFORMATION:	Patent No. 6683165								
APPLICANT: Chow, Robert	GENERAL INFORMATION:								
APPLICANT: Tonai, Richard	APPLICANT: Keith, Tim								
APPLICANT: StemCyte, Inc	TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND								
TITLE OF INVENTION: High Throughput Methods of HLA Typing	TITLE OF INVENTION: OBESITY								
FILE REFERENCE: 020035-000210US	FILE REFERENCE: 2976-4039								
CURRENT APPLICATION NUMBER: US/09/747,391	CURRENT APPLICATION NUMBER: US/09/548,797B								
CURRENT FILING DATE: 2001-07-13	CURRENT FILING DATE: 2002-11-26								
PRIOR APPLICATION NUMBER: US 60/172,768	PRIOR APPLICATION NUMBER: 60/129,391								
PRIOR FILING DATE: 1999-12-20	PRIOR FILING DATE: 1999-04-13								
NUMBER OF SEQ ID NOS: 278	NUMBER OF SEQ ID NOS: 170								
SOFTWARE: FastSeq for Windows Version 3.0	SOFTWARE: PatentIn Ver. 2.1								
SEQ ID NO 20	SEQ ID NO 106								
LENGTH: 18	LENGTH: 18								
TYPE: DNA	TYPE: DNA								
ORGANISM: Homo sapiens	ORGANISM: Artificial Sequence								
US-09-747-391-20	US-09-548-797B-106								
Query Match	Query Match								
Best Local Similarity	Best Local Similarity								
Mismatches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Mismatches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;								
QY 1653 CAGGACACCGGCTCA 1667	QY 1649 AAGGCAAGCACCAGG 1663								
Db 2 CAGGCGCCAGGCACA 16	Db 17 ATGGGAGCACCAGG 3								
RESULT 176	RESULT 177								
US-09-548-797B-106/c	US-08-544-381B-27/c								
Sequence 106, Application US/09548797B	Sequence 27, Application US/08544381B								
Patent No. 6683165	Patent No. 6027880								
GENERAL INFORMATION:	GENERAL INFORMATION:								
APPLICANT: KEITH, TIM	APPLICANT: Cronin, Maureen T.								
TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND	APPLICANT: Miyada, Charles Garrett								
TITLE OF INVENTION: OBESITY	APPLICANT: Hubbell, Earl A.								
FILE REFERENCE: 2976-4039	APPLICANT: Chee, Mark								
CURRENT APPLICATION NUMBER: US/09/548,797B	APPLICANT: Fodor, Stephen P.A.								
CURRENT FILING DATE: 2002-11-26	APPLICANT: Huang, Xiaohua C.								
PRIOR APPLICATION NUMBER: 60/129,391	APPLICANT: Lipshutz, Robert J.								
PRIOR FILING DATE: 1999-04-13	APPLICANT: Lobban, Peter E.								
NUMBER OF SEQ ID NOS: 170									
SOFTWARE: PatentIn Ver. 2.1									
SEQ ID NO 106									
LENGTH: 18									
TYPE: DNA									
ORGANISM: Artificial Sequence									
FEATURE:									
OTHER INFORMATION: Description of Artificial Sequence: Primer									
US-09-548-797B-106									
Query Match	Query Match								
Best Local Similarity	Best Local Similarity								
Mismatches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Mismatches 12; Conservative 0; Mismatches 1; Indels								
QY 1649 AAGGCAAGCACCAGG 1663	QY 1649 AAGGCAAGCACCACCA 1661								

APPLICANT: Morris, MacDonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes
TITLE OF INVENTION: for Analyzing Biotransformation Genes
NUMBER OF SEQUENCES: 156
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/778,794A
FILING DATE: 03-JAN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
APPLICATION NUMBER: WO PCT/US94/12305
FILING DATE: 26-OCT-1994
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
APPLICATION NUMBER: US 08/544,381
FILING DATE: 10-OCT-1995
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-015700US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0200
TELEX:
INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-778-794A-85

Query Match 8.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1649 AAGGCAAGCACCA 1661
Db 13 AGGCAAGCACCA 1

RESULT 179
US-09-922-445-17/c
Sequence 17, Application US/09922445
Patent No. 6528268
GENERAL INFORMATION:
APPLICANT: Andersson, Maria K.
APPLICANT: Berglund, Lars G. T.
APPLICANT: Reneland, Rikard H.
APPLICANT: Adam, Gail I. R.
TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
FILE REFERENCE: GG126US
CURRENT APPLICATION NUMBER: US/09/922,445
CURRENT FILING DATE: 2001-08-03
NUMBER OF SEQ ID NOS: 51
SOFTWARE: PatentIn version 3.1

SEQ ID NO 17
LENGTH: 13
TYPE: DNA
ORGANISM: synthetic
US-09-922-445-17

Query Match 8.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1662 GGCTCAGCTGG 1674
Db 13 GGCTCAGCTGG 1

RESULT 180
US-09-922-445-27
Sequence 27, Application US/09922445
Patent No. 6528268
GENERAL INFORMATION:
APPLICANT: Andersson, Maria K.
APPLICANT: Berglund, Lars G. T.
APPLICANT: Reneland, Rikard H.
APPLICANT: Adam, Gail I. R.
TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
FILE REFERENCE: GG126US
CURRENT APPLICATION NUMBER: US/09/922,445
CURRENT FILING DATE: 2001-08-03
NUMBER OF SEQ ID NOS: 51
SOFTWARE: PatentIn version 3.1
SEQ ID NO 27
LENGTH: 13
TYPE: DNA
ORGANISM: synthetic
US-09-922-445-27

Query Match 8.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1662 GGCTCAGCTGG 1674
Db 1 GGCTCAGCTGG 13

RESULT 181
US-08-913-833-9
Sequence 9, Application US/08913833
Patent No. 6087093
GENERAL INFORMATION:
APPLICANT: STUYVER, LIEVEN
APPLICANT: LOUWAGIE, JOOST
APPLICANT: ROSSAU, RUDI
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
NUMBER OF SEQUENCES: 164
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARNOLD, WHITE & DURKEE
STREET: P.O. BOX 4433
CITY: HOUSTON
STATE: TEXAS
COUNTRY: USA
ZIP: 77210-4433
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word 6.0 / ASCII text output
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/913,833
FILING DATE: 15 Sep 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP97/00211


```
/ FILING DATE: 17 Jan 1997
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 96870005.4
/ FILING DATE: 26 Jan 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 968700081.5
/ FILING DATE: 25 Jun 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: KAMMERER, PATRICIA A.
/ REGISTRATION NUMBER: 29,775
/ REFERENCE/DOCKET NUMBER: INNS:008
/ INFORMATION FOR SEQ ID NO: 9:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 14 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ HYPOTHEICAL: NO
/ ANTI-SENSE: NO
/ US-08-913-833-9

Query Match      8.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1717 GTACGAGATGGA 1729
Db 1 GTACAGAGATGGA 13

RESULT 182
US-09-580-794C-9
/ Sequence 9, Application US/09580794C
/ Patent No. 6331389
/ GENERAL INFORMATION:
/ APPLICANT: Stuyver, Lieven
/ APPLICANT: Louwaghe, Joost
/ APPLICANT: Rossau, Rudi
/ TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
/ FILE REFERENCE: INNS008-2
/ CURRENT APPLICATION NUMBER: US/09/580,794C
/ CURRENT FILING DATE: 2000-05-30
/ PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
/ PRIOR FILING DATE: 1997-09-15
/ PRIOR APPLICATION NUMBER: PCT/EP 97/00211
/ PRIOR FILING DATE: 1997-01-17
/ PRIOR APPLICATION NUMBER: EP 96870005.4
/ PRIOR FILING DATE: 1996-01-26
/ PRIOR APPLICATION NUMBER: EP 968700081.5
/ PRIOR FILING DATE: 1996-06-25
/ NUMBER OF SEQ ID NOS: 164
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 9
/ LENGTH: 14
/ TYPE: DNA
/ ORGANISM: Artificial sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Primer
/ US-09-580-794C-9

Query Match      8.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1717 GTACGAGATGGA 1729
Db 1 GTACAGAGATGGA 13

RESULT 183
US-08-111-076-17/c
```

```
/ Sequence 17, Application 08/111076
/ Patent No. 5470723
/ GENERAL INFORMATION:
/ APPLICANT: Walker, George T.
/ APPLICANT: Nadeau, James G.
/ APPLICANT: Nycz, Colleen M.
/ APPLICANT: Spears, Patricia A.
/ APPLICANT: Shank, Daryl S.
/ APPLICANT: Schram, James L.
/ APPLICANT: Jurgensen, Stewart R.
/ TITLE OF INVENTION: DETECTION OF MYCOBACTERIA BY MULTIPLEX
/ TITLE OF INVENTION: NUCLEIC ACID AMPLIFICATION
/ NUMBER OF SEQUENCES: 19
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
/ ADDRESSEE: Company
/ STREET: 1 Becton Drive
/ CITY: Franklin Lakes
/ STATE: NJ
/ COUNTRY: US
/ ZIP: 07417
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 08/111,076
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 073197
/ FILING DATE: 04-JUN-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 058648
/ FILING DATE: 05-MAY-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fugit, Donna R.
/ REGISTRATION NUMBER: 32,135
/ REFERENCE/DOCKET NUMBER: P-2894
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 201-847-7166
/ TELEFAX: 201-848-9228
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-111-076-17

Query Match      8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1658 ACCAGGCTCACAG 1670
Db 14 ACCAGGCTCACAG 2

RESULT 184
US-08-398-305-17/c
/ Sequence 17, Application US/08398305
/ Patent No. 5561044
/ GENERAL INFORMATION:
/ APPLICANT: Walker, George T.
/ APPLICANT: Nadeau, James G.
/ APPLICANT: Nycz, Colleen M.
/ APPLICANT: Spears, Patricia A.
/ APPLICANT: Shank, Daryl S.
/ APPLICANT: Schram, James L.
/ APPLICANT: Jurgensen, Stewart R.
/ TITLE OF INVENTION: DETECTION OF MYCOBACTERIA BY MULTIPLEX
```

```
; TITLE OF INVENTION: NUCLEIC ACID AMPLIFICATION
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/398,305
; FILING DATE: 03-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/111,076
; FILING DATE: 24-AUG-1993
; APPLICATION NUMBER: US 073197
; FILING DATE: 04-JUN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 058648
; FILING DATE: 05-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-2894
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-847-7166
; TELEFAX: 201-848-9228
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-398-305-17

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1658 ACCAGGCTCACAG 1670
DB 14 ACCAGGCTCACAG 2

RESULT 185
US-08-182-968A-452
; Sequence 452, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
```

```
; OPERATING SYSTEM: IEM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTG 1698
DB 3 CUCCUCCACGUG 15

RESULT 186
US-08-705-225-17/c
; Sequence 17, Application US/08705225
; Patent No. 5736365
; GENERAL INFORMATION:
; APPLICANT: Walker, George T.
; APPLICANT: Nadeau, James G.
; APPLICANT: Nycz, Colleen M.
; APPLICANT: Spears, Patricia A.
; APPLICANT: Shank, Daryl S.
; APPLICANT: Schram, James L.
; APPLICANT: Jurgensen, Stewart R.
; TITLE OF INVENTION: DETECTION OF MYCOBACTERIA BY MULTIPLEX
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/705,225
; FILING DATE: 29-AUG-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/111,076
; FILING DATE: 24-AUG-1993
; APPLICATION NUMBER: US 073197
; FILING DATE: 04-JUN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 058648
; FILING DATE: 05-MAY-1993
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-2894
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-847-7166
; TELEFAX: 201-848-9228
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-705-225-17
;
Query Match      8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1658 ACCAGGCTCACAG 1670
Db      14  ACCAGGCTCACAG 2
      ||||| ||||| |||||
;
RESULT 187
US-08-513-841-16
; Sequence 16, Application US/08513841
; Patent No. 5753481
; GENERAL INFORMATION:
; APPLICANT: Niwa, Mineo
; APPLICANT: Saito, Yoshimasa
; APPLICANT: Ishii, Yoshinori
; APPLICANT: Yoshida, Masaru
; APPLICANT: Suzuki, Hiromi
; TITLE OF INVENTION: No. 5753481 L-sorbose Dehydrogenase and No. 5753481 L-sorbi
; TITLE OF INVENTION: Dehydrogenase Obtained from Gluconobacter oxydans T-100
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Obion, Spivak, McClelland, Maier & Neustadt, P.C.
; STREET: 1755 Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS-DOS Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/513.841
; FILING DATE: 01-NOV-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: UK 9304700.9
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 241851/1993
; FILING DATE: 28-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: NORMAN F. OBLON
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 18-909-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: other nucleic acid (synthetic DNA)
;
US-08-513-841-16
;
Query Match      8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1724 GATGGAGATTGGC 1736
Db      2    GATGGAGATTGGC 14
      ||||| ||||| |||||
;
RESULT 188
US-08-696-834-17
; Sequence 17, Application US/08696834
; Patent No. 5834263
; GENERAL INFORMATION:
; APPLICANT: Niwa, Mineo
; APPLICANT: Saito, Yoshimasa
; APPLICANT: Ishii, Yoshinori
; APPLICANT: Yoshida, Masaru
; APPLICANT: Hayashi, Hiromi
; TITLE OF INVENTION: Method for Producing 2-keto-L-Gulonic Acid
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Obion, Spivak, McClelland, Maier & Neustadt,
; ADDRESSEE: P.C.
; STREET: 1755 Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE:
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/696.834
; FILING DATE: 24-SEP-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 28612/1994
; FILING DATE: 25-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME:
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid (synthetic DNA)
;
US-08-696-834-17
;
Query Match      8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1724 GATGGAGATTGGC 1736
Db      2    GATGGAGATTGGC 14
      ||||| ||||| |||||
;
RESULT 189
US-08-942-673-16
; Sequence 16, Application US/08942673
```

```
; Patent No. 5861292
; GENERAL INFORMATION:
; APPLICANT: Niwa, Mineo
; APPLICANT: Saito, Yoshimasa
; APPLICANT: Ishii, Yoshinori
; APPLICANT: Yoshida, Masaru
; APPLICANT: Suzuki, Hiromi
; TITLE OF INVENTION: No. 5861292el L-sorbose Dehydrogenase and No. 5861292el
; TITLE OF INVENTION: L-sorbose Dehydrogenase Obtained from Gluconobacter
; TITLE OF INVENTION: oxydans T-100
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
; STREET: 1755 Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS-DOS Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/942,673
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/513,841
; FILING DATE: 01-NOV-1995
; APPLICATION NUMBER: UK 9304700.9
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 241851/1993
; FILING DATE: 28-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: NORMAN F. OBLON
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 18-909-0 PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 16:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid (synthetic DNA)
; US-08-942-673-16

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1724 GATGAGATTGGC 1736
Db 2 GATGAGATTGGC 14

RESULT 190
US-08-774-306A-452
; Sequence 452, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; US-08-774-306A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTG 1698
Db 3 CUCCUCCAACGUG 15

RESULT 191
US-09-064-156A-452
; Sequence 452, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; US-08-774-306A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTG 1698
Db 3 CUCCUCCAACGUG 15

RESULT 191
US-09-064-156A-452
; Sequence 452, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; US-08-774-306A-452
```

```
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: linear
US-09-064-156A-452

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 1.3e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCTG 1698
Db 3 CUCUCCAAACGUG 15

RESULT 192
US-09-118-317-16
; Sequence 16, Application US/09118317
; Patent No. 6197562
; GENERAL INFORMATION:
; APPLICANT: Niwa, Mineo
; APPLICANT: Saito, Yoshimasa
; APPLICANT: Ishii, Yoshinori
; APPLICANT: Yoshida, Masaru
; APPLICANT: Suzuki, Hiromi
; TITLE OF INVENTION: No. 6197562el L-sorbose Dehydrogenase and No. 6197562el
; TITLE OF INVENTION: L-sorbose Dehydrogenase Obtained from Gluconobacter
; TITLE OF INVENTION: oxydans 1-100
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oblon, Spivak, McEllelland, Maier & Neustadt, P.C.
; STREET: 1755 Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS-DOS Editor
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/118,317
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 241851/1993
; FILING DATE: 28-SEP-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: NORMAN F. OBLON
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 18-909-0 PCT
```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid (synthetic DNA)
US-09-118-317-16

Query Match 8.2%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1724 GATGGAGATTGGC 1736
Db 2 GATGGAGATTGGC 14

RESULT 193
US-07-696-793A-18/c
; Sequence 18, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: Wordperfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-18

Query Match 8.2%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1699 GTGGAGTTGGGT 1711
Db 1 GTGGAGTTGGGT 1711
```

Db 16 GTGGAAGCTGGGT 4

RESULT 194
US-07-977-694-18/c
; Sequence 18, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Naeerabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 18:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-977-694-18

Query Match 8.2%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 GTGGAAGCTGGGT 1711
|||||
Db 16 GTGGAAGCTGGGT 4

RESULT 195
US-08-303-004-32
; Sequence 32, Application US/08303004
; Patent No. 5556955
; GENERAL INFORMATION:
; APPLICANT: Vergnaud, Gilles
; TITLE OF INVENTION: Process for Detection of New Polymor-
; TITLE OF INVENTION: phic Loci in an ADN Sequence, Nucleotide Sequences Forming
; TITLE OF INVENTION: Hybridisation Probes and Their Biological Applications
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oliff & Berridge
; STREET: P.O. Box 19928
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: U.S.A

ZIP: 22320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/303,004
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/931,311B
; FILING DATE: 19920818
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 28264
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6400
; TELEFAX: (703) 836-2787
; TELEX: 90-1799 PTO ALEX
; INFORMATION FOR SEQ ID NC: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-303-004-32

Query Match 8.2%; Score 11.4; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 AGCACCAGGCTCA 1667
|||||
Db 1 AGAACCAGGCTCA 13

RESULT 196
US-08-491-976-5/c
; Sequence 5, Application US/08491976
; Patent No. 5783416
; GENERAL INFORMATION:
; APPLICANT: Thim, Lars
; APPLICANT: NO. 5783416ris, Kjeld
; APPLICANT: NO. 5783416ris, Fanny
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Christensen, Mogens
; APPLICANT: Nielsen, Per F.
; TITLE OF INVENTION: Human Spasmodytic Polypeptide in
; TITLE OF INVENTION: Glycosylated Form
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5783416o No. 5783416disk of No. 5783416th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/491,976
; FILING DATE: 02-AUG-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lambiris, Elias J.

REGISTRATION NUMBER: 33,728
REFERENCE/DOCKET NUMBER: 3951.204-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-491-976-5

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1677 CCTGTGTCCTCC 1689
|||||
DB 14 CCTGTGTCCTCC 2

RESULT 197

US-08-985-162-299
Sequence 299, Application US/08985162
Patent No. 6057156

GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fast-SEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162

FILING DATE: 04 December 1997

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/036,476

FILING DATE: 31 January 1997

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 230/107

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 299:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-985-162-299

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCCA 1741
||:||||:||||
DB 5 AUAUGGCCUCCCA 17

RESULT 198

US-09-187-946-16/c
Sequence 16, Application US/09187946
Patent No. 6255467

GENERAL INFORMATION:
APPLICANT: Lindner, Luther E.
APPLICANT: Macphree, Kathleen
TITLE OF INVENTION: Human Blood Bacterium
FILE REFERENCE: D6026
CURRENT APPLICATION NUMBER: US/09/187,946
CURRENT FILING DATE: 1998-11-02
EARLIER APPLICATION NUMBER: US 60/064,472
EARLIER FILING DATE: 1997-11-06
NUMBER OF SEQ ID NOS: 20
SEQ ID NO 16
LENGTH: 17

TYPE: DNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: primer bind

OTHER INFORMATION: primer specific for intergenic spacer region (IGS)
OTHER INFORMATION: sequence of a new human blood bacterium
US-09-187-946-16

Query Match

Best Local Similarity 8.2%; Score 11.4; DB 1; Length 17;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGAAGTGGG 1710
|||||
DB 16 GGTGAAGTGGG 4

RESULT 199

US-09-564-805-88/c
Sequence 88, Application US/09564805
Patent No. 6333403

GENERAL INFORMATION:

APPLICANT: Tavtigian, Sean V.

APPLICANT: Teng, David H.F.

APPLICANT: Simard, Jacques

APPLICANT: Rommens, Johanna M.

APPLICANT: Myriad Genetics, Inc.

TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
TITLE OF INVENTION: Gene and a Patalog and Orthologous Genes

FILE REFERENCE: 2318-258

CURRENT APPLICATION NUMBER: US/09/564,805

CURRENT FILING DATE: 2000-05-05

PRIOR APPLICATION NUMBER: US 60/107,468

PRIOR FILING DATE: 1998-11-06

PRIOR APPLICATION NUMBER: 09/434,382

PRIOR FILING DATE: 1999-11-05

NUMBER OF SEQ ID NOS: 240

SOFTWARE: Patent in Ver. 2.0

SEQ ID NO 88

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-564-805-88

Query Match

Best Local Similarity 8.2%; Score 11.4; DB 1; Length 17;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 1657 CACCAGGCTCACA 1669
Db 17 CACCAGGCTGACA 5

RESULT 200
US-08-584-040-2852
; Sequence 2852, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2852:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2852

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCT 1737
Db 1 AUGGAUAUUGGCU 13
; :|||:|:|:|:
; :|||:|:|:|:

RESULT 202
US-08-679-645-53/c
; Sequence 53, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent B.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2852:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2852

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCT 1737
Db 3 AUGGAUAUUGGCU 15
; :|||:|:|:|:
; :|||:|:|:|:

RESULT 201
US-08-584-040-2853
; Sequence 2853, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
```



```
; ADDRESS: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 53:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-679-645-53
```

```
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1636 GCGCTTGACGAC 1648
Db 16 GCGCTTGACGAC 4
```

```
RESULT 203
US-09-474-432B-460
; Sequence 460, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 460
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-460
```

```
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1663 GCTCACAGCTGGA 1675
Db 2 GCUCACUGCUGGA 14
```

RESULT 204

```
US-09-371-772B-1376
; Sequence 1376, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1376
```

```
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1725 ATGGAGATTGGCT 1737
Db 3 AUGGAUAUUGGCU 15
```

RESULT 205

```
US-09-371-772B-1377
; Sequence 1377, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 1377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1377

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.7e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCT 1737
Db 1 AUGGAUUAUGGCU 13

RESULT 206
US-09-371-772B-4992/c
; Sequence 4992, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4992

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676
Db 17 CCCACAGCTGGAA 5

RESULT 207
US-09-476-387-459
; Sequence 459, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MEHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
```

```
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 459
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-459

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.7e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GTCACAGCTGGA 1675
Db 2 GCUCACUCGUGGA 14

RESULT 208
US-09-401-063-299
; Sequence 299, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saqhir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 299:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-299
```

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCCA 1741
|:|:|:|:|:
Db 5 AUAUUGGCCUCCA 17

RESULT 209
US-09-866-108A-7827
; Sequence 7827, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7827
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7827

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCCA 1741
|:|:|:|:|:
Db 5 AUAUUGGCCUCCA 17

RESULT 210
US-09-866-108A-7828
; Sequence 7828, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

QY 1661 AGGCTCAGCTG 1673
|:|:|:|:|:
Db 5 AGCCTCAGCTG 17

RESULT 210
US-09-866-108A-7828
; Sequence 7828, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7828
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7828

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCAGCTG 1673
|:|:|:|:|:
Db 4 AGCCTCAGCTG 16

RESULT 211
US-08-222-177A-434/c
; Sequence 434, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dG-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Demitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562

```
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 434:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-222-177A-434

Query Match      8.2%; Score 11.4; DB 1; Length 20;
Best Local Similarity 92.3%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1735 GCTCCCACTCT 1747
Db 13 GCTCCTAACTCT 1

RESULT 212
US-07-696-793A-7/c
; Sequence 7, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-9

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCTGCTG 1684
Db 16 AGGTGGAAGCTTGCTG 1

RESULT 214
US-07-977-694-7/c
; Sequence 7, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,694
FILING DATE: 19921117
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Stacey R. Sias, Ph.D.
REGISTRATION NUMBER: 32,630
REFERENCE/DOCKET NUMBER: 8733
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2863
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-977-694-7

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGT 1685
DB 16 GGTGGAAGCTGGTGT 1

RESULT 215
US-07-977-694-9/c
; Sequence 9, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,694
FILING DATE: 19921117
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:

NAME: Stacey R. Sias, Ph.D.
REGISTRATION NUMBER: 32,630
REFERENCE/DOCKET NUMBER: 8733
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2863
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-977-694-9

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCTGGTG 1684
DB 16 AGGTGGAAGCTGGTG 1

RESULT 216
US-08-872-917-11/c
; Sequence 11, Application US/08872917
; Patent No. 6096549
; GENERAL INFORMATION:
; APPLICANT: PELICIC, Vladimir
; APPLICANT: REYRAT, Jean-Marc
; APPLICANT: GICQUEL, Brigitte
; TITLE OF INVENTION: METHOD OF SELECTION OF ALLELIC EXCHANGE MUTANTS
; FILE REFERENCE: 03495.0148-01
; CURRENT APPLICATION NUMBER: US/08/872,917
; CURRENT FILING DATE: 1997-07-11
; EARLIER APPLICATION NUMBER: 08/661,658
; EARLIER FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Mycobacterium sp.
US-08-872-917-11

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1754 CCTAAAGGCCCACTGG 1769
DB 16 CCTAATGGCCTAATGG 1

RESULT 217
US-09-371-772B-5657/c
; Sequence 5657, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040

```
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5657
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5657

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGACCCCTG 1681
DB 16 CACAGCAGGACCCCGG 1

RESULT 218
US-09-371-772B-5658/c
; Sequence 5658, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5658
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5658

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGACCC 1678
DB 16 GCGCACAGCAGGACCC 1

RESULT 219
US-09-371-772B-5954/c
; Sequence 5954, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
```

```
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5954

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1676
DB 16 AGGCTCACAGCTGGA 1

RESULT 220
US-09-479-005A-154/c
; Sequence 154, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 154
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-154

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACCAGCTCACA 1669
DB 16 AAGCTCAAGGTTTACA 1

RESULT 221
US-07-696-793A-2/c
; Sequence 2, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/07/696,793A
FILING DATE: 19910507
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kevin R. Kaster
REGISTRATION NUMBER: 32704
REFERENCE/DOCKET NUMBER: 2598
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 420-3444
TELEFAX: (415) 658-5239
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-696-793A-2

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGT 1685
DB 17 GGTGGAAGCTGGTGT 2

RESULT 222
US-07-696-793A-3/c
Sequence 3, Application US/07696793A
Patent No. 5220004
GENERAL INFORMATION:
APPLICANT: Saiki, Randall K.
APPLICANT: Nasarabadi, Shanavaz L.
TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cetus Corporation
STREET: 1400 Fifty-Third Street
CITY: Emeryville
STATE: California
COUNTRY: U.S.A.
ZIP: 94608
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/696,793A
FILING DATE: 19910507
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kevin R. Kaster
REGISTRATION NUMBER: 32704
REFERENCE/DOCKET NUMBER: 2598
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 420-3444
TELEFAX: (415) 658-5239
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid
US-07-696-793A-3

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TCGAACCTGGTGTCT 1687
DB 17 TCGAAGCTGGTGTGT 2

RESULT 223
US-07-696-793A-24/c
Sequence 24, Application US/07696793A
Patent No. 5220004
GENERAL INFORMATION:
APPLICANT: Saiki, Randall K.
APPLICANT: Nasarabadi, Shanavaz L.
TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cetus Corporation
STREET: 1400 Fifty-Third Street
CITY: Emeryville
STATE: California
COUNTRY: U.S.A.
ZIP: 94608
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/696,793A
FILING DATE: 19910507
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kevin R. Kaster
REGISTRATION NUMBER: 32704
REFERENCE/DOCKET NUMBER: 2598
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 420-3444
TELEFAX: (415) 658-5239
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-696-793A-24

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGT 1685
DB 17 GGTGGAATCTGGTGT 2

RESULT 224
US-07-696-793A-25/c
Sequence 25, Application US/07696793A
Patent No. 5220004
GENERAL INFORMATION:
APPLICANT: Saiki, Randall K.
APPLICANT: Nasarabadi, Shanavaz L.

```
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
;
; TITLE OF INVENTION: Typing
;
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
;
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
;
; US-07-696-793A-25
;
; Query Match 8.1%; Score 11.2; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 1.9e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
; QY 1672 TGGAAACCCCTGGTGCT 1687
; Db 17 TGGAACTCTGGTGCT 2
;
; RESULT 225
; US-07-696-793A-26/c
; Sequence 26, Application US/07696793A
; Patent No. 5220004
;
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
;
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
;
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
;
; US-07-696-793A-26
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
;
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
;
; US-07-696-793A-26
;
; Query Match 8.1%; Score 11.2; DB 1; Length 17;
; Best Local Similarity 82.2%; Pred. No. 1.9e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
; QY 1672 TGGAAACCCCTGGTGCT 1687
; Db 17 TGGAACTCTGGTGCT 2
;
; RESULT 226
; US-07-696-793A-28
; Sequence 28, Application US/07696793A
; Patent No. 5220004
;
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
;
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
;
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
;
; US-07-696-793A-28
```


Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGCT 1687
DB 2 TGGAACTCTGGTGCT 17

RESULT 227
US-07-696-793A-29
; Sequence 29, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; APPLICATION DATA:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-29

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGCT 1685
DB 1 GGTGGAATCTGGTGCT 16

RESULT 228
US-07-977-694-2/c
; Sequence 2, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-977-694-2

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGCT 1685
DB 17 GGTGGAAGCTTGCTGT 2

RESULT 229
US-07-977-694-3/c
; Sequence 3, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:

Query Match	8.1%;	Score 11.2;	DB 1;	Length 17;
Best Local Similarity	81.2%;	Pred. No. 1.9e+02;		
Matches	12.	Conservative	0.	Mismatches 3;
			Indels	0;
			Gaps	0;

```
/ CITY: Nutley
/ STATE: New Jersey
/ COUNTRY: U.S.A.
/ ZIP: 07110-1199
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/977,694
/ FILING DATE: 19921117
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stacey R. Sias, Ph.D.
/ REGISTRATION NUMBER: 32,630
/ REFERENCE/DOCKET NUMBER: 8733
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 26:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-26

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGCT 1687
Db 17 TGGAACTTGGTGCT 2

RESULT 233
US-07-977-694-28
/ Sequence 28, Application US/07977694
/ Patent No. 5273883
/ GENERAL INFORMATION:
/ APPLICANT: Saiki, Randall K.
/ APPLICANT: Nasarabadi, Shanavaz L.
/ TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
/ TITLE OF INVENTION: Typing
/ NUMBER OF SEQUENCES: 58
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hoffmann-La Roche Inc.
/ STREET: 340 Kingsland Street
/ CITY: Nutley
/ STATE: New Jersey
/ COUNTRY: U.S.A.
/ ZIP: 07110-1199
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/977,694
/ FILING DATE: 19921117
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stacey R. Sias, Ph.D.
/ REGISTRATION NUMBER: 32,630
/ REFERENCE/DOCKET NUMBER: 8733
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 29:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-29

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGCT 1687
Db 17 TGGAACTTGGTGCT 2
```

```
/ REFERENCE/DOCKET NUMBER: 8733
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 28:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-28

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGCT 1687
Db 2 TGGAACTTGGTGCT 17

RESULT 234
US-07-977-694-29
/ Sequence 29, Application US/07977694
/ Patent No. 5273883
/ GENERAL INFORMATION:
/ APPLICANT: Saiki, Randall K.
/ APPLICANT: Nasarabadi, Shanavaz L.
/ TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
/ TITLE OF INVENTION: Typing
/ NUMBER OF SEQUENCES: 58
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hoffmann-La Roche Inc.
/ STREET: 340 Kingsland Street
/ CITY: Nutley
/ STATE: New Jersey
/ COUNTRY: U.S.A.
/ ZIP: 07110-1199
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/977,694
/ FILING DATE: 19921117
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stacey R. Sias, Ph.D.
/ REGISTRATION NUMBER: 32,630
/ REFERENCE/DOCKET NUMBER: 8733
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 29:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-29

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGAACCTGGTGCT 1685
Db 17 TGGAACTTGGTGCT 17
```

DB 1 GGTGGAATCTTGGTGT 16

RESULT 235
US-08-255-264-25
; Sequence 25, Application US/08255264
; Patent No. 5643724
; GENERAL INFORMATION:
; APPLICANT: Filides, Nicola J.
; APPLICANT: Reynolds, Rebecca L.
; TITLE OF INVENTION: Methods and Reagents for Glycophorin A
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingeland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/255.264
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry Ph.D., Douglas A.
; REGISTRATION NUMBER: 35,321
; REFERENCE/DOCKET NUMBER: 8865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2974
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-255-264-25

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGACCTGGTGT 1685
DB 1 GGTGGAATCTTGGTGT 16

RESULT 236
US-08-373-124A-1363/c
; Sequence 1363, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1670 GCTGGACCTGGTGT 1685
DB 1 GGTGGAATCTTGGTGT 16

RESULT 237
US-08-612-986-16
; Sequence 16, Application US/08612986
; Patent No. 5770384
; GENERAL INFORMATION:
; APPLICANT: Elliot J. Androphy
; APPLICANT: Dave E. Breiding
; TITLE OF INVENTION: E2 BINDING PROTEINS
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lahive & Cockfield
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/612,986
; FILING DATE:
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: 08/361,806
; FILING DATE: 22 DEC 1994

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1715 GAGTACGGAGATGGAG 1730
DB 16 GAGAGCTGAGATGGAG 1

US-08-373-124A-1363

COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1363:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-373-124A-1363

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1715 GAGTACGGAGATGGAG 1730
DB 16 GAGAGCTGAGATGGAG 1

US-08-373-124A-1363

```

; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Myers, Paul L. 35,965
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: NEP-004DV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-612-986-16

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1691 CCAGCGTGGTGAAGT 1706
Db 1 CCAGCGTGGTAGAGT 16

RESULT 238
US-08-361-806A-16
; Sequence 16, Application US/08361806A
; Patent No. 5792833
; GENERAL INFORMATION:
; APPLICANT: Elliot J. Androphy
; APPLICANT: Dave E. Breiding
; TITLE OF INVENTION: E2 BINDING PROTEINS
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lahive & Cockfield
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/361,806A
; FILING DATE: 22 DEC 1994
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Myers, Paul L.
; REGISTRATION NUMBER: 35,965
; REFERENCE/DOCKET NUMBER: NEP-004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-361-806A-16

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1691 CCAGCGTGGTGAAGT 1706

```

```

Db 1 CCAGCGTGGTAGAGT 16

RESULT 239
US-08-435-628-1363/c
; Sequence 1363, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1363:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1363

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1715 GAGTACGAGATCGAG 1730
Db 16 GAGAGCTGAGATGGAG 1

RESULT 240
US-08-292-620A-1670/c
; Sequence 1670, Application US/08292620A

```

Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1670:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1670

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTTGGGTTAGGAGTA 1719
Db 17 AGGTGGGTGAGGGGTA 2

RESULT 241
US-08-292-620A-1974/c
Sequence 1974, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1974:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1974

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTTGGGTTAGGAGTA 1719
Db 17 AGGTGGGTGAGGGGTA 2

RESULT 242
US-08-985-162-300
Sequence 300, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
OF DISEASES OR CONDITIONS RELATED
TO LEVELS OF EPIDERMAL GROWTH
FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

```
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ CLASSIFICATION: 514
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/
/ INFORMATION FOR SEQ ID NO: 371:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-985-162-371
/
/ Query Match      8.1%; Score 11.2; DB 1; Length 17;
/ Best Local Similarity 62.5%; Pred. No. 1.9e+02;
/ Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
/
/ QY 1731 ATTGGCTCCCAACTCC 1746
/      |::|||::|||
/ Db 2 AUGGCUCCCAAGUACC 17
/
/ RESULT 243
/ US-08-985-162-371/c
/ Sequence 371, Application US/08985162
/ Patent No. 6057156
/
/ GENERAL INFORMATION:
/ APPLICANT: Akhtar, Saghir
/ APPLICANT: Fell, Patricia
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
/ TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
/ TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
/ TITLE OF INVENTION: FACTOR RECEPTORS
/ NUMBER OF SEQUENCES: 1877
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/985,162
/ FILING DATE: 04 December 1997
/ CLASSIFICATION: 514
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/068,737
/ FILING DATE: 24-DEC-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Ihnen, Jeffrey L.
/ REGISTRATION NUMBER: 28,957
/ REFERENCE/DOCKET NUMBER: 2314-133
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-783-6031
/ TELEFAX: 202-783-6040
/
/ INFORMATION FOR SEQ ID NO: 28:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "oligomer for colony
/ DESCRIPTION: hybridization"
/
/ US-09-061-026-28
```

```
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ CLASSIFICATION: 514
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/
/ INFORMATION FOR SEQ ID NO: 300:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-985-162-300
/
/ Query Match      8.1%; Score 11.2; DB 1; Length 17;
/ Best Local Similarity 62.5%; Pred. No. 1.9e+02;
/ Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
/
/ QY 1694 GCGTGGTGGAGTTGG 1709
/      |||||
/ Db 17 GCACGGTAGAGTTGG 2
/
/ RESULT 244
/ US-09-061-026-28/c
/ Sequence 28, Application US/09061026
/ Patent No. 6077934
/
/ GENERAL INFORMATION:
/ APPLICANT: Jacobsen, Richard
/ APPLICANT: Olivera, Baldomero M.
/ TITLE OF INVENTION: Contryphan Peptides
/ NUMBER OF SEQUENCES: 29
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P.C.
/ STREET: 755 Thirteenth Street N.W., Suite 701-E
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20004
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/061,026
/ FILING DATE:
/ CLASSIFICATION:
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/068,737
/ FILING DATE: 24-DEC-1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Ihnen, Jeffrey L.
/ REGISTRATION NUMBER: 28,957
/ REFERENCE/DOCKET NUMBER: 2314-133
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-783-6031
/ TELEFAX: 202-783-6040
/
/ INFORMATION FOR SEQ ID NO: 28:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "oligomer for colony
/ DESCRIPTION: hybridization"
/
/ US-09-061-026-28
```

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.9e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCTGGTGT 1685
DB 15 GGARCCNTGGTGY 3

RESULT 245
US-08-827-036A-12
; Sequence 12, Application US/08827036A
; Patent No. 6080727
; GENERAL INFORMATION:
; APPLICANT: Gabriella Zupi
; TITLE OF INVENTION: Oligonucleotide Treatments and
; TITLE OF INVENTION: Compositions for Human Melanoma
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSER: James A. Bradburne, Ph.D.
; STREET: 5 Palo Alto Square,
; STREET: 3000 El Camino Real
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/827,036A
; FILING DATE: 03/25/97
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: USSN 60/014,089
; FILING DATE: 26-MAR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: James A. Bradburne, Ph.D.
; REGISTRATION NUMBER: 38,389
; REFERENCE/DOCKET NUMBER: LYNN-031/01US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 843-5095
; TELEFAX: (650) 857-0663
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-827-036A-12

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1731 ATTGGCTCCCACTCC 1746
DB 2 ATTGTTTCCCACTCC 17

RESULT 246
US-09-071-845-1670/c
; Sequence 1670, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTTGGTTAGGAGTA 1719
DB 17 AGTGGGTGAGGGGTA 2

RESULT 247
US-09-071-845-1974/c
; Sequence 1974, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:


```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1974:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1974

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTGGGTTAGGATTA 1719
Db 17 AGGTGGGTGAGGGGTA 2

RESULT 248
US-09-466-138-28/c
; Sequence 28, Application US/09466138
; Patent No. 6153738
; GENERAL INFORMATION:
; APPLICANT: Jacobsen, Richard
; APPLICANT: Olivera, Baldomero M.
; TITLE OF INVENTION: Contryphan Peptides
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz, P.C.
; STREET: 755 Thirteenth Street N.W., Suite 701-E
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/466,138
; FILING DATE:

```

```

; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/061,026
; FILING DATE:
; APPLICATION NUMBER: US 60/068,737
; FILING DATE: 24-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Innen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 2314-133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "oligomer for colony
; DESCRIPTION: hybridization"
; US-09-466-138-28

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 1.9e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGGTGT 1685
Db 15 GGARCCNTGGTGY 3

RESULT 249
US-09-215-221-7/c
; Sequence 7, Application US/09215221
; Patent No. 6265562
; GENERAL INFORMATION:
; APPLICANT: EILERS, MARTIN
; APPLICANT: BUERGIN, ANDREA
; APPLICANT: SEDLACEK, HANS-HARALD
; TITLE OF INVENTION: NUCLEIC ACID CONSTRUCTS WHOSE ACTIVITY IS AFFECTED BY
; TITLE OF INVENTION: INHIBITORS OF CYCLIN-DEPENDANT KINASES AND USES THEREOF
; FILE REFERENCE: 026083/0192
; CURRENT APPLICATION NUMBER: US/09/215,221
; CURRENT FILING DATE: 1998-12-18
; PRIOR APPLICATION NUMBER: 197 56 975.7
; PRIOR FILING DATE: 1997-12-20
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
; US-09-215-221-7

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1734 GGCTCCCAACTCCTCC 1749
Db 17 GCCTCCCAACACTGC 2

RESULT 250
US-08-424-991B-10
; Sequence 10, Application US/08424991B
; Patent No. 6323184
; GENERAL INFORMATION:

```

APPLICANT: Yi Shi and Andrew Zalewski
TITLE OF INVENTION: Arteriovenous and Venous Graft
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: John D. Mendlein, Ph.D.
STREET: Five Palo Alto Square
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 3.1/DOS 5.0
SOFTWARE: Microsoft Word for Windows, vers.
SOFTWARE: 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/424,991B
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT Application US94/11853
FILING DATE: October 17, 1994
ATTORNEY/AGENT INFORMATION:
NAME: John D. Mendlein, Ph.D.
REGISTRATION NUMBER: 38,770
REFERENCE/DOCKET NUMBER: LYNX-014/02US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 843-5020
TELEFAX: (415) 857-0663
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-424-991B-10
Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1731 ATTGGCTCCCACTCC 1746
Db 2 ATTGTTTCCCACTCC 17
RESULT 251
US-08-584-040-1477/c
Sequence 1477, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1477:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1477
Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1666 CACAGCTGGAACCTG 1681
Db 17 CACAGCAGGACCCCG 2
RESULT 252
US-08-584-040-2237/c
Sequence 2237, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:

```
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/064
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 2237:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-584-040-2237

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGAA 1676
Db 16 AGGTCAGAGCTGGGA 1

RESULT 253
US-08-584-040-5698/c
; Sequence 5698, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5698:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-5698

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCTG 1681
Db 17 CCAGCAGAAACCTG 2

RESULT 254
US-08-584-040-6055/c
; Sequence 6055, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6055:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-6055

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCTG 1681
Db 17 CCAGCAGAAACCTG 2
```

Page 52

Page 52

ATTORNEY/AGENT INFORMATION:
NAME: SANDERCOCK, Colin G.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 026083/0180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-025-343-3

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1734 GGCTCCCAACTCTCC 1749
Db 17 GCCTCCCAACCTGC 2

RESULT 259

US-09-474-432B-580
Sequence 580, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
FILE REFERENCE: MSHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 580
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-580

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1677 CCTGGTGTCTCTCC 1692
Db 1 CGUGGGGCUCCUCC 16

RESULT 260

US-09-371-772B-22/c
Sequence 22, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 687:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-687

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1733 TGGTCCCAACTCTC 1748
Db 17 TGGTCCCAACACTC 2

RESULT 258

US-09-025-343-3/c
Sequence 3, Application US/09025343
Patent No. 6380170
GENERAL INFORMATION:

APPLICANT: MUELLER, Rolf
LIU, Ningshu
ZWICKER, Joerk
SEDLACEK, Hans-Harald
TITLE OF INVENTION: NUCLEIC ACID CONSTRUCT FOR THE CELL
CYCLE REGULATED EXPRESSION OF STRUCTURAL GENES
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: FOLEY & LARDNER
STREET: 3000 K Street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/025,343
FILING DATE: 18-Feb-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 97 102 547.3
FILING DATE: 18-FEB-1997

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 22
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-22

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
DB 17 CACAGCAGGAGCCCGG 2

RESULT 261
US-09-371-772B-782/c
Sequence 782, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 782
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-782

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCAGCTGGAA 1676
DB 16 AGGCTCAGCTGGGA 1

RESULT 262
US-09-371-772B-2582/c
Sequence 2582, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
FILE REFERENCE: MBH00,875-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2582
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-2582

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1642 GTAGCAGAGGCAAGC 1657
DB 16 GCATCATAGGCAAGC 1

RESULT 263
US-09-371-772B-2892/c
Sequence 2892, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2892
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-2892

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
DB 17 CCCAGCAGAAACCCCTG 2

RESULT 264
US-09-371-772B-2893/c
Sequence 2893, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

```
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 2893
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Mus sp.
US-09-371-772B-2893

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAAACCCCTG 1681
Db 16 CCCAGCAGAACCCCTG 1

RESULT 265
US-09-371-772B-2911
/ Sequence 2911, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyne Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 2911
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Mus sp.
US-09-371-772B-2911

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.9e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCCCTAT 1753
Db 2 CCCAGUCCUAGU 17

RESULT 266
US-09-371-772B-4204/c
/ Sequence 4204, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyne Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
```

```
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4204
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-4204

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAAACCCCTG 1681
Db 16 CACAGCAGGACCCGG 1

RESULT 267
US-09-371-772B-4205/c
/ Sequence 4205, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyne Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 4205
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-4205

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAAACCC 1679
Db 17 CGCACAGCAGGACCC 2

RESULT 268
US-09-371-772B-5053/c
/ Sequence 5053, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyne Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
```

APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5053

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACCAGGCTCACA 1669
Db 17 AAGCAGCTGGCTCCCA 2

RESULT 269
US-09-371-772B-5054/c
; Sequence 5054, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5054

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACCAGGCTCACA 1669
Db 16 AAGCAGCTGGCTCCCA 1

RESULT 270
US-09-371-772B-5167/c
; Sequence 5167, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5167

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGAA 1676
Db 17 AGGCTCACAGCTGGGA 2

RESULT 271
US-09-476-387-579
; Sequence 579, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-579

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGGTGTCTCTCC 1692
Db 1 CGCUGGGGCGCUCUCC 16

RESULT 272
US-09-401-063-300
; Sequence 300, Application US/09401063
; Patent No. 6623962


```

;
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 300:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-300

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1731 ATTGGCTCCCACTCC 1746
      |||:|||||
Db 2 AATGGCUCCAGUACC 17

RESULT 273
US-09-401-063-371/c
; Sequence 371, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 300:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-300
```

```

;
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 371:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-371

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1694 GCCTGGTGAAGTTGG 1709
      |||:|||||
Db 17 GCACGTAGAAGTTGG 2

RESULT 274
US-09-554-726A-24/c
; Sequence 24, Application US/09554726A
; Patent No. 664369
; GENERAL INFORMATION:
; APPLICANT: HERRMANN, Bernhard
; APPLICANT: KOSCHORZ, Birgit
; APPLICANT: KISPERT, Andreas
; TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATIONS
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 258.0009 0101
; CURRENT APPLICATION NUMBER: US/09/554,726A
; CURRENT FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: PCT/EP 98/07395
; PRIOR FILING DATE: 1998-11-18
; PRIOR APPLICATION NUMBER: EP 98 10 3596.7
; PRIOR FILING DATE: 1998-03-02
; PRIOR APPLICATION NUMBER: EP 97 12 0190.0
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; US-09-554-726A-24
```

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 TCCAGCGTGGTGAG 1705
DB 16 TCCAGCCAGGGGAAG 1

RESULT 275
US-09-805-127-4/c
; Sequence 4, Application US/09805127
; Patent No. 6653119
; GENERAL INFORMATION:
; APPLICANT: BIO MEDIATION TECHNOLOGIE, INC.
; TITLE OF INVENTION: WHITE ROT FUNGI AND METHOD FOR DECOMPOSING DIOXINS USING THEM
; FILE REFERENCE: WKO-101PCT
; CURRENT APPLICATION NUMBER: US/09/805,127
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: JP 1998-260707
; PRIOR FILING DATE: 1998-09-14
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: artificially synthesized sequ
US-09-805-127-4

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAAGGCAGCACCAGG 1663
DB 16 GAAGGCAGCACCAGG 1

RESULT 276
US-09-805-127-5
; Sequence 5, Application US/09805127
; Patent No. 6653119
; GENERAL INFORMATION:
; APPLICANT: BIO MEDIATION TECHNOLOGIE, INC.
; TITLE OF INVENTION: WHITE ROT FUNGI AND METHOD FOR DECOMPOSING DIOXINS USING THEM
; FILE REFERENCE: WKO-101PCT
; CURRENT APPLICATION NUMBER: US/09/805,127
; CURRENT FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: JP 1998-260707
; PRIOR FILING DATE: 1998-09-14
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: artificially synthesized sequ
US-09-805-127-5

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAAGGCAGCACCAGG 1663
DB 2 GAAGGCAGCACCAGG 17

RESULT 277

US-09-529-812A-4/c
; Sequence 4, Application US/09529812A
; Patent No. 6682930
; GENERAL INFORMATION:
; APPLICANT: LU, CHANGDE
; TITLE OF INVENTION: NEW TRIPLEX FORMING OLIGONUCLEOTIDES AND THEIR USE IN
; FILE REFERENCE: ANTI-HBV
; FILE REFERENCE: 017227/0150
; CURRENT APPLICATION NUMBER: US/09/529,812A
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/CN98/00248
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: CN 97106667.1
; PRIOR FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Triplex
; OTHER INFORMATION: forming oligonucleotide
; OTHER INFORMATION: This oligo may or may not be 3'-monophosphorylated
US-09-529-812A-4

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1736 CTCCTCCCTCTCTCTCT 1751
DB 16 CTCCTCTCTCTCTCTCT 1

RESULT 278
US-09-866-108A-529
; Sequence 529, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 529
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-529

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1646 CAGAAGGCAAGCACCA 1661
||||| ||||| |||||
Db 1 CAGATGACAGCATCA 16

RESULT 279

US-09-866-108A-1263/c
; Sequence 1263, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1263

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1730 GATTGGCTCCCAACTC 1745
||||| ||||| |||||
Db 17 GATCGTCCCCCAACTC 2

RESULT 280

US-09-866-108A-1285/c
; Sequence 1285, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1263

US-09-866-108A-1265/c
; Sequence 1265, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1265
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1265

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCAACT 1744
||||| ||||| |||||
Db 16 AGATCGTCCCCCAACT 1

RESULT 281

US-09-866-108A-1285/c
; Sequence 1285, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1263

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCAACT 1744
||||| ||||| |||||
Db 16 AGATCGTCCCCCAACT 1

RESULT 282

US-09-866-108A-1285/c
; Sequence 1285, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1263

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1286

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1678 CCTGGTGTCTCTCCA 1693
DB 16 CCTGCTTTCTCCCCA 1

RESULT 282
US-09-866-108A-7832
; Sequence 7832, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7832
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7832

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCAGCTGGAAC 1677
DB 1 GCCTCAGCTGAAC 16

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1286

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1678 CCTGGTGTCTCTCCA 1693
DB 16 CCTGCTTTCTCCCCA 1

RESULT 283
US-09-866-108A-7832
; Sequence 7832, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7832
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7832

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1678 CCTGGTGTCTCTCCA 1693
DB 17 CCTGCTTTCTCCCCA 2

RESULT 282
US-09-866-108A-1286/c
; Sequence 1286, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1285

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1678 CCTGGTGTCTCTCCA 1693
DB 17 CCTGCTTTCTCCCCA 2

RESULT 283
US-09-866-108A-1286/c
; Sequence 1286, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1285
```

RESULT 284

US-09-866-108A-7984
; Sequence 7984, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AECOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 7984

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-7984

Query Match

Best Local Similarity 8.1%; Score 11.2; DB 1; Length 17;

Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy

1646 CAGAAGCGACGACCA 1661

|||||

2 CAGCAGGAAACACCA 17

RESULT 285

US-09-866-108A-7985

; Sequence 7985, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AECOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9657
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9657

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGGTGCTC 1688
Db 17 GGACCCCTGGCCTCTC 2

RESULT 287
US-09-866-108A-9659/c
; Sequence 9659, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9659
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9659

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGAACCCCTGGTGCTC 1687
Db 16 TGAACCCCTGGCCTCT 1
```

```
RESULT 288
US-09-866-108A-10208
; Sequence 10208, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10208
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10208

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCCCTAAGGCCCA 1765
Db 2 CTATCCGGAAGCCCA 17

RESULT 289
US-09-866-108A-10209
; Sequence 10209, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10209
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10209

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGCCCA 1765
||||| ||| ||||
Db 1 CTATCCGAAGCCCA 16

RESULT 290
PCT-US95-16806A-16
; Sequence 16, Application PC/TUS9516806A
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: E2 Binding Proteins
; NUMBER OF SEQUENCES: 21
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII (text)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/16806A
; FILING DATE: December 22, 1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/361,806
; FILING DATE: 22-DEC-1994
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
PCT-US95-16806A-16

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCGTGGTGAAGT 1706
||||| ||||| ||||
Db 1 CCAGGGTGGTAGGT 16

RESULT 291
US-09-280-409-75/c
; Sequence 75, Application US/09280409
; Patent No. 6107092
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: C. Frank Bennett
; APPLICANT: Bert W. O'Malley

; TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
; FILE REFERENCE: RTS-0048
; CURRENT APPLICATION NUMBER: US/09/280,409
; CURRENT FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 75
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-75

Query Match 8.1%; Score 11.2; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1658 ACCAGGCTCACAGCTG 1673
||||| ||||| |||||
Db 16 ACCAGGCTCCAGCAG 1

RESULT 292
US-09-624-945-19/c
; Sequence 19, Application US/09624945
; Patent No. 6607915
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Wanciewicz, Edward
; TITLE OF INVENTION: Antisense Modulation of E2A-Pbx1 Expression
; FILE REFERENCE: ISPH-0477
; CURRENT APPLICATION NUMBER: US/09/624,945
; CURRENT FILING DATE: 2000-07-25
; PRIOR APPLICATION NUMBER: 60/156,836
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-624-945-19

Query Match 8.1%; Score 11.2; DB 1; Length 20;
Best Local Similarity 81.2%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCTCGT 1683
||||| ||||| |||||
Db 16 CAGCTGTCAGCTCGT 1

RESULT 293
US-09-081-646-218
; Sequence 218, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
 ; FILE REFERENCE: 01107.74664
 ; CURRENT APPLICATION NUMBER: US/09/081,646
 ; EARLIER FILING DATE: 1998-05-20
 ; EARLIER FILING DATE: 1997-05-21
 ; NUMBER OF SEQ ID NOS: 871
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 218
 ; LENGTH: 15
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-081-646-218

Query Match 7.9%; Score 11; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1672 TGGACCCCTGG 1682
 DB 3 TGGACCCCTGG 13

RESULT 294
 US-09-081-646-855
 ; Sequence 855, Application US/09081646
 ; Patent No. 6333152
 ; GENERAL INFORMATION:
 ; APPLICANT: Kinzler, Kenneth
 ; APPLICANT: Vogelstein, Bert
 ; APPLICANT: Zhang, Lin
 ; APPLICANT: Zhou, Wei
 ; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
 ; FILE REFERENCE: 01107.74664
 ; CURRENT APPLICATION NUMBER: US/09/081,646
 ; CURRENT FILING DATE: 1998-05-20
 ; EARLIER APPLICATION NUMBER: 60/047,352
 ; EARLIER FILING DATE: 1997-05-21
 ; NUMBER OF SEQ ID NOS: 871
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 855
 ; LENGTH: 15
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-081-646-855

Query Match 7.9%; Score 11; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1672 TGGACCCCTGG 1682
 DB 3 TGGACCCCTGG 13

RESULT 295
 US-08-135-511-2
 ; Sequence 2, Application US/08135511
 ; Patent No. 5558999
 ; GENERAL INFORMATION:
 ; APPLICANT: Chiang, John
 ; TITLE OF INVENTION: Cholesterol 7a-Hydroxylase Gene
 ; TITLE OF INVENTION: Regulatory Elements and Methods for Using Them
 ; NUMBER OF SEQUENCES: 35
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Foley & Lardner
 ; STREET: 3000 K Street, N.W., Suite 500
 ; CITY: Washington, D.C.
 ; COUNTRY: USA
 ; ZIP: 20007-5109
 ; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/135,511
 ; FILING DATE: 13-OCT-1993
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: SANDERCOCK, Colin G.
 ; REGISTRATION NUMBER: 31,298
 ; REFERENCE/DOCKET NUMBER: 18748/175
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202)672-5300
 ; TELEFAX: (202)672-5399
 ; TELEX: 904136
 ; INFORMATION FOR SEQ ID NC: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 US-08-135-511-2

Query Match 7.9%; Score 11; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1740 CAACTCCTCCC 1750
 DB 1 CAACTCCTCCC 11

RESULT 296
 US-08-187-453-2
 ; Sequence 2, Application US/08187453
 ; Patent No. 5753431
 ; GENERAL INFORMATION:
 ; APPLICANT: Chiang, John
 ; TITLE OF INVENTION: Cholesterol 7a-Hydroxylase Gene
 ; TITLE OF INVENTION: Regulatory Elements and Transcription Factors
 ; NUMBER OF SEQUENCES: 37
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Foley & Lardner
 ; STREET: 3000 K Street, N.W., Suite 500
 ; CITY: Washington, D.C.
 ; COUNTRY: USA
 ; ZIP: 20007-5109
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/187,453
 ; FILING DATE: 28-JAN-1994
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/135,488
 ; FILING DATE: 13-OCT-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/135,511
 ; FILING DATE: 13-OCT-1993
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/135,510
 ; FILING DATE: 13-OCT-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: SANDERCOCK, Colin G.
 ; REGISTRATION NUMBER: 31,298
 ; REFERENCE/DOCKET NUMBER: 18748/188
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202)672-5300


```
;
; TELEFAX: (202) 672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-187-453-2
Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1740 CAACTCTCTCCC 1750
|||||
Db 1 CAACTCTCTCCC 11

RESULT 297
US-08-379-482A-6
; Sequence 6, Application US/08379482A
; Patent No. 5859334
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/379,482A
; FILING DATE: 30-JUL-1993
; CLASSIFICATION: 800
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9590
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516)742-4343
; TELEFAX: (516)742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-379-482A-6
Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1683 TGTCTCTCTCCA 1693
|||||
Db 2 TGTCTCTCTCCA 12

RESULT 298
US-08-464-582-16
; Sequence 16, Application US/08464582
; Patent No. 6114598
; GENERAL INFORMATION:
; APPLICANT: Kucherlapati, Raju
; APPLICANT: Jakobovits, Aya
; APPLICANT: Klapholz, Sue
; APPLICANT: Brenner, Daniel G.
; APPLICANT: Capon, Daniel J.
; TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
; FILE REFERENCE: CELL 4.10
; CURRENT APPLICATION NUMBER: US/08/464,582
; CURRENT FILING DATE: 1995-06-05
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-464-582-16
Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||||
Db 1 AGCTGGAACCC 11

RESULT 299
US-08-462-513-16
; Sequence 16, Application US/08462513
; Patent No. 6162963
; GENERAL INFORMATION:
; APPLICANT: Kucherlapati, Raju
; APPLICANT: Jakobovits, Aya
; APPLICANT: Klapholz, Sue
; APPLICANT: Brenner, Daniel G.
; APPLICANT: Capon, Daniel J.
; TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
; FILE REFERENCE: CELL 4.16
; CURRENT APPLICATION NUMBER: US/08/462,513
; CURRENT FILING DATE: 1995-06-05
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-462-513-16
Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred.No. 1.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||||
Db 1 AGCTGGAACCC 11

RESULT 300
US-08-031-801-17
; Sequence 17, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
```

AGC I G G A A C C C
| | | | | | | | | |

U	—
U	—
T	—
T	—
U	—
U	—
T	—
U	—
U	—
T	—
U	—

Db 1 CTCCTTCTTCCT 14

RESULT 303
US-08-913-833-4
; Sequence 4, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS: 164
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913.833
; FILING DATE: 15 Sep 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/00211
; FILING DATE: 17 Jan 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
US-08-913-833-4

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1718 TACGAGATGGAGA 1731
Db 1 TACAGATGGAAA 14

RESULT 304
US-09-580-794C-4
; Sequence 4, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; APPLICANT: Louwagie, Joost
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
; TITLE OF INVENTION: TRANSCRIPTASE GENE
; FILE REFERENCE: INNS008--2

; CURRENT APPLICATION NUMBER: US/09/580,794C
; CURRENT FILING DATE: 2000-05-30
; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
; PRIOR FILING DATE: 1997-09-15
; PRIOR APPLICATION NUMBER: PCT/EP 97/00211
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: EP 96870005.4
; PRIOR FILING DATE: 1996-01-26
; PRIOR APPLICATION NUMBER: EP 96870081.5
; PRIOR FILING DATE: 1996-06-25
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-580-794C-4

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1718 TACGAGATGGAGA 1731
Db 1 TACAGATGGAAA 14

RESULT 305
US-07-998-973A-18
; Sequence 18, Application US/07998973A
; Patent No. 5514579
; GENERAL INFORMATION:
; APPLICANT: O'Hara, Patrick J
; APPLICANT: Grant, Francis J
; APPLICANT: Sheppard, Paul O
; TITLE OF INVENTION: NOVEL HUMAN TRANSGLUTAMINASES
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Steuart Street Tower
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,973A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,284
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steve W
; REGISTRATION NUMBER: 31-990
; REFERENCE/DOCKET NUMBER: 13952-13-1
; TELEPHONE: 206-467-9600
; TELEFAX: 206-623-6793
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC4048

```
US-07-998-973A-18
Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1663 GCTCAGCTGGA 1676
DB 1 GCGCTCAGCTGGA 14

RESULT 306
US-08-479-248-1/c
; Sequence 1, Application US/08479248
; Patent No. 5594121
; GENERAL INFORMATION:
; APPLICANT: FROELER, BRIAN
; APPLICANT: MATTEUCCI, MARK
; TITLE OF INVENTION: ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
; TITLE OF INVENTION: FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GILEAD SCIENCES INC.
; STREET: 353 Lakeside Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MUENCHAU, DARYL
; REGISTRATION NUMBER: 36,616
; REFERENCE/DOCKET NUMBER: 160.1C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 574-3000
; TELEFAX: (415) 573-4899
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-08-479-248-1

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCT 1756
DB 2 CTCCTCCCTATCCT 15

RESULT 308
US-08-462-305-8
; Sequence 8, Application US/08462305
; Patent No. 5696248
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161X US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 513-948-7183
; TELEFAX: 513-948-7960 or 4681
; TELEX: 214320
; INFORMATION FOR SEQ ID NO: 8:

US-07-998-973A-18
Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1663 GCTCAGCTGGA 1676
DB 1 GCGCTCAGCTGGA 14

RESULT 307
US-08-479-248-2
; Sequence 2, Application US/08479248
; Patent No. 5594121
; GENERAL INFORMATION:
; APPLICANT: FROELER, BRIAN
; APPLICANT: MATTEUCCI, MARK
; TITLE OF INVENTION: ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
; TITLE OF INVENTION: FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GILEAD SCIENCES INC.
; STREET: 353 Lakeside Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MUENCHAU, DARYL
; REGISTRATION NUMBER: 36,616
; REFERENCE/DOCKET NUMBER: 160.1C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 574-3000
; TELEFAX: (415) 573-4899
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-08-479-248-1

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCT 1756
DB 14 CTCCTCCCTATCCT 1

RESULT 309
US-08-479-248-3
; Sequence 3, Application US/08479248
; Patent No. 5594121
; GENERAL INFORMATION:
; APPLICANT: FROELER, BRIAN
; APPLICANT: MATTEUCCI, MARK
; TITLE OF INVENTION: ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
; TITLE OF INVENTION: FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GILEAD SCIENCES INC.
; STREET: 353 Lakeside Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MUENCHAU, DARYL
; REGISTRATION NUMBER: 36,616
; REFERENCE/DOCKET NUMBER: 160.1C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 574-3000
; TELEFAX: (415) 573-4899
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-08-479-248-1
```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-462-305-8

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCTG 1681

DB 1 CAGCTGCAACCCAG 14

RESULT 309

US-08-363-240A-602/c
Sequence 602, Application US/08363240A
Patent No. 5705388

GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 602:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-602

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734

|||||

DB 15 GGAGATGAAGTTTG 2

RESULT 310

US-08-363-240A-603/c
Sequence 603, Application US/08363240A
Patent No. 5705388

GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:

FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 603:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-603

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734

DB 14 GGAGATGAAGTTTG 1

RESULT 311

US-08-311-486C-598/c
Sequence 598, Application US/08311486C
Patent No. 5811300

GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kisich
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
TITLE OF INVENTION: RIBOZYME TREATMENT OF

;; TITLE OF INVENTION: DISEASES OR CONDITIONS
;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: TNF-
;; NUMBER OF SEQUENCES: 1157
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,486C
;; FILING DATE: September 23, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/166
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 598:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-311-486C-598

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1708 GGGTTAGGAGTACG 1721
Db 15 GGGTGAGGAGCAG 2

RESULT 312
US-08-311-486C-599/c
; Sequence 599, Application US/08311486C
; Patent No. 581300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-598

two

;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,486C
;; FILING DATE: September 23, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/166
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 599:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-311-486C-599

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1708 GGGTTAGGAGTACG 1721
Db 15 GGGTGAGGAGCAG 2

RESULT 313
US-08-613-417A-8
; Sequence 8, Application US/08613417A
; Patent No. 5874553
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids, and their use
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0. Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/613,417A
; FILING DATE:
; CLASSIFICATION: 514
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:

two

```
; NAME/KEY: exon
; LOCATION: 1..15
US-08-613-417A-8

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGACCTG 1681
DB 1 CAGCTGCAACCCAG 14

RESULT 314
US-08-585-684B-2047
; Sequence 2047, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2047:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-2047

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 1.8e+02;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1678 CCTGGTCTCTCTC 1691
DB 2 CCUGGUCACCCUC 15

RESULT 315
US-08-452-800-18
; Sequence 18, Application US/08452800
; Patent No. 5952011
; GENERAL INFORMATION:
; APPLICANT: O'Hara, Patrick J
; APPLICANT: Grant, Francis J
; APPLICANT: Shepard, Paul O
; TITLE OF INVENTION: NOVEL HUMAN TRANSGLUTAMINASES
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Steuart Street Tower
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,800
; FILING DATE: 30-MAY-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,973
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/816,284
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steve W
; REGISTRATION NUMBER: 31-990
; REFERENCE/DOCKET NUMBER: 13952-13-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 206-623-6793
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC4048
US-08-452-800-18

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1663 GCTCAGCTGGAA 1676
DB 1 GCGCTCAGCTGGAA 14

RESULT 316
US-08-594-452-8
; Sequence 8, Application US/08594452
; Patent No. 6013639
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anushirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 X Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/594,452
; FILING DATE: 31-JAN-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 195 02 912.7
; FILING DATE: 31-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-594-452-8

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1668 CAGCTGGAACCCCTG 1681
Db      1 CAGCTGCAACCCAG 14

RESULT 317
US-08-578-686C-7
; Sequence 7, Application US/08578686C
; Patent No. 6028182
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; TITLE OF INVENTION: Methyolphosphonic Acid Ester, Process For
; TITLE OF INVENTION: Preparing The Same And Its Use
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I. Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3315
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/578,686C
; FILING DATE: January 2, 1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Johnson, Lori-Ann
; REGISTRATION NUMBER: 34,498
; REFERENCE/DOCKET NUMBER: 2481.1481-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
; US-08-578-686C-7

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1668 CAGCTGGAACCCCTG 1681
Db      1 CAGCTGCAACCCAG 14

RESULT 318
US-09-094-405-8
; Sequence 8, Application US/09094405
; Patent No. 6066720
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Modified oligonucleotides, their preparation
; TITLE OF INVENTION: and use
; NUMBER OF SEQUENCES: 30
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,405
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,196
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..15
; OTHER INFORMATION: /note= "c-Ha-ras"
; US-09-094-405-8

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1668 CAGCTGGAACCCCTG 1681
Db      1 CAGCTGCAACCCAG 14

RESULT 319
US-09-258-408-8
; Sequence 8, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: FEIMAN, Anushirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
```



```

; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-258-408-8

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14

RESULT 320
US-09-144-112-7
; Sequence 7, Application US/09144112
; Patent No. 6150510
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; TITLE OF INVENTION: USE
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/144,112
; CURRENT FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: DE P 44 38 918.3
; PRIOR FILING DATE: 1994-11-04
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
; US-09-144-112-7

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14

RESULT 322
US-09-038-073-2047
; Sequence 2047, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; US-09-196-132-8

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14

RESULT 320
US-09-196-132-8
; Sequence 8, Application US/09196132
; Patent No. 6127346
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphomonoester nucleic acids, and their use
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/196,132
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/613,417
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: Yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..15
; US-09-196-132-8
```

```

STATE: Ohio
COUNTRY: USA
ZIP: 45215-6300
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/895,981
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/462,305
FILING DATE: 05-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Payne, T. Helen
REGISTRATION NUMBER: 36,889
REFERENCE/DOCKET NUMBER: HOE94/F161K US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 513-948-7183
TELEFAX: 513-948-7960 or 4681
TELEX: 214320
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-895-981-8

Query Match 7.8%; Score 10.8; DB 1; Length 15
Best Local Similarity 85.7%; Pred: No.1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels

Qy 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14

RESULT 325
US-08-337-120A-8
Sequence 8, Application US/08337120A
Patent No. 6348312
GENERAL INFORMATION:
APPLICANT: Peyman, Anuschirwan
APPLICANT: Uhlmann, Eugen
APPLICANT: Mag, Matthias
APPLICANT: Kretzschmar, Gerhard
APPLICANT: Hellsberg, Matthias
APPLICANT: Winkler, Irvin
TITLE OF INVENTION: Stabilized Oligonucleotides And Their
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
ADDRESSEE: Dunner, L.L.P.
STREET: 1300 I Street, N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/337,120A
FILING DATE: 12-NOV-1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:

```

```
; APPLICATION NUMBER: DE P 43 38 704.7
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Einaudi, Carol P.
; REGISTRATION NUMBER: 32,220
; REFERENCE/DOCKET NUMBER: 02481.1409-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)408-4000
; TELEFAX: (202)408-4400
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-337-120A-8

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCTG 1681
      ||||| |||||
Db 1 CAGCTGCAACCCAG 14

RESULT 326
US-09-643-233-7
; Sequence 7, Application US/09643233
; Patent No. 6479651
; GENERAL INFORMATION:
; APPLICANT: SEEBA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/643,233
; CURRENT FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 09/144,112
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
US-09-643-233-7

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCTG 1681
      ||||| |||||
Db 1 CAGCTGCAACCCAG 14

RESULT 327
PCT-US92-11353-18
; Sequence 18, Application PC/TUS9211353
; GENERAL INFORMATION:
; APPLICANT: O'Hara, Patrick J
; APPLICANT: Grant, Francis J
; APPLICANT: Sheppard, Paul O
; TITLE OF INVENTION: NOVEL HUMAN TRANSGLUTAMINASES
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stuart Street Tower
```

```
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11353
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,284
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steve W
; REGISTRATION NUMBER: 31-990
; REFERENCE/DOCKET NUMBER: 13952-13-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 206-623-6793
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC4048
PCT-US92-11353-18

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1663 GCTCAGCTGGAA 1676
      ||||| |||||
Db 1 GCGCTCAGCTGGAA 14

RESULT 328
US-07-696-793A-1/c
; Sequence 1, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
```

; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-1

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGT 1685
DB 15 TGGAACTGGTGT 2

RESULT 329
US-07-696-793A-5/c
; Sequence 5, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE:
US-07-696-793A-5

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGAAGTTGGT 1711

DB 15 GGTGAAGCTGGT 2

RESULT 330
US-07-696-793A-10/c
; Sequence 10, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:

; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-10

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTGT 1685
DB 15 TGGAACTGGTGT 2

RESULT 331
US-07-696-793A-23/c
; Sequence 23, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California

```
/
/ COUNTRY: U.S.A.
/ ZIP: 94608
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/696,793A
/ FILING DATE: 19910507
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kevin R. Kaster
/ REGISTRATION NUMBER: 32704
/ REFERENCE/DOCKET NUMBER: 2598
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 420-3444
/ TELEFAX: (415) 658-5239
/ INFORMATION FOR SEQ ID NO: 23:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-696-793A-23

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1672 TGGAAACCTGGTGT 1685
Db 15 TGGAACTTGGTGT 2

RESULT 332
US-07-977-694-1/c
; Sequence 1, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE:
; US-07-977-694-5

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGCTTGGCT 1711
Db 15 GTTGAAGCTTGGT 2

RESULT 332
US-07-977-694-1/c
; Sequence 1, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
```

```
/
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 1:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-1

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1672 TGGAAACCTGGTGT 1685
Db 15 TGGAACTTGGTGT 2

RESULT 333
US-07-977-694-5/c
; Sequence 5, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE:
; US-07-977-694-5

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1698 GGTGGAAGCTTGGCT 1711
Db 15 GTTGAAGCTTGGT 2
```

RESULT 334
US-07-977-694-10/c
; Sequence 10, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-977-694-10

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 2;

QY 1672 TGAACCTGGTGT 1685
Db 15 TGAAGCTGGTGT 2

RESULT 335
US-07-977-694-23/c
; Sequence 23, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 6.0.5
SOFTWARE: WordPerfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,694
FILING DATE: 19921117
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Stacey R. Sias, Ph.D.
REGISTRATION NUMBER: 32,630
REFERENCE/DOCKET NUMBER: 8733
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2863
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single stranded
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-07-977-694-23

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 2;

QY 1672 TGAACCTGGTGT 1685
Db 15 TGAATCTGGTGT 2

RESULT 336
US-08-255-264-23/c
; Sequence 23, Application US/08255264
; Patent No. 5643724
; GENERAL INFORMATION:
; APPLICANT: Filides, Nicola J.
; APPLICANT: Reynolds, Rebecca L.
; TITLE OF INVENTION: Methods and Reagents for Glycophorin A
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/08/255,264
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry Ph.D., Douglas A.
; REGISTRATION NUMBER: 35,321
; REFERENCE/DOCKET NUMBER: 8865
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2974
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-255-264-23

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1672 TGAACCTGGTGT 1685

Db 15 TGAAGCTGGTGT 2

RESULT 337

US-08-232-620A-1628
; Sequence 1628, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1628:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-1628

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 2e+02; 2; Indels 1;

Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1689 CTCACGCTGGTGG 1702

Db 1 CUACAGCCUGGUGG 14

RESULT 338

US-09-071-845-1628

; Sequence 1628, Application US/09071845

; Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: California

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/071,845

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620

FILING DATE: August 17, 1994

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1628:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-071-845-1628

Query Match 7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 2e+02; 2; Indels 1;

Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1689 CTCACGCTGGTGG 1702

Db 1 CUACAGCCUGGUGG 14

```
RESULT 339
US-09-270-933-6
; Sequence 6, Application US/09270933
; Patent No. 6365375
; GENERAL INFORMATION:
; APPLICANT: Dietmaier, Wolfgang
; APPLICANT: Ruschoff, Josef
; TITLE OF INVENTION: IMPROVED METHOD OF PRIMER-EXTENSION PREAMPLIFICATION
; TITLE OF INVENTION: PCR
; FILE REFERENCE: 4802
; CURRENT APPLICATION NUMBER: US/09/270,933
; CURRENT FILING DATE: 1999-03-16
; EARLIER APPLICATION NUMBER: DE 198 13 317.0
; EARLIER FILING DATE: 1998-03-26
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer for
; OTHER INFORMATION: Human Genomic Sequence
US-09-270-933-6

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1713 AGCAGTACGAGAT 1726
Db      ||||| |||||
        2 AGCAGTAGGAGAT 15

RESULT 340
US-09-371-772B-5803
; Sequence 5803, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5803
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5803

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1746 CTCCTATCCTATAA 1759
Db      ||||| :|||
        1 CUCCUUAUCCGAA 14

RESULT 341
US-09-371-772B-5880
; Sequence 5880, Application US/09371772B
```

```
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5880
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5880

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCCT 1751
Db      ||||| :|||
        1 CUCAAACUCCUGCCU 14

RESULT 342
US-09-371-772B-5912/c
; Sequence 5912, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5912
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5912

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1692 CACGGTGGTGGAG 1705
Db      ||||| :|||
        14 CACGGTGGTGGTAG 1

RESULT 343
US-09-280-409-109/c
; Sequence 109, Application US/09280409
; Patent No. 6107092
```



```
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: C. Frank Bennett
; APPLICANT: Bert W. O'Malley
; TITLE OF INVENTION: ANTISENSE MODULATION OF SRA EXPRESSION
; FILE REFERENCE: RTS-0048
; CURRENT APPLICATION NUMBER: US/09/280,409
; CURRENT FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 146
; SEQ ID NO 109
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-280-409-109
```

```
Query Match 7.8%; Score 10.8; DB 1; Length 18;
Best Local Similarity 85.7%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1658 ACCAGGCTCAGC 1671
Db 15 ACCAGGCTCCAGC 2
```

```
RESULT 344
US-09-516-667-56
; Sequence 56, Application US/09516667
; Patent No. 6610533
; GENERAL INFORMATION:
; APPLICANT: Inouye, Masayori
; APPLICANT: Wang, Nan
; APPLICANT: Yamanaka, Kunitoshi
; TITLE OF INVENTION: COLD-SHOCK REGULATORY ELEMENTS, CONSTRUCTS THEREOF, AND
; TITLE OF INVENTION: METHODS OF USE
; FILE REFERENCE: 1053-00
; CURRENT APPLICATION NUMBER: US/09/516,667
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 56
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide
US-09-516-667-56
```

```
Query Match 7.5%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 1.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1754 CCTAAGGCCCA 1765
Db 2 CCGAAGGCCCA 13
```

```
RESULT 345
US-08-985-162-1849/c
; Sequence 1849, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1849:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-1849
```

```
Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1639 CTTGTAGCAGAA 1650
Db 13 CTTGAGCAGAA 2
```

```
RESULT 346
US-08-535-249-90/c
; Sequence 90, Application US/08535249
; Patent No. 6455889
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; TITLE OF INVENTION: immuno-suppressive effect of transforming-growth-factor beta (1)
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 849.7
; FILING DATE: 13-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31.409
; REFERENCE/DOCKET NUMBER: 10577/P5841B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-08-535-249-90

Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 14;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 ACAGAGAGCGCA 1655
Db 14 ACAGAGAGCGCA 3

RESULT 347
US-09-401-063-1849/c
; Sequence 1849, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 849.7
; FILING DATE: 13-MAY-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31.409
; REFERENCE/DOCKET NUMBER: 10577/P5841B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 90:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
; US-08-535-249-90

Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 14;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 ACAGAGAGCGCA 1655
Db 14 ACAGAGAGCGCA 3

RESULT 348
US-07-783-861C-14/c
; Sequence 14, Application US/07783861C
; Patent No. 5460949
; GENERAL INFORMATION:
; APPLICANT: Saunders, Court A.
; APPLICANT: Wolf, Fred R.
; APPLICANT: Mukharji, Indrani
; TITLE OF INVENTION: A Method and Composition for Increasing
; TITLE OF INVENTION: the Accumulation of Squalene and Specific Sterols in
; TITLE OF INVENTION: Yeast
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amoco Corp., Patents and Licensing Dept.
; STREET: 200 East Randolph St.
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680-0703
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/783,861C
; FILING DATE: 19911028
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/613,380
; FILING DATE: 15-NOV-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Galloway, No. 5460949vall B.
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312 856-7180
; TELEFAX: 312 856-4972
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-783-861C-14

Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 15;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAC 1677
Db 12 CACAGCTGGATC 1
```

```

RESULT 349
US-08-182-968A-339/c
; Sequence 339, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; FILING DATE: 13-JANUARY-1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 07/982,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 339:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-339

```

```

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1695 CGTGTGGAGT 1706
Db 15 CGTAGTGGAGT 4

```

```

RESULT 350
US-08-291-932A-211/c
; Sequence 211, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street

```

```

; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 211:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-211

```

```

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1639 CTTGTACGAGAA 1650
Db 12 CTTGTACGAGAA 1

```

```

RESULT 351
US-08-363-240A-760
; Sequence 760, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgater, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible

```

schultz139-3.rni

Mon Aug 30 09:26:46 2004

```

; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363.240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 760:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-760

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1738 CCCACTCTCC 1749
DB 1 CCCACUCCUUC 12

RESULT 352
US-08-774-306A-339/C
; Sequence 339, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774.306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 339:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-306A-339

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1695 CGTGTGGAAGT 1706
DB 15 CGTAGTGAAGT 4

RESULT 353
US-08-585-684B-1270
; Sequence 1270, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1270:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGTAACA 1647
DB 3 GGGCUUGUAUCA 14

```

```
RESULT 354
US-08-232-081B-16
; Sequence 16, Application US/08232081B
; Patent No. 5886152
; GENERAL INFORMATION:
; APPLICANT: NAKATANI, TOMOYUKI
; APPLICANT: GOMI, HIDEYUKI
; APPLICANT: WIDENES, JOHN
; APPLICANT: NOGUCHI, HIROSHI
; TITLE OF INVENTION: HUMANIZED B-B10
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIRCH, STEWART, KOLASCH AND BIRCH
; STREET: PO BOX 747
; CITY: FALLS CHURCH
; STATE: VA
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,081B
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: SVENSSON, LEONARD R
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 20-3484
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 205-8000
; TELEFAX: (703) 205-8050
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-232-081B-16

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1689 CTCACGCTGCT 1700
Db 1 CTCACGCTGCT 12
||||| |||||

RESULT 355
US-09-064-156A-339/c
; Sequence 339, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
US-09-064-156A-339/c

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1695 CGTGTGGAAGT 1706
Db 15 CGTGTGGAAGT 4
||||| ||||| |||||

RESULT 356
US-09-038-073-1270
; Sequence 1270, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
```

Db 15 GTACAGAAGGC 4

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGAGCA 1647
||||:|:|

Db 3 GGGCUUGUAUCA 14

RESULT 357

US-09-066-046-42/c
; Sequence 42, Application US/09066046A
; Patent No. 6204252
; GENERAL INFORMATION:
; APPLICANT: MURPHY, Cheryl
; STOREY, James
; BELTZ, Gerald A.
; COUGHLIN, Richard T.
; TITLE OF INVENTION: CHARACTERIZATION OF GRANULOCYTIC
; EHRLLICHA AND METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE AND DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: United States
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/066,046A
; FILING DATE: 24-Apr-1998
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Superko, Colleen
; REGISTRATION NUMBER: 39,850
; REFERENCE/DOCKET NUMBER: 106.941.155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 526-6000
; TELEFAX: (617) 526-5000
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-066-046-42

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1642 GTACAGAAGGC 1653

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGAGCA 1647
||||:|:|

Db 3 GGGCUUGUAUCA 14

RESULT 357

US-09-066-046-42/c
; Sequence 42, Application US/09066046A
; Patent No. 6204252
; GENERAL INFORMATION:
; APPLICANT: MURPHY, Cheryl
; STOREY, James
; BELTZ, Gerald A.
; COUGHLIN, Richard T.
; TITLE OF INVENTION: CHARACTERIZATION OF GRANULOCYTIC
; EHRLLICHA AND METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE AND DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: United States
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/066,046A
; FILING DATE: 24-Apr-1998
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Superko, Colleen
; REGISTRATION NUMBER: 39,850
; REFERENCE/DOCKET NUMBER: 106.941.155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 526-6000
; TELEFAX: (617) 526-5000
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-066-046-42

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1642 GTACAGAAGGC 1653

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGAGCA 1647
||||:|:|

Db 3 GGGCUUGUAUCA 14

RESULT 357

US-09-066-046-42/c
; Sequence 42, Application US/09066046A
; Patent No. 6204252
; GENERAL INFORMATION:
; APPLICANT: MURPHY, Cheryl
; STOREY, James
; BELTZ, Gerald A.
; COUGHLIN, Richard T.
; TITLE OF INVENTION: CHARACTERIZATION OF GRANULOCYTIC
; EHRLLICHA AND METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE AND DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: United States
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/066,046A
; FILING DATE: 24-Apr-1998
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Superko, Colleen
; REGISTRATION NUMBER: 39,850
; REFERENCE/DOCKET NUMBER: 106.941.155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 526-6000
; TELEFAX: (617) 526-5000
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-066-046-42

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1642 GTACAGAAGGC 1653

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGAGCA 1647
||||:|:|

Db 3 GGGCUUGUAUCA 14

RESULT 357

US-09-066-046-42/c
; Sequence 42, Application US/09066046A
; Patent No. 6204252
; GENERAL INFORMATION:
; APPLICANT: MURPHY, Cheryl
; STOREY, James
; BELTZ, Gerald A.
; COUGHLIN, Richard T.
; TITLE OF INVENTION: CHARACTERIZATION OF GRANULOCYTIC
; EHRLLICHA AND METHODS OF USE
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE AND DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: United States
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/066,046A
; FILING DATE: 24-Apr-1998
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Superko, Colleen
; REGISTRATION NUMBER: 39,850
; REFERENCE/DOCKET NUMBER: 106.941.155
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 526-6000
; TELEFAX: (617) 526-5000
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-066-046-42

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 2.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1642 GTACAGAAGGC 1653

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1270:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-038-073-1270

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGAGCA 1647
||||:|:|

Db 3 GGGCUUGUAUCA 14

RESULT 357

US-09-066-046-42/c
; Sequence 42, Application US/09066046A
; Patent No. 6204252
; GENERAL INFORMATION:
; APPLICANT: MURPHY, Cheryl
; STOREY, James
; BELTZ, Gerald A.
; COUGHLIN, Richard T.
;

```
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ HYPOTHETICAL: NO
/ ANTI-SENSE: YES
/ ORIGINAL SOURCE:
/ ORGANISM: Hepatitis B virus
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: 1
/ OTHER INFORMATION: /mod_base= OTHER
/
US-07-991-199D-8
Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 16;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAG 1730
Db 12 ACGAGATGGAG 1

RESULT 360
US-09-371-772B-5910
/ Sequence 5910, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 5910
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-5910

Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 16;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCAC 1659
Db 1 GAAGGCAAGCGC 12

RESULT 361
US-09-371-772B-7125/c
/ Sequence 7125, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
```

```
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 7125
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-371-772B-7125

Query Match
Best Local Similarity 7.5%; Score 10.4; DB 1; Length 16;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCA 1661
Db 14 AGGCAAGAACCA 3

RESULT 362
PCT-US93-12246-8/c
/ Sequence 8, Application PC/TUS9312246
/ GENERAL INFORMATION:
/ APPLICANT: Meyer Jr., Rich B.
/ APPLICANT: Gall, Alexander A.
/ APPLICANT: Reed, Michael W.
/ TITLE OF INVENTION: Peptide Linkers For Improved
/ TITLE OF INVENTION: Oligonucleotide Delivery
/ NUMBER OF SEQUENCES: 12
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Klein & Szekeres
/ STREET: 4199 Campus Drive, Suite 700
/ CITY: Irvine
/ STATE: CA
/ COUNTRY: U.S.A.
/ ZIP: 92715
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US93/12246
/ FILING DATE: 15-DEC-1993
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/991,199
/ FILING DATE: 15-DEC-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Szekeres, Gabor L.
/ REGISTRATION NUMBER: 28,675
/ REFERENCE/DOCKET NUMBER: 491-04-PA
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (714) 854-5502
/ TELEFAX: (714) 854-4897
/ INFORMATION FOR SEQ ID NO: 8:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ HYPOTHETICAL: NO
/ ANTI-SENSE: YES
/ ORIGINAL SOURCE:
/ ORGANISM: Hepatitis B virus
/ FEATURE:
/ NAME/KEY: modified_base
/ LOCATION: 1
/ OTHER INFORMATION: /mod_base= OTHER
```

OTHER INFORMATION: /note= "Nucleotide 1 is H2N-(CH2)6-OP02-5'-O-C."

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACAGGATGGAG 1730
Db 12 ACAGGATGGAG 1

RESULT 363
US-08-363-240A-242/c
Sequence 242, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaler, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
PREVENTION, INHIBITION OF
PROGRESSION AND REGRESSION
OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 242:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-363-240A-242
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1668 CAGCTGGAGCCTGG 1682
Db 15 CAGCTGGAGCCTGG 1

RESULT 364
US-08-136-118-12/c
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Sequence 12, Application US/08136118
Patent No. 5580969
GENERAL INFORMATION:
APPLICANT: HOKE, Glenn D
APPLICANT: BRADLEY, Matthews O
APPLICANT: WILLIAMS, Taiffy J
APPLICANT: LEE, Che-Hung
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED
AGAINST HUMAN ICAM-1
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Naval Medical Res. & Dev. Cmd.
STREET: 8901 Wisconsin Ave.
CITY: Bethesda
STATE: Maryland
COUNTRY: USA
ZIP: 20889-5606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/136,118
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/918,259
FILING DATE: 24-JUL-1992
ATTORNEY/AGENT INFORMATION:
NAME: Spevack, A. David
REGISTRATION NUMBER: 24,743
REFERENCE/DOCKET NUMBER: N.C. 75,776
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 295-6759
TELEFAX: (202) 295-1022
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
HYPOTHEICAL: NO
ANTI-SENSE: YES
US-08-136-118-12

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAACC 1678
Db 15 CTCACAGCTGGAACC 1

RESULT 365
US-08-319-492B-378/c
Sequence 378, Application US/08319492B
Patent No. 5616488
GENERAL INFORMATION:
APPLICANT: Sullivan, Sean M.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
RELATED TO LEVELS
OF IL-5
NUMBER OF SEQUENCES: 751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles

US-08-319-492B-378/c
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1668 CAGCTGGAGCCTGG 1682
Db 15 CAGCTGGAGCCTGG 1

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/319,492B
FILING DATE: October 7, 1994
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 378:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-319-492B-378

Two

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1711 TTAGGAGTACGAGA 1725
Db 15 TTATGAGTAGGACA 1

RESULT 366
US-08-291-932A-340
Sequence 340, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A

FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 340:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-340

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 2.5e+02;
Matches 7; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1680 TGGTGCTCTCCAG 1694
Db 1 DGGGUGUCCUCUG 15

RESULT 367
US-08-363-240A-227
Sequence 227, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwiggen, James
APPLICANT: Bisgaier, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:

```

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 227:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-227

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCTCC 1739
   ||| :||| :
Db 1 AUGGACUUUGGCUUC 15

RESULT 368
US-08-363-240A-228
; Sequence 228, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Biggaler, Charles
; APPLICANT: Pope, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 228:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-228

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```

; Sequence 151, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; NUMBER OF SEQUENCES: TNF-
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311.486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 151:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-151

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 CTCACAGCTGGAAC 1678
Db 1 CUGACAUCUGGAUC 15

RESULT 371
US-08-311-486C-747
; Sequence 747, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen

; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311.486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-747

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1676 ACCCTGGTGTCTCT 1690
Db 1 ACCUUGUUGCCUCU 15

RESULT 372
US-08-292-620A-352
; Sequence 352, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon

two

two


```
/
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 529:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-292-620A-529

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1650 AGGCAAGCAGCAGGC 1664
Db 15 AGGCAGGAACAGGC 1

RESULT 375
US-08-531-743-4/c
/ Sequence 4, Application US/08531743
/ Patent No. 5856096
/ GENERAL INFORMATION:
/ APPLICANT: Windle, Bradford E.
/ APPLICANT: Qiu, Ming
/ APPLICANT: Chen, Shi-fong
/ APPLICANT: Fletcher, Terrace M.
/ APPLICANT: Maine, Ira
/ TITLE OF INVENTION: Rapid and Sensitive Assays for Detecting and
/ TITLE OF INVENTION: Distinguishing Between Processive and
/ TITLE OF INVENTION: No. 5856096-Processive Telomerase Activities
/ NUMBER OF SEQUENCES: 17
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Arnold, White & Durkee
/ STREET: P.O. Box 4433
/ CITY: Houston
/ STATE: Texas
/ COUNTRY: United States of America
/ ZIP: 77210
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/531,743
/ FILING DATE: 20-SEP-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Highlander, Steven L.
/ REGISTRATION NUMBER: 37,642
/ REFERENCE/DOCKET NUMBER: CTCR:026/HYL
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (512) 418-3000
/ TELEFAX: (512) 474-7577
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
```

```
/
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-531-743-4

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1708 GGGTTAGGAGTACGG 1722
Db 15 GGGTTAGGTTAGGG 1

RESULT 376
US-08-585-684B-263/c
/ Sequence 263, Application US/08585684B
/ Patent No. 5877021
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: Jarvis, Thale
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: METHOD AND REAGENT FOR THE
/ TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
/ TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
/ NUMBER OF SEQUENCES: 2751
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/585,684B
/ FILING DATE: January 16, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/000,951
/ FILING DATE: July 7, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 263:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-585-684B-263

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1715 GAGTACGGAGATCGA 1729
Db 15 GAGAAAGGAGAGGGA 1

RESULT 377
```

```
US-08-585-684B-1201/c
; Sequence 1201, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Waxburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1201:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-1201
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644 AGCAGAGGCAAGCA 1658
Db 15 AGCAGCAGAGCA 1

RESULT 378
US-08-757-024-579
; Sequence 579, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

US-08-585-684B-1201/c
; Sequence 61, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, COOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,833
; FILING DATE: 15 Sep 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/00211
; FILING DATE: 17 Jan 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 61:

QY 1722 GAGATGGAGATGGC 1736
Db 1 GAGATGGAGGCGGC 15

RESULT 379
US-08-913-833-61/c
; Sequence 61, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, COOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,833
; FILING DATE: 15 Sep 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/00211
; FILING DATE: 17 Jan 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 61:
```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-913-833-61

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1691 CCAGCGTGTGGGAG 1705
Db 15 CCATCTTGTGGAG 1

RESULT 380

US-08-873-437-24/c
Sequence 24, Application US/08973437
Patent No. 6124092

GENERAL INFORMATION:
APPLICANT: O'Neill, Roger A.
APPLICANT: Chen, Jer-Kang
APPLICANT: Chiesa, Claudia
APPLICANT: Fry, George
TITLE OF INVENTION: Multiplex Polynucleotide Capture
TITLE OF INVENTION: METHODS AND COMPOSITIONS
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: PE Applied Biosystems
STREET: 850 Lincoln Centre Drive
CITY: Foster City
STATE: CA
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/873,437
FILING DATE: 12-JUN-1997

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/027,832
FILING DATE: 04-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bortner, Scott R.
REGISTRATION NUMBER: 34,298
REFERENCE/DOCKET NUMBER: 4294
TELEPHONE: 415-638-6245
TELEFAX: 415-638-6071
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-873-437-24

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1636 GGGCTGTAGCAGAA 1650
Db 15 GCGATAGTAGCAGAA 1

RESULT 381

US-09-071-845-352
Sequence 352, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 352:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-352

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1731 ATGGCTCCCACTC 1745
Db 1 AUAGGCUCAACAC 15

RESULT 382

US-09-071-845-424/c
Sequence 424, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 529:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-529
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1650 AGCGAGCAGCAGGC 1664
Db 15 AGCGAGGAAACAGGC 1
RESULT 384
US-09-071-845-529/c
Sequence 529, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION

APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 424:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-424
Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1650 AGCGAGCAGCAGGC 1664
Db 15 AGCGAGGAAACAGGC 1
RESULT 383
US-09-071-845-529/c
Sequence 529, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 263:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-263

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1715 GAGTACGAGAGATGGA 1729
||| ||||| |||
Db 15 GAGAAAGAGAGGGA 1

RESULT 385
US-09-038-073-1201/c
Sequence 1201, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1201:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1201

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1644 AGCAGAAGCGAAGCA 1658
||||| ||||| |||
Db 15 AGCAGCAGAGAAGCA 1

RESULT 386
US-09-580-794C-61/c
Sequence 61, Application US/09580794C
Patent No. 6331389
GENERAL INFORMATION:
APPLICANT: Stuyver, Lieven
APPLICANT: Louwagie, Joost
APPLICANT: Rossau, Rudi
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
TITLE OF INVENTION: TRANSCRIPTASE GENE
FILE REFERENCE: INNS008--2
CURRENT APPLICATION NUMBER: US/09/580,794C
CURRENT FILING DATE: 2000-05-30
PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
PRIOR FILING DATE: 1997-09-15
PRIOR APPLICATION NUMBER: PCT/EP 97/00211
PRIOR FILING DATE: 1997-01-17
PRIOR APPLICATION NUMBER: EP 96870005.4
PRIOR FILING DATE: 1996-01-26
PRIOR APPLICATION NUMBER: EP 96870081.5
PRIOR FILING DATE: 1996-06-25
NUMBER OF SEQ ID NOS: 164
SOFTWARE: Patent in version 3.0
SEQ ID NO 61
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-09-580-794C-61

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1691 CCAGCGTGGTGAAG 1705
||| ||||| |||
Db 15 CCATCCTGTGGAAG 1

RESULT 387
US-09-081-646-342/c
Sequence 342, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
TITLE OF INVENTION: Cancer Cells
FILE REFERENCE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646

```
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 342
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-342

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1642 GTAGCAGAGGCAAG 1656
Db 15 GTAGCTGGAGGATG 1

RESULT 388
US-09-081-646-467/c
; Sequence 467, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; EARLIER FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 467
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-467

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGTTAGG 1715
Db 15 GGCAGTTGGGTCATG 1

RESULT 389
US-09-011-336-18
; Sequence 18, Application US/09011336
; Patent No. 6472586
; GENERAL INFORMATION:
; APPLICANT: Maliga, Pal
; APPLICANT: Allison, Lori A.
; APPLICANT: Hasdukiewicz, Peter T.
; TITLE OF INVENTION: Nuclear-Encoded Transcription System in
; TITLE OF INVENTION: Plasmids of Higher Plants
; FILE REFERENCE: Rut-95-08031
; CURRENT APPLICATION NUMBER: US/09/011,336
; CURRENT FILING DATE: 1998-02-10
; PRIOR APPLICATION NUMBER: PCT/US96/12671
; PRIOR FILING DATE: 1996-08-01
; PRIOR APPLICATION NUMBER: 60/002,136
; PRIOR FILING DATE: 1995-08-10
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 18
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-011-336-18

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGG 1710
Db 1 GTGAAGAAGTTGG 15

RESULT 390
US-09-593-312-24/c
; Sequence 24, Application US/09593312
; Patent No. 6514699
; GENERAL INFORMATION:
; APPLICANT: O'Neill, Roger A.
; APPLICANT: Chen, Jer-Kang
; APPLICANT: Chiesa, Claudia
; APPLICANT: Fry, George
; TITLE OF INVENTION: Multiplex Polynucleotide Capture
; TITLE OF INVENTION: Methods and Compositions
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESS: PE Applied Biosystems
; STREET: 850 Lincoln Centre Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DCS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/593,312
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/873,437
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Boitner, Scott R
; REGISTRATION NUMBER: 34,298
; REFERENCE/DOCKET NUMBER: 4294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-638-6245
; TELEFAX: 415-638-6071
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-593-312-24

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1636 GGGCTTGTAGCAGAA 1650
Db 15 GCGATAGTAGCAGAA 1

RESULT 391
US-07-696-793A-17
```

```
/ Sequence 17, Application US/07696793A
/ Patent No. 5220004
/ GENERAL INFORMATION:
/ APPLICANT: Saiki, Randall K.
/ APPLICANT: Nasarabadi, Shanavaz L.
/ TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
/ TITLE OF INVENTION: Typing
/ NUMBER OF SEQUENCES: 58
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cetus Corporation
/ STREET: 1400 Fifty-Third Street
/ CITY: Emeryville
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 94608
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/696,793A
/ FILING DATE: 19910507
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kevin R. Kaster
/ REGISTRATION NUMBER: 32704
/ REFERENCE/DOCKET NUMBER: 2598
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 420-3444
/ TELEFAX: (415) 658-5239
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-696-793A-17

Query Match 7.3%; Score 10.2; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.8e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1657 CACGAGCTCACGC 1671
Db ||||| |||
5 CACGAGCTCCACC 19

RESULT 392
US-07-977-694-17
/ Sequence 17, Application US/07977694
/ Patent No. 5273883
/ GENERAL INFORMATION:
/ APPLICANT: Saiki, Randall K.
/ APPLICANT: Nasarabadi, Shanavaz L.
/ TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
/ TITLE OF INVENTION: Typing
/ NUMBER OF SEQUENCES: 58
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hoffmann-La Roche Inc.
/ STREET: 340 Kingsland Street
/ CITY: Nutley
/ STATE: New Jersey
/ COUNTRY: U.S.A.
/ ZIP: 07110-1199
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
/ COMPUTER: Apple Macintosh
/ OPERATING SYSTEM: Macintosh 6.0.5
```

```
/ SOFTWARE: WordPerfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/977,694
/ FILING DATE: 19921117
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stacey R. Sias, Ph.D.
/ REGISTRATION NUMBER: 32,630
/ REFERENCE/DOCKET NUMBER: 8733
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (510) 814-2863
/ TELEFAX: (510) 814-2977
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: Other nucleic acid
/ US-07-977-694-17

Query Match 7.3%; Score 10.2; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.8e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1657 CACGAGCTCACGC 1671
Db ||||| |||
5 CACGAGCTCCACC 19

RESULT 393
US-08-171-718-43/c
/ Sequence 43, Application US/08171718
/ Patent No. 5707863
/ GENERAL INFORMATION:
/ APPLICANT: Trofatter, James A.
/ APPLICANT: MacCollin, Mia M.
/ APPLICANT: Gusella, James F.
/ TITLE OF INVENTION: Tumor Suppressor Gene Merlin and Uses
/ TITLE OF INVENTION: Thereof
/ NUMBER OF SEQUENCES: 120
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sterne, Kessler, Goldstein & Fox
/ STREET: 1100 New York Avenue, N.W., Suite 600
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20005-3934
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/171,718
/ FILING DATE: 22-DEC-1993
/ CLASSIFICATION: 436
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/108,808
/ FILING DATE: 19-AUG-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/022,034
/ FILING DATE: 25-FEB-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/026,063
/ FILING DATE: 04-MAR-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Brown, Anne
/ REGISTRATION NUMBER: 36,463
/ REFERENCE/DOCKET NUMBER: 0609.3850003
```

schultz139-3.rni

Mon Aug 30 09:26:46 2004

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-2600
TELEFAX: (202) 371-2540
INFORMATION FOR SEQ ID NO: 43:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-171-718-43

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1659 CCAGGCTCAC 1668
|||||
DB 10 CCAGGCTCAC 1

RESULT 394
US-08-388-353-425/c
Sequence 425, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learnmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 425:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-425

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1638 GCTTGATGCA 1647
|||||
DB 10 GCTTGATGCA 1

RESULT 395
US-08-388-353-501/c
Sequence 501, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learnmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 501:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-501

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1661 AGGCTCACAG 1670
|||||
DB 10 AGGCTCACAG 1

RESULT 396
US-08-388-353-502/c
Sequence 502, Application US/08388353
Patent No. 6010895
GENERAL INFORMATION:
APPLICANT: Deacon, Nicholas J.
APPLICANT: Learnmont, Jennifer C.
APPLICANT: McPhee, Dale A.
APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States

ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/388,353
FILING DATE: 14-FEB-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 502:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-502

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred.No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1660 CAGGCTCACA 1669
Db 10 CAGGCTCACA 1

RESULT 397
US-08-488-551B-425/c
Sequence 425, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
ATTORNEY/AGENT INFORMATION:
NAME: DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 501:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-501

NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 425:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-425

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred.No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1638 GCTTGTCACA 1647
Db 10 GCTTGTCACA 1

RESULT 398
US-08-488-551B-501/c
Sequence 501, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 501:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-501

schultz139-3.rni

Mon Aug 30 09:26:46 2004

```

Query Match          7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1661 AGGCTCACAG 1670
Db 10 AGGCTCACAG 1

RESULT 399
US-08-488-551B-502/c
; Sequence 502, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 819:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-488-551B-819

Query Match          7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1661 AGGCTCACAG 1670
Db 10 AGGCTCACAG 1

RESULT 401
US-08-488-551B-820/c
; Sequence 820, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PM3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 502:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-488-551B-502

Query Match          7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACA 1669
Db 10 CAGGCTCACA 1

RESULT 400
US-08-488-551B-819/c
; Sequence 819, Application US/08488551B

```

```
;
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: PNO284 (AU)
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: US 08/388,353
; APPLICATION NUMBER: FN3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGILIO
; REFERENCE/DOCKET NUMBER: 9606Z
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 820:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-820

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACA 1669
Db 10 CAGGCTCACA 1

RESULT 402
US-08-478-087-43/c
; Sequence 43, Application US/08478087
; Patent No. 607685
; GENERAL INFORMATION:
; APPLICANT: Trofatter, James A.
; APPLICANT: MacCollin, Mia M.
; APPLICANT: Gusella, James F.
; TITLE OF INVENTION: Tumor Suppressor Gene Merlin and Uses
; TITLE OF INVENTION: Thereof
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, N.W., Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/478,087
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/171,718
```

```
;
; FILING DATE: 22-DEC-1993
; APPLICATION NUMBER: US 08/108,808
; FILING DATE: 19-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/022,034
; FILING DATE: 25-FEB-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/026,063
; FILING DATE: 04-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Anne
; REGISTRATION NUMBER: 36,463
; REFERENCE/DOCKET NUMBER: 0609.3850003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-478-087-43

Query Match 7.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1659 CCAGGCTCAC 1669
Db 10 CCAGGCTCAC 1

RESULT 403
US-08-173-489C-255
; Sequence 255, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 255:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
```

```

; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 238 rRNA gene from Micrococcus luteus
; DESCRIPTION: (Accession # X06484) nucleotides 2795 to 2806
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Micrococcus luteus
; STRAIN: dsm 20030
; PUBLICATION INFORMATION:
; AUTHORS: Regensburger, A, Ludwig, W, Frank, R,
; AUTHORS: Bloecker, H, Schleifer, K H.
; TITLE: Complete nucleotide sequence
; TITLE: of a 23S ribosomal RNA gene from Micrococcus
; TITLE: luteus
; JOURNAL: Nucleic Acids Research
; VOLUME: 16
; PAGES: 2344-2344
; DATE: 1988
; RELEVANT RESIDUES IN SEQ ID NO: 255 :FROM 1 TO 12
;
US-08-173-489C-255
Query Match 7.2%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1747 TCCTATCCT 1756
Db 1 TCCTATCCT 10

RESULT 404
US-08-889-502-3
; Sequence 3, Application US/08889502
; Patent No. 6066726
; GENERAL INFORMATION:
; APPLICANT: Farb, David H
; APPLICANT: Russek, Shelley J
; TITLE OF INVENTION: GENE THERAPY VECTOR WITH TISSUE
; TITLE OF INVENTION: SPECIFICITY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kevin M. Farrell
; STREET: P.O. Box 999
; CITY: York Harbor
; STATE: ME
; COUNTRY: USA
; ZIP: 03911
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/889,502
; FILING DATE: 08-JUL-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Farrell, Kevin M
; REGISTRATION NUMBER: 35,505
; REFERENCE/DOCKET NUMBER: 0146-2008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (207) 363-0558
; TELEFAX: (207) 363-0528
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
;
US-08-889-502-3

```

```

Query Match 7.2%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAG 1730
Db 2 GGAGATGGAG 11

RESULT 405
US-08-889-502-16
; Sequence 16, Application US/08889502
; Patent No. 6066726
; GENERAL INFORMATION:
; APPLICANT: Farb, David H
; APPLICANT: Russek, Shelley J
; TITLE OF INVENTION: GENE THERAPY VECTOR WITH TISSUE
; TITLE OF INVENTION: SPECIFICITY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kevin M. Farrell
; STREET: P.O. Box 999
; CITY: York Harbor
; STATE: ME
; COUNTRY: USA
; ZIP: 03911
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/889,502
; FILING DATE: 08-JUL-1997
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Farrell, Kevin M
; REGISTRATION NUMBER: 35,505
; REFERENCE/DOCKET NUMBER: 0146-2008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (207) 363-0558
; TELEFAX: (207) 363-0528
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
;
US-08-889-502-16
Query Match 7.2%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAG 1730
Db 2 GGAGATGGAG 11

RESULT 406
US-08-192-943-11/c
; Sequence 11, Application US/08192943
; Patent No. 654755
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF DISEASES CAUSED
; TITLE OF INVENTION: BY EXPRESSION OF THE c-MYC
; TITLE OF INVENTION: GENE
; NUMBER OF SEQUENCES: 41
;
US-08-192-943-11/c

```



```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/192,943
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/936,422
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 197/241
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-192-943-11

Query Match 7.2%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1683 TGTCTCTCTCC 1692
Db 11 TGTCTCTCTCC 2

RESULT 407
US-08-434-503-10/c
Sequence 10, Application US/08434503
Patent No. 5616490
GENERAL INFORMATION:
APPLICANT: Sean M. Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: TREATMENT OF INFLAMMATORY
TITLE OF INVENTION: DISEASE
NUMBER OF SEQUENCES: 54
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/434,503
FILING DATE: 04-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/008,895

```

```

FILING DATE: 19-JAN-1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 200/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-503-10

Query Match 7.2%; Score 10; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1693 AGCGTGGTGG 1702
Db 10 AGCGTGGTGG 1

RESULT 408
US-08-440-787A-128/c
Sequence 128, Application US/08440787A
Patent No. 5770434
GENERAL INFORMATION:
APPLICANT: Huse, William D.
TITLE OF INVENTION: Soluble Peptides Having Constrained,
TITLE OF INVENTION: Secondary Conformation in Solution and Method of Making
TITLE OF INVENTION: Same.
NUMBER OF SEQUENCES: 174
CORRESPONDENCE ADDRESS:
ADDRESSEE: Campbell & Flores LLP
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/440,787A
FILING DATE: 15-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/978,893
FILING DATE: 10-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,615
REFERENCE/DOCKET NUMBER: P-IX 1586
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 128:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: misc_feature
LOCATION: 13..14

```

schultz139-3.rni

Mon Aug 30 09:26:46 2004

OTHER INFORMATION: /note= "N = X (used in Table VI),
OTHER INFORMATION: which represents an equal mixture of all four
OTHER INFORMATION: nucleotides."

US-08-440-787A-128

Query Match 7.2%; Score 10; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1718 TACGAGATGGA 1729

Db 15 TNNGAGATGGA 4

RESULT 409

US-08-292-620A-105/c
Sequence 105, Application US/08292620A

Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292.620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 105:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-105

Query Match 7.2%; Score 10; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1670 GCTGGAACCC 1679

Db 13 GCTGGAACCC 4

RESULT 410

US-08-292-620A-106/c

Sequence 106, Application US/08292620A

Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwiggen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292.620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 106:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-106

Query Match 7.2%; Score 10; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1670 GCTGGAACCC 1679

Db 12 GCTGGAACCC 3

RESULT 411

US-09-071-845-105/c
; Sequence 105, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-105

Query Match 7.2%; Score 10; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1670 GCTGGAACCC 1679

Db 13 GCTGGAACCC 4

RESULT 412

US-09-071-845-106/c
; Sequence 106, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 106:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-106

Query Match 7.2%; Score 10; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1670 GCTGGAACCC 1679

Db 12 GCTGGAACCC 3

RESULT 413

US-09-377-310-26
; Sequence 26, Application US/09377310B
; Patent No. 6133031
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: Antisense Modulation of Focal Adhesion Kinase
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0389
; CURRENT APPLICATION NUMBER: US/09/377,310B
; CURRENT FILING DATE: 1999-08-19
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn Ver. 2.0

1668 CAGCTGGAACTGGTGT 1685

STREET: 995 E. Arques

ADDRESSEE: Pharmacyplics, I

[illegible]

```
;
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-06284-2

Query Match
Best Local Similarity 7.2%; Score 10; DB 1; Length 20;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCGTGTGT 1685
Db 1 CATCTGTGAGCCGGTGT 18

RESULT 419
US-09-198-452A-6714
; Sequence 6714, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6714
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6714

Query Match
Best Local Similarity 7.2%; Score 10; DB 1; Length 20;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1746 CTCCTATCC 1755
Db 10 CTCCTATCC 19

RESULT 420
US-08-544-381B-19/c
; Sequence 19, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
```

```
;
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (cligonucleotide)
US-08-544-381B-19
```

```
Query Match
Best Local Similarity 7.1%; Score 9.8; DB 1; Length 13;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGCGACGACCA 1661
Db 13 AGGCGAGACCA 1
```

```
RESULT 421
US-08-544-381B-23/c
; Sequence 23, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
```

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/12305
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004130US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-576-0300
TELEFAX: 415-576-0300
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-23

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGCGAGCACCA 1

RESULT 422
US-08-544-381B-24/c
Sequence 24, Application US/08544381B
Patent No. 6027880
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
TITLE OF INVENTION: Detecting Cystic Fibrosis
NUMBER OF SEQUENCES: 250
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/544,381B
FILING DATE: 10-OCT-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/12305
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-004130US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-576-0200
TELEFAX: 415-576-0300
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-24

Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGCGAGCACCA 1

RESULT 423
US-08-544-381B-26/c
Sequence 26, Application US/08544381B
Patent No. 6027880
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
TITLE OF INVENTION: Detecting Cystic Fibrosis
NUMBER OF SEQUENCES: 250
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/544,381B
FILING DATE: 10-OCT-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995

;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US94/12305
;; FILING DATE: 26-OCT-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/284,064
;; FILING DATE: 02-AUG-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/143,312
;; FILING DATE: 26-OCT-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Liebeschuetz, Joe
;; REGISTRATION NUMBER: 37,505
;; REFERENCE/DOCKET NUMBER: 018547-0041300S
;; TELEPHONE: 415-576-0200
;; TELEFAX: 415-576-0300
;; INFORMATION FOR SEQ ID NO: 26:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (oligonucleotide)
;; US-08-544-381B-26
;
Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1649 AAGGCAAGCACCA 1661
DB 13 AGGCAATCACCA 1
;
RESULT 424
US-08-544-381B-28/c
; Sequence 28, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; TITLE OF INVENTION: Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:

;;
;; FILING DATE: 26-OCT-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/284,064
;; FILING DATE: 02-AUG-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/143,312
;; FILING DATE: 26-OCT-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Liebeschuetz, Joe
;; REGISTRATION NUMBER: 37,505
;; REFERENCE/DOCKET NUMBER: 018547-0041300S
;; TELEPHONE: 415-576-0200
;; TELEFAX: 415-576-0300
;; INFORMATION FOR SEQ ID NO: 28:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 13 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (oligonucleotide)
;; US-08-544-381B-28
;
Query Match 7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1649 AAGGCAAGCACCA 1661
DB 13 AGGCAATCACCA 1
;
RESULT 425
US-08-544-381B-29/c
; Sequence 29, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; TITLE OF INVENTION: Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-00413005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-576-0200
TELEFAX: 415-576-0300
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-29

Query Match 7.1% Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGCAACACCA 1

RESULT 426

US-08-778-794A-77/c
Sequence 77, Application US/08778794A
Patent No. 6309823
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes
TITLE OF INVENTION: for Analyzing Biotransformation Genes
NUMBER OF SEQUENCES: 156
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/778,794A
FILING DATE: 03-JAN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
APPLICATION NUMBER: WO PCT/US94/12305
FILING DATE: 26-OCT-1994
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995

APPLICATION NUMBER: US 08/544,381
FILING DATE: 10-OCT-1995
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-01570005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0200
TELEX:
INFORMATION FOR SEQ ID NO: 77:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-778-794A-77

Query Match 7.1% Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGCGAGCACCA 1

RESULT 427

US-08-778-794A-81/c
Sequence 81, Application US/08778794A
Patent No. 6309823
GENERAL INFORMATION:
APPLICANT: Cronin, Maureen T.
APPLICANT: Miyada, Charles Garrett
APPLICANT: Hubbell, Earl A.
APPLICANT: Chee, Mark
APPLICANT: Fodor, Stephen P.A.
APPLICANT: Huang, Xiaohua C.
APPLICANT: Lipshutz, Robert J.
APPLICANT: Lobban, Peter E.
APPLICANT: Morris, Macdonald S.
APPLICANT: Sheldon, Edward L.
TITLE OF INVENTION: Arrays of Nucleic Acid Probes
TITLE OF INVENTION: for Analyzing Biotransformation Genes
NUMBER OF SEQUENCES: 156
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/778,794A
FILING DATE: 03-JAN-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/143,312
FILING DATE: 26-OCT-1993
APPLICATION NUMBER: US 08/284,064
FILING DATE: 02-AUG-1994
APPLICATION NUMBER: WO PCT/US94/12305
FILING DATE: 26-OCT-1994
APPLICATION NUMBER: US 08/510,521
FILING DATE: 02-AUG-1995
APPLICATION NUMBER: US 08/544,381
FILING DATE: 10-OCT-1995

Mon Aug 30 09:26:46 2004

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-778-794A-81
;
; Query Match 7.1%; Score 9.8; DB 1; Length 13;
; Best Local Similarity 84.6%; Pred. No. 2.3e+02;
; Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1649 AAGGCAAGCACCACCA 1661
DB 13 AGGCGACGACCA 1

RESULT 428
US-08-778-794A-84/C
; Sequence 84, Application US/08778794A
; Patent No. 6309823
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes
; TITLE OF INVENTION: for Analyzing Biotransformation Genes
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/778,794A
; FILING DATE: 03-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: WO PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: US 08/544,381
; FILING DATE: 10-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US

```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 86:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-778-794A-86

Query Match          7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1649 AAGGCAAGCACCA 1661
Db 13 AGGCAACACCA 1

RESULT 430
US-08-778-794A-87/c
; Sequence 87, Application US/08778794A
; Patent No. 6309823
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobb, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/778,794A
; FILING DATE: 03-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: WO PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: US 08/544,381
; FILING DATE: 10-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-778-794A-87

Query Match          7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1649 AAGGCAAGCACCA 1661
Db 13 AGGCAACACCA 1

RESULT 431
US-09-922-445-16/c
; Sequence 16, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
; APPLICANT: Andersson, Maria K.
; APPLICANT: Berglund, Lars G. T.
; APPLICANT: Reneland, Rikard H.
; APPLICANT: Adam, Gail I. R.
; TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
; FILE REFERENCE: GG126US
; CURRENT APPLICATION NUMBER: US/09/922,445
; CURRENT FILING DATE: 2001-08-03
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 13
; TYPE: DNA
; ORGANISM: synthetic
US-09-922-445-16

Query Match          7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1662 GGCTCAGACTCTGG 1674
Db 13 GGCTCAGACTCTGG 1

RESULT 432
US-09-922-445-26
; Sequence 26, Application US/09922445
; Patent No. 6528268
; GENERAL INFORMATION:
; APPLICANT: Andersson, Maria K.
; APPLICANT: Berglund, Lars G. T.
; APPLICANT: Reneland, Rikard H.
; APPLICANT: Adam, Gail I. R.
; TITLE OF INVENTION: REAGENTS AND METHODS FOR DETECTION OF HEART FAILURE
; FILE REFERENCE: GG126US
; CURRENT APPLICATION NUMBER: US/09/922,445
; CURRENT FILING DATE: 2001-08-03
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 13
; TYPE: DNA
; ORGANISM: synthetic
US-09-922-445-26

Query Match          7.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.3e+02;
```

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1662 GGCTCAGACTGG 1674
|||||
Db 1 GGCTCAGACTGG 13

RESULT 433
US-08-913-833-8
; Sequence 8, Application US/08913833
; Patent No. 6087093
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; TITLE OF INVENTION: MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,833
; FILING DATE: 15 Sep 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/00211
; FILING DATE: 17 Jan 1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-913-833-8

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAGA 1731
|||||
Db 1 ACAGAGATGGAAA 13

RESULT 434
US-08-913-833-8
; Sequence 8, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; APPLICANT: Louwagie, Joost

; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
; TITLE OF INVENTION: TRANSCRIPTASE GENE
; FILE REFERENCE: INNS008--2
; CURRENT APPLICATION NUMBER: US/09/580,794C
; CURRENT FILING DATE: 2000-05-30
; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
; PRIOR FILING DATE: 1997-09-15
; PRIOR APPLICATION NUMBER: PCT/EP 97/00211
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: EP 96870005.4
; PRIOR FILING DATE: 1996-01-26
; PRIOR APPLICATION NUMBER: EP 96870081.5
; PRIOR FILING DATE: 1996-06-25
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 8
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-580-794C-8

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAGA 1731
|||||
Db 1 ACAGAGATGGAAA 13

RESULT 435
US-09-328-174A-40/c
; Sequence 40, Application US/09328174A
; Patent No. 6448003
; GENERAL INFORMATION:
; APPLICANT: Guida, Marco
; APPLICANT: Kurth, Janice
; TITLE OF INVENTION: Genotyping Human Phenol Sulfotransferase
; TITLE OF INVENTION: (STP2)
; FILE REFERENCE: 4389-6 (formerly SEQ-16P)
; CURRENT APPLICATION NUMBER: US/09/328,174A
; CURRENT FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: 09/328,174
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 40
; LENGTH: 14
; TYPE: DNA
; ORGANISM: H. sapiens
US-09-328-174A-40

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 TGTAGCAGAGGC 1653
|||||
Db 14 TGTGCGAGCAGGC 2

RESULT 436
US-09-230-652-23
; Sequence 23, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois

;
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/230,652A
; CURRENT FILING DATE: 1999-05-17
; EARLIER APPLICATION NUMBER: FR 96 09733
; EARLIER FILING DATE: 1996-08-01
; EARLIER APPLICATION NUMBER: FR 97 04680
; EARLIER FILING DATE: 1997-04-16
; EARLIER APPLICATION NUMBER: PCT/FR97/01433
; EARLIER FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-23

Query Match 7.1%; Score 9.8; DB 1; Length 14;
Best Local Similarity 84.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CACAGCTGGACC 1678
||| ||| ||| |||
DB 2 CACAGGTGGACC 14

RESULT 437
US-08-050-073-153
; Sequence 153, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A. L.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRbeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 153:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

;
; MOLECULE TYPE: genomic DNA
US-08-050-073-153

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1639 CTTGTAGCAGAAG 1651
||| ||| ||| |||
DB 3 CCTGGAGCAGAAG 15

RESULT 438
US-08-182-968A-29
; Sequence 29, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-29

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1749 CCTATCCTAAAGG 1761
||| ||| ||| |||
DB 3 CCUAUCCCAAGG 15

RESULT 439
US-08-182-968A-483/c
; Sequence 483, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 0;

QY 1728 GAGATTGGCTCC 1740
DB 13 GTGATTAGCTCC 1

RESULT 441
US-08-291-932A-8
Sequence 8, Application US/08291932A
Patent No. 5638780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: described below:
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
FILING DATE: December 7, 1992
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 205/277
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 494:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-968A-494

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 0;

QY 1642 GTAGAGAGGCA 1654
DB 15 GTAGAGTAGGCA 3

RESULT 440
US-08-182-968A-494/c
Sequence 494, Application US/08182968A
Patent No. 5610054
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-8

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 61.5%; Pred. No. 3e+02;
Matches 8; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1689 CTCACGCTGGTG 1701
Db 3 CUCCUACGGUGG 15

RESULT 442

US-08-291-932A-54/c
Sequence 54, Application US/08291932A
Patent No. 5658780

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
FILING DATE: December 7, 1992

Two

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-291-932A-54

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1712 TAGGAGTAGCGAG 1724
Db 14 TCGGCGTAGCGAG 2

RESULT 443

US-08-291-932A-159
Sequence 159, Application US/08291932A
Patent No. 5658780

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
FILING DATE: December 7, 1992

Two

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 159:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

Two

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 159:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCC 1750
Db 1 CCCAGCUCUGCC 13

```

;
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 189:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-291-932A-189
Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 65.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCC 1750
Db 1 CCCAGCUCGCGCC 13

RESULT 446
US-08-291-932A-339
; Sequence 339, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California

```

Two

```

;
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 161:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-291-932A-161
Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCC 1750
Db 1 CCCAGCUCGCGCC 13

RESULT 445
US-08-291-932A-189
; Sequence 189, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF

```

Two

/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/291,932A
/ FILING DATE: August 15, 1994
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/245,466
/ FILING DATE: May 18, 1994
/ APPLICATION NUMBER: 07/987,132
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/157
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 339:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-291-932A-339

Two

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 3e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1680 TGGTGTCCTCC 1692
Db 2 UGGUGUCCUUC 14

RESULT 447
US-08-291-932A-348
/ Sequence 348, Application US/08291932A
/ Patent No. 5658780
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: NF-KB
/ NUMBER OF SEQUENCES: 830
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/291,932A

/ FILING DATE: August 15, 1994
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/245,466
/ FILING DATE: May 18, 1994
/ APPLICATION NUMBER: 07/987,132
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/157
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 348:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-291-932A-348

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAAGUCCG 1750
Db 1 CCCAAGUCCG 13

RESULT 448
US-08-393-219-8
/ Sequence 8, Application US/08393219
/ Patent No. 5689040
/ GENERAL INFORMATION:
/ APPLICANT: HARADA, John J.
/ TITLE OF INVENTION: PLANT PROMOTER SEQUENCES USEFUL FOR GENE
/ TITLE OF INVENTION: EXPRESSION IN SEEDS AND SEEDLINGS
/ NUMBER OF SEQUENCES: 25
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend Kourie and Crew
/ STREET: One Market Plaza, Steuart Street tower, 20th
/ STREET: Floor
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: US
/ ZIP: 94105
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/393,219
/ FILING DATE: 23-FEB-1995
/ CLASSIFICATION: 800
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Bastian, Kevin L.
/ REGISTRATION NUMBER: 34,774
/ REFERENCE/DOCKET NUMBER: 2307E-581
/ TELEPHONE: (415) 543-9600
/ TELEFAX: (415) 543-5043
/ INFORMATION FOR SEQ ID NO: 8:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear

```

; MOLECULE TYPE: DNA
US-08-393-219-8
;
; Query Match 7.1%; Score 9.8; DB 1; Length 15;
; Best Local Similarity 84.6%; Pred. No. 3e+02;
; Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCACTC 1745
Db 3 TGGATCCAGCTC 15

RESULT 449
US-08-334-847-309/c
; Sequence 309, Application US/08334847
; Patent No. 5693532
;
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
;
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYIAL VIRUS
;
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
;
; INFORMATION FOR SEQ ID NO: 309:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-334-847-309
;
; Query Match 7.1%; Score 9.8; DB 1; Length 15;
; Best Local Similarity 84.6%; Pred. No. 3e+02;
; Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1724 GATGAGATTGCG 1736
Db 14 GATGAATATTGCG 2

RESULT 450
US-08-305-699-1/c
; Sequence 1, Application US/08305699
;
; GENERAL INFORMATION:
; APPLICANT: Klump, Wolfgang M.
; APPLICANT: Jolly, Douglas J.
;
; TITLE OF INVENTION: Methods and Compositions for Inhibiting
; TITLE OF INVENTION: Production of Replication Competent Virus
;
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: U.S.A.
; ZIP: 98104-7092
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/305,699
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Chambers, Daniel M.
; REGISTRATION NUMBER: 34,561
; REFERENCE/DOCKET NUMBER: 930049.436
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; TELEX: 3723836 seedanberry
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
;
; US-08-305-699-1
;
; Query Match 7.1%; Score 9.8; DB 1; Length 15;
; Best Local Similarity 84.6%; Pred. No. 3e+02;
; Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1695 CGTGTGGAGATT 1707
Db 13 CATGTGGAGCT 1

RESULT 451
US-08-363-240A-626/c
; Sequence 626, Application US/08363240A
; Patent No. 5705388
;
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
;
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
;
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 626:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-626

```

```

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCCTGGTGCTC 1688
    ||||| |||||
DB 13 ACCCGATGTCTC 1

```

```

RESULT 452
US-08-363-240A-684
; Sequence 684, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096

```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEX: (213) 955-0440
; TELEFAX: 67-3510
; INFORMATION FOR SEQ ID NO: 684:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-684

```

```

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 46.2%; Pred. No. 3e+02;
Matches 6; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1680 TGGTGCTCTCTCC 1692
    :|||:|:|:|:|
DB 2 DGGUGUCUUCUUC 14

```

```

RESULT 453
US-08-221-816B-21/c
; Sequence 21, Application US/08221816B
; Patent No. 5738985
; GENERAL INFORMATION:
; APPLICANT: Miles, Vincent J.
; APPLICANT: Mathews, Michael B.
; APPLICANT: Katze, Michael G.
; APPLICANT: Witherell, Gary
; APPLICANT: Watson, Julia C.
; TITLE OF INVENTION: METHOD FOR SELECTIVE INACTIVATION
; TITLE OF INVENTION: OF VIRAL REPLICATION
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/221,816B
; FILING DATE: 01-APR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7960-030
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-221-816B-21

```

```

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCTGGTG 1684
    ||||| |||||

```

Db 13 TCGAACCCAGGTG 1

RESULT 454

US-08-311-486C-77/C

; Sequence 77, Application US/08311486C

; Patent No. 5811300

; GENERAL INFORMATION:

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth Draper

; APPLICANT: Kevin Kisich

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: TNF-

; NUMBER OF SEQUENCES: 1157

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/311,486C

; FILING DATE: September 23, 1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA: including application

; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 209/166

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 77:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-311-486C-77

Query Match 7.1%; Score 9.8; DB 1; Length 15;

Best Local Similarity 84.6%; Pred. No. 3e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1708 GGGTTAGGAGTAC 1720

Db 15 GGGTGAGGAGCAC 3

RESULT 455

US-08-311-486C-78/C

; Sequence 78, Application US/08311486C

; Patent No. 5811300

; GENERAL INFORMATION:

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth Draper

; APPLICANT: Kevin Kisich

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: TNF-

; NUMBER OF SEQUENCES: 1157

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/311,486C

; FILING DATE: September 23, 1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA: including application

; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 209/166

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 77:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-311-486C-78

Query Match 7.1%; Score 9.8; DB 1; Length 15;

Best Local Similarity 84.6%; Pred. No. 3e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1707 TGGGTTAGGAGTA 1719

Db 13 TGGGTGAGGAGCA 1

RESULT 456

US-08-311-486C-600/C

; Sequence 600, Application US/08311486C

; Patent No. 5811300

; GENERAL INFORMATION:

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth Draper

; APPLICANT: Kevin Kisich

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: TNF-

; NUMBER OF SEQUENCES: 1157

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/311,486C

; FILING DATE: September 23, 1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA: including application

; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 209/166

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 78:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-311-486C-78

Query Match 7.1%; Score 9.8; DB 1; Length 15;

Best Local Similarity 84.6%; Pred. No. 3e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1707 TGGGTTAGGAGTA 1719

Db 13 TGGGTGAGGAGCA 1

;; TITLE OF INVENTION: TNF-
;; NUMBER OF SEQUENCES: 1157
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,486C
;; FILING DATE: September 23, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/166
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 600:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-311-486C-600

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1707 TGGGTAGGAGTA 1719
Db 13 TGGGTAGGAGCA 1

RESULT 457
US-08-311-486C-621/c
; Sequence 621, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California

;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/311,486C
;; FILING DATE: September 23, 1994
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/166
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 621:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-311-486C-621

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACCCCT 1680
Db 15 CAGCTGGAGACT 3

RESULT 458
US-08-311-486C-622/c
; Sequence 622, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; NAME: Warburg, Richard J.
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 622:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-622

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCT 1680
DB 14 CAGCTGGAAGACT 2

RESULT 459
US-08-292-620A-500
; Sequence 500, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below;
```

```
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; NAME: Warburg, Richard J.
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 500:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-500

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 61.5%; Pred. No. 3e+02;
Matches 8; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCC 1755
DB 3 CUCCUCCAUCC 15

RESULT 460
US-08-173-489C-277
; Sequence 277, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 277:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 16S rRNA gene from Alcaligenes
```

two

DESCRIPTION: faecalis (Accession # M22508, M22467)
HYPOTHETICAL: nucleotides 1169 to 1183
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Alcaligenes faecalis
PUBLICATION INFORMATION:
AUTHORS: Dewhirst, F E, Paster, B J, Bright,
P.L.
TITLE: Chromobacterium, Bikenella,
Kingella, Neisseria, Simonsiella and
Vitreoscilla species comprise a major branch of
the beta group Proteobacteria by 16S rRNA
TITLE: sequence comparison
JOURNAL: International Journal of Systematic
JOURNAL: Biology
VOLUME: 0
PAGES: 0-0
DATE: 1990
RELEVANT RESIDUES IN SEQ ID NO: 277 :FROM 1 TO 15
US-08-173-489C-277

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGG 1710
DB 1 GGAGGAAGTGGG 13

RESULT 461
US-08-173-489C-283
Sequence 283, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 283:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear

MOLECULE TYPE: genomic DNA
DESCRIPTION: 16s rRNA gene from *Coxiella burnetii*
HYPOTHETICAL: (Accession # M21291) nucleotides 1174 to 1188
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: *Coxiella burnetii*
PUBLICATION INFORMATION:
AUTHORS: Weisburg, W G, Dobson, M E, Samuel, J E,
AUTHORS: Dasch, G A, Mallavia, L P, Mandelco, L,
AUTHORS: Schrest, J E, Weiss, E, Woese, C R.
TITLE: Phylogenetic diversity of the
TITLE: Rickettsiae
JOURNAL: Journal of Bacteriology
VOLUME: 171
PAGES: 4202-4206
DATE: 1989
RELEVANT RESIDUES IN SEQ ID NO: 283 :FROM 1 TO 15
US-08-173-489C-283

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGG 1710
DB 1 GGAGGAAGTGGG 13

RESULT 462
US-08-173-489C-327
Sequence 327, Application US/08173489C
Patent No. 5861244
GENERAL INFORMATION:
APPLICANT: WANG, C. -G.
APPLICANT: HEPBURN, A. G.
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
NUMBER OF SEQUENCES: 365
CORRESPONDENCE ADDRESS:
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
STREET: 510 EAST 73RD STREET,
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10021.
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44mb storage
COMPUTER: IBM PC/XT/AT
OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 327:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
DESCRIPTION: 16s rRNA gene from *Mycobacterium*

```
;
; DESCRIPTION: paratuberculosis (Accession # M29569)
; DESCRIPTION: nucleotides 1159 to 1173
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Mycobacterium paratuberculosis
; PUBLICATION INFORMATION:
; AUTHORS: Stahl, D A, Urbance, J W.
; TITLE: The division between fast-
; TITLE: and slow-growing species corresponds to natural
; TITLE: relationships among the mycobacteria
; JOURNAL: Journal of Bacteriology
; VOLUME: 172
; PAGES: 116-124
; DATE: 1989
; RELEVANT RESIDUES IN SEQ ID NO: 327 :FROM 1 TO 15
US-08-173-489C-327

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1698 GGTGGAAGTTGGG 1710
      || ||||| |||||
Db      1 GGAGGAGGTGGG 13

RESULT 463
US-08-173-489C-337
; Sequence 337, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 337:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 16S rRNA gene from Neisseria
; DESCRIPTION: gonorrhoeae (Accession # X07714) nucleotides
; DESCRIPTION: 1174 to 1188
```

```
;
; HYPOTHETICAL: no
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Neisseria gonorrhoeae
; STRAIN: NCTC 83785
; PUBLICATION INFORMATION:
; AUTHORS: Rossau, R, Heyndrickx, L, van
; AUTHORS: Heuvels, H.
; TITLE: Nucleotide sequence of a 16S
; TITLE: ribosomal RNA gene from Neisseria gonorrhoeae
; JOURNAL: Nucleic Acids Research
; VOLUME: 16
; PAGES: 6227-6227
; DATE: 1988
; RELEVANT RESIDUES IN SEQ ID NO: 337 :FROM 1 TO 15
US-08-173-489C-337

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1698 GGTGGAAGTTGGG 1710
      || ||||| |||||
Db      1 GGAGGAGGTGGG 13

RESULT 464
US-08-173-489C-343
; Sequence 343, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 343:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 16S rRNA gene from Pseudomonas cepacia
; DESCRIPTION: (Accession # M22518, M22467) nucleotides 1165
; HYPOTHETICAL: no
; ANTI-SENSE: no
```



```
;
; ORIGINAL SOURCE:
; ORGANISM: Pseudomonas cepacea
; PUBLICATION INFORMATION:
; AUTHORS: Dewhirst, F E, Paster, B J, Bright, P L.
; TITLE: Chromobacterium, Eikenella,
; TITLE: Kingella, Neisseria, Simonsiella and
; TITLE: Vitreoscilla species comprise a major branch of
; TITLE: the beta group Proteobacteria by 16S rRNA
; TITLE: sequence comparison
; JOURNAL: International Journal of Systematic
; JOURNAL: Bacteriology
; VOLUME: 0
; PAGES: 0-0
; DATE: 1990
; RELEVANT RESIDUES IN SEQ ID NO: 343 :FROM 1 TO 15
US-08-173-489C-343

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred.No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGG 1710
Db 1 GGAGGAGGTGGG 13

RESULT 465
US-08-173-489C-347
; Sequence 347, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 347:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; DESCRIPTION: 16S rRNA gene from Streptococcus
; DESCRIPTION: parasanguis (Accession # X53652) nucleotides
; DESCRIPTION: 1178 to 1192
; HYPOTHETICAL: no
```

```
;
; ANTI-SENSE: no
; ORIGINAL SOURCE:
; ORGANISM: Streptococcus parasanguis
; STRAIN: 85-81
; PUBLICATION INFORMATION:
; AUTHORS: Whitley, R A, Fraser, H Y, Douglas, C W
; AUTHORS: I, Hardie, J M, Williams, A M, Collins, M D.
; TITLE: Streptococcus parasanguis sp
; TITLE: nov., an atypical viridans Streptococcus from
; TITLE: human clinical specimens
; JOURNAL: FEMS Microbiology Letters
; VOLUME: 68
; PAGES: 115-122
; DATE: 1990
; RELEVANT RESIDUES IN SEQ ID NO: 347 :FROM 1 TO 15
US-08-173-489C-347

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred.No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGG 1710
Db 1 GGAGGAGGTGGG 13

RESULT 466
US-08-774-306A-29
; Sequence 29, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-306A-29
```

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 3e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1749 CCTATCCTAAAGG 1761
DB 3 CCUAUCCCCAAGG 15

RESULT 467
US-08-774-306A-483/c
; Sequence 483, Application US/08774306A
; Patent No. 5869253

; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; INHIBITING HEPATITIS C
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 483:

SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-774-306A-483

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1642 GTAGCAGTAGGCA 1654
DB 15 GTAGGAGTAGGCA 3

RESULT 468
US-08-774-306A-494/c
; Sequence 494, Application US/08774306A
; Patent No. 5869253

; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.

; TITLE OF INVENTION: METHOD AND REAGENT FOR
; INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 494:

SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-774-306A-494

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1728 GAGATTGGCTCCC 1740
DB 13 GTGATTAGCTCCC 1

RESULT 469
US-08-585-684B-186
; Sequence 186, Application US/08585684B
; Patent No. 5877021

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 186:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-186

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 3e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1682 GTGTCCTCTCCAG 1694
Db 2 GUGUCUACUACAG 14

RESULT 470
US-08-585-684B-1364/c
; Sequence 1364, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2048:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2048

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 3e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1679 CTGCTGTCCTC 1691
Db 1 CTGCTGTCCTC 1691

RESULT 471
US-08-585-684B-2048
; Sequence 2048, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2048:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2048

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 3e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1679 CTGCTGTCCTC 1691
Db 1 CTGCTGTCCTC 1691
```

Db 1 CUGGUCUACCUC 13

RESULT 472

US-08-182-067-11/c

; Sequence 11, Application US/08182067

; Patent No. 5985279

; GENERAL INFORMATION:

; APPLICANT: WALDMANN, HERMAN

; APPLICANT: SIMS, MARTIN

; APPLICANT: CROME, J. SCOTT

; TITLE OF INVENTION: HUMANIZED ANTIBODY AGAINST CD18

; NUMBER OF SEQUENCES: 35

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Rothwell, Figg Ernst & Kurz

; STREET: Suite 701-E, 555 Thirteenth St., N.W.

; CITY: Washington

; STATE: D. C.

; COUNTRY: U.S.A.

; ZIP: 20004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/182,067

; FILING DATE: 23-MAR-1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/GB92/01289

; FILING DATE: 15-JUL-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9115364.3

; FILING DATE: 16-JUL-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: ERNST, BARBARA G.

; REGISTRATION NUMBER: 30,377

; REFERENCE/DOCKET NUMBER: 1786-118A

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202)783-6040

; TELEFAX: (202)783-6031

; INFORMATION FOR SEQ ID NO: 11:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; ORIGINAL SOURCE:

; ORGANISM: Rattus rattus

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: 1..15

; OTHER INFORMATION: /function= "CDR 1"

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 1..15

US-08-182-067-11

Query Match

Best Local Similarity 7.1%; Score 9.8; DB 1; Length 15;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCAGAGGCGAAGC 1657

Db 13 GCAGAGGCGTAATC 1

RESULT 473

US-08-465-313-11/c

; Sequence 11, Application US/08465313

; Patent No. 5997867

; GENERAL INFORMATION:

; APPLICANT: WALDMANN, HERMAN

; APPLICANT: SIMS, MARTIN J.

; APPLICANT: CROME, J. SCOTT

; TITLE OF INVENTION: HUMANIZED ANTIBODY AGAINST CD18

; NUMBER OF SEQUENCES: 35

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

; STREET: TWO MILITIA DRIVE

; CITY: LEXINGTON

; STATE: MASSACHUSETTS

; COUNTRY: USA

; ZIP: 02173

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/465,313

; FILING DATE: 05-JUN-1995

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/182,067

; FILING DATE: 23-MAR-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/GB92/01289

; FILING DATE: 15-JUL-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9115364.3

; FILING DATE: 16-JUL-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: BROOK, DAVID E.

; REGISTRATION NUMBER: 22,592

; REFERENCE/DOCKET NUMBER: LYNX91-01A2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 861-6240

; TELEFAX: (617) 861-9540

; INFORMATION FOR SEQ ID NO: 11:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; ORIGINAL SOURCE:

; ORGANISM: Rattus rattus

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: 1..15

; OTHER INFORMATION: /function= "CDR 1"

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 1..15

US-08-465-313-11

Query Match

Best Local Similarity 7.1%; Score 9.8; DB 1; Length 15;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCAGAGGCGAAGC 1657

Db 13 GCAGAGGCGTAATC 1

RESULT 474

US-08-486-343A-6

; Sequence 6, Application US/08486343A

; Patent No. 6071695

; GENERAL INFORMATION:

; APPLICANT: OZKAYNAK, ENGIN

; APPLICANT: OPPERMANN, HERMANN

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING


```

; TELEFAX: 781-276-4931
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "OLIGONUCLEOTIDE"
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-963-472-10
;
Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1634 TGGGGCTTGTGAC 1646
Db 15 TGGAGCTTGTGC 3

RESULT 478
US-09-064-156A-29
; Sequence 29, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-064-156A-29
;
Query Match 7.1%; Score 9.8; DB 1; Length 15;

```

Best Local Similarity 69.2%; Pred. No. 3e+02; Indels 2; Mismatches 2; Gaps 0;
Matches 9; Conservative 0;

Qy 1749 CCTATCCTAAAGG 1761
||:|:|:|
Db 3 CCUAUCCCAAGG 15

RESULT 479

US-09-064-156A-483/c
; Sequence 483, Application US/09064156A
; Patent No. 6132966

GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998

PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992

ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

; TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 483:

SEQUENCE CHARACTERISTICS:

; LENGTH: 15

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-09-064-156A-483

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1642 GTAGCAGAAGCA 1654
|||:|:|:|
Db 15 GTAGAGTAGGCA 3

RESULT 480

US-09-064-156A-494/c

; Sequence 494, Application US/09064156A
; Patent No. 6132966

GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.

; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998

PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992

ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

; TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 494:

SEQUENCE CHARACTERISTICS:

; LENGTH: 15

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-09-064-156A-494

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1728 GAGATTGGCTCCC 1740
|||:|:|:|
Db 13 GTGATTAGCTCCC 1

RESULT 481

US-09-071-845-500

; Sequence 500, Application US/09071845
; Patent No. 6132967

GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 500:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-500

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 61.5%; Pred. No. 3e+02;
Matches 8; Conservative 3; Mismatches 2; Indels

Qy 1743 CTCCTCCCTATCC 1755
|:|:|:|:|:|:
Db 3 CUCUCCACAUC 15

RESULT 482
US-09-038-073-186
; Sequence 186, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/038,078
 FILING DATE:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/585,684
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 218/078
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 186:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-09-038-073-186

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 3e+02;
Matches 7; Conservative 4; Mismatches 2; Indels

Qy 1682 GTGTCTCTCCAG 1694
|:|:|:|:|:|
Db 2 GUGUCUCAUCAAG 14

RESULT 483
US-09-038-073-1364/c
; Sequence 1364, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1364:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs


```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-1364

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1667 ACAGCTGGAACCC 1679
   |||||
Db 15 ACAGCTGTAATCC 3

RESULT 484
US-09-038-073-2048
; Sequence 2048, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2048:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2048

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 53.8%; Pred. No. 3e+02;
Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1679 CTGGTGCTCCTC 1691
   |||:|:|:|:|
Db 1 CUGGUCACCCUC 13

RESULT 485
US-09-580-794C-2

; Sequence 2, Application US/09580794C
; Patent No. 6331389
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; APPLICANT: Louwagie, Joost
; APPLICANT: Rossau, Rudi
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
; TITLE OF INVENTION: TRANSCRIPTASE GENE
; FILE REFERENCE: INNS008--2
; CURRENT APPLICATION NUMBER: US/09/580,794C
; CURRENT FILING DATE: 2000-05-30
; PRIOR APPLICATION NUMBER: 08/913,833 now US/6,087,093
; PRIOR FILING DATE: 1997-09-15
; PRIOR APPLICATION NUMBER: PCT/EP 97/00211
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: EP 96870005.4
; PRIOR FILING DATE: 1996-01-26
; PRIOR APPLICATION NUMBER: EP 96870081.5
; PRIOR FILING DATE: 1996-06-25
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-09-580-794C-2

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGA 1729
   |||||
Db 2 GTACAGAAATGGA 14

RESULT 486
US-09-081-646-50
; Sequence 50, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 50
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-50

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 AGCAAGCACCAG 1662
   |||||
Db 2 ATGCAAGGACCAG 14

RESULT 487
US-09-081-646-294/c
```

```
; Sequence 294, Application US/09081646
; Patent No. 633152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 633152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 294
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-294

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1669 AGCTGAACCCCTG 1681
DB 13 AGCTGAAGCATG 1

RESULT 488
US-09-081-646-621/c
; Sequence 621, Application US/09081646
; Patent No. 633152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 633152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 621
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-621

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1669 AGCTGAACCCCTG 1681
DB 13 AGCTGAAGCATG 1

RESULT 489
US-09-081-646-639
; Sequence 639, Application US/09081646
; Patent No. 633152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 633152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 639
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-639

Query Match          7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1725 ATGGAGATGGCT 1737
DB 2 ATGGAGAGTGCT 14

RESULT 490
US-08-584-040-8497
; Sequence 8497, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IEM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 485-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8497:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

APPLICANT: HYLDIG-NIELSEN, Jens J

PCT-US95-07349-6

Query Match 7.1%; Score 9.8; DB 1; Length 15;
Best Local Similarity 84.6%; Pred.No.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 TCCTCCCTATCCT 1756
|||||||
Db 1 TCCTCCGCTCCT 13

RESULT 498
US-09-050-159-111/c
; Sequence 111, Application US/09050159A
; Patent No. 6197505
; GENERAL INFORMATION:
; APPLICANT: No. 6197505berg, Leif T
; APPLICANT: Andersson, Maria K
; APPLICANT: Linstrom, Per H
; TITLE OF INVENTION: METHODS FOR ASSESSING CARDIOVASCULAR STATUS AND
; FILE OF INVENTION: COMPOSITIONS FOR USE THEREOF
; FILE REFERENCE: 1248/1D042
; CURRENT APPLICATION NUMBER: US/09/050,159A
; CURRENT FILING DATE: 1998-03-27
; EARLIER APPLICATION NUMBER: 60/042,930
; EARLIER FILING DATE: 1987-04-03
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 111
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-09-050-159-111

Query Match 7.1%; Score 9.8; DB 1; Length 18;
Best Local Similarity 84.6%; Pred.No.3.9e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAGGTGGG 1710
|||||
Db 13 GGAGGAGGTGGG 1

RESULT 499
US-09-548-797B-106
; Sequence 106, Application US/09548797B
; Patent No. 6683165
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND
; FILE REFERENCE: 2976-4039
; CURRENT APPLICATION NUMBER: US/09/548,797B
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: 60/129,391
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 106
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-548-797B-106

Query Match 7.1%; Score 9.8; DB 1; Length 18;
Best Local Similarity 84.6%; Pred.No.3.9e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCCTGGTGTCTCC 1689

Db 2 CCTGGTGTCTCC 14

RESULT 500
US-08-544-381B-13/c
; Sequence 13, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; TITLE OF INVENTION: Detecting Cystic Fibrosis
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; PRIOR APPLICATION DATA: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; US-08-544-381B-13

Query Match 6.9%; Score 9.6; DB 1; Length 13;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGGRMNCACCA 1

RESULT 501
US-08-778-794A-71/c
; Sequence 71, Application US/08778794A
; Patent No. 6309823
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes
; TITLE OF INVENTION: for Analyzing Biotransformation Genes
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/778,794A
; FILING DATE: 03-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: WO PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: US 08/544,381
; FILING DATE: 10-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-778-794A-71

Query Match 6.9%; Score 9.6; DB 1; Length 13;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGGRMNCACCA 1

RESULT 502
US-08-778-794A-95/c
; Sequence 95, Application US/08778794A
; Patent No. 6309823
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes
; TITLE OF INVENTION: for Analyzing Biotransformation Genes
; NUMBER OF SEQUENCES: 156
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/778,794A
; FILING DATE: 03-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: WO PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: US 08/544,381
; FILING DATE: 10-OCT-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-015700US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-778-794A-95

Query Match 6.9%; Score 9.6; DB 1; Length 13;
Best Local Similarity 69.2%; Pred. No. 2.6e+02;
Matches 9; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1649 AAGGCAAGCACCA 1661
Db 13 AGGCGRNACCA 1

RESULT 503
US-07-696-793A-9

; Sequence 9, Application US/07696793A
; Patent No. 5220004
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cetus Corporation
; STREET: 1400 Fifty-Third Street
; CITY: Emeryville
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 94608
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/696,793A
; FILING DATE: 19910507
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kevin R. Kaster
; REGISTRATION NUMBER: 32704
; REFERENCE/DOCKET NUMBER: 2598
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 420-3444
; TELEFAX: (415) 658-5239
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-07-696-793A-9

Query Match 6.9%; Score 9.6; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1657 CACCAGGCTCACGCT 1672
Db 1 CACCAAGCTTCCACCT 16

RESULT 504
US-07-977-694-9
; Sequence 9, Application US/07977694
; Patent No. 5273883
; GENERAL INFORMATION:
; APPLICANT: Saiki, Randall K.
; APPLICANT: Nasarabadi, Shanavaz L.
; TITLE OF INVENTION: Methods and Reagents for G Gamma Globin
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 58
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110-1199
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5

```

;
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,694
; FILING DATE: 19921117
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Stacey R. Sias, Ph.D.
; REGISTRATION NUMBER: 32,630
; REFERENCE/DOCKET NUMBER: 8733
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2863
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
;
US-07-977-694-9
Query Match 6.9%; Score 9.6; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 3.6e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1657 CACCAGGCTCACAGCT 1672
Db 1 CACCAGGCTCCACCT 16

RESULT 505
US-09-371-772B-5954
; Sequence 5954, Application US/09371772B
; Patent No. 6566127
;
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-371-772B-5954
Query Match 6.9%; Score 9.6; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 3.6e+02;
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAACCT 1680
Db 1 UCCAGCUCUGACCCU 16

RESULT 506
US-09-187-946-16
; Sequence 16, Application US/09187946
; Patent No. 6255467
;
; GENERAL INFORMATION:
; APPLICANT: Lindner, Luther E.
; APPLICANT: Macphee, Kathleen
; TITLE OF INVENTION: Human Blood Bacterium
; FILE REFERENCE: D6026
; CURRENT APPLICATION NUMBER: US/09/187,946
; CURRENT FILING DATE: 1998-11-02
; EARLIER APPLICATION NUMBER: US 60/064,472
; EARLIER FILING DATE: 1997-11-06
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 16
; LENGTH: 17
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: primer bind
; OTHER INFORMATION: primer specific for intergenic spacer region (IGS)
; OTHER INFORMATION: sequence of a new human blood bacterium
;
US-09-187-946-16
Query Match 6.9%; Score 9.6; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.9e+02;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAACCC 1679
Db 2 CTCACAGCTTCCACCC 17

RESULT 507
US-08-584-040-2237
; Sequence 2237, Application US/08584040
; Patent No. 6346398
;
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Watburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
;

```


; INFORMATION FOR SEQ ID NO: 2237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2237

Query Match
Best Local Similarity 6.9%; Score 9.6; DB 1; Length 17;
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAAACCT 1680
:|||||: |||:
Db 1 UCCAGCUCUGACCCU 16

RESULT 508

US-09-371-772B-782
; Sequence 782, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 782
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-782

Query Match
Best Local Similarity 6.9%; Score 9.6; DB 1; Length 17;
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAAACCT 1680
:|||||: |||:
Db 1 UCCAGCUCUGACCCU 16

RESULT 509

US-09-371-772B-5167
; Sequence 5167, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Treatment of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5167

Query Match
Best Local Similarity 6.9%; Score 9.6; DB 1; Length 17;
Matches 9; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1665 TCACAGCTGGAAACCT 1680
:|||||: |||:
Db 2 UCCAGCUCUGACCCU 17

RESULT 510

US-08-754-477A-109/c
; Sequence 109, Application US/08754477A
; Patent No. 6518411
; GENERAL INFORMATION:
; APPLICANT: Murray, Jeffrey
; APPLICANT: Semina, Elena
; TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
; TITLE OF INVENTION: AND DIAGNOSTIC USES THEREFOR
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477A
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-754-477A-109

Query Match
Best Local Similarity 6.9%; Score 9.6; DB 1; Length 20;
Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1710 GTTAGGATCGGAGA 1725
:|||||: |||:
Db 19 GTGAGGAATTCGAGA 4

RESULT 511

US-08-757-024-530
; Sequence 530, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA

11 TTGGCTTCCAA 1
Db
RESULT 513
US-09-249-155A-43
Sequence 43, Application US/09249155A
Patent No. 6538173
GENERAL INFORMATION:
APPLICANT: Heber-Katz, Ellen
TITLE OF INVENTION: Compositions and Methods for Wound
Healing
FILE REFERENCE: 00486.78503
CURRENT APPLICATION NUMBER: US/09/249,155A
CURRENT FILING DATE: 1993-02-12
PRIOR APPLICATION NUMBER: US 60/074,737
PRIOR FILING DATE: 1998-02-13
PRIOR APPLICATION NUMBER: US 60/097,937
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: US 60/102,051
PRIOR FILING DATE: 1998-09-28
NUMBER OF SEQ ID NOS: 346
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 43
LENGTH: 11
TYPE: DNA
ORGANISM: Mus musculus
US-09-249-155A-43
Query Match 6.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1651 GGCAAGCACCA 1661
Db 1 GGCAAGCCCCA 11
RESULT 514
US-09-249-155A-181
Sequence 181, Application US/09249155A
Patent No. 6538173
GENERAL INFORMATION:
APPLICANT: Heber-Katz, Ellen
TITLE OF INVENTION: Compositions and Methods for Wound
Healing
FILE REFERENCE: 00486.78503
CURRENT APPLICATION NUMBER: US/09/249,155A
CURRENT FILING DATE: 1999-02-12
PRIOR APPLICATION NUMBER: US 60/074,737
PRIOR FILING DATE: 1998-02-13
PRIOR APPLICATION NUMBER: US 60/097,937
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: US 60/102,051
PRIOR FILING DATE: 1998-09-28
NUMBER OF SEQ ID NOS: 346
SOFTWARE: FastSEQ for Windows Version 4.0
SEQ ID NO 181
LENGTH: 11
TYPE: DNA
ORGANISM: Mus musculus
US-09-249-155A-181
Query Match 5.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1651 GGCAAGCACCA 1661
Db 1 GGCAAGCCCCA 11
RESULT 515

NUMBER OF SEQUENCES: 952
CORRESPONDENCE ADDRESS:
ADDRESSEE: BELL, SELTZER, PARK & GIBSON
STREET: P.O. Drawer 34009
CITY: Charlotte
STATE: No. 6025339th Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/757,024
FILING DATE: 26-NOV-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5218-41
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-881-3140
TELEFAX: 919-881-3175
TELEX: 575102
INFORMATION FOR SEQ ID NO: 530:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-757-024-530
Query Match 6.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1720 CGGAGATGGAG 1730
Db 1 CTGAGATGGAG 11
RESULT 512
US-09-617-548-12/c
Sequence 12, Application US/09617548
Patent No. 6478214
GENERAL INFORMATION:
APPLICANT: EAGLES, Peter Anthony Minter
APPLICANT: ZHENG, Richard Qihao
TITLE OF INVENTION: INHIBITION OF CYTOKINE PRODUCTION
FILE REFERENCE: N & V 604-557 BTG 137 766
CURRENT APPLICATION NUMBER: US/09/617,548
CURRENT FILING DATE: 2000-07-14
PRIOR APPLICATION NUMBER: GB 9601391.5
PRIOR FILING DATE: 1998-01-22
PRIOR APPLICATION NUMBER: GB 9824794.3
PRIOR FILING DATE: 1998-11-11
PRIOR APPLICATION NUMBER: PCT/GB99/00179
PRIOR FILING DATE: 1999-01-20
NUMBER OF SEQ ID NOS: 15
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 12
LENGTH: 11
TYPE: DNA
ORGANISM: Human tumour necrosis factor alpha promoter
US-09-617-548-12
Query Match 6.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1732 TTGGCTCCCA 1742

```

PCT-US94-08023-37/c
; Sequence 37, Application PC/TUS9408023
; GENERAL INFORMATION:
; APPLICANT: de Kloet, Siwo R.
; TITLE OF INVENTION: Sex-Specific DNA Probe For Parrots,
; TITLE OF INVENTION: Methods And Kits
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSEE: Russell, P.A.
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/08023
; FILING DATE: 15-JUL-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/093,198
; FILING DATE: 15-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: FL20979-34
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4996
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US94-08023-37

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1708 GGGTTAGGAGT 1718
Db 11 GGGTTAGGAAT 1

```

```

RESULT 516
US-08-192-300-5
; Sequence 5, Application US/08192300
; Patent No. 5580759
; GENERAL INFORMATION:
; APPLICANT: Yang, Yih-Sheng
; APPLICANT: Tucker, Philip W.
; APPLICANT: Capra, J. Donald
; TITLE OF INVENTION: CONSTRUCTION OF RECOMBINANT DNA BY
; TITLE OF INVENTION: EXONUCLEASE RESECTION
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC Compatible

```

```

; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/192,300
; FILING DATE: February 3, 1994
; CLASSIFICATION: 535
; ATTORNEY/AGENT INFORMATION:
; NAME: Denise L. Mayfield
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTSD:327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 320-7200
; TELEFAX: (512) 474-7577
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; MOLECULE TYPE: Oligonucleotide
US-08-192-300-5

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1696 GTGGTGAAGT 1706
Db 2 GTGGTGAATT 12

```

```

RESULT 517
US-08-221-816B-27/c
; Sequence 27, Application US/08221816B
; Patent No. 5738985
; GENERAL INFORMATION:
; APPLICANT: Miles, Vincent J.
; APPLICANT: Mathews, Michael B.
; APPLICANT: Katze, Michael G.
; APPLICANT: Witherell, Gary
; APPLICANT: Watson, Julia C.
; TITLE OF INVENTION: METHOD FOR SELECTIVE INACTIVATION
; TITLE OF INVENTION: OF VIRAL REPLICATION
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/221,816B
; FILING DATE: 01-APR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7960-030
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```

TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-221-816B-27

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1740 CAACCTCTCCC 1750
Db 1 CGACTCTCTCC 11

RESULT 519
US-08-441-887A-338
; Sequence 339, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004160US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 339:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-339

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1740 CAACCTCTCCC 1750
Db 2 CGACTCTCTCC 12

RESULT 520
US-08-757-024-501
; Sequence 501, Application US/08757024

TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-221-816B-27

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1674 GAACCCGCTGGT 1684
Db 11 GAACCCAGGTG 1

RESULT 518
US-08-441-887A-338
; Sequence 338, Application US/08441887A
; Patent No. 5837832
; GENERAL INFORMATION:
; APPLICANT: Chee, Mark
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua X.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobban, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes on
; TITLE OF INVENTION: Biological Chips
; NUMBER OF SEQUENCES: 360
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/441,887A
; FILING DATE: 16-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/082,937
; FILING DATE: 25-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joseph O.
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004160US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-326-2400
; TELEFAX: 650-326-2422
; INFORMATION FOR SEQ ID NO: 338:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (probe)
; US-08-441-887A-338

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 501:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-501

Query Match          6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGATGGAG 1730
Db 2 CTGAGATGGAG 12

RESULT 521
US-08-757-024-529
; Sequence 529, Application US/08/57024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
```

```
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 529:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-529

Query Match          6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGATGGAG 1730
Db 1 CTGAGATGGAG 11

RESULT 522
US-07-794-396-6
; Sequence 6, Application US/07794396
; Patent No. 6034233
; GENERAL INFORMATION:
; APPLICANT: David Ecker et al.
; TITLE OF INVENTION: Modulation of HIV Gene Expression
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 6034233ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/794,396
; FILING DATE: 19911119
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 518,929
; FILING DATE: May 4, 1990
; APPLICATION NUMBER: PCT/US91/02558
; FILING DATE: April 15, 1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0478
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: yes
; US-07-794-396-6

Query Match          6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
```

Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCAC 1669
|||||:||||
Db 2 CCAGGCUCAGA 12

RESULT 523
US-08-959-853-8/c
; Sequence 8, Application US/08959853
; Patent No. 6090553
; GENERAL INFORMATION:
; APPLICANT: Robert S. Matson
; TITLE OF INVENTION: USE OF URACIL-DNA GLYCOSYLASE
; TITLE OF INVENTION: IN GENETIC ANALYSIS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Beckman Instruments, Inc.
; STREET: 2500 Harbor Boulevard
; CITY: Fullerton
; STATE: California
; ZIP: 92834-3100
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: WINDOWS 95 - WORDPERFECT 7.0
; SOFTWARE: ASCII (DOS) TEXT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/959,853
; FILING DATE: herewith
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: P.R. Harder
; REGISTRATION NUMBER: 20,022
; REFERENCE/DOCKET NUMBER: 450-1566
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (714) 773-6929
; TELEFAX: (714) 773-7936
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-959-853-8

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1680 TGGTGTCTCCT 1690
|||||:||||
Db 11 TGGTGTCTCT 1

RESULT 524
US-08-713-742-8
; Sequence 8, Application US/08713742
; Patent No. 611085
; GENERAL INFORMATION:
; APPLICANT: Cook and Manoharan
; TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
; TITLE OF INVENTION: Oligonucleosides
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6111085ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/713,742
FILING DATE: 17-SEP-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2350
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-713-742-8

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCAC 1669
|||||:||||
Db 2 CCAGGCUCAGA 12

RESULT 525
US-08-211-882-5
; Sequence 5, Application US/08211882
; Patent No. 6153737
; GENERAL INFORMATION:
; APPLICANT: Manoharan et al.
; TITLE OF INVENTION: Derivatized Oligonucleotides Having
; TITLE OF INVENTION: Improved Uptake And Other Properties
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/211,882
; FILING DATE: 22-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/782,374
; FILING DATE: 24-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0649
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-211-882-5

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
|||||:|
Db 2 CCAGGCUCAGA 12

RESULT 526

US-08-211-882-9
; Sequence 9, Application US/08211882
; Patent No. 6153737
; GENERAL INFORMATION:
; APPLICANT: Manoharan et al.
; TITLE OF INVENTION: Derivatized Oligonucleotides Having
; TITLE OF INVENTION: Improved Uptake And Other Properties
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/211,882
FILING DATE: 22-APR-1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/782,374
FILING DATE: 24-OCT-1991

ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-0649
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-211-882-9
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
|||||:|
Db 1 CCAGGCUCAGA 11

RESULT 527

US-09-372-856-8
; Sequence 8, Application US/09372856
; Patent No. 6166188
; GENERAL INFORMATION:
; APPLICANT: Cook and Manoharan
; TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
; TITLE OF INVENTION: Oligonucleosides
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/211,882
FILING DATE: 22-APR-1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/782,374
FILING DATE: 24-OCT-1991

ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-0649
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-211-882-9
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
|||||:|
Db 1 CCAGGCUCAGA 11

RESULT 527

US-09-372-856-8
; Sequence 8, Application US/09372856
; Patent No. 6166188
; GENERAL INFORMATION:
; APPLICANT: Cook and Manoharan
; TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
; TITLE OF INVENTION: Oligonucleosides
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6166188ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT 4.0
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/372,856
FILING DATE: 12-AUG-1999
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/713,742
FILING DATE: 13-SEP-1996
CLASSIFICATION: 536

ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-4070
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-372-856-8
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
|||||:|
Db 2 CCAGGCUCAGA 12

RESULT 528
US-09-281-418-20/c
; Sequence 20, Application US/09281418
; Patent No. 6287769
; GENERAL INFORMATION:
; APPLICANT: Inoue, Takakazu
; TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
; TITLE OF INVENTION: agment, Method of Assaying Microorganisms, Method of Analyzing Mic
; TITLE OF INVENTION: nisms and Method of Assaying Contaminant
; FILE REFERENCE: 9982-7

CURRENT APPLICATION NUMBER: US/09/281,418
CURRENT FILING DATE: 1999-03-30
EARLIER APPLICATION NUMBER: JP/1998/87651
EARLIER FILING DATE: 1998-03-31
EARLIER APPLICATION NUMBER: JP/1999/69694
EARLIER FILING DATE: 1999-03-16
NUMBER OF SEQ ID NOS: 216
SEQ ID NO 20
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer

US-09-281-418-20
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CCCTATCCTAA 1758

TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-688-394-8

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
Db 2 CCAGGCUCAGA 12

RESULT 531
US-09-633-659-5
Sequence 5, Application US/09633659
Patent No. 6395492
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Bennet, Clarence Frank
TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And
TITLE OF INVENTION: Other Properties
FILE REFERENCE: ISIS4470
CURRENT APPLICATION NUMBER: US/09/633,659
CURRENT FILING DATE: 2000-08-07
PRIOR APPLICATION NUMBER: 08/211,882
PRIOR FILING DATE: 1994-04-22
PRIOR APPLICATION NUMBER: 07/782,374
PRIOR FILING DATE: 1991-10-24
NUMBER OF SEQ ID NOS: 18
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 5
LENGTH: 12
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence

US-09-633-659-5
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 2.5e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACA 1669
Db 2 CCAGGCUCAGA 12

RESULT 532
US-09-633-659-9
Sequence 9, Application US/09633659
Patent No. 6395492
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Bennet, Clarence Frank
TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And
TITLE OF INVENTION: Other Properties
FILE REFERENCE: ISIS4470
CURRENT APPLICATION NUMBER: US/09/633,659
CURRENT FILING DATE: 2000-08-07
PRIOR APPLICATION NUMBER: 08/211,882
PRIOR FILING DATE: 1994-04-22
PRIOR APPLICATION NUMBER: 07/782,374
PRIOR FILING DATE: 1991-10-24
NUMBER OF SEQ ID NOS: 18

12 CCCTATCACA 2

RESULT 529
US-09-281-418-74/c
Sequence 74, Application US/09281418
Patent No. 6287769
GENERAL INFORMATION:
APPLICANT: Inoue, Takakazu
TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
TITLE OF INVENTION: agent, Method of Assaying Microorganisms, Method of Analyzing Mi
TITLE OF INVENTION: nisms and Method of Assaying Contaminant
FILE REFERENCE: 9982-7
CURRENT APPLICATION NUMBER: US/09/281,418
CURRENT FILING DATE: 1999-03-30
EARLIER APPLICATION NUMBER: JP/1998/87651
EARLIER FILING DATE: 1998-03-31
EARLIER APPLICATION NUMBER: JP/1999/69694
EARLIER FILING DATE: 1999-03-16
NUMBER OF SEQ ID NOS: 216
SEQ ID NO 74
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer

US-09-281-418-74
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 GTTGGTAGG 1715
Db 11 GTTGGTAGG 1

RESULT 530
US-09-688-394-8
Sequence 8, Application US/09688394
Patent No. 6322987
GENERAL INFORMATION:
APPLICANT: Cook and Manoharan
TITLE OF INVENTION: Carbamate-Derivatized Nucleosides And
TITLE OF INVENTION: Oligonucleosides
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6322987ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows NT 4.0
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/688,394
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/372,856
FILING DATE: 12-AUG-1999
APPLICATION NUMBER: 08/713,742
FILING DATE: 13-SEP-1996
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-4070
TELECOMMUNICATION INFORMATION:

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 9

; LENGTH: 12

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:

; OTHER INFORMATION: Oligonucleotide

; OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence
US-09-633-659-9

Query Match

Best Local Similarity 6.8%; Score 9.4; DB 1; Length 12;

Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1659 CCAGGCTCAC 1669

Db 1 CCAGGCUCAGA 11

RESULT 533

US-10-112-547-27/c

; Sequence 27, Application US/10112547

; Patent No. 6579674

; GENERAL INFORMATION:

; APPLICANT: Miles, Vincent J.

; Mathews, Michael B.

; Katze, Michael G.

; Witherell, Gary

; Watson, Julia C.

; TITLE OF INVENTION: METHOD FOR SELECTIVE INACTIVATION

; CORRESPONDENCE ADDRESS:

; NUMBER OF SEQUENCES: 33

; ADDRESS: Pennie & Edmonds

; STREET: 1155 Avenue of the Americas

; CITY: New York

; STATE: New York

; COUNTRY: USA

; ZIP: 10036/2711

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSEQ Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/112,547

; FILING DATE: 28-Mar-2002

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/221,816B

; FILING DATE: 01-APR-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Coruzzi, Laura A

; REGISTRATION NUMBER: 30,742

; REFERENCE/DOCKET NUMBER: 7960-030

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 790-9090

; TELEFAX: (212) 869-8864

; TELEX: 66141 PENNIE

; INFORMATION FOR SEQ ID NO: 27:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 12 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA

; SEQUENCE DESCRIPTION: SEQ ID NO: 27:

US-10-112-547-27

Query Match

Best Local Similarity 6.8%; Score 9.4; DB 1; Length 12;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1674 GAACCTGGTG 1684

Db 11 GAACCCAGGTG 1

RESULT 534

US-09-574-117A-26/c

; Sequence 26, Application US/09574117A

; Patent No. 6620584

; GENERAL INFORMATION:

; APPLICANT: Chee, Mark

; APPLICANT: Walt, David R.

; TITLE OF INVENTION: Combinatorial Decoding of Random Nucleic Acid Arrays

; FILE REFERENCE: A-67498-1

; CURRENT APPLICATION NUMBER: US/09/574,117A

; CURRENT FILING DATE: 2000-05-19

; PRIOR APPLICATION NUMBER: US 60/135,052

; PRIOR FILING DATE: 1999-05-20

; NUMBER OF SEQ ID NOS: 39

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 26

; LENGTH: 12

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: synthetic.

US-09-574-117A-26

Query Match

Best Local Similarity 6.8%; Score 9.4; DB 1; Length 12;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1674 GAACCTGGTG 1684

Db 11 GAACCTGGCG 1

RESULT 535

US-10-112-241-27/c

; Sequence 27, Application US/10112241

; Patent No. 6623961

; GENERAL INFORMATION:

; APPLICANT: Miles, Vincent J.

; Mathews, Michael B.

; Katze, Michael G.

; Witherell, Gary

; Watson, Julia C.

; TITLE OF INVENTION: METHOD FOR SELECTIVE INACTIVATION

; CORRESPONDENCE ADDRESS:

; NUMBER OF SEQUENCES: 33

; ADDRESS: Pennie & Edmonds

; STREET: 1155 Avenue of the Americas

; CITY: New York

; STATE: New York

; COUNTRY: USA

; ZIP: 10036/2711

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSEQ Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/112,241

; FILING DATE: 28-Mar-2002

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/221,816B

; FILING DATE: 01-APR-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Coruzzi, Laura A

; REGISTRATION NUMBER: 30,742


```

;          FILING DATE: 01-MAY-1990
;SEQ ID NO:14:
;          LENGTH: 12
5427911-14

```

Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 2.5e+02;
Matches 10; Conservative 0; Mismatches 1; Indels

QY 1750 CTATCCTAAAG 1760
|||
Db 2 CTCCTCTAAAG 12

```

RESULT 540
US-08-123-449A-17
; Sequence 17, Application US/08123449A
; Patent No. 5583032
; GENERAL INFORMATION:
; APPLICANT: TORRENCE, PAUL
; APPLICANT: ROBERT, SILVERMAN
; APPLICANT: RATAN, MAITRA
; APPLICANT: KRYSZYNA, LESIAK
; TITLE OF INVENTION: METHOD OF CLEAVING SPECIFIC SEQUENCES
; TITLE OF INVENTION: OF RNA
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:

```

```

Query Match      6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e-02;
Matches 10; Conservative 0; Mismatches 1; Indels
QY 1741 AACTCTCCCT 1751
Db 3 AACTACTCCCT 13

```

RESULT 541
 US-08-458-050-17
 ; Sequence 17, Application US/08458050
 ; Patent No. 567289
 ; GENERAL INFORMATION:
 ; APPLICANT: TORRENCE, PAUL
 ; APPLICANT: ROBERT, SILVERMAN
 ; APPLICANT: RATAN, MAITRA
 ; APPLICANT: KRYSZYNA, LESIAK
 ; TITLE OF INVENTION: METHOD OF CLEAVING SPECIFIC SEQUENCES
 ; TITLE OF INVENTION: OF RNA
 ; NUMBER OF SEQUENCES: 22
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Knobbe, Martens, Olson and Bear
 ; STREET: 620 Newport Center Drive
 ; CITY: Newport Beach
 ; STATE: CA
 ; COUNTRY: USA
 ; ZIP: 92660
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS version
 ; SOFTWARE: FastSeq version 1.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/458,050
 ; FILING DATE: 01-JUN-1995
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/123,449
 ; FILING DATE: 17-SEP-1993
 ; APPLICATION NUMBER: PCT/US93/10103
 ; FILING DATE: 10-OCT-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Fedrick, Michael F.
 ; REGISTRATION NUMBER: 36,799
 ; REFERENCE/DOCKET NUMBER: NIH034.001QPC
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 714-760-0404
 ; TELEFAX: 714-760-9502
 ; INFORMATION FOR SEQ ID NO: 17:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 13 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cdna
 ; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 ; FRAGMENT TYPE:
 ; ORIGINAL SOURCE:
 ; FEATURE:
 ; NAME/KEY: miscellaneous feature
 ; LOCATION: 1-4
 ; OTHER INFORMATION: A is linked by 2',5'-linkage
 ; FEATURE:
 ; NAME/KEY: miscellaneous feature
 ; LOCATION: 4
 ; OTHER INFORMATION: A is linked at 2' end to following
 ; OTHER INFORMATION: base through a linker moiety
 US-08-458-050-17

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1741 AACTCCTCCT 1751
Db 3 AACTACTCCT 13

RESULT 542
US-08-667-023-3/c
; Sequence 3, Application US/08667023
; Patent No. 5817783
; GENERAL INFORMATION:
; APPLICANT: Callabretta, Bruno
; APPLICANT: Venturelli, Donatella
; APPLICANT: Martinez, Robert V.
; TITLE OF INVENTION: DR-nm23 AND COMPOSITIONS, METHODS OF MAKING AND
; TITLE OF INVENTION: METHODS OF USING THE SAME
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5817783ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/667,023
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 60/000,427
; FILING DATE: 22-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1992
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-667-023-3

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 12 GTGGTGAATT 2

RESULT 543
US-08-671-975A-17/c
; Sequence 17, Application US/08671975A
; Patent No. 5830656
; GENERAL INFORMATION:
; APPLICANT: Milo, George
; TITLE OF INVENTION: CATR GENE
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CALFEE, HALTER & GRISWOLD

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 12 GTGGTGAATT 2

RESULT 544
US-08-757-024-471
; Sequence 471, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: NC. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 12 GTGGTGAATT 2

RESULT 545
US-08-757-024-471
; Sequence 471, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: NC. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102

; INFORMATION FOR SEQ ID NO: 471:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-471

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGTGGAG 1730
Db 3 CTGAGTGGAG 13

RESULT 545

US-08-757-024-500
; Sequence 500, Application US/08757024
; Patent No. 6025339

; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102

; INFORMATION FOR SEQ ID NO: 500:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-500

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGTGGAG 1730
Db 2 CTGAGTGGAG 12

RESULT 546

US-08-757-024-528
; Sequence 528, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:

; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514

; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102

; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-528

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGTGGAG 1730
Db 1 CTGAGTGGAG 11

RESULT 547

US-08-950-196-17
; Sequence 17, Application US/08950196
; Patent No. 6271369

; GENERAL INFORMATION:
; APPLICANT: TORRENCE, PAUL
; APPLICANT: ROBERT, SILVERMAN
; APPLICANT: RATAN, MAITRA
; APPLICANT: KRYSZYNA, LESIAK
; TITLE OF INVENTION: METHOD OF CLEAVING SPECIFIC SEQUENCES
; TITLE OF INVENTION: OF RNA
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson and Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS version
; SOFTWARE: FastSeq Version 1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/950,196
; FILING DATE:
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/123,449
FILING DATE: PCT/US93/10103
APPLICATION NUMBER: PCT/US93/10103
FILING DATE: 10-OCT-1993
ATTORNEY/AGENT INFORMATION:
NAME: Fredrick, Michael F.
REGISTRATION NUMBER: 36,799
REFERENCE/DOCKET NUMBER: NIH034.001QPC
TELEPHONE: 714-760-0404
TELEFAX: 714-760-9502
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
FEATURE:
NAME/KEY: miscellaneous feature
LOCATION: 1-4
OTHER INFORMATION: A is linked by 2',5'-linkage
FEATURE:
NAME/KEY: miscellaneous feature
LOCATION: 4
OTHER INFORMATION: A is linked at 2' end to following
OTHER INFORMATION: base through a linker moiety
US-08-950-196-17
Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1741 AACTCTCCCT 1751
DB 3 AACTACTCCCT 13
RESULT 548
US-09-474-432B-120/c
Sequence 120, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1596
SOFTWARE: PatentIn version 3.0
SEQ ID NO 120
LENGTH: 13
TYPE: RNA
ORGANISM: Homo sapiens

US-09-474-432B-120
Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1659 CCAGGCTCACA 1669
DB 12 CCAGGCTCACA 2
RESULT 549
US-09-216-584-18
Sequence 18, Application US/09216584
Patent No. 6548657
GENERAL INFORMATION:
APPLICANT: Alex, Burgin
APPLICANT: Leonid, Beigelman
APPLICANT: Laurent, Bellon
TITLE OF INVENTION: Method for Screening Nucleic Acid Catalysts
FILE REFERENCE: MHB00-853-A; RPI 237/167
CURRENT APPLICATION NUMBER: US/09/216,584
CURRENT FILING DATE: 1998-12-18
PRIOR APPLICATION NUMBER: 09/094,381
PRIOR FILING DATE: 1998-06-09
PRIOR APPLICATION NUMBER: 60/068,212
PRIOR FILING DATE: 1997-12-19
PRIOR APPLICATION NUMBER: 60/049,002
PRIOR FILING DATE: 1997-06-09
NUMBER OF SEQ ID NOS: 52
SOFTWARE: PatentIn version 3.0
SEQ ID NO 18
LENGTH: 13
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc feature
OTHER INFORMATION: Accessible site within Kras transcript
US-09-216-584-18
Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1699 GTGGAAGTTGG 1709
DB 2 GTGGAAGTTGG 12
RESULT 550
US-09-476-387-120/c
Sequence 120, Application US/09476387
Patent No. 6617438
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MHB00-831-C (249/073)
CURRENT APPLICATION NUMBER: US/09/476,387
CURRENT FILING DATE: 2001-04-04
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29

;; PRIOR APPLICATION NUMBER: 60/064,866
;; PRIOR FILING DATE: 1997-11-05
;; NUMBER OF SEQ ID NOS: 1524
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 120
;; LENGTH: 13
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-476-387-120

Query Match 6.8%; Score 9.4; DB 1; Length 13;
Best Local Similarity 90.9%; Pred. No. 2.8e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1659 CCAGGCTCACA 1669

Db 12 CCAGGCTCCA 2

RESULT 551

US-07-933-469A-1/c
; Sequence 1, Application US/07933469A
; Patent No. 5318896

;; GENERAL INFORMATION:
;; APPLICANT: Conder, Michael J.
;; APPLICANT: McAda, Phyllis and
;; APPLICANT: Rambosek, John
;; TITLE OF INVENTION: NOVEL BIOPROCESS FOR PREPARING 7-ADCA
;; NUMBER OF SEQUENCES: 12
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Merck & Co., Inc.
;; STREET: 126 E. Lincoln Avenue
;; CITY: Rahway,
;; STATE: New Jersey
;; COUNTRY: USA
;; ZIP: 07065

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/933,469A
;; FILING DATE: 19920828
;; CLASSIFICATION: 435

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/757,879
;; FILING DATE: 11-SEP-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Speer, Raymond M.
;; REGISTRATION NUMBER: 26,810
;; REFERENCE/DOCKET NUMBER: [07/757,879] 18532
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (908) 594-4481
;; TELEFAX: (908) 594-4720
;; INFORMATION FOR SEQ ID NO: 1:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 14 base pairs
;; TYPE: NUCLEIC ACID
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)

US-07-933-469A-1

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1677 CCCTGGTGCTCT 1687

Db 14 CCATGGTGCTCT 4

RESULT 552

US-08-250-310-1/c
; Sequence 1, Application US/08250310
; Patent No. 5559005

;; GENERAL INFORMATION:
;; APPLICANT: Conder, Michael J.
;; APPLICANT: McAda, Phyllis
;; APPLICANT: Rambosek, John
;; APPLICANT: Reeves, Christopher D.
;; TITLE OF INVENTION: No. 5559005el Bioprocess for Preparing 7-ACA and 7-ADAC
;; NUMBER OF SEQUENCES: 17
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Merck & Co., Inc.
;; STREET: 126 E. Lincoln Ave
;; CITY: Rahway
;; STATE: New Jersey
;; COUNTRY: USA
;; ZIP: 07065

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/250,310
;; FILING DATE:
;; CLASSIFICATION: 435

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/07/953,492
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Speer, Raymond M.
;; REGISTRATION NUMBER: 26,810
;; REFERENCE/DOCKET NUMBER: 185721A
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (908) 594-4481
;; TELEFAX: (908) 594-4720
;; INFORMATION FOR SEQ ID NO: 1:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 14 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)

US-08-250-310-1

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1677 CCCTGGTGCTCT 1687

Db 14 CCATGGTGCTCT 4

RESULT 553

US-08-379-496-7/c
; Sequence 7, Application US/08379496
; Patent No. 5593833

;; GENERAL INFORMATION:
;; APPLICANT: MORRISON, Nigel A
;; APPLICANT: EISMAN, John A
;; APPLICANT: KELLY, Paul J
;; TITLE OF INVENTION: Assessment of Trans-Acting Factors Allelic
;; TITLE OF INVENTION: Variation
;; NUMBER OF SEQUENCES: 8
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Rothwell, Figg, Ernst & Kurz
;; STREET: Suite 701-E, 555 13th Street.N.W.
;; CITY: Washington
;; STATE: D.C.
;; COUNTRY: USA
;; ZIP: 20004

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1677 CCCTGGTGCTCT 1687

Db 14 CCATGGTGCTCT 4

```

; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-439-404-1

Query Match      6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1677 CCCTGGTGTCT 1687
Db      14 CCATGCTGTCT 4

RESULT 556
US-08-390-858B-28/c
; Sequence 28, Application US/08390858B
; Patent No. 5643727
; GENERAL INFORMATION:
; APPLICANT: Reed, John C.
; APPLICANT: Harigai, Masayoshi
; TITLE OF INVENTION: Bcl-2 Gene Inhibitory Element Binding
; TITLE OF INVENTION: Factor
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESS: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,858B
; FILING DATE: 16-FEB-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LJ 1366
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdNA
US-08-390-858B-28

Query Match      6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1647 AGAAGGCAAGC 1657
Db      12 AGAATGCAAGC 2

RESULT 556
US-08-282-197C-5/c
; Sequence 5, Application US/08282197C
; Patent No. 5871730
; GENERAL INFORMATION:
; APPLICANT: Brzezinski, Ryszard
; APPLICANT: Dery, Claude V

```


APPLICANT: Beaulieu, Carole
TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and
METHODS OF USE
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
STREET: 1100 New York Ave., NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/282,197C
FILING DATE: 29-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Cimbala, Michele A
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 1050.0410000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both
US-08-282-197C-5

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 TGTCTCTCCCA 1693
Db 12 TGTCTCCOCCA 2

RESULT 557
US-08-839-327-1/C
Sequence 1, Application US/08839327
Patent No. 6017726
GENERAL INFORMATION:
APPLICANT: CONDER, MICHAEL;
APPLICANT: MCADA, PHYLLIS; RAMBOSEK, JOHN;
APPLICANT: REEVES, CHRISTOPHER
TITLE OF INVENTION: NOVEL BIOPROCESS FOR
PREPARING 7-ACA AND 7-ADAC
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: BIERMAN, MUSERLIAN AND
ADDRESSEE: LUCAS, LLP
STREET: 600 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10016
COMPUTER READABLE FORM:
MEDIUM TYPE: FLOPPY DISK
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS WORD 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/839,327
FILING DATE: 17-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 439,404

FILING DATE: 11-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 250,310
FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 953,492
FILING DATE: 06-OCT-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 777,833
FILING DATE: 15-OCT-1991
ATTORNEY/AGENT INFORMATION:
NAME: CHARLES A. MUSERLIAN
REGISTRATION NUMBER: 19,683
REFERENCE/DOCKET NUMBER: 253.171-DIV
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-661-8000
TELEFAX: 212-661-8002
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-839-327-1

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1677 CCCTGGTGCT 1687
Db 14 CCATGGTGCT 4

RESULT 558
US-08-757-024-440
Sequence 440, Application US/08757024
Patent No. 6025339
GENERAL INFORMATION:
APPLICANT: NYCE, Jonathan W.
TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
NUMBER OF SEQUENCES: 952
CORRESPONDENCE ADDRESS:
ADDRESSEE: BELL, SELTZER, PARK & GIBSON
STREET: P.O. Drawer 34009
CITY: Charlotte
STATE: No. 6025339th Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/757,024
FILING DATE: 26-NOV-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5218-41
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-881-3140
TELEFAX: 919-881-3175
TELEX: 575102
INFORMATION FOR SEQ ID NO: 440:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

```

; MOLECULE TYPE: DNA (genomic)
US-08-757-024-440
Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAG 1730
Db 4 CTGAGATGGAG 14

RESULT 559
US-08-757-024-470
; Sequence 470, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 499:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-499
Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAG 1730
Db 2 CTGAGATGGAG 12

RESULT 561
US-08-757-024-527
; Sequence 527, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 527:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-470
Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAG 1730
Db 3 CTGAGATGGAG 13

RESULT 560
US-08-757-024-499
; Sequence 499, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
```

```
/ LENGTH: 14 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-08-757-024-527

Query Match
Best Local Similarity 6.8%; Score 9.4; DB 1; Length 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1720 CGGAGTGAG 1730
Db 1 CTGAGATGAG 11

RESULT 562
US-08-985-162-1845
; Sequence 1845, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1845:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-1845

Query Match
Best Local Similarity 6.8%; Score 9.4; DB 1; Length 14;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1666 CACAGCTGGAA 1676
Db 2 CACAGCTGAAA 12

/ LENGTH: 14 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
US-09-340-781B-1/c
; Sequence 1, Application US/09340781B
; Patent No. 6071713
; GENERAL INFORMATION:
; APPLICANT: Conder, Michael J.
; APPLICANT: MCAda, Phyllis
; APPLICANT: Rambosek, John
; APPLICANT: Reeves, Christopher D.
; TITLE OF INVENTION: No. 6071713el Bioprocess for Preparing 7-ACA and 7-ADAC
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John W. Wallen, III
; STREET: 126 E. Lincoln Ave; P.O. Box 2000
; CITY: Rahway
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07065-0907
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/340,781B
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/439,404
; FILING DATE: 11-May-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wallen, John W.
; REGISTRATION NUMBER: 35,403
; REFERENCE/DOCKET NUMBER: 18572DA
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 594-3905
; TELEFAX: (908) 594-4720
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-340-781B-1

Query Match
Best Local Similarity 6.8%; Score 9.4; DB 1; Length 14;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1677 CCTGGTGTCT 1687
Db 14 CCAATGGTCT 4

RESULT 564
US-08-666-341A-21
; Sequence 21, Application US/08666341A
; Patent No. 6365345
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Antisense nucleic Acids for the
; TITLE OF INVENTION: Prevention and treatment of disorders in which expression
; TITLE OF INVENTION: of c-erbB plays a role
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman and Stern, PLLC
; STREET: 400 Seventh street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
```

ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disc
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/666,341A
FILING DATE: 15-AUG-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-666-341A-21

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 3 GTGGTGAAGT 13

RESULT 565
US-08-666-341A-36
Sequence 36, Application US/08666341A
Patent No. 6365345
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Antisense nucleic Acids for the
TITLE OF INVENTION: prevention and treatment of disorders in which expression
TITLE OF INVENTION: of c-erbB plays a role
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman and Stern, PLLC
STREET: 400 Seventh street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disc
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/666,341A
FILING DATE: 15-AUG-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93120710.4
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-666-341A-36

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 3 GTGGTGAAGT 13

RESULT 566
US-09-136-080E-34
Sequence 34, Application US/09136080E
Patent No. 6518017
GENERAL INFORMATION:
APPLICANT: Riley, Timothy A.
APPLICANT: Brown, Bob D.
APPLICANT: Arnold, Lyle J.
TITLE OF INVENTION: COMBINATORIAL ANTISENSE LIBRARY
FILE REFERENCE: OASBIO.003A
CURRENT APPLICATION NUMBER: US/09/136,080E
CURRENT FILING DATE: 1998-08-18
NUMBER OF SEQ ID NOS: 54
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 34
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthetic oligonucleotide
OTHER INFORMATION: combined DNA/RNA
NAME/KEY: misc feature
LOCATION: (6)-(6); (7)...(7)
OTHER INFORMATION: Glen research spacer 9 (cat # 10-1909-90) between t 6 and g 7
LOCATION: (14)...(14)
OTHER INFORMATION: propyl linker attached to g 14
US-09-136-080E-34

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 81.8%; Pred. No. 3.2e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1692 CAGCGTGGTGG 1702
Db 1 CAGCATGGUGG 11

RESULT 567
US-09-401-063-1845
Sequence 1845, Application US/09401063
Patent No. 6623962
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:
CLASSIFICATION:

ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disc
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/666,341A
FILING DATE: 15-AUG-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-666-341A-21

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 3 GTGGTGAAGT 13

RESULT 565
US-08-666-341A-36
Sequence 36, Application US/08666341A
Patent No. 6365345
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Antisense nucleic Acids for the
TITLE OF INVENTION: prevention and treatment of disorders in which expression
TITLE OF INVENTION: of c-erbB plays a role
NUMBER OF SEQUENCES: 106
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman and Stern, PLLC
STREET: 400 Seventh street, N.W.
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disc
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/666,341A
FILING DATE: 15-AUG-1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 93120710.4
INFORMATION FOR SEQ ID NO: 36:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-08-666-341A-36

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGT 1706
Db 3 GTGGTGAAGT 13

RESULT 566
US-09-136-080E-34
Sequence 34, Application US/09136080E
Patent No. 6518017
GENERAL INFORMATION:
APPLICANT: Riley, Timothy A.
APPLICANT: Brown, Bob D.
APPLICANT: Arnold, Lyle J.
TITLE OF INVENTION: COMBINATORIAL ANTISENSE LIBRARY
FILE REFERENCE: OASBIO.003A
CURRENT APPLICATION NUMBER: US/09/136,080E
CURRENT FILING DATE: 1998-08-18
NUMBER OF SEQ ID NOS: 54
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 34
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthetic oligonucleotide
OTHER INFORMATION: combined DNA/RNA
NAME/KEY: misc feature
LOCATION: (6)-(6); (7)...(7)
OTHER INFORMATION: Glen research spacer 9 (cat # 10-1909-90) between t 6 and g 7
LOCATION: (14)...(14)
OTHER INFORMATION: propyl linker attached to g 14
US-09-136-080E-34

Query Match 6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 81.8%; Pred. No. 3.2e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1692 CAGCGTGGTGG 1702
Db 1 CAGCATGGUGG 11

RESULT 567
US-09-401-063-1845
Sequence 1845, Application US/09401063
Patent No. 6623962
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:
CLASSIFICATION:

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1845:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-1845

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 81.8%; Pred. No. 3.2e+02;
Matches 9; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1666 CACAGCTGCAA 1676
Db 2 CACAGCUGAAA 12

```

```

RESULT 568
US-09-874-601-5/c
; Sequence 5, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
; TITLE OF INVENTION: THE TREATMENT OF RETINAL DISEASES
; FILE REFERENCE: 4300.014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; CURRENT FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/063,667
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: ()..()
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-5

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1648 GAAGGCCAGCA 1658
Db 11 GAAGGCCAGCA 1

```

```

RESULT 569
US-09-874-601-120
; Sequence 120, Application US/09874601

```

```

; Patent No. 6632057
; GENERAL INFORMATION:
; APPLICANT: LEWIN, ALFRED S.
; APPLICANT: SHAW, LYNN C.
; APPLICANT: GRANT, MARIA B.
; TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
; TITLE OF INVENTION: THE TREATMENT OF RETINAL DISEASES
; FILE REFERENCE: 4300.014100
; CURRENT APPLICATION NUMBER: US/09/874,601
; CURRENT FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/063,667
; PRIOR FILING DATE: 1998-04-21
; PRIOR APPLICATION NUMBER: 60/046,147
; PRIOR FILING DATE: 1997-05-09
; PRIOR APPLICATION NUMBER: 60/044,492
; PRIOR FILING DATE: 1997-04-21
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 120
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: ()..()
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-120

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 72.7%; Pred. No. 3.2e+02;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1641 TGTCAGCAGAAG 1651
Db 1 UGUAGUGAGAAG 11

```

```

RESULT 570
5171843-1
; Patent No. 5171843
; APPLICANT: NUSSENZWEIG, VICTOR
; TITLE OF INVENTION: IMMUNOGENIC POLYPEPTIDE AND METHOD FOR
; PURIFYING IT
; NUMBER OF SEQUENCES: 13
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/175,112
; FILING DATE: 30-MAR-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 754,645
; FILING DATE: 9-JUL-1985
; APPLICATION NUMBER: 115,634
; FILING DATE: 26-OCT-1987
; APPLICATION NUMBER: 649,903
; FILING DATE: 12-SEP-1984
; SEQ ID NO:1:
; LENGTH: 14
; 5171843-1

```

```

Query Match          6.8%; Score 9.4; DB 1; Length 14;
Best Local Similarity 90.9%; Pred. No. 3.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1672 TGGAAACCTGG 1682
Db 4 TGGAAACCATGG 14

```

```

RESULT 571
US-08-584-040-8497/c
; Sequence 8497, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela

```

```

; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8497:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-8497

Query Match 6.8%; Score 9.4; DB 1; Length 15;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGA 1731
Db 15 GGATATGGAGA 5

RESULT 572
US-09-371-772B-4151/c
; Sequence 4151, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040

```

```

; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4151
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4151

Query Match 6.8%; Score 9.4; DB 1; Length 15;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGA 1731
Db 15 GGATATGGAGA 5

RESULT 573
US-09-798-096-16
; Sequence 16, Application US/09798096
; Patent No. 6399378
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF REQL2 EXPRESSION
; FILE REFERENCE: RTS-0207
; CURRENT APPLICATION NUMBER: US/09/798,096
; CURRENT FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-798-096-16

Query Match 6.8%; Score 9.4; DB 1; Length 20;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1661 AGGTCACAGCTGGAACCC 1679
Db 2 AGGATTACAGGTGTGAGCC 20

RESULT 574
US-08-311-486C-622
; Sequence 622, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage

```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 622:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-622

Query Match 6.6%; Score 9.2; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.9e+02;
Matches 9; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1661 AGGCTCAGCTGG 1674
Db 2 AGUCUCCAGCUGG 15
|||: |||||

RESULT 575
US-08-584-040-7909
Sequence 7909, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:

two

APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7909:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7909

Query Match 6.6%; Score 9.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 4.6e+02;
Matches 7; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1726 TGGAGATTGGCTCC 1739
Db 2 UGGCGCUUGGCUUC 15
:|||: |||||

RESULT 576
US-09-371-772B-3692
Sequence 3692, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3692
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-3692

Query Match 6.6%; Score 9.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 4.6e+02;
Matches 7; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1726 TGGAGATTGGCTCC 1739
Db 2 UGGCGCUUGGCUUC 15
:|||: |||||

RESULT 577
US-08-432-871C-4/c
Sequence 4, Application US/08432871C
Patent No. 5877010
GENERAL INFORMATION:
APPLICANT: Loeb, Lawrence A.
APPLICANT: Black, Margaret E.
TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:

ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/432,871C
FILING DATE: 02-MAY-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.409C1
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-432-871C-4

Query Match 6.6%; Score 9.2; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 4.6e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGAG 1730
Db 17 GTACCGCGCTGGAG 4

RESULT 578
US-09-270-956-4/c
Sequence 4, Application US/09270956
Patent No. 6451571
GENERAL INFORMATION:
APPLICANT: Loeb, Lawrence A.
APPLICANT: Black, Margaret E.
TITLE OF INVENTION: THYMIDINE KINASE MUTANTS
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED AND BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/270,956
FILING DATE: 17-MAR-1999
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.409C3
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836

INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-270-956-4

Query Match 6.6%; Score 9.2; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 4.6e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGAG 1730
Db 17 GTACCGCGCTGGAG 4

RESULT 579
US-09-823-549-1
Sequence 1, Application US/09823549
Patent No. 6664442
GENERAL INFORMATION:
APPLICANT: McConlogue, Lisa C
APPLICANT: Games, Kate L.
APPLICANT: Yednock, Theodore A.
APPLICANT: Hua, Tan
APPLICANT: Messersmith, Elizabeth
APPLICANT: Bard, Frederique
TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS
FILE REFERENCE: 015270-0C9110US
CURRENT APPLICATION NUMBER: US/09/823,549
CURRENT FILING DATE: 20C1-03-30
PRIOR APPLICATION NUMBER: US 60/193,847
PRIOR FILING DATE: 2000-C3-30
NUMBER OF SEQ ID NOS: 85
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: M0gapdh251F forward primer
US-09-823-549-1

Query Match 6.6%; Score 9.2; DB 1; Length 20;
Best Local Similarity 78.8%; Pred. No. 5.5e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCACCA 1661
Db 3 GAAGCCCATCACCA 16

RESULT 580
US-09-249-155A-43/c
Sequence 43, Application US/09249155A
Patent No. 6538173
GENERAL INFORMATION:
APPLICANT: Heber-Katz, Ellen
TITLE OF INVENTION: Compositions and Methods for Wound
HEALING
FILE REFERENCE: 00486.78503
CURRENT APPLICATION NUMBER: US/09/249,155A
CURRENT FILING DATE: 1999-02-12
PRIOR APPLICATION NUMBER: US 60/074,737
PRIOR FILING DATE: 1998-02-13
PRIOR APPLICATION NUMBER: US 60/097,937
PRIOR FILING DATE: 1998-08-26
PRIOR APPLICATION NUMBER: US 60/102,051
PRIOR FILING DATE: 1998-09-28
NUMBER OF SEQ ID NOS: 346
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 43

; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-43

Query Match 6.5%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred.No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1634 TGGGGCTTG 1642
| | | | |
Db 11 TGGGGCTTG 3

RESULT 581

US-09-249-155A-181/c
; Sequence 181, Application US/09249155A
; Patent No. 6538173
; GENERAL INFORMATION:
; APPLICANT: Heber-Katz, Ellen
; TITLE OF INVENTION: Compositions and Methods for Wound
; FILE REFERENCE: 00486.78503
; CURRENT APPLICATION NUMBER: US/09/249.155A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,737
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/097,937
; PRIOR FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 60/102,051
; PRIOR FILING DATE: 1998-09-28
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 181
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-249-155A-181

Query Match 6.5%; Score 9; DB 1; Length 11;
Best Local Similarity 100.0%; Pred.No. 2.6e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1634 TGGGGCTTG 1642
| | | | |
Db 11 TGGGGCTTG 3

Search completed: August 30, 2004, 09:22:43
Job time : 2 secs

107	12.8	9.2	16	1	US-10-174-465-6	Sequence 6, Appli	c 180	12.2	8.8	17	1	US-10-061-201-1763	Sequence 1763, Ap
108	12.8	9.2	16	1	US-10-348-431-6	Sequence 6, Appli	c 181	12.2	8.8	17	1	US-10-339-793-72	Sequence 72, Appl
109	12.8	9.2	17	1	US-09-877-478-994	Sequence 994, App	c 182	12.2	8.8	17	1	US-10-138-674-7831	Sequence 7198, Ap
110	12.8	9.2	17	1	US-09-877-478-1614	Sequence 1614, App	c 183	12.2	8.8	17	1	US-10-138-674-7831	Sequence 7831, Ap
111	12.8	9.2	17	1	US-09-848-754A-2544	Sequence 2544, App	c 184	12.2	8.8	17	1	US-10-287-949A-7831	Sequence 7198, Ap
112	12.8	9.2	17	1	US-10-342-902-994	Sequence 994, App	c 185	12.2	8.8	17	1	US-10-287-949A-7831	Sequence 7831, Ap
113	12.8	9.2	17	1	US-10-342-902-1614	Sequence 1614, App	c 186	12.2	8.8	17	1	US-10-712-672-476	Sequence 476, App
114	12.8	9.2	17	1	US-10-237-068-1050	Sequence 1050, App	c 187	12.2	8.8	17	1	US-10-712-672-523	Sequence 523, App
115	12.8	9.2	17	1	US-10-138-674-3692	Sequence 3692, App	c 188	12.2	8.8	17	1	US-10-712-672-2523	Sequence 2523, App
116	12.8	9.2	17	1	US-10-287-949A-3692	Sequence 3692, App	c 189	12.2	8.8	17	1	US-10-669-841-2162	Sequence 2162, App
117	12.8	9.2	17	1	US-10-712-672-475	Sequence 475, App	c 190	12.2	8.8	17	1	US-10-723-361-527	Sequence 527, App
118	12.8	9.2	17	1	US-10-669-841-994	Sequence 994, App	c 191	12.2	8.8	17	1	US-10-723-361-528	Sequence 528, App
119	12.8	9.2	17	1	US-10-669-841-1614	Sequence 1614, App	c 192	12.2	8.8	17	1	US-10-723-361-1264	Sequence 1264, App
120	12.8	9.2	19	1	US-10-224-005-20	Sequence 20, Appli	c 193	12.2	8.8	17	1	US-10-723-361-7831	Sequence 7831, Ap
121	12.8	9.2	19	1	US-10-224-005-181	Sequence 181, App	c 194	12.2	8.8	17	1	US-10-723-361-9658	Sequence 9658, Ap
122	12.8	9.2	19	1	US-10-251-117-746	Sequence 746, App	c 195	12.2	8.8	18	1	US-09-969-373-2481	Sequence 2481, Ap
123	12.8	9.2	19	1	US-10-251-117-1053	Sequence 1053, App	c 196	12.2	8.8	13	1	US-09-779-152-46	Sequence 46, Appl
124	12.6	9.1	19	1	US-08-983-605-55	Sequence 55, Appli	c 197	12.2	8.8	13	1	US-10-382-248-49	Sequence 49, Appl
125	12.6	9.1	19	1	US-10-251-117-717	Sequence 717, App	c 198	12.2	8.8	13	1	US-10-252-155-119	Sequence 119, App
126	12.6	9.1	19	1	US-10-251-117-1024	Sequence 1024, App	c 199	12.2	8.8	13	1	US-10-001-632A-5	Sequence 5, Appli
127	12.6	9.1	19	1	US-10-349-143-8278	Sequence 8278, App	c 200	12.2	8.8	13	1	US-10-023-610-46	Sequence 46, Appl
128	12.4	8.9	16	1	US-10-308-264-637	Sequence 637, App	c 201	12.2	8.8	13	1	US-10-428-868-20	Sequence 20, Appl
129	12.4	8.9	16	1	US-10-138-674-5908	Sequence 5908, App	c 202	12.2	8.8	13	1	US-10-395-607-177	Sequence 177, App
130	12.4	8.9	16	1	US-10-287-949A-5908	Sequence 5908, App	c 203	12.2	8.8	13	1	US-10-212-848-46	Sequence 46, Appl
131	12.4	8.9	17	1	US-09-818-875-3470	Sequence 3470, App	c 204	12.2	8.8	13	1	US-10-799-870-177	Sequence 177, App
132	12.4	8.9	17	1	US-09-818-875-3471	Sequence 3471, App	c 205	12.2	8.8	21	1	US-10-239-504-34	Sequence 34, Appl
133	12.4	8.9	17	1	US-09-877-478-386	Sequence 386, App	c 206	12	8.6	15	1	US-10-232-634-5	Sequence 5, Appli
134	12.4	8.9	17	1	US-09-827-395A-479	Sequence 479, App	c 207	12	8.6	15	1	US-10-407-807-18	Sequence 18, Appl
135	12.4	8.9	17	1	US-09-827-395A-990	Sequence 990, App	c 208	12	8.6	17	1	US-09-827-395A-755	Sequence 755, App
136	12.4	8.9	17	1	US-10-342-902-386	Sequence 386, App	c 209	12	8.6	17	1	US-10-430-882-755	Sequence 755, App
137	12.4	8.9	17	1	US-10-430-882-479	Sequence 479, App	c 210	12	8.6	17	1	US-10-061-201-945	Sequence 945, App
138	12.4	8.9	17	1	US-10-430-882-990	Sequence 990, App	c 211	12	8.6	17	1	US-10-061-201-946	Sequence 946, App
139	12.4	8.9	17	1	US-10-209-787-3470	Sequence 3470, App	c 212	12	8.6	17	1	US-10-061-201-947	Sequence 947, App
140	12.4	8.9	17	1	US-10-209-787-3471	Sequence 3471, App	c 213	12	8.6	17	1	US-10-061-201-948	Sequence 948, App
141	12.4	8.9	17	1	US-10-261-185-3470	Sequence 3470, App	c 214	12	8.6	17	1	US-10-061-201-949	Sequence 949, App
142	12.4	8.9	17	1	US-10-261-185-3471	Sequence 3471, App	c 215	12	8.6	17	1	US-10-061-201-950	Sequence 950, App
143	12.4	8.9	17	1	US-10-138-674-4993	Sequence 4993, App	c 216	12	8.6	13	1	US-09-832-648-9	Sequence 9, Appli
144	12.4	8.9	17	1	US-10-138-674-7822	Sequence 7822, App	c 217	12	8.6	13	1	US-09-832-648-27	Sequence 27, Appl
145	12.4	8.9	17	1	US-10-138-674-7823	Sequence 7823, App	c 218	12	8.6	13	1	US-09-832-648-28	Sequence 28, Appl
146	12.4	8.9	17	1	US-10-287-949A-4993	Sequence 4993, App	c 219	12	8.6	13	1	US-09-753-169A-9	Sequence 9, Appli
147	12.4	8.9	17	1	US-10-287-949A-7822	Sequence 7822, App	c 220	12	8.6	13	1	US-09-753-169A-27	Sequence 27, Appl
148	12.4	8.9	17	1	US-10-287-949A-7823	Sequence 7823, App	c 221	12	8.6	13	1	US-09-753-169A-28	Sequence 28, Appl
149	12.4	8.9	17	1	US-10-669-841-386	Sequence 386, App	c 222	11.8	8.5	15	1	US-09-877-478-6527	Sequence 6527, Ap
150	12.4	8.9	18	1	US-09-822-722-18	Sequence 18, Appl	c 223	11.8	8.5	15	1	US-09-943-983-5	Sequence 5, Appli
151	12.4	8.9	18	1	US-09-969-373-1963	Sequence 1963, App	c 224	11.8	8.5	15	1	US-10-342-902-6527	Sequence 6527, Ap
152	12.4	8.9	18	1	US-10-059-579-71	Sequence 71, Appl	c 225	11.8	8.5	15	1	US-10-669-841-2580	Sequence 2580, App
153	12.4	8.9	18	1	US-10-285-976-185	Sequence 185, App	c 226	11.8	8.5	15	1	US-09-866-108-525	Sequence 525, App
154	12.4	8.9	18	1	US-10-349-143-11223	Sequence 11223, A	c 227	11.8	8.5	17	1	US-09-866-108-526	Sequence 526, App
155	12.4	8.9	18	1	US-10-138-674-1468	Sequence 1468, App	c 228	11.8	8.5	17	1	US-09-866-108-2351	Sequence 2351, Ap
156	12.4	8.9	18	1	US-10-287-949A-1468	Sequence 1468, App	c 229	11.8	8.5	17	1	US-09-866-108-2352	Sequence 2352, Ap
157	12.4	8.9	19	1	US-09-728-552-1	Sequence 1, Appli	c 230	11.8	8.5	17	1	US-09-866-108-2353	Sequence 2353, Ap
158	12.4	8.9	19	1	US-10-349-143-10908	Sequence 10908, A	c 231	11.8	8.5	17	1	US-09-866-108-7829	Sequence 7829, Ap
159	12.4	8.9	19	1	US-10-463-981B-1	Sequence 1, Appli	c 232	11.8	8.5	17	1	US-09-866-108-7830	Sequence 7830, Ap
160	12.2	8.8	17	1	US-09-866-108-527	Sequence 527, App	c 233	11.8	8.5	17	1	US-09-969-373-1602	Sequence 1602, Ap
161	12.2	8.8	17	1	US-09-866-108-528	Sequence 528, App	c 234	11.8	8.5	17	1	US-09-864-785-1556	Sequence 1556, Ap
162	12.2	8.8	17	1	US-09-866-108-1264	Sequence 1264, App	c 235	11.8	8.5	17	1	US-09-825-805-403	Sequence 403, App
163	12.2	8.8	17	1	US-09-866-108-7831	Sequence 7831, App	c 236	11.8	8.5	17	1	US-09-825-805-503	Sequence 503, App
164	12.2	8.8	17	1	US-09-866-108-9658	Sequence 9658, App	c 237	11.8	8.5	17	1	US-09-825-805-504	Sequence 504, App
165	12.2	8.8	17	1	US-09-416-384A-26	Sequence 26, Appl	c 238	11.8	8.5	17	1	US-09-825-805-512	Sequence 512, App
166	12.2	8.8	17	1	US-09-864-785-1557	Sequence 1557, App	c 239	11.8	8.5	17	1	US-09-825-805-548	Sequence 548, App
167	12.2	8.8	17	1	US-09-864-785-2921	Sequence 2921, App	c 240	11.8	8.5	17	1	US-09-730-289B-80	Sequence 80, Appl
168	12.2	8.8	17	1	US-09-864-785-2922	Sequence 2922, App	c 241	11.8	8.5	17	1	US-09-818-875-403	Sequence 403, App
169	12.2	8.8	17	1	US-09-780-533A-576	Sequence 576, App	c 242	11.8	8.5	17	1	US-09-818-875-404	Sequence 404, App
170	12.2	8.8	17	1	US-09-877-478-2359	Sequence 2359, App	c 243	11.8	8.5	17	1	US-09-818-875-407	Sequence 407, App
171	12.2	8.8	17	1	US-09-848-754A-1430	Sequence 1430, App	c 244	11.8	8.5	17	1	US-09-818-875-408	Sequence 408, App
172	12.2	8.8	17	1	US-09-848-754A-1500	Sequence 1500, App	c 245	11.8	8.5	17	1	US-09-818-875-3958	Sequence 3958, Ap
173	12.2	8.8	17	1	US-10-342-902-2359	Sequence 2359, App	c 246	11.8	8.5	17	1	US-09-818-875-3959	Sequence 3959, Ap
174	12.2	8.8	17	1	US-10-060-756A-752	Sequence 752, App	c 247	11.8	8.5	17	1	US-09-877-478-993	Sequence 993, App
175	12.2	8.8	17	1	US-10-163-552-471	Sequence 471, App	c 248	11.8	8.5	17	1	US-09-848-754A-338	Sequence 338, App
176	12.2	8.8	17	1	US-10-061-201-1606	Sequence 1606, App	c 249	11.8	8.5	17	1	US-09-848-754A-1499	Sequence 1499, Ap
177	12.2	8.8	17	1	US-10-061-201-1608	Sequence 1608, App	c 250	11.8	8.5	17	1	US-09-848-754A-1639	Sequence 1639, Ap
178	12.2	8.8	17	1	US-10-061-201-1612	Sequence 1612, App	c 251	11.8	8.5	17	1	US-09-848-754A-3578	Sequence 3578, Ap
179	12.2	8.8	17	1	US-10-061-201-1762	Sequence 1762, App	c 252	11.8	8.5	17	1	US-09-930-423-18	Sequence 18, Appl

C 253	11.8	8.5	17	1	US-09-930-423-404	Sequence 404, App	326	11.4	8.2	15	1	US-09-274-553D-474	Sequence 474, App
C 254	11.8	8.5	17	1	US-09-930-423-405	Sequence 405, App	c 327	11.4	8.2	17	1	US-09-818-875-3958	Sequence 3958, App
C 255	11.8	8.5	17	1	US-09-930-423-406	Sequence 406, App	328	11.4	8.2	17	1	US-09-818-875-3958	Sequence 3958, App
C 256	11.8	8.5	17	1	US-09-740-332-3106	Sequence 3106, App	c 329	11.4	8.2	17	1	US-10-209-787-3958	Sequence 3958, App
C 257	11.8	8.5	17	1	US-09-740-332-3107	Sequence 3107, App	330	11.4	8.2	17	1	US-10-209-787-3958	Sequence 3958, App
C 258	11.8	8.5	17	1	US-09-745-237A-18	Sequence 18, App	c 331	11.4	8.2	17	1	US-10-261-185-3958	Sequence 3958, App
C 259	11.8	8.5	17	1	US-09-745-237A-404	Sequence 404, App	332	11.4	8.2	17	1	US-10-261-185-3958	Sequence 3958, App
C 260	11.8	8.5	17	1	US-09-745-237A-405	Sequence 405, App	333	11.4	8.2	17	1	US-09-866-108-7827	Sequence 7827, App
C 261	11.8	8.5	17	1	US-09-817-879-1449	Sequence 1449, App	334	11.4	8.2	17	1	US-09-866-108-7828	Sequence 7828, App
C 262	11.8	8.5	17	1	US-09-817-879-3106	Sequence 3106, App	c 335	11.4	8.2	17	1	US-09-894-467-16	Sequence 16, Appl
C 263	11.8	8.5	17	1	US-09-817-879-3107	Sequence 3107, App	c 336	11.4	8.2	17	1	US-09-864-785-25	Sequence 25, Appl
C 264	11.8	8.5	17	1	US-10-342-902-993	Sequence 993, App	c 337	11.4	8.2	17	1	US-09-864-785-26	Sequence 26, Appl
C 265	11.8	8.5	17	1	US-10-060-756A-211	Sequence 211, App	c 338	11.4	8.2	17	1	US-09-864-785-1438	Sequence 1438, App
C 266	11.8	8.5	17	1	US-10-060-756A-212	Sequence 212, App	c 339	11.4	8.2	17	1	US-09-864-785-2015	Sequence 2015, App
C 267	11.8	8.5	17	1	US-10-060-756A-213	Sequence 213, App	340	11.4	8.2	17	1	US-09-864-785-2015	Sequence 2015, App
C 268	11.8	8.5	17	1	US-10-060-756A-753	Sequence 753, App	c 341	11.4	8.2	17	1	US-09-825-807-459	Sequence 459, App
C 269	11.8	8.5	17	1	US-10-060-756A-754	Sequence 754, App	c 342	11.4	8.2	17	1	US-09-961-077-53	Sequence 53, Appl
C 270	11.8	8.5	17	1	US-10-163-552-248	Sequence 248, App	c 343	11.4	8.2	17	1	US-09-988-628-88	Sequence 88, Appl
C 271	11.8	8.5	17	1	US-10-163-552-249	Sequence 249, App	c 344	11.4	8.2	17	1	US-09-988-628-88	Sequence 88, Appl
C 272	11.8	8.5	17	1	US-10-163-552-403	Sequence 403, App	c 345	11.4	8.2	17	1	US-09-730-289B-751	Sequence 751, App
C 273	11.8	8.5	17	1	US-10-163-552-404	Sequence 404, App	c 346	11.4	8.2	17	1	US-09-848-754A-2362	Sequence 2362, App
C 274	11.8	8.5	17	1	US-10-163-552-904	Sequence 904, App	347	11.4	8.2	17	1	US-09-848-754A-1429	Sequence 1429, App
C 275	11.8	8.5	17	1	US-10-139-604-6	Sequence 6, Appl	348	11.4	8.2	17	1	US-09-848-754A-1640	Sequence 1640, App
C 276	11.8	8.5	17	1	US-10-061-201-1607	Sequence 1607, App	349	11.4	8.2	17	1	US-09-848-754A-2450	Sequence 2450, App
C 277	11.8	8.5	17	1	US-10-061-201-1760	Sequence 1760, App	350	11.4	8.2	17	1	US-09-848-754A-2545	Sequence 2545, App
C 278	11.8	8.5	17	1	US-10-061-201-1761	Sequence 1761, App	351	11.4	8.2	17	1	US-09-848-754A-3453	Sequence 3453, App
C 279	11.8	8.5	17	1	US-10-209-787-403	Sequence 403, App	c 352	11.4	8.2	17	1	US-09-528-644-5	Sequence 5, Appl
C 280	11.8	8.5	17	1	US-10-209-787-404	Sequence 404, App	c 353	11.4	8.2	17	1	US-09-827-395A-478	Sequence 478, App
C 281	11.8	8.5	17	1	US-10-209-787-407	Sequence 407, App	c 354	11.4	8.2	17	1	US-09-988-686-88	Sequence 88, Appl
C 282	11.8	8.5	17	1	US-10-209-787-408	Sequence 408, App	c 355	11.4	8.2	17	1	US-09-740-332-1231	Sequence 1231, App
C 283	11.8	8.5	17	1	US-10-209-787-3958	Sequence 3958, App	c 356	11.4	8.2	17	1	US-09-740-332-1232	Sequence 1232, App
C 284	11.8	8.5	17	1	US-10-209-787-3959	Sequence 3959, App	c 357	11.4	8.2	17	1	US-09-740-332-3324	Sequence 3324, App
C 285	11.8	8.5	17	1	US-10-261-185-403	Sequence 403, App	c 358	11.4	8.2	17	1	US-09-792-818-96	Sequence 96, Appl
C 286	11.8	8.5	17	1	US-10-261-185-404	Sequence 404, App	c 359	11.4	8.2	17	1	US-09-792-818-282	Sequence 282, App
C 287	11.8	8.5	17	1	US-10-261-185-407	Sequence 407, App	c 360	11.4	8.2	17	1	US-09-792-818-283	Sequence 283, App
C 288	11.8	8.5	17	1	US-10-261-185-408	Sequence 408, App	c 361	11.4	8.2	17	1	US-09-817-879-1231	Sequence 1231, App
C 289	11.8	8.5	17	1	US-10-261-185-3958	Sequence 3958, App	c 362	11.4	8.2	17	1	US-09-817-879-1232	Sequence 1232, App
C 290	11.8	8.5	17	1	US-10-261-185-3959	Sequence 3959, App	c 363	11.4	8.2	17	1	US-09-817-879-1232	Sequence 1232, App
C 291	11.8	8.5	17	1	US-10-138-674-421	Sequence 421, App	364	11.4	8.2	17	1	US-10-342-902-2362	Sequence 2362, App
C 292	11.8	8.5	17	1	US-10-138-674-422	Sequence 422, App	c 365	11.4	8.2	17	1	US-09-918-715-314	Sequence 314, App
C 293	11.8	8.5	17	1	US-10-287-949A-421	Sequence 421, App	c 366	11.4	8.2	17	1	US-10-430-883-478	Sequence 478, App
C 294	11.8	8.5	17	1	US-10-287-949A-422	Sequence 422, App	c 367	11.4	8.2	17	1	US-10-060-756A-209	Sequence 209, App
C 295	11.8	8.5	17	1	US-10-712-672-2730	Sequence 2730, App	368	11.4	8.2	17	1	US-10-060-756A-210	Sequence 210, App
C 296	11.8	8.5	17	1	US-10-669-841-993	Sequence 993, App	369	11.4	8.2	17	1	US-10-060-756A-214	Sequence 214, App
C 297	11.8	8.5	17	1	US-10-669-841-4042	Sequence 4042, App	370	11.4	8.2	17	1	US-10-060-756A-215	Sequence 215, App
C 298	11.8	8.5	17	1	US-10-669-841-5699	Sequence 5699, App	371	11.4	8.2	17	1	US-10-060-756A-736	Sequence 736, App
C 299	11.8	8.5	17	1	US-10-669-841-5700	Sequence 5700, App	372	11.4	8.2	17	1	US-10-060-756A-737	Sequence 737, App
C 300	11.8	8.5	17	1	US-10-723-361-525	Sequence 525, App	373	11.4	8.2	17	1	US-10-060-756A-738	Sequence 738, App
C 301	11.8	8.5	17	1	US-10-723-361-526	Sequence 526, App	374	11.4	8.2	17	1	US-10-060-756A-739	Sequence 739, App
C 302	11.8	8.5	17	1	US-10-723-361-2351	Sequence 2351, App	375	11.4	8.2	17	1	US-10-060-756A-740	Sequence 740, App
C 303	11.8	8.5	17	1	US-10-723-361-2352	Sequence 2352, App	376	11.4	8.2	17	1	US-10-163-552-747	Sequence 747, App
C 304	11.8	8.5	17	1	US-10-723-361-2353	Sequence 2353, App	377	11.4	8.2	17	1	US-10-163-552-748	Sequence 748, App
C 305	11.8	8.5	17	1	US-10-723-361-7829	Sequence 7829, App	378	11.4	8.2	17	1	US-10-339-782-249	Sequence 249, App
C 306	11.8	8.5	17	1	US-10-723-361-7830	Sequence 7830, App	c 379	11.4	8.2	17	1	US-10-061-201-1296	Sequence 1296, App
C 307	11.8	8.5	18	1	US-09-863-777-3	Sequence 3, Appl	c 380	11.4	8.2	17	1	US-10-061-201-1297	Sequence 1297, App
C 308	11.8	8.5	18	1	US-09-863-777-4	Sequence 4, Appl	c 381	11.4	8.2	17	1	US-10-061-201-1298	Sequence 1298, App
C 309	11.8	8.5	18	1	US-09-969-373-1855	Sequence 1855, App	c 382	11.4	8.2	17	1	US-10-061-201-1299	Sequence 1299, App
C 310	11.8	8.5	18	1	US-09-969-373-2246	Sequence 2246, App	c 383	11.4	8.2	17	1	US-10-061-201-1300	Sequence 1300, App
C 311	11.8	8.5	18	1	US-09-306-333A-114	Sequence 114, App	c 384	11.4	8.2	17	1	US-10-061-201-1300	Sequence 1300, App
C 312	11.8	8.5	18	1	US-09-362-485-19	Sequence 19, Appl	c 385	11.4	8.2	17	1	US-10-061-201-1758	Sequence 1758, App
C 313	11.8	8.5	18	1	US-10-434-387-10	Sequence 10, Appl	c 386	11.4	8.2	17	1	US-10-061-201-1759	Sequence 1759, App
C 314	11.8	8.5	18	1	US-10-133-779-20	Sequence 20, Appl	c 387	11.4	8.2	17	1	US-10-084-839-3116	Sequence 3116, App
C 315	11.8	8.5	18	1	US-10-114-824A-52	Sequence 52, Appl	c 388	11.4	8.2	17	1	US-10-297-068-1053	Sequence 1053, App
C 316	11.8	8.5	18	1	US-10-237-068-30	Sequence 30, Appl	c 389	11.4	8.2	17	1	US-10-297-068-1160	Sequence 1160, App
C 317	11.8	8.5	18	1	US-10-277-216-163	Sequence 163, App	390	11.4	8.2	17	1	US-10-138-674-1376	Sequence 1376, App
C 318	11.8	8.5	18	1	US-10-349-143-6052	Sequence 6052, App	391	11.4	8.2	17	1	US-10-138-674-1377	Sequence 1377, App
C 319	11.8	8.5	18	1	US-10-126-022-163	Sequence 163, App	c 392	11.4	8.2	17	1	US-10-138-674-4992	Sequence 4992, App
C 320	11.8	8.5	18	1	US-10-670-184-106	Sequence 106, App	c 393	11.4	8.2	17	1	US-10-138-674-8011	Sequence 8011, App
C 321	11.8	8.5	20	1	US-10-243-035-7	Sequence 7, Appl	394	11.4	8.2	17	1	US-10-138-674-8348	Sequence 8348, App
C 322	11.4	8.2	13	1	US-09-510-378-27	Sequence 27, Appl	395	11.4	8.2	17	1	US-10-287-949A-1376	Sequence 1376, App
C 323	11.4	8.2	13	1	US-09-798-260-85	Sequence 85, Appl	396	11.4	8.2	17	1	US-10-287-949A-1377	Sequence 1377, App
C 324	11.4	8.2	14	1	US-09-943-983-9	Sequence 9, Appl	c 397	11.4	8.2	17	1	US-10-287-949A-4992	Sequence 4992, App
C 325	11.4	8.2	15	1	US-09-504-231A-474	Sequence 474, App	c 398	11.4	8.2	17	1	US-10-287-949A-8011	Sequence 8011, App

399	11.4	17	1	US-10-287-949A-8348	Sequence 8348, Ap	472	11.2	8.1	17	1	US-09-792-818-409	Sequence 409, Ap
400	11.4	17	1	US-10-712-672-1303	Sequence 1303, Ap	c 473	11.2	8.1	17	1	US-09-792-818-603	Sequence 603, Ap
401	8.2	17	1	US-10-712-672-1304	Sequence 1304, Ap	c 474	11.2	8.1	17	1	US-09-745-237A-1237	Sequence 1237, Ap
402	8.2	17	1	US-10-712-672-2491	Sequence 2491, Ap	c 475	11.2	8.1	17	1	US-09-745-237A-1604	Sequence 1604, Ap
403	11.4	17	1	US-10-669-841-2165	Sequence 2165, Ap	c 476	11.2	8.1	17	1	US-09-817-879-559	Sequence 559, Ap
404	8.2	17	1	US-10-669-841-3824	Sequence 3824, Ap	c 477	11.2	8.1	17	1	US-09-817-879-819	Sequence 819, Ap
405	11.4	17	1	US-10-669-841-3825	Sequence 3825, Ap	c 478	11.2	8.1	17	1	US-09-817-879-859	Sequence 859, Ap
406	11.4	17	1	US-10-669-841-5917	Sequence 5917, Ap	c 479	11.2	8.1	17	1	US-09-817-879-3696	Sequence 3696, Ap
407	8.2	17	1	US-10-723-361-7827	Sequence 7827, Ap	c 480	11.2	8.1	17	1	US-09-817-879-3736	Sequence 3736, Ap
408	11.4	17	1	US-10-723-361-7828	Sequence 7828, Ap	c 481	11.2	8.1	17	1	US-09-817-879-3996	Sequence 3996, Ap
409	11.2	16	1	US-10-043-875-261	Sequence 261, App	c 482	11.2	8.1	17	1	US-09-591-552-7	Sequence 7, Appli
410	11.2	8.1	16	US-10-091-281-319	Sequence 319, App	c 483	11.2	8.1	17	1	US-10-453-792-42	Sequence 42, Appl
411	11.2	8.1	16	US-10-138-674-5657	Sequence 5657, Ap	c 484	11.2	8.1	17	1	US-10-342-903-399	Sequence 399, App
412	8.1	16	1	US-10-138-674-5658	Sequence 5658, Ap	c 485	11.2	8.1	17	1	US-10-342-903-571	Sequence 571, App
413	11.2	8.1	16	US-10-138-674-5954	Sequence 5954, Ap	c 486	11.2	8.1	17	1	US-10-342-903-572	Sequence 572, App
414	11.2	8.1	16	US-10-287-949A-5657	Sequence 5657, Ap	c 487	11.2	8.1	17	1	US-10-342-902-1746	Sequence 1746, Ap
415	11.2	8.1	16	US-10-287-949A-5658	Sequence 5658, Ap	c 488	11.2	8.1	17	1	US-10-342-902-2358	Sequence 2358, Ap
416	11.2	8.1	16	US-10-287-949A-5954	Sequence 5954, Ap	c 489	11.2	8.1	17	1	US-10-342-903-2363	Sequence 2363, Ap
417	11.2	8.1	16	US-10-712-672-1597	Sequence 1597, Ap	c 490	11.2	8.1	17	1	US-10-342-903-2364	Sequence 2364, Ap
418	11.2	8.1	16	US-10-376-770-213	Sequence 213, App	c 491	11.2	8.1	17	1	US-10-686-736-10	Sequence 10, Appl
419	11.2	8.1	16	US-10-661-165-213	Sequence 213, App	c 492	11.2	8.1	17	1	US-10-688-108-7	Sequence 7, Appli
420	11.2	8.1	17	US-10-163-552-471	Sequence 471, App	c 493	11.2	8.1	17	1	US-09-918-715-331	Sequence 331, App
421	11.2	8.1	17	US-09-866-108-529	Sequence 529, App	c 494	11.2	8.1	17	1	US-09-927-046-499	Sequence 499, App
422	11.2	8.1	17	US-09-866-108-1263	Sequence 1263, Ap	c 495	11.2	8.1	17	1	US-09-927-046-1174	Sequence 1174, Ap
423	11.2	8.1	17	US-09-866-108-1285	Sequence 1285, Ap	c 496	11.2	8.1	17	1	US-10-430-882-65	Sequence 65, Appl
424	11.2	8.1	17	US-09-866-108-1286	Sequence 1286, Ap	c 497	11.2	8.1	17	1	US-10-430-882-367	Sequence 367, App
425	11.2	8.1	17	US-09-866-108-7832	Sequence 7832, Ap	c 498	11.2	8.1	17	1	US-10-060-830-137	Sequence 137, App
426	11.2	8.1	17	US-09-866-108-7984	Sequence 7984, Ap	c 499	11.2	8.1	17	1	US-10-060-830-138	Sequence 138, App
427	11.2	8.1	17	US-09-866-108-7985	Sequence 7985, Ap	c 500	11.2	8.1	17	1	US-10-060	

C 545	11.2	8.1	17	1	US-10-454-224-24	Sequence 24, Appl	C 618	10.8	7.8	15	1	US-09-880-313A-49	Sequence 49, Appl
C 546	11.2	8.1	17	1	US-10-210-130-362	Sequence 362, App	619	10.8	7.8	15	1	US-09-793-146-7	Sequence 7, Appl
C 547	11.2	8.1	17	1	US-10-261-185-1703	Sequence 1703, Ap	C 620	10.8	7.8	15	1	US-10-010-802-130	Sequence 130, App
C 548	11.2	8.1	17	1	US-10-261-185-1704	Sequence 1704, Ap	621	10.8	7.8	15	1	US-10-440-850-823	Sequence 823, App
C 549	11.2	8.1	17	1	US-10-138-674-22	Sequence 22, Appl	622	10.8	7.8	15	1	US-10-418-182-186	Sequence 186, App
C 550	11.2	8.1	17	1	US-10-138-674-782	Sequence 782, App	C 623	10.8	7.8	16	1	US-09-965-876A-15	Sequence 15, Appl
C 551	11.2	8.1	17	1	US-10-138-674-2582	Sequence 2582, Ap	C 624	10.8	7.8	16	1	US-09-882-945A-268	Sequence 268, App
C 552	11.2	8.1	17	1	US-10-138-674-2892	Sequence 2892, Ap	625	10.8	7.8	16	1	US-10-087-082-6	Sequence 6, Appl
C 553	11.2	8.1	17	1	US-10-138-674-2893	Sequence 2893, Ap	626	10.8	7.8	16	1	US-10-123-731-8	Sequence 8, Appl
C 554	11.2	8.1	17	1	US-10-138-674-2911	Sequence 2911, Ap	627	10.8	7.8	16	1	US-10-138-674-5803	Sequence 5803, Ap
C 555	11.2	8.1	17	1	US-10-138-674-4204	Sequence 4204, Ap	628	10.8	7.8	16	1	US-10-138-674-5880	Sequence 5880, Ap
C 556	11.2	8.1	17	1	US-10-138-674-4205	Sequence 4205, Ap	C 629	10.8	7.8	16	1	US-10-138-674-5912	Sequence 5912, Ap
C 557	11.2	8.1	17	1	US-10-138-674-4205	Sequence 4205, Ap	630	10.8	7.8	16	1	US-10-287-949A-5880	Sequence 5880, Ap
C 558	11.2	8.1	17	1	US-10-138-674-5053	Sequence 5053, Ap	631	10.8	7.8	16	1	US-10-287-949A-5912	Sequence 5912, Ap
C 559	11.2	8.1	17	1	US-10-138-674-5054	Sequence 5054, Ap	C 632	10.8	7.8	16	1	US-10-287-949A-5912	Sequence 5912, Ap
C 560	11.2	8.1	17	1	US-10-138-674-5167	Sequence 5167, Ap	633	10.6	7.6	17	1	US-09-877-478-2360	Sequence 2360, Ap
C 561	11.2	8.1	17	1	US-10-287-949A-22	Sequence 22, Appl	634	10.6	7.6	17	1	US-10-342-902-2360	Sequence 2360, Ap
C 562	11.2	8.1	17	1	US-10-287-949A-2582	Sequence 2582, Ap	635	10.6	7.6	17	1	US-10-669-841-2163	Sequence 2163, Ap
C 563	11.2	8.1	17	1	US-10-287-949A-2892	Sequence 2892, Ap	C 636	10.6	7.6	17	1	US-10-061-201-1961	Sequence 1961, Ap
C 564	11.2	8.1	17	1	US-10-287-949A-2893	Sequence 2893, Ap	C 637	10.6	7.6	17	1	US-10-061-201-1961	Sequence 1961, Ap
C 565	11.2	8.1	17	1	US-10-287-949A-2911	Sequence 2911, Ap	C 638	10.6	7.6	17	1	US-10-251-117-717	Sequence 717, App
C 566	11.2	8.1	17	1	US-10-287-949A-4204	Sequence 4204, Ap	639	10.6	7.6	19	1	US-10-251-117-717	Sequence 717, App
C 567	11.2	8.1	17	1	US-10-287-949A-4205	Sequence 4205, Ap	C 640	10.4	7.5	14	1	US-10-027-632-51889	Sequence 1024, Ap
C 568	11.2	8.1	17	1	US-10-287-949A-5053	Sequence 5053, Ap	C 641	10.4	7.5	14	1	US-10-027-632-51889	Sequence 51889, A
C 569	11.2	8.1	17	1	US-10-287-949A-5054	Sequence 5054, Ap	C 642	10.4	7.5	14	1	US-10-027-632-51889	Sequence 51889, A
C 570	11.2	8.1	17	1	US-10-287-949A-5167	Sequence 5167, Ap	C 643	10.4	7.5	14	1	US-10-027-632-51894	Sequence 51894, A
C 571	11.2	8.1	17	1	US-10-712-672-14	Sequence 14, Appl	C 644	10.4	7.5	14	1	US-10-146-058-90	Sequence 90, Appl
C 572	11.2	8.1	17	1	US-10-712-672-522	Sequence 522, App	645	10.4	7.5	14	1	US-10-376-770-65	Sequence 65, Appl
C 573	11.2	8.1	17	1	US-10-712-672-556	Sequence 556, App	646	10.4	7.5	14	1	US-10-661-165-65	Sequence 65, Appl
C 574	11.2	8.1	17	1	US-10-712-672-556	Sequence 557, App	C 647	10.4	7.5	15	1	US-09-504-231A-361	Sequence 361, App
C 575	11.2	8.1	17	1	US-10-712-672-2295	Sequence 2295, Ap	C 648	10.4	7.5	15	1	US-09-504-231A-361	Sequence 361, App
C 576	11.2	8.1	17	1	US-10-712-672-2501	Sequence 2501, Ap	C 649	10.4	7.5	15	1	US-09-274-553D-361	Sequence 361, App
C 577	11.2	8.1	17	1	US-10-712-672-2328	Sequence 2328, Ap	650	10.4	7.5	15	1	US-09-274-553D-361	Sequence 361, App
C 578	11.2	8.1	17	1	US-10-669-841-3399	Sequence 3399, App	651	10.4	7.5	15	1	US-09-877-478-5948	Sequence 5948, Ap
C 579	11.2	8.1	17	1	US-10-669-841-571	Sequence 571, App	652	10.4	7.5	15	1	US-10-342-902-5948	Sequence 5948, Ap
C 580	11.2	8.1	17	1	US-10-669-841-572	Sequence 572, App	653	10.4	7.5	15	1	US-10-391-415-8	Sequence 8, Appl
C 581	11.2	8.1	17	1	US-10-669-841-1746	Sequence 1746, Ap	C 654	10.4	7.5	15	1	US-10-056-414-211	Sequence 211, App
C 582	11.2	8.1	17	1	US-10-669-841-2161	Sequence 2161, Ap	C 655	10.4	7.5	15	1	US-10-287-919-793	Sequence 793, App
C 583	11.2	8.1	17	1	US-10-669-841-2166	Sequence 2166, Ap	C 656	10.4	7.5	15	1	US-10-203-896-27	Sequence 27, Appl
C 584	11.2	8.1	17	1	US-10-669-841-2167	Sequence 2167, Ap	657	10.4	7.5	15	1	US-10-044-674-6	Sequence 6, Appl
C 585	11.2	8.1	17	1	US-10-669-841-3152	Sequence 3152, Ap	658	10.4	7.5	15	1	US-10-044-674-56	Sequence 56, Appl
C 586	11.2	8.1	17	1	US-10-669-841-3412	Sequence 3412, Ap	659	10.4	7.5	15	1	US-10-440-860-645	Sequence 645, App
C 587	11.2	8.1	17	1	US-10-669-841-3452	Sequence 3452, Ap	C 660	10.4	7.5	15	1	US-10-333-088-114	Sequence 114, App
C 588	11.2	8.1	17	1	US-10-669-841-6289	Sequence 6289, Ap	C 661	10.4	7.5	15	1	US-10-376-770-211	Sequence 211, App
C 589	11.2	8.1	17	1	US-10-669-841-6329	Sequence 6329, Ap	662	10.4	7.5	15	1	US-10-669-841-2351	Sequence 2351, Ap
C 590	11.2	8.1	17	1	US-10-669-841-6529	Sequence 6529, Ap	C 663	10.4	7.5	15	1	US-10-661-165-211	Sequence 211, App
C 591	11.2	8.1	17	1	US-10-669-841-6589	Sequence 6589, Ap	664	10.4	7.5	16	1	US-10-227-719D-12	Sequence 12, Appl
C 592	11.2	8.1	17	1	US-10-723-361-529	Sequence 529, App	C 665	10.4	7.5	16	1	US-10-092-208-2	Sequence 2, Appl
C 593	11.2	8.1	17	1	US-10-723-361-1263	Sequence 1263, Ap	666	10.4	7.5	16	1	US-10-091-281-124	Sequence 124, App
C 594	11.2	8.1	17	1	US-10-723-361-1265	Sequence 1265, Ap	667	10.4	7.5	16	1	US-10-331-109-11	Sequence 11, Appl
C 595	11.2	8.1	17	1	US-10-723-361-1286	Sequence 1286, Ap	668	10.4	7.5	16	1	US-10-138-674-5910	Sequence 5910, Ap
C 596	11.2	8.1	17	1	US-10-723-361-7832	Sequence 7832, Ap	C 669	10.4	7.5	16	1	US-10-138-674-7125	Sequence 7125, Ap
C 597	11.2	8.1	17	1	US-10-723-361-7984	Sequence 7984, Ap	C 670	10.4	7.5	16	1	US-10-407-807-32	Sequence 32, Appl
C 598	11.2	8.1	17	1	US-10-723-361-7985	Sequence 7985, Ap	C 671	10.4	7.5	16	1	US-10-287-949A-5910	Sequence 5910, Ap
C 599	11.2	8.1	17	1	US-10-723-361-9657	Sequence 9657, Ap	C 672	10.4	7.5	16	1	US-10-287-949A-7125	Sequence 7125, Ap
C 600	11.2	8.1	17	1	US-10-723-361-9659	Sequence 9659, Ap	C 673	10.4	7.5	16	1	US-10-459-184-37	Sequence 37, Appl
C 601	11.2	8.1	17	1	US-10-723-361-10208	Sequence 10208, A	C 674	10.4	7.5	17	1	US-09-877-478-2363	Sequence 2363, Ap
C 602	11.2	8.1	17	1	US-10-723-361-10209	Sequence 10209, A	C 675	10.4	7.5	17	1	US-10-342-902-2363	Sequence 2363, Ap
C 603	11.2	8.1	17	1	US-10-417-264-4	Sequence 4, Appl	C 676	10.4	7.5	17	1	US-10-669-841-2166	Sequence 2166, Ap
C 604	11.2	8.1	17	1	US-10-417-264-5	Sequence 5, Appl	C 677	10.4	7.5	18	1	US-10-114-824A-52	Sequence 52, Appl
C 605	11	7.9	12	1	US-10-661-165-376	Sequence 376, App	C 678	10.4	7.5	19	1	US-10-224-005-20	Sequence 20, Appl
C 606	11	7.9	15	1	US-10-287-226-558	Sequence 558, App	C 679	10.4	7.5	19	1	US-10-224-005-181	Sequence 181, App
C 607	11	7.9	16	1	US-10-331-109-15	Sequence 15, Appl	680	10.2	7.3	15	1	US-09-864-785-3708	Sequence 3708, Ap
C 608	11	7.9	16	1	US-10-455-013-17	Sequence 17, Appl	681	10.2	7.3	15	1	US-09-877-478-5955	Sequence 5955, Ap
C 609	11	7.9	16	1	US-10-455-013-29	Sequence 29, Appl	682	10.2	7.3	15	1	US-09-877-478-6533	Sequence 6533, Ap
C 610	11	7.9	16	1	US-10-627-250-17	Sequence 27, Appl	C 683	10.2	7.3	15	1	US-09-943-983-61	Sequence 61, Appl
C 611	11	7.9	16	1	US-10-627-250-29	Sequence 29, Appl	684	10.2	7.3	15	1	US-09-093-972C-579	Sequence 579, App
C 612	10.8	7.8	14	1	US-09-943-983-4	Sequence 4, Appl	C 685	10.2	7.3	15	1	US-09-740-332-4786	Sequence 4786, Ap
C 613	10.8	7.8	15	1	US-09-263-959-672	Sequence 672, App	C 686	10.2	7.3	15	1	US-09-740-332-4796	Sequence 4796, Ap
C 614	10.8	7.8	15	1	US-09-263-959-708	Sequence 708, App	C 687	10.2	7.3	15	1	US-09-817-879-4786	Sequence 4786, Ap
C 615	10.8	7.8	15	1	US-09-860-784-8	Sequence 8, Appl	C 688	10.2	7.3	15	1	US-09-817-879-4796	Sequence 4796, Ap
C 616	10.8	7.8	15	1	US-09-835-371-5	Sequence 5, Appl	689	10.2	7.3	15	1	US-09-835-694-19	Sequence 19, Appl
C 617	10.8	7.8	15	1	US-09-835-370-5	Sequence 5, Appl	690	10.2	7.3	15	1	US-09-835-694-23	Sequence 23, Appl

691 10.2 7.3 15 1 US-10-342-902-5955 Sequence 5955, Ap
692 10.2 7.3 15 1 US-10-342-902-6533 Sequence 6533, Ap
693 10.2 7.3 15 1 US-10-339-674-1741 Sequence 1741, Ap
C 694 10.2 7.3 15 1 US-10-339-674-3176 Sequence 3176, Ap
695 10.2 7.3 15 1 US-10-056-414-340 Sequence 340, App
C 696 10.2 7.3 15 1 US-10-043-875-258 Sequence 258, App
C 697 10.2 7.3 15 1 US-10-043-875-262 Sequence 262, App
698 10.2 7.3 15 1 US-10-156-306-7875 Sequence 7875, Ap
C 699 10.2 7.3 15 1 US-10-160-358-31 Sequence 31, Appl
C 700 10.2 7.3 15 1 US-10-440-850-282 Sequence 282, App
C 701 10.2 7.3 15 1 US-10-440-850-497 Sequence 497, App
C 702 10.2 7.3 15 1 US-10-271-602B-193 Sequence 193, App
C 703 10.2 7.3 15 1 US-10-271-602B-195 Sequence 195, App
704 10.2 7.3 15 1 US-10-376-341-211 Sequence 211, App
705 10.2 7.3 15 1 US-10-669-841-2358 Sequence 2358, Ap
706 10.2 7.3 15 1 US-10-669-841-2586 Sequence 2586, Ap
C 707 10.2 7.3 15 1 US-10-669-841-7362 Sequence 7362, Ap
C 708 10.2 7.3 15 1 US-10-669-841-7383 Sequence 7383, Ap

ALIGNMENTS

RESULT 1
US-10-131-827-1795
; Sequence 1795, Application US/10131827
; Publication No. US2004009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: FV, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131.827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1795
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-1795

Query Match 24.5%; Score 34; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 0.35;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1736 CTCCCAACTCTCCCTATCTCTAAAGGCCACTGG 1769
Db 1 CTCCCAACTCTCCCTATCTCTAAAGGCCACTGG 34

RESULT 2
US-10-239-504-34/c
; Sequence 34, Application US/10239504
; Publication No. US20040132018A1
; GENERAL INFORMATION:
; APPLICANT: NAGANO, MAKOTO
; APPLICANT: ITO, MAYUMI
; APPLICANT: SAGEHASHI, YUKIKO
; APPLICANT: HATTORI, HIROAKI
; APPLICANT: EGASHIRA, SHIZUYA
; APPLICANT: MATSUZAWA, YUJI
; TITLE OF INVENTION: METHOD OF DETECTING RISK FACTOR FOR THE ONSET OF
; FILE REFERENCE: Q72096
; CURRENT APPLICATION NUMBER: US/10/239,504

; CURRENT FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: PCT/JP01/02327
; PRIOR FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: JP 2000-84264
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-10-239-504-34

Query Match 15.1%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1665 TCACAGCTGGACCCCTGGTGT 1685
Db 21 TCACAGCTGGACCCCTGGTGT 1

RESULT 3
US-09-802-640-52/c
; Sequence 52, Application US/09802640
; Publication No. US20030036057A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Bonsal Aruna
; APPLICANT: Kleyrn Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; FILE REFERENCE: 24736-2048
; CURRENT APPLICATION NUMBER: US/09/802,640
; CURRENT FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-802-640-52

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1639 CTTGTAGCAGAG3CAAGCA 1658
Db 20 CTTGTAGCAGAG3CAAGCA 1

RESULT 4
US-09-925-139-5/c
; Sequence 5, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5

;
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-925-139-5

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1695 CQTGGTGGAGTTGGGTAG 1714
|||||
Db 20 CQTGGTGGAGTTGGGTAG 1

RESULT 5

US-09-925-139-28/c
; Sequence 28, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-28

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1631 GGATGGGCTGTAGCAGAA 1650
|||||
Db 20 GGATGGGCTGTAGCAGAA 1

RESULT 6

US-09-925-139-29/c
; Sequence 29, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-29

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1671 CTGGAACCTGTGTCTCCT 1690
|||||
Db 20 CTGGAACCTGTGTCTCCT 1

RESULT 7

US-09-925-139-30/c
; Sequence 30, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-30

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGTTAGGATAC 1720
|||||
Db 20 GGAAGTTGGTTAGGATAC 1

RESULT 8

US-09-925-139-47/c
; Sequence 47, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wanciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-47

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1638 GCTTGTAGCAGGCAAGC 1657
|||||
Db 20 GCTTGTAGCAGGCAAGC 1

RESULT 9

US-09-925-139-48/c

; Sequence 48, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-48

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1693 AGCGTGGTGAAGTTGGGTT 1712
Db 20 AGCGTGGTGAAGTTGGGTT 1

RESULT 10
US-09-925-139-49/c
; Sequence 49, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596
; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-49

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1714 GGAGTACGGAGATGGAGATT 1733
Db 20 GGAGTACGGAGATGGAGATT 1

RESULT 11
US-09-925-139-50/c
; Sequence 50, Application US/09925139
; Publication No. US20030092647A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; APPLICANT: Pam Nero
; APPLICANT: Edward Wancewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRES
; FILE REFERENCE: ISPH-0596

; CURRENT APPLICATION NUMBER: US/09/925,139
; CURRENT FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-925-139-50

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGGCCCACTGG 1769
Db 20 CTATCCTAAAGGCCCACTGG 1

RESULT 12
US-10-403-902A-52/c
; Sequence 52, Application US/10403902A
; Publication No. US20030224418A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Bansal, Arune
; APPLICANT: Klynn, Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISEASE AND THEIR USE
; FILE REFERENCE: 24736-2048B
; CURRENT APPLICATION NUMBER: US/10/403,902A
; CURRENT FILING DATE: 2003-07-21
; PRIOR APPLICATION NUMBER: 09/802,640
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-403-902A-52

Query Match 14.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1639 CTTGTAGCAGAGGCAAGCA 1658
Db 20 CTTGTAGCAGAGGCAAGCA 1

RESULT 13
US-10-257-080-5
; Sequence 5, Application US/10257080
; Publication No. US20030166000A1
; GENERAL INFORMATION:
; APPLICANT: MIWA, Masanori
; APPLICANT: MATSUI, Hideki
; APPLICANT: SHINTANI, Yasuhiro
; TITLE OF INVENTION: No. US20030166000A1e1 G Protein Coupled Receptor and its DNA
; FILE REFERENCE: 2715 USOP
; CURRENT APPLICATION NUMBER: US/10/257,080
; CURRENT FILING DATE: 2002-10-08
; PRIOR APPLICATION NUMBER: PCT/JP01/03143
; PRIOR FILING DATE: 2001-04-12
; PRIOR APPLICATION NUMBER: JP 2000-110765
; PRIOR FILING DATE: 2000-04-12
; NUMBER OF SEQ ID NOS: 7
; SEQ ID NO 5

;
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-257-080-5

Query Match 12.1%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 55;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1732 TTGGTCCCAACTCTCCT 1751
|||||
Db 1 TTGGTCCCAACTCTCCTT 20

RESULT 14
US-09-754-106-102
; Sequence 102, Application US/09754106
; Publication No. US20030224355A1
; GENERAL INFORMATION:
; APPLICANT: Bell, Graeme I.
; APPLICANT: Yamagata, Kazuya
; APPLICANT: Oda, Naohisha
; APPLICANT: Kaisaki, Pamela J.
; APPLICANT: Furuta, Hitoto
; APPLICANT: Horikawa, Yukio
; APPLICANT: Menzel, Stephen
; TITLE OF INVENTION: MUTATIONS IN THE DIABETES SUSCEPTIBILITY
; TITLE OF INVENTION: GENES HEPATOCYTE NUCLEAR FACTOR (HNF) 1 ALPHA, HNF-1BETA
; TITLE OF INVENTION: AND HNF-4ALPHA
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/754.106
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/927,219
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/028,056
FILING DATE: 02-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/025,719
FILING DATE: 10-SEP-1996

ATTORNEY/AGENT INFORMATION:
NAME: Wilson, Mark B.
REGISTRATION NUMBER: 37,259
REFERENCE/DOCKET NUMBER: ARCD:272
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 102:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-754-106-102

Query Match 11.7%; Score 16.2; DB 1; Length 22;

Best Local Similarity 85.7%; Pred. No. 78;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1658 ACCAGGCTCACAGCTGGAACC 1678
|||||
Db 2 ACCAGACTCACAGCTGAACC 22

RESULT 15
US-09-865-879-19
; Sequence 19, Application US/09865879
; Publication No. US20030180707A1
; GENERAL INFORMATION:
; APPLICANT: Roninson, Igor
; APPLICANT: Dokmanovic, Milos
; APPLICANT: Chang, Bey-Dih
; TITLE OF INVENTION: REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF
; TITLE OF INVENTION: REGULATED BY RETINOIDS
; FILE REFERENCE: 99,216-H
; CURRENT APPLICATION NUMBER: US/09/865,879
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/207,535
; PRIOR FILING DATE: 2000-05-26
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Antisense primer for beta IG-H3
US-09-865-879-19

Query Match 10.9%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 93;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1653 CAAGCACCAGGCTCACAGCT 1672
|||||
Db 1 CATGCACAAGGCTCACATCT 20

RESULT 16
US-10-648-512-62
; Sequence 62, Application US/10648512
; Publication No. US20040096922A1
; GENERAL INFORMATION:
; APPLICANT: Hildebrandt, Friedhelm
; APPLICANT: Otto, Edgar
; APPLICANT: Hofeife, Julia
; APPLICANT: Ruf, Rainer
; APPLICANT: Mueller, Adelheid M.
; APPLICANT: Hiller, Karl S.
; APPLICANT: Wolf, Matthias T.F.
; APPLICANT: Schuermann, Maria J.
; APPLICANT: Becker, Achim
; TITLE OF INVENTION: NPHP Nucleic Acids and Proteins
; FILE REFERENCE: UM-08333
; CURRENT APPLICATION NUMBER: US/10/648,512
; CURRENT FILING DATE: 2003-08-26
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-648-512-62

Query Match 10.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 85;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCTGGTGTCTCTCCAG 1694
|||||
Db 1 CCTGGTGTCTCTCTG 18

RESULT 17

US-10-005-956-1205/c
; Sequence 1205, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS

; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; PRIOR FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-956-1205

Query Match 10.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCTGGTCTC 1686
|||||
Db 19 AGCTGGAACCTGGTCTC 2

RESULT 18

US-10-671-395-411/c
; Sequence 411, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE

; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 411
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-411

Query Match 10.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTGGGTTAG 1714
|||||
Db 20 TGGTGAAGCTGGGTGAG 3

RESULT 19

US-10-671-395-451/c
; Sequence 451, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 451
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-451

Query Match 10.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTGGGTTAG 1714
|||||
Db 19 TGGTGAAGCTGGGTGAG 2

RESULT 20

US-10-671-395-555/c
; Sequence 555, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 555
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-555

Query Match 10.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTGGGTTAG 1714
|||||
Db 18 TGGTGAAGCTGGGTGAG 1

RESULT 21

US-10-044-423-19/c
; Sequence 19, Application US/10044423
; Publication No. US20030165862A1
; GENERAL INFORMATION:
; APPLICANT: Chou, Tze-Bin
; TITLE OF INVENTION: DROSOPHILA CLIPPED FRT (CFRT) CHROMOSOME

```
/ TITLE OF INVENTION: INSENSITIVE TO P TRANSPOSASE, GENERATING METHOD THEREOF, AND
/ TITLE OF INVENTION: APPLICATION THEREOF
/ FILE REFERENCE: 529872000100
/ CURRENT APPLICATION NUMBER: US/10/044,423
/ CURRENT FILING DATE: 2002-09-05
/ NUMBER OF SEQ ID NOS: 35
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 19
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic Construct
US-10-044-423-19
```

```
Query Match          10.6%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1648 GAAAGCAAGCACCAGGCT 1665
      ||| ||||| ||||| |||
Db 19 GAAAGCAAGCACCAGGAT 2
```

RESULT 22

```
US-09-382-860-231/c
/ Sequence 231, Application US/09382860
/ Publication No. US20030110526A1
/ GENERAL INFORMATION:
/ APPLICANT: Brown, Jr., Robert H.
/ APPLICANT: Liu, Jing
/ APPLICANT: Aoki, Masashi
/ APPLICANT: Hoffman, Eric
/ APPLICANT: Chou, Fan-Li
```

```
/ TITLE OF INVENTION: DYSFERLIN MUTATIONS
/ FILE REFERENCE: 00786/401002
/ CURRENT APPLICATION NUMBER: US/09/382,860
/ CURRENT FILING DATE: 1999-08-25
/ EARLIER APPLICATION NUMBER: US 60/097,930
/ EARLIER FILING DATE: 1998-08-25
/ NUMBER OF SEQ ID NOS: 283
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 231
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-382-860-231
```

```
Query Match          10.5%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 1677 CCTGGTGTCTCTCCAGCGT 1697
      ||| ||| ||| ||| ||| |||
Db 21 CCGTGGGTCCCTCCAGCAT 1
```

RESULT 23

```
US-09-827-395A-480/c
/ Sequence 480, Application US/09827395A
/ Publication No. US20030113891A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Lawrence Blatt
/ APPLICANT: James McSwiggen
/ APPLICANT: Bharat Chowrira
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
/ FILE REFERENCE: MBH00-878-C (400/017)
/ CURRENT APPLICATION NUMBER: US/09/827,395A
/ CURRENT FILING DATE: 2001-04-05
/ PRIOR APPLICATION NUMBER: 09/780,533
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: 60/181,797
```

```
/ PRIOR FILING DATE: 2000-02-11
/ NUMBER OF SEQ ID NOS: 2617
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 480
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-827-395A-480
```

```
Query Match          10.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1673 GGAACCCCTGGTGCTC 1688
      ||||| ||||| |||
Db 17 GGAACCCCTGGTGCTC 2
```

RESULT 24

```
US-09-827-395A-481/c
/ Sequence 481, Application US/09827395A
/ Publication No. US20030113891A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Lawrence Blatt
/ APPLICANT: James McSwiggen
/ APPLICANT: Bharat Chowrira
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
/ FILE REFERENCE: MBH00-878-C (400/017)
/ CURRENT APPLICATION NUMBER: US/09/827,395A
/ CURRENT FILING DATE: 2001-04-05
/ PRIOR APPLICATION NUMBER: 09/780,533
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: 60/181,797
/ NUMBER OF SEQ ID NOS: 2617
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 481
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-827-395A-481
```

```
Query Match          10.4%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 88;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1673 GGAACCCCTGGTGCTC 1688
      ||||| ||||| |||
Db 16 GGAACCCCTGGTGCTC 1
```

RESULT 25

```
US-10-430-882-480/c
/ Sequence 480, Application US/10430882
/ Publication No. US20030203870A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Lawrence Blatt
/ APPLICANT: James McSwiggen
/ APPLICANT: Bharat Chowrira
/ APPLICANT: Peter Haerberli
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
/ FILE REFERENCE: MBH00-878-H (400/112)
/ CURRENT APPLICATION NUMBER: US/10/430,882
/ CURRENT FILING DATE: 2003-05-06
/ PRIOR APPLICATION NUMBER: 09/827,395
/ PRIOR FILING DATE: 2001-04-05
/ PRIOR APPLICATION NUMBER: 09/780,533
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: PCT/US01/04273
/ PRIOR FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: 60/181,797
```

```

; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-480

Query Match
Best Local Similarity 10.4%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCTGGTGCTC 1688
Db 17 GGAACCTGGTGCTC 2

RESULT 26
US-10-430-882-481/c
; Sequence 481, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 481
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-481

Query Match
Best Local Similarity 10.4%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCTGGTGCTC 1688
Db 16 GGAACCTGGTGCTC 1

RESULT 27
US-10-032-585-5725
; Sequence 5725, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jlang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585

; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8003
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5725
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-5725

Query Match
Best Local Similarity 10.4%; Score 14.4; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1737 TCCCAACTCCTCCCTA 1752
Db 1 TCCCAACTCCTCCCA 16

RESULT 28
US-09-770-107-60/c
; Sequence 60, Application US/09770107
; Publication No. US20030054345A1
; GENERAL INFORMATION:
; APPLICANT: Millennium Pharmaceuticals, Inc.
; APPLICANT: Meyer, Joanne
; APPLICANT: Barrington-Martin, Rory
; APPLICANT: Parker, Alexander
; APPLICANT: Barnes, Glen
; TITLE OF INVENTION: Compositions and methods for the diagnosis and treatment of
; FILE REFERENCE: 3322/0H4C1
; CURRENT APPLICATION NUMBER: US/09/770,107
; CURRENT FILING DATE: 2001-01-24
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 60
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-770-107-60

Query Match
Best Local Similarity 10.4%; Score 14.4; DB 1; Length 21;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1640 TTGTAGCAGAGGCAA 1655
Db 19 TTGCAGCAGAGGCAA 4

RESULT 29
US-10-642-802-147/c
; Sequence 147, Application US/10642802
; Publication No. US20040043956A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RTS-0329
; CURRENT APPLICATION NUMBER: US/10/642,802
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US/10/001,076
; PRIOR FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 173
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-642-802-147

Query Match
Best Local Similarity 10.2%; Score 14.2; DB 1; Length 20;
```

```
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1653 CAAGCACCAGGCTCAGC 1671
Db 19 CCAGCACCCTGGCTGACG 1

RESULT 30
US-10-238-011-39
; Sequence 39, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
; APPLICANT: Frey Jorgen
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
; FILE REFERENCE: 516326-2002
; CURRENT APPLICATION NUMBER: US/10/238,011
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: EP 00 107 515.9
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/827,406
; PRIOR FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-238-011-39

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCCTATCCT 1756
Db 1 CTCCTACTCCTCCCTTTCT 19

RESULT 31
US-10-001-076-147/c
; Sequence 147, Application US/10001076
; Publication No. US20030096775A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RTS-0329
; CURRENT APPLICATION NUMBER: US/10/001,076
; CURRENT FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-076-147

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1653 CAAGCACCAGGCTCAGC 1671
Db 19 CCAGCACCCTGGCTGACG 1

RESULT 32
US-10-105-004-109
; Sequence 109, Application US/10105004
; Publication No. US20030105002A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Murray, Jeffrey
; Semina, Elena
; TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
; AND DIAGNOSTIC USES THEREFOR
; NUMBER OF SEQUENCES: 139
; CORRESPONDENCE ADDRESS:
; ADDRESSER: FOLEY, HOAG & ELIOT LLP
; STREET: One Post Office Square
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/105,004
; FILING DATE: 22-Mar-2002
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E.
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 109:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 109:
US-10-105-004-109

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1733 TGGCTCCCAACTCCTCCT 1751
Db 2 TGTCTCCCAATTCCTCACT 20

RESULT 33
US-10-007-078-60
; Sequence 60, Application US/10007078
; Publication No. US20030105042A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF EIF2C1 EXPRESSION
; FILE REFERENCE: RTS-0236
; CURRENT APPLICATION NUMBER: US/10/007,078
; CURRENT FILING DATE: 2001-11-08
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-007-078-60

Query Match 10.2%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```



```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-303

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1673 GGAACCTGGTCTCTCC 1689
Db 1 GGAACCUUGUGUCCU 17

RESULT 38
US-09-877-478-1613
; Sequence 1613, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1613

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCCCTATC 1754
Db 17 CCCAACTCTCCCACTC 1

RESULT 40
US-10-342-902-302
; Sequence 302, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-302

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 17;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1674 GAACCTGGTCTCTCTC 1690
Db 1 GAACCUUGUGUCCU 17

RESULT 39
US-09-877-478-2360/c
; Sequence 2360, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)

```

```
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGAACCCCTGGTGCTC 1688
      :|||||: |:|:|
Db 1 UGAACCUUGUGUCUC 17

RESULT 41
US-10-342-902-303
; Sequence 303, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 303
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-303

Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGGTGCTCC 1689
      :|||||: |:|:|
Db 1 GGAACCUUGUGUCUC 17

RESULT 42
US-10-342-902-1613
; Sequence 1613, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 303
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-303

Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```

; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1613

Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1674 GAACCCCTGGTGCTCCT 1690
      :||||: |:|:|
Db 1 GAACCUUGUGUCUCU 17

RESULT 43
US-10-342-902-2360/c
; Sequence 2360, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2360

Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCCTATC 1754
      :|||||: |:|:|
Db 17 CCCAACTCCTCCCACTC 1

RESULT 44
US-10-669-841-302
; Sequence 302, Application US/10669841
; Publication No. US20040127446A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 302
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-302
```

```
Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1672 TGGAAACCTGGTGCTC 1688
||||| : : : :
Db 1 UGGAACCUUGUGUC 17
```

```
RESULT 45
US-10-669-841-303
; Sequence 303, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
```

```
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 303
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-303
```

```
Query Match 9.9%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1673 GGAACCTGGTGCTCC 1689
||||| : : : :
Db 1 GGAACCUUGUGUC 17
```

```
RESULT 46
US-10-669-841-1613
; Sequence 1613, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
```

; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1613

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 17;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1674 GAACCTGGTCTCTCT 1690
Db 1 GAACUUUGUCUCCU 17

RESULT 47
US-10-669-841-2163/c
; Sequence 2163, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/0420S (MBH02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2163
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2163

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCCCTATC 1754
Db 17 CCCAACTCTCCCACTC 1

RESULT 48
US-10-252-155-188/c
; Sequence 188, Application US/10252155
; Publication No. US20040068096A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT 1
; FILE REFERENCE: D0152 NP
; CURRENT APPLICATION NUMBER: US/10/252,155
; CURRENT FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/324,172
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: US 60/333,700
; PRIOR FILING DATE: 2001-11-27
; NUMBER OF SEQ ID NOS: 783
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 188
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-252-155-188

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 TCCTCCCTATCCTAAAG 1760
Db 18 TCCTCCCTATCAGAAAG 2

RESULT 49
US-10-239-652A-21/c
; Sequence 21, Application US/10239652A
; Publication No. US20040051234A1
; GENERAL INFORMATION:
; APPLICANT: Michael David Winther; Heidi Lynn Smith; Andre Ponton;
; APPLICANT: Roberto Justo De Antueno; Stephen John Allen
; TITLE OF INVENTION: Polynucleotides that Control Delta-6-Desaturase Genes
; TITLE OF INVENTION: and Methods for Identifying Compounds for Modulating
; TITLE OF INVENTION: Delta-6-Desaturase
; FILE REFERENCE: 42320-0010
; CURRENT APPLICATION NUMBER: US/10/239,652A
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: PCT/CA01/00398
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: CA2,301,158
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer
US-10-239-652A-21

Query Match
Best Local Similarity 9.9%; Score 13.8; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGTG 1701
Db 19 TCTTCTCAGCGTAGTG 3

```
RESULT 50
US-09-912-680-4
; Sequence 4, Application US/09912680
; Publication No. US20010051611A1
; GENERAL INFORMATION:
; APPLICANT: Srivastava, Arun
; APPLICANT: Ponnazhagan, Selvarangan
; APPLICANT: Chloemer, Robert H.
; APPLICANT: Wang, Xu-Shan
; APPLICANT: Yoder, Mervin C.
; APPLICANT: Zhou, Shang-Zhen
; APPLICANT: Escobedo, Jaime
; APPLICANT: Varivani, Dwarzi
; TITLE OF INVENTION: An AAV Vector Having Two Modified D-Sequences (As Amended)
; FILE REFERENCE: 1242.003
; CURRENT APPLICATION NUMBER: US/09/912,680
; PRIOR FILING DATE: 2001-07-24
; PRIOR APPLICATION NUMBER: US/08/921,497
; PRIOR FILING DATE: 1997-09-02
; PRIOR APPLICATION NUMBER: US 60/025,616
; PRIOR FILING DATE: 1996-09-06
; PRIOR APPLICATION NUMBER: US 60/025,649
; PRIOR FILING DATE: 1996-09-11
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: primer for human gamma-globin
US-09-912-680-4

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1681 GGTGTCTCTCCAGCGT 1697
      |||||
Db 2 GGTTCCTCTCCAGCAT 18

RESULT 51
US-10-243-035-7
; Sequence 7, Application US/10243035
; Publication No. US20030049697A1
; GENERAL INFORMATION:
; APPLICANT: LAZDUNSKI, MICHEL
; APPLICANT: LESAGE, FLORIAN
; APPLICANT: MAINGRET, FRANCOIS
; TITLE OF INVENTION: NEW FAMILY OF MECHANORESENSITIVE HUMAN POTASSIUM CHANNELS
; FILE REFERENCE: 1317-02
; CURRENT APPLICATION NUMBER: US/10/243,035
; CURRENT FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-243-035-7

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACAGCTGGA 1675
      |||||
Db 2 GGTTCCTCTCCAGCAT 18
```

```
Db 1 CCAGGCTGCCAGCTGGA 17

RESULT 52
US-10-006-911-59/c
; Sequence 59, Application US/10006911
; Publication No. US20030125274A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COLLAPLIN RESPONSE MEDIATOR PROTEIN 2 EXPRESSION
; FILE REFERENCE: RTS-0200
; CURRENT APPLICATION NUMBER: US/10/006,911
; CURRENT FILING DATE: 2001-11-08
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-911-59

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1649 AAGGCAAGCACCGGCT 1665
      |||||
Db 17 AAGGCAGGAGCAGGCT 1

RESULT 53
US-10-109-799-4
; Sequence 4, Application US/10109799
; Publication No. US20030166284A1
; GENERAL INFORMATION:
; APPLICANT: Srivastava, Arun
; APPLICANT: Ponnazhagan, Selvarangan
; APPLICANT: Chloemer, Robert H.
; APPLICANT: Wang, Xu-Shan
; APPLICANT: Yoder, Mervin C.
; APPLICANT: Zhou, Shang-Zhen
; APPLICANT: Escobedo, Jaime
; APPLICANT: Varivani, Dwarzi
; TITLE OF INVENTION: An AAV Vector Having Two Modified D-Sequences (As Amended)
; FILE REFERENCE: 1242.003
; CURRENT APPLICATION NUMBER: US/10/109,799
; CURRENT FILING DATE: 2002-03-28
; PRIOR APPLICATION NUMBER: US/08/921,497
; PRIOR FILING DATE: 1997-09-02
; PRIOR APPLICATION NUMBER: US 60/025,616
; PRIOR FILING DATE: 1996-09-06
; PRIOR APPLICATION NUMBER: US 60/025,649
; PRIOR FILING DATE: 1996-09-11
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: primer for human gamma-globin
US-10-109-799-4

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1681 GGTGTCTCTCCAGCGT 1697
      |||||
Db 2 GGTTCCTCTCCAGCAT 18
```

```

; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 466
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-466

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGGTAG 1714
Db 20 GGTGGAAGCTGGGTGAG 4

RESULT 57
US-10-671-395-1023/c
; Sequence 1023, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1023
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1023

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 83.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 TGGTGAAGTTGGGTGA 1713
Db 17 TGGTGAAGCTGGGTGA 1

RESULT 58
US-09-944-326-12/c
; Sequence 12, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726

; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 466
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-466

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1735 GCTCCCACTCCCTCCCT 1751
Db 17 GCTTCAGCTCCCTCCCT 1

RESULT 55
US-10-673-860-56/c
; Sequence 56, Application US/10673860
; Publication No. US20040126847A1
; GENERAL INFORMATION:
; APPLICANT: Ajinomoto Co., Inc.
; TITLE OF INVENTION: A method of secreting and producing proteins
; FILE REFERENCE: Y1J0182
; CURRENT APPLICATION NUMBER: US/10/673,860
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: JP 2001-98808
; PRIOR FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:PCR primer
US-10-673-860-56

Query Match          9.9%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCTCCCA 1741
Db 19 ATGGAGATAGCTCCCA 3

RESULT 56
US-10-671-395-466/c
; Sequence 466, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
```

; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-12

Query Match 9.9%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1734 GGCTCCCAACTCTCTCC 1750
||| ||||| ||||| |||||
Db 20 GGCCCCCAACTCGGCC 4

RESULT 59
US-09-967-726A-12/c
; Sequence 12, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-12

Query Match 9.9%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1734 GGCTCCCAACTCTCTCC 1750
||| ||||| ||||| |||||
Db 20 GGCCCCCAACTCGGCC 4

RESULT 60
US-10-080-794-12/c
; Sequence 12, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; TITLE OF INVENTION: HAVING 2'-O- (2-METHOXY)ETHYL MODIFICATIONS
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10

; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-12

Query Match 9.9%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1734 GGCTCCCAACTCTCTCC 1750
||| ||||| ||||| |||||
Db 20 GGCCCCCAACTCGGCC 4

RESULT 61
US-10-646-391A-12/c
; Sequence 12, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-12

Query Match 9.9%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1734 GGCTCCCAACTCTCTCC 1750
||| ||||| ||||| |||||
Db 20 GGCCCCCAACTCGGCC 4

RESULT 62
US-09-784-674-587/c
; Sequence 587, Application US/09784674
; Publication No. US20030054346A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; Wolber, Paul K.
; Delenstarr, Glenda C.
; Webb, Peter G.
; Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
; Company M/S 2080

STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-FEB-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 587:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 587:
US-09-784-674-587

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1701 GGAAGTTGGTTAGGAGTAC 1720
||||| ||||| ||||| |||||
DB 20 GGAAGTTCAATTAGGAATAC 1

RESULT 63
US-10-268-948-19
; Sequence 19, Application US/10268948
; Publication No. US20030161844A1
; GENERAL INFORMATION:
; APPLICANT: Gencell S.A.
; APPLICANT: Soubrier, Fabienne
; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Met
; FILE REFERENCE: 8988.0132-01
; CURRENT APPLICATION NUMBER: US/10/268,948
; CURRENT FILING DATE: 2002-10-11
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; PRIOR FILING DATE: 1996-09-13
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-268-948-19

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGGTTAGG 1715
||||| ||||| ||||| |||||
DB 1 GTGGTGAAGTTGGTTAGG 20

RESULT 64
US-10-148-355A-88
; Sequence 88, Application US/10148355A
; Publication No. US20030207831A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; APPLICANT: ISIS PHARMACEUTICALS, INC.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTSP-0082
; CURRENT APPLICATION NUMBER: US/10/148,355A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: 09/467,642
; PRIOR FILING DATE: 1999-12-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-148-355A-88

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1640 TTGTACGAGGCGAAGCAC 1659
||||| ||||| ||||| |||||
DB 1 TTGCATCAGAAGGCCAGAAC 20

RESULT 65
US-10-349-143-10402/c
; Sequence 10402, Application US/10349143
; Publication No. US2004000584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10402
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-11658 for SEQ 2537, in complement
US-10-349-143-10402

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;


```
QY 1746 CTCCTATCTCTAAAGGCCCA 1765
Db 20 CTCCTATCTCTACTCCCA 1

RESULT 66
US-10-289-762-6657/c
; Sequence 6657, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6657
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6657

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1633 ATGGGGCTGTAGCAGAGG 1652
Db 20 ATGGTGCTAGTATCAGCAG 1

RESULT 67
US-10-289-762-6714/c
; Sequence 6714, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6714
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6714

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1720 CGGATCGAGATGGCTCC 1739
Db 20 CGGATGGGAGACTGGCTGC 1

RESULT 68
US-10-444-778-5
; Sequence 5, Application US/10444778
; Publication No. US20040106121A1
; GENERAL INFORMATION:
; APPLICANT: COMMISSARIAT A L'ENERGIE ATOMIQUE
; TITLE OF INVENTION: A STATIC MICRO-ARRAY OF BIOLOGICAL OR CHEMICAL PROBES FIXED ON A
; FILE REFERENCE: B4677AB - AD/VMA/VG
; CURRENT APPLICATION NUMBER: US/10/444,778
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: FR 0015398
```

```
; PRIOR FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: PRIMER
US-10-444-778-5

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1679 CTGGTGTCCTCCACGCGTG 1698
Db 1 CTGGTGTCCTCACCACCATG 20

RESULT 69
US-10-316-515-33/c
; Sequence 33, Application US/10316515
; Publication No. US20040116365A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF LCK EXPRESSION
; FILE REFERENCE: RTS-0344
; CURRENT APPLICATION NUMBER: US/10/316,515
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 76
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-515-33

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1646 CAGAAGCAGCAGCAGCGCT 1665
Db 20 CAGAGGGCCAGTACCAGCCT 1

RESULT 70
US-10-316-515-63
; Sequence 63, Application US/10316515
; Publication No. US20040116365A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: MODULATION OF LCK EXPRESSION
; FILE REFERENCE: RTS-0344
; CURRENT APPLICATION NUMBER: US/10/316,515
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 76
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-515-63

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1646 CAGAAGCAGCAGCAGCGCT 1665
```



```

; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; PRIOR FILING DATE: 1996-09-13
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-684-830-19

```

Query Match 9.8%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGGGTAGG 1715
|||
Db 1 GTGGTGGAAATGGCGATAGG 20

RESULT 76
US-09-877-1745/c
; Sequence 1745, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1745

```

Query Match          9.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1736 CTCCCAACTCCTCC 1750
Db 16 CCCCCAACTCCTCC 2

RESULT 77
US-09-827-395A-989/c
; Sequence 989, Application US/09827395A
; Publication No. US20030113891A1

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowira
; TITLE OF INVENTION: Method and Reagent for
; FILE REFERENCE: MEHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 989
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-989

```

```

Query Match          9.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1673 GGAACCTGGTGTCT 1687
Db 15 GGAACCTGGTGGCT 1

```

RESULT 78
US-10-342-902-1745/c
; Sequence 1745, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1745

```

```

Query Match          9.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels

```

QY	1736	CTCCCAACTCCTCCC	1750
Db	16	CCCCCAACTCCTCCC	2

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1745
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1745

Query Match          9.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1736 CTCGCAACTCTCTCCC 1750
Db      16 CCCCCCACTCTCTCCC 2

RESULT 81
US-10-321-625-8
; Sequence 8, Application US/10321625
; Publication No. US20030211577A1
; GENERAL INFORMATION:
; APPLICANT: EISHINGDELO, HIFENG
; APPLICANT: JIDONG, CAI
; APPLICANT: ARDAIL, ALI
; TITLE OF INVENTION: NOVEL G PROTEIN-COUPLED RECEPTOR, GAVE7
; FILE REFERENCE: 2101976.991200
; CURRENT APPLICATION NUMBER: US/10/321.625
; CURRENT FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: 60/341,271
; PRIOR FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-321-625-8

Query Match          9.6%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1734 GGCTCCCAACTCTCTC 1748
Db      1 GGCTCCCAACTCTCTC 15

RESULT 82
US-09-843-377-20
; Sequence 20, Application US/09843377
; Publication No. US20030176371A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0235
; CURRENT APPLICATION NUMBER: US/09/843.377
; CURRENT FILING DATE: 2001-04-26
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 20

```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-843-377-20

Query Match
Best Local Similarity 9.6%; Score 13.4; DB 1; Length 20;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1731 ATTGGCTCCCAACTC 1745
Db 3 ACTGGCTCCCAACTC 17

RESULT 83
US-10-175-225-9/c
; Sequence 9, Application US/10175225
; Publication No. US20030082582A1
; GENERAL INFORMATION:
; APPLICANT: Richard A. Gatti
; TITLE OF INVENTION: METHODS FOR DETECTION OF ATAXIA
; FILE REFERENCE: TELANGIECTASIA MUTATIONS
; CURRENT APPLICATION NUMBER: US/10/175,225
; CURRENT FILING DATE: 2002-08-23
; PRIOR APPLICATION NUMBER: US 09/360,416
; PRIOR FILING DATE: 1999-07-23
; NUMBER OF SEQ ID NOS: 143
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human
US-10-175-225-9

Query Match
Best Local Similarity 9.6%; Score 13.4; DB 1; Length 20;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1742 ACTCCTCCCTATCCT 1756
Db 15 ACTCCTCCCTCCTCT 1

RESULT 84
US-10-671-395-864/c
; Sequence 864, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 864
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-864

Query Match
Best Local Similarity 9.6%; Score 13.4; DB 1; Length 20;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1697 TGGTGAAGTTGGT 1711
Db 16 TGGTGAAGCTGGT 2

RESULT 85
US-09-972-115A-27
; Sequence 27, Application US/09972115A
; Publication No. US20030032769A1
; GENERAL INFORMATION:
; APPLICANT: Geron Corporation
; APPLICANT: Gregg, Morin B.
; APPLICANT: Walter, Funk D.
; APPLICANT: Mieczyslaw, Piatyszek A.
; TITLE OF INVENTION: A Second Mammalian Telomerase
; FILE REFERENCE: 080/003C
; CURRENT APPLICATION NUMBER: US/09/972,115A
; CURRENT FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: US 60/128,577
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/129,123
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-972-115A-27

Query Match
Best Local Similarity 9.5%; Score 13.2; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1715 GAGTACGAGATGGAGAT 1732
Db 1 GAGCACAGATGGAGGT 18

RESULT 86
US-09-745-605-16
; Sequence 16, Application US/09745605
; Patent No. US20020123617A1
; GENERAL INFORMATION:
; APPLICANT: Starling, Gary C.
; APPLICANT: Finger, Joshua N.
; TITLE OF INVENTION: NOVEL IMMUNOGLOBIN SUPERFAMILY MEMBERS APEX-1, APEX-2,
; FILE REFERENCE: AND APEX-3 AND USES THEREOF
; FILE REFERENCE: DB13NP
; CURRENT APPLICATION NUMBER: US/09/745,605
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 60/172,025
; PRIOR FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: UNF14 PRIMER
US-09-745-605-16

Query Match
Best Local Similarity 9.5%; Score 13.2; DB 1; Length 20;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCACAGCTGGACCC 1679
Db 2 GGCTCACCTGTATCC 19
```

```
RESULT 87
US-09-969-373-1709/c
; Sequence 1709, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Haug, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1709
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1709

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGGATTG 1734
DB 20 GGATGGAGATTGAGATTG 3

RESULT 88
US-09-837-306-338
; Sequence 338, Application US/09837306
; Publication No. US20040029113A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES OF GENETIC
; TITLE OF INVENTION: PACKAGES THAT COLLECTIVELY DISPLAY THE MEMBERS OF A
; TITLE OF INVENTION: DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS
; FILE REFERENCE: DYAX/002
; CURRENT APPLICATION NUMBER: US/09/837,306
; CURRENT FILING DATE: 2001-09-24
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 428
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 338
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-837-306-338

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTGGCTC 1738
DB 3 GAAGATGGAGACTGGGTC 20
```

```
RESULT 89
US-10-006-191-68
; Sequence 68, Application US/10006191
; Publication No. US2003014223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
; FILE REFERENCE: RTS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-68

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1651 GGCAGCAGCAGGCTCAC 1668
DB 3 GTCCAGCAGAGGCTCAC 20

RESULT 90
US-10-045-674-468
; Sequence 468, Application US/10045674
; Publication No. US20030232333A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, ROBERT C.
; APPLICANT: COHEN, EDWARD H.
; APPLICANT: NASTRI, HORACIO G.
; APPLICANT: ROOKEY, KRISTIN L.
; APPLICANT: HOET, RENE
; APPLICANT: HOOGENBOOM, HENDRICUS R. J. M.
; TITLE OF INVENTION: NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING
; TITLE OF INVENTION: DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY
; TITLE OF INVENTION: OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL
; TITLE OF INVENTION: LIBRARIES
; FILE REFERENCE: DYAX/002 CIP2
; CURRENT APPLICATION NUMBER: US/10/045,674
; CURRENT FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 60/198,069
; PRIOR FILING DATE: 2000-04-17
; PRIOR APPLICATION NUMBER: 09/837,306
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 635
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 468
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-045-674-468

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTGGCTC 1738
DB 3 GAAGATGGAGACTGGGTC 20

RESULT 91
US-10-289-762-6149
```

```
; Sequence 6149, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequences and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6149

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1744 TCCTCCCTATCTCTAAGG 1761
Db 3 TGCTCTCTACCCCTAAAGG 20

RESULT 92
US-10-211-859-43
; Sequence 43, Application US/10211859
; Publication No. US20040022765A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAN GTPASE ACTIVATING PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0013
; CURRENT APPLICATION NUMBER: US/10/211,859
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-211-859-43

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGCTCTCTCCAGCGTGG 1699
Db 2 GTGCTCTGCCAGCTTGG 19

RESULT 93
US-10-211-859-74/c
; Sequence 74, Application US/10211859
; Publication No. US20040022765A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF RAN GTPASE ACTIVATING PROTEIN 1 EXPRESSION
; FILE REFERENCE: HTS-0013
; CURRENT APPLICATION NUMBER: US/10/211,859
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-211-859-74
```

```
Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGCTCTCTCCAGCGTGG 1699
Db 19 GTGCTCTCTGCCAGCTTGG 2

RESULT 94
US-10-247-843-12
; Sequence 12, Application US/10247843
; Publication No. US20040076606A1
; GENERAL INFORMATION:
; APPLICANT: Chang, et al.
; TITLE OF INVENTION: METHODS OF MODULATING INFLAMMATION BY ADMINISTRATION OF INTERLEUKIN-19 AND INHIBITORS OF IL-19 BINDING
; FILE REFERENCE: 30515/38768
; CURRENT APPLICATION NUMBER: US/10/247,843
; CURRENT FILING DATE: 2002-09-14
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-10-247-843-12

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1707 TGGGTAGGAGTACGAG 1724
Db 2 TGGGTAGGAGCACGTAG 19

RESULT 95
US-10-304-116-26/c
; Sequence 26, Application US/10304116
; Publication No. US20040101857A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: MODULATION OF CYTOKINE-INDUCIBLE KINASE EXPRESSION
; FILE REFERENCE: RTS-0397
; CURRENT APPLICATION NUMBER: US/10/304,116
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 138
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-116-26

Query Match          9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACAGCTGGAA 1676
Db 20 CCTGGCCACATCTGGAA 3

RESULT 96
US-10-317-277A-20/c
; Sequence 20, Application US/10317277A
; Publication No. US20040110159A1
```


; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MITOCHONDRIAL EXPRESSION
; FILE REFERENCE: 01455.1
; CURRENT APPLICATION NUMBER: US/10/728,399
; CURRENT FILING DATE: 2003-12-05
; NUMBER OF SEQ ID NOS: 627
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human mitochondria antisense
US-10-728-399-261

Query Match 9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1732 TTGGCTCCCACTCTCC 1749
||| ||||| |||||
DB 2 TTATCTCCCAATCTCC 19

RESULT 102
US-10-695-089-76
; Sequence 76, Application US/10695089
; Publication No. US20040142353A1
; GENERAL INFORMATION:
; APPLICANT: CHEUNG, WING Y.
; APPLICANT: GAGNON, MARIE-JOSEE
; APPLICANT: LAFOREST, MARTIN
; APPLICANT: LANDRY, BENOIT S.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR IDENTIFYING PLANTS HAVING
; FILE REFERENCE: 15039-2
; CURRENT APPLICATION NUMBER: US/10/695,089
; CURRENT FILING DATE: 2003-10-28
; PRIOR APPLICATION NUMBER: 60/421,993
; PRIOR FILING DATE: 2002-10-29
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-695-089-76

Query Match 9.5%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCGAGCTGGAACCTG 1681
||| ||||| |||||
DB 1 CTCGAGCTGGAATCCG 18

RESULT 103
US-09-877-478-2361/c
; Sequence 2361, Application US/09877478
; Publication No. US2003006301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2361

Query Match 9.4%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCTCC 1750
||| ||||| |||||
DB 16 CCCAACTCTCTCC 4

RESULT 104
US-10-342-902-2361/c
; Sequence 2361, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2361
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2361

Query Match 9.4%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.5e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 1738 CCCAACTCTCTCC 1750
|||||
Db 16 CCCAACTCTCTCC 4

RESULT 105
US-10-669-841-2164/c
; Sequence 2164, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2164
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2164

Query Match 9.4%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCTCC 1750
|||||
Db 16 CCCAACTCTCTCC 4

RESULT 106
US-10-633-843-78/c
; Sequence 78, Application US/10633843
; Publication No. US2004009191A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESIO

; FILE REFERENCE: ISPH-0756
; CURRENT APPLICATION NUMBER: US/10/633,843
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: US 09/888,360
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-633-843-78

Query Match 9.4%; Score 13; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1644 AGCAGAAGGCAAG 1656
|||||
Db 18 AGCAGAAGGCAAG 6

RESULT 107
US-10-174-465-6
; Sequence 6, Application US/10174465
; Publication No. US20030232772A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF EXTRACELLULAR-SIGNAL-REGULATED KINASE-6
; FILE REFERENCE: PTS-0055
; CURRENT APPLICATION NUMBER: US/10/174,465
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 70
; SEQ ID NO 6
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-174-465-6

Query Match 9.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAAACCCGTGTGTCT 1687
|||||
Db 1 TGGAAACCCGTGTCT 16

RESULT 108
US-10-348-431-6
; Sequence 6, Application US/10348431
; Publication No. US20030232778A1
; GENERAL INFORMATION:
; APPLICANT: Eric G. Marcussen
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
; FILE REFERENCE: ISPH-0728
; CURRENT APPLICATION NUMBER: US/10/348,431
; CURRENT FILING DATE: 2003-01-17
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 6
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-348-431-6

```
Query Match          9.2%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAACTCGTGCTCT 1687
Db 1 TGGAACTCGTGCTCT 16

RESULT 109
US-09-877-478-994
; Sequence 994, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 994
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-994

Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCGTGCTCTCCTC 1691
Db 1 ACCUUGUGUCUCCUC 16

RESULT 111
US-09-848-754A-2544
; Sequence 2544, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2544
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2544

Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CCTAAGCCCTGCTGG 1769
Db 2 CCAAAAGCCCGCUGG 17

RESULT 112
US-09-842-902-994
; Sequence 994, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
```

```
Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCGTGCTCTCCTC 1691
Db 1 ACCUUGUGUCUCCUC 16

RESULT 111
US-09-848-754A-2544
; Sequence 2544, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2544
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2544

Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CCTAAGCCCTGCTGG 1769
Db 2 CCAAAAGCCCGCUGG 17

RESULT 112
US-09-842-902-994
; Sequence 994, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
```

Query Match 9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. NO. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCCTGGTGTCCTC 1691
|||||:|:|:|:|:|

RESULT 116
IIS-10-287-949A-3692/C

; Sequence 3692, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Ram
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3692
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3692

Query Match 9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1646 CAGAAGGCAAGCACCA 1661
||||| ||||| |||||
DB 17 CAGAAGCCAAGGCCA 2

RESULT 117
US-10-712-672-475/c
; Sequence 475, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 475
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-475

Query Match 9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 AGCAGAAGGCAAGCAC 1659
||| ||||| |||||
DB 16 AGCCGAAGGCCAGCAC 1

RESULT 118
US-10-669-841-994
; Sequence 994, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt

; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 994
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-994

Query Match 9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGAACCCCTGGTGCT 1687
:|||||:|:|:
DB 2 UGGAACCUUGUGUCU 17

RESULT 119
US-10-669-841-1614
; Sequence 1614, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08

```

; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
; US-10-669-841-1614

Query Match          9.2%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCGTGTCCTCCTC 1691
DB 1 ACCUUGUGUCUCCUC 16

RESULT 120
US-10-224-005-20/c
; Sequence 20, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense 1
US-10-224-005-20

Query Match          9.2%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCAGGCT 1665
DB 19 AGGCAAGCACCATCTCT 4

RESULT 121
US-10-224-005-181
; Sequence 181, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-181

Query Match          9.2%; Score 12.8; DB 1; Length 19;
Best Local Similarity 81.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCAGGCT 1665
DB 1 AGGCAAGCACCACCUCC 16

RESULT 122
US-10-251-117-746
; Sequence 746, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Receptor (EGFR)
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Receptor (EGFR)
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 746
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense 1
US-10-251-117-746

Query Match          9.2%; Score 12.8; DB 1; Length 19;
Best Local Similarity 81.2%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CCTAAGGCCCACTGG 1769
DB 3 CCAAAAGGCCCGUGG 18

RESULT 123
US-10-251-117-1053/c
; Sequence 1053, Application US/10251117

```

```

; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1053
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-1053

Query Match          9.2%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CCTAAGGCCCACTGG 1769
Db 17 CCAAGGCCCGCTGG 2

RESULT 124
US-08-983-605-55
; Sequence 55, Application US/08983605A
; Publication No. US20020066118A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum aestivum and Tribe Triticeae and the Use of
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-55

Query Match          9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1709 GGTAGGATGACGAGATG 1727
Db 1 GGGTGGGAGAAAGGAGATG 19

RESULT 125
US-10-251-117-717
; Sequence 717, Application US/10251117
; Publication No. US20030170891A1

```

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 717
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense re
US-10-251-117-717

Query Match          9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2.3e+02;
Matches 12; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGTGGAA 1704
Db 1 CUCCUCCAUCUGGAGAAA 19

RESULT 126
US-10-251-117-1024/c
; Sequence 1024, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
; FILE REFERENCE: 900/042 (MBHB02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1024
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-251-117-1024

Query Match          9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

QY 1686 CTCCTCCAGCGGTGGAA 1704
||||| | | | |
Db 19 CTCCTCCATCCTGGAGAA 1

RESULT 127
US-10-143-8278/c
; Sequence 8278, Application US/10349143
; Publication No. US2004000584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8278
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: downstream amplification primer 99-14699 for SEQ 413, in compleme

US-10-349-143-8278
Query Match 9.1%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1694 GCGTGGTGAAGTTGGGT 1712
||||| | | | |
Db 19 GAGTTGGATGTGGGT 1

RESULT 128
US-10-308-264-637
; Sequence 637, Application US/10308264
; Publication No. US20040029133A1
; GENERAL INFORMATION:
; APPLICANT: HerrinStadt, Corinna
; TITLE OF INVENTION: MITOCHONDRIAL DNA POLYMORPHISM
; FILE REFERENCE: 660088.461
; CURRENT APPLICATION NUMBER: US/10/308,264
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 637
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-308-264-637

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1709 GGTAGGAGTACGG 1722
||||| | | | |
Db 3 GGTAGGAGTACGG 16

RESULT 129
US-10-138-674-5908/c
; Sequence 5908, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5908
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5908

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1663 GCTCACAGCTGGAA 1676
||||| | | | |
Db 16 GCCCACAGCTGGAA 3

RESULT 130
US-10-287-949A-5908/c
; Sequence 5908, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20322
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5908
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5908

Query Match 8.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1663 GCTCACAGCTGGAA 1676
||||| | | | |
Db 16 GCCCACAGCTGGAA 3

RESULT 131
US-09-818-875-3470/c
; Sequence 3470, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kniec, Eric E.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.


```
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Stranded Oligonucleotides
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3470
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-818-875-3470

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGG 1699
Db 14 CTCCTCCAGCTTGG 1

RESULT 132
US-09-818-875-3471
; Sequence 3471, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kniec, Eric B.
; APPLICANT: Gampier, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Stranded Oligonucleotides
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3471
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-818-875-3471

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGG 1699
Db 4 CTCCTCCAGCTTGG 17

RESULT 133
US-09-877-478-386/c
; Sequence 386, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 386
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-09-877-478-386

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCCAGCTTGG 1749
Db 14 CTCCTCCAGCTTGG 1

RESULT 134
US-09-827-395A-479/c
; Sequence 479, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-827-395A-479

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCTCGGTGCTTC 1688
Db 17 AACCTCGGTGCTTC 1688
```

Db 17 AACCTGTGTGCTC 4

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 13; Conservative 0; Mismatches 0; Indels 1; Gaps 0;

RESULT 135
 US-09-827-395A-990/c
 ; Sequence 990, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; CURRENT FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 990
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-990

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 13; Conservative 0; Mismatches 0; Indels 1; Gaps 0;

QY 1673 GGAACCTGTGTGTC 1686
 Db 14 GGAACCTGTGTGTC 1

RESULT 136
 US-10-342-902-386/c
 ; Sequence 386, Application US/10342902
 ; Publication No. US20040054156A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Sirna Therapeutics, Inc.
 ; APPLICANT: Draper, Kenneth
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Morrissey, Dave
 ; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
 ; FILE REFERENCE: 400/075 (MBH00-845-I)
 ; CURRENT APPLICATION NUMBER: US/10/342,902
 ; CURRENT FILING DATE: 2003-01-15
 ; PRIOR APPLICATION NUMBER: US 09/877,478
 ; PRIOR FILING DATE: 2001-06-08
 ; PRIOR APPLICATION NUMBER: US 09/531,025
 ; PRIOR FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: US 09/636,385
 ; PRIOR FILING DATE: 2000-08-09
 ; PRIOR APPLICATION NUMBER: US 09/696,347
 ; PRIOR FILING DATE: 2000-10-24
 ; PRIOR APPLICATION NUMBER: US 08/193,627
 ; PRIOR FILING DATE: 1994-02-07
 ; PRIOR APPLICATION NUMBER: US 07/882,712
 ; PRIOR FILING DATE: 1992-05-14
 ; PRIOR APPLICATION NUMBER: US 09/436,430
 ; PRIOR FILING DATE: 1999-11-08
 ; NUMBER OF SEQ ID NOS: 6592
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 386
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Hepatitis B virus
 US-10-342-902-386

QY 1736 CTCCCACTCTCTC 1749
 Db 14 CCCCCAATCTCTC 1

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 13; Conservative 0; Mismatches 0; Indels 1; Gaps 0;

RESULT 137
 US-10-430-882-479/c
 ; Sequence 479, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haeberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 479
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-479

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 13; Conservative 0; Mismatches 0; Indels 1; Gaps 0;

QY 1675 AACCTGTGTGCTC 1688
 Db 17 AACCTGTGTGCTC 4

RESULT 138
 US-10-430-882-990/c
 ; Sequence 990, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haeberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MBH00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; CURRENT FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512

; PRIOR FILING DATE: 2002-04-03
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 990
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-990

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGGTGC 1686
 Db 14 GGAACCCCTGGTGC 1

RESULT 139
 US-10-209-787-3470/c
 ; Sequence 3470, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; PRIOR FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3470
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-209-787-3470

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCTGG 1699
 Db 14 CTCCTCCAGCTGG 1

RESULT 140
 US-10-209-787-3471
 ; Sequence 3471, Application US/10209787
 ; Publication No. US20030217377A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4
 ; CURRENT APPLICATION NUMBER: US/10/209,787
 ; PRIOR FILING DATE: 2002-07-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27

; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3471
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-209-787-3471

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCTGG 1699
 Db 4 CTCCTCCAGCTGG 17

RESULT 141
 US-10-261-185-3470/c
 ; Sequence 3470, Application US/10261185
 ; Publication No. US20040014057A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
 ; FILE REFERENCE: Napro-4CON
 ; CURRENT APPLICATION NUMBER: US/10/261,185
 ; CURRENT FILING DATE: 2002-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/09761
 ; PRIOR FILING DATE: 2001-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,176
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/192,179
 ; PRIOR FILING DATE: 2000-03-27
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; NUMBER OF SEQ ID NOS: 4385
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 3470
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-261-185-3470

Query Match 8.9%; Score 12.4; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 2e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCTGG 1699
 Db 14 CTCCTCCAGCTGG 1

RESULT 142
 US-10-261-185-3471
 ; Sequence 3471, Application US/10261185
 ; Publication No. US20040014057A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Kmiec, Eric B.
 ; APPLICANT: Gamper, Howard B.
 ; APPLICANT: Rice, Michael C.

Mon Aug 30 09:26:47 2004

```

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3471
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3471

Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 1686 CTCCTCCAGCTGG 1699
DB 4 CTCCTCCAGCTGG 17

RESULT 143
US-10-138-674-4993/c
; Sequence 4993, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4993

Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 1663 GCTCACAGCTGGAA 1676
DB 15 GCCCACAGCTGGAA 2

RESULT 144
US-10-138-674-7822/c
; Sequence 7822, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```

```

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7822

Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 1663 GCTCACAGCTGGAA 1676
DB 17 GCCCACAGCTGGAA 4

RESULT 145
US-10-138-674-7823/c
; Sequence 7823, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7823

Query Match      8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;

QY 1663 GCTCACAGCTGGAA 1676
DB 14 GCCCACAGCTGGAA 1

RESULT 146
US-10-287-949A-4993/c
; Sequence 4993, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4993

```

;
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4993

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAA 1676
||| ||||| |||||
Db 15 GCCCACAGCTGGAA 2

RESULT 147

US-10-287-949A-7822/c
; Sequence 7822, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7822

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAA 1676
||| ||||| |||||
Db 17 GCCCACAGCTGGAA 4

RESULT 148

US-10-287-949A-7823/c
; Sequence 7823, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7823

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAA 1676
||| ||||| |||||
Db 14 GCCCACAGCTGGAA 1

RESULT 149

US-10-669-841-386/c
; Sequence 386, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 386
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-386

Query Match 8.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCACTCTCTC 1749
||| ||||| |||||
Db 14 CCCCCCACTCTCTC 1

RESULT 150

US-09-822-722-18
; Sequence 18, Application US/09822722
; Patent No. US20020114772A1
; GENERAL INFORMATION:
; APPLICANT: Kishimoto, Jiro
; APPLICANT: Morgan, Bruce A.
; APPLICANT: Burgeson, Robert
; TITLE OF INVENTION: METHODS OF MODULATING HAIR GROWTH
; FILE REFERENCE: 10287-058001
; CURRENT APPLICATION NUMBER: US/09/822,722

Mon Aug 30 09:26:47 2004

```

; CURRENT FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 60/261,690
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 60/193,771
; PRIOR FILING DATE: 2000-03-31
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer for PCR
US-09-822-722-18

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTG 1698
Db      4 TCTCTCCAGCATG 17

RESULT 151
US-09-969-373-1963
; Sequence 1963, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Haug, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1963
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1963

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1677 CCCTGGTGTCCT 1690
Db      2 CCCTGGTGTCCT 15

RESULT 152
US-10-059-579-71
; Sequence 71, Application US/10059579
; Publication No. US20030138783A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SUDHAR, Saraswati
; APPLICANT: EVRON, Ella
; APPLICANT: DOOLEY, William C.
; APPLICANT: DAVIDSON, Nancy
; APPLICANT: FACKLER, Mary Jo.
; TITLE OF INVENTION: ABERRANTLY METHYLATED GENES AS MARKERS OF BREAST MALIGNANCY
; FILE REFERENCE: JHUI630-1
; CURRENT APPLICATION NUMBER: US/10/059,579
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: US 09/771,357

```

```

; PRIOR FILING DATE: 2001-01-26
; NUMBER OF SEQ ID NOS: 136
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 71
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR sense primer
US-10-059-579-71

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1698 GGTGAAGTTGGT 1711
Db      4 GTTGAAGTTGGT 17

RESULT 153
US-10-285-976-185
; Sequence 185, Application US/10285976
; Publication No. US20030165500A1
; GENERAL INFORMATION:
; APPLICANT: Rhee, Chae-Sec
; APPLICANT: Malini, Sen
; APPLICANT: Wu, Christina
; APPLICANT: Leoni, Lorenzo M.
; APPLICANT: Corr, Maripat
; APPLICANT: Carson, Dennis A.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Wnt and Frizzled Receptors as Targets for Immunotherapy
; FILE REFERENCE: in Head and Neck Squamous Cell Carcinomas
; FILE REFERENCE: 023070-130320US
; CURRENT APPLICATION NUMBER: US/10/285,976
; CURRENT FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/287,995
; PRIOR FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: WO PCT/US02/13802
; PRIOR FILING DATE: 2002-05-01
; NUMBER OF SEQ ID NOS: 232
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 185
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:DKK3 probe
US-10-285-976-185

Query Match      8.9%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1692 CAGCGGTGGTGAAG 1705
Db      5 CAGCGGTGGTGAAG 18

RESULT 154
US-10-349-143-11223
; Sequence 11223, Application US/10349143
; Publication No. US2004000584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CF1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978

```

```

; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11223
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-3479 for SEQ 3358, in complete
US-10-349-143-11223

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 18;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATTGG 1735
Db 5 GAGATGGAGATTGG 18

RESULT 155
US-10-138-674-1468/c
; Sequence 1468, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1468
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1468

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 18;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAA 1676
Db 16 GCCACAGCTGGAA 3

RESULT 156
US-10-287-949A-1468/c
; Sequence 1468, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A

```

```

; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1468
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1468

```

```

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 18;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1663 GCTCACAGCTGGAA 1676
Db 16 GCCACAGCTGGAA 3

```

```

RESULT 157
US-09-728-552-1/c
; Sequence 1, Application US/09728552
; Publication No. US20030096398A1
; GENERAL INFORMATION:
; APPLICANT: Choo, Kong-Hong Andy
; APPLICANT: Du Sart, Desiree
; APPLICANT: Cancilla, Michael R.
; TITLE OF INVENTION: A NOVEL NUCLEIC ACID MOLECULE
; FILE REFERENCE: Davies Col
; CURRENT APPLICATION NUMBER: US/09/728,552
; CURRENT FILING DATE: 2000-12-02
; PRIOR APPLICATION NUMBER: 09/078,294
; PRIOR FILING DATE: 1998-05-13
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: DNA primer
US-09-728-552-1

```

```

Query Match
Best Local Similarity 8.9%; Score 12.4; DB 1; Length 19;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCACAGCTGGAAACC 1679
Db 18 GGCTCAVRCCTGTAATCC 1

```

```

RESULT 158
US-10-349-143-10908/c
; Sequence 10908, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10908
; LENGTH: 19
; TYPE: DNA

```

RESULT 161
US-09-866-108-528
; Sequence 528, Application US/09866108
; Patent No. US20020048900A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSION
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30


```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 528
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-528

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1645 GCAGAGGACGACCA 1661
    ||||| ||||| |||||
DB 1 GCAGATGACAGCATCA 17

```

```

RESULT 162
US-09-866-108-1264/c
; Sequence 1264, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-10-04
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1264
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1264

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1729 AGATTGGCTCCCACTC 1745
    ||||| ||||| |||||
DB 17 AGATCGTCCCACTC 1

```

```

RESULT 163
US-09-866-108-7831
; Sequence 7831, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR FILING DATE: 2000-10-04
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7831
; LENGTH: 17

```

schultz139-3.rnpb

Mon Aug 30 09:26:47 2004

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7831

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGGAC 1677
DB 1 AGCCTCACAGCTGAAC 17

RESULT 164
US-09-866-108-9658/c
; Sequence 9658, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9658
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9658

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGACCCCTGCTCTC 1688
DB 1 TGGACCCCTGCTCTC 17

RESULT 165
US-09-416-384A-26
; Sequence 26, Application US/09416384A
; Patent No. US20020081584A1
; GENERAL INFORMATION:
; APPLICANT: BLUMENFELD, Marta
; APPLICANT: BOUGUELERET, Lydie
; APPLICANT: CHUMAKOV, Ilya
; APPLICANT: COHEN, Daniel
; APPLICANT: ESSIOUX, Laurent
; TITLE OF INVENTION: Genes, proteins and biallelic markers related to central...
; FILE REFERENCE: GENSET.045AUS
; CURRENT FILING DATE: 1999-10-12
; CURRENT APPLICATION NUMBER: US/09/416,384A
; PRIOR APPLICATION NUMBER: 60/106,457
; PRIOR FILING DATE: 1999-10-30
; PRIOR APPLICATION NUMBER: 60/103,955
; PRIOR FILING DATE: 1998-10-12
; PRIOR APPLICATION NUMBER: 60/132,277
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 71
; SOFTWARE: Patent.pm
; SEQ ID NO 26
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide moCTGR1511
US-09-416-384A-26

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGGTG 1701
DB 1 TGTCTCGAGCGTGGGG 17

RESULT 166
US-09-864-785-1557
; Sequence 1557, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Jan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1557

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1676 ACCCTGGTCTCTCTCC 1692
DB 1 ACCAUGGUGUUCUUC 17

```

```
RESULT 167
US-09-864-785-2921/c
; Sequence 2921, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2921
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2921

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 CCAACTCCTCCCTATCC 1755
Db 17 CCAGCTCCCTCCCTATCC 1

RESULT 168
US-09-864-785-2922/c
; Sequence 2922, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2922
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2922

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCAACTCCTCCCTATC 1754
Db 17 CCCAGCTCCCTCCCTATC 1

RESULT 169
US-09-780-533A-576
; Sequence 576, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 576
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-576

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTGGGTAGGAGTAC 1720
Db 1 AGUGGUUCAGAGUAC 17

RESULT 170
US-09-877-478-2359/c
; Sequence 2359, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2359

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1740 CCACTCCTCCCTATCCT 1756
Db 17 CCACTCCTCCCTATCAT 1
```

Mon Aug 30 09:26:47 2004

```

; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2359

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1740 CAACTCTCTCCCTATCCT 1756
Db 17 CAACTCTCTCCCTATCAT 1

```

```

RESULT 174
US-10-060-756A-752
; Sequence 752, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aesomica Sequence Listing Engine
; SEQ ID NO 752
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-752

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCCTCACAGCTGGACCC 1678
Db 1 GACTCACTGCTGGACCC 17

```

```

RESULT 173
US-10-342-902-2359/c
; Sequence 2359, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478

```

```

US-09-848-754A-1430
; Sequence 1430, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1430
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1430

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1731 ATTGGCTCCCACTCCT 1747
Db 1 AUUGGCUCCAGUACCU 17

```

```

RESULT 172
US-09-848-754A-1500
; Sequence 1500, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1500
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1500

```

```

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCTGGTG 1701
Db 1 UCUCUCCUCCUGGAG 17

```

```

RESULT 173
US-10-342-902-2359/c
; Sequence 2359, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478

```

```

Db      1  CCGAGGCCCTGGTCTCT 17

RESULT 177
US-10-061-201-1608
; Sequence 1608, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1608
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1608

Query Match      8.8%; Score 12.2; DB
Best Local Similarity 82.4%; Pred. No. 2.1e+
Matches 14; Conservative 0; Mismatches

QY      1673  GCAACCTGGTGTCTCC 1689
          ||| ||| ||| ||| ||| ||| |||
Db      1  GGAGCCCTGGTCTCTAC 17

RESULT 178
US-10-061-201-1612
; Sequence 1612, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

```

schultz139-3.rnpb

Mon Aug 30 09:26:47 2004

```

; Sequence 1763, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1612
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-061-201-1612

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGTGTCCTCTCCA 1693
DB 1 CCTGTGTCCTCTACCA 17

RESULT 179
US-10-061-201-1762/c
; Sequence 1762, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1762
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-061-201-1762

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 CCTATCCTTAAGGCCA 1765
DB 17 CTTGTCTTAAGTCCCA 1

RESULT 180
US-10-061-201-1763/c
; Sequence 1763, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1763
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-061-201-1763

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1748 CCTATCCTTAAGGCC 1764
DB 17 CTTGTCTTAAGTCCC 1

RESULT 181
US-10-339-793-72
; Sequence 72, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
; APPLICANT: Bowen, Benjamin
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 72
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-339-793-72

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1735 GCTCCCAACTCTCCCT 1751
DB 1 GATCCCAACTCTCTCTT 17

```

```
RESULT 182
US-10-138-674-7198/c
; Sequence 7198, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7198

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAACCC 1679
Db 17 GCGCACAGCAGGACCCC 1

RESULT 183
US-10-138-674-7831/c
; Sequence 7831, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7831

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 CAGCGTGGTGGAGTTG 1708
Db 17 CAGCGTGGTGGTAGGTG 1

RESULT 184
US-10-287-949A-7198/c
; Sequence 7198, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
```

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7198

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAACCC 1679
Db 17 GCGCACAGCAGGACCCC 1

RESULT 185
US-10-287-949A-7831/c
; Sequence 7831, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7831

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 CAGCGTGGTGGAGTTG 1708
Db 17 CAGCGTGGTGGTAGGTG 1

RESULT 186
US-10-712-672-476/c
; Sequence 476, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
```

Mon Aug 30 09:26:47 2004

```

; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 476
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-476

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1642 GTAGCAGAGGCGAAGCA 1658
DB 17 GAAGCCGAAGGCCAGCA 1

RESULT 187
US-10-712-672-523
; Sequence 523, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-523

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1733 TGGCTCCCAACTCTCTCC 1749
DB 1 UGGCUCCAGCGGCGCC 17

RESULT 188
US-10-712-672-2523/c
; Sequence 2523, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713

; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2523
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2523

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1646 CAGAAGCGAAGCAGCAG 1662
DB 17 CAGCAGGCCGCGACAG 1

RESULT 189
US-10-669-841-2162/c
; Sequence 2162, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavcc
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Drafer
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04305 (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-23-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2162
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2162

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1740 CAACTCTCTCTCTCTCTCT 1756
DB 17 CAACTCTCTCTCTCTCTCT 1

```



```

US-10-723-361-9658/C
; Sequence 9658, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9658
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9658

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1672 TGGAAACCCCTGGTGCTC 1688
DB      17 TGGACCCCTGGCCCTC 1

RESULT 195
US-09-969-373-2481/c
; Sequence 2481, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2481
; LENGTH: 18

US-10-723-361-1264
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1264
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1264

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1729 AGATTGGCTCCCACTC 1745
DB      17 AGATCGTCCCACTC 1

RESULT 193
US-10-723-361-7831
; Sequence 7831, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7831
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7831

Query Match      8.8%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1661 AGGCTCAGCTGAAC 1677
DB      1 AGCTCAGCTGAAGC 17

```

```

; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2481

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1697 TGGTGGAGTTGGGTTA 1713
      ||||| ||||| |||||
Db 18 TGGTGGAGTTGGGTTA 2

RESULT 196
US-09-779-152-46/c
; Sequence 46, Application US/09779152
; Publication No. US20030044782A1
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; APPLICANT: McCarthy, Jose M.
; APPLICANT: Ordovas, Jose M.
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS AND KITS FOR BODY MASS AND
; TITLE OF INVENTION: CARDIOVASCULAR DISORDERS
; FILE REFERENCE: MNI-172CP2
; CURRENT APPLICATION NUMBER: US/09/779,152
; CURRENT FILING DATE: 2001-02-08
; PRIOR APPLICATION NUMBER: 08/890,979
; PRIOR FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-779-152-46

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCTCCAGCGTG 1698
      ||||| ||||| |||||
Db 2 GTGTCCTCTCGAGCTTG 18

RESULT 198
US-10-252-155-119/c
; Sequence 119, Application US/10252155
; Publication No. US20040068096A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT 1
; TITLE OF INVENTION: MULTI-DRUG RESISTANT PROTEINS
; FILE REFERENCE: D0152 NP
; CURRENT APPLICATION NUMBER: US/10/252,155
; CURRENT FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US 60/324,172
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: US 60/333,700
; PRIOR FILING DATE: 2001-11-27
; NUMBER OF SEQ ID NOS: 783
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 119
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-252-155-119

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1744 TCCTCCCTATCTCTAAAG 1760
      ||||| ||||| |||||
Db 18 TCCTCCCTGTGAGAAAG 2

RESULT 199
US-10-001-632A-5/c
; Sequence 5, Application US/10001632A
; Publication No. US20020151492A1
; GENERAL INFORMATION:
; APPLICANT: Conklin, Darrell C.
; APPLICANT: Feldhaus, Andrew L.
; APPLICANT: Holderman, Susan D.
; TITLE OF INVENTION: Testis Specific Protein
; FILE REFERENCE: 99-17C1
; CURRENT APPLICATION NUMBER: US/10/001,632A
; CURRENT FILING DATE: 2002-03-13
; PRIOR APPLICATION NUMBER: 60/128,210
; PRIOR FILING DATE: 199-04-07
; PRIOR APPLICATION NUMBER: 60/166,040
; PRIOR FILING DATE: 1999-11-17
; PRIOR APPLICATION NUMBER: 09/541,9190
; PRIOR FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-001-632A-5

Query Match      8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCTCCAGCGTG 1698
      ||||| ||||| |||||
Db 17 GTGTCCTCTCCGCGCTG 1

RESULT 197
US-10-382-248-49
; Sequence 49, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-588C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 49
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-382-248-49
```

QY 1721 GGAGATGGAGATTGGCT 1737
|||
Db 18 GTAAATGGAGCTTGGCT 2

```

RESULT 200
US-10-023-610-46/c
; Sequence 46, Application US/10023610
; Publication No. US20030023059A1
; GENERAL INFORMATION:
; APPLICANT: Acton, Susan L.
; TITLE OF INVENTION: SR-BI NUCLEIC ACIDS AND USES THEREFOR
; FILE REFERENCE: MIA-005.03
; CURRENT APPLICATION NUMBER: US/10/023,610
; CURRENT FILING DATE: 2001-12-17
; EARLIER APPLICATION NUMBER: 09/686,106
; EARLIER FILING DATE: 2000-10-10
; EARLIER APPLICATION NUMBER: 09/032,894
; EARLIER FILING DATE: 1998-02-27
; EARLIER APPLICATION NUMBER: 08/990,980
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-10-023-610-46

```

```

RESULT 201
US-10-428-868-20/c
; Sequence 20, Application US/10428868
; Publication No. US2003023532A1
; GENERAL INFORMATION:
; APPLICANT: Russell, Stephen
; APPLICANT: Kay Whyte, Feng
; TITLE OF INVENTION: System for Monitoring the Location of
; TITLE OF INVENTION: Transgenes
; FILE REFERENCE: 07039-295001
; CURRENT APPLICATION NUMBER: US/10/428,868
; CURRENT FILING DATE: 2003-05-01
; PRIOR APPLICATION NUMBER: US/09/640,198D
; PRIOR FILING DATE: 2000-08-16
; PRIOR APPLICATION NUMBER: US 60/149,168
; PRIOR FILING DATE: 1993-08-17
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-428-868-20

```

RESULT 202
US-10-395-607-177/c

```

; Sequence 177, Application. US/10395607
; Publication No. US20040019928A1
; GENERAL INFORMATION:
; APPLICANT: Wright, David A.
; APPLICANT: Voytas, Daniel F.
; TITLE OF INVENTION: Plant Retroelements and Methods Related
; TITLE OF INVENTION: Thereto
; FILE REFERENCE: 08411/036001
; CURRENT APPLICATION NUMBER: US/10/395,607
; CURRENT FILING DATE: 2003-03-24
; PRIOR APPLICATION NUMBER: 09/586,106
; PRIOR FILING DATE: 2000-06-02
; PRIOR APPLICATION NUMBER: 09/322,478
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: 60/087,125
; PRIOR FILING DATE: 1998-05-29
; NUMBER OF SEQ ID NOS: 200
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-10-395-607-177

```

```

RESULT 203
US-10-212-848-46/c
; Sequence 46, Application US/10212848
; Publication No. US20040023225A1
; GENERAL INFORMATION:
; APPLICANT: MCCARTHY, Jeanette
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR IDENTIFYING RISK FACTORS
; TITLE OF INVENTION: FOR ABNORMAL LIPID LEVELS AND THE DISEASES AND DISORDERS
; FILE REFERENCE: ASSOCIATED THEREWITH
; FILE REFERENCE: MMI-012
; CURRENT APPLICATION NUMBER: US/10/212,848
; CURRENT FILING DATE: 2002-08-05
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-212-848-46

```

```

RESULT 204
US-10-799-870-177/c
; Sequence 177, Application US/10799870
; Publication No. US2004015888A1
; GENERAL INFORMATION:
; APPLICANT: Wright, David A.
; APPLICANT: Voytas, Daniel F.
; TITLE OF INVENTION: PLANT RETROELEMENTS AND METHODS RELATED THERETO
; FILE REFERENCE: P-1065A
; CURRENT APPLICATION NUMBER: US/10/799, 870
; CURRENT FILING DATE: 2004-03-12

```

; PRIOR APPLICATION NUMBER: US/09/586,106
; PRIOR FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: 60/087,125
; PRIOR FILING DATE: 1998-05-29
; PRIOR APPLICATION NUMBER: 09/322,478
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 190
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-10-799-870-177

Query Match 8.8%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1732 TTGGCTCCCACTGCTC 1748
||| | |||| ||||
Db 17 TTGCCCCCAAGTCCTC 1

RESULT 205
US-10-239-504-34
; Sequence 34, Application US/10239504
; Publication No. US20040132016A1
; GENERAL INFORMATION:
; APPLICANT: NAGANO, MAKOTO
; APPLICANT: ITO, MAYUMI
; APPLICANT: SAGEHASHI, YUKIKO
; APPLICANT: HATTORI, HIROAKI
; APPLICANT: EGASHIRA, SHIZUYA
; APPLICANT: MATSUZAWA, YUJI
; TITLE OF INVENTION: METHOD OF DETECTING RISK FACTOR FOR THE ONSET OF
; TITLE OF INVENTION: ARTERIOSCLEROSIS
; FILE REFERENCE: Q72096
; CURRENT APPLICATION NUMBER: US/10/239,504
; CURRENT FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: PCT/JP01/02327
; PRIOR FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: JP 2000-84264
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-239-504-34

Query Match 8.8%; Score 12.2; DB 1; Length 21;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1657 CACCAGGCTCAGCTG 1673
||||| | |||||
Db 2 CACCAGGTTCCAGCTG 18

RESULT 206
US-10-232-634-5
; Sequence 5, Application US/10232634
; Publication No. US20030105314A1
; GENERAL INFORMATION:
; APPLICANT: Guida, Marco
; APPLICANT: Hall, Jeff
; TITLE OF INVENTION: GENETIC TYPING OF THE HUMAN CYTOCHROME P450 2A6 GENE
; TITLE OF INVENTION: AND RELATED MATERIALS AND METHODS
; FILE REFERENCE: 4389-20

; CURRENT APPLICATION NUMBER: US/10/232,634
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/586,376
; PRIOR FILING DATE: 2000-06-02
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-232-634-5

Query Match 8.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1634 TGGGGCTTGAG 1645
||||| | |||||
Db 1 TGGGGCTTGAG 12

RESULT 207
US-10-407-807-18
; Sequence 18, Application US/10407807
; Publication No. US20040096848A1
; GENERAL INFORMATION:
; APPLICANT: THRUE, ANJA MOLHART
; APPLICANT: KRISTJANSEN, PAUL E. G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 57390 (45120)
; CURRENT APPLICATION NUMBER: US/10/407,807
; CURRENT FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: 60/370,126
; PRIOR FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 18
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-407-807-18

Query Match 8.6%; Score 12; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGAT 1732
||||| | |||||
Db 3 GGAGATGGAGAT 14

RESULT 208
US-09-827-395A-755/c
; Sequence 755, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11

Query Match	Best Local Similarity	Score	DB 1	Length	Mismatches	Indels	Gaps
Query Match	Best Local Similarity	8.6%;	DB 1;	Length 17;			
US-10-430-882-755/c	US-10-430-882-755/c	100.0%;	Pred. No. 2.3e+02;		0;	0;	0;
Sequence 755, Application US/10430882	Sequence 755, Application US/10430882						
Publication No. US20030203870A1	Publication No. US20030203870A1						
GENERAL INFORMATION:	GENERAL INFORMATION:						
APPLICANT: Ribozyme Pharmaceuticals, Inc.	APPLICANT: Ribozyme Pharmaceuticals, Inc.						
APPLICANT: Lawrence Blatt	APPLICANT: Lawrence Blatt						
APPLICANT: James McSwiggen	APPLICANT: James McSwiggen						
APPLICANT: Bharat Chowhira	APPLICANT: Bharat Chowhira						
APPLICANT: Peter Haeblerli	APPLICANT: Peter Haeblerli						
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor	TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor						
FILE REFERENCE: MEH00-878-H (400/112)	FILE REFERENCE: MEH00-878-H (400/112)						
CURRENT APPLICATION NUMBER: US/10/430,882	CURRENT APPLICATION NUMBER: US/10/430,882						
CURRENT FILING DATE: 2003-05-06	CURRENT FILING DATE: 2003-05-06						
PRIOR APPLICATION NUMBER: 09/827,395	PRIOR APPLICATION NUMBER: 09/827,395						
PRIOR FILING DATE: 2001-04-05	PRIOR FILING DATE: 2001-04-05						
PRIOR APPLICATION NUMBER: 09/780,533	PRIOR APPLICATION NUMBER: 09/780,533						
PRIOR FILING DATE: 2001-02-09	PRIOR FILING DATE: 2001-02-09						
PRIOR APPLICATION NUMBER: PCT/US01/04273	PRIOR APPLICATION NUMBER: PCT/US01/04273						
PRIOR FILING DATE: 2001-02-09	PRIOR FILING DATE: 2001-02-09						
PRIOR APPLICATION NUMBER: 60/181,797	PRIOR APPLICATION NUMBER: 60/181,797						
PRIOR FILING DATE: 2000-02-11	PRIOR FILING DATE: 2000-02-11						
PRIOR APPLICATION NUMBER: PCT/US02/10512	PRIOR APPLICATION NUMBER: PCT/US02/10512						
PRIOR FILING DATE: 2002-04-03	PRIOR FILING DATE: 2002-04-03						
NUMBER OF SEQ ID NOS: 2617	NUMBER OF SEQ ID NOS: 2617						
SOFTWARE: PatentIn version 3.0	SOFTWARE: PatentIn version 3.0						
SEQ ID NO 755	SEQ ID NO 755						
LENGTH: 17	LENGTH: 17						
TYPE: RNA	TYPE: RNA						
ORGANISM: Homo sapiens	ORGANISM: Homo sapiens						
US-10-430-882-755	US-10-430-882-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches 12; Conservative 0;	Mismatches 12; Conservative 0;						
US-09-827-395A-755	US-09-827-395A-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches 12; Conservative 0;	Mismatches 12; Conservative 0;						
US-09-827-395A-755	US-09-827-395A-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches 12; Conservative 0;	Mismatches 12; Conservative 0;						
US-09-827-395A-755	US-09-827-395A-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches 12; Conservative 0;	Mismatches 12; Conservative 0;						
US-09-827-395A-755	US-09-827-395A-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches 12; Conservative 0;	Mismatches 12; Conservative 0;						
US-09-827-395A-755	US-09-827-395A-755						
Query Match	Query Match	8.6%;	Score 12;	DB 1;	Length 17;		
Best Local Similarity	Best Local Similarity	100.0%;	Pred. No. 2.3e+02;				
Mismatches							

```
QY 1645 GCAGAAGGCAAG 1656
Db 5 GCAGAAGGCAAG 16

RESULT 212
US-10-061-201-947
; Sequence 947, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-947

Query Match 8.6%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 GCAGAAGGCAAG 1656
Db 3 GCAGAAGGCAAG 14

RESULT 214
US-10-061-201-949
; Sequence 949, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 949
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-949

Query Match 8.6%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 GCAGAAGGCAAG 1656
Db 4 GCAGAAGGCAAG 15

RESULT 213
US-10-061-201-948
; Sequence 948, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
```

RESULT 215
US-10-061-201-950
; Sequence 950, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-950

Query Match 8.6%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 GCAGAGGGCAAG 1656
Db 1 GCAGAGGGCAAG 12

RESULT 216
US-09-832-648-9/c
; Sequence 9, Application US/09832648
; Patent No. US20020098231A1
; GENERAL INFORMATION:
; APPLICANT: STEIN, CY A
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669Z
; CURRENT APPLICATION NUMBER: US/09/832,648
; CURRENT FILING DATE: 2001-04-11
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
US-09-832-648-9

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CGAGATGGAGA 1731
Db 14 CGAGATGGAGA 3

RESULT 217
US-09-832-648-27/c
; Sequence 27, Application US/09832648
; Patent No. US20020098231A1
; GENERAL INFORMATION:
; APPLICANT: STEIN, CY A
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669Z
; CURRENT APPLICATION NUMBER: US/09/832,648
; CURRENT FILING DATE: 2001-04-11
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHATE LINKAGE
; NAME/KEY: modified_base
; LOCATION: (3)..(3)
; OTHER INFORMATION: PROP'NYL dt
; NAME/KEY: modified_base
; LOCATION: (4)..(4)
; OTHER INFORMATION: PROP'NYL dc
; NAME/KEY: modified_base
; LOCATION: (6)..(7)
; OTHER INFORMATION: PROP'NYL dc
; NAME/KEY: modified_base
; LOCATION: (5)..(5)
; OTHER INFORMATION: PROP'NYL dt
; NAME/KEY: modified_base
; LOCATION: (9)..(9)
; OTHER INFORMATION: PROP'NYL dt
; NAME/KEY: modified_base
; LOCATION: (10)..(10)
; OTHER INFORMATION: PROP'NYL dc
; NAME/KEY: modified_base
; LOCATION: (11)..(11)
; OTHER INFORMATION: PROP'NYL dt
; NAME/KEY: modified_base
; LOCATION: (12)..(13)
; OTHER INFORMATION: PROP'NYL dc
; NAME/KEY: modified_base
; LOCATION: (16)..(17)
; OTHER INFORMATION: PROP'NYL dt
US-09-832-648-27

Query Match 3.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
QY 1720 CGGAGATGGAGA 1731
Db 14 CGGAGATGGAGA 3

RESULT 218
US-09-832-648-28/c
; Sequence 28, Application US/09832648
; Patent No. US20020098231A1
; GENERAL INFORMATION:
; APPLICANT: STEIN, CY A
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669Z
; CURRENT APPLICATION NUMBER: US/09/832,648
; CURRENT FILING DATE: 2001-04-11
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-832-648-28

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAGA 1731
Db 14 CGGAGATGGAGA 3

RESULT 219
US-09-753-169A-9/c
; Sequence 9, Application US/09753169A
; Publication No. US20030017196A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of Columbia University In The City of New York
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669-A-PCT-US
; CURRENT APPLICATION NUMBER: US/09/753,169A
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: PCT/US99/15250
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-753-169A-9

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAGA 1731
Db 14 CGGAGATGGAGA 3

RESULT 220
US-09-753-169A-27/c
; Sequence 27, Application US/09753169A
; Publication No. US20030017196A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of Columbia University In The City of New York
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669-A-PCT-US
; CURRENT APPLICATION NUMBER: US/09/753,169A
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: PCT/US99/15250
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-753-169A-9

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAGA 1731
Db 14 CGGAGATGGAGA 3

RESULT 221
US-09-753-169A-9/c
; Sequence 9, Application US/09753169A
; Publication No. US20030017196A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of Columbia University In The City of New York
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669-A-PCT-US
; CURRENT APPLICATION NUMBER: US/09/753,169A
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: PCT/US99/15250
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-753-169A-9

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CGGAGATGGAGA 1731
Db 14 CGGAGATGGAGA 3

RESULT 222
US-09-753-169A-27/c
; Sequence 27, Application US/09753169A
; Publication No. US20030017196A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of Columbia University In The City of New York
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669-A-PCT-US
; CURRENT APPLICATION NUMBER: US/09/753,169A
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: PCT/US99/15250
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-753-169A-9

Query Match 8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

; OTHER INFORMATION: PROPYNVL dT
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (10)..(10)
; OTHER INFORMATION: PROPYNVL dC
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (11)..(11)
; OTHER INFORMATION: PROPYNVL dT
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (12)..(13)
; OTHER INFORMATION: PROPYNVL dC
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (16)..(17)
; OTHER INFORMATION: PROPYNVL dT
US-09-753-169A-27

Query Match      8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1720 CGGAGATGGAGA 1731
Db      14 CGGAGATGGAGA 3

RESULT 221
US-09-753-169A-28/c
; Sequence 28, Application US/09753169A
; Publication No. US20030017196A1
; GENERAL INFORMATION:
; APPLICANT: The Trustees of Columbia University In The City of New York
; TITLE OF INVENTION: OLIGONUCLEOTIDE INHIBITORS OF BCL-XL
; FILE REFERENCE: 0575/55669-A-PCT-US
; CURRENT APPLICATION NUMBER: US/09/753,169A
; CURRENT FILING DATE: 2001-01-02
; PRIOR APPLICATION NUMBER: 09/109,614
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: PCT/US99/15250
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ANTISENSE OLIGONUCLEOTIDE
; NAME/KEY: misc_binding
; LOCATION: (1)..(4)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; FEATURE:
; NAME/KEY: misc_binding
; LOCATION: (5)..(7)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; FEATURE:
; NAME/KEY: misc_binding
; LOCATION: (9)..(10)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; FEATURE:
; NAME/KEY: misc_binding
; LOCATION: (11)..(12)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
; FEATURE:
; NAME/KEY: misc_binding
; LOCATION: (15)..(18)
; OTHER INFORMATION: PHOSPHOROTHIOATE LINKAGE
US-09-753-169A-28

Query Match      8.6%; Score 12; DB 1; Length 18;

; OTHER INFORMATION: PROPYNVL dT
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (10)..(10)
; OTHER INFORMATION: PROPYNVL dC
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (11)..(11)
; OTHER INFORMATION: PROPYNVL dT
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (12)..(13)
; OTHER INFORMATION: PROPYNVL dC
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (16)..(17)
; OTHER INFORMATION: PROPYNVL dT
US-09-753-169A-27

Query Match      8.6%; Score 12; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1720 CGGAGATGGAGA 1731
Db      14 CGGAGATGGAGA 3

RESULT 222
US-09-877-478-6527
; Sequence 6527, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: MCSwiggan, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6536
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6527
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-6527

Query Match      8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      1677 CCCTGGTGTCCTCCTC 1691
Db      1 CCUUGUGUCCUC 15

RESULT 223
US-09-943-983-5
; Sequence 5, Application US/09943983
; Publication No. US20030077575A1
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; LOUWAGIE, JOOST
; ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
```

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word 6.0 / ASCII text output
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/943,983
FILING DATE: 31-Aug-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/913,833
FILING DATE: 1997-09-15
APPLICATION NUMBER: EP 96870005.4
FILING DATE: 26 Jan 1996
APPLICATION NUMBER: EP 96870081.5
FILING DATE: 25 Jun 1996
ATTORNEY/AGENT INFORMATION:
NAME: KAMMERER, PATRICIA A.
REGISTRATION NUMBER: 29,775
REFERENCE/DOCKET NUMBER: INNS:008
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Query Match 8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 GTACGGAGATGGAGA 1731
||| |||||
Db 1 GTACAGAGATGGAAA 15

RESULT 224
US-10-342-902-6527
; Sequence 6527, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6527
; LENGTH: 15
; TYPE: RNA

; ORGANISM: Hepatitis B virus
US-10-342-902-6527
Query Match 8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1677 CCTGGTGTCTCTC 1691
||:|:|:|:
Db 1 CCUUGUGUCUCCUC 15
RESULT 225
US-10-669-841-2580
; Sequence 2580, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2580
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-669-841-2580
Query Match 8.5%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1677 CCTGGTGTCTCTC 1691
||:|:|:|:
Db 1 CCUUGUGUCUCCUC 15
RESULT 226
US-09-866-108-525
; Sequence 525, Application US/09866108
; Patent No. US20020048800A1

```

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-526

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1644 AGCAGAGGCAAGCA 1658
Db      2 AGCAGATGACAGCA 16

RESULT 228
US-09-866-108-2351/c
; Sequence 2351, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; FILE REFERENCE: AEOMICA-7

QY      1644 AGCAGAGGCAAGCA 1658
Db      3 AGCAGATGACAGCA 17

RESULT 227
US-09-866-108-526
; Sequence 526, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2351
```

```
Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1632 GATGGGCTGTAGC 1646
Db 17 GATGGGCTGTAGC 3
```

RESULT 229

```
US-09-866-108-2352/c
; Sequence 2352, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2352
```

```
Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1632 GATGGGCTGTAGC 1646
Db 16 GATGGGCTGTAGC 2
```

RESULT 230

```
US-09-866-108-2353/c
; Sequence 2353, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
```

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
||| |||||
Db 3 AGCCTCACAGCTGAA 17

RESULT 232
US-09-866-108-7830
; Sequence 7830, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 7830
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7830

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
||| |||||
Db 2 AGCCTCACAGCTGAA 16

RESULT 233

PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aemica Sequence Listing Engine
SEQ ID NO 2353
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2353

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1632 GATGGGGCTGTGAGC 1646
||| |||||
Db 15 GATGGGGCTGTAGC 1

RESULT 231
US-09-866-108-7829
; Sequence 7829, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 7829
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7829

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

US-09-969-373-1602/c
; Sequence 1602, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Efftetz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1602
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1602

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1691 CCAGCGTGGTGAAG 1705
| | | | | | | | | | | | | | | | | | | | | |
Db 17 CGAGAGTGGTGAAG 3

RESULT 234
US-09-864-785-1556
; Sequence 1556, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1556

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1676 ACCCTGGTGTCTCCCT 1690
| | | | | | | | | | | | | | | | | | | | | |
Db 3 ACCAUGGUGUUCU 17

RESULT 235
US-09-825-805-403/c
; Sequence 403, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-403

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1660 CAGGCTCACAGCTGG 1674
| | | | | | | | | | | | | | | | | | | | | |
Db 15 CGGGCGCACAGCTGG 1

RESULT 236
US-09-825-805-503/c
; Sequence 503, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 503
; LENGTH: 17

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-503

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
    ||| |||||
Db 17 CAGTCACACAGCTGG 3

RESULT 237
US-09-825-805-504/c
; Sequence 504, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 504
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-504

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
    ||| |||||
Db 15 CAGTCACACAGCTGG 1

RESULT 238
US-09-825-805-512/c
; Sequence 512, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
```

```

; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 512
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-512

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
    ||| |||||
Db 17 CGGGCGCACAGCTGG 3

RESULT 239
US-09-825-805-548
; Sequence 548, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBHB00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 548
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-548

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
    ||| |||||
Db 17 CGGGCGCACAGCTGG 3
```


Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCCTGGGTCTCCNC 1691
DB 2 CCCUGAUGGUCCUC 16

RESULT 240
US-09-730-289B-80/c
; Sequence 80, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH00-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 80
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-80

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1636 GGCCTTGACGAA 1650
DB 16 GAGGTTGACGAA 2

RESULT 241
US-09-818-875-403
; Sequence 403, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 403
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-403

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGGAAGTTGG 1709

DB 1 CGTGGATGAAGTTGG 15

RESULT 242
US-09-818-875-404/c
; Sequence 404, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 404
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-404

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGGAAGTTGG 1709
DB 17 CGTGGATGAAGTTGG 3

RESULT 243
US-09-818-875-407
; Sequence 407, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 407
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-407

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;

```
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 2 CGTGGTGAAGTTGG 16

RESULT 244
US-09-818-875-408/c
; Sequence 408, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 408
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-408

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 2 CGTGGTGAAGTTGG 16

RESULT 245
US-09-818-875-3958
; Sequence 3958, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3958

Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 2 CGTGGTGAAGTTGG 16

RESULT 246
US-09-818-875-3959/c
; Sequence 3959, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3959
```

```
Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1661 AGGCTCACAGCTGGA 1675
||||| |||||||
Db 2 AGGCTTCCAGCTGGA 16

RESULT 247
US-09-877-478-993
; Sequence 993, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Lave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1661 AGGCTCACAGCTGGA 1675
||||| |||||||
Db 2 AGGCTTCCAGCTGGA 2

RESULT 247
US-09-877-478-993
; Sequence 993, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Lave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
```

; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-993

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1672 TGGAACTCGTGTGC 1686
:|||||:|:|:
Db 3 UGGAACCUUGUGTC 17

RESULT 248
US-09-848-754A-338
; Sequence 338, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 338
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-338

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGG 1699
:|||||:|:|:
Db 3 UCUCUCCAUCCUGG 17

RESULT 249
US-09-848-754A-1499
; Sequence 1499, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1499
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1499

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGG 1699
:|||||:|:|:
Db 3 UCUCUCCAUCCUGG 17

RESULT 249
US-09-848-754A-1499
; Sequence 1499, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1499
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1499

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1685 TCTCTCCAGCGTGG 1699
:|||||:|:|:
Db 2 UCUCUCCAUCCUGG 16

RESULT 250
US-09-848-754A-1639
; Sequence 1639, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1639
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1639

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1755 CTAAGGCCCACTGG 1769
:|||||:|:|:
Db 1 CAAAGGCCCGCUGG 15

RESULT 251
US-09-848-754A-3578
; Sequence 3578, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3578

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1755 CTAAGGCCCACTGG 1769
:|||||:|:|:
Db 1 CAAAGGCCCGCUGG 15

RESULT 251
US-09-848-754A-3578
; Sequence 3578, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3578
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3578

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CTAAGGCCCACTG 1768
:|||||:|:|:
Db 3 CCAAAAGGCCCGCUG 17

RESULT 252
US-09-930-423-18/c
; Sequence 18, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00, 918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CTAAGGCCCACTG 1768
:|||||:|:|:
Db 3 CCAAAAGGCCCGCUG 17

RESULT 252
US-09-930-423-18/c
; Sequence 18, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00, 918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1754 CTAAGGCCCACTG 1768
:|||||:|:|:
Db 3 CCAAAAGGCCCGCUG 17

RESULT 252
US-09-930-423-18/c
; Sequence 18, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00, 918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15

```

; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
; US-09-930-423-18

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTGG 1735
Db 16 GGAGAGGGAGCTTGG 2

RESULT 253
US-09-930-423-404/c
; Sequence 404, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MSHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
; US-09-930-423-404

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTGG 1735
Db 17 GGAGAGGGAGCTTGG 3

RESULT 254
US-09-930-423-405/c
; Sequence 405, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MSHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
; US-09-930-423-405

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTGG 1735
Db 15 GGAGAGGGAGCTTGG 1
```

```

RESULT 255
US-09-740-332-1449
; Sequence 1449, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1449
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-740-332-1449

Query Match      3.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 65.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1631 GGATGGGGCTTGTAG 1645
Db 2 GGAAGGUGCUUGUAG 16

RESULT 256
US-09-740-332-3106/c
; Sequence 3106, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3106
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-740-332-3106

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1631 GGATGGGGCTTGTAG 1645
Db 17 GGAAGGCTTGTAG 3

RESULT 257
US-09-740-332-3107/c
; Sequence 3107, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
```

; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3107
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3107

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1631 GGATGGGCTTGAG 1645
Db 15 GGAAGGTGCTTGAG 1

RESULT 258
US-09-745-237A-18/c
; Sequence 18, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-18

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGATTGG 1735
Db 16 GGAGAGGGAGCTTGG 2

RESULT 259
US-09-745-237A-404/c
; Sequence 404, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-404

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGATTGG 1735
Db 17 GGAGAGGGAGCTTGG 3

RESULT 260
US-09-745-237A-405/c
; Sequence 405, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 405
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-405

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1721 GGAGATGGAGATTGG 1735
Db 15 GGAGAGGGAGCTTGG 1

RESULT 261
US-09-817-879-1449
; Sequence 1449, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1449
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1449

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1631 GGATGGGCTTGAG 1645
Db 2 GGAAGGCGUGUAG 16

RESULT 262
US-09-817-879-3106/c

```
; Sequence 3106, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3106
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3106

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1631 GGATGGGCTTGTAG 1645
Db      17  GGAAGGTGCTTGTAG 3

RESULT 263
US-09-817-879-3107/c
; Sequence 3107, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3107
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3107

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1631 GGATGGGCTTGTAG 1645
Db      15  GGAAGGTGCTTGTAG 1

RESULT 264
US-10-342-902-993
; Sequence 993, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
```

```
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-993

Query Match      9.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      1672 TGAACCCCTGCTGTC 1686
Db      3  UGGAACCUUUGUGJC 17

RESULT 265
US-10-060-756A-211
; Sequence 211, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PH0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 211
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-211

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1646 CAGAAGGCAAGCACC 1660
```

```
Db      3 CGGAAGGCAAGCAGC 17
|||||
RESULT 266
US-10-060-756A-212
; Sequence 212, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 212
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-212

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1646 CAGAAGGCAAGCAGC 1660
Db      2 CGGAAGGCAAGCAGC 16
|||||
RESULT 267
US-10-060-756A-213
; Sequence 213, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
```

```
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 213
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-213

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1646 CAGAAGGCAAGCAGC 1660
Db      1 CGGAAGGCAAGCAGC 15
|||||
RESULT 268
US-10-060-756A-753
; Sequence 753, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 753
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-753

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1664 CTCACAGCTGGAGCC 1678
Db      2 CTCACGTCTGGAGCC 16
|||||
RESULT 269
US-10-060-756A-754
; Sequence 754, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 754
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-754

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1664 CTCACAGCTGAACC 1678
|||||
Db 1 CTCACAGCTGAACC 15

RESULT 270
US-10-163-552-248/c
; Sequence 248, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: HER2
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 248
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-248

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
|||||
Db 17 CAGTACACAGCTGG 3

RESULT 271
US-10-163-552-249/c
; Sequence 249, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: HER2
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 249
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-249

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
|||||
Db 15 CAGTACACAGCTGG 1

RESULT 272
US-10-163-552-403/c
; Sequence 403, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: HER2
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 403
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-403

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
|||||
Db 17 CGGGCGCACAGCTGG 3

RESULT 273
US-10-163-552-404/c
; Sequence 404, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: HER2
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 404
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-404

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGG 1674
|||||
Db 15 CGGGCGCACAGCTGG 1


```
RESULT 274
US-10-163-552-904
; Sequence 904, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; PRIOR FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-904

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 2.5e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1677 CCTGTGTCTCTCTC 1691
|||:|:|:|:|:|
Db 2 CCUGAUGUGUCUC 16

RESULT 275
US-10-139-604-6
; Sequence 6, Application US/10139604
; Publication No. US20030124551A1
; GENERAL INFORMATION:
; APPLICANT: METRIS THERAPEUTICS LIMITED
; APPLICANT: LLENICEK, Mirna
; APPLICANT: PAPP, Helen
; TITLE OF INVENTION: AGENTS IMPLICATED IN ENDOMETRIOSIS
; FILE REFERENCE: 1396-1-006
; CURRENT APPLICATION NUMBER: US/10/139,604
; PRIOR FILING DATE: 2002-08-23
; PRIOR APPLICATION NUMBER: GB 9926081.2
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926074.7
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926079.6
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926076.2
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: SeqWin99, version 1.02
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 5' RT-PCR primer for Ferritin L chain
US-10-139-604-6

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCACCAG 1662
|||||:|:|:|:|
Db 3 GAAGGCTGCACCAG 17

RESULT 276
US-10-061-201-1607
; Sequence 1607, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
```

```
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1607
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1607

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGTGTCT 1687
|||||:|:|:|:|
Db 2 GGAGCCCTGTGTCTCT 16

RESULT 277
US-10-061-201-1760/c
; Sequence 1760, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
```

```
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1760

Query Match
Best Local Similarity 8.5%; Score 11.8; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ 1751 TATCCTAAAGGCCCA 1765
DB 17 TGTCTAAAGTCCCA 3

RESULT 278
US-10-061-201-1761/c
; Sequence 1761, Application US/10061201
; Publication No. US20030166223A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1761

Query Match
Best Local Similarity 8.5%; Score 11.8; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ 1751 TATCCTAAAGGCCCA 1765
DB 16 TGTCTAAAGTCCCA 2

RESULT 279
US-10-209-787-403
; Sequence 403, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 404
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-404

Query Match
Best Local Similarity 8.5%; Score 11.8; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ 1695 CGTGTGGAAGTTGG 1709
DB 17 CGTGTGGAAGTTGG 3

RESULT 281
US-10-209-787-407
; Sequence 407, Application US/10209787
```

Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Stranded Oligonucleotides
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US 10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 407
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-407

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709
Db 2 CGTGGATGAAGTTGG 16

RESULT 282
US-10-209-787-408/c
Sequence 408, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Stranded Oligonucleotides
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US 10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 408
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-408

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709

Db 16 CGTGGATGAAGTTGG 2

RESULT 283
US-10-209-787-3958
Sequence 3958, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Stranded Oligonucleotides
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US 10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 3958
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-209-787-3958

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
Db 2 AGGCTCCAGCTGGA 16

RESULT 284
US-10-209-787-3959/c
Sequence 3959, Application US/10209787
Publication No. US20030217377A1
GENERAL INFORMATION:
APPLICANT: Kmiec, Eric B.
APPLICANT: Gamper, Howard B.
APPLICANT: Rice, Michael C.
TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
TITLE OF INVENTION: Stranded Oligonucleotides
FILE REFERENCE: Napro-4
CURRENT APPLICATION NUMBER: US 10/209,787
CURRENT FILING DATE: 2002-07-30
PRIOR APPLICATION NUMBER: US 09/818,875
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/192,176
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/192,179
PRIOR FILING DATE: 2000-03-27
PRIOR APPLICATION NUMBER: US 60/208,538
PRIOR FILING DATE: 2000-06-01
PRIOR APPLICATION NUMBER: US 60/244,989
PRIOR FILING DATE: 2000-10-30
NUMBER OF SEQ ID NOS: 4385
SOFTWARE: Friedman macro Napro4
SEQ ID NO 3959
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens

US-10-209-787-3959

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGTGG 1675
||||| |||||||
Db 16 AGGCTCCAGCTGGA 2

RESULT 285

US-10-261-185-403
; Sequence 403, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 403
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-403

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 1 CGTGGATGAAGTTGG 15

RESULT 286

US-10-261-185-404/c
; Sequence 404, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989

; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 404
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-404

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 17 CGTGGATGAAGTTGG 3

RESULT 287

US-10-261-185-407
; Sequence 407, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 407
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-407

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 2 CGTGGATGAAGTTGG 16

RESULT 288

US-10-261-185-408/c
; Sequence 408, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27

; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 408
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-408

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1695 CGTGGTGAAGTTGG 1709
||||| |||||||
Db 16 CGTGGTGAAGTTGG 2

RESULT 289
US-10-261-185-3958
; Sequence 3958, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3958

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
||||| |||||||
Db 2 AGGCTTCACAGCTGGA 16

RESULT 290
US-10-261-185-3959/c
; Sequence 3959, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3959

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGGA 1675
||||| |||||||
Db 16 AGGCTTCACAGCTGGA 2

RESULT 291
US-10-138-674-421
; Sequence 421, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH900-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-421

Query Match 8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1745 CCTCCCTATCCTAAA 1759
||:|:|:|:|:|:|:|
Db 3 CCUCCUUUCCGAAA 17

RESULT 292
US-10-138-674-422
; Sequence 422, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-422

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1745 CTCTCCCTATCCTTAA 1759
Db 2 CCUCUUAUCCGAAA 16
||:||:|:|||||

RESULT 293
US-10-287-949A-421
; Sequence 421, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-421

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1745 CTCTCCCTATCCTTAA 1759
Db 3 CCUCUUAUCCGAAA 17
||:||:|:|||||

RESULT 294
US-10-287-949A-422
; Sequence 422, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 422
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-422

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1745 CTCTCCCTATCCTTAA 1759
Db 2 CCUCUUAUCCGAAA 16
||:||:|:|||||

RESULT 295
US-10-712-672-2730
; Sequence 2730, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2730
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2730

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.5e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1734 GCTCCCGAACTCCTC 1748
Db 2 GGCUCUCCAAUCUCCCC 16
||:||:|:|||||

RESULT 296
US-10-669-841-993
; Sequence 993, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
```

```
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-993
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1672 TGAACCCCTGCTGTC 1686
      :|||||:|:|:|
Db 3 UGGAACCUUGUGUC 17
```

RESULT 297

```
US-10-669-841-4042
; Sequence 4042, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4042
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4042
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1631 GGATGGGGCTTGTAAG 1645
      |||||:|:|:|
Db 2 GGAAGGUGCUUGUAG 16
```

RESULT 298

```
US-10-669-841-5699/c
; Sequence 5699, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5699
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5699

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1631 GGATGGGCTGTAG 1645
Db      17  GGAAGGTGCTGTAG 3

RESULT 299
US-10-669-841-5700/c
; Sequence 5700, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (WBH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5700
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5700

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1631 GGATGGGCTGTAG 1645
```

```
Db      15  GGAAGGTGCTGTAG 1

RESULT 300
US-10-723-361-525
; Sequence 525, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Asomica Sequence Listing Engine
; SEQ ID NO 525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-525

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1644 AGCAGAGGCAAGCA 1658
Db      3  AGCAGATGACAAGCA 17

RESULT 301
US-10-723-361-526
; Sequence 526, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
```



```
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-526
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred.No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1644 AGCAGAAGCAAGCA 1658
      ||||| |||||
Db      2 AGCAGATGACAAGCA 16
```

RESULT 302

```
US-10-723-361-2351/c
; Sequence 2351, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2351
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2351
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred.No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1632 GATGGGCGCTTGAGC 1646
      ||||| |||||
Db      17 GATCGGCGCTGTAGC 3
```

RESULT 303

```
US-10-723-361-2352/c
; Sequence 2352, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2352
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2352
```

```
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred.No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1632 GATGGGCGCTTGAGC 1646
      ||||| |||||
Db      16 GATCGGCGCTGTAGC 2
```

```
RESULT 304
US-10-723-361-2353/c
; Sequence 2353, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2353
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1632 GATGGGCTTGAGC 1646
Db 15 GATGGGCTGTGAC 1

RESULT 305
US-10-723-361-7829
; Sequence 7829, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2353
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1632 GATGGGCTTGAGC 1646
Db 15 GATGGGCTGTGAC 1
```

```
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7829
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7829
Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1661 AGGCTCACAGCTGGA 1675
Db 3 AGCTCACAGCTGAA 17

RESULT 306
US-10-723-361-7830
; Sequence 7830, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7830
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7830

Query Match      8.5%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1661 AGGCTCACAGCTGGA 1675
Db 2 AGCCTCACAGCTGAA 16
|||||

RESULT 307
US-09-863-777-3
; Sequence 3, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Fett, James W.
; APPLICANT: Olson, Karen A.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-3

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATTGGC 1736
Db 4 GAGATGGTGTGATGGC 18
|||||

RESULT 308
US-09-863-777-4/c
; Sequence 4, Application US/09863777
; Patent No. US20020019359A1
; GENERAL INFORMATION:
; APPLICANT: Fett, James W.
; APPLICANT: Olson, Karen A.
; TITLE OF INVENTION: Antisense Inhibition of Angiogenin Expression
; FILE REFERENCE: 10498/05286
; CURRENT APPLICATION NUMBER: US/09/863,777
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/041182
; PRIOR FILING DATE: 1997-03-21
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: phosphorothioate oligodeoxynucleotide
US-09-863-777-4

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATTGGC 1736
Db 15 GAGATGGTGTGATGGC 1
|||||

RESULT 309
US-09-969-373-1855
; Sequence 1855, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1855
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1855

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1579 CTGGTGTCCTCTCCA 1693
Db 3 CTGATGTTCTCTCCA 17
|||||

RESULT 310
US-09-969-373-2246
; Sequence 2246, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2246
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2246

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1709 GGTAGGACTACGGA 1723
Db |||||
```

```
Db      1  GGTGAGGATATGGA 15

RESULT 311
US-09-306-333A-114
; Sequence 114, Application US/09306333A
; Publication No. US20030152918A1
; GENERAL INFORMATION:
; APPLICANT: Academy of Applied Science
; TITLE OF INVENTION: BRCAL and hMLH1 Gene Primer Sequences and Method for
; FILE REFERENCE: BRCAL
; CURRENT APPLICATION NUMBER: US/09/306,333A
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/IB00/01607
; PRIOR FILING DATE: 2000-11-06
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 114
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-306-333A-114

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1671 CTGAACCTCTGGTGT 1685
Db      1  CTGGACTCTGGGT 15

RESULT 312
US-09-362-485-19/c
; Sequence 19, Application US/09362485
; Publication No. US20030162171A1
; GENERAL INFORMATION:
; APPLICANT: Floh, Leopold
; APPLICANT: Singh, Mahavir
; APPLICANT: Hutter, Bernd
; APPLICANT: Kolk, Arend
; TITLE OF INVENTION: Test-Kit For Tuberculosis Diagnosis etc.
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESSES:
; ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/362,485
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/EP98/00483
; FILING DATE: 29-JAN-1998
; PRIOR APPLICATION NUMBER: EP 97101338.8
; FILING DATE: 29-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Zeller, James P.
; REGISTRATION NUMBER: 28,491
; REFERENCE/DOCKET NUMBER: 29473/35834
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448

; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
US-09-362-485-19

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1688 CCTCAGCGTGTGG 1702
Db      17  CCGCAGCGTGTGG 3

RESULT 313
US-10-054-387-10
; Sequence 10, Application US/10054387
; Publication No. US20030054365A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Minzhen
; APPLICANT: Qiu, Gang
; APPLICANT: Humphreys, Robert
; TITLE OF INVENTION: CANCER CELL VACCINE
; FILE REFERENCE: U.S. Application 09/205,995, (CIP)
; CURRENT APPLICATION NUMBER: US/10/054,387
; CURRENT FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: 09/036,746
; PRIOR FILING DATE: 1998-03-09
; PRIOR APPLICATION NUMBER: 08/661,627
; PRIOR FILING DATE: 1996-06-11
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide corresponding to a specific region
; OTHER INFORMATION: of the mouse li gene.
US-10-054-387-10

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1656 GCACAGCGCTACAG 1670
Db      3  GCATCTGGCTACAG 17

RESULT 314
US-10-133-779-20
; Sequence 20, Application US/10133779
; Publication No. US20030165884A1
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCite, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/10/133,779
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US/09/747,391
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
```

```

; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 20
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-133-779-20

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1653 CAAGCACCAGGCTCA 1667
    ||||| ||||| ||
Db 2 CAAGCGCCAGGCACA 16

RESULT 315
US-10-114-824A-52
; Sequence 52, Application US/10114824A
; Publication No. US20030196215A1
; GENERAL INFORMATION:
; APPLICANT: JOSELYNE OLIVIER
; TITLE OF INVENTION: No. US20030196215A1 Class of Proteins and Uses Thereof for Plan
; FILE REFERENCE: Pat. 006US
; CURRENT APPLICATION NUMBER: US/10/114,824A
; CURRENT FILING DATE: 2002-08-16
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 52
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-114-824A-52

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1741 AACTCTCCTATCC 1755
    ||||| ||||| ||
Db 1 AACTCTCCTATGTC 15

RESULT 316
US-10-297-068-30/c
; Sequence 30, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 30
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: capture
US-10-297-068-30

Query Match      8.5%; Score 11.8; DB 1; Length 18;

```

```

Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 AGCAAGCACCAGGC 1664
    ||||| ||||| ||
Db 18 AGCAACACCAGAC 4

RESULT 317
US-10-277-216-163/c
; Sequence 163, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 163
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-163

Query Match      8.5%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1649 AAGGCAAGCACCAGG 1663
    ||||| ||||| ||
Db 17 ATGGGAGCACCAGG 3

RESULT 318
US-10-349-143-6052/c
; Sequence 6052, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6052
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8626 for SEQ 2118,

```

US-10-349-143-6052		Db		17 ATGGAAGCACCAGG 3	
Query Match		8.5%;		Score 11.8; DB 1; Length 18;	
Best Local Similarity		86.7%;		Pred. No. 2.8e+02;	
Matches 13;		Conservative 0;		Mismatches 2; Indels 0; Gaps 0;	
Qy		1721 GGAGATGGAGATTGG 1735			
Db		18 GAAGTTGGAGATTGG 4			
RESULT 319					
US-10-126-022-163/c					
; Sequence 163, Application US/10126022					
; Publication No. US20040023215A1					
; GENERAL INFORMATION:					
; APPLICANT: KEITH, TIM					
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,					
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE					
; FILE REFERENCE: 2976-4039US2					
; CURRENT APPLICATION NUMBER: US/10/126,022					
; CURRENT FILING DATE: 2002-04-19					
; PRIOR APPLICATION NUMBER: 09/834,597					
; PRIOR FILING DATE: 2001-04-13					
; PRIOR APPLICATION NUMBER: 09/548,797					
; PRIOR FILING DATE: 2000-04-13					
; NUMBER OF SEQ ID NOS: 420					
; SOFTWARE: PatentIn Ver. 2.1					
; SEQ ID NO 163					
; LENGTH: 18					
; TYPE: DNA					
; ORGANISM: Artificial Sequence					
; FEATURE:					
; OTHER INFORMATION: Description of Artificial Sequence: Primer					
US-10-126-022-163					
Query Match		8.5%;		Score 11.8; DB 1; Length 18;	
Best Local Similarity		86.7%;		Pred. No. 2.8e+02;	
Matches 13;		Conservative 0;		Mismatches 2; Indels 0; Gaps 0;	
Qy		1649 AAGGCAAGCACCAGG 1663			
Db		17 ATGGAAGCACCAGG 3			
RESULT 320					
US-10-670-184-106/c					
; Sequence 106, Application US/10670184					
; Publication No. US20040077011A1					
; GENERAL INFORMATION:					
; APPLICANT: KEITH, TIM					
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND					
; TITLE OF INVENTION: OBESITY					
; FILE REFERENCE: 2976-4039					
; CURRENT APPLICATION NUMBER: US/10/670,184					
; CURRENT FILING DATE: 2003-09-24					
; PRIOR APPLICATION NUMBER: 60/129,391					
; PRIOR FILING DATE: 1999-04-13					
; NUMBER OF SEQ ID NOS: 170					
; SOFTWARE: PatentIn Ver. 2.1					
; SEQ ID NO 106					
; LENGTH: 18					
; TYPE: DNA					
; ORGANISM: Artificial Sequence					
; FEATURE:					
; OTHER INFORMATION: Description of Artificial Sequence: Primer					
US-10-670-184-106					
Query Match		8.5%;		Score 11.8; DB 1; Length 18;	
Best Local Similarity		86.7%;		Pred. No. 2.8e+02;	
Matches 13;		Conservative 0;		Mismatches 2; Indels 0; Gaps 0;	
Qy		1649 AAGGCAAGCACCAGG 1663			

```
;
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
; SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-510-378-27
Query Match      8.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1649 AAGGCAAGCACCA 1661
Db      13 AGGCAAGCACCA 1

RESULT 323
US-09-798-260-85/c
; Sequence 85, Application US/09798260
; Publication No. US20030165830A1
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles G.
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P. A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobbhan, Peter E.
; APPLICANT: Morris, MacDonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: ARRAYS OF NUCLEIC ACID PROBES FOR ANALYZING
; TITLE OF INVENTION: BIOTRANSFORMATION GENES
; FILE REFERENCE: 018547-015720US
; CURRENT APPLICATION NUMBER: US/09/798,260
; CURRENT FILING DATE: 2002-05-01
; PRIOR APPLICATION NUMBER: US 08/778,794
; PRIOR FILING DATE: 1997-01-03
; PRIOR APPLICATION NUMBER: US 08/544,381
; PRIOR FILING DATE: 1995-10-10
; PRIOR APPLICATION NUMBER: US 08/510,521
; PRIOR FILING DATE: 1995-08-02
; PRIOR APPLICATION NUMBER: WO PCT/US94/12305
; PRIOR FILING DATE: 1994-10-26
; PRIOR APPLICATION NUMBER: US 08/284,064
; PRIOR FILING DATE: 1994-08-02
; PRIOR APPLICATION NUMBER: US 08/143,312
; PRIOR FILING DATE: 1993-10-26
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 85
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-798-260-85
Query Match      8.2%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.6e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1649 AAGGCAAGCACCA 1661
Db      13 AGGCAAGCACCA 1

RESULT 324
US-09-943-983-9
; Sequence 9, Application US/09943983
; Publication No. US20030077575A1
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
; MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION NUMBER: US/09/943,983
; FILING DATE: 31-Aug-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/913,833
; FILING DATE: 1997-09-15
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-943-983-9
Query Match      8.2%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1717 GTACGAGATGGA 1729
Db      1 GTACAGAGATGGA 13

RESULT 325
US-09-504-231A-474
```

; Sequence 474, Application US/09504231A

; Patent No. US20020013458A1

; GENERAL INFORMATION:

; APPLICANT: Blatt, Lawrence

; APPLICANT: McSwiggen, James

; APPLICANT: Roberts, Beth

; APPLICANT: Pavco, Pamela

; APPLICANT: Macejak, Dennis

; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION

; FILE REFERENCE: IPI 247/282

; CURRENT APPLICATION NUMBER: US/09/504,231A

; CURRENT FILING DATE: 2000-02-15

; PRIOR APPLICATION NUMBER: 09/274,553

; PRIOR FILING DATE: 1999-03-23

; PRIOR APPLICATION NUMBER: 09/257,608

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/100,842

; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/083,217

; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3242

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 474

; LENGTH: 15

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-504-231A-474

Query Match 8.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 69.2%; Pred. No. 2.2e+02;

Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698

Db 3 CUCCUCCACGUG 15

RESULT 326

US-09-274-553D-474

; Sequence 474, Application US/09274553D

; Patent No. US20020082225A1

; GENERAL INFORMATION:

; APPLICANT: Blatt, Lawrence

; APPLICANT: McSwiggen, James

; APPLICANT: Roberts, Beth

; APPLICANT: Pavco, Pamela

; APPLICANT: Macejak, Dennis

; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION

; FILE REFERENCE: IPI 247/282

; CURRENT APPLICATION NUMBER: US/09/274,553D

; CURRENT FILING DATE: 1999-03-23

; PRIOR APPLICATION NUMBER: 09/257,608

; PRIOR FILING DATE: 1999-02-24

; PRIOR APPLICATION NUMBER: 60/100,842

; PRIOR FILING DATE: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/083,217

; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3148

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 474

; LENGTH: 15

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-274-553D-474

Query Match 8.2%; Score 11.4; DB 1; Length 15;

Best Local Similarity 69.2%; Pred. No. 2.2e+02;

Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1686 CTCCTCCAGCGTG 1698

Db 3 CUCCUCCACGUG 15

RESULT 327

US-09-818-875-3958/c

; Sequence 3958, Application US/09818875

; Publication No. US20030051270A1

; GENERAL INFORMATION:

; APPLICANT: Kmiec, Eric B.

; APPLICANT: Gamper, Howard B.

; APPLICANT: Rice, Michael C.

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single

; TITLE OF INVENTION: Stranded Oligonucleotides

; FILE REFERENCE: Napro-4

; CURRENT APPLICATION NUMBER: US/09/818,875

; CURRENT FILING DATE: 2001-03-27

; PRIOR APPLICATION NUMBER: US 60/192,176

; PRIOR FILING DATE: 2000-03-27

; PRIOR APPLICATION NUMBER: US 60/192,179

; PRIOR FILING DATE: 2000-03-27

; PRIOR APPLICATION NUMBER: US 60/208,538

; PRIOR FILING DATE: 2000-06-01

; PRIOR APPLICATION NUMBER: US 60/244,989

; PRIOR FILING DATE: 2000-10-30

; NUMBER OF SEQ ID NOS: 4395

; SOFTWARE: Friedman macro Napro4

; SEQ ID NO 3958

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-818-875-3958

Query Match 8.2%; Score 11.4; DB 1; Length 17;

Best Local Similarity 92.3%; Pred. No. 2.9e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1668 CAGCTGGAACGCT 1680

Db 14 CAGCTGGAACGCT 2

RESULT 328

US-09-818-875-3959

; Sequence 3959, Application US/09818875

; Publication No. US20030051270A1

; GENERAL INFORMATION:

; APPLICANT: Kmiec, Eric B.

; APPLICANT: Gamper, Howard B.

; APPLICANT: Rice, Michael C.

; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single

; TITLE OF INVENTION: Stranded Oligonucleotides

; FILE REFERENCE: Napro-4

; CURRENT APPLICATION NUMBER: US/09/818,875

; CURRENT FILING DATE: 2001-03-27

; PRIOR APPLICATION NUMBER: US 60/192,176

; PRIOR FILING DATE: 2000-03-27

; PRIOR APPLICATION NUMBER: US 60/192,179

; PRIOR FILING DATE: 2000-03-27

; PRIOR APPLICATION NUMBER: US 60/208,538

; PRIOR FILING DATE: 2000-06-01

; PRIOR APPLICATION NUMBER: US 60/244,989

; PRIOR FILING DATE: 2000-10-30

; NUMBER OF SEQ ID NOS: 4385

; SOFTWARE: Friedman macro Napro4

; SEQ ID NO 3959

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-818-875-3959


```
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3959

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCT 1680
   |||||
Db 4 CAGCTGGAAGCCT 16

RESULT 329
US-10-209-787-3958/c
; Sequence 3958, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3958

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCT 1680
   |||||
Db 14 CAGCTGGAAGCCT 2

RESULT 330
US-10-209-787-3959
; Sequence 3959, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
```

```
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3959

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCT 1680
   |||||
Db 4 CAGCTGGAAGCCT 16

RESULT 331
US-10-261-185-3958/c
; Sequence 3958, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3958
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3958

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCT 1680
   |||||
Db 14 CAGCTGGAAGCCT 2

RESULT 332
US-10-261-185-3959
; Sequence 3959, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
```

```

; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3959

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1661 AGGCTCACAGCTG 1673
Db      5 AGCCTCACAGCTG 17

RESULT 334
US-09-866-108-7828
; Sequence 7828, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7828
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7828

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1661 AGGCTCACAGCTG 1673
```

```

; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3959
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3959

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1668 CAGCTGGAACCT 1690
Db      4 CAGCTGGAACCT 16

RESULT 333
US-09-866-108-7827
; Sequence 7827, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7827
```


Publication No. US20030014775A1
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
Edington, Brent E.
McSwiggen, James A.
Merlo, Patricia Ann Owens
Guo, Lining
Skokut, Thomas A.
Young, Scott A.
Folkerts, Otto
Merlo, Donald J.
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2056
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/961.077
FILING DATE: 21-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/679,645
FILING DATE: July 12, 1996
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 53:
US-09-961-077-53
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1636 GGGCTTGTAGCAG 1648
Db 16 GGGCTTGTAGCAG 4
RESULT 342
US-09-988-626-88/c
Sequence 88, Application US/09988626
Publication No. US20030044959A1
GENERAL INFORMATION:
APPLICANT: Tavtigan, Sean V.
APPLICANT: Teng, David H.F.

Publication No. US20030004122A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka Matulic
APPLICANT: Sweedler, Dave
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
FILE REFERENCE: MEHB00-831-F (400/809)
CURRENT APPLICATION NUMBER: US/09/825,805
CURRENT FILING DATE: 2001-09-27
PRIOR APPLICATION NUMBER: 09/578,223
PRIOR FILING DATE: 2000-05-23
PRIOR APPLICATION NUMBER: 09/476,387
PRIOR FILING DATE: 1999-12-30
PRIOR APPLICATION NUMBER: 09/474,432
PRIOR FILING DATE: 1999-12-29
PRIOR APPLICATION NUMBER: 09/301,511
PRIOR FILING DATE: 1999-04-28
PRIOR APPLICATION NUMBER: 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: 60/083,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/064,866
PRIOR FILING DATE: 1997-11-05
NUMBER OF SEQ ID NOS: 1558
SOFTWARE: PatentIn version 3.0
SEQ ID NO 459
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-825-805-459
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1663 GCTCACAGCTGGA 1675
Db 2 GCUCACUCUGGA 14
RESULT 341
US-09-961-077-53/c
Sequence 53, Application US/09961077

Publication No. US20030014775A1
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
Edington, Brent E.
McSwiggen, James A.
Merlo, Patricia Ann Owens
Guo, Lining
Skokut, Thomas A.
Young, Scott A.
Folkerts, Otto
Merlo, Donald J.
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2056
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/961.077
FILING DATE: 21-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/679,645
FILING DATE: July 12, 1996
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 53:
US-09-961-077-53
Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1636 GGGCTTGTAGCAG 1648
Db 16 GGGCTTGTAGCAG 4
RESULT 342
US-09-988-626-88/c
Sequence 88, Application US/09988626
Publication No. US20030044959A1
GENERAL INFORMATION:
APPLICANT: Tavtigan, Sean V.
APPLICANT: Teng, David H.F.

```
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/988,626
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/564,805
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 88
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-988-626-88

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1657 CACCAGGCTCACA 1669
Db 17 CACCAGGCTGACA 5

RESULT 343
US-09-988-687-88/c
; Sequence 88, Application US/09988687
; Publication No. US20030045704A1
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/988,687
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/564,805
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 88
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-988-687-88

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1657 CACCAGGCTCACA 1669
Db 17 CACCAGGCTGACA 5

RESULT 344
US-09-988-687-88/c
; Sequence 88, Application US/09988687
; Publication No. US20030045704A1
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/988,687
; CURRENT FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/564,805
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 88
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-988-687-88

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1657 CACCAGGCTCACA 1669
Db 17 CACCAGGCTGACA 5

RESULT 345
US-09-877-478-2362/c
; Sequence 2362, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2362

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCACTCTCTC 1748
Db 13 CCCCCCACTCTCTC 1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH00-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 751
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-751
```

```
Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1638 GCTTGTAGCAGAA 1650
Db 17 GCTTGTAGCAGAA 5
```

```
RESULT 345
US-09-877-478-2362/c
; Sequence 2362, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2362
```

```
Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1736 CTCCTCACTCTCTC 1748
Db 13 CCCCCCACTCTCTC 1
```

```
; ORGANISM: Homo sapiens
US-09-848-754A-1640

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1757 AAAGGCCCACTGG 1769
Db 2 AAAGGCCCGCUGG 14

RESULT 346
US-09-848-754A-2450
; Sequence 2450, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2450
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-299

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.9e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCA 1741
Db 5 AUAUUGGCCUCCA 17

RESULT 347
US-09-848-754A-1429
; Sequence 1429, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1429

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.9e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCA 1741
Db 1 AUAUUGGCCUCCA 13

RESULT 348
US-09-848-754A-1640
; Sequence 1640, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1640
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-09-848-754A-1640

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1757 AAAGGCCCACTGG 1769
Db 2 AAAGGCCCGCUGG 14

RESULT 349
US-09-848-754A-2450
; Sequence 2450, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2450
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2450

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.9e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCA 1741
Db 3 AUAUUGGCCUCCA 15

RESULT 350
US-09-848-754A-2545
; Sequence 2545, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2545
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2545

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1757 AAAGGCCCACTGG 1769
Db 1 AAAGGCCCGCUGG 13

RESULT 351
US-09-848-754A-3453
; Sequence 3453, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MEHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; PRIORITY FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 3453
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3453

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 9; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCCA 1741
Db 4 AUAUUGGCUCCCA 16

RESULT 352
US-09-528-644-5/c
; Sequence 5, Application US/09528644
; Publication No. US20030077696A1
; GENERAL INFORMATION:
; APPLICANT: Thim, Lars
; APPLICANT: No. US20030077696A1, Kjel
; APPLICANT: No. US20030077696A1, Fanny
; APPLICANT: Bjorn, Soren
; APPLICANT: Christensen, Mogens
; APPLICANT: Nielsen, Per Franklin
; TITLE OF INVENTION: Human Spasmodic Polypeptide in
; FILE REFERENCE: 3951.224-US
; CURRENT APPLICATION NUMBER: US/09/528,644
; PRIORITY FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/580,964
; PRIOR FILING DATE: 2000-05-30
; PRIOR APPLICATION NUMBER: US 09/027,893
; PRIOR FILING DATE: 1998-02-23
; PRIOR APPLICATION NUMBER: US 08/491,979
; PRIOR FILING DATE: 1995-08-02
; PRIOR APPLICATION NUMBER: PCT/DK94/00037
; PRIOR FILING DATE: 1994-01-20
; PRIOR APPLICATION NUMBER: 0069/93
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Synthetic
US-09-528-644-5

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1677 CCCTGGTGTCTCC 1689
Db 14 CCCTGGTGTCTCC 2

RESULT 353
US-09-827-395A-478/c
; Sequence 478, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
```

```
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowdhry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MEHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIORITY FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 478
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-478
```

```
Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1676 ACCCTGGTGTCTC 1688
Db 17 ACCCTGGTGTCTC 5
```

RESULT 354

```
US-09-988-686-88/c
; Sequence 88, Application US/09988686
; Publication No. US20030120052A1
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/988,686
; PRIORITY FILING DATE: 2001-11-20
; PRIOR APPLICATION NUMBER: 09/564,805
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 88
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-988-686-88
```

```
Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1657 CACCAGGCTCACA 1669
Db 17 CACCAGGCTCACA 5
```

RESULT 355

```
US-09-740-332-1231/c
; Sequence 1231, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
```

FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1231
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1231

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCTGGTGTCT 1687
|||||:|||||
Db 17 AACCTGGTGTAT 5

RESULT 356
US-09-740-332-1232/c
Sequence 1232, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1232
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1232

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GGAACCCCTGGTGT 1685
|||||:|||||
Db 13 GCAACCCCTGGTGT 1

RESULT 357
US-09-740-332-3324
Sequence 3324, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3324
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence

FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3324

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCTGGTGTCT 1687
|||||:|||||
Db 2 AACCCUGUGUAU 14

RESULT 358
US-09-792-818-96/c
Sequence 96, Application US/09792818
Publication No. US20030134806A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Jarvis, Thale
APPLICANT: Von Carlowitz, Ira
APPLICANT: McSwiggen, Jim
APPLICANT: Hamblin, Paul
APPLICANT: Ellis, Jonathan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion of Grb-2-related with Insertion
FILE REFERENCE: MBH00-901-A (400/013)
CURRENT APPLICATION NUMBER: US/09/792,818
CURRENT FILING DATE: 2001-02-23
NUMBER OF SEQ ID NOS: 2304
SOFTWARE: PatentIn version 3.0
SEQ ID NO 96
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-792-818-96

Query Match 3.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACGAGATGGAGA 1731
|||||:|||||
Db 14 ACAGATGGAGA 2

RESULT 359
US-09-792-818-282/c
Sequence 282, Application US/09792818
Publication No. US20030134806A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Jarvis, Thale
APPLICANT: Von Carlowitz, Ira
APPLICANT: McSwiggen, Jim
APPLICANT: Hamblin, Paul
APPLICANT: Ellis, Jonathan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insertion of Grb-2-related with Insertion
FILE REFERENCE: MBH00-901-A (400/013)
CURRENT APPLICATION NUMBER: US/09/792,818
CURRENT FILING DATE: 2001-02-23
NUMBER OF SEQ ID NOS: 2304
SOFTWARE: PatentIn version 3.0
SEQ ID NO 282
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-792-818-282

Query Match 8.2%; Score 11.4; DB 1; Length 17;


```
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAGA 1731
Db 17 ACAGAGATGGAGA 5

RESULT 360
US-09-792-818-283/c
; Sequence 283, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-283

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAGA 1731
Db 16 ACAGAGATGGAGA 4

RESULT 361
US-09-792-818-284/c
; Sequence 284, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 284
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-284

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1719 ACGGAGATGGAGA 1731
Db 13 ACAGAGATGGAGA 1
```

```
RESULT 362
US-09-817-879-1231/c
; Sequence 1231, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1231
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1231

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCCCTGGTGCT 1687
Db 17 AACCCCTGGTGAT 5

RESULT 363
US-09-817-879-1232/c
; Sequence 1232, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1232
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1232

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1673 GCAACCTGGTGCT 1685
Db 13 GCAACCTGGTGCT 1

RESULT 364
US-09-817-879-3324
; Sequence 3324, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
```

; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 324
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3324

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCTGGTGCTC 1687
| | | | | : | | : | :
Db 2 AACCCUGGUGAU 14

RESULT 365

US-10-342-902-2362/c
; Sequence 2362, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2362
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2362

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCCAACTCCTC 1748
| | | | | : | | : | :
Db 13 CCCCCAACTCCTC 1

RESULT 366

US-09-918-715-314/c
; Sequence 314, Application US/09918715
; Publication No. US20030017157A1

; GENERAL INFORMATION:
; APPLICANT: Brad St. Croix
; APPLICANT: Bert Vogelstein
; APPLICANT: Kenneth Kinzler
; TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
; FILE REFERENCE: 1107.00134
; CURRENT APPLICATION NUMBER: US/09/918,715
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/222,599
; PRIOR FILING DATE: 2000-08-02
; PRIOR APPLICATION NUMBER: 60/224,360
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/282,850
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 314
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-918-715-314

Query Match 9.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1678 CCTGGTGCTCCT 1690
| | | | | : | | : | :
Db 14 CCTGGGTCTCCT 2

RESULT 367

US-10-430-882-478/c
; Sequence 478, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 478
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-478

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1676 ACCCTGGTGCTC 1688
| | | | | : | | : | :
Db 17 ACCCTGGTGCTC 5

RESULT 368

; ORGANISM: Homo sapiens		8.2%; Score 11.4; DB 1; Length 17;	
US-10-060-756A-210		Best Local Similarity 92.3%; Pred. No. 2.9e+02;	
		Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	1646 CAGAAGGCAAGCA 1658		
Db	4 CGGAAGGCAAGCA 16		
RESULT 370			
US-10-060-756A-214			
; Sequence 214, Application US/10060756A			
; Publication No. US20030046717A1			
; GENERAL INFORMATION:			
; APPLICANT: Zhang, Jian			
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN			
; FILE REFERENCE: PB0177			
; CURRENT APPLICATION NUMBER: US/10/060,756A			
; CURRENT FILING DATE: 2002-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006667			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006664			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006669			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006665			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006668			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006663			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: US 09/864,761			
; PRIOR FILING DATE: 2001-05-23			
; PRIOR APPLICATION NUMBER: US 60/327,898			
; PRIOR FILING DATE: 2001-10-09			
; NUMBER OF SEQ ID NOS: 4804			
; SOFTWARE: Aecomica Sequence Listing Engine			
; SEQ ID NO 214			
; LENGTH: 17			
; TYPE: DNA			
; ORGANISM: Homo sapiens		8.2%; Score 11.4; DB 1; Length 17;	
US-10-060-756A-214		Best Local Similarity 92.3%; Pred. No. 2.9e+02;	
		Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	1648 GAAGGCAAGCACC 1660		
Db	2 GAAGGCAAGCAGC 14		
RESULT 371			
US-10-060-756A-215			
; Sequence 215, Application US/10060756A			
; Publication No. US20030046717A1			
; GENERAL INFORMATION:			
; APPLICANT: Zhang, Jian			
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN			
; FILE REFERENCE: PB0177			
; CURRENT APPLICATION NUMBER: US/10/060,756A			
; CURRENT FILING DATE: 2002-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006667			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006664			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006669			
; PRIOR FILING DATE: 2001-01-30			
; PRIOR APPLICATION NUMBER: PCT/US01/006665			
; PRIOR FILING DATE: 2001-01-30			

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 215
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-215

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1648 GAAGCGACGACC 1660
|||||
DB 1 GAAGCGACGACG 13

RESULT 372

US-10-060-756A-736
; Sequence 736, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian

; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN

; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 736
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-736

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1684 GTCTCTCCAGCG 1696
|||||
DB 5 GTCTCTACAGCG 17

RESULT 373

US-10-060-756A-737
; Sequence 737, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:

; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 737
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-737

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1684 GTCTCTCCAGCG 1696
|||||
DB 4 GTCTCTACAGCG 16

RESULT 374

US-10-060-756A-738
; Sequence 738, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian

; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 738
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-738

Query Match 8.2%; Score 11.4; DB 1; Length 17;

Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1684 GTCTCTCCAGCG 1696
|||||
Db 3 GTCTCTACAGCG 15

RESULT 375

US-10-060-756A-739
; Sequence 739, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 739
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-739

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1684 GTCTCTCCAGCG 1696
|||||
Db 2 GTCTCTACAGCG 14

RESULT 376

US-10-060-756A-740
; Sequence 740, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 740
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-740

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1684 GTCTCTCCAGCG 1696
|||||
Db 1 GTCTCTACAGCG 13

RESULT 377

US-10-163-552-747
; Sequence 747, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 747
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-747

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1663 GTCACAGCTGGA 1675
||:||||:
Db 5 GCUCACUGCUGA 17

RESULT 378

US-10-163-552-748
; Sequence 748, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 748
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-748

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 76.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1663 GTCACAGCTGGAA 1675
||:|||||:|||||
Db 2 GCACACUGCUGGA 14

RESULT 379

US-10-339-782-249/c
; Sequence 249, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 249
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-249

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1637 GGCTTGTAGCAGA 1649
||:|||||:|||||
Db 15 GGTGTAGCAGA 3

RESULT 380

US-10-061-201-1296/c
; Sequence 1296, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 1296
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1296

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1664 CTCACAGCTGGAA 1676
||:|||||:|||||
Db 17 CACACAGCTGGAA 5

RESULT 381

US-10-061-201-1297/c
; Sequence 1297, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 1297
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1297

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1664 CTCACAGCTGGAA 1676
||:|||||:|||||
Db 16 CACACAGCTGGAA 4

RESULT 382

US-10-061-201-1298/c
; Sequence 1298, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 1298
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1298

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1298
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1298

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676
Db 15 CACACAGCTGGAA 3

RESULT 383
US-10-061-201-1299/c
; Sequence 1299, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0176
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1299
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1299

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676

Db 14 CACACAGCTGGAA 2

RESULT 384
US-10-061-201-1300/c
; Sequence 1300, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1300
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1300

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676
Db 13 CACACAGCTGGAA 1

RESULT 385
US-10-061-201-1758/c
; Sequence 1758, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1758
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-1758

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1753 TCCTAAAGGCCCA 1765
|||||
Db 17 TCCTAAAGTCCCA 5

RESULT 386

US-10-061-201-1759/c
Sequence 1759, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: PH0178
CURRENT APPLICATION NUMBER: US/10/061,201
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1759
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-1759

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1753 TCCTAAAGGCCCA 1765
|||||
Db 16 TCCTAAAGTCCCA 4

RESULT 387

US-10-084-839-3116/c
Sequence 3116, Application US/10084839
Publication No. US20030186238A1
GENERAL INFORMATION:
APPLICANT: Third Wave Technologies
APPLICANT: Allawi, Hatim
APPLICANT: Argue, Brad T.
APPLICANT: Bartholomay, Christian T.
APPLICANT: Chehak, LuAnne
APPLICANT: Curtis, Michelle L.
APPLICANT: Eis, Peggy S.
APPLICANT: Hall, Jeff G.
APPLICANT: Ip, Hon S.
APPLICANT: Ji, Lin
APPLICANT: Kaiser, Michael
APPLICANT: Kwiatkowski, Jr., Robert W.
APPLICANT: Lukowiak, Andrew A.
APPLICANT: Lyamichev, Victor
APPLICANT: Lymaicheva, Natalie E.
APPLICANT: Ma, WuPo
APPLICANT: Neri, Bruce P.
APPLICANT: Olson, Sarah M.
APPLICANT: Olson-Munoz, Marilyn C.
APPLICANT: Schaefer, James J.
APPLICANT: Skrzypczynski, Zbigniew
APPLICANT: Takova, Tsetska Y.
APPLICANT: Thompson, Lisa C.
APPLICANT: Vedvik, Kevin L.
TITLE OF INVENTION: RNA Detection Assays
FILE REFERENCE: FORS-06666
CURRENT APPLICATION NUMBER: US/10/084,839
CURRENT FILING DATE: 2002-02-26
NUMBER OF SEQ ID NOS: 4004
SOFTWARE: PatentIn version 3.1
SEQ ID NO 3116
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-084-839-3116

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1739 CCAACTCTCTCCT 1751
|||||
Db 15 CCAGCTCTCTCCT 3

RESULT 388

US-10-297-068-1053/c
Sequence 1053, Application US/10297068
Publication No. US20030228585A1
GENERAL INFORMATION:
APPLICANT: INOKO, Hidetoshi
APPLICANT: KAGIYA, Taeko
APPLICANT: ICHIHARA, Tatsuo
APPLICANT: Matsumura, Yoshiyuki
APPLICANT: MORIYA, Shogo
APPLICANT: NISHIDA, Michio
TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
FILE REFERENCE: 13140P1174
CURRENT APPLICATION NUMBER: US/10/297,068
CURRENT FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: JP 2000-164798
PRIOR FILING DATE: 2000-06-01
NUMBER OF SEQ ID NOS: 1298
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1053
LENGTH: 17
TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1053

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCAGCTG 1673
Db 17 AGGCTCAGCTG 5

RESULT 389

US-10-297-068-1160/c
; Sequence 1160, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140P1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 1160
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1160

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCAGCTG 1673
Db 17 AGGCTCAGCTG 5

RESULT 390

US-10-138-674-1376
; Sequence 1376, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1376

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCT 1737
Db 3 AUGGAUAUUGGU 15

RESULT 391

US-10-138-674-1377
; Sequence 1377, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1377

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1725 ATGGAGATTGGCT 1737
Db 1 AUGGAUAUUGGU 13

RESULT 392

US-10-138-674-4992/c
; Sequence 4992, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Favco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4992

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676
Db 17 CCCACAGCTGGAA 5

```
RESULT 393
US-10-138-674-8011/c
; Sequence 8011, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8011
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8011

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1732 TTGGCTCCCACT 1744
Db 14 TTGGTCCCACT 2
|||||

RESULT 394
US-10-138-674-8348
; Sequence 8348, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8348
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8348

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1725 ATGGAGATTGGCT 1737
Db 5 AUGGAUAUUGGCU 17
|||||

RESULT 395
US-10-287-949A-1376
; Sequence 1376, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1376
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1376

Query Match      3.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1725 ATGGAGATTGGCT 1737
Db 3 AUGGAUAUUGGCU 15
|||||

RESULT 396
US-10-287-949A-1377
; Sequence 1377, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1377

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1725 ATGGAGATTGGCT 1737
Db 1 AUGGAUAUUGGCU 13
|||||

RESULT 397
US-10-287-949A-4992/c
; Sequence 4992, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4992
```

```
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4992

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGAA 1676
Db 17 CCCACAGCTGGAA 5

RESULT 398
US-10-287-949A-8011/c
; Sequence 8011, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8011
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8011

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1732 TTGGTCCCAACT 1744
Db 14 TTGGTCCCAACT 2

RESULT 399
US-10-287-949A-8348
; Sequence 8348, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8348
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8348

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.9e+02;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1725 ATGGAGATTGGCT 1737
Db 5 AUGGAUAUUGGCU 17

RESULT 400
US-10-712-672-1303/c
; Sequence 1303, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1303
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1303

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1679 CTGGTGCTCTCCTC 1691
Db 17 CTGGTGCTCTCCTC 5

RESULT 401
US-10-712-672-1304/c
; Sequence 1304, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1304
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1304

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1679 CTGGTGCTCTCCTC 1691
```

Db 13 CTGGTCTGCTC 1

RESULT 402

```

US-10-712-672-2491
; Sequence 2491, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2491
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2491

```

Query Match	8.2%	Score 11.4;	DB 1;	Length 17;
Best Local Similarity	76.9%;	Pred. No. 2.9e+02;		
Matches 10;	Conservative	2;	Mismatches 1;	Indels 0;
				Gaps 0;

QY 1671 CTGGAACCTGGT 1683
db 5 CAGGAACCCUGU 17

RESULT 403

US-10-669-841-2165/C
; Sequence 2165, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Favco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26

```

; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2165
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
; US-10-669-841-2165

```

Query Match 8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12: Conservative 0; Mismatches 1; Indels

QY 1736 CTCCCAACTCCTC 1748
Db 13 CCCCCAACTCCTC 1

RESULT 404

```

US-10-669-841-3824/c
; Sequence 3824, Application US/10669841
; Publication No. US20040127446A1
;
; GENERAL INFORMATION:
;
; APPLICANT: Sina Therapeutics, Inc.
;
; APPLICANT: Lawrence, Blatt
;
; APPLICANT: Dennis, Macejak
;
; APPLICANT: James, MCSwigen
;
; APPLICANT: David, Morrissey
;
; APPLICANT: Pamela, Pavco
;
; APPLICANT: Patricia, Lee
;
; APPLICANT: Kenneth, Draper
;
; APPLICANT: Elisabeth, Roberts
;
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIA
;
; TITLE OF INVENTION: VIRUS REPLICATION
;
; FILE REFERENCE: 400/042US (MHB02-249-E)
;
; CURRENT APPLICATION NUMBER: US/10/669,841
;
; CURRENT FILING DATE: 2003-09-23
;
; PRIOR APPLICATION NUMBER: PCT/US02/09187
;
; PRIOR FILING DATE: 2002-03-26
;
; PRIOR APPLICATION NUMBER: US 60/296,876
;
; PRIOR FILING DATE: 2001-06-08
;
; PRIOR APPLICATION NUMBER: US 60/335,059
;
; PRIOR FILING DATE: 2001-10-24
;
; PRIOR APPLICATION NUMBER: US 60/337,055
;
; PRIOR FILING DATE: 2001-12-05
;
; PRIOR APPLICATION NUMBER: US 60/358,580
;
; PRIOR FILING DATE: 2002-02-20
;
; PRIOR APPLICATION NUMBER: US 60/363,124
;
; PRIOR FILING DATE: 2002-03-11
;
; PRIOR APPLICATION NUMBER: US 09/817,879
;
; PRIOR FILING DATE: 2001-03-26
;
; PRIOR APPLICATION NUMBER: US 09/740,332
;
; PRIOR FILING DATE: 2000-12-18
;
; PRIOR APPLICATION NUMBER: US 09/611,931
;
; PRIOR FILING DATE: 2000-07-07
;
; PRIOR APPLICATION NUMBER: US 09/504,321
;
; PRIOR FILING DATE: 2000-02-15
;
; Remaining Prior Application data removed
;
; NUMBER OF SEQ ID NOS: 16207
;
; SOFTWARE: PatentIn version 3.0
;
; SEQ ID NO 3824
;
; LENGTH: 17
;
; TYPE: RNA
;
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Description of Artificial Sequence
;
; FEATURE:

```



```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7827
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7827

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTG 1673
Db 5 AGGCTCACAGCTG 17

RESULT 408
US-10-723-361-7828
; Sequence 7828, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTG 1673
Db 5 AGGCTCACAGCTG 17

RESULT 409
US-10-043-875-261/c
; Sequence 261, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 261
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-261

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 TCCAGCGTGGTGGAG 1705
Db 16 TCCATCCTTGTGGAG 1

RESULT 410
US-10-091-281-319/c
; Sequence 319, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7828
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7828

Query Match      8.2%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTG 1673
Db 4 AGGCTCACAGCTG 16

RESULT 409
US-10-043-875-261/c
; Sequence 261, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 261
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-261

Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 TCCAGCGTGGTGGAG 1705
Db 16 TCCATCCTTGTGGAG 1

RESULT 410
US-10-091-281-319/c
; Sequence 319, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
```

```

; FILE REFERENCE: 13597.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 319
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative MYOD:E47.02 motif
US-10-091-281-319

```

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAACC 1678
|||
Db 16 GCTCACACCTGTAATC 1

```

RESULT 411
US-10-138-674-5657/c
; Sequence 5657, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Regulation of Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5657
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5657

```

```
Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1666 CACAGCTGGAACCTG 1681
Db 16 CACAGCAGGACCCCG 1

RESULT 412
 US-10-138-674-5658/c
 ; Sequence 5658, Application US/10138674
 ; Publication No. US2004007565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBHB00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 5658
 ; LENGTH: 16

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5658

```

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCACAGCTGGAACC 1678
Db 16 GCGCACAGCAGGACCC 1

RESULT 413
US-10-138-674-5954/c
; Sequence 5954, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MH000-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5954

```
Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1661 AGGCTCACAGCTGGAA 1676
Db 16 AGGGTCAGAGCTGGGA 1

RESULT 414
US-10-287-949A-5657/c
; Sequence 5657, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5657
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5657

```
Query Match      8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 1666 CACAGCTGGAACCCCTG 1681

Db 16 CACAGAGGACCCGG 1
||||| ||| ||| |||

RESULT 415

US-10-287-949A-5658/c
; Sequence 5658, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5658
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5658

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1663 GCTCAGAGCTGGAC 1678
||| ||| ||| ||| |||

Db 16 GCGCAGCAGGAGCC 1

RESULT 416

US-10-287-949A-5954/c
; Sequence 5954, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5954
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5954

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1661 AGGCTCAGAGCTGGAA 1676
||| ||| ||| ||| |||

Db 16 AGGCTCAGAGCTGGGA 1

RESULT 417

US-10-712-672-1597
; Sequence 1597, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MEHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1597
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1597

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 2.7e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1753 TCCTAAGGCCCACTG 1768
:|:|:|:|:|:|:|:|:|

Db 1 UCCUCAAGACGACUG 16

RESULT 418

US-10-376-770-213/c
; Sequence 213, Application US/10376770
; Publication No. US20040105102A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
; FILE REFERENCE: 54331200320
; CURRENT APPLICATION NUMBER: US/10/376,770
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 262
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 5, 6
; OTHER INFORMATION: These nucleotides may be absent
US-10-376-770-213

Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1672 TGGAAACCTCGTGCT 1687
| | | | | | | | | | | | | |

Db 16 TAGAACCCTGCAGTCT 1

RESULT 419

US-10-661-165-213/c
; Sequence 213, Application US/10661165
; Publication No. US20040137470A1
; GENERAL INFORMATION:


```
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
; FILE REFERENCE: 543312000420
; CURRENT APPLICATION NUMBER: US/10/661,165
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: PCT/US03/06198
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: PCT/US03/27308
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/376,770
; PRIOR FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 628
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)...(6)
; OTHER INFORMATION: These nucleotides may be absent
US-10-661-165-213
```

```
Query Match 8.1%; Score 11.2; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1672 TCGAACCCCTGGTGCT 1687
Db 16 TAGAACCCCTGCAGTCT 1
```

```
RESULT 420
US-10-163-552-471/c
; Sequence 471, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: HER2
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-471
```

```
Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1636 GGGCTTGTAGCAGAG 1651
Db 16 GGCATGTAGGAGAG 1
```

```
RESULT 421
US-09-866-108-529
; Sequence 529, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 529
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-529
```

```
Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1646 CAGAAGCAAGCACCA 1661
Db 1 CAGATGACAAGCATCA 16
```

```
RESULT 422
US-09-866-108-1263/c
; Sequence 1263, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1263

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1730 GATTGGCTCCCACTC 1745
||| | | | | | | | | | | | | | | |
Db 17 GATCGTCCCCCACTC 2

RESULT 423
US-09-866-108-1265/c
; Sequence 1265, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US/09/866,108
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1265
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1265

Query Match 9.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1729 AGATTGGCTCCCACT 1744
||| | | | | | | | | | | | | | | |
Db 16 AGATCGTCCCCCACT 1

RESULT 424
US-09-866-108-1285/c
; Sequence 1285, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1285
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1678 CCTGGTGCTCTCTCCA 1693
      ||||| ||||| |||||
Db      17  CCTGCTTTCTCCCCCA 2
```

RESULT 425

```
US-09-866-108-1286/c
; Sequence 1286, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
```

```
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1286
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1678 CCTGGTGCTCTCTCCA 1693
      ||||| ||||| |||||
Db      16  CCTGCTTTCTCCCCCA 1
```

RESULT 426

```
US-09-866-108-7832
; Sequence 7832, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 7832
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7832
```

Query Match

8.1%; Score 11.2; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 GGCTCACAGCTGAAC 1677
| | | | | | | | | |
Db 1 GCCTCACAGCTGAAGC 16

RESULT 427

US-09-866-108-7984
; Sequence 7984, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7984
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7984

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1646 CAGAAGCAGCAGCA 1661
| | | | | | | | | |
Db 2 CAGCAGGAAACACCA 17

RESULT 428

US-09-866-108-7985

Sequence 7985, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7985
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7985

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1646 CAGAAGCAGCAGCA 1661
| | | | | | | | | |
Db 1 CAGCAGGAAACACCA 16

RESULT 429

US-09-866-108-9657/c
; Sequence 9657, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9657
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9657

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e-02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1673 GGAAACCCCTGGTGCTC 1688
Db 17 GGACCCCTGGCTCTC 2

RESULT 430
US-09-866-108-9659/c
; Sequence 9659, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2000-09-27

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9659
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9659

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e-02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGACCCCTGGTGCTC 1687
Db 16 TGGACCCCTGGCTCT 1

RESULT 431
US-09-866-108-10208
; Sequence 10208, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10208
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10208

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGGCCCA 1765
||||| |||||
Db 2 CTATCCGGAAGCCCA 17

RESULT 432

US-09-866-108-10209
; Sequence 10209, Application US/09866108
; Patent No. US20020048900A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10209
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10209

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGGCCCA 1765
||||| |||||
Db 1 CTATCCGGAAGCCCA 16

RESULT 433

US-09-864-785-202
; Sequence 202, Application US/09864785
; Patent No. US20020177568A:
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 202
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-202

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1737 TCCCAACTCCTCCCTA 1752
:||| |||||
Db 2 UCCGACCCCUCCUA 17

RESULT 434

US-09-864-785-203
; Sequence 203, Application US/09864785
; Patent No. US20020177568A:
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 203
; LENGTH: 17
; TYPE: RNA

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-203

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1737 TCCCAACTCTCCTCCTA 1752
Db      1 UCCGGACCCCUCCUA 16

RESULT 435
US-09-864-785-2920/c
; Sequence 2920, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2920

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1740 CAACTCTCCTCCTATCC 1755
Db      17 CAGTCCCCCCTTCC 2

RESULT 436
US-09-864-785-2923/c
; Sequence 2923, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2923

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCAACTCTCCTCCTAT 1753
Db      16 CCCAGCTCCCCCTTT 1

RESULT 437
US-09-825-805-579
; Sequence 579, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-579

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGTGTCTCCTCC 1692
Db      1 CGCUGGGGCGCUCUCC 16

RESULT 438
US-09-961-077-687/c
; Sequence 687, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR MODULATION OF GENE EXPRESSION IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-203

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1737 TCCCAACTCTCCTCCTA 1752
Db      1 UCCGGACCCCUCCUA 16

RESULT 435
US-09-864-785-2920/c
; Sequence 2920, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2920
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2920

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1740 CAACTCTCCTCCTATCC 1755
Db      17 CAGTCCCCCCTTCC 2

RESULT 436
US-09-864-785-2923/c
; Sequence 2923, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2923
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2923

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCAACTCTCCTCCTAT 1753
Db      16 CCCAGCTCCCCCTTT 1

RESULT 437
US-09-825-805-579
; Sequence 579, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-579

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGTGTCTCCTCC 1692
Db      1 CGCUGGGGCGCUCUCC 16

RESULT 438
US-09-961-077-687/c
; Sequence 687, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR MODULATION OF GENE EXPRESSION IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 687:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 687:
;
US-09-961-077-687
;
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 8.1%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1733 TGGCTCCCACTCTC 1748
      ||||| ||||| |||
Db 17 TGGCTGCCAACACTTC 2

RESULT 439
US-09-818-875-1703/c
; Sequence 1703, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQUENCE DESCRIPTION: SEQ ID NO: 687:
;
US-09-961-077-687
```

```
; SEQ ID NO 1703
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1703
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 8.1%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCCGTGTCTCC 1689
      ||||| ||||| |||
Db 16 GAACCCGTGTCTGC 1

RESULT 440
US-09-818-875-1704
; Sequence 1704, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1704
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 8.1%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCCGTGTCTCC 1689
      ||||| ||||| |||
Db 2 GAACCCGTGTCTGC 17

RESULT 441
US-09-780-533A-575
; Sequence 575, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 575
; LENGTH: 17
```



```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-575

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1704 AGTTGGTGTAGAGTA 1719
DB 2 AGUGGUUCAGAGUA 17

RESULT 442
US-09-780-533A-1446
; Sequence 1446, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1446

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1705 GTTGGTGTAGAGTAC 1720
DB 1 GUUGGUUCAGAGUAC 16

RESULT 443
US-09-877-478-399
; Sequence 399, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 571
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-571

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1741 AACTCTCTCCTATCCT 1756
DB 2 AACUCCUUCUUUCCU 17

RESULT 445
US-09-877-478-572
; Sequence 572, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-572
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1741 AACTCCTCCCTATCCT 1756
Db      1 AACUCCUUCUUUCU 16
|||||:|:|:|:
```

```
RESULT 446
US-09-877-478-1746
; Sequence 1746, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 1746
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1746
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1698 GGTGGAAGTTGGGTTA 1713
Db      2 GGAGGAGGUUAGGUUA 17
|||||:|:|:|:
```

```
RESULT 447
US-09-877-478-2358/c
; Sequence 2358, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2358
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2358

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1741 AACTCCTCCCTATCCT 1756
Db      17 AACTCCTCCCACTCAT 2
|||||:|:|:|:
```

```
RESULT 448
US-09-877-478-2363
; Sequence 2363, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
```

```
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2363
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2363
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1702 GAAGTTGGTTAGGAG 1717
|||:|||||
Db 2 GGAGUUGGGGAGGAG 17
```

```
RESULT 449
US-09-877-478-2364
; Sequence 2364, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2364
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2364
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1702 GAAGTTGGTTAGGAG 1717
|||:|||||
Db 1 GGAGUUGGGGAGGAG 16
```

```
RESULT 450
US-09-848-754A-300
; Sequence 300, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 300
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-300
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1731 ATTGGCTCCCACTCC 1746
|||:|||||
Db 2 AUUGGCUCCAGUACC 17
```

```
RESULT 451
US-09-848-754A-371/c
; Sequence 371, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBHB00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 371
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-371
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1694 GCGTGTGGAAGTTGG 1709
|||:|||||
Db 17 GCACGGTAGAGTTGG 2
```

```
RESULT 452
US-09-848-754A-1431
; Sequence 1431, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
```

; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1431

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1732 TTGGTCCCAACCTCT 1747
Db 1 UUGGCCCCAGUACCU 16

RESULT 453

US-09-848-754A-1552/c
; Sequence 1552, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1552
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1552

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1694 GCCTGTGGAGTTGG 1709
Db 16 GCACGGTAGAGTTGG 1

RESULT 454

US-09-848-754A-2715/c
; Sequence 2715, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2715
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2715

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCCACT 1744

Db 16 AAATGGGCTCCTACT 1

RESULT 455

US-09-848-754A-3660/c
; Sequence 3660, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3660

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1659 CCAGGCTCACAGCTGG 1674
Db 16 CTTGCTCACAGTTGG 1

RESULT 456

US-09-930-423-1237/c
; Sequence 1237, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1237
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1237

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1650 AGCCAGCCACCGCT 1665
Db 16 AGCCAGCCACCGAT 1

RESULT 457

US-09-930-423-1604/c
; Sequence 1604, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15

```
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1604

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCAGCT 1665
DB 17 AGGCCAGCCCCAGGAT 2

RESULT 458
US-09-780-164-135/c
; Sequence 135, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-135

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 AGAAGCGCAAGCACCAG 1662
DB 17 AGAAGCGCAAGATCAG 2

RESULT 459
US-09-780-164-136/c
; Sequence 136, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 136
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-136

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 AGAAGCGCAAGCACCAG 1662
DB 17 AGAAGCGCAAGATCAG 2

RESULT 460
US-09-780-164-511/c
; Sequence 511, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 511
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-511

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1706 TTGGGTTAGGAGTACG 1721
DB 17 TTGGGTTCTGGAGCAG 2

RESULT 461
US-09-780-164-512/c
; Sequence 512, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 512
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-512

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1706 TTGGGTTAGGAGTACG 1721
DB 16 TTGGGTTCTGGAGCAG 1

RESULT 462
US-09-827-395A-65
; Sequence 65, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-827-395A-65

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGGTG 1701
Db 1 CUCCUCCUCCGAGGUG 16

RESULT 463
US-09-827-395A-367
; Sequence 367, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 367
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-827-395A-367

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1686 CTCCTCCAGCGTGGTG 1701
Db 2 CUCCUCCUCCGAGGUG 17

RESULT 464
US-09-740-332-559
; Sequence 559, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-740-332-559
```

```
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-559

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1660 CAGGCTCACAGCTGGA 1675
Db 2 CAGGCUCACGCGCGCA 17

RESULT 465
US-09-740-332-819/C
; Sequence 819, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-819

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTCGGTGTCCTCC 1692
Db 17 CCGCGGTGTCCTCCCC 2

RESULT 466
US-09-740-332-859
; Sequence 859, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; US-09-740-332-859
```

```
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-859

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCACAG 1670
Db 2 AUCACCAGCCUACGG 17

RESULT 467
US-09-740-332-3696/c
; Sequence 3696, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3696

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1660 CAGGCTCACAGCTGGA 1675
Db 17 CAGGCTCACGCCGCCA 2

RESULT 470
US-09-792-818-119/c
; Sequence 119, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 119
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-119

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1721 GGAGATGGAGATTGGC 1736
Db 17 GGAGATGGAAATTGTC 2

RESULT 471
US-09-792-818-120/c
; Sequence 120, Application US/09792818
; Publication No. US20030134806A1
```

```
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-859

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCACAG 1670
Db 2 AUCACCAGCCUACGG 17

RESULT 467
US-09-740-332-3696/c
; Sequence 3696, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3696

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCACAG 1670
Db 17 ATCACCAGCCTCACGG 2

RESULT 468
US-09-740-332-3736
; Sequence 3736, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3736
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3736

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1677 CCTGTGTCTCTCTCC 1692
```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 120
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-120

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTGGC 1736
|||||
Db 16 GGAGATGGAATTGTC 1

RESULT 472

US-09-792-818-409
; Sequence 409, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 409
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-409

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1632 GATGGGCTTGATGCA 1647
||:||||:|
Db 2 GAUGGCAUUGUGCA 17

RESULT 473

US-09-792-818-603/c
; Sequence 603, Application US/09792818
; Publication No. US20030134806A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan

; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Insert
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MHB00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-603

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1753 TCCTAAAGGCCACTG 1768
|||||
Db 17 TCCACAGCCCACTG 2

RESULT 474

US-09-745-237A-1237/c
; Sequence 1237, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1237
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1237

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1650 AGGCACGACCCAGGCT 1665
|||||
Db 16 AGGCCAGCCCAAGAT 1

RESULT 475

US-09-745-237A-1604/c
; Sequence 1604, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1604

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;

Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1650 AGCAAGCAGCAGGCT 1665
|||||
Db 17 AGGCCAGCCCGAGT 2

RESULT 476

US-09-817-879-559
; Sequence 559, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-559

Query Match 8.1%; Score 11.2; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1660 CAGGCTCAGCTGGA 1675
|||||
Db 2 CAGGCUCACCCCGCA 17

RESULT 477

US-09-817-879-819/c
; Sequence 819, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 819
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-819

Query Match 8.1%; Score 11.2; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1677 CCTGTGTCTCTCTCC 1692
|||
Db 17 CCGCGGTGTCTCCCC 2

RESULT 478

US-09-817-879-859

; Sequence 859, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 859
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-859

Query Match 8.1%; Score 11.2; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCAG 1670
|||||
Db 2 AUCACCAGCCUCACGG 17

RESULT 479

US-09-817-879-3696/c
; Sequence 3696, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3696
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3696

Query Match 8.1%; Score 11.2; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1655 AGCACCAGGCTCAG 1670
|||||
Db 17 ATCACCAGCCTCAGG 2

RESULT 480

US-09-817-879-3736
; Sequence 3736, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3736
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3736

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGTGTCCTCTCC 1692
|||:|:|:|:|
Db 2 CCGCGGUGUCUCCCC 17

RESULT 481
US-09-817-879-3996/c
; Sequence 3996, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MEHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3996
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3996

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1660 CAGGCTCAGCTGGA 1675
|||:|:|:|:|
Db 17 CAGGCTCAGCGGCA 2

RESULT 482
US-09-991-552-7
; Sequence 7, Application US/09991552
; Publication No. US2003023230A1
; GENERAL INFORMATION:
; APPLICANT: Quirk, S.
; TITLE OF INVENTION: Detection and identification of enteric bacteria
; FILE REFERENCE: 1443.013US1
; CURRENT APPLICATION NUMBER: US/09/991,552
; CURRENT FILING DATE: 2001-11-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A primer.
US-09-991-552-7

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1689 CTCAGCGTGGTGGAA 1704
|||:|:|:|:|
Db 2 CTGAGCGTGGCGCA 17

RESULT 483
US-10-453-792-42/c
; Sequence 42, Application US/10453792
; Publication No. US20040029110A1
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (BPO)
; CURRENT APPLICATION DATA: US/10/453,792
; APPLICATION NUMBER: US/10/453,792
; FILING DATE: 04-Jun-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-10-453-792-42

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1747 TCCATATCCTAAAGGC 1762
|||:|:|:|:|
Db 17 TCCATGTCCTAAAGCC 2

RESULT 484
US-10-342-902-399
; Sequence 399, Application US/10342902

```

; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 399
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-10-342-902-399

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1680 TGGTGTCCTCCGACG 1695
Db 1 UGGUGUGUACCGACG 16

RESULT 485
US-10-342-902-571
; Sequence 571, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 571
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-10-342-902-571

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1680 TGGTGTCCTCCGACG 1695
Db 1 UGGUGUGUACCGACG 16

RESULT 485
US-10-342-902-571
; Sequence 571, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 571

```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-10-342-902-571

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1741 AACCTCTCCCTATCCT 1756
Db 2 AACUCCUUCUUUCCU 17

RESULT 486
US-10-342-902-572
; Sequence 572, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-10-342-902-572

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1741 AACCTCTCCCTATCCT 1756
Db 1 AACUCCUUCUUUCCU 16

RESULT 487
US-10-342-902-1746
; Sequence 1746, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15

```

```

; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 1746
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1746

```

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy	1698	GGTGGAA	GTTGGG	TTA	1713
Db	2	GGAGGAG	GUUAGG	UUA	17

RESULT 488

US-10-342-902-2358/c
; Sequence 2358, Application US/10342902
; Publication No. US20040054156A1

; GENERAL INFORMATION:

```

/ / APPLICANT: Sirna Therapeutics, Inc.
/ / APPLICANT: Draper, Kenneth
/ / APPLICANT: Blatt, Larry
/ / APPLICANT: McSwiggen, Jim
/ / APPLICANT: Morrissey, Dave
/ / TITLE OF INVENTION: Method and Reagent for
/ / FILE REFERENCE: 400/075 (MBH00-845-I)
/ / CURRENT APPLICATION NUMBER: US 10/342,901
/ / CURRENT FILING DATE: 2003-01-15
/ / PRIOR APPLICATION NUMBER: US 09/877,478
/ / PRIOR FILING DATE: 2001-06-08
/ / PRIOR APPLICATION NUMBER: US 09/531,025
/ / PRIOR FILING DATE: 2000-03-20
/ / PRIOR APPLICATION NUMBER: US 09/636,385
/ / PRIOR FILING DATE: 2000-08-09
/ / PRIOR APPLICATION NUMBER: US 09/696,347
/ / PRIOR FILING DATE: 2000-10-24
/ / PRIOR APPLICATION NUMBER: US 08/193,627
/ / PRIOR FILING DATE: 1994-02-07
/ / PRIOR APPLICATION NUMBER: US 07/882,712
/ / PRIOR FILING DATE: 1992-05-14
/ / PRIOR APPLICATION NUMBER: US 09/436,430
/ / PRIOR FILING DATE: 1999-11-08
/ / NUMBER OF SEQ ID NOS: 6592
/ / SOFTWARE: PatentIn version 3.2
/ / SEQ ID NO 2358
/ / LENGTH: 17
/ / TYPE: RNA
/ / ORGANISM: Hepatitis B virus
US-10-342-902-2358

```

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels

QY 1741 AACTCCTCCCTATCCT 1756

Db 17 AACTCCTCCCACTCAT 2

RESULT 489

```

US-10-342-902-2363
; Sequence 2363, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2363
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2363

```

Query Match	8.1%	Score 11.2;	DB 1;	Length 17;
Best Local Similarity	68.8%	Pred. No. 3.1e+03;		
Matches 11; Conservative	3	2; Mismatches 3	Indels 0;	Gaps 0;

QY 1702 GAAGTTGGTTAGGAG 1717

D_b 2 GGAGTTGGGGGAG 17

RESULT 490

US-10-342-902-2364
 ; Sequence 2364, Application US/10342902
 ; Publication No. US20040054156A1
 ; GENERAL INFORMATION:
 ; APPLICANT: sirna Therapeutics, Inc.
 ; APPLICANT: Draper, Kenneth
 ; APPLICANT: Blatt, Larry
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Morrissey, Dave
 ; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
 ; FILE REFERENCE: 400/075 (MBHQ00-845-I)
 ; CURRENT APPLICATION NUMBER: US/10/342,902
 ; CURRENT FILING DATE: 2003-01-15
 ; PRIOR APPLICATION NUMBER: US 09/877,478
 ; PRIOR FILING DATE: 2001-05-08
 ; PRIOR APPLICATION NUMBER: US 09/531,025
 ; PRIOR FILING DATE: 2000-03-20
 ; PRIOR APPLICATION NUMBER: US 09/636,385
 ; PRIOR FILING DATE: 2000-03-09
 ; PRIOR APPLICATION NUMBER: US 09/696,347
 ; PRIOR FILING DATE: 2000-10-24
 ; PRIOR APPLICATION NUMBER: US 08/193,627
 ; PRIOR FILING DATE: 1994-02-07
 ; PRIOR APPLICATION NUMBER: US 07/882,712

```
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2364
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2364

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3.1e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1702 GAAGTTGGGTTAGGAG 1717
Db 1 GGAGUUGGGGAGGAG 16

RESULT 491
US-10-686-736-10/c
; Sequence 10, Application US/10686736
; Publication No. US20040063181A1
; GENERAL INFORMATION:
; APPLICANT: Dunican, Rita
; APPLICANT: McCormack, Ashling
; APPLICANT: Stapleton, Cliona
; APPLICANT: Burke, Kevin
; APPLICANT: Mockel, Bettina
; TITLE OF INVENTION: Process for the preparation of L-amino acids using
; FILE REFERENCE: 990229 BT-US-B
; CURRENT APPLICATION NUMBER: US/10/686,736
; PRIOR FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: US/10/078,167A
; PRIOR FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: Internal
; OTHER INFORMATION: primer 2
US-10-686-736-10

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1645 GCAGAAGGCAAGCACC 1660
Db 16 GCAGCAGGCATGCAGC 1

RESULT 492
US-10-688-108-7
; Sequence 7, Application US/10688108
; Publication No. US20040063139A1
; GENERAL INFORMATION:
; APPLICANT: Quirk, S.
; TITLE OF INVENTION: Detection and identification of enteric bacteria
; FILE REFERENCE: 1443.013U51
; CURRENT APPLICATION NUMBER: US/10/688,108
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: US/09/991,552
; PRIOR FILING DATE: 2001-11-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A primer.
US-10-688-108-7

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1689 CTCGAGCGTGGTGGAA 1704
Db 2 CTGACGCGTGGCGGCA 17

RESULT 493
US-09-918-715-331
; Sequence 331, Application US/09918715
; Publication No. US20030017157A1
; GENERAL INFORMATION:
; APPLICANT: Brad St. Croix
; APPLICANT: Bert Vogelstein
; APPLICANT: Kenneth Kinzler
; TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
; FILE REFERENCE: 1107.00134
; CURRENT APPLICATION NUMBER: US/09/918,715
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/222,599
; PRIOR FILING DATE: 2000-08-02
; PRIOR APPLICATION NUMBER: 60/224,360
; PRIOR FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/282,850
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 331
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-918-715-331

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1741 AACTCCTCCCTATCCT 1756
Db 2 ACCACCTCCTTTCCT 17

RESULT 494
US-09-927-046-499
; Sequence 499, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 245/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 499
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-09-927-046-499

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCTAA 1758
| : | : | : | : | :
Db 1 CUGCUCCUUGUCCUAA 16

RESULT 495

US-09-927-046-1174
; Sequence 1174, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1174
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-927-046-1174

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCTAA 1758
 |:|:|:|:|:|:|:
Db 2 CUGCUCUUGUCCUAA 17

RESULT 496

```

US-10-430-882-65
; Sequence 65, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggan
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Hasberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Q
; FILE REFERENCE: MBHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 65
; LENGTH: 17

```

; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-65

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
```

QY 1686 CTCCTCCAGCGTGGTG 1701
|:|:|:|:|:|:|:
Db 1 CUCCUCCUCCGAGGUG 16

RESULT 497

```

US-10-430-882-367
; Sequence 367, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowhira
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent fo
; FILE REFERENCE: MEHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 367
; LENGTH: 17.
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-367

```

Query Match	8.1%	Score 11.2;	DB 1;	Length 17;
Best Local Similarity	62.5%	Pred. No. 3.1e+02;		
Matches 10: Conservative	3;	Mismatches 3;	Indels	

Qy 1686 CTCCTCCAGCGTGTG 1701
Db 2 CUCCUCCUCCGAGGUG 17

RESULT 498

```

US-10-060-830-137/c
; Sequence 137, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; PRIORITY FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30

```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 137
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-137
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1753 TCCTAAAGGCCCACTG 1768
      ||||| |||||
Db 17 TCCTCATGGTCCACTG 2
```

```
RESULT 499
US-10-060-830-138/c
; Sequence 138, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 138
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-138
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1753 TCCTAAAGGCCCACTG 1768
      ||||| |||||
Db 16 TCCTCATGGTCCACTG 1
```

```
RESULT 500
US-10-060-830-649/c
; Sequence 649, Application US/10060830
; Publication No. US20030032154A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 649
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-649
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGGGT 1711
      ||||| |||||
Db 17 GTGGGGGAGTTGGTT 2
```

```
RESULT 501
US-10-060-830-650/c
; Sequence 650, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 650
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
US-10-060-830-650
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 CTGGTGAAGTTGGT 1711
      ||||| ||||| |||||
Db 16 GTGGGGGAGTTGGT 1

RESULT 502
US-10-060-756A-269
; Sequence 269, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 269
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-269
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1671 CTGGACCCCTGGGTC 1686
      ||||| ||||| |||||
Db 1 CAGGACCCCTGGGTC 16

RESULT 504
US-10-060-756A-751
; Sequence 751, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 269
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-269
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1671 CTGGACCCCTGGGTC 1686
      ||||| ||||| |||||
Db 2 CAGGACCCCTGGGTC 17

RESULT 503
US-10-060-756A-270
; Sequence 270, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 269
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-270
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1662 GGCTCAGCTGGAC 1677
      ||||| ||||| |||||
Db 2 GACTCAGCTGGAC 17

RESULT 505
US-10-060-998-716
; Sequence 716, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
```



```
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 716
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-716
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1679 CTGGTGTCTCTCCAG 1694
      ||| ||||| |||
Db 2 CTGATGTCGTCTACAG 17
```

```
RESULT 506
US-10-060-998-717
; Sequence 717, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 717
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-717
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1679 CTGGTGTCTCTCCAG 1694
      ||| ||||| |||
Db 1 CTGATGTCGTCTACAG 16
```

```
RESULT 507
US-10-060-998-1329/c
; Sequence 1329, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
```

```
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1329
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1713 AGGAGTACGAGATGG 1728
      ||||| ||||| ||
Db 17 AGGAGGAAGGAGAGGG 2
```

```
RESULT 508
US-10-060-998-1330/c
; Sequence 1330, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1330
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1330
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1713 AGGAGTACGAGATGG 1728
      ||||| ||||| ||
Db 16 AGGAGGAAGGAGAGGG 1
```

```
RESULT 509
US-10-163-552-46
; Sequence 46, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 46
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-46
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCCTGGTCTCTCTCC 1692
Db 1 CGCUGGGGCUCCUCC 16

RESULT 510
US-10-163-552-560
; Sequence 560, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 560
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-560

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1668 CACCTGGAACCTGGT 1693
Db 2 CAUCUGGAUCCUGAU 17

RESULT 511
US-10-163-552-903
; Sequence 903, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 903
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-903

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1675 AACCTGGTCTCTCT 1690
Db 2 AGCCCGAUGUGUCCU 17

RESULT 512
US-10-156-306-6840/c
; Sequence 6840, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6840
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6840

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1679 CTGGTCTCTCTCCAG 1694
Db 16 CTGTATCTCTCCAG 1

RESULT 513
US-10-078-167-10/c
; Sequence 10, Application US/10078167
; Publication No. US20030119154A1
; GENERAL INFORMATION:
; APPLICANT: Dunican, Rita
; APPLICANT: McCormack, Ashling
; APPLICANT: Stapleton, Cliona
; APPLICANT: Burke, Kevin
; APPLICANT: Mockel, Bettina
; TITLE OF INVENTION: Process for the preparation of L-amino acids using
; FILE REFERENCE: 990229 BT-US-B
; CURRENT FILING DATE: 2002-02-20
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: Internal
; OTHER INFORMATION: primer 2
US-10-078-167-10

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1645 GCAGAGGCAAGCAC 1660
Db 16 GCAGCAGGCATGCAGC 1

RESULT 514
US-10-139-604-25
; Sequence 25, Application US/10139604
; Publication No. US20030124551A1
; GENERAL INFORMATION:
; APPLICANT: METRIS THERAPEUTICS LIMITED
; APPLICANT: LLENICEK, Mirna
; APPLICANT: PAPP, Helen
; TITLE OF INVENTION: AGENTS IMPLICATED IN ENDOMETRIOSIS
; FILE REFERENCE: 1396-1-006
; CURRENT FILING DATE: 2002-08-23
; PRIOR APPLICATION NUMBER: GB 9926081.2
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926074.7
```

```
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926079.6
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926076.2
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: SeqWin99, version 1.02
; SEQ ID NO 25
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 3' RT-PCR primer for Stromelysin
US-10-139-604-25
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1647 AGAAGGCAAGACCCAG 1662
      ||||| ||||| |||||
Db 2 AGAAGGCATGGGCCAG 17
```

```
RESULT 515
US-10-021-425-46
; Sequence 46, Application US/10021425
; Publication No. US20030148420A1
; GENERAL INFORMATION:
; APPLICANT: Suzanne L. Bolten
; APPLICANT: Alan M. Easton
; APPLICANT: Leslie C. Engel
; APPLICANT: Dean M. Messing
; APPLICANT: John S. Ng
; APPLICANT: Beverly A. Reitz
; APPLICANT: Scott A. Vaccaro
; APPLICANT: Mark C. Walker
; APPLICANT: Ping T. Wang
; APPLICANT: Robin A. Weinberg
; TITLE OF INVENTION: Aspergillus ochraceus 11 alpha
; TITLE OF INVENTION: hydroxylase and oxidoreductase
; FILE REFERENCE: S03196-00-US
; CURRENT APPLICATION NUMBER: US/10/021,425
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: US98 60/244,300
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Aspergillus ochraceus Primer 45624-for1
US-10-021-425-46
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1722 GAGATGGAGATTGGCT 1737
      ||||| ||||| |||||
Db 1 GAGATCAAGATTGCT 16
```

```
RESULT 516
US-10-238-700-575/c
; Sequence 575, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
```

```
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 575
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-575
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1633 ATGGGGCTTGAGCAG 1648
      ||||| ||||| |||||
Db 17 ATGGGCATGTGGAG 2
```

```
RESULT 517
US-10-238-700-1089/c
; Sequence 1089, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1089
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1728 GAGATGGCTCCCAAC 1743
      ||||| ||||| |||||
Db 17 GAGATGGCGCCTCAAC 2
```

```
RESULT 518
US-10-238-700-3257/c
; Sequence 3257, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3257
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3257

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1736 CTCGCCAACTCCTCCCT 1751
      |||||
Db 16 CTCCCAACCTCCCCCT 1

RESULT 519
US-10-339-782-25
; Sequence 25, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-25

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1663 GCTCAGCTGGGAGCC 1678
      |||||
Db 1 GATCAGCAGGAGCC 16

RESULT 520
US-10-339-782-69
; Sequence 69, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 69
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-69

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1752 ATCCTAAGGCCCACT 1767
      |||||
Db 2 ATCCTAATGAACCACT 17

RESULT 521
US-10-339-782-158
; Sequence 158, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 158
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-158

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1735 GTCGCCAACTCCTCC 1750
      |||||
Db 1 GATCCAGCACCTCC 16

RESULT 522
US-10-339-782-297
; Sequence 297, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Goodman, Laurie J
; APPLICANT: Bowen, Benjamin A
; TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
; FILE REFERENCE: 37-000110US
; CURRENT APPLICATION NUMBER: US/10/339,782
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 495
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 297
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-782-297

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1655 AGCACGAGCTCAG 1670
      |||||
Db 2 ATCACAGGCTTACAG 17

RESULT 523
US-10-061-201-785
; Sequence 785, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 785
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-785

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCTCGTGAAGT 1706
||||| |||||
Db 2 CCAGCTCGTGAAGT 17

RESULT 524
US-10-061-201-786
; Sequence 786, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 786
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-786

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCTCGTGAAGT 1706

Db 1 CCAGCTCGTGAAGT 16
||||| |||||

RESULT 525
US-10-061-201-1605
; Sequence 1605, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1605
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1605

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1671 CTGGAACCCCTGGTGC 1686
||||| |||||
Db 2 CCGAGCCCTGGTCTC 17

RESULT 526
US-10-061-201-1609
; Sequence 1609, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1609
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1609

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCTGGTGCTCC 1689
DB 1 GAGCCCTGCTCTAC 16

RESULT 527
US-10-061-201-1611
; Sequence 1611, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1611
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1611

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCCTGGTGCTCTCC 1692
DB 2 CCCTGGTGCTCTACC 17

RESULT 528

US-10-061-201-1613
; Sequence 1613, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1613
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1613

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1678 CCTGGTGCTCTCCA 1693
DB 1 CCTGGTGCTCTACCA 16

RESULT 529
US-10-061-201-1764/c
; Sequence 1764, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761

```
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1764
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1764

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1748 CCTTCCTCTAAAGGCC 1763
Db 16 CCTTGTCTCTAAAGTCC 1

RESULT 530
US-10-061-201-1784/c
; Sequence 1784, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1785
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1785

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCTAA 1758
Db 16 CTCGCCCTTCCGAA 1

RESULT 532
US-10-061-201-1957
; Sequence 1957, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1784
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1784

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCTAA 1758
Db 17 CTCGCCCTTCCGAA 2

RESULT 531
US-10-061-201-1785/c
; Sequence 1785, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
```

```
; SEQ ID NO 1957
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1957

Query Match
Best Local Similarity 8.1%; Score 11.2; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGGGT 1711
Db 2 GTGGTGAAGTTGGGT 17

RESULT 533
US-10-061-201-1958
; Sequence 1958, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1958
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1959

Query Match
Best Local Similarity 8.1%; Score 11.2; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1724 GATGGAGATTGGCTCC 1739
Db 2 GGTGGAGATGGGGTCC 17

RESULT 535
US-10-061-201-1960
; Sequence 1960, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1960

Query Match
Best Local Similarity 8.1%; Score 11.2; DB 1; Length 17;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GTGGTGAAGTTGGGT 1711
Db 1 GTGGTGAAGTTGGGT 16

RESULT 534
US-10-061-201-1959
; Sequence 1959, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```



```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1724 GATGGAGATTGGCTCC 1739
Db 1 GGTGGAGATGGGGTCC 16

RESULT 536
US-10-061-201-1961
; Sequence 1961, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1961
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1961

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1726 TGGAGATTGGCTCCA 1741
Db 2 TGGAGATGGGGTCCAA 17

RESULT 537
US-10-061-201-1962
; Sequence 1962, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1962
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1962

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1726 TGGAGATTGGCTCCA 1741
Db 1 TGGAGATGGGGTCCAA 16

RESULT 538
US-10-230-006-1224
; Sequence 1224, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1224
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1224

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1649 AAGCAAGCACCAGGC 1664
Db 2 AAUGCCAGCGCCAGGC 17

RESULT 539
US-10-209-787-1703/c
; Sequence 1703, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Knies, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
```


; APPLICANT: University of Delaware
 ; APPLICANT: Eric B. Kmiec
 ; APPLICANT: Howard B. Gamper
 ; APPLICANT: Michael C. Rice
 ; APPLICANT: Jungsup Kim
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
 ; FILE REFERENCE: Using Modified Single Stranded Oligonucleotides
 ; CURRENT APPLICATION NUMBER: US/10/307,005
 ; CURRENT FILING DATE: 2002-11-26
 ; PRIOR APPLICATION NUMBER: PCT/US01/17672
 ; PRIOR FILING DATE: 2001-06-01
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; NUMBER OF SEQ ID NOS: 2717
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 2651
 ; TYPE: DNA
 ; ORGANISM: Triticum aestivum
 US-10-307-005-2651

Query Match 8.1%; Score 11.2; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1642 GTAGCAGAGGCGAGC 1657
 Db 2 GGAGCAGTAGCGGAGC 17

RESULT 544
 US-10-307-005-2652/c
 ; Sequence 2652, Application US/10307005
 ; Publication No. US20030236208A1
 ; GENERAL INFORMATION:
 ; APPLICANT: University of Delaware
 ; APPLICANT: Eric B. Kmiec
 ; APPLICANT: Howard B. Gamper
 ; APPLICANT: Michael C. Rice
 ; APPLICANT: Jungsup Kim
 ; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
 ; FILE REFERENCE: Napro/009 PCT
 ; CURRENT APPLICATION NUMBER: US/10/307,005
 ; CURRENT FILING DATE: 2002-11-26
 ; PRIOR APPLICATION NUMBER: PCT/US01/17672
 ; PRIOR FILING DATE: 2001-06-01
 ; PRIOR APPLICATION NUMBER: US 60/208,538
 ; PRIOR FILING DATE: 2000-06-01
 ; PRIOR APPLICATION NUMBER: US 60/244,989
 ; PRIOR FILING DATE: 2000-10-30
 ; PRIOR APPLICATION NUMBER: US 09/818,875
 ; PRIOR FILING DATE: 2001-03-27
 ; NUMBER OF SEQ ID NOS: 2717
 ; SOFTWARE: Friedman macro Napro4
 ; SEQ ID NO 2652
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Triticum aestivum
 US-10-307-005-2652

Query Match 8.1%; Score 11.2; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1642 GTAGCAGAGGCGAGC 1657
 Db 16 GGAGCAGTAGCGGAGC 1

RESULT 545
 US-10-454-224-24/c
 ; Sequence 24, Application US/10454224
 ; Publication No. US20040010814A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HERRMANN, Bernhard
 ; APPLICANT: KOSCHORZ, Birgit
 ; APPLICANT: KISPERT, Andreas
 ; TITLE OF INVENTION: NUCLEIC ACIDS INVOLVED IN THE RESPONDER PHENOTYPE AND APPLICATION
 ; FILE REFERENCE: THEREOF
 ; CURRENT APPLICATION NUMBER: US/10/454,224
 ; CURRENT FILING DATE: 2003-06-04
 ; PRIOR APPLICATION NUMBER: US/09/554,726A
 ; PRIOR FILING DATE: 2000-05-18
 ; PRIOR APPLICATION NUMBER: PCT/EP 98/07395
 ; PRIOR FILING DATE: 1998-11-18
 ; PRIOR APPLICATION NUMBER: EP 98 10 3596.7
 ; PRIOR FILING DATE: 1998-03-02
 ; PRIOR APPLICATION NUMBER: EP 97 12 0190.0
 ; PRIOR FILING DATE: 1997-11-18
 ; NUMBER OF SEQ ID NOS: 53
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 24
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Primer
 US-10-454-224-24

Query Match 8.1%; Score 11.2; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 3.1e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1690 TCCAGCGGTGTGGAAG 1705
 Db 16 TCCAGCCAGGGGGAAG 1

RESULT 546
 US-10-210-130-362/c
 ; Sequence 362, Application US/10210130
 ; Publication No. US20040014053A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Zerhusen, Bryan D.
 ; APPLICANT: Patturajan, Meera
 ; APPLICANT: Kekuda, Ramesh
 ; APPLICANT: Miller, Charles E.
 ; APPLICANT: Rieger, Daniel K.
 ; APPLICANT: Pena, Carol E.A.
 ; APPLICANT: Shimkets, Richard A.
 ; APPLICANT: Li, Li
 ; APPLICANT: Berghs, Constance
 ; APPLICANT: Zhong, Mei
 ; APPLICANT: Casman, Stacie J.
 ; APPLICANT: Voss, Edward Z.
 ; APPLICANT: Boldog, Terenc L.
 ; APPLICANT: Padigaru, Muralidhara
 ; APPLICANT: Smithson, Glennnda
 ; APPLICANT: Ji, Weizhen
 ; APPLICANT: Gorman, Linda
 ; APPLICANT: Vernet, Corine A.M.
 ; APPLICANT: Leite, Mario W.
 ; APPLICANT: Guo, Xiaojia Sasha
 ; APPLICANT: Anderson, David W.
 ; APPLICANT: Spytek, Kimberly A.
 ; APPLICANT: Gerlach, Valerie
 ; APPLICANT: Burgess, Catherine E.
 ; APPLICANT: Khrantsov, Nikolai V.
 ; APPLICANT: Ort, Tatiana

```
; APPLICANT: Ellerman, Karen
; APPLICANT: Rastelli, Luca
; APPLICANT: Agee, Michele L.
; APPLICANT: Chaudhuri, Amitabha
; APPLICANT: Chant, John S.
; APPLICANT: DiPippo, Vincent A.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Eisen, Andrew J.
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Giot, Loic
; APPLICANT: Ooi, Chean Eng
; APPLICANT: Rothenberg, Mark E.
; APPLICANT: Spaderna, Steven K.
; APPLICANT: Hjal, Tord
; APPLICANT: Liu, Xiaohong
; APPLICANT: Taupier, Raymond J., Jr.
; APPLICANT: Catterton, Elina
; APPLICANT: Shenoy, Suresh G.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-416C (Cura-716 SWT)
; CURRENT APPLICATION NUMBER: US/10/210,130
; CURRENT FILING DATE: 2002-08-01
; PRIOR APPLICATION NUMBER: 60/309,501
; PRIOR FILING DATE: 2001-08-02
; PRIOR APPLICATION NUMBER: 60/316,508
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: 60/354,655
; PRIOR FILING DATE: 2002-02-05
; PRIOR APPLICATION NUMBER: 60/310,291
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 60/383,887
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: 60/310,951
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/323,936
; PRIOR FILING DATE: 2001-09-21
; PRIOR APPLICATION NUMBER: 60/381,039
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/311,292
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 60/311,979
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 369
; SOFTWARE: CuraSeqlist version 0.1
; SEQ ID NO 362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-210-130-362

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1719 ACGGAGTGGAGATTG 1734
Db 16 ACGGAGCTGGAGGTGG 1

RESULT 547
US-10-261-185-1703/c
; Sequence 1703, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CCN
; CURRENT APPLICATION NUMBER: US/10261185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1704

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCTGGTGTCTCC 1689
Db 2 GAACCTGGCAGTCTGC 17

RESULT 549
US-10-138-674-22/c
; Sequence 22, Application US/10138674
; Publication No. US2004007565A1
; FILE REFERENCE: NaPro-4CCN
```

```
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1703
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1703

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCTGGTGTCTCC 1689
Db 16 GAACCTGGCAGTCTGC 1

RESULT 548
US-10-261-185-1704
; Sequence 1704, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: NaPro-4CCN
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1704

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1674 GAACCTGGTGTCTCC 1689
Db 2 GAACCTGGCAGTCTGC 17

RESULT 549
US-10-138-674-22/c
; Sequence 22, Application US/10138674
; Publication No. US2004007565A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-22

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
DB 17 CACAGCAGGACCCCG 2

RESULT 550
US-10-138-674-782/c
; Sequence 782, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 782
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-782

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCAGAGTGGAA 1676
DB 16 AGGCTCAGAGTGGGA 1

RESULT 551
US-10-138-674-2582/c
; Sequence 2582, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
```

```
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2582
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2582

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1642 GTAGCAGAGGCAAGC 1657
DB 16 GCATCATAGGCAAGC 1

RESULT 552
US-10-138-674-2892/c
; Sequence 2892, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2892

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
DB 17 CCCAGCAGAAACCCCTG 2

RESULT 553
US-10-138-674-2893/c
; Sequence 2893, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2893
```

Qy 1666 CACAGCTGGAACCCCTG 1681
db 16 CACAGCAGGACCCCGG 1

```

RESULT 558
US-10-138-674-5054/c
; Sequence 5054, Application US10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: pavco, pam
; APPLICANT: MCSwigen, Jim

```

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5054

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACCAGGCTCACA 1669
||||| ||||| |||||
Db 16 AAGCAGCTGGCTCCCA 1

RESULT 559
US-10-138-674-5167/c
; Sequence 5167, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5167

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGTCACAGCTGGAA 1676
||||| ||||| |||||
Db 17 AGGTCAGAGCTGGGA 2

RESULT 560
US-10-287-949A-22/c
; Sequence 22, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 22
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-22

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAGCCCTG 1681
||||| ||||| |||||
Db 17 CACAGCAGGACCCCGG 2

RESULT 561
US-10-287-949A-782/c
; Sequence 782, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 782
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-782

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGTCACAGCTGGAA 1676
||||| ||||| |||||
Db 16 AGGTCAGAGCTGGGA 1

RESULT 562
US-10-287-949A-2582/c
; Sequence 2582, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2582
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2582

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1642 GTAGCAGAGGCAAGC 1657
| | | | | | | | | |
Db 16 GCATCATAGGCAAGC 1

RESULT 563
US-10-287-949A-2892/c
; Sequence 2892, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2892
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2892

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
| | | | | | | | | |
Db 17 CCCAGCAGAAACCCCTG 2

RESULT 564
US-10-287-949A-2893/c
; Sequence 2893, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2893
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2893

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
| | | | | | | | | |
Db 16 CCCAGCAGAAACCCCTG 1

RESULT 565
US-10-287-949A-2911
; Sequence 2911, Application US/10287949A

Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2911

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1738 CCCAACTCCTCCCTAT 1753
| | | | | | | | | |
Db 2 CCCAGUCUCACGUAU 17

RESULT 566
US-10-287-949A-4204/c
; Sequence 4204, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4204
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4204

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 6.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAACCCCTG 1681
| | | | | | | | | |
Db 16 CACAGCAGGACCCCTG 1

RESULT 567
US-10-287-949A-4205/c
; Sequence 4205, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4205
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4205

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACAGCTGGACCC 1679
Db 17 CGCACAGCAGGACCCC 2

RESULT 568
US-10-287-949A-5053/c
; Sequence 5053, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5053

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACAGGCTCACA 1669
Db 17 AAGCAGCTGGCTCCCA 2

RESULT 569
US-10-287-949A-5054/c
; Sequence 5054, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-10-287-949A-5054

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1654 AAGCACAGGCTCACA 1669
Db 16 AAGCAGCTGGCTCCCA 1

RESULT 570
US-10-287-949A-5167/c
; Sequence 5167, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5167

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1661 AGGCTCAGAGCTGGAA 1676
Db 17 AGGGTCAGAGCTGGGA 2

RESULT 571
US-10-712-672-14/c
; Sequence 14, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-14

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1671 CTGGAACCCCTGGTGC 1686
|:|||||:|:|:
Db 2 CUGGAACCAUAGCGUC 17

RESULT 574
US-10-712-672-557
; Sequence 557, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-557

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1671 CTGGAACCCCTGGTGC 1686
|:|||||:|:|:
Db 1 CUGGAACCAUAGCGUC 16

RESULT 575
US-10-712-672-2295/c
; Sequence 2295, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2295
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-2295

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 TGGGCTTGTAGCAGA 1649

QY 1642 GTAGCAGAGGCAAGC 1657
| ||| ||||| |||
Db 16 GAAGCGAAGGCCAGC 1

RESULT 572
US-10-712-672-522
; Sequence 522, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 522
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-522

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1733 TGGCTCCCACTCCTC 1748
|:|||||:|:|:
Db 2 UGGCUCCAGCUGCGC 17

RESULT 573
US-10-712-672-556
; Sequence 556, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 556
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-556

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

;
; FEATURE: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3412

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCTGTGTCCTCC 1692
||| ||||| |||||
Db 17 CCGGGTGTCCCC 2

RESULT 587
US-10-669-841-3452
; Sequence 3452, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3452
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3452

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3.1e+02;

Matches 12; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1655 AGCACCAGGCTCAG 1670
||||| |||||
Db 2 AUCACCAGCUCACGG 17

RESULT 588
US-10-669-841-6289/c
; Sequence 6289, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6289
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6289

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1655 AGCACCAGGCTCAG 1670
||||| ||||| |||||
Db 17 ATCACCAGCUCACGG 2

RESULT 589
US-10-669-841-6329
; Sequence 6329, Application US/10669841

```
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Maciejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6329
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6329
;
; Query Match 8.1%; Score 11.2; DB 1; Length 17;
; Best Local Similarity 62.5%; Pred. No. 3.le+02;
; Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
;
Qy 1677 CCCTGGTGCTCTCTCC 1692
Db 2 CCGCGGUGUCUCCCC 17
|||:|:|:|:|:|
|||:|:|:|:|:|

RESULT 590
US-10-669-841-6589/c
; Sequence 6589, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Maciejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6329
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6329
;
; Query Match 8.1%; Score 11.2; DB 1; Length 17;
; Best Local Similarity 62.5%; Pred. No. 3.le+02;
; Matches 10; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
;
Qy 1677 CCCTGGTGCTCTCTCC 1692
Db 2 CCGCGGUGUCUCCCC 17
|||:|:|:|:|:|
|||:|:~|:~|:~|:~|

RESULT 591
US-10-723-361-529
; Sequence 529, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6589
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6589
;
; Query Match 8.1%; Score 11.2; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 3.le+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
Qy 1660 CAGGCTCAGCTGGA 1675
Db 17 CAGGCTCAGCGCGCA 2
|||||:|:|:|:|:|
|||||:|:|:|:|:|

RESULT 591
US-10-723-361-529
; Sequence 529, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```



```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 529
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-529
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1646 CAGAAGCGCAAGCACCA 1661

Db 1 CAGATGACAGCATCA 16

RESULT 592

```
US-10-723-361-1263/c
; Sequence 1263, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1263
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-10-723-361-1263
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1730 GATTGGCTCCCAACTC 1745

Db 17 GATCGTCCCAACTC 2

RESULT 593

```
US-10-723-361-1265/c
; Sequence 1265, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1265
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1265
```

```
Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 1729 AGATTGGCTCCCAACT 1744

Db 16 AGATCGTCCCAACT 1

RESULT 594

```
US-10-723-361-1285/c
; Sequence 1285, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1285

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1678 CCTGGTGTCTCTCCCA 1693
Db 17 CCTGCTTCTCCCCCA 2

RESULT 595
US-10-723-361-1286/c
; Sequence 1286, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1285
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1286
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1286

Query Match      8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1678 CCTGGTGTCTCTCCCA 1693
Db 16 CCTGCTTCTCCCCCA 1

RESULT 596
US-10-723-361-7832
; Sequence 7832, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 7832
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7832
```

Query Match	8.1%;	Score 11.2;	DB 1;	Length 17;
Best Local Similarity	81.2%;	Pred. NO. 3.1e+02;		
Matches 13;	Conservative	0;	Mismatches 3;	Indels

Qy 1662 GGCTCACAGCTGGAAC 1677
Db 1 GCCTCACAGCTGAAGC 16

RESULT 597

US-10-723-361-7984
 ; Sequence 7984, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POL
 ; FILE REFERENCE: PB0105

```

/ CURRENT APPLICATION NUMBER: US/10/723,351
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecolma Sequence Listing Engine
/ SEQ ID NO 7984

```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7984

```

Query Match

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels

QY 1646 CAGAGGCAAGCACCA 1661
||| ||| ||| ||| |||
Db 2 CAGCAGGAAAACACCA 17

RESULT 598

US-101-723-361-7985
; Sequence 7985, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

Query Match	8.1%;	Score 11.2;	DB 1;	Length 17;
Best Local Similarity	81.2%;	Pred. No. 3.1e+02;		
Matches 13;	Conservative	0;	Mismatches 3;	Indels 0;
Gaps	0;			

Qy 1662 GGCTCACAGCTGGAAC 1677
Db 1 GCCTCACAGCTGAAGC 16

RESULT 597

US-10-723-361-7984
 ; Sequence 7984, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
 ; FILE REFERENCE: PB0105

```

/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.

```

```

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aomica Sequence Listing Engine
; SEQ ID NO 7984
; LENGTH: 17

```

; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-723-361-7984

Query Match

Query Match	8.1%;	Score 11.2;	DB 1;
Best Local Similarity	81.2%;	Pred. No. 3.1e+02;	Length 17;
Matches 13;	Conservative	0;	Mismatches 3;
			Indels 0;
			Gaps 0;

QY
1646 CAGAAAGGCAAGCACCA 1661

Db
2 CAGCAGGAAAACACCA 17

RESULT 598

RESULT 3996
 US-10-723-361-7985
 ; Sequence 7985, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.

```

1  APPLICANT: CHEN, Wensheng
2  APPLICANT: SHANNON, Mark
3  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
4  FILE REFERENCE: PB0105
5  CURRENT APPLICATION NUMBER: US/10/723,361
6  CURRENT FILING DATE: 2003-11-26
7  PRIOR APPLICATION NUMBER: US 09/866,108
8  PRIOR FILING DATE: 2001-05-25
9  PRIOR APPLICATION NUMBER: US 60/207,456
10 PRIOR FILING DATE: 2000-05-26
11 PRIOR APPLICATION NUMBER: GB 24263.6
12 PRIOR FILING DATE: 2000-10-04
13 PRIOR APPLICATION NUMBER: US 60/236,359
14 PRIOR FILING DATE: 2000-09-27
15 PRIOR APPLICATION NUMBER: PCT/US01/00666
16 PRIOR FILING DATE: 2001-01-30
17 PRIOR APPLICATION NUMBER: PCT/US01/00667
18 PRIOR FILING DATE: 2001-01-30
19 PRIOR APPLICATION NUMBER: PCT/US01/00664
20 PRIOR FILING DATE: 2001-01-30
21 PRIOR APPLICATION NUMBER: PCT/US01/00669
22 PRIOR FILING DATE: 2001-01-30
23 PRIOR APPLICATION NUMBER: PCT/US01/00665
24 PRIOR FILING DATE: 2001-01-30
25 PRIOR APPLICATION NUMBER: PCT/US01/00668
26 PRIOR FILING DATE: 2001-01-30
27 Remaining Prior Application data removed - See File Wrapper or PALM.
28 NUMBER OF SEQ ID NOS: 15755
29 SOFTWARE: Aesomica Sequence Listing Engine
30 SEQ ID NO 7985
31 LENGTH: 17
32 TYPE: DNA
33 ORGANISM: Homo sapiens
34 US-10-723-361-7985

```

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels

QY 1646 CAGAAGGCAAGCACCA 1661
Db 1 CAGCAGGAAAACACCA 16

RESULT 599

US-10-723-361-9657/c
; Sequence 9657, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION

;
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron
; APPLICANT: HANZEL, David
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON Mark

```

, TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
,
, FILE REFERENCE: PE0105
,
, CURRENT APPLICATION NUMBER: US/10/723,361
,
, CURRENT FILING DATE: 2003-11-26
,
, PRIOR APPLICATION NUMBER: US 09/866,108
,
, PRIOR FILING DATE: 2001-05-25
,
, PRIOR APPLICATION NUMBER: US 60/207,456
,
, PRIOR FILING DATE: 2000-05-26
,
, PRIOR APPLICATION NUMBER: GB 24263.6
,
, PRIOR FILING DATE: 2000-10-04
,
, PRIOR APPLICATION NUMBER: US 60/236,359
,
, PRIOR FILING DATE: 2000-09-27
,
, PRIOR APPLICATION NUMBER: PCT/US01/00666
,
, PRIOR FILING DATE: 2001-01-30
,
, PRIOR APPLICATION NUMBER: PCT/US01/00667
,
, PRIOR FILING DATE: 2001-01-30
,
, PRIOR APPLICATION NUMBER: PCT/US01/00664
,

```

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9657
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-9657

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1673 GGAAACCTGGTGCTC 1688
DB 17 GGAAACCTGGCTCTC 2

RESULT 600
US-10-723-361-9659/c
Sequence 9659, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 9659
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-9659

Query Match 9.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGAACCCCTGGTGCTC 1687
DB 16 TGAACCCCTGGCTCTC 1

RESULT 601
US-10-723-361-10208
Sequence 10208, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 10208
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-10208

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCCTAAAGGCCCA 1765
DB 2 CTATCCGGAAGGCCCA 17

RESULT 602
US-10-723-361-10209
Sequence 10209, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 10209
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-10209

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 CTATCTAAAGGCCCA 1765
||||| ||| |||||
DB 1 CTATCGGAAGGCCCA 16

RESULT 603
US-10-417-264-4/c
Sequence 4, Application US/10417264
Publication No. US20040142458A1
GENERAL INFORMATION:
APPLICANT: BIO MEDIATION TECHNOLOGIE, INC.
TITLE OF INVENTION: WHITE ROT FUNGI AND METHOD FOR DECOMPOSING DIOXINS USING THEM
FILE REFERENCE: WKO-101PCT
CURRENT APPLICATION NUMBER: US/10/417,264
CURRENT FILING DATE: 2003-04-17
PRIOR APPLICATION NUMBER: US/09/805,127
PRIOR FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: JP 1998-260707
PRIOR FILING DATE: 1998-09-14
NUMBER OF SEQ ID NOS: 7
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 4
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: artificially synthesized sequ
US-10-417-264-4

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCACCAGG 1663
||||| ||| |||||
DB 16 GAAGGGCACCACCAGG 1

RESULT 604
US-10-417-264-5
Sequence 5, Application US/10417264
Publication No. US20040142458A1
GENERAL INFORMATION:
APPLICANT: BIO MEDIATION TECHNOLOGIE, INC.
TITLE OF INVENTION: WHITE ROT FUNGI AND METHOD FOR DECOMPOSING DIOXINS USING THEM
FILE REFERENCE: WKO-101PCT
CURRENT APPLICATION NUMBER: US/10/417,264
CURRENT FILING DATE: 2003-04-17
PRIOR APPLICATION NUMBER: US/09/805,127
PRIOR FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: JP 1998-260707
PRIOR FILING DATE: 1998-09-14
NUMBER OF SEQ ID NOS: 7
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 5
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: artificially synthesized sequ
US-10-417-264-5

Query Match 8.1%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCACCAGG 1663
||||| ||| |||||
DB 2 GAAGGGCACCACCAGG 17

RESULT 605
US-10-661-165-376/c
Sequence 376, Application US/10661165
Publication No. US20040137470A1
GENERAL INFORMATION:
APPLICANT: Dhallan, Ravinder S.
TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
FILE REFERENCE: 543312000420
CURRENT APPLICATION NUMBER: US/10/661,165
CURRENT FILING DATE: 2003-09-11
PRIOR APPLICATION NUMBER: PCT/US03/06198
PRIOR FILING DATE: 2003-02-28
PRIOR APPLICATION NUMBER: US 60/378,354
PRIOR FILING DATE: 2002-05-08
PRIOR APPLICATION NUMBER: US 10/093,618
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/360,232
PRIOR FILING DATE: 2002-03-01
PRIOR APPLICATION NUMBER: PCT/US03/27308
PRIOR FILING DATE: 2003-08-29
PRIOR APPLICATION NUMBER: US 10/376,770
PRIOR FILING DATE: 2003-02-28
NUMBER OF SEQ ID NOS: 628
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 376
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-661-165-376

Query Match 7.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1683 TGTCTCTCTCCA 1693
||||| ||| |||||

Db 11 TCTCTCTCCA 1

RESULT 606

US-10-287-226-558
 ; Sequence 558, Application US/10287226
 ; Publication No. US20040086875A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Agee, Michelle L.,
 ; APPLICANT: Alsobrook, John P.,
 ; APPLICANT: Berghs, Constance,
 ; APPLICANT: Boldog, Ference,
 ; APPLICANT: Burgess, Catherine E.,
 ; APPLICANT: Chant, John S.,
 ; APPLICANT: Chaudhuri, Amitabha,
 ; APPLICANT: Dipippo, Vincent A.,
 ; APPLICANT: Edinger, Shlomit R.,
 ; APPLICANT: Eisen, Andrew,
 ; APPLICANT: Ellerman, Karen,
 ; APPLICANT: Gangolli, Esha A.,
 ; APPLICANT: Gorman, Linda,
 ; APPLICANT: Gerlach, Valerie,
 ; APPLICANT: Ji, Weizhen,
 ; APPLICANT: Kekuda, Ramesh,
 ; APPLICANT: Khramtsov, Nikolai,
 ; APPLICANT: Li, Li,
 ; APPLICANT: Malyankar, Uriel M.,
 ; APPLICANT: MacDougall, John R.,
 ; APPLICANT: Mezes, Peter S.,
 ; APPLICANT: Miller, Charles E.,
 ; APPLICANT: Millet, Isabelle,
 ; APPLICANT: Ooi, Chean Eng,
 ; APPLICANT: Ort, Tatiana,
 ; APPLICANT: Padigar, Muralidhara,
 ; APPLICANT: Patturajan, Meera,
 ; APPLICANT: Rastelli, Luca,
 ; APPLICANT: Rieger, Daniel K.,
 ; APPLICANT: Rothenberg, Mark E.,
 ; APPLICANT: Shenoy, Suresh G.,
 ; APPLICANT: Spaderna, Steven K.,
 ; APPLICANT: Spytek, Kimberley A.,
 ; APPLICANT: Taupier, Jr., Raymond J.,
 ; APPLICANT: Vernet, Corine A.M.,
 ; APPLICANT: Zerhusen, Bryan D.,
 ; APPLICANT: Zhong, Mei
 ; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
 ; FILE REFERENCE: 21402-480C
 ; CURRENT APPLICATION NUMBER: US/10/287,226
 ; PRIOR FILING DATE: 2002-11-04
 ; PRIOR APPLICATION NUMBER: 60/334,421
 ; PRIOR FILING DATE: 2001-11-30
 ; PRIOR APPLICATION NUMBER: 60/354,392
 ; PRIOR FILING DATE: 2002-02-04
 ; PRIOR APPLICATION NUMBER: 60/360,148
 ; PRIOR FILING DATE: 2002-02-27
 ; PRIOR APPLICATION NUMBER: 60/364,000
 ; PRIOR FILING DATE: 2002-03-13
 ; PRIOR APPLICATION NUMBER: 60/404,821
 ; PRIOR FILING DATE: 2002-08-20
 ; PRIOR APPLICATION NUMBER: 60/334,526
 ; PRIOR FILING DATE: 2001-11-30
 ; PRIOR APPLICATION NUMBER: 60/354,409
 ; PRIOR FILING DATE: 2002-02-04
 ; PRIOR APPLICATION NUMBER: 60/364,227
 ; PRIOR FILING DATE: 2002-03-13
 ; PRIOR APPLICATION NUMBER: 60/334,027
 ; PRIOR FILING DATE: 2001-11-28
 ; PRIOR APPLICATION NUMBER: 60/331,641
 ; PRIOR FILING DATE: 2001-11-20
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 673
 ; SOFTWARE: CuraSeqList version 0.1
 ; SEQ ID NO 558

LENGTH: 15

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe

US-10-287-226-558

Query Match 7.9%; Score 11; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1733 TGGCTCCCAAC 1743

DB 2 TGGCTCCCAAC 12

RESULT 607

US-10-331-109-15/c

; Sequence 15, Application US/10331109

; Publication No. US20030215891A1

; GENERAL INFORMATION:

; APPLICANT: Bickel, et al

; TITLE OF INVENTION: Method for the qualitative and/or quantitative detection of molecul

; FILE REFERENCE: 12671/1

; CURRENT APPLICATION NUMBER: US/10/331,109

; PRIOR FILING DATE: 2002-12-27

; PRIOR APPLICATION NUMBER: PCT/EP01/07575

; PRIOR FILING DATE: 2001-07-02

; PRIOR APPLICATION NUMBER: DE 100 33 334.6

; PRIOR FILING DATE: 2000-07-01

; NUMBER OF SEQ ID NOS: 34

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 15

LENGTH: 16

TYPE: DNA

ORGANISM: Artificial sequence

FEATURE:

OTHER INFORMATION: Description of the artificial sequence:

US-10-331-109-15

Query Match 7.9%; Score 11; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.9e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1753 TCCTAAAGGCC 1763

DB 13 TCCTAAAGGCC 3

RESULT 608

US-10-455-013-17

; Sequence 17, Application US/10455013

; Publication No. US20040010810A1

; GENERAL INFORMATION:

; APPLICANT: KUCHERLAPATI, RAJU

; APPLICANT: JAKOBOVITS, AYA

; APPLICANT: KLAPHOLZ, SUE

; APPLICANT: BRENNER, DANIEL G.

; APPLICANT: CAPON, DANIEL J.

; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES

; FILE REFERENCE: CELL 4.6 CON 2

; CURRENT APPLICATION NUMBER: US/10/455,013

; CURRENT FILING DATE: 2003-06-04

; PRIOR APPLICATION NUMBER: 09/019,523

; PRIOR FILING DATE: 1998-02-05

; PRIOR APPLICATION NUMBER: 08/234,145

; PRIOR FILING DATE: 1994-04-28

; PRIOR APPLICATION NUMBER: 08/112,848

; PRIOR FILING DATE: 1993-08-27

; PRIOR APPLICATION NUMBER: 08/031,801

; PRIOR FILING DATE: 1993-03-15

; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-455-013-17

Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||
Db 1 AGCTGGAACCC 11

RESULT 609
US-10-455-013-29
; Sequence 29, Application US/10455013
; Publication No. US20040010810A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.6 CON 2
; CURRENT APPLICATION NUMBER: US/10/455,013
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/019,523
; PRIOR FILING DATE: 1998-02-05
; PRIOR APPLICATION NUMBER: 08/234,145
; PRIOR FILING DATE: 1994-04-28
; PRIOR APPLICATION NUMBER: 08/112,848
; PRIOR FILING DATE: 1993-08-27
; PRIOR APPLICATION NUMBER: 08/031,801
; PRIOR FILING DATE: 1993-03-15
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-455-013-29

Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||
Db 1 AGCTGGAACCC 11

RESULT 610
US-10-627-250-17
; Sequence 17, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/10/627,250
; CURRENT FILING DATE: 2003-07-24
; PRIOR APPLICATION NUMBER: US/08/031,801
; PRIOR FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-627-250-17

Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||
Db 1 AGCTGGAACCC 11

RESULT 611
US-10-627-250-29
; Sequence 29, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/10/627,250
; CURRENT FILING DATE: 2003-07-24
; PRIOR APPLICATION NUMBER: US/08/031,801
; PRIOR FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 16

TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: polylinker
US-10-627-250-29

Query Match 7.9%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1669 AGCTGGAACCC 1679
|||||
DB 1 AGCTGGAACCC 11

RESULT 612
US-09-943-983-4
Sequence 4, Application US/09943983
Publication No. US20030077575A1
GENERAL INFORMATION:
APPLICANT: STUYVER, LIEVEN
LOUWAGIE, JOOST
ROSSAU, RUDI
TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE

NUMBER OF SEQUENCES: 164
CORRESPONDENCE ADDRESS:
ADDRESSEE: ARNOLD, WHITE & DURKEE
STREET: P.O. BOX 4433
CITY: HOUSTON
STATE: TEXAS
COUNTRY: USA
ZIP: 77210-4433
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Microsoft Word 6.0 / ASCII text output
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/943,983
FILING DATE: 31-Aug-2001

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/913,833
FILING DATE: 1997-09-15
APPLICATION NUMBER: EP 96870005.4
FILING DATE: 26 Jan 1996
APPLICATION NUMBER: EP 96870081.5
FILING DATE: 25 Jun 1996
ATTORNEY/AGENT INFORMATION:
NAME: KAMMERER, PATRICIA A.
REGISTRATION NUMBER: 29,775
REFERENCE/DOCKET NUMBER: INNS:008

INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-943-983-4

Query Match 7.8%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1718 TACGAGATGGAGA 1731
|||||
DB 1 TACAGATGGAAA 14

RESULT 613
US-09-263-959-672
Sequence 672, Application US/09263959
Patent No. US20020150891A1
GENERAL INFORMATION:
APPLICANT: Hood, Leroy E.
APPLICANT: Rowen, Lee
APPLICANT: Koop, Ben F.
TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
NUMBER OF SEQUENCES: 1279
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/263,959
FILING DATE: 05-MAR-1999
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-5031
INFORMATION FOR SEQ ID NO: 672:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-672

Query Match 7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCTTCCT 1756
|||||
DB 2 CTCCTCCTTCCT 15

RESULT 614
US-09-263-959-708
Sequence 708, Application US/09263959
Patent No. US20020150891A1
GENERAL INFORMATION:
APPLICANT: Hood, Leroy E.
APPLICANT: Rowen, Lee
APPLICANT: Koop, Ben F.
TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
NUMBER OF SEQUENCES: 1279
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25


```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McWaters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 708:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-263-959-708

Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCTTACT 1756
Db 2 CTCCTCCTTCTCT 15

RESULT 615
US-09-860-784-8
; Sequence 8, Application US/09860784
; Patent No. US20020151512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/860,784
; FILING DATE: 21-May-2001
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE: 04-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-860-784-8
```

```
Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14

RESULT 616
US-09-835-371-5
; Sequence 5, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,371
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-5
```

```
Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14
```

```
RESULT 617
US-09-835-370-5
; Sequence 5, Application US/09835370
; Publication No. US20030022172A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-09-835-370-5
```

```
Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CAGCTGGAACCCCTG 1681
Db 1 CAGCTGCAACCCAG 14
```

```
Db      1  CAGCTGCAACCCAG 14

RESULT 618
US-09-880-313A-49/c
; Sequence 49, Application US/09880313A
; Publication No. US20030044791A1
; GENERAL INFORMATION:
; APPLICANT: Fleming, Erik K
; TITLE OF INVENTION: Adaptors and Methods of Use
; FILE REFERENCE: 9397/1000
; CURRENT APPLICATION NUMBER: US/09/880,313A
; CURRENT FILING DATE: 2001-06-13
; NUMBER OF SEQ ID NOS: 276
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 49
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-880-313A-49

Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1644 AGCAGAAGGCAAGC 1657
      ||| ||| ||| ||| |||
Db      15 AGCTGCAGGCAGC 2

RESULT 619
US-09-793-146-7
; Sequence 7, Application US/09793146
; Publication No. US20030203359A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/09/793,146
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 7
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-7

Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1668 CAGCTGGAACCTGTG 1681
      ||| ||| ||| ||| |||
Db      1  CAGCTGCAACCCAG 14

RESULT 620
US-10-010-802-130/c
; Sequence 130, Application US/10010802
; Publication No. US20030078220A1
; GENERAL INFORMATION:
; APPLICANT: Genaisance Pharmaceuticals
```

```
; APPLICANT: Chew, Anne
; APPLICANT: Denton, R. Rex
; APPLICANT: Duda, Amy
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stephens, J. Claiborne
; APPLICANT: Windemuth, Andreas
; TITLE OF INVENTION: Drug Target Isoenes: Polymorphisms in the Interleukin
; TITLE OF INVENTION: 4 Receptor Alpha Gene
; FILE REFERENCE: MMH-0002US2 IL4R alpha
; CURRENT APPLICATION NUMBER: US/10/010,802
; CURRENT FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: PCT/US00/19094
; PRIOR FILING DATE: 2000-07-13
; NUMBER OF SEQ ID NOS: 413
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 130
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-010-802-130

Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1728 GAGATTGGCTCCCA 1741
      ||| ||| ||| ||| |||
Db      15 GAGCTTGCCTCCCA 2
```

```
RESULT 621
US-10-440-850-823
; Sequence 823, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revers
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MBHE00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 823
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-823

Query Match      7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 2.7e+02;
Matches 8; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1678 CCTGGTGTCTCTC 1691
      ||| ||| : ||| |||
Db      2  CCUGGUCUCCACCUC 15
```

```
RESULT 622
US-10-418-182-186
; Sequence 186, Application US/10418182
; Publication No. US20030228302A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto
; TITLE OF INVENTION: UNIVERSAL LIBRARIES FOR IMMUNOGLOBULINS
; FILE REFERENCE: 1551-2001-001
; CURRENT APPLICATION NUMBER: US/10/418,182
; CURRENT FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: 60/373,558
; PRIOR FILING DATE: 2002-04-17
; NUMBER OF SEQ ID NOS: 423
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 186
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-418-182-186

Query Match          7.8%; Score 10.8; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 2.7e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1743 CTCCTCCCTATCCT 1756
Db 1 CTCCTCCCTCTCCT 14

RESULT 623
US-09-965-876A-15/c
; Sequence 15, Application US/09965876A
; Publication No. US20030096243A1
; GENERAL INFORMATION:
; APPLICANT: Cellomics, Inc.
; APPLICANT: Busa, William B.
; TITLE OF INVENTION: Methods and Reagents for Live-cell Gene Expression Quantification
; FILE REFERENCE: 00-789-A
; CURRENT APPLICATION NUMBER: US/09/965,876A
; CURRENT FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 60/236,407
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 16
; TYPE: RNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-965-876A-15

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1661 AGGCTCACAGCTGG 1674
Db 16 AGGCTCAGATCTGG 3

RESULT 624
US-09-882-945A-268/c
; Sequence 268, Application US/09882945A
; Publication No. US2003014353A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
```

```
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 268
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-268
```

```
Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1685 TCTCTCCACGCTG 1698
Db 16 TCTCTCCATCATG 3
```

```
RESULT 625
US-10-087-082-6
; Sequence 6, Application US/10087082
; Publication No. US2002016040A1
; GENERAL INFORMATION:
; APPLICANT: Dietmaier, Wolfgang
; APPLICANT: Ruschoff, Josef
; TITLE OF INVENTION: IMPROVED METHOD OF PRIMER-EXTENSION PREAMPLIFICATION PCR
; FILE REFERENCE: 4802
; CURRENT APPLICATION NUMBER: US/10/087,082
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: DE 198 13 317.0
; PRIOR FILING DATE: 1998-03-26
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: Primer for Human genomic sequence
US-10-087-082-6
```

```
Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1713 AGGAGTACGGAGAT 1726
Db 2 AGCAGTAAGGAGAT 15
```

```
RESULT 626
US-10-123-731-8
; Sequence 8, Application US/10123731
; Publication No. US20030195138A1
; GENERAL INFORMATION:
; APPLICANT: Hitoshi, Yasumichi
; APPLICANT: Jenkins, Yonchu
; APPLICANT: Rigel Pharmaceuticals, Inc.
; TITLE OF INVENTION: BAP-1: Methods of Assaying for Cell Cycle Modulators
; FILE REFERENCE: 021044-003500US
; CURRENT APPLICATION NUMBER: US/10/123,731
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:BstXI linker
US-10-123-731-8
```

```
Query Match      7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1691 CCAGCGTGTGGAA 1704
Db 1 CCAGTGTGTGGAA 14

RESULT 627
US-10-138-674-5803
; Sequence 5803, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5803
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5803

Query Match      7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 3.2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1746 CTCCTATCCTAAA 1759
Db 1 CUCCUUAUCCGAAA 14

RESULT 628
US-10-138-674-5880
; Sequence 5880, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5880
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5880

Query Match      7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 3.2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1738 CCCAACTCCTCCT 1751
Db 1 CUCAACUCCGCGU 14
```

```
RESULT 629
US-10-138-674-5912/c
; Sequence 5912, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5912
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5912

Query Match      7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1692 CAGCGTGTGGAA 1705
Db 14 CAGCGTGTGTAG 1

RESULT 630
US-10-287-949A-5803
; Sequence 5803, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5803
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5803

Query Match      7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 3.2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1746 CTCCTATCCTAAA 1759
Db 1 CUCCUUAUCCGAAA 14

RESULT 631
US-10-287-949A-5880
; Sequence 5880, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5880
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5880

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 3.2e+02;
Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1738 CCCAACTCTCCCT 1751
Db 1 CUCAACUCCUGCCU 14

RESULT 632
US-10-287-949A-5912/c
; Sequence 5912, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5912
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5912

Query Match          7.8%; Score 10.8; DB 1; Length 16;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1692 CAGCGTGTGGAAG 1705
Db 14 CAGCGTGTGCTGAG 1

RESULT 633
US-09-877-478-2360
; Sequence 2360, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
```

```
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2360
```

```
Query Match          7.6%; Score 10.6; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 3.8e+02;
Matches 10; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 1694 GCGTGTGGAAGTTGGG 1710
Db 1 GAGUGGAGGAGUUGGG 17
```

```
RESULT 634
US-10-342-902-2360
; Sequence 2360, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2360
```

```
Query Match          7.6%; Score 10.6; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 3.8e+02;
Matches 10; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 1694 GCGTGTGGAAGTTGGG 1710
Db 1 GAGUGGAGGAGUUGGG 17
```

Query Match 7.6%; Score 10.6; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 4; Indels

```

RESULT 636
US-10-061-201-1960/c
; Sequence 1960, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

```

```
QY 1732 TTGGCTCCCACTCTC 1748
      ||||| ||||| |||||
Db 17 TTGACCCCACTCTCAC 1
      ||||| ||||| |||||

RESULT 638
US-10-251-117-717/c
; Sequence 1024, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 717
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siRNA sense
US-10-251-117-717

Query Match 7.6%; Score 10.6; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1687 TCCTCCAGCGTGTGGA 1703
      ||||| ||||| |||||
Db 18 TTCTCCAGGATGAGGA 2
      ||||| ||||| |||||

RESULT 639
US-10-251-117-1024
; Sequence 1024, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
; FILE REFERENCE: 900/042 (MBH02-468-A)
; CURRENT APPLICATION NUMBER: US/10/251,117
; CURRENT FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: US 60/393,924
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/916,466
; PRIOR FILING DATE: 2001-07-25
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 1213
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1024
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-251-117-1024

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
      ||||| ||||| |||||
Db 14 KGAGATGCAGATAG 1
      ||||| ||||| |||||

RESULT 641
US-10-027-632-51889/c
; Sequence 51889, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51889
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Human
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-027-632-51889

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1721 GGAGATGGAGATTG 1734
      ||||| ||||| |||||
Db 14 KGAGATGCAGATAG 1
      ||||| ||||| |||||

RESULT 641
US-10-027-632-51889/c
; Sequence 51889, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51889
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Human
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-027-632-51889
```

schultz139-3.rnpb

Mon Aug 30 09:26:47 2004

```

; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51889
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51889

Query Match      7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy      1721 GGAGATGGAGATTG 1734
Db      14 KGAGATGCAGATAG 1

RESULT 642
US-10-632-51894/C
; Sequence 51894, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51894
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51894

Query Match      7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 78.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy      1721 GGAGATGGAGATTG 1734
Db      14 KGAGATGCAGATAG 1

RESULT 643
US-10-632-51894/C
; Sequence 51894, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:

```

```

; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE OF INVENTION: Polymorphisms in the Human Genome
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51894
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51894

Query Match      7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 79.6%; Pred. No. 2.7e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy      1721 GGAGATGGAGATTG 1734
Db      14 KGAGATGCAGATAG 1

RESULT 644
US-10-146-058-90/C
; Sequence 90, Application US/10146058
; Publication No. US20030040499A1
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; TITLE OF INVENTION: immuno-suppressive effect of transforming-growth-factor beta
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/146,058
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/535,249
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 089.0
; FILING DATE: 30-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 93 107 849.7

```


FILE REFERENCE: 13-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDEA UR
INFORMATION FOR SEQ ID NO: 90:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
ANTI-SENSE: YES
US-10-146-058-90

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 AGCAGAAGGCAA 1655
DB 14 AGCAGAAGGCGA 3

RESULT 645
US-10-376-770-65
Sequence 65, Application US/10376770
Publication No. US20040106102A1
GENERAL INFORMATION:
APPLICANT: Dhallan, Ravinder S.
TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
FILE REFERENCE: 543312000320
CURRENT APPLICATION NUMBER: US/10/376,770
PRIOR FILING DATE: 2003-02-28
PRIOR APPLICATION NUMBER: US 10/093,618
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/360,232
PRIOR FILING DATE: 2002-03-01
PRIOR APPLICATION NUMBER: US 60/378,354
PRIOR FILING DATE: 2002-05-08
NUMBER OF SEQ ID NOS: 262
SOFTWARE: Fast-SEQ for Windows Version 4.0
SEQ ID NO 65
LENGTH: 14
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: 4
OTHER INFORMATION: This nucleotide may be absent
US-10-376-770-65

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 AGCAGAAGGCAA 1655
DB 1 ACCAGAAGGCGA 12

RESULT 646
US-10-661-165-65
Sequence 65, Application US/10661165
Publication No. US20040137470A1
GENERAL INFORMATION:
APPLICANT: Dhallan, Ravinder S.
TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
DISORDERS

FILE REFERENCE: 543312000420
CURRENT APPLICATION NUMBER: US/10/661,165
CURRENT FILING DATE: 2003-09-11
PRIOR APPLICATION NUMBER: PCT/US03/06198
PRIOR FILING DATE: 2003-02-28
PRIOR APPLICATION NUMBER: US 60/378,354
PRIOR FILING DATE: 2002-05-08
PRIOR APPLICATION NUMBER: US 10/093,618
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/360,232
PRIOR FILING DATE: 2002-03-01
PRIOR APPLICATION NUMBER: PCT/US03/27308
PRIOR FILING DATE: 2003-08-29
PRIOR APPLICATION NUMBER: US 10/376,770
PRIOR FILING DATE: 2003-02-28
NUMBER OF SEQ ID NOS: 628
SOFTWARE: Fast-SEQ for Windows Version 4.0
SEQ ID NO 65
LENGTH: 14
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: 4
OTHER INFORMATION: This nucleotide may be absent
US-10-661-165-65

Query Match 7.5%; Score 10.4; DB 1; Length 14;
Best Local Similarity 91.7%; Pred. No. 2.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1644 AGCAGAAGGCAA 1655
DB 1 ACCAGAAGGCGA 12

RESULT 647
US-09-504-231A-361/c
Sequence 361, Application US/09504231A
Patent No. US20020013458A1
GENERAL INFORMATION:
APPLICANT: Blatt, Lawrence
APPLICANT: McSwiggen, James
APPLICANT: Roberts, Beth
APPLICANT: Pavco, Pamela
APPLICANT: Macejak, Dennis
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
FILE REFERENCE: rpi 247/282
CURRENT APPLICATION NUMBER: US/09/504,231A
CURRENT FILING DATE: 2000-02-15
PRIOR APPLICATION NUMBER: 09/274,553
PRIOR FILING DATE: 1999-03-23
PRIOR APPLICATION NUMBER: 09/257,608
PRIOR FILING DATE: 1999-02-24
PRIOR APPLICATION NUMBER: 60/100,842
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/083,217
PRIOR FILING DATE: 1998-04-27
NUMBER OF SEQ ID NOS: 3242
SOFTWARE: Patentin version 3.0
SEQ ID NO 361
LENGTH: 15
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-361

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Mon Aug 30 09:26:47 2004

```
QY      1695 CGTGGTGGAGT 1706
Db      15  CGTAGTGGAGT  4

RESULT 648
US-09-504-231A-951
; Sequence 951, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: fpi 247/282
; CURRENT APPLICATION NUMBER: US/09/504,231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274,553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 951
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-951

Query Match      7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 3.2e+02;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1688 CCTCCAGCGTGG 1699
Db      1  CCUCCAUCCUGG 12

RESULT 649
US-09-274-553D-361/c
; Sequence 361, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: fpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 361
; LENGTH: 15
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-361

Query Match      7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1695 CGTGGTGGAGT 1706
Db      15  CGTAGTGGAGT  4

RESULT 650
US-09-274-553D-951
; Sequence 951, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: fpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 951
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-951

Query Match      7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 3.2e+02;
Matches 9; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1688 CCTCCAGCGTGG 1699
Db      1  CCUCCAUCCUGG 12

RESULT 651
US-09-877-478-5948
; Sequence 5948, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHE00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
```

;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 5948
;; LENGTH: 15
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-5948

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 6; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1680 TGGTGTCTCTC 1691
: |:|:|:|:|
Db 2 UUGUGUCUCC 13

RESULT 652
US-10-342-902-5948
;; Sequence 5948, Application US/10342902
;; Publication No. US20040054156A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Draper, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwiggen, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: 400/075 (MBH00-845-1)
;; CURRENT APPLICATION NUMBER: US/10/342,902
;; CURRENT FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: US 09/877,478
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 07/882,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6592
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 5948
;; LENGTH: 15
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-10-342-902-5948

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 6; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1680 TGGTGTCTCTC 1691
: |:|:|:|:|
Db 2 UUGUGUCUCC 13

RESULT 653
US-10-391-415-8
;; Sequence 8, Application US/10391415
;; Publication No. US20040063922A1
;; GENERAL INFORMATION:
;; APPLICANT: CONRAD, CHARLES A.
;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR CATALYTIC DNA EXCHANGE IN
;; FILE REFERENCE: P02449US2
;; CURRENT APPLICATION NUMBER: US/10/391,415
;; CURRENT FILING DATE: 2003-03-18
;; PRIOR APPLICATION NUMBER: 09/836,136
;; PRIOR FILING DATE: 2001-04-17
;; PRIOR APPLICATION NUMBER: 09/836,126
;; PRIOR FILING DATE: 2001-04-17
;; PRIOR APPLICATION NUMBER: 09/836,366
;; PRIOR FILING DATE: 2001-04-17
;; PRIOR APPLICATION NUMBER: 09/836,608
;; PRIOR FILING DATE: 2001-04-17
;; PRIOR APPLICATION NUMBER: 09/836,358
;; PRIOR FILING DATE: 2001-04-17
;; PRIOR APPLICATION NUMBER: 60/197,859
;; PRIOR FILING DATE: 2000-04-14
;; PRIOR APPLICATION NUMBER: 60/197,858
;; PRIOR FILING DATE: 2000-04-14
;; PRIOR APPLICATION NUMBER: 60/197,856
;; PRIOR FILING DATE: 2000-04-14
;; PRIOR APPLICATION NUMBER: 60/197,860
;; PRIOR FILING DATE: 2000-04-14
;; PRIOR APPLICATION NUMBER: 60/197,857
;; PRIOR FILING DATE: 2000-04-14
;; NUMBER OF SEQ ID NOS: 29
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 8
;; LENGTH: 15
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-391-415-8

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1729 AGATTGGCTCCC 1740
: |:|:|:|:|:|
Db 4 AGTTTGGCTCCC 15

RESULT 654
US-10-056-414-211/c
;; Sequence 211, Application US/10056414
;; Publication No. US20030003469A1
;; GENERAL INFORMATION:
;; APPLICANT: Stinchcomb, Dan T.
;; Draper, Kenneth G.
;; McSwiggen, James
;; TITLE OF INVENTION: RIBOZYME TREATMENT OF
;; DISEASES OR CONDITIONS
;; RELATED TO LEVELS OF
;; NF-KB
;; NUMBER OF SEQUENCES: 830
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/056,414
FILING DATE: 23-Jan-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 211:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 211:
US-10-056-414-211
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1639 CTTGTAGCAGAA 1650
Db 12 CTTGTAGCGGAA 1
RESULT 655
US-10-287-919-793/c
Sequence 793, Application US/10287919
Publication No. US20030085830A1
GENERAL INFORMATION:
APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
TITLE OF INVENTION: Methanococcus jannaschii complete genome.
FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
CURRENT APPLICATION NUMBER: US/10/287,919
CURRENT FILING DATE: 2002-11-05
NUMBER OF SEQ ID NOS: 2706
SOFTWARE: Proprietary
SEQ ID NO 793
LENGTH: 15
TYPE: DNA
ORGANISM: Methanococcus jannaschii complete genome.
FEATURE:
LOCATION: (301101)...(301115)
OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 974
US-10-287-919-793
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1741 AACTCTCCCTA 1752
Db 13 AACTCTTCCTA 2
RESULT 656

US-10-202-896-27/c
Sequence 27, Application US/10202896
Publication No. US20030165913A1
GENERAL INFORMATION:
APPLICANT: WANG, SHA-SHA
APPLICANT: THORNTON, KEITH
APPLICANT: NADEAU, JAMES G.
APPLICANT: HELLVER, TOBIN J.
TITLE OF INVENTION: METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIATIONS
FILE REFERENCE: 020187.0149
CURRENT APPLICATION NUMBER: US/10/202,896
CURRENT FILING DATE: 2002-07-06
PRIOR APPLICATION NUMBER: 09/894,788
PRIOR FILING DATE: 2001-06-28
PRIOR APPLICATION NUMBER: 09/590,691
PRIOR FILING DATE: 2000-06-09
PRIOR APPLICATION NUMBER: 09/335,218
PRIOR FILING DATE: 1999-06-17
NUMBER OF SEQ ID NOS: 60
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 27
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-202-896-27
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1740 CAACTCCTCCT 1751
Db 15 CAACTGCTCCT 4
RESULT 657
US-10-044-674-6
Sequence 6, Application US/10044674
Publication No. US20030175710A1
GENERAL INFORMATION:
APPLICANT: Chew, Anne
APPLICANT: Denton, R. Rex
APPLICANT: Bieglecki, Karyn M
APPLICANT: Nandabalan, Krishnan
APPLICANT: Stephens, J. Claiborne
TITLE OF INVENTION: HAPLOTYPES OF THE TNFRSF11B GENE
FILE REFERENCE: TNFRSF11B MMH-0001US (CIP)
CURRENT APPLICATION NUMBER: US/10/044,674
CURRENT FILING DATE: 2002-01-09
PRIOR APPLICATION NUMBER: PCT/US00/18803
PRIOR FILING DATE: 2000-07-10
NUMBER OF SEQ ID NOS: 94
SOFTWARE: PatentIn version 3.1
SEQ ID NO 6
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-10-044-674-6
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 1677 CCTGTGTCTCCT 1690
Db 2 CCTGTGTCTCCT 15
RESULT 658
US-10-044-674-56
Sequence 56, Application US/10044674

```
; Publication No. US20030175710A1
; GENERAL INFORMATION:
; APPLICANT: Chew, Anne
; APPLICANT: Denton, R. Rex
; APPLICANT: Bieglecki, Karyn M
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Stephens, J. Claiborne
; TITLE OF INVENTION: HAPLOTYPES OF THE TNFRSF11B GENE
; FILE REFERENCE: TNFRSF11B.MW-0001US (CIP)
; CURRENT APPLICATION NUMBER: US/10/044,674
; CURRENT FILING DATE: 2002-01-09
; PRIOR APPLICATION NUMBER: PCT/US00/18803
; PRIOR FILING DATE: 2000-07-10
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 56
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-044-674-56

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1640 TTGTATCAGAG 1651
Db 2 TTGTATCAGAG 13

RESULT 659
US-10-440-850-645
; Sequence 645, Application US/10440850
; Publication No. US2003020787A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal
; FILE REFERENCE: 250/130 (MBH00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/595,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 645
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-440-850-645

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 3.2e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTGTAGCA 1647
Db 3 GGGCTGTAGCA 14

RESULT 660
US-10-333-068-114/c
; Sequence 114, Application US/10333068
; Publication No. US20040101863A1
; GENERAL INFORMATION:
; APPLICANT: HAITORI, Hiroaki
; TITLE OF INVENTION: METHOD OF DETECTING ABNORMALITY OF LIPID METABOLISM
; FILE REFERENCE: Q73807
; CURRENT APPLICATION NUMBER: US/10/333,068
; CURRENT FILING DATE: 2003-01-16
; PRIOR APPLICATION NUMBER: PCT/JP01/06153
; PRIOR FILING DATE: 2001-07-21
; PRIOR APPLICATION NUMBER: JPA 2000-218039
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 114
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Hominidae
; NAME/KEY: misc feature
; LOCATION: (8)-(8)
; OTHER INFORMATION: n is a, c, g, or t
; US-10-333-068-114

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1631 GGATGGGCTTGT 1643
Db 13 GGATGGGCTTGT 1

RESULT 661
US-10-376-770-211/c
; Sequence 211, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
; FILE REFERENCE: 543312000320
; CURRENT APPLICATION NUMBER: US/10/376,770
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 262
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 211
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; NAME/KEY: misc_feature
; LOCATION: 5
; OTHER INFORMATION: This nucleotide may be absent
; US-10-376-770-211

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1666 CACAGCTGGAC 1677
Db 12 CACTGCTGGAC 1

RESULT 662
US-10-669-841-2351
; Sequence 2351, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; Sequence 2351, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
```

APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Lawrence, Blatt
APPLICANT: Dennis, Macejak
APPLICANT: James, McSwiggen
APPLICANT: David, Morrissey
APPLICANT: Pamela, Pavco
APPLICANT: Patricia, Lee
APPLICANT: Kenneth, Draper
APPLICANT: Elisabeth, Roberts
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
FILE REFERENCE: 400/042US (WBH02-249-E)
CURRENT APPLICATION NUMBER: US/10/669,841
PCT FILING DATE: 2003-09-23
PCT APPLICATION NUMBER: PCT/US02/09187
PCT FILING DATE: 2002-03-26
PCT APPLICATION NUMBER: US 60/296,876
PCT FILING DATE: 2001-06-08
PCT APPLICATION NUMBER: US 60/335,059
PCT FILING DATE: 2001-10-24
PCT APPLICATION NUMBER: US 60/337,055
PCT FILING DATE: 2001-12-05
PCT APPLICATION NUMBER: US 60/358,580
PCT FILING DATE: 2002-02-20
PCT APPLICATION NUMBER: US 60/363,124
PCT FILING DATE: 2002-03-11
PCT APPLICATION NUMBER: US 09/817,879
PCT FILING DATE: 2001-03-26
PCT APPLICATION NUMBER: US 09/740,332
PCT FILING DATE: 2000-12-18
PCT APPLICATION NUMBER: US 09/611,931
PCT FILING DATE: 2000-07-07
PCT APPLICATION NUMBER: US 09/504,321
PCT FILING DATE: 2000-02-15
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 16207
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2351
LENGTH: 15
TYPE: RNA
ORGANISM: Hepatitis B Virus
US-10-669-841-2351

Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 6; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1680 TGGTGTCTCTC 1691
Db 2 UUGUGUCCUC 13

RESULT 663
US-10-661-165-211/c
Sequence 211, Application US/10661165
Publication No. US20040137470A1
GENERAL INFORMATION:
APPLICANT: Dhallan, Ravinder S.
TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC DISORDERS
FILE REFERENCE: 543312000420
CURRENT APPLICATION NUMBER: US/10/661,165
CURRENT FILING DATE: 2003-09-11
PCT APPLICATION NUMBER: PCT/US03/06198
PCT FILING DATE: 2003-02-28
PCT APPLICATION NUMBER: US 60/378,354
PCT FILING DATE: 2002-05-08
PCT APPLICATION NUMBER: US 10/093,618
PCT FILING DATE: 2002-03-11
PCT APPLICATION NUMBER: US 60/360,232
PCT FILING DATE: 2002-03-01
PCT APPLICATION NUMBER: PCT/US03/27308
PCT FILING DATE: 2003-08-29

PRIOR APPLICATION NUMBER: US 10/376,770
PCT FILING DATE: 2003-02-28
NUMBER OF SEQ ID NOS: 628
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 211
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5
OTHER INFORMATION: This nucleotide may be present
US-10-661-165-211
Query Match 7.5%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1666 CACAGCTGGAAC 1677
Db 12 CACTGCTGGAAC 1
RESULT 664
US-10-227-719D-12
Sequence 12, Application US/10227719D
Publication No. US20030143578A1
GENERAL INFORMATION:
APPLICANT: Pruitt, Steven
TITLE OF INVENTION: A High Throughput Method for Identification of Sequence Tags
FILE REFERENCE: 03551.0108
CURRENT APPLICATION NUMBER: US/10/227,719D
CURRENT FILING DATE: 2002-08-26
PCT APPLICATION NUMBER: US/60/314,991
PCT FILING DATE: 2001-08-24
NUMBER OF SEQ ID NOS: 13
SEQ ID NO 12
LENGTH: 16
TYPE: DNA
ORGANISM: mus musculus
FEATURE:
OTHER INFORMATION: exon from actin binding protein
US-10-227-719D-12
Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1740 CAACTCTCTCCCT 1751
Db 5 CATCTCTCCCT 16
RESULT 665
US-10-092-208-2
Sequence 2, Application US/10092208
Publication No. US20030170637A1
GENERAL INFORMATION:
APPLICANT: Kim, Hyunsoo
APPLICANT: Pirrung, Michael C.
TITLE OF INVENTION: METHOD OF ANALYZING mRNA SPLICE VARIANTS USING ARRAYED PRIMER EXTENSION
FILE REFERENCE: 5405-274
CURRENT APPLICATION NUMBER: US/10/092,208
CURRENT FILING DATE: 2002-03-06
NUMBER OF SEQ ID NOS: 40
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide V3.

US-10-092-208-2

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1732 TTGGCTCCCAAC 1743
|||||
DB 4 TTGGCTCCGAC 15

RESULT 666

US-10-091-281-124/c
; Sequence 124, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091.281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 124
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative AHRH/AHRARNT.01 motif
US-10-091-281-124

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCA 1661
|||||
DB 16 AGGCAAGCACCA 5

RESULT 667

US-10-331-109-11
; Sequence 11, Application US/10331109
; Publication No. US20030215891A1
; GENERAL INFORMATION:
; APPLICANT: Bickel, et al.
; TITLE OF INVENTION: Method for the qualitative and/or quantitative detection of mole
; FILE REFERENCE: 12671/1
; CURRENT APPLICATION NUMBER: US/10/331.109
; PRIOR APPLICATION NUMBER: 2002-12-27
; PRIOR FILING DATE: 2001-07-02
; PRIOR APPLICATION NUMBER: DE 100 33 334.6
; PRIOR FILING DATE: 2000-07-01
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of the artificial sequence:
; OTHER INFORMATION: Oligonucleotide probe
US-10-331-109-11

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1636 GGGCTTGACCA 1647

DB 2 GGGCTTTAGCA 13
|||||

RESULT 668
US-10-138-674-5910
; Sequence 5910, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138.674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5910
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5910

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1648 GAAGGCAAGCAC 1659
|||||
DB 1 GAAGGCAAGCGC 12

RESULT 669

US-10-138-674-7125/c
; Sequence 7125, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138.674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7125
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7125

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1650 AGGCAAGCACCA 1661
|||||
DB 14 AGGCAAGCACCA 3

RESULT 670

US-10-407-807-32/c
; Sequence 32, Application US/10407807
; Publication No. US20040096948A1
; GENERAL INFORMATION:

; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: HOG, ANJA MOLHART
; APPLICANT: KRISTJANSEN, PAUL E.G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 57390 (45120)
; CURRENT APPLICATION NUMBER: US/10/407,807
; CURRENT FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: 60/370,126
; PRIOR FILING DATE: 2002-04-05
; NUMBER OF SEQ ID NOS: 124
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 32
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-807-32

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1696 GTGTGGAGTT 1707
Db 16 GTTGTGGAGTT 5
|||||

RESULT 671
US-10-287-949A-5910
; Sequence 5910, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20622
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5910
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5910

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1648 GAAGGCAAGCAC 1659
Db 1 GAAGGCAAGCGC 12
|||||

RESULT 672
US-10-287-949A-7125/c
; Sequence 7125, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20622
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7125
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7125

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1650 AGGCAAGCACCA 1661
Db 14 AGGCAAGAACCA 3
|||||

RESULT 673
US-10-459-184-37/c
; Sequence 37, Application US/10459184
; Publication No. US20040110173A1
; GENERAL INFORMATION:
; APPLICANT: University of Wales College of Medicine
; APPLICANT: COOPER, David N
; APPLICANT: PROCTER, Anne M
; APPLICANT: MILLAR, David S
; APPLICANT: GREGORY, John
; TITLE OF INVENTION: Haplotype Partitioning in the Proximal Promoter of the Human Growth
; TITLE OF INVENTION: Hormone (GH1) Gene
; FILE REFERENCE: WCM.102A
; CURRENT APPLICATION NUMBER: US/10/459,184
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: GB 0229725.7
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: GB 0306417.7
; PRIOR FILING DATE: 2003-03-20
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; LENGTH: 16
; TYPE: DNA
; ORGANISM: human
US-10-459-184-37

Query Match 7.5%; Score 10.4; DB 1; Length 16;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1744 TCCTCCCTATCC 1755
Db 15 TCCTCCCTAACCC 4
|||||

RESULT 674
US-09-877-478-2363/c
; Sequence 2363, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14

;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2363
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-2363

Query Match 7.5%; Score 10.4; DB 1; Length 17;
Best Local Similarity 91.7%; Pred. No. 4.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCAACTCCT 1747
Db 12 CCCCCCAACTCCT 1

RESULT 675
US-10-342-902-2363/c
;; Sequence 2363, Application US/10342902
;; Publication No. US20040054156A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Blatt, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwiggan, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: 400/075 (MBH00-845-I)
;; CURRENT APPLICATION NUMBER: US/10/342,902
;; CURRENT FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: US 09/877,478
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 07/892,712
;; PRIOR FILING DATE: 1992-05-14
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6592
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 2363
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-10-342-902-2363

Query Match 7.5%; Score 10.4; DB 1; Length 17;
Best Local Similarity 91.7%; Pred. No. 4.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCAACTCCT 1747
Db 12 CCCCCCAACTCCT 1

Db 12 CCCCCCAACTCCT 1

RESULT 676
US-10-669-841-2166/c
;; Sequence 2166, Application US/10669841
;; Publication No. US20040127446A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Lawrence, Blatt
;; APPLICANT: Dennis, Macejak
;; APPLICANT: James, McSwiggan
;; APPLICANT: David, Morrissey
;; APPLICANT: Pamela, Favco
;; APPLICANT: Patricia, Lee
;; APPLICANT: Kenneth, Draper
;; APPLICANT: Elisabeth, Roberts
;; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS B VIRUS REPLICATION
;; FILE REFERENCE: 400/042US (MBH02-249-E)
;; CURRENT APPLICATION NUMBER: US/10/669,841
;; CURRENT FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: PCT/US02/09187
;; PRIOR FILING DATE: 2002-03-26
;; PRIOR APPLICATION NUMBER: US 60/296,876
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 60/335,059
;; PRIOR FILING DATE: 2001-10-24
;; PRIOR APPLICATION NUMBER: US 60/337,055
;; PRIOR FILING DATE: 2001-12-05
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 09/817,879
;; PRIOR FILING DATE: 2001-03-26
;; PRIOR APPLICATION NUMBER: US 09/740,332
;; PRIOR FILING DATE: 2000-12-18
;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2166
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B Virus
US-10-669-841-2166

Query Match 7.5%; Score 10.4; DB 1; Length 17;
Best Local Similarity 91.7%; Pred. No. 4.1e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1736 CTCCTCAACTCCT 1747
Db 12 CCCCCCAACTCCT 1

RESULT 677
US-10-114-824A-52/c
;; Sequence 52, Application US/10114824A
;; Publication No. US20030196215A1
;; GENERAL INFORMATION:
;; APPLICANT: JOSELYNE OLIVIER
;; TITLE OF INVENTION: No. US20030196215A1e1 Class of Proteins and Uses Thereof for Plant
;; FILE REFERENCE: Patented Agents
;; FILE REFERENCE: CHEP:006US
;; CURRENT APPLICATION NUMBER: US/10/114,824A
;; CURRENT FILING DATE: 2002-08-16
;; NUMBER OF SEQ ID NOS: 61
;; SOFTWARE: PatentIn Ver. 2.1

```
; SEQ ID NO 52
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-114-824A-52

Query Match          7.5%; Score 10.4; DB 1; Length 18;
Best Local Similarity 91.7%; Pred. No. 4.6e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1719 ACGGAGATGGAG 1730
Db 17 ACGGACATGGAG 6

RESULT 678
US-10-224-005-20
; Sequence 20, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; PRIOR FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-224-005-20

Query Match          7.5%; Score 10.4; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 5e+02;
Matches 8; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 GGATGGGGCTTG 1642
Db 5 GGAUGGUGCUUG 16

RESULT 679
US-10-224-005-181/c
; Sequence 181, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fossnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD)
; FILE REFERENCE: 900/041 (MBHB01-1110-A)
; CURRENT APPLICATION NUMBER: US/10/224,005
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 347
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-181
```

```
Query Match          7.5%; Score 10.4; DB 1; Length 19;
Best Local Similarity 91.7%; Pred. No. 5e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 GGATGGGGCTTG 1642
Db 15 GGATGGTGGCTTG 4

RESULT 680
US-09-864-785-3708
; Sequence 3708, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3708
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-3708

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 3.4e+02;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1685 TCTCTCCAGCGTGG 1699
Db 1 UCUCUCCUAGUGCGG 15

RESULT 681
US-09-877-478-5955
; Sequence 5955, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Lave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
```

```
;
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5955
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-5955

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 3.4e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GTGTCCTCCTCCAGCG 1696
   |||::|||::||
Db 1 GUGUCUCCUCUGCG 15

RESULT 682
US-09-877-478-6533
; Sequence 6533, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: Morrissey, Jim
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MEH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6533
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-6533

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 3.4e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1698 GTGGAGTGGGTT 1712
   |||::|||::||
Db 1 GGAGGAGGUAGGU 15

RESULT 683
US-09-943-983-61/c
; Sequence 61, Application US/09943983
; Publication No. US2003007757A1
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: LOUWAGIE, JOOST
; APPLICANT: ROSSAU, RUDI
; TITLE OF INVENTION: METHOD FOR DETECTION OF DRUG-INDUCED
```

```
;
; NUMBER OF SEQUENCES: 164
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ARNOLD, WHITE & DURKEE
; STREET: P.O. BOX 4433
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: USA
; ZIP: 77210-4433
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Microsoft Word 6.0 / ASCII text output
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/943,983
; FILING DATE: 31-Aug-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/913,833
; FILING DATE: 1997-09-15
; APPLICATION NUMBER: EP 96870005.4
; FILING DATE: 26 Jan 1996
; APPLICATION NUMBER: EP 96870081.5
; FILING DATE: 25 Jun 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: KAMMERER, PATRICIA A.
; REGISTRATION NUMBER: 29,775
; REFERENCE/DOCKET NUMBER: INNS:008
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 61:
US-09-943-983-61

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCGTGTGGAAG 1705
   |||::|||::||
Db 15 CCATCCTGTGGAAG 1

RESULT 684
US-09-093-972C-579
; Sequence 579, Application US/09093972C
; Publication No. US20030087845A1
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
```

FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Anzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 579:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (Genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 579:
US-09-093-972C-579

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1722 GAGATGGAGATTGGC 1736
|||||
Db 1 GAGATGGAGGGCGC 15

RESULT 685
US-09-740-332-4786/c
Sequence 4786, Application US/09740332
Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: Patent in version 3.0
SEQ ID NO 4786
LENGTH: 15
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4786

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1711 TTAGGAGTACGGAGA 1725
|||||
Db 15 TGAGGAGTACGTGGA 1

RESULT 686
US-09-740-332-4796/c
Sequence 4796, Application US/09740332

Publication No. US20030125270A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: RPI 400/003
CURRENT APPLICATION NUMBER: US/09/740,332
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9704
SOFTWARE: Patent in version 3.0
SEQ ID NO 4796
LENGTH: 15
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4796

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1713 AGGAGTACGGAGATG 1727
|||||
Db 15 AGGAGTACGTGGAGG 1

RESULT 687
US-09-817-879-4786/c
Sequence 4786, Application US/09817879
Publication No. US2003017131A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: Patent in version 3.0
SEQ ID NO 4786
LENGTH: 15
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4786

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1711 TTAGGAGTACGGAGA 1725
|||||
Db 15 TGAGGAGTACGTGGA 1

RESULT 688
US-09-817-879-4796/c
Sequence 4796, Application US/09817879
Publication No. US2003017131A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
FILE REFERENCE: MBHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4796
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4796

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1713 AGGAGTACGAGATG 1727
|||||||
Db 15 AGGAGTACGTGGAGG 1

RESULT 689
US-09-835-694-19
; Sequence 19, Application US/09835694
; Publication No. US20040087521A1
; GENERAL INFORMATION:
; APPLICANT: DONNELLY, JOHN J.
; LIU, MARGARET A.
; MONTGOMERY, DONNA L.
; PARKER, SUEZANNE E.
; SHIVER, JOHN W.
; ULMER, JEFFREY B.

TITLE OF INVENTION: NUCLEIC ACID PHARMACEUTICALS - INFLUENZA MATRIX
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:

ADDRESSEE: J. MARK HAND - MERCK & CO., INC.
STREET: 126 EAST LINCOLN AVENUE - P.O. BOX 2000
CITY: RAHWAY
STATE: NJ
COUNTRY: USA
ZIP: 07065-0907

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/835,694
FILING DATE: 16-Apr-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/461,268
FILING DATE: 05-June-1995
APPLICATION NUMBER: PCT/US94/02751
FILING DATE: 14-March-1994
APPLICATION NUMBER: 08/089,985
FILING DATE: 08-July-1993
APPLICATION NUMBER: 08/032,383
FILING DATE: 18-March-1993

ATTORNEY/AGENT INFORMATION:

NAME: HAND, J. MARK
REGISTRATION NUMBER: 36,545
REFERENCE/DOCKET NUMBER: 18972PCA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 732-594-3905
TELEFAX: 732-594-4720
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-835-694-19

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644 AGCAGAGGCAAGCA 1658
|||||||
Db 1 AGCAGAGGCAAGCA 15

RESULT 690
US-09-835-694-23
; Sequence 23, Application US/09835694
; Publication No. US20040087521A1
; GENERAL INFORMATION:
; APPLICANT: DONNELLY, JOHN J.
; LIU, MARGARET A.
; MONTGOMERY, DONNA L.
; PARKER, SUEZANNE E.
; SHIVER, JOHN W.
; ULMER, JEFFREY B.

TITLE OF INVENTION: NUCLEIC ACID PHARMACEUTICALS - INFLUENZA MATRIX
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:

ADDRESSEE: J. MARK HAND - MERCK & CO., INC.
STREET: 126 EAST LINCOLN AVENUE - P.O. BOX 2000
CITY: RAHWAY
STATE: NJ
COUNTRY: USA
ZIP: 07065-0907

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/835,694
FILING DATE: 16-Apr-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/461,268
FILING DATE: 05-June-1995
APPLICATION NUMBER: PCT/US94/02751
FILING DATE: 14-March-1994
APPLICATION NUMBER: 08/089,985
FILING DATE: 08-July-1993
APPLICATION NUMBER: 08/032,383
FILING DATE: 18-March-1993

ATTORNEY/AGENT INFORMATION:

NAME: HAND, J. MARK
REGISTRATION NUMBER: 36,545
REFERENCE/DOCKET NUMBER: 18972PCA
TELECOMMUNICATION INFORMATION:
TELEPHONE: 732-594-3905
TELEFAX: 732-594-4720
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 23:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO

```
;
; PRAGMENT TYPE: <Unknown>
; ORIGINAL SOURCE:
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-09-835-694-23

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644 AGCAGAAAGCAAGCA 1658
Db 1 AGCAGAAAGCAAGCA 15

RESULT 691
US-10-342-902-5955
; Sequence 5955, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5955
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-5955

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 3.4e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GGTGCTCTCCAGCG 1696
Db 1 GUGUCUCCUCCGCG 15

RESULT 692
US-10-342-902-6533
; Sequence 6533, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
```

```
;
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6533
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-6533

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 3.4e+02;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1698 GGTGGAAGTTGGTT 1712
Db 1 GGAGGAGGUAGGUU 15

RESULT 693
US-10-339-674-1741/C
; Sequence 1741, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/339,674
; CURRENT FILING DATE: 2003-06-06
; NUMBER OF SEQ ID NOS: 3537
; SOFTWARE: Proprietary
; SEQ ID NO 1741
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Escherichia coli K-12 MG1655 complete genome.
; FEATURE:
; LOCATION: (2353745)...(2353759)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 2298
US-10-339-674-1741

Query Match          7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1722 GAGATGGAGATTGGC 1736
Db 15 GATGTGAAGATTGGC 1

RESULT 694
US-10-339-674-3176/c
; Sequence 3176, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/339,674
; CURRENT FILING DATE: 2003-06-06
; NUMBER OF SEQ ID NOS: 3537
; SOFTWARE: Proprietary
```

; SEQ ID NO 3176
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Escherichia coli K-12 MG1655 complete genome.
; FEATURE:
; LOCATION: (4251177)...(4251191)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 4212
US-10-339-674-3176

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1722 GAGATGAGATTGCG 1736
Db 15 GATGTGAAGATTGCG 1

RESULT 695
US-10-056-414-340
; Sequence 340, Application US/10056414
; Publication No. US20030003469A1
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; Draper, Kenneth G.
; McSwiggen, James
; TITLE OF INVENTION: RIBOSOME TREATMENT OF
; DISEASES OR CONDITIONS
; RELATED TO LEVELS OF
; NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/056,414
FILING DATE: 23-Jan-2002
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 499-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 340:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 340:
US-10-056-414-340

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 3.4e+02;
Matches 7; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
QY 1680 TGGTGCTCTCTCCAG 1694
Db 1 UGGUGUUUCCUUCUG 15

RESULT 696
US-10-043-875-258/c
; Sequence 258, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; Transcriptionase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 258
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-258

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 CCAGCGTGTGGAAG 1705
Db 15 CCATCCTGTGGAAG 1

RESULT 697
US-10-043-875-262/c
; Sequence 262, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; Transcriptionase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 262
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-262

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 TCACGCTGTGGAA 1704
|||||
Db 15 TCCATCCTTGTGGAA 1

RESULT 698

US-10-156-306-7875
; Sequence 7875, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7875
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7875

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 3.4e+02;
Matches 7; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1677 CCCTGGTGTCTCCNC 1691
|||:|:|:|:
Db 1 CCCUUCUGUCGUC 15

RESULT 699

US-10-160-358-31/c
; Sequence 31, Application US/10160358
; Publication No. US20030198969A1
; GENERAL INFORMATION:
; APPLICANT: Genaisance Pharmaceuticals, Inc.
; APPLICANT: Bieglecki, Karyn
; APPLICANT: Cappola, Gina-Marie
; APPLICANT: Koshy, Beena
; APPLICANT: Monroe, Glen
; TITLE OF INVENTION: HAPLOTYPES OF THE TACR2 GENE
; FILE REFERENCE: TACR2 MWH-0225US
; CURRENT APPLICATION NUMBER: US/10/160,358
; CURRENT FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: PCT/US01/47394
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: 60/247,649
; PRIOR FILING DATE: 2000-11-09
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-160-358-31

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 TGGAAACCCCTGGTGC 1686
|||||
Db 15 TVGAACCCAGGTTTC 1

RESULT 700

US-10-440-850-282/c
; Sequence 282, Application US/10440850

; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal of
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MBH00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 282
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-282

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1715 GAGTACGAGATGCA 1729
|||||
Db 15 GAGAAAGAGAGGCA 1

RESULT 701

US-10-440-850-497/c
; Sequence 497, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reversal of
; TITLE OF INVENTION: Immune Responses
; FILE REFERENCE: 250/130 (MBH00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 497
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-497

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1644 AGCAGAGGCGACCA 1658
|||||
Db 15 AGCAGAGAGAGCA 1


```
RESULT 702
US-10-271-602B-193/c
; Sequence 193, Application US/10271602B
; Publication No. US20040002073A1
; GENERAL INFORMATION:
; APPLICANT: Alice Xiang Li
; APPLICANT: Ghazala Hashmi
; APPLICANT: Michael Seul
; TITLE OF INVENTION: MULTIPLEXED ANALYSIS OF POLYMORPHIC LOCI
; TITLE OF INVENTION: BY CONCURRENT INTERROGATION AND ENZYME-MEDIATED DETECTION
; FILE REFERENCE: eMAP-US
; CURRENT APPLICATION NUMBER: US/10/271,602B
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/329,427
; PRIOR FILING DATE: 2001-10-14
; PRIOR APPLICATION NUMBER: 60/329,620
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/329,428
; PRIOR FILING DATE: 2001-10-14
; PRIOR APPLICATION NUMBER: 60/329,619
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/364,416
; PRIOR FILING DATE: 2002-03-14
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 193
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe sequence derived from human genomic sequence
US-10-271-602B-193

Query Match      7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACGCTGGGAACC 1678
Db 15 CTCACGTGGCGGAACC 1

RESULT 703
US-10-271-602B-195/c
; Sequence 195, Application US/10271602B
; Publication No. US20040002073A1
; GENERAL INFORMATION:
; APPLICANT: Alice Xiang Li
; APPLICANT: Ghazala Hashmi
; APPLICANT: Michael Seul
; TITLE OF INVENTION: MULTIPLEXED ANALYSIS OF POLYMORPHIC LOCI
; TITLE OF INVENTION: BY CONCURRENT INTERROGATION AND ENZYME-MEDIATED DETECTION
; FILE REFERENCE: eMAP-US
; CURRENT APPLICATION NUMBER: US/10/271,602B
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/329,427
; PRIOR FILING DATE: 2001-10-14
; PRIOR APPLICATION NUMBER: 60/329,620
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/329,428
; PRIOR FILING DATE: 2001-10-14
; PRIOR APPLICATION NUMBER: 60/329,619
; PRIOR FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 60/364,416
; PRIOR FILING DATE: 2002-03-14
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 195
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe sequence derived from human genomic sequence
US-10-271-602B-195

Query Match      7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 CTCACGCTGGGAACC 1678
Db 15 CTCACGTGGCGGAACC 1

RESULT 704
US-10-376-341-211
; Sequence 211, Application US/10376341
; Publication No. US20040002473A1
; GENERAL INFORMATION:
; APPLICANT: KURRECK, Jens
; APPLICANT: ERDMANN, Volker A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST VRL
; FILE REFERENCE: 029310.52142US
; CURRENT APPLICATION NUMBER: US/10/376,341
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: PCT/EP01/10081
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: 100 43 674.9
; PRIOR FILING DATE: 2000-09-02
; PRIOR APPLICATION NUMBER: 100 43 702.8
; PRIOR FILING DATE: 2000-09-04
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 211
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-376-341-211

Query Match      7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1689 CTCACGCTGGTGGGA 1703
Db 1 CTCACGCGAGGTGGGA 15

RESULT 705
US-10-669-841-2358
; Sequence 2358, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HBPAJ
; FILE REFERENCE: 400/042US (WBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
```

```
; FEATURE:
; OTHER INFORMATION: Probe sequence derived from human genomic sequence
US-10-271-602B-195
```

```
Query Match      7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1664 CTCACGCTGGGAACC 1678
Db 15 CTCACGTGGCGGAACC 1
```

```
RESULT 704
US-10-376-341-211
; Sequence 211, Application US/10376341
; Publication No. US20040002473A1
; GENERAL INFORMATION:
; APPLICANT: KURRECK, Jens
; APPLICANT: ERDMANN, Volker A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST VRL
; FILE REFERENCE: 029310.52142US
; CURRENT APPLICATION NUMBER: US/10/376,341
; CURRENT FILING DATE: 2003-03-03
; PRIOR APPLICATION NUMBER: PCT/EP01/10081
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: 100 43 674.9
; PRIOR FILING DATE: 2000-09-02
; PRIOR APPLICATION NUMBER: 100 43 702.8
; PRIOR FILING DATE: 2000-09-04
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 211
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-376-341-211
```

```
Query Match      7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY 1689 CTCACGCTGGTGGGA 1703
Db 1 CTCACGCGAGGTGGGA 15
```

```
RESULT 705
US-10-669-841-2358
; Sequence 2358, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HBPAJ
; FILE REFERENCE: 400/042US (WBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
```



```

Qy 1713 AGGAGTACGGAGATG 1727
Db 15 AGGAGTACGTGGAGG 1

RESULT 708
US-10-669-841-7383/c
; Sequence 7383, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (WBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7383
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-7383

Query Match 7.3%; Score 10.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1711 TTAGGAGTACGGAGA 1725
Db 15 TCAGGAGTACGTGGA 1

```


Query Match

Mon Aug 30 09:26:47 2004

```

.9%; Pred. NO. 0.73;
Best Local Similarity .ve 0; Mismatches 1; Indels 0; Gaps 0;
Matches 10; Conserv 1666
QY 1656 GCACGAGCTC 11
D 1 GCACG
Db

RESULT 3 33 12 bp mRNA linear EST 15-AUG-2003
CF306933 -05-E05-g1 OSHDAC1-overexpressing transgenic rice lambda phage
LOCUS library I (HDAL) Oryza sativa cDNA clone HDAL--05-E05, mRNA
DEFINITION sense.
306933
.F306933.1 GI:33678694
ACCESSION EST.
VERSION Oryza sativa
KEYWORDS Oryza sativa
SOURCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Ehrhartoideae; Oryzae; Oryza.
1 (bases 1 to 13)
1 (bases 1 to 13)
CONTACT: Kim J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.myongji.ac.kr.
FURS
source
1. .12
Location/Qualifiers
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="HDAL--05-E05"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDAC1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. NO. 1.2;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1656 GCACGAGCTC 1666
D 1 GCACGAGGCTC 11
Db

RESULT 4
BM395359/c
LOCUS
DEFINITION 17 bp mRNA linear EST 17-JAN-2002
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymena.
.9%; Pred. NO. 0.73;
Best Local Similarity .ve 0; Mismatches 1; Indels 0; Gaps 0;
Matches 10; Conserv 1666
QY 1656 GCACGAGCTC 11
D 1 GCACG
Db

RESULT 3 33 12 bp mRNA linear EST 15-AUG-2003
CF306933 -05-E05-g1 OSHDAC1-overexpressing transgenic rice lambda phage
LOCUS library I (HDAL) Oryza sativa cDNA clone HDAL--05-E05, mRNA
DEFINITION sense.
306933
.F306933.1 GI:33678694
ACCESSION EST.
VERSION Oryza sativa
KEYWORDS Oryza sativa
SOURCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Ehrhartoideae; Oryzae; Oryza.
1 (bases 1 to 13)
1 (bases 1 to 13)
CONTACT: Kim J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.myongji.ac.kr.
FURS
source
1. .12
Location/Qualifiers
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="HDAL--05-E05"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDAC1-overexpressing transgenic rice lambda
phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."
Query Match 6.8%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. NO. 1.2;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1656 GCACGAGCTC 1666
D 1 GCACGAGGCTC 11
Db

RESULT 4
BM395359/c
LOCUS
DEFINITION 17 bp mRNA linear EST 17-JAN-2002
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymena.

```

```

REFERENCE
AUTHORS
Turkewitz, A.P., Karer, K.M., Jahn, C., Orlas, E., Kirk, K.E.,
Frankel, J. and Kloubutcher, L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells
Unpublished (2002)
Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.
FEATURES
source
1. .17
Location/Qualifiers
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/notes="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."
Query Match 6.8%; Score 9.2; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. NO. 7.7;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1686 CTCCTCCAGCGTGG 1699
D 15 CTCACACCGGTGG 2
Db

RESULT 5
BM169696
LOCUS
DEFINITION 12 bp DNA linear GSS 03-OCT-2001
SALK_001766 Arabidopsis thaliana TDNA insertion lines Arabidopsis
thaliana genomic clone SALK_001766, genomic survey sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
Arabidopsis thaliana (thale cress)
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1 (bases 1 to 12)
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."
REFERENCE
AUTHORS
Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R.,
Gadriab, C., Jeske, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,
Shinn, P., Zimmermann, J. and Ecker, J.R.
A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
Unpublished (2001)
Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
Location/Qualifiers
1. .12
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/strain="Columbia 0"
/db_xref="taxon:3702"
/clone="SALK_001766"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/notes="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion

```

elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at http://signal.salk.edu/cdna_protocols.html.

Query Match 6.3%; Score 8.8; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 2.1;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1733 TGGCTCCCACT 1744
|||||
Db 1 TGGCCCCCAACT 12

RESULT 6
LOCUS AA913242 13 bp mRNA linear EST 26-AUG-1998
DEFINITION ol43g11.s1 Soares NFL T GBC_S1 Homo sapiens cDNA clone
IMAGE:1526276 3' similar to WP:E02A10.2 CE09116 ;, mRNA sequence.

ACCESSION AA913242
VERSION AA913242
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 13)
AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cygabs@mail.nih.gov
This clone is available royalty-free through LBNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Trace considered overall poor quality
Insert Length: 614 Std Error: 0.00
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.

FEATURES
source
1..13
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:1526276"
/lab_host="DH10B"
/clone_lib="Soares NFL T GBC_S1"
/note="Organ: pooled; Vector: p7T3D-Pac (Pharmacia) with a modified polylinker; Site 1: Not 1; Site 2: Eco RI; Equal amounts of plasmid DNA from three normalized libraries (fetal lung NBHL19W, testis NHT, and B-cell NCI CGAP GCBI) were mixed, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from pools of 5,000 clones made from the same 3 libraries. The pools consisted of I.M.A.G.E. clones 297480-302087, 682632-687239, 726408-728711, and 729096-731399. Subtraction by Bento Soares and M. Fatima Bonaldo."

Query Match 6.3%; Score 8.8; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 3.2;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1697 TGGTGGAGTTG 1708
|||||
Db 1 TGGTGGTGGTTG 12

RESULT 7
LOCUS BQ587766 12 bp mRNA linear EST 06-DEC-2002
DEFINITION E012340-024-010-M01-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone

024-010-M01 5-PRIME, mRNA sequence.
BQ587766
BQ587766.1 GI:26117348
EST.

ACCESSION Beta vulgaris
VERSION Beta vulgaris
KEYWORDS Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
SOURCE 1 (bases 1 to 12)
AUTHORS Herwig, R., Schulz, B., Weishaar, B., Hennig, S., Steinfath, M., Drungowski, M., Stahl, D., Wruck, W., Menze, A., O'Brien, J., Lehrach, H. and Radelof, U.

TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL Plant J. 32 (5), 845-857 (2002)
MEDLINE 22362189
PUBMED 12472698

COMMENT Contact: Weishaar B
ADIS DNA core facility at MPIZ
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weishaar@mpiz-koeln.mpg.de
Insert length: 12 Std Error: 0.00
Plate: 10 Row: M Column: 01
Seq primer: SP6; CATACGATTAGTGACACTATAG.
Location/Qualifiers

FEATURES
source
1..12
Location/Qualifiers
/organism="Beta vulgaris"
/mol_type="mRNA"
/cultivar="KWS2320 (double haploid, monogerm breeding line)"
/db_xref="GABI:185095"
/db_xref="taxon:161934"
/clone="024-010-M01"
/tissue_type="leaf"
/lab_host="EMDH10B"
/clone_lib="MPIZ-ADIS-024-leaf"
/note="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI; cDNA library from sugar beet, library provided by KWS Kleinvanzlebener Saatucht AG Einbeck, Germany, contact: b.schulz@kws.de; cloning sites Sali-NotI, primer sites and orientation:
SP6-Sali-CCACGGCTCG-5prime-cDNA-polyA-CC-NotI-T7; Note: Sequencing granted in the context of the GABI-Beet project, local PI: Dr. Katharina Schneider, coordinator: Prof. Christian Jung; Sequence submission managed by RZPD/GABI-Primary database:<http://gabi.rzpd.de>"

Query Match 6.0%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.1;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 TGCTCTCTCC 1692
|||||
Db 2 TGCTCTCTCC 11

RESULT 8
LOCUS CF306837/c 12 bp mRNA linear EST 15-AUG-2003
DEFINITION HDAL--04-P19.g1 OshDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDAL) Oryza sativa cDNA clone HDAL--04-P19, mRNA sequence.

ACCESSION CF306837
VERSION CF306837.1 GI:33678598
KEYWORDS EST.
SOURCE CF306837.1
ORGANISM Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.

```

REFERENCE
AUTHORS      Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
              Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE        Large-scale Sequencing Analysis of Rice ESTs
JOURNAL      Unpublished (2003)
COMMENT      Contact: Nahm B.H.
              Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
              of Bioscience and Bioinformatics, Myongji University
              Yongin, Kyeonggi, Korea
              Tel: 82 31 330 6193
              Fax: 82 31 321 6355
              Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .12
   /organism="Oryza sativa"
   /mol_type="mRNA"
   /cultivar="Nackdong"
   /db_xref="taxon:4530"
   /clone="HDA1-04-P19"
   /tissue_type="callus"
   /dev_stage="proliferated callus on 2N6 media for 2 weeks"
   /lab_host="E.coli SOLR"
   /clone_lib="OSHAC1-overexpressing transgenic rice lambda
   phage cDNA library I (HDA1)"
   /note="vector: phuscript SK(+); Site 1: EcoRI; Site 2:
   XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
   was inserted into lambda Uni-ZAP XR vector at 5' end with
   EcoRI and 3' end with XhoI site. mRNA was derived from
   rice Histone Deacetylase overexpression line."

Query Match      6.0%; Score 8.4; DB 1; Length 12;
Best Local Similarity 90.0%; Pred. No. 3.1;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1675 AACCTGCGTG 1684
Db 11 AACCTGCGTG 2

RESULT 9
CF311011
LOCUS
DEFINITION      ABF--06-B02.b1 ABF3-overexpressing transgenic rice plasmid cDNA
                  library (ABF) Oryza sativa cDNA clone ABF--06-B02, mRNA sequence.
ACCESSION      CF311011
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE
AUTHORS      Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
              Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE        Large-scale Sequencing Analysis of Rice ESTs
JOURNAL      Unpublished (2003)
COMMENT      Contact: Nahm B.H.
              Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
              of Bioscience and Bioinformatics, Myongji University
              Yongin, Kyeonggi, Korea
              Tel: 82 31 330 6193
              Fax: 82 31 321 6355
              Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1. .10
   /organism="Oryza sativa"
   /mol_type="mRNA"
   /cultivar="Nackdong"
   /db_xref="taxon:4530"
   /clone="ABF--06-B02"
   /tissue_type="leaf"
   /dev_stage="14 days after germination"

/ lab host="E.coli DH10B"
/ clone lib="ABF3-overexpressing transgenic rice plasmid
cDNA library (ABF)"
/ note="Vector: PCR4-TOPO; Site 1: EcoRI; Leaf was dried
for 2hrs. Oligo-capped mRNA was reverse transcribed and
then used for PCR. mRNA was prepared from ABA-responsive
element binding transcription factor 3 overexpression
line."

Query Match      5.8%; Score 8; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1742 ACTCTCTCC 1749
Db 1 ACTCTCTCC 8

RESULT 10
BM395899
LOCUS
DEFINITION      5009-0-13-G03.t.1 Chilcoat/Turkewitz cDNA (large fraction)
                  Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM395899
VERSION
KEYWORDS
SOURCE
ORGANISM
Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymena.

REFERENCE
AUTHORS      Turkewitz,A.P., Karrer,K.M., Jahn,C., Orlas,E., Kirk,K.E.,
              Frankel,J. and Klobutcher,L.
TITLE        EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL      Unpublished (2002)
COMMENT      Contact: Turkewitz AP
              Molecular Genetics and Cell Biology
              University of Chicago
              920 E. 58th Street, Chicago, IL 60637, USA
              Tel: 773 702 4374
              Fax: 773 702 3172
              Email: apturkew@midway.uchicago.edu
              Seq primer: T3.

FEATURES
source
1. .12
   /organism="Tetrahymena thermophila"
   /mol_type="mRNA"
   /strain="CU428.1"
   /db_xref="taxon:5911"
   /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
   /note="Vector: BlueScript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      5.6%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 5.4;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1692 GACGCGTGCG 1702
Db 1 CAACGCGGTGG 11

RESULT 11
BM398341
LOCUS
DEFINITION      5009-0-44-D05.t.2 Chilcoat/Turkewitz cDNA (large fraction)
                  Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM398341
VERSION
KEYWORDS
SOURCE
ORGANISM
Tetrahymena thermophila

```


Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymena.
1 (bases 1 to 12)
AUTHORS Turkewitz A.P., Karrer, K.M., Jahn, C., Orias, E., Kirk, K.E.,
Frankel, J., and Klobutcher, L.
TITLE EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL Unpublished (2002)
COMMENT Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.

FEATURES
source
1..12
Location/Qualifiers
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/note="Vector: BlueScript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 5.6%; Score 7.8; DB 1; Length 12;
Best Local Similarity 81.8%; Pred. No. 5.4;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1695 CGTGTGGAAG 1705
|||
Db 2 CGCGTGGCAG 12

Search completed: August 30, 2004, 09:26:09
Job time : 0.001 secs

